<SEC-DOCUMENT>0001144204-19-023895.txt : 20190506
<SEC-HEADER>0001144204-19-023895.hdr.sgml : 20190506
<ACCEPTANCE-DATETIME>20190506160617
ACCESSION NUMBER:		0001144204-19-023895
CONFORMED SUBMISSION TYPE:	10-Q
PUBLIC DOCUMENT COUNT:		45
CONFORMED PERIOD OF REPORT:	20190331
FILED AS OF DATE:		20190506
DATE AS OF CHANGE:		20190506

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Protalix BioTherapeutics, Inc.
		CENTRAL INDEX KEY:			0001006281
		STANDARD INDUSTRIAL CLASSIFICATION:	BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
		IRS NUMBER:				650643773
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		10-Q
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-33357
		FILM NUMBER:		19799340

	BUSINESS ADDRESS:	
		STREET 1:		2 SNUNIT ST
		STREET 2:		SCIENCE PARK, POB 455
		CITY:			CARMIEL
		STATE:			L3
		ZIP:			20100
		BUSINESS PHONE:		972-4-988-9488

	MAIL ADDRESS:	
		STREET 1:		2 SNUNIT ST
		STREET 2:		SCIENCE PARK, POB 455
		CITY:			CARMIEL
		STATE:			L3
		ZIP:			20100

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	ORTHODONTIX INC
		DATE OF NAME CHANGE:	19980422

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	EMBASSY ACQUISITION CORP
		DATE OF NAME CHANGE:	19960124
</SEC-HEADER>
<DOCUMENT>
<TYPE>10-Q
<SEQUENCE>1
<FILENAME>tv519981_10q.htm
<DESCRIPTION>FORM 10-Q
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0">&nbsp;&nbsp;</P>

<!-- Field: Rule-Page --><DIV ALIGN="LEFT" STYLE="margin-top: 0pt; margin-bottom: 0"><DIV STYLE="font-size: 1pt; border-top: Black 2pt solid; border-bottom: Black 1pt solid; width: 100%">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 18pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-size: 12pt"><B>UNITED
STATES</B></FONT></P>

<P STYLE="font: 18pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-size: 12pt"><B>SECURITIES
AND EXCHANGE COMMISSION</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Washington, D.C. 20549</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<!-- Field: Rule-Page --><DIV ALIGN="CENTER" STYLE="margin-top: 3pt; margin-bottom: 3pt"><DIV STYLE="font-size: 1pt; border-top: Black 1pt solid; width: 25%">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 18pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;FORM 10-Q</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: center; margin-bottom: 0pt">&nbsp;&nbsp;</P>

<!-- Field: Rule-Page --><DIV ALIGN="CENTER" STYLE="margin-top: 3pt; margin-bottom: 3pt"><DIV STYLE="font-size: 1pt; border-top: Black 1pt solid; width: 25%">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: center; margin-bottom: 0pt"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: center; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>(Mark One) </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.25in; text-align: left; font-size: 12pt"><FONT STYLE="font-family: Wingdings"><B>x</B></FONT></TD><TD STYLE="text-align: justify; font-size: 12pt"><B>QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF
THE SECURITIES EXCHANGE ACT OF 1934</B></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left"><B>For</B></TD><TD STYLE="text-align: justify"><B>the quarterly period ended March</B>&nbsp;<B>31,
2019</B></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>OR </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.25in; text-align: left; font-size: 12pt"><FONT STYLE="font-family: Wingdings"><B>&uml;</B></FONT></TD><TD STYLE="text-align: justify; font-size: 12pt"><B>TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d)
OF THE SECURITIES EXCHANGE ACT OF 1934</B></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left"><B>For</B></TD><TD STYLE="text-align: justify"><B>the transition period from <U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</U>to</B><U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U>
</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>001-33357 </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>(Commission file number)</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;&nbsp;&nbsp;</B></P>

<!-- Field: Rule-Page --><DIV ALIGN="CENTER" STYLE="margin-top: 3pt; margin-bottom: 3pt"><DIV STYLE="font-size: 1pt; border-top: Black 1pt solid; width: 25%">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 18pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>PROTALIX BIOTHERAPEUTICS, INC.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>(Exact name of registrant as specified
in its charter)</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<!-- Field: Rule-Page --><DIV ALIGN="CENTER" STYLE="margin-top: 3pt; margin-bottom: 3pt"><DIV STYLE="font-size: 1pt; border-top: Black 1pt solid; width: 25%">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="margin-top: 0; text-align: center; margin-bottom: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="font-size: 10pt; text-align: center; width: 50%"><B><U>Delaware</U></B></TD>
    <TD STYLE="font-size: 10pt; text-align: center; width: 50%">&nbsp;<B>__<U>65-0643773</U>__</B></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>(State or other jurisdiction</B></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>of incorporation or organization)&nbsp;</B></P></TD>
    <TD>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>(I.R.S. Employer</B></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Identification No.)&nbsp;</B></P></TD></TR>
<TR>
    <TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>2 Snunit Street</B></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Science Park</B></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>POB 455</B></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><U>Carmiel, Israel</U></B></P></TD>
    <TD>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><U>20100</U></B></P></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="font-size: 10pt; text-align: center"><FONT STYLE="font-size: 10pt"><B>(Address of principal executive offices)</B></FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: center"><FONT STYLE="font-size: 10pt"><B>(Zip Code)</B></FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><U>+972-4-988-9488</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>(Registrant&rsquo;s telephone number,
including area code)</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><U>N/A</U></B><BR>
<FONT STYLE="font-size: 10pt"><B>(Former name, former address and former fiscal year, if changed since last report)</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Securities registered pursuant to Section 12(b) of the Act:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="width: 33%; padding-right: 5.4pt; padding-left: 5.4pt">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; border-bottom: Black 0.5pt solid"><B>Title
        of each class</B></P></TD>
    <TD STYLE="width: 34%; padding-right: 5.4pt; padding-left: 5.4pt">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; border-bottom: Black 0.5pt solid"><B>Trading
        Symbol(s)</B></P></TD>
    <TD STYLE="width: 33%; padding-right: 5.4pt; padding-left: 5.4pt">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; border-bottom: Black 0.5pt solid"><B>Name
        of each exchange on which registered</B></P></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: center; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">common stock, $0.001 par value</FONT></TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: center; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">PLX</FONT></TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: center; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">NYSE American</FONT></TD></TR>
</TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">Indicate by check mark whether the registrant
(1)&nbsp;has filed all reports required to be filed by Section&nbsp;13 or 15(d) of the Securities Exchange Act of 1934 during the
preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2)&nbsp;has been subject
to such filing requirements for the past 90 days.&nbsp;&nbsp;Yes&nbsp;&nbsp;<FONT STYLE="font-family: Wingdings">x</FONT>&nbsp;&nbsp;No&nbsp;&nbsp;<FONT STYLE="font-family: Wingdings">&uml;</FONT>&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">Indicate by check mark whether the registrant
has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (&sect;
232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit
such files). Yes <FONT STYLE="font-family: Wingdings">x</FONT>&nbsp; No&nbsp;&nbsp;<FONT STYLE="font-family: Wingdings">&uml;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">Indicate by check mark whether the
registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an
emerging growth company. See the definitions of &ldquo;large accelerated filer,&rdquo; &ldquo;accelerated filer,&rdquo;
 &ldquo;smaller reporting company,&rdquo; and &ldquo;emerging growth company&rdquo; in Rule 12b-2 of the Exchange Act:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in"></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 26%; text-indent: 0in">Large accelerated filer</TD>
    <TD STYLE="width: 38%; text-indent: 0in"><FONT STYLE="font-family: Wingdings">&uml;</FONT></TD>
    <TD STYLE="width: 25%; text-indent: 0in">Accelerated filer</TD>
    <TD STYLE="width: 11%; text-indent: 0in"><FONT STYLE="font-family: Wingdings"><FONT STYLE="font-family: Wingdings">&#120;</FONT></FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-indent: 0in">Non-accelerated filer</TD>
    <TD STYLE="text-indent: 0in"><FONT STYLE="font-family: Wingdings">&uml;</FONT></TD>
    <TD STYLE="text-indent: 0in">Smaller reporting company</TD>
    <TD STYLE="text-indent: 0in"><FONT STYLE="font-family: Wingdings">&#120;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-indent: 0in"></TD>
    <TD STYLE="text-indent: 0in"><FONT STYLE="font-family: Wingdings"></FONT></TD>
    <TD STYLE="text-indent: 0in">Emerging growth company</TD>
    <TD STYLE="text-indent: 0in"><FONT STYLE="font-family: Wingdings">&uml;</FONT></TD></TR>
</TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">If an emerging growth company, indicate by
check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial
accounting standards provided pursuant to Section 13(a) of the Exchange Act. &#9;&#9;<FONT STYLE="font-family: Wingdings">&uml;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">Indicate by check mark whether the registrant
is a shell company (as defined in Rule 12b-2 of the Exchange Act).&nbsp;&nbsp;Yes&nbsp;&nbsp;<FONT STYLE="font-family: Wingdings">&uml;</FONT>&nbsp;&nbsp;No&nbsp;&nbsp;<FONT STYLE="font-family: Wingdings">x</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">On May&nbsp;1, 2019, approximately 148,382,299
shares of the Registrant&rsquo;s common stock, $0.001 par value, were outstanding.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">&nbsp;&nbsp;</P>

<!-- Field: Rule-Page --><DIV ALIGN="LEFT" STYLE="margin-top: 3pt; margin-bottom: 12pt"><DIV STYLE="font-size: 1pt; border-top: Black 1pt solid; border-bottom: Black 2pt solid; width: 100%">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in"></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">FORM 10-Q</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">TABLE OF CONTENTS</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR>
    <TD STYLE="width: 9%; background-color: White">&nbsp;</TD>
    <TD STYLE="width: 79%; background-color: White">&nbsp;</TD>
    <TD STYLE="width: 12%; background-color: White"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; border-bottom: Black 0.5pt solid"><B>Page</B></P></TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="padding-left: 0.1in; background-color: White">&nbsp;</TD>
    <TD STYLE="padding-left: 0.1in; background-color: White">&nbsp;</TD>
    <TD STYLE="padding-left: 0.1in; text-align: center; background-color: White">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD COLSPAN="3" STYLE="padding-left: 0.1in; text-align: center"><A HREF="#a_002"><B>PART I &ndash; FINANCIAL INFORMATION</B></A></TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="padding-left: 0.1in">&nbsp;</TD>
    <TD STYLE="padding-bottom: 3pt"><A HREF="#a_001"><B>Cautionary Statement Regarding Forward-Looking Statements</B></A></TD>
    <TD STYLE="padding-left: 0.1in; text-align: center"><A HREF="#a_001">ii</A></TD></TR>
<TR STYLE="background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top"><A HREF="#a_003">Item&nbsp;1.</A></TD>
    <TD STYLE="vertical-align: bottom"><A HREF="#a_003">Financial Statements</A></TD>
    <TD STYLE="white-space: nowrap; vertical-align: bottom; padding-right: -0.6pt; padding-left: 0.1in; text-align: center">&nbsp;</TD></TR>
<TR STYLE="background-color: White">
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; padding-left: 0.375in; text-indent: -0.125in"><A HREF="#a_004"> Condensed Consolidated
    Balance Sheets &ndash; <BR>
    As of March&nbsp;31, 2019 (Unaudited) and December&nbsp;31, 2018</A></TD>
    <TD STYLE="white-space: nowrap; vertical-align: bottom; padding-left: 0.1in; text-align: center"><A HREF="#a_004">1</A></TD></TR>
<TR STYLE="background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; padding-left: 0.375in; text-indent: -0.125in"><A HREF="#a_005"> Condensed Consolidated
    Statements of Operations (Unaudited) &ndash;<BR>
    For the Three Months Ended March&nbsp;31, 2019 and 2018</A></TD>
    <TD STYLE="white-space: nowrap; vertical-align: bottom; padding-left: 0.1in; text-align: center"><A HREF="#a_005">2</A></TD></TR>
<TR STYLE="background-color: White">
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; padding-left: 0.375in; text-indent: -0.125in"><A HREF="#a_006">Condensed Consolidated Statements
    of Changes in Capital Deficiency (Unaudited) &ndash;<BR>
    For the Three Months Ended March&nbsp;31, 2019 and 2018</A></TD>
    <TD STYLE="white-space: nowrap; vertical-align: bottom; padding-left: 0.1in; text-align: center"><A HREF="#a_006">3</A></TD></TR>
<TR STYLE="background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; padding-left: 0.375in; text-indent: -0.125in"><A HREF="#a_007"> Condensed Consolidated
    Statements of Cash Flows (Unaudited) &ndash; <BR>
    For the Three Months Ended March&nbsp;31, 2019 and 2018</A></TD>
    <TD STYLE="white-space: nowrap; vertical-align: bottom; padding-left: 0.1in; text-align: center"><A HREF="#a_007">4</A></TD></TR>
<TR STYLE="background-color: White">
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; padding-left: 0.375in; text-indent: -0.125in"><A HREF="#a_008">Notes to Condensed Consolidated
    Financial Statements</A></TD>
    <TD STYLE="white-space: nowrap; vertical-align: bottom; padding-left: 0.1in; text-align: center"><A HREF="#a_008">6</A></TD></TR>
<TR STYLE="background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top"><A HREF="#a_009">Item&nbsp;2.</A></TD>
    <TD STYLE="vertical-align: bottom"><A HREF="#a_009">Management&rsquo;s Discussion and Analysis of Financial Condition and
    Results of Operations</A></TD>
    <TD STYLE="white-space: nowrap; vertical-align: bottom; padding-left: 0.1in; text-align: center"><A HREF="#a_009">11</A></TD></TR>
<TR STYLE="background-color: White">
    <TD STYLE="vertical-align: top"><A HREF="#a_010">Item 3.</A></TD>
    <TD STYLE="vertical-align: bottom"><A HREF="#a_010">Quantitative and Qualitative Disclosures About Market Risk</A></TD>
    <TD STYLE="white-space: nowrap; vertical-align: bottom; padding-left: 0.1in; text-align: center"><A HREF="#a_010">16</A></TD></TR>
<TR STYLE="background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top"><A HREF="#a_011">Item&nbsp;4.</A></TD>
    <TD STYLE="vertical-align: bottom"><A HREF="#a_011">Controls and Procedures</A></TD>
    <TD STYLE="white-space: nowrap; vertical-align: bottom; padding-left: 0.1in; text-align: center"><A HREF="#a_011">16</A></TD></TR>
<TR STYLE="background-color: White">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD COLSPAN="3" STYLE="padding-left: 0.1in; text-align: center"><A HREF="#a_012"><B>PART II &ndash; OTHER INFORMATION</B></A></TD></TR>
<TR STYLE="background-color: White">
    <TD STYLE="vertical-align: top"><A HREF="#a_013">Item&nbsp;1.</A></TD>
    <TD STYLE="vertical-align: bottom"><A HREF="#a_013">Legal Proceedings</A></TD>
    <TD STYLE="white-space: nowrap; vertical-align: bottom; padding-left: 0.1in; text-align: center"><A HREF="#a_013">19</A></TD></TR>
<TR STYLE="background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top"><A HREF="#a_014">Item&nbsp;1A.</A></TD>
    <TD STYLE="vertical-align: bottom"><A HREF="#a_014">Risk Factors</A></TD>
    <TD STYLE="white-space: nowrap; vertical-align: bottom; padding-left: 0.1in; text-align: center"><A HREF="#a_014">19</A></TD></TR>
<TR STYLE="background-color: White">
    <TD STYLE="vertical-align: top"><A HREF="#a_015">Item&nbsp;2.</A></TD>
    <TD STYLE="vertical-align: bottom"><A HREF="#a_015">Unregistered Sales of Equity Securities and Use of Proceeds</A></TD>
    <TD STYLE="white-space: nowrap; vertical-align: bottom; padding-left: 0.1in; text-align: center"><A HREF="#a_015">19</A></TD></TR>
<TR STYLE="background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top"><A HREF="#a_016">Item&nbsp;3.</A></TD>
    <TD STYLE="vertical-align: bottom"><A HREF="#a_016">Defaults Upon Senior Securities</A></TD>
    <TD STYLE="white-space: nowrap; vertical-align: bottom; padding-left: 0.1in; text-align: center"><A HREF="#a_016">19</A></TD></TR>
<TR STYLE="background-color: White">
    <TD STYLE="vertical-align: top"><A HREF="#a_017">Item&nbsp;4.</A></TD>
    <TD STYLE="vertical-align: bottom"><A HREF="#a_017">Mine Safety Disclosures</A></TD>
    <TD STYLE="white-space: nowrap; vertical-align: bottom; padding-left: 0.1in; text-align: center"><A HREF="#a_017">19</A></TD></TR>
<TR STYLE="background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top"><A HREF="#a_018">Item&nbsp;5.</A></TD>
    <TD STYLE="vertical-align: bottom"><A HREF="#a_018">Other Information</A></TD>
    <TD STYLE="white-space: nowrap; vertical-align: bottom; padding-left: 0.1in; text-align: center"><A HREF="#a_018">19</A></TD></TR>
<TR STYLE="background-color: White">
    <TD STYLE="vertical-align: top"><A HREF="#a_019">Item&nbsp;6.</A></TD>
    <TD STYLE="vertical-align: bottom"><A HREF="#a_019">Exhibits</A></TD>
    <TD STYLE="white-space: nowrap; vertical-align: bottom; padding-left: 0.1in; text-align: center"><A HREF="#a_019">20</A></TD></TR>
<TR STYLE="background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; vertical-align: bottom; padding-left: 0.1in; text-align: center">&nbsp;</TD></TR>
<TR STYLE="background-color: White">
    <TD COLSPAN="2" STYLE="vertical-align: top"><A HREF="#a_020">Signatures</A></TD>
    <TD STYLE="white-space: nowrap; vertical-align: bottom; padding-left: 0.1in; text-align: center"><A HREF="#a_020">21</A></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">&nbsp;<!-- Field: Sequence; Type: LowerRoman; Name: PageNo -->i<!-- Field: /Sequence --></TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 4.5pt"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 4.5pt"><B><A NAME="a_001" TITLE="cautiionary statement"></A>CAUTIONARY STATEMENT
REGARDING FORWARD-LOOKING STATEMENTS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 4.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The statements set forth under the caption &ldquo;Management&rsquo;s
Discussion and Analysis of Financial Condition and Results of Operations,&rdquo; and other statements included elsewhere in this
Quarterly Report on Form 10-Q, which are not historical, constitute &ldquo;forward-looking statements&rdquo; within the meanings
of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, or
the Exchange Act, including statements regarding expectations, beliefs, intentions or strategies for the future. When used in this
report, the terms &ldquo;anticipate,&rdquo; &ldquo;believe,&rdquo; &ldquo;estimate,&rdquo; &ldquo;expect,&rdquo; &ldquo;can,&rdquo;
 &ldquo;continue,&rdquo; &ldquo;could,&rdquo; &ldquo;intend,&rdquo; &ldquo;may,&rdquo; &ldquo;plan,&rdquo; &ldquo;potential,&rdquo;
 &ldquo;predict,&rdquo; &ldquo;project,&rdquo; &ldquo;should,&rdquo; &ldquo;will,&rdquo; &ldquo;would&rdquo; and words or phrases
of similar import, as they relate to the Company or our management, are intended to identify forward-looking statements. We intend
that all forward-looking statements be subject to the safe-harbor provisions of the Private Securities Litigation Reform Act of
1995. These forward-looking statements are only predictions and reflect our views as of the date they are made with respect to
future events and financial performance, and we undertake no obligation to update or revise, nor do we have a policy of updating
or revising, any forward-looking statement to reflect events or circumstances after the date on which the statement is made or
to reflect the occurrence of unanticipated events, except as may be required under applicable law. Forward-looking statements are
subject to many risks and uncertainties that could cause our actual results to differ materially from any future results expressed
or implied by the forward-looking statements.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Examples of the risks and uncertainties include, but are not
limited to, the following:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>failure or delay in the commencement or completion of our preclinical studies and clinical trials, which may be caused by several
factors, including: slower than expected rates of patient recruitment; unforeseen safety issues; determination of dosing issues;
lack of effectiveness during clinical trials; inability or unwillingness of medical investigators and institutional review boards
to follow our clinical protocols; inability to monitor patients adequately during or after treatment; and or lack of sufficient
funding to finance our clinical trials;</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>the risk that the results of our clinical trials will not support the applicable claims of superiority, safety or efficacy
and that our product candidates will not have the desired effects or will have undesirable side effects or other unexpected characteristics;</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>the risk that the U.S. Food and Drug Administration, or the FDA, the European Medicines Agency, or the EMA, or foreign regulatory
authorities may not accept or approve a marketing application we file for any of our product candidates;</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>our ability to remediate the material weakness in internal control over financial reporting and to maintain effective internal
control over financial reporting;</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>risks relating to our ability to manage our relationship with Chiesi Farmaceutici S.p.A., or Chiesi, and any other collaborator,
distributor or partner;</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>risks relating to our ability to make scheduled payments of the principal of, to pay interest on or to refinance or satisfy
conversions of our outstanding convertible notes or any other indebtedness;</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>risks relating to the compliance by Funda&ccedil;&atilde;o Oswaldo Cruz, or Fiocruz, an arm of the Brazilian Ministry of Health,
or the Brazilian MoH, with its purchase obligations under our supply and technology transfer agreement, which may have a material
adverse effect on us and may also result in the termination of such agreement;</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>risks related to our ability to maintain compliance with the continued listing standards of the NYSE American;</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>our dependence on performance by third-party providers of services and supplies, including without limitation, clinical trial
services;</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>risks relating to our ability to finance our activities and research programs;</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>delays in preparing and filing applications for regulatory approval of our product candidates in the United States, the European
Union and elsewhere;</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>the impact of development of competing therapies and/or technologies by other companies;</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;&nbsp;</P>

<!-- Field: Page; Sequence: 3 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">&nbsp;<!-- Field: Sequence; Type: LowerRoman; Name: PageNo -->ii<!-- Field: /Sequence --></TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif"></P>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif"></P>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>the risk that products that are competitive to our product candidates may be granted orphan drug status in certain territories
and, therefore, one or more of our product candidates may become be subject to potential marketing and commercialization restrictions;</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>risks related to our supply of drug product to Pfizer Inc., or Pfizer, pursuant to our amended and restated exclusive license
and supply agreement with Pfizer;</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>risks related to the commercialization efforts for taliglucerase alfa in Brazil;</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>risks related to our expectations with respect to the potential commercial value of our product and product candidates;</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>the inherent risks and uncertainties in developing the types of drug platforms and products we are developing;</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>potential product liability risks, and risks of securing adequate levels of product liability and clinical trial insurance
coverage;</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>the possibility of infringing a third-party&rsquo;s patents or other intellectual property rights;</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>the uncertainty of obtaining patents covering our products and processes and  successfully enforcing our intellectual property
rights against third-parties;</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>risks relating to changes in healthcare laws, rules and regulations in the United States or elsewhere; and</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>the possible disruption of our operations due to terrorist activities and armed conflict, including as a result of the disruption
of the operations of regulatory authorities, our subsidiaries, our manufacturing facilities and our customers, suppliers, distributors,
collaborative partners, licensees and clinical trial sites.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Companies in the pharmaceutical and biotechnology industries
have suffered significant setbacks in advanced or late-stage clinical trials, even after obtaining promising earlier trial results
or preliminary findings for such clinical trials. Even if favorable testing data is generated from clinical trials of a drug product,
the FDA, the EMA or foreign regulatory authorities may not accept or approve a marketing application filed by a pharmaceutical
or biotechnology company for the drug product.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">These forward-looking statements reflect our current views with
respect to future events and are based on assumptions and subject to numerous risks and uncertainties. Given these uncertainties,
you should not place undue reliance on these forward-looking statements. These and other risks and uncertainties are detailed under
the heading <FONT STYLE="text-transform: uppercase">&ldquo;</FONT>Risk Factors<FONT STYLE="text-transform: uppercase">&rdquo;</FONT>
in our Annual Report on Form&nbsp;10-K for the year ended December&nbsp;31, 2018, and are described from time to time in the reports
we file with the U.S. Securities and Exchange Commission, or the&nbsp;Commission.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 4 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">&nbsp;<!-- Field: Sequence; Type: LowerRoman; Name: PageNo -->iii<!-- Field: /Sequence --></TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;&nbsp;&nbsp;<B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><A NAME="a_002" TITLE="part1"></A><B>PART I &ndash; FINANCIAL INFORMATION</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><A NAME="a_003" TITLE="item1"></A>Item&nbsp;1. Financial Statements</B></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.75in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>PROTALIX BIOTHERAPEUTICS, INC.</B><BR>
<B><A NAME="a_004"></A>CONDENSED CONSOLIDATED BALANCE SHEETS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">(U.S. dollars in thousands)<BR>
<FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-size: 10pt; text-align: center">&nbsp;</TD><TD STYLE="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt; font-weight: bold; text-align: center; padding-bottom: 1pt">March&nbsp;31, 2019</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt; font-weight: bold; text-align: center; padding-bottom: 1pt">December&nbsp;31, 2018</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-size: 10pt; text-align: center">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1pt; border-bottom: Black 1pt solid">(Unaudited)</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font-size: 1pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-size: 1pt; border-bottom: Black 1pt solid">&nbsp;</TD><TD STYLE="padding-bottom: 1pt; font-size: 1pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt; font-weight: bold; text-align: center">ASSETS</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; text-align: center">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt; font-weight: bold; text-align: left; text-indent: -0.1in; padding-left: 0.1in">CURRENT ASSETS: &#9;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="width: 66%; font-size: 10pt; text-align: left; text-indent: -0.1in; padding-left: 16.2pt">Cash and cash equivalents&#9;</TD><TD STYLE="width: 2%; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="width: 1%; font-size: 10pt; text-align: left">$</TD><TD STYLE="width: 13%; font-size: 10pt; text-align: right">30,363</TD><TD STYLE="width: 1%; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="width: 2%; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="width: 1%; font-size: 10pt; text-align: left">$</TD><TD STYLE="width: 13%; font-size: 10pt; text-align: right">37,808</TD><TD STYLE="width: 1%; font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt; text-align: left; text-indent: -0.1in; padding-left: 16.2pt">Accounts receivable &ndash; Trade&#9;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">8,565</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">4,729</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; text-align: left; text-indent: -0.1in; padding-left: 16.2pt">Other assets&#9;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">1,706</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">1,877</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt; padding-bottom: 1pt; text-indent: -0.1in; padding-left: 16.2pt">Inventories&#9;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">6,707</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">8,569</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; text-align: left; padding-bottom: 1pt; text-indent: -0.1in; padding-left: 0.35in">Total current assets&#9;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">47,341</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">52,983</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt; text-indent: -0.1in; padding-left: 0.1in">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; font-weight: bold; text-align: left; text-indent: -0.1in; padding-left: 0.1in">FUNDS IN RESPECT OF EMPLOYEE RIGHTS UPON RETIREMENT&#9;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">$</TD><TD STYLE="font-size: 10pt; text-align: right">1,801</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">$</TD><TD STYLE="font-size: 10pt; text-align: right">1,758</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt; font-weight: bold; text-align: left; padding-bottom: 1pt; text-indent: -0.1in; padding-left: 0.1in">PROPERTY AND EQUIPMENT, NET&#9;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: right">6,058</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: right">6,390</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; font-weight: bold; text-align: left; padding-bottom: 1pt; text-indent: -0.1in; padding-left: 0.1in">OPERATING LEASE RIGHT OF USE ASSETS</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">5,844</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">-</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt; text-align: left; padding-bottom: 2.5pt; text-indent: -0.1in; padding-left: 0.35in">Total assets&#9;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">61,044</TD><TD STYLE="padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">61,131</TD><TD STYLE="padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; text-indent: -0.1in; padding-left: 0.1in">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt; font-weight: bold; text-align: left">LIABILITIES NET OF CAPITAL DEFICIENCY&#9;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; text-indent: -0.1in; padding-left: 0.1in">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt; font-weight: bold; text-align: left; text-indent: -0.1in; padding-left: 0.1in">CURRENT LIABILITIES: &#9;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; text-align: left; text-indent: -0.1in; padding-left: 16.2pt">Accounts payable and accruals: &#9;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt; text-indent: -0.1in; padding-left: 0.35in">Trade&#9;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">$</TD><TD STYLE="font-size: 10pt; text-align: right">5,870</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">$</TD><TD STYLE="font-size: 10pt; text-align: right">5,211</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; text-indent: -0.1in; padding-left: 0.35in">Other&#9;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">10,480</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">10,274</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt; text-indent: -0.1in; padding-left: 0.25in">Operating lease liabilities</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">1,257</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; text-align: left; text-indent: -0.1in; padding-left: 0.25in; padding-bottom: 1pt">Contracts liability&#9;</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left; border-bottom: Black 1pt solid">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right; border-bottom: Black 1pt solid">9,429</TD><TD STYLE="font-size: 10pt; text-align: left; padding-bottom: 1pt">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left; border-bottom: Black 1pt solid">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right; border-bottom: Black 1pt solid">9,868</TD><TD STYLE="font-size: 10pt; text-align: left; padding-bottom: 1pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt; text-align: left; padding-bottom: 1pt; text-indent: -0.1in; padding-left: 0.35in">Total current liabilities&#9;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">27,036</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">25,353</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; text-indent: -0.1in; padding-left: 0.1in">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt; font-weight: bold; text-align: left; text-indent: -0.1in; padding-left: 0.1in">LONG TERM LIABILITIES:</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; text-align: left; text-indent: -0.1in; padding-left: 16.2pt">Convertible notes&#9;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">$</TD><TD STYLE="font-size: 10pt; text-align: right">48,670</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">$</TD><TD STYLE="font-size: 10pt; text-align: right">47,966</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt; text-align: left; text-indent: -0.1in; padding-left: 16.2pt">Contracts liability&#9;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">32,979</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">33,027</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; text-align: left; text-indent: -0.1in; padding-left: 16.2pt">Liability for employee rights upon retirement&#9;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">2,426</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">2,374</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt; text-align: left; text-indent: -0.1in; padding-left: 16.2pt">Operating lease liabilities</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">4,498</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; text-align: left; padding-bottom: 1pt; text-indent: -0.1in; padding-left: 16.2pt">Other long term liabilities&#9;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">5,290</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">5,292</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt; text-align: left; padding-bottom: 1pt; text-indent: -0.1in; padding-left: 0.35in">Total long term liabilities&#9;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">93,863</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">88,659</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; text-align: left; padding-bottom: 1pt; text-indent: -0.1in; padding-left: 0.35in">Total liabilities&#9;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">120,899</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">114,012</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt; text-indent: -0.1in; padding-left: 0.1in">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; font-weight: bold; text-indent: -0.1in; padding-left: 0.1in">COMMITMENTS</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt; text-indent: -0.1in; padding-left: 45pt">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; font-weight: bold; text-align: left; padding-bottom: 1pt; text-indent: -0.1in; padding-left: 0.1in">CAPITAL DEFICIENCY&#9;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">(59,855</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">)</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">(52,881</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt; text-align: left; padding-bottom: 2.5pt; text-indent: -0.1in; padding-left: 0.35in">Total liabilities net of capital deficiency&#9;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">61,044</TD><TD STYLE="padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">61,131</TD><TD STYLE="padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
</TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0.5in">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>The accompanying notes are an integral
part of the condensed consolidated financial statements.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<!-- Field: Page; Sequence: 5; Options: NewSection; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt; font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-size: 10pt"><B>&nbsp;&nbsp;&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-size: 10pt"><B>PROTALIX
BIOTHERAPEUTICS, INC. </B></FONT><BR>
<FONT STYLE="font-size: 10pt"><B><A NAME="a_005"></A>CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS </B></FONT><BR>
<FONT STYLE="font-size: 10pt">(U.S. dollars in thousands, except per share data) </FONT><BR>
(Unaudited)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="6" STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1pt solid">Three Months Ended</TD><TD STYLE="padding-bottom: 1pt; font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1pt"><DIV STYLE="padding: 0in 0in 1pt; border-bottom: Black 0.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>March</B>&nbsp;<B>31,
2019</B></P> </DIV></TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1pt"><DIV STYLE="padding: 0in 0in 1pt; border-bottom: Black 0.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>March</B>&nbsp;<B>31, 2018</B></P> <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B></B></P> </DIV></TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 68%; font-size: 10pt; font-weight: bold; text-align: left; text-indent: -0.1in; padding-left: 0.1in">REVENUES FROM SELLING GOODS</TD><TD STYLE="width: 2%; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="width: 1%; font-size: 10pt; text-align: left">$</TD><TD STYLE="width: 12%; font-size: 10pt; text-align: right">3,530</TD><TD STYLE="width: 1%; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="width: 2%; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="width: 1%; font-size: 10pt; text-align: left">$</TD><TD STYLE="width: 12%; font-size: 10pt; text-align: right">4,553</TD><TD STYLE="width: 1%; font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; font-weight: bold; text-align: left; text-indent: -0.1in; padding-left: 0.1in">REVENUES FROM LICENSE AND R&amp;D SERVICES</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">6,909</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">2,161</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt; font-weight: bold; text-align: left; padding-bottom: 1pt; text-indent: -0.1in; padding-left: 0.1in">COST OF GOODS SOLD</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">(2,045</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">)</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">(2,924</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; font-weight: bold; text-align: left; text-indent: -0.1in; padding-left: 0.1in">RESEARCH AND DEVELOPMENT EXPENSES (1)</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">(11,701</TD><TD STYLE="font-size: 10pt; text-align: left">)</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">(7,286</TD><TD STYLE="font-size: 10pt; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt; font-weight: bold; text-align: left; padding-bottom: 1pt; text-indent: -0.1in; padding-left: 0.5in">Less &ndash; grants</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">3</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">843</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; font-weight: bold; text-align: left; padding-bottom: 1pt; text-indent: -0.1in; padding-left: 0.1in">RESEARCH AND DEVELOPMENT EXPENSES, NET</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">(11,698</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">)</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">(6,443</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt; font-weight: bold; text-align: left; padding-bottom: 1pt; text-indent: -0.1in; padding-left: 0.1in">SELLING, GENERAL AND ADMINISTRATIVE EXPENSES (2)</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">(2,230</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">)</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">(2,498</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; font-weight: bold; text-align: left; padding-bottom: 1pt; text-indent: -0.1in; padding-left: 0.1in">OPERATING LOSS</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">(5,534</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">)</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">(5,151</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt; font-weight: bold; text-align: left; text-indent: -0.1in; padding-left: 0.1in">FINANCIAL EXPENSES</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">(1,920</TD><TD STYLE="font-size: 10pt; text-align: left">)</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">(2,220</TD><TD STYLE="font-size: 10pt; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; font-weight: bold; text-align: left; text-indent: -0.1in; padding-left: 0.1in; padding-bottom: 1pt">FINANCIAL INCOME</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left; border-bottom: Black 1pt solid">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right; border-bottom: Black 1pt solid">190</TD><TD STYLE="font-size: 10pt; text-align: left; padding-bottom: 1pt">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left; border-bottom: Black 1pt solid">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right; border-bottom: Black 1pt solid">132</TD><TD STYLE="font-size: 10pt; text-align: left; padding-bottom: 1pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt; font-weight: bold; text-align: left; padding-bottom: 1pt; text-indent: -0.1in; padding-left: 0.1in">FINANCIAL EXPENSES, NET</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">(1,730</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">)</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">(2,088</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; font-weight: bold; text-align: left; padding-bottom: 1pt; text-indent: -0.1in; padding-left: 0.1in">LOSS FOR THE PERIOD</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">(7,264</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">)</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">(7,239</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt; font-weight: bold; text-align: left; padding-bottom: 2.5pt; text-indent: -0.1in; padding-left: 0.1in">NET LOSS PER SHARE OF COMMON STOCK &ndash; BASIC AND DILUTED</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">(0.05</TD><TD STYLE="padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left">)</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">(0.05</TD><TD STYLE="padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; font-weight: bold; text-align: left; padding-bottom: 2.5pt; text-indent: -0.1in; padding-left: 0.1in">WEIGHTED AVERAGE NUMBER OF SHARES OF COMMON STOCK USED IN COMPUTING LOSS PER SHARE-BASIC AND DILUTED</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">148,382,299</TD><TD STYLE="padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">145,305,982</TD><TD STYLE="padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt; font-weight: bold; text-align: left; text-indent: -0.1in; padding-left: 34.2pt">(1) Includes share-based compensation</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">$</TD><TD STYLE="font-size: 10pt; text-align: right">178</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">$</TD><TD STYLE="font-size: 10pt; text-align: right">42</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; font-weight: bold; text-align: left; padding-bottom: 1pt; text-indent: -0.1in; padding-left: 34.2pt">(2) Includes share-based compensation</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">112</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">20</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: -0.35pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: -0.35pt"><B>The accompanying
notes are an integral part of the condensed consolidated financial statements.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: -0.35pt">&nbsp;</P>

<!-- Field: Page; Sequence: 6; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt; font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: -0.35pt"><B>&nbsp;&nbsp;&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>PROTALIX BIOTHERAPEUTICS, INC. </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><A NAME="a_006"></A>CONDENSED CONSOLIDATED STATEMENTS OF
CHANGES IN </B><BR>
<B>CAPITAL DEFICIENCY</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">(U.S. dollars in thousands)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">(Unaudited)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt; font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt; font-weight: bold; text-align: center">Common</TD><TD STYLE="font-size: 10pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-size: 10pt; font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt; font-weight: bold; text-align: center">Common</TD><TD STYLE="font-size: 10pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-size: 10pt; font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt; font-weight: bold; text-align: center">Additional<BR>
Paid&ndash;In</TD><TD STYLE="font-size: 10pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-size: 10pt; font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt; font-weight: bold; text-align: center">Accumulated</TD><TD STYLE="font-size: 10pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-size: 10pt; text-align: center">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1pt solid">Stock (1)</TD><TD STYLE="padding-bottom: 1pt; font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1pt solid">Stock</TD><TD STYLE="padding-bottom: 1pt; font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1pt solid">Capital</TD><TD STYLE="padding-bottom: 1pt; font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1pt solid">Deficit</TD><TD STYLE="padding-bottom: 1pt; font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1pt solid">Total</TD><TD STYLE="padding-bottom: 1pt; font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1pt solid">Number of<BR> Shares</TD><TD STYLE="padding-bottom: 1pt; font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="14" STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1pt solid">Amount</TD><TD STYLE="padding-bottom: 1pt; font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 40%; font-size: 10pt; font-weight: bold; text-indent: -0.1in; padding-left: 0.1in">Balance at&nbsp;January 1, 2018</TD><TD STYLE="width: 2%; font-size: 10pt; font-weight: bold">&nbsp;</TD>
    <TD STYLE="width: 1%; font-size: 10pt; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="width: 8%; font-size: 10pt; font-weight: bold; text-align: right">143,728,797</TD><TD STYLE="width: 1%; font-size: 10pt; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="width: 2%; font-size: 10pt; font-weight: bold">&nbsp;</TD>
    <TD STYLE="width: 1%; font-size: 10pt; font-weight: bold; text-align: left">$</TD><TD STYLE="width: 8%; font-size: 10pt; font-weight: bold; text-align: right">144</TD><TD STYLE="width: 1%; font-size: 10pt; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="width: 2%; font-size: 10pt; font-weight: bold">&nbsp;</TD>
    <TD STYLE="width: 1%; font-size: 10pt; font-weight: bold; text-align: left">$</TD><TD STYLE="width: 8%; font-size: 10pt; font-weight: bold; text-align: right">266,495</TD><TD STYLE="width: 1%; font-size: 10pt; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="width: 2%; font-size: 10pt; font-weight: bold">&nbsp;</TD>
    <TD STYLE="width: 1%; font-size: 10pt; font-weight: bold; text-align: left">$</TD><TD STYLE="width: 8%; font-size: 10pt; font-weight: bold; text-align: right">(296,096</TD><TD STYLE="width: 1%; font-size: 10pt; font-weight: bold; text-align: left">)</TD><TD STYLE="width: 2%; font-size: 10pt; font-weight: bold">&nbsp;</TD>
    <TD STYLE="width: 1%; font-size: 10pt; font-weight: bold; text-align: left">$</TD><TD STYLE="width: 8%; font-size: 10pt; font-weight: bold; text-align: right">(29,457</TD><TD STYLE="width: 1%; font-size: 10pt; font-weight: bold; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; font-weight: bold; text-indent: -0.1in; padding-left: 0.1in">Changes during the three-month period ended March&nbsp;31, 2018:</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt; text-align: left; text-indent: -0.1in; padding-left: 0.1in">Share-based compensation related to stock options&#9;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">46</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">46</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; text-align: left; text-indent: -0.1in; padding-left: 0.1in">Share-based compensation related to restricted stock award&#9;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">29,898</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right"><FONT STYLE="font-size: 10pt">*</FONT></TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">16</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">16</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt; text-align: left; text-indent: -0.1in; padding-left: 0.1in">Convertible notes conversions&#9;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">1,811,260</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">2</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">1,190</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">1,192</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; text-align: left; padding-bottom: 1pt; text-indent: -0.1in; padding-left: 0.1in">Net loss for the period&#9;</TD><TD STYLE="font-size: 1pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 1pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 1pt; text-align: right">&nbsp;</TD><TD STYLE="padding-bottom: 1pt; font-size: 1pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 1pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 1pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 1pt; text-align: right">&nbsp;</TD><TD STYLE="padding-bottom: 1pt; font-size: 1pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 1pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 1pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 1pt; text-align: right">&nbsp;</TD><TD STYLE="padding-bottom: 1pt; font-size: 1pt; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">(7,239</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">)</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">(7,239</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt; font-weight: bold; padding-bottom: 2.5pt; text-indent: -0.1in; padding-left: 0.1in">Balance at March&nbsp;31, 2018&#9;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font: bold 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; font: bold 10pt Times New Roman, Times, Serif; text-align: right">145,569,955</TD><TD STYLE="padding-bottom: 2.5pt; font: bold 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font: bold 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font: bold 10pt Times New Roman, Times, Serif; text-align: right">146</TD><TD STYLE="padding-bottom: 2.5pt; font: bold 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font: bold 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font: bold 10pt Times New Roman, Times, Serif; text-align: right">267,747</TD><TD STYLE="padding-bottom: 2.5pt; font: bold 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font: bold 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font: bold 10pt Times New Roman, Times, Serif; text-align: right">(303,335</TD><TD STYLE="padding-bottom: 2.5pt; font: bold 10pt Times New Roman, Times, Serif; text-align: left">)</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font: bold 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font: bold 10pt Times New Roman, Times, Serif; text-align: right">(35,442</TD><TD STYLE="padding-bottom: 2.5pt; font: bold 10pt Times New Roman, Times, Serif; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; font-weight: bold; padding-bottom: 2.5pt; text-indent: -0.1in; padding-left: 0.1in">Balance at January 1, 2019</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font: bold 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; font: bold 10pt Times New Roman, Times, Serif; text-align: right">148,382,299</TD><TD STYLE="padding-bottom: 2.5pt; font: bold 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font: bold 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font: bold 10pt Times New Roman, Times, Serif; text-align: right">148</TD><TD STYLE="padding-bottom: 2.5pt; font: bold 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font: bold 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font: bold 10pt Times New Roman, Times, Serif; text-align: right">269,524</TD><TD STYLE="padding-bottom: 2.5pt; font: bold 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font: bold 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font: bold 10pt Times New Roman, Times, Serif; text-align: right">(322,553</TD><TD STYLE="padding-bottom: 2.5pt; font: bold 10pt Times New Roman, Times, Serif; text-align: left">)</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font: bold 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font: bold 10pt Times New Roman, Times, Serif; text-align: right">(52,881</TD><TD STYLE="padding-bottom: 2.5pt; font: bold 10pt Times New Roman, Times, Serif; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt; font-weight: bold; text-indent: -0.1in; padding-left: 0.1in">Changes during the three-month period ended March&nbsp;31, 2019:</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; text-align: left; text-indent: -0.1in; padding-left: 0.1in">Share-based compensation related to stock options&#9;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; font-weight: bold">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; font-weight: bold; text-align: right">290</TD><TD STYLE="font-size: 10pt; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; font-weight: bold">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; font-weight: bold; text-align: right">290</TD><TD STYLE="font-size: 10pt; font-weight: bold; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt; text-align: left; padding-bottom: 2.5pt; text-indent: -0.1in; padding-left: 0.1in">Net loss for the period</TD><TD STYLE="font-size: 0.5pt; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-size: 0.5pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; font-size: 0.5pt; text-align: right">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt; font-size: 0.5pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 0.5pt; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-size: 0.5pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; font-size: 0.5pt; text-align: right">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt; font-size: 0.5pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 0.5pt; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-size: 0.5pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; font-size: 0.5pt; text-align: right">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt; font-size: 0.5pt; text-align: left">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font: bold 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; font: bold 10pt Times New Roman, Times, Serif; text-align: right">(7,264</TD><TD STYLE="padding-bottom: 2.5pt; font: bold 10pt Times New Roman, Times, Serif; text-align: left">)</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font: bold 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; font: bold 10pt Times New Roman, Times, Serif; text-align: right">(7,264</TD><TD STYLE="padding-bottom: 2.5pt; font: bold 10pt Times New Roman, Times, Serif; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; font-weight: bold; padding-bottom: 2.5pt; text-indent: -0.1in; padding-left: 0.1in">Balance at March&nbsp;31, 2019&#9;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font: bold 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; font: bold 10pt Times New Roman, Times, Serif; text-align: right">148,382,299</TD><TD STYLE="padding-bottom: 2.5pt; font: bold 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font: bold 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font: bold 10pt Times New Roman, Times, Serif; text-align: right">148</TD><TD STYLE="padding-bottom: 2.5pt; font: bold 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font: bold 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font: bold 10pt Times New Roman, Times, Serif; text-align: right">269,814</TD><TD STYLE="padding-bottom: 2.5pt; font: bold 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font: bold 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font: bold 10pt Times New Roman, Times, Serif; text-align: right">(329,817</TD><TD STYLE="padding-bottom: 2.5pt; font: bold 10pt Times New Roman, Times, Serif; text-align: left">)</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font: bold 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font: bold 10pt Times New Roman, Times, Serif; text-align: right">(59,855</TD><TD STYLE="padding-bottom: 2.5pt; font: bold 10pt Times New Roman, Times, Serif; text-align: left">)</TD></TR>
</TABLE>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0px">&nbsp;</TD>
    <TD STYLE="width: 24px">*</TD>
    <TD STYLE="text-align: justify">Represents an amount less than $1.</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0px">&nbsp;</TD>
    <TD STYLE="width: 24px">(1)</TD>
    <TD STYLE="text-align: justify">Common Stock, $0.001 par value; Authorized &ndash; as of March&nbsp;31, 2019 and 2018 - 250,000,000.</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: -0.35pt"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: -0.35pt"><B>The accompanying
notes are an integral part of the condensed consolidated financial statements.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: -0.35pt">&nbsp;&nbsp;</P>

<!-- Field: Page; Sequence: 7; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt; font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>PROTALIX BIOTHERAPEUTICS, INC. </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><A NAME="a_007"></A>CONDENSED CONSOLIDATED STATEMENTS OF
CASH FLOWS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">(U.S. dollars in thousands)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">(Unaudited)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>


<P STYLE="margin: 0"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD><TD STYLE="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="7" STYLE="font-size: 10pt; font-weight: bold; text-align: center; padding-bottom: 1pt; border-bottom: Black 1pt solid">Three Months Ended &nbsp;&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-size: 10pt; padding-bottom: 1pt"><B>&nbsp;</B></TD><TD STYLE="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"><B>&nbsp;</B></TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid"><B>&nbsp;March&nbsp;31,
    2019 &nbsp;</B></TD><TD STYLE="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"><B>&nbsp;</B></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><B>&nbsp;</B></TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1pt solid">&nbsp; <B>March&nbsp;31,
    2018 &nbsp;&nbsp;</B></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt; font-weight: bold; text-align: left; text-indent: -0.1in; padding-left: 0.1in">CASH FLOWS FROM OPERATING ACTIVITIES:</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="width: 68%; font-size: 10pt; text-align: left; text-indent: -0.1in; padding-left: 16.2pt">Net loss&#9;</TD><TD STYLE="width: 2%; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="width: 1%; font-size: 10pt; text-align: left">$</TD><TD STYLE="width: 12%; font-size: 10pt; text-align: right">(7,264</TD><TD STYLE="width: 1%; font-size: 10pt; text-align: left">)</TD><TD STYLE="width: 2%; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="width: 1%; font-size: 10pt; text-align: left">$</TD><TD STYLE="width: 12%; font-size: 10pt; text-align: right">(7,239</TD><TD STYLE="width: 1%; font-size: 10pt; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt; text-align: left; text-indent: -0.1in; padding-left: 16.2pt">Adjustments required to reconcile net loss to net cash used in operating activities: &#9;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; text-indent: -0.1in; padding-left: 16.2pt">Share based compensation&#9;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">290</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">62</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt; text-indent: -0.1in; padding-left: 16.2pt">Depreciation&#9;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">405</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">430</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; text-align: left; text-indent: -0.1in; padding-left: 16.2pt">Financial expenses, net (mainly exchange differences) &#9;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">20</TD><TD STYLE="font-size: 10pt; text-align: left"></TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">28</TD><TD STYLE="font-size: 10pt; text-align: left"></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt; text-align: left; text-indent: -0.1in; padding-left: 16.2pt">Changes in accrued liability for employee rights upon retirement&#9;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">(24</TD><TD STYLE="font-size: 10pt; text-align: left">)</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">(124</TD><TD STYLE="font-size: 10pt; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; text-align: left; text-indent: -0.1in; padding-left: 16.2pt">Gain on amounts funded in respect of employee rights upon retirement&#9;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">(44</TD><TD STYLE="font-size: 10pt; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt; text-align: left; padding-left: 9pt"> Net loss in connection with conversions&nbsp;of convertible notes&#9;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">218</TD><TD STYLE="font-size: 10pt; text-align: left"></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; text-align: left; text-indent: -0.1in; padding-left: 16.2pt">Amortization of debt issuance costs and debt discount&#9;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">704</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">619</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt; text-align: left; text-indent: -0.1in; padding-left: 16.2pt">Issuance of shares for interest payment in connection with conversions of convertible notes&#9;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">205</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; text-align: left; text-indent: -0.1in; padding-left: 16.2pt">Changes in operating assets and liabilities:</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt; text-align: left; text-indent: -0.1in; padding-left: 0.35in">Increase (decrease) in contracts liability (including non-current portion)&#9;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">(487</TD><TD STYLE="font-size: 10pt; text-align: left">)</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">18</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; text-align: left; text-indent: -0.1in; padding-left: 0.35in">Increase in accounts receivable and other assets&#9;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">(3,608</TD><TD STYLE="font-size: 10pt; text-align: left">)</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">(3,512</TD><TD STYLE="font-size: 10pt; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt; text-align: left; text-indent: -0.1in; padding-left: 0.35in">Changes in right of use assets</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">(36</TD><TD STYLE="font-size: 10pt; text-align: left">)</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; text-align: left; text-indent: -0.1in; padding-left: 0.35in">Decrease in inventories&#9;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">1,862</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">814</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt; text-align: left; text-indent: -0.1in; padding-left: 0.35in">Increase (decrease) in accounts
    payable and accruals&#9;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">864</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">(1,009</TD><TD STYLE="font-size: 10pt; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; text-align: left; padding-bottom: 1pt; text-indent: -16.2pt; padding-left: 0.35in">Increase
    (decrease) in other long term liabilities&#9;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">(2</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">)</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">121</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt; text-align: left; padding-bottom: 1pt; text-indent: -11.45pt; padding-left: 16.2pt">Net cash used in operating activities&#9;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">(7,276</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">)</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">(9,413</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; text-indent: -0.1in; padding-left: 0.1in">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt; font-weight: bold; text-align: left; text-indent: -0.1in; padding-left: 0.1in">CASH FLOWS FROM INVESTING ACTIVITIES:</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; text-align: left; text-indent: -0.1in; padding-left: 16.2pt">Purchase of property and equipment&#9;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">$</TD><TD STYLE="font-size: 10pt; text-align: right">(170</TD><TD STYLE="font-size: 10pt; text-align: left">)</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">$</TD><TD STYLE="font-size: 10pt; text-align: right">(249</TD><TD STYLE="font-size: 10pt; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt; text-align: left; text-indent: -0.1in; padding-left: 16.2pt">Increase in restricted deposit&#9;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">(214</TD><TD STYLE="font-size: 10pt; text-align: left">)</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">(188</TD><TD STYLE="font-size: 10pt; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; text-align: left; padding-bottom: 1pt; text-indent: -0.1in; padding-left: 16.2pt">Amounts funded in respect of employee rights upon retirement, net&#9;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">13</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">109</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt; text-align: left; padding-bottom: 1pt; text-indent: -0.1in; padding-left: 16.2pt">Net cash used in investing activities&#9;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">(371</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">)</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">(328</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; font-weight: bold; text-align: left; text-indent: -0.1in; padding-left: 9pt">EFFECT OF EXCHANGE RATE CHANGES ON CASH</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt; font-weight: bold; text-align: left; padding-bottom: 1pt; text-indent: -0.1in; padding-left: 9pt">&nbsp;&nbsp;AND CASH EQUIVALENTS&#9;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">202</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">(103</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; font-weight: bold; text-align: left; text-indent: -0.1in; padding-left: 0.1in">NET DECREASE IN CASH AND CASH EQUIVALENTS&#9;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">(7,445</TD><TD STYLE="font-size: 10pt; text-align: left">)</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">(9,844</TD><TD STYLE="font-size: 10pt; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt; font-weight: bold; text-align: left; text-indent: -0.1in; padding-left: 0.1in">BALANCE OF CASH AND CASH EQUIVALENTS</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; font-weight: bold; text-indent: -0.1in; padding-left: 0.1in; padding-bottom: 1pt">&nbsp;&nbsp;AT BEGINNING OF PERIOD&#9;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt; border-bottom: Black 1pt solid">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right; border-bottom: Black 1pt solid">37,808</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt; border-bottom: Black 1pt solid">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right; border-bottom: Black 1pt solid">51,163</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt; font-weight: bold; text-align: left; padding-bottom: 2.5pt; text-indent: -0.1in; padding-left: 0.1in">BALANCE OF CASH AND CASH EQUIVALENTS AT END OF PERIOD&#9;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">30,363</TD><TD STYLE="padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">41,319</TD><TD STYLE="padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
</TABLE>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: -0.35pt"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: -0.35pt"><B>The accompanying
notes are an integral part of the condensed consolidated financial statements.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: -0.35pt"><B>&nbsp;</B></P>

<!-- Field: Page; Sequence: 8; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt; font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: -0.35pt"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>PROTALIX BIOTHERAPEUTICS, INC. </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>CONDENSED CONSOLIDATED STATEMENTS OF
CASH FLOWS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">(U.S. dollars in thousands)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 12.9pt 0pt 0; text-align: center">(Unaudited)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">(Continued) - 2</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-size: 10pt; text-align: center">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="6" STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1pt solid">Three Months Ended</TD><TD STYLE="padding-bottom: 1pt; font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1pt solid">March&nbsp;31, 2019</TD><TD STYLE="padding-bottom: 1pt; font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1pt solid">March&nbsp;31, 2018</TD><TD STYLE="padding-bottom: 1pt; font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt; font-weight: bold; text-align: left; text-indent: -0.1in; padding-left: 0.1in">SUPPLEMENTARY INFORMATION ON INVESTING AND FINANCING ACTIVITIES NOT INVOLVING CASH FLOWS:</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="width: 72%; font-size: 10pt; text-align: left; padding-bottom: 2.5pt; text-indent: -0.1in; padding-left: 16.2pt">Purchase of property and equipment</TD><TD STYLE="width: 2%; font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="width: 1%; border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="width: 10%; border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">128</TD><TD STYLE="width: 1%; padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="width: 2%; font-size: 10pt; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="width: 1%; border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">$</TD><TD STYLE="width: 10%; border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right">342</TD><TD STYLE="width: 1%; padding-bottom: 2.5pt; font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt; text-align: left; padding-bottom: 2.5pt; text-indent: -0.1in; padding-left: 16.2pt">Convertible notes conversions</TD><TD STYLE="font-size: 10pt; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 2.5pt; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt; font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">987</TD><TD STYLE="padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; text-indent: -0.1in; padding-left: 16.2pt">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt; font-weight: bold; text-align: left; text-indent: -0.1in; padding-left: 0.1in">SUPPLEMENTARY DISCLOSURE ON CASH FLOWS</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; text-align: left; padding-bottom: 2.5pt; text-indent: -0.1in; padding-left: 16.2pt">Interest paid</TD><TD STYLE="font-size: 10pt; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 2.5pt; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt; font-size: 10pt; text-align: right"></TD><TD STYLE="padding-bottom: 2.5pt; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right">145</TD><TD STYLE="padding-bottom: 2.5pt; font-size: 10pt; text-align: left">&nbsp;</TD></TR>
</TABLE>




<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: -0.35pt"><B>The accompanying
notes are an integral part of the condensed consolidated financial statements.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<!-- Field: Split-Segment; Name: notes -->
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 9; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt; font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>PROTALIX BIOTHERAPEUTICS, INC.</B></P><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><A NAME="a_008"></A>NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</B>&nbsp;</P><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">(Unaudited)</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>NOTE 1 - SIGNIFICANT ACCOUNTING POLICIES </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><B>a.</B></TD><TD><B>General</B></TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0in">Protalix BioTherapeutics, Inc. (collectively
with its subsidiaries, the &ldquo;Company&rdquo;) and its wholly-owned subsidiaries, Protalix Ltd. and Protalix B.V. (the &ldquo;Subsidiaries&rdquo;),
are biopharmaceutical companies focused on the development and commercialization of recombinant therapeutic proteins based on the
Company&rsquo;s proprietary ProCellEx<SUP>&reg;</SUP> protein expression system (&ldquo;ProCellEx&rdquo;). To date, the Company
has successfully developed taliglucerase alfa (marketed under the name alfataliglicerase in Brazil and certain other Latin American
countries and Elelyso<SUP>&reg;</SUP> in the rest of the territories) for the treatment of Gaucher disease that has been approved
for marketing in the United States, Brazil, Israel and other markets. The Company has a number of product candidates in varying
stages of the clinical development process. The Company&rsquo;s strategy is to develop proprietary recombinant proteins that are
therapeutically superior to existing recombinant proteins currently marketed for the same indications.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0in">The Company&rsquo;s product pipeline
currently includes, among other candidates:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0in">(1) pegunigalsidase alfa, or PRX-102,
a therapeutic protein candidate for the treatment of Fabry disease, a rare, genetic lysosomal disorder;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0in">(2) alidornase alfa, or PRX-110,
a proprietary plant cell recombinant human Deoxyribonuclease 1, or DNase, under development for the treatment of Cystic Fibrosis,
to be administered by inhalation; and</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0in">(3) OPRX-106, the Company&rsquo;s
oral antiTNF product candidate which is being developed as an orally-delivered anti-inflammatory treatment using plant cells as
a natural capsule for the expressed protein.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0in">Obtaining marketing approval with
respect to any product candidate in any country is dependent on the Company&rsquo;s ability to implement the necessary regulatory
steps required to obtain such approvals. The Company cannot reasonably predict the outcome of these activities.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0in">On October&nbsp;19, 2017, Protalix
Ltd. and Chiesi Farmaceutici S.p.A. (&ldquo;Chiesi&rdquo;) entered into an Exclusive License and Supply Agreement (the &ldquo;Chiesi
Ex-US Agreement&rdquo;) pursuant to which Chiesi was granted an exclusive license for all markets outside of the United States
to commercialize pegunigalsidase alfa. On July&nbsp;23, 2018, Protalix Ltd. entered into an Exclusive License and Supply Agreement
with Chiesi (the &ldquo;Chiesi US Agreement&rdquo;) with respect to the commercialization of pegunigalsidase alfa in the United
States.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0in">Under each of the Chiesi Ex-US Agreement
and the Chiesi US Agreement (collectively,&nbsp;the &ldquo;Chiesi Agreements&rdquo;), Chiesi made an upfront payment to Protalix Ltd. of $25.0&nbsp;million in
connection with the execution of the agreement. In addition, under the Chiesi Ex-US Agreement, Protalix Ltd. is entitled to additional
payments of up to $25.0&nbsp;million in pegunigalsidase alfa development costs, capped at $10.0&nbsp;million per year, and to receive
additional payments of up to $320.0&nbsp;million, in the aggregate, in regulatory and commercial milestone payments. Under the
Chiesi US Agreement, Protalix Ltd. is entitled to payments of up to a maximum of $20.0&nbsp;million to cover development costs
for pegunigalsidase alfa, subject to a maximum of $7.5&nbsp;million per year, and to receive an additional up to a maximum of $760.0&nbsp;million,
in the aggregate, in regulatory and commercial milestone payments.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0in">Under the terms of both of the Chiesi
Agreements, Protalix Ltd. will manufacture all of the pegunigalsidase alfa needed under the agreements, subject to certain exceptions,
and Chiesi will purchase pegunigalsidase alfa from Protalix, subject to certain terms and conditions. Under the Chiesi Ex-US Agreement,
Chiesi is required to make tiered payments of 15% to 35% of its net sales, depending on the amount of annual sales outside of the
United States, as consideration for product supply. Under the Chiesi US Agreement, Chiesi is required to make tiered payments of
15% to 40% of its net sales, depending on the amount of annual sales in the United States, as consideration for product supply.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0in">&nbsp;&nbsp;</P>

<!-- Field: Page; Sequence: 10; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt; font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>PROTALIX BIOTHERAPEUTICS, INC.</B></P><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</B>&nbsp;</P><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">(Unaudited)</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in"><B>NOTE 1 - SIGNIFICANT ACCOUNTING POLICIES
(continued):</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0in">Since its approval by the FDA, taliglucerase
alfa has been marketed by Pfizer in accordance with the exclusive license and supply agreement entered into&nbsp;between Protalix Ltd. and Pfizer,
which is referred to herein as the Pfizer Agreement. In October 2015, the Company sold to Pfizer its share in the collaboration
created under the Pfizer Agreement for the commercialization of Elelyso. As part of the sale, the Company agreed to transfer its
rights to Elelyso in Israel to Pfizer while gaining full rights to it in Brazil. Under the Amended Pfizer Agreement, Pfizer is
entitled to all of the revenues, and is responsible for 100% of expenses globally for Elelyso, excluding Brazil where the Company
is responsible for all expenses and retains all revenues.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0in">On June&nbsp;18, 2013, the Company
entered into a Supply and Technology Transfer Agreement (the &ldquo;Brazil Agreement&rdquo;) with Fiocruz, an arm of the Brazilian
MoH, for taliglucerase alfa. Fiocruz&rsquo;s purchases of alfataliglicerase to date have been significantly below certain agreed
upon purchase milestones and, accordingly, the Company has the right to terminate the Brazil Agreement. Notwithstanding the termination
right, the Company is, at this time, continuing to supply alfataliglicerase to Fiocruz under the Brazil Agreement, and patients
continue to be treated with alfataliglicerase in Brazil.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0in">Based on its current cash resources
and commitments, the Company believes it will be able to maintain its current planned development activities and the corresponding
level of expenditures for at least 12 months from the date of approval of the financial statements as of March&nbsp;31, 2019,
although no assurance can be given that it will not need additional funds prior to such time. If there are unexpected increases
in general and administrative expenses or research and development expenses, the Company may need to seek additional financing.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><B>b.</B></TD><TD STYLE="padding-right: 81.35pt"><B>Basis of presentation</B></TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">The accompanying unaudited condensed consolidated
financial statements of the Company have been prepared in accordance with accounting principles generally accepted in the United
States (&ldquo;GAAP&rdquo;) for interim financial information. Accordingly, they do not include all of the information and notes
required by GAAP for annual financial statements. In the opinion of management, all adjustments (of a normal recurring nature)
considered necessary for a fair statement of the results for the interim periods presented have been included. Operating results
for the interim period are not necessarily indicative of the results that may be expected for the full year.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">These unaudited condensed consolidated financial statements
should be read in conjunction with the audited consolidated financial statements in the Annual Report on Form 10-K for the year
ended December&nbsp;31, 2018, filed by the Company with the Commission. The comparative balance sheet at December&nbsp;31, 2018
has been derived from the audited financial statements at that date.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><B>c.</B></TD><TD STYLE="padding-right: 81.35pt"><B>Net loss per share</B></TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">Basic and diluted loss per share (&ldquo;LPS&rdquo;)
are computed by dividing net loss by the weighted average number of shares of the Company&rsquo;s common stock, par value $0.001
per share (the &ldquo;Common Stock&rdquo;), outstanding for each period.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">Diluted LPS is calculated in continuing operations.
The calculation of diluted LPS does not include 73,800,491 and 78,202,020 shares of Common Stock underlying outstanding options
and restricted shares of Common Stock and shares issuable upon conversion of outstanding convertible notes for the three months
ended March&nbsp;31, 2018 and 2019, respectively, because the effect would be anti-dilutive.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<!-- Field: Page; Sequence: 11; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt; font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>PROTALIX BIOTHERAPEUTICS, INC.</B></P><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</B>&nbsp;</P><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">(Unaudited)</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>NOTE 1 - SIGNIFICANT ACCOUNTING POLICIES (continued):</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><B>d.</B></TD><TD STYLE="padding-right: 81.35pt"><B>Recently adopted standards</B></TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">In February 2016, the Financial Accounting Standards
Board (&ldquo;FASB&rdquo;) issued ASU No. 2016-02, Leases (Topic 842), which supersedes the existing guidance for lease accounting,
Leases (Topic 840). The new standard requires a lessee to record assets and liabilities on its balance sheet for all leases with
terms longer than 12 months. Leases will be classified as either finance or operating, with classification affecting the pattern
of expense recognition in the lessee&rsquo;s income statement. The Company adopted this standard as of January 1, 2019 on a modified
retrospective basis and will not restate comparative periods. The Company will elect the package of practical expedients permitted
under the transition guidance within the new standard which, among other things, allows the Company to carryforward the historical
lease classification. The Company made an accounting policy election to keep leases with an initial term of 12 months or less off
of its balance sheet. The Company recognized those lease payments in its statements of operations on a straight-line basis over
the lease period.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">As of the adoption date, the Company
recognized an operating lease asset and liability of $5.9&nbsp;million and $5.7 million, respectively, as of January&nbsp;1,
2019 on its balance sheet.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><B>e.</B></TD><TD STYLE="padding-right: 81.35pt"><B>Newly issued accounting pronouncements</B></TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<P STYLE="margin: 0pt 0 0pt 0.5in">In June 2018, the FASB issued ASU 2018-07, &ldquo;Compensation &ndash; Stock Compensation (Topic 718):
Improvements to Nonemployee Share-based Payment Accounting&rdquo; that expands the scope of ASC Topic 718 to include share-based
payment transactions for acquiring goods and services from nonemployees. An entity should apply the requirements of ASC Topic 718
to nonemployee awards except for certain exemptions specified in ASU 2018-07. The guidance is effective for fiscal years beginning
after December 15, 2018, including interim reporting periods within that fiscal year. Early adoption is permitted, but no earlier
than an entity&rsquo;s adoption date of Topic 606. The Company does not expect the adoption of ASU 2018-07 to have a material impact
on its financial statements.</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in"></P>

<!-- Field: Page; Sequence: 12; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt; font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>PROTALIX BIOTHERAPEUTICS, INC.</B></P><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</B>&nbsp;</P><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">(Unaudited)</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in"><B>NOTE 2 - INVENTORIES</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in">a.</TD><TD>Inventories at March&nbsp;31, 2019 and December&nbsp;31, 2018 consisted of the following:</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" ALIGN="RIGHT" STYLE="border-collapse: collapse; width: 94%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-size: 10pt; text-align: center">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1pt solid">March&nbsp;31,</TD><TD STYLE="padding-bottom: 1pt; font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1pt solid">December&nbsp;31,</TD><TD STYLE="padding-bottom: 1pt; font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-size: 10pt; padding-bottom: 1pt">(<I>U.S. dollars in thousands)</I></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1pt solid">2019</TD><TD STYLE="padding-bottom: 1pt; font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1pt solid">2018</TD><TD STYLE="padding-bottom: 1pt; font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 68%; font-size: 10pt; text-align: left">Raw materials&#9;</TD><TD STYLE="width: 2%; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="width: 1%; font-size: 10pt; text-align: left">$</TD><TD STYLE="width: 12%; font-size: 10pt; text-align: right">3,047</TD><TD STYLE="width: 1%; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="width: 2%; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="width: 1%; font-size: 10pt; text-align: left">$</TD><TD STYLE="width: 12%; font-size: 10pt; text-align: right">3,792</TD><TD STYLE="width: 1%; font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; text-align: left">Work in progress&#9;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">45</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt; text-align: left; padding-bottom: 1pt">Finished goods&#9;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">3,615</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">4,777</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; text-align: left; padding-bottom: 2.5pt">Total inventory&#9;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">6,707</TD><TD STYLE="padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">8,569</TD><TD STYLE="padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
</TABLE><BR STYLE="clear: both">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 56.9pt"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in">b.</TD><TD>During the year ended December&nbsp;31, 2018 and the three months ended March&nbsp;31, 2019, the Company recorded approximately
$1.1&nbsp;million and $65,000, respectively, for write-down of inventory under cost of goods sold.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>NOTE 3 &ndash; FAIR VALUE MEASUREMENT</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.45pt">The Company measures fair value and discloses fair
value measurements for financial assets and liabilities. Fair value is based on the price that would be received from the sale
of an asset, or paid to transfer a liability, in an orderly transaction between market participants at the measurement date.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.45pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.45pt">The accounting standard establishes a fair value
hierarchy that prioritizes observable and unobservable inputs used to measure fair value into three broad levels, which are described
below:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.45pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.45pt">Level 1: Quoted prices (unadjusted) in active markets
that are accessible at the measurement date for assets or liabilities. The fair value hierarchy gives the highest priority to Level
1 inputs.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.45pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.45pt">Level 2: Observable prices that are based on inputs
not quoted on active markets, but corroborated by market data.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.45pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.45pt">Level 3: Unobservable inputs are used when little
or no market data is available. The fair value hierarchy gives the lowest priority to Level 3 inputs.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.45pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.45pt">In determining fair value, the Company utilizes
valuation techniques that maximize the use of observable inputs and minimize the use of unobservable inputs to the extent possible
and considers counterparty credit risk in its assessment of fair value.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.45pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.45pt">The fair value of the financial instruments included
in the working capital of the Company is usually identical or close to their carrying value. The fair value of the convertible
notes derivative is based on Level 3 measurement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.45pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.45pt">The fair value of the
$57.9&nbsp;million principal amount of the Company&rsquo;s outstanding 7.50% convertible promissory notes due 2021 (the
 &ldquo;2021 Notes&rdquo;) as of March&nbsp;31, 2019 is approximately $64.5&nbsp;million based on a Level 3 measurement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.45pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.45pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">The
Company prepared a valuation of the fair value of the Company&rsquo;s outstanding 2021 Notes (a Level 3 valuation) as of March</FONT>&nbsp;<FONT STYLE="font-family: Times New Roman, Times, Serif">31, 2019.
The value of these notes was estimated by implementing the binomial model. The liability component was valued based on
the Income Approach. The following parameters were used:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.45pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 55%; font: 10pt Times New Roman, Times, Serif; margin-left: 0.5in">
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; padding-bottom: 1pt; padding-left: 5.4pt">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt; font: bold 10pt Times New Roman, Times, Serif; text-align: right"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; border-bottom: Black 0.5pt solid"><B>2021 Notes</B></P></TD><TD STYLE="padding-bottom: 1pt; font: bold 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 76%; font-size: 10pt; text-indent: -10pt; padding-left: 10pt">Stock price (USD)</TD><TD STYLE="width: 2%; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="width: 1%; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="width: 20%; font-size: 10pt; text-align: center">0.44</TD><TD STYLE="width: 1%; font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; text-align: left; text-indent: -10pt; padding-left: 10pt">Expected term</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: center">2.63</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt; text-align: left; text-indent: -10pt; padding-left: 10pt">Risk free rate</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: center">2.21<FONT STYLE="font-size: 10pt">%</FONT></TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; text-indent: -10pt; padding-left: 10pt">Volatility</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: center">81.56%</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt; text-indent: -10pt; padding-left: 10pt">Yield</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: center">12.6%</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 70.75pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>NOTE 4 &ndash; OPERATING LEASES</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">The Company is a party to a number of
lease agreements for its facilities, the latest of which has been extended until 2021. The Company has the option to extend
certain of such agreements on two additional occasions for additional five-year periods each, for a total of 10 additional
years. During the extended lease period, the aggregate monthly rental payments will increase by 7.5% - 10% for each option.
The Company expects to exercise these options in future periods. As of March&nbsp;31, 2019, the Company provided bank
guarantees of approximately $412,000, in the aggregate, to secure the fulfillment of its obligations under the lease
agreements. As of December 31, 2018, the future minimum lease payments required under the operating leases for such premises
are approximately $758,000, $758,000 and $621,000, for fiscal years 2019 through 2021, respectively.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">The Company entered into several
three-year leases for vehicles which are regularly amended as new vehicles are leased. As of December 31, 2018, the future
minimum lease payments for the years ending December&nbsp;31, 2019, 2020 and 2021 are approximately $474,000, $333,000
and $82,000, respectively.</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 70.75pt">&nbsp;</P>


<!-- Field: Page; Sequence: 13; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt; font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>PROTALIX BIOTHERAPEUTICS, INC.</B></P><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</B>&nbsp;</P><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">(Unaudited)</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.45pt"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.45pt"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in"></P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>NOTE 4 &ndash; OPERATING LEASES (continued):</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0in">The following table sets forth data regarding the Company&rsquo;s operating leases for the three months ended March 31, 2019:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&nbsp;&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 55%; font: 10pt Times New Roman, Times, Serif; margin-left: 0.5in">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-size: 10pt; padding-bottom: 1pt">(<I>U.S. dollars in thousands)</I></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1pt solid">March 31, 2019</TD><TD STYLE="padding-bottom: 1pt; font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 76%; font-size: 10pt; text-align: left; padding-bottom: 2.5pt; padding-left: 0in">Operating lease costs&#9;</TD><TD STYLE="width: 2%; font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="width: 1%; border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="width: 20%; border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">292</TD><TD STYLE="width: 1%; padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; text-align: left; padding-bottom: 2.5pt; padding-left: 0in">Cash paid for amounts included in the&nbsp;measurement of lease liabilities&#9;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">328</TD><TD STYLE="padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt; text-align: left; padding-left: 0in; padding-bottom: 2.5pt">Right of use assets obtained in exchange&nbsp;for new operating lease liabilities&#9;</TD><TD STYLE="font-size: 10pt; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left; border-bottom: Black 2.5pt double">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right; border-bottom: Black 2.5pt double">52</TD><TD STYLE="font-size: 10pt; text-align: left; padding-bottom: 2.5pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; text-align: left; padding-bottom: 2.5pt; padding-left: 0in">Weighted average remaining lease term&nbsp;(in years)&#9;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">10.84</TD><TD STYLE="padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt; padding-bottom: 2.5pt; padding-left: 0in">Weighted average discount rate</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">12.58</TD><TD STYLE="padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left">%</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 56.9pt"></P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in"></P>




<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">The following table sets forth a maturity analysis
of the Company&rsquo;s operating lease liabilities as of March&nbsp;31, 2019:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 55%; font: 10pt Times New Roman, Times, Serif; margin-left: 0.5in">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-size: 10pt; padding-bottom: 1pt">(<I>U.S. dollars in thousands)</I></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1pt solid">March 31, 2019</TD><TD STYLE="padding-bottom: 1pt; font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 76%; font-size: 10pt; text-align: left; padding-left: 0in">2019 (excluding the three months ended March 31, 2019)</TD><TD STYLE="width: 2%; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="width: 1%; font-size: 10pt; text-align: left">$</TD><TD STYLE="width: 20%; font-size: 10pt; text-align: right">947</TD><TD STYLE="width: 1%; font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; text-align: left; padding-left: 0in">2020</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">$</TD><TD STYLE="font-size: 10pt; text-align: right">1,135</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt; text-align: left; padding-left: 0in">2021</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">$</TD><TD STYLE="font-size: 10pt; text-align: right">888</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; text-align: left; padding-left: 0in">2022</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">$</TD><TD STYLE="font-size: 10pt; text-align: right">774</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt; text-align: left; padding-left: 0in">2023</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">$</TD><TD STYLE="font-size: 10pt; text-align: right">770</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; padding-bottom: 2.5pt; padding-left: 0in">After 2024&#9;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">6,380</TD><TD STYLE="padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt; text-align: left; padding-bottom: 2.5pt; padding-left: 0in">Total undiscounted cash flows&#9;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">10,894</TD><TD STYLE="padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; padding-bottom: 2.5pt; padding-left: 0in">Less: imputed interest</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">5,139</TD><TD STYLE="padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt; text-align: left; padding-bottom: 2.5pt; padding-left: 0in">Present value of lease
    liabilities&#9;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">5,755</TD><TD STYLE="padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
</TABLE>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>NOTE 5 &ndash; REVENUES</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0in">The following table summarizes the
Company&rsquo;s disaggregation of revenues:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0in"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 55%; margin-left: 0.5in">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="6" STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1pt solid; white-space: nowrap">Three
    months ended March&nbsp;31,</TD><TD STYLE="padding-bottom: 1pt; font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-size: 10pt; font-style: italic; padding-bottom: 1pt">(U.S. dollars in thousands)</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1pt solid; white-space: nowrap">2019</TD><TD STYLE="padding-bottom: 1pt; font: bold 10pt Times New Roman, Times, Serif; white-space: nowrap">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; white-space: nowrap">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1pt solid; white-space: nowrap">2018</TD><TD STYLE="padding-bottom: 1pt; font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 56%; font-size: 10pt; padding-left: 0.375in">Pfizer&#9;</TD><TD STYLE="width: 2%; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="width: 1%; font-size: 10pt; text-align: left; white-space: nowrap">$</TD><TD STYLE="width: 18%; font-size: 10pt; text-align: right; white-space: nowrap">1,356</TD><TD STYLE="width: 1%; font-size: 10pt; text-align: left; white-space: nowrap">&nbsp;</TD><TD STYLE="width: 2%; font-size: 10pt; white-space: nowrap">&nbsp;</TD>
    <TD STYLE="width: 1%; font-size: 10pt; text-align: left; white-space: nowrap">$</TD><TD STYLE="width: 18%; font-size: 10pt; text-align: right; white-space: nowrap">1,980</TD><TD STYLE="width: 1%; font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; padding-bottom: 1pt; padding-left: 0.375in">Brazil&#9;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left; white-space: nowrap">$</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right; white-space: nowrap">2,174</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left; white-space: nowrap">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; white-space: nowrap">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left; white-space: nowrap">$</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right; white-space: nowrap">2,573</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt; padding-bottom: 1pt; padding-left: 0.375in">Total revenues from selling goods</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font: bold 10pt Times New Roman, Times, Serif; text-align: left; white-space: nowrap">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font: bold 10pt Times New Roman, Times, Serif; text-align: right; white-space: nowrap">3,530</TD><TD STYLE="padding-bottom: 2.5pt; font: bold 10pt Times New Roman, Times, Serif; text-align: left; white-space: nowrap">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; white-space: nowrap">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font: bold 10pt Times New Roman, Times, Serif; text-align: left; white-space: nowrap">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font: bold 10pt Times New Roman, Times, Serif; text-align: right; white-space: nowrap">4,553</TD><TD STYLE="padding-bottom: 2.5pt; font: bold 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; padding-bottom: 1pt; padding-left: 0.375in">Revenues from license and R&amp;D services</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font: bold 10pt Times New Roman, Times, Serif; text-align: left; white-space: nowrap">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font: bold 10pt Times New Roman, Times, Serif; text-align: right; white-space: nowrap">6,909</TD><TD STYLE="padding-bottom: 2.5pt; font: bold 10pt Times New Roman, Times, Serif; text-align: left; white-space: nowrap">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; white-space: nowrap">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font: bold 10pt Times New Roman, Times, Serif; text-align: left; white-space: nowrap">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font: bold 10pt Times New Roman, Times, Serif; text-align: right; white-space: nowrap">2,161</TD><TD STYLE="padding-bottom: 2.5pt; font: bold 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
</TABLE>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0in">The following table sets forth data regarding
the Company&rsquo;s contract liability:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 55%; margin-left: 0.5in">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-size: 10pt; padding: 0; text-indent: 0">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="6" STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1pt solid; white-space: nowrap">Three months ended March&nbsp;31,</TD><TD STYLE="padding-bottom: 1pt; font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font: italic 10pt Times New Roman, Times, Serif; padding: 0; border-bottom: Black 1pt solid; text-indent: 0">(U.S. dollars in thousands)</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1pt solid; white-space: nowrap">2019</TD><TD STYLE="padding-bottom: 1pt; font: bold 10pt Times New Roman, Times, Serif; white-space: nowrap">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; white-space: nowrap">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1pt solid; white-space: nowrap">2018</TD><TD STYLE="padding-bottom: 1pt; font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 56%; font: 10pt Times New Roman, Times, Serif; padding: 0; text-align: left; text-indent: 0">Contract liabilities at the beginning of the period&#9;</TD><TD STYLE="width: 2%; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left; white-space: nowrap">$</TD><TD STYLE="width: 18%; font: 10pt Times New Roman, Times, Serif; text-align: right; white-space: nowrap">42,895</TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left; white-space: nowrap">&nbsp;</TD><TD STYLE="width: 2%; font: 10pt Times New Roman, Times, Serif; white-space: nowrap">&nbsp;</TD>
    <TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left; white-space: nowrap">$</TD><TD STYLE="width: 18%; font: 10pt Times New Roman, Times, Serif; text-align: right; white-space: nowrap">25,015</TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0; text-align: left; text-indent: 0">Additions during the period</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; white-space: nowrap">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right; white-space: nowrap">6,422</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; white-space: nowrap">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; white-space: nowrap">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; white-space: nowrap">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right; white-space: nowrap">2,179</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0; text-align: left; text-indent: 0">Revenue recognized during the period &#9;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left; white-space: nowrap">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right; white-space: nowrap">(6,909</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left; white-space: nowrap">)</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; white-space: nowrap">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left; white-space: nowrap">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right; white-space: nowrap">(2,161</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0; text-align: left; text-indent: 0">Contract liabilities at the end of the period</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left; white-space: nowrap">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right; white-space: nowrap">42,408</TD><TD STYLE="padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left; white-space: nowrap">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; white-space: nowrap">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left; white-space: nowrap">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right; white-space: nowrap">25,033</TD><TD STYLE="padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in"><B>&nbsp;</B>&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0in">The following table represents the Company's
unsatisfied performance obligation:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 55%; margin-left: 0.5in">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-size: 10pt; padding: 0; text-indent: 0">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="6" STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1pt solid">March&nbsp;31,</TD><TD STYLE="padding-bottom: 1pt; font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font: italic 10pt Times New Roman, Times, Serif; padding: 0; border-bottom: Black 1pt solid; text-indent: 0">(U.S. dollars in thousands)</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1pt solid">2019</TD><TD STYLE="padding-bottom: 1pt; font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1pt solid">2018</TD><TD STYLE="padding-bottom: 1pt; font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 56%; font: 10pt Times New Roman, Times, Serif; padding: 0; text-align: left; text-indent: 0">Unsatisfied performance obligation&#9;</TD><TD STYLE="width: 2%; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="width: 18%; font: 10pt Times New Roman, Times, Serif; text-align: right">64,581</TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="width: 2%; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="width: 18%; font: 10pt Times New Roman, Times, Serif; text-align: right">91,033</TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
</TABLE>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in"><B>NOTE 6 &ndash; SUBSEQUENT
EVENTS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The Company has evaluated subsequent events through the date
on which the consolidated financial statements were available to be issued and no subsequent events were identified.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<!-- Field: Page; Sequence: 14; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt; font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><A NAME="a_009"></A><B>Item&nbsp;2. Management&rsquo;s Discussion and Analysis of
Financial Condition and Results of Operations </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in"><I>You should read the following discussion
and analysis of our financial condition and results of operations together with our financial statements and the consolidated financial
statements and the related notes included elsewhere in this Form 10-Q and in our Annual Report on Form 10-K for the year ended
December</I>&nbsp;<I>31, 2018. Some of the information contained in this discussion and analysis, particularly with respect to
our plans and strategy for our business and related financing, includes forward-looking statements that involve risks and uncertainties.
You should read &ldquo;Risk Factors&rdquo; in our Annual Report on Form 10-K for the year ended December</I>&nbsp;<I>31, 2018 for
a discussion of important factors that could cause actual results to differ materially from the results described in or implied
by the forward-looking statements contained in the following discussion and analysis. </I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Overview</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">We are a biopharmaceutical company focused on the development
and commercialization of recombinant therapeutic proteins based on our proprietary ProCellEx<SUP>&reg;</SUP> protein expression
system. We developed our first commercial drug product, Elelyso<SUP>&reg;</SUP>, using our ProCellEx system and we are now focused
on utilizing the system to develop a pipeline of proprietary, clinically superior versions of recombinant therapeutic proteins
that primarily target large, established pharmaceutical markets and that in most cases rely upon known biological mechanisms of
action. With our experience to date, we believe ProCellEx will enable us to develop additional proprietary recombinant proteins
that are therapeutically superior to existing recombinant proteins currently marketed for the same indications, including applying
the unique properties of our ProCellEx system for the oral delivery of therapeutic proteins.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">On
October</FONT>&nbsp;<FONT STYLE="font-family: Times New Roman, Times, Serif">19, 2017, Protalix Ltd., our
wholly-owned subsidiary, and Chiesi entered into the Chiesi Ex-US Agreement pursuant to which Chiesi was granted an exclusive
license for all markets outside of the United States to commercialize pegunigalsidase alfa. </FONT>Pegunigalsidase alfa is
our chemically modified version of the recombinant protein alpha-Galactosidase-A protein that is currently being evaluated in
phase&nbsp;III clinical trials for the treatment of Fabry disease<FONT STYLE="font-family: Times New Roman, Times, Serif">.
Under the terms and conditions of the Chiesi Ex-US Agreement, Protalix Ltd. retained the right to commercialize
pegunigalsidase alfa in the United States. Under the Chiesi Ex-US Agreement, Chiesi made an upfront payment to Protalix Ltd.
of $25.0</FONT>&nbsp;<FONT STYLE="font-family: Times New Roman, Times, Serif">million in connection with the execution of the
agreement and Protalix Ltd. is entitled to additional payments of up to $25.0</FONT>&nbsp;<FONT STYLE="font-family: Times New Roman, Times, Serif">million
in development costs in the aggregate, capped at $10.0</FONT>&nbsp;<FONT STYLE="font-family: Times New Roman, Times, Serif">million
per year. Protalix Ltd. is also eligible to receive an additional up to a maximum of $320.0</FONT>&nbsp;<FONT STYLE="font-family: Times New Roman, Times, Serif">million,
in the aggregate, in regulatory and commercial milestone payments. Protalix Ltd. agreed to manufacture all of the PRX-102
needed for all purposes under the agreement, subject to certain exceptions, and Chiesi will purchase pegunigalsidase alfa
from Protalix, subject to certain terms and conditions. Chiesi is required to make tiered payments of 15% to 35% of its net
sales, depending on the amount of annual sales, as consideration for the supply of pegunigalsidase alfa. </FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">On
July</FONT>&nbsp;<FONT STYLE="font-family: Times New Roman, Times, Serif">23, 2018, Protalix Ltd. entered into the Chiesi US Agreement
with respect to the development and commercialization of pegunigalsidase alfa in the United States. Under the terms of the Chiesi
US Agreement, Protalix Ltd. granted to Chiesi exclusive licensing rights for the commercialization of PRX-102 in the United States.
Protalix Ltd. is entitled to an upfront, non-refundable, non-creditable payment of $25.0</FONT>&nbsp;<FONT STYLE="font-family: Times New Roman, Times, Serif">million
from Chiesi and additional payments of up to a maximum of $20.0</FONT>&nbsp;<FONT STYLE="font-family: Times New Roman, Times, Serif">million, in the aggregate,
to cover development costs for PRX-102, subject to a maximum of $7.5</FONT>&nbsp;<FONT STYLE="font-family: Times New Roman, Times, Serif">million
per year. Protalix Ltd. is also eligible to receive an additional up to a maximum of $760.0</FONT>&nbsp;<FONT STYLE="font-family: Times New Roman, Times, Serif">million,
in the aggregate, in regulatory and commercial milestone payments. Chiesi will also make tiered payments of 15% to 40% of its net
sales under the Chiesi US Agreement to Protalix Ltd., depending on the amount of annual sales, subject to certain terms and conditions,
as consideration for product supply.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">In December 2017, the European Commission granted Orphan Drug
Designation for pegunigalsidase alfa for the treatment of Fabry disease. The designation was granted after the European Medicine
Agency&rsquo;s Committee for Orphan Medicinal Products, or the COMP, issued a positive opinion supporting the designation noting
that we had established that there was medically plausible evidence that pegunigalsidase alfa will provide a significant benefit
over existing approved therapies in the European Union for the treatment of Fabry disease. The COMP cited clinical and non-clinical
justifications we provided to establish the significant benefit of pegunigalsidase alfa, noting that the COMP considered the justifications
to constitute a clinically relevant advantage. Orphan Drug Designation for pegunigalsidase alfa qualifies Protalix Ltd. for access
to a centralized marketing authorization procedure, including applications for inspections and for protocol assistance. If the
orphan drug designation is maintained at the time pegunigalsidase alfa is approved for marketing in the European Union, if at all,
we expect that PRX-102 will benefit from 10 years of market exclusivity within the European Union. The market exclusivity will
not have any effect on Fabry disease treatments already approved at that time.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<!-- Field: Page; Sequence: 15; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt; font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">In January 2018, the FDA granted Fast Track designation to PRX-102.
Fast Track designation is a process designed to facilitate the development and expedite the review of drugs and vaccines for serious
conditions that fill an unmet medical need.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">On
May</FONT>&nbsp;<FONT STYLE="font-family: Times New Roman, Times, Serif">1, 2012, the FDA approved for sale our first commercial
product, taliglucerase alfa for injection, an ERT for the long-term treatment of adult patients with a confirmed diagnosis of type
1 Gaucher disease. Subsequently, taliglucerase alfa was approved for marketing by the regulatory authorities of other countries.
Taliglucerase alfa is marketed under the name alfataliglicerase in Brazil and certain other Latin American countries, and under
the name Elelyso in other territories.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">Since
its approval by the FDA, taliglucerase alfa has been marketed by Pfizer, as provided in the Pfizer Agreement. In </FONT>October
2015, we entered into the Amended Pfizer Agreement which amends and restates the Pfizer Agreement in its entirety. Pursuant to
the Amended Pfizer Agreement, we sold to Pfizer our share in the collaboration created under the initial Pfizer Agreement for the
commercialization of Elelyso. As part of the sale, we agreed to transfer our rights to Elelyso in Israel to Pfizer, while gaining
full rights to Elelyso in Brazil. We will continue to manufacture drug substance for Pfizer, subject to certain terms and conditions.
Under the Amended Pfizer Agreement, Pfizer is responsible for 100% of expenses, and entitled to all revenues globally for Elelyso,
excluding Brazil, where we are responsible for all expenses and retain all revenues.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">For the first 10-year period after the execution of the Amended
Pfizer Agreement, we have agreed to sell drug substance to Pfizer for the production of Elelyso, and Pfizer maintains the right
to extend the supply period for up to two additional 30-month periods subject to certain terms and conditions. Any failure to comply
with our supply commitments may subject us to substantial financial penalties, which will have a material adverse effect on our
business, results of operations and financial condition. The Amended Pfizer Agreement also includes customary provisions regarding
cooperation for regulatory matters, patent enforcement, termination, indemnification and insurance requirements.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">On
June</FONT>&nbsp;<FONT STYLE="font-family: Times New Roman, Times, Serif">18, 2013, we entered into the Brazil Agreement with </FONT>Fiocruz,
an arm of the Brazilian MoH, <FONT STYLE="font-family: Times New Roman, Times, Serif">for taliglucerase alfa. </FONT>Fiocruz&rsquo;s
purchases of <FONT STYLE="font-family: Times New Roman, Times, Serif">alfataliglicerase</FONT> to date have been significantly
below certain agreed upon purchase milestones and, accordingly, we have the right to terminate the Brazil Agreement. Notwithstanding
our termination right, we are, at this time, continuing to supply <FONT STYLE="font-family: Times New Roman, Times, Serif">alfataliglicerase</FONT>
to Fiocruz under the Brazil Agreement, and patients continue to be treated with <FONT STYLE="font-family: Times New Roman, Times, Serif">alfataliglicerase</FONT>
in Brazil.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">We are developing an innovative product pipeline using our ProCellEx
protein expression system. Our product pipeline currently includes, among other candidates:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">(1) pegunigalsidase alfa, or PRX-102, a therapeutic protein
candidate for the treatment of Fabry disease, a rare, genetic lysosomal disorder in humans, currently in an ongoing phase III clinical
trial.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">(2) alidornase alfa, or PRX-110, a proprietary plant cell recombinant
human Deoxyribonuclease 1 under development for the treatment of Cystic Fibrosis, or CF, to be administered by inhalation. We recently
completed a phase IIa efficacy and safety study of alidornase alfa for the treatment of CF.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">(3)
OPRX-106, </FONT>our oral antiTNF product candidate <FONT STYLE="font-family: Times New Roman, Times, Serif">which is being developed
as </FONT>an orally-delivered anti-inflammatory treatment using plant cells as a natural capsule for the expressed protein. We
released final data generated in our phase II clinical trial of OPRX-106 for the treatment of ulcerative colitis in March 2018<FONT STYLE="font-family: Times New Roman, Times, Serif">.</FONT>
Additional data was released in June 2018.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">We have licensed the rights to commercialize taliglucerase alfa
worldwide (other than Brazil) to Pfizer, and the rights to commercialize pegunigalsidase alfa worldwide to Chiesi. Otherwise, we
hold the worldwide commercialization rights to our other proprietary development candidates. In addition, we continuously evaluate
potential strategic marketing partnerships as well as collaboration programs with biotechnology and pharmaceutical companies and
academic research institutes.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 16; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt; font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->12<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Critical Accounting Policies</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Our significant accounting policies are more fully described
in Note&nbsp;1 to our consolidated financial statements appearing in this Quarterly Report. There have been no material changes
to our critical accounting policies since we filed our Annual Report on Form 10-K for the year ended December&nbsp;31, 2018. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The discussion and analysis of our financial condition and results
of operations is based on our financial statements, which we prepared in accordance with U.S. generally accepted accounting principles.
The preparation of these financial statements requires us to make estimates and assumptions that affect the reported amounts of
assets and liabilities and the disclosure of contingent assets and liabilities at the date of the financial statements, as well
as the reported revenues and expenses during the reporting periods. On an ongoing basis, we evaluate such estimates and judgments,
including those described in greater detail below. We base our estimates on historical experience and on various other factors
that we believe are reasonable under the circumstances, the results of which form the basis for making judgments about the carrying
value of assets and liabilities that are not readily apparent from other sources. Actual results may differ from these estimates
under different assumptions or conditions.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Results of Operations</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>Three months ended March 31, 2019 compared to the three
months ended March 31, 2018</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><I>Revenues from Selling Goods</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">We recorded revenues from selling goods of $3.5&nbsp;million
during the three months ended March&nbsp;31, 2019, a decrease of $1.0&nbsp;million, or 22%, compared to revenues of $4.6&nbsp;million
for the three months ended March&nbsp;31, 2018. The decrease resulted primarily from a decrease of $0.6&nbsp;million in sales of
drug substance to Pfizer.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><I>Revenues from License and R&amp;D Services</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">We recorded revenues from license and R&amp;D services of $6.9&nbsp;million
for the three months ended March&nbsp;31, 2019, an increase of $4.7&nbsp;million compared to revenues of $2.2&nbsp;million for
the three months ended March&nbsp;31, 2018. Revenues from the license agreements represent the revenues we recognized in connection
with the Chiesi Agreements.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><I>Cost of Goods Sold</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Cost of goods sold was $2.0&nbsp;million for the three months
ended March&nbsp;31, 2019, a decrease of $0.9&nbsp;million, or 30%, from cost of goods sold of $2.9&nbsp;million for the three
months ended March&nbsp;31, 2018. The decrease is mainly due to a decrease in selling goods.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 17; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt; font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->13<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><I>Research and Development Expenses, Net</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Research and development expenses were $11.7&nbsp;million for
the three months ended March&nbsp;31, 2019, an increase of $5.3&nbsp;million, or 82%, compared to $6.4&nbsp;million of research
and development expenses for the three months ended March&nbsp;31, 2018. The increase resulted primarily from an increase of $3.0&nbsp;million
in clinical trial related costs.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">We expect research and development expenses to continue to be
our primary expense as we enter into a more advanced stage of preclinical and clinical trials for certain of our product candidates,
primarily with respect to pegunigalsidase alfa<FONT STYLE="font-family: Times New Roman, Times, Serif">.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><I>Selling, General and Administrative Expenses</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Selling, general and administrative expenses were $2.2&nbsp;million
for the three months ended March&nbsp;31, 2019, a decrease of $0.3&nbsp;million, or 11%, compared to $2.5&nbsp;million for the
three months ended March&nbsp;31, 2018.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><I>Financial Expenses, net </I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">Financial expenses net
were $1.7&nbsp;million for the three months ended March&nbsp;31, 2019, a decrease of $0.4&nbsp;million, or 17%, compared
to financial expenses net of $2.1&nbsp;million for the three months ended March&nbsp;31, 2018. Financial expenses are
comprised primarily from interest expense on outstanding convertible notes of $1.1&nbsp;million and $1.2&nbsp;million for the
three months ended March&nbsp;31, 2019 and 2018, respectively.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Liquidity and Capital Resources</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><I>Sources of Liquidity</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">As a result of our significant
research and development expenditures and the lack of significant revenue from sales of taliglucerase alfa, we have
generated operating losses from our continuing operations since our inception. To date, we have funded our operations
primarily with net proceeds equal to $31.3&nbsp;million from the sale of shares of convertible preferred and ordinary shares
of Protalix Ltd., and an additional $14.1&nbsp;million in connection with the exercise of warrants issued in connection with
the sale of such shares, through December&nbsp;31, 2008. In addition, on October&nbsp;25, 2007, we generated gross proceeds
of $50.0&nbsp;million in connection with an underwritten public offering of our common stock and on each of March&nbsp;23,
2011 and February&nbsp;22, 2012, we generated gross proceeds of $22.0&nbsp;million and $27.2&nbsp;million, respectively,
in connection with underwritten public offerings of our common stock. We believe that the funds currently available to us
are sufficient to satisfy our capital needs for at least 12 months.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">In addition to the foregoing, on September&nbsp;18, 2013, we
completed a private placement of $69.0&nbsp;million in aggregate principal amount of our 2018 Notes, including $9.0&nbsp;million
aggregate principal amount of 2018 Notes related to the offering&rsquo;s initial purchaser&rsquo;s over-allotment option, which
was exercised in full. In December 2016, we completed a private placement of $22.5&nbsp;million in aggregate principal amount of
2021 Notes. Finally, on July&nbsp;25, 2017, we completed a private placement of an additional $10.0&nbsp;million in aggregate principal
amount of 2021 Notes.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">Pfizer
paid Protalix Ltd. $60.0</FONT>&nbsp;<FONT STYLE="font-family: Times New Roman, Times, Serif">million as an upfront payment in
connection with the execution of the Pfizer Agreement and subsequently paid to Protalix Ltd. an additional $5.0</FONT>&nbsp;<FONT STYLE="font-family: Times New Roman, Times, Serif">million
upon Protalix Ltd.&rsquo;s meeting a certain milestone. Protalix Ltd. also received a milestone payment of $25.0</FONT>&nbsp;million
<FONT STYLE="font-family: Times New Roman, Times, Serif">in connection with the FDA&rsquo;s approval of taliglucerase alfa in May
2012. </FONT>Pfizer has also paid Protalix Ltd. $8.3&nbsp;million in connection with the successful achievement of certain milestones
under a clinical development agreement between Pfizer and Protalix Ltd. In connection with the execution of the Amended Pfizer
Agreement, we received a $36.0&nbsp;million payment from Pfizer, and Pfizer purchased 5,649,079 shares of our common stock for
$10.0&nbsp;million.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">In
the fourth quarter of 2017, Chiesi made a payment to Protalix Ltd. of $25.0</FONT>&nbsp;<FONT STYLE="font-family: Times New Roman, Times, Serif">million
in connection with the execution of the Chiesi Ex-US Agreement and in the third quarter of 2018, Chiesi made a payment to
Protalix Ltd. of $25.0</FONT>&nbsp;<FONT STYLE="font-family: Times New Roman, Times, Serif">million in connection with the
execution of the Chiesi US Agreement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 18; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt; font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->14<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><I>Cash Flows</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">Net cash used in operations was $7.3&nbsp;million
for the three months ended March&nbsp;31, 2019. The net loss for the three months ended March&nbsp;31, 2019 of $7.3&nbsp;million
was further increased by a $3.6&nbsp;million increase in accounts receivable, but was partially offset by an increase of $0.9&nbsp;million
in accounts payable and accruals and by a decrease in inventories of $1.9 million. Net cash used in investing activities for the
three months ended March&nbsp;31, 2019 was $0.4 million and consisted primarily of purchases of property and equipment, and an
increase in restricted deposit.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">Net cash used in operations was $9.4&nbsp;million
for the three months ended March&nbsp;31, 2018. The net loss for the three months ended March&nbsp;31, 2018 of $7.2&nbsp;million
was further increased by a $3.5&nbsp;million increase in accounts receivable, and a decrease of $1.0&nbsp;million in accounts payable
and accruals, but was partially offset by a decrease in inventories of $814,000. Net cash used in investing activities for the
three months ended March&nbsp;31, 2018 was $328,000 and consisted primarily of purchases of property and equipment, and an increase
in restricted deposit.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in"><I>Future Funding Requirements </I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">We expect to continue to incur significant expenditures in the
near future, including significant research and development expenses related primarily to the clinical trials of PRX-102. We believe
that our existing cash and cash equivalents and commitments will be sufficient for at least 12 months. We have based this estimate
on assumptions that are subject to change and may prove to be wrong, and we may be required to use our available capital resources
sooner than we currently expect. Because of the numerous risks and uncertainties associated with the development and commercialization
of our product candidates, we are unable to estimate the amounts of increased capital outlays and operating expenditures associated
with our current and anticipated clinical trials.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">Our future capital requirements will depend
on many other factors, including our progress in commercializing <FONT STYLE="font-family: Times New Roman, Times, Serif">alfataliglicerase</FONT>
in Brazil, the progress and results of our clinical trials, particularly our clinical trials of pegunigalsidase alfa, the duration
and cost of discovery and preclinical development and laboratory testing and clinical trials for our product candidates, conversions
of our 2021 Notes from time to time, the timing and outcome of regulatory review of our product candidates, the costs involved
in preparing, filing, prosecuting, maintaining, defending and enforcing patent claims and other intellectual property rights, the
number and development requirements of other product candidates that we pursue and the costs of commercialization activities, including
product marketing, sales and distribution.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">We may need to finance our future cash needs through corporate
collaboration, licensing or similar arrangements, public or private equity offerings and/or debt financings. We currently do not
have any commitments for future external funding, except with respect to the development-related payments and milestone payments
that may become payable under the Chiesi Agreements. We may need to raise additional funds more quickly if one or more of our assumptions
prove to be incorrect or if we choose to expand our product development efforts more rapidly than we presently anticipate. We may
also decide to raise additional funds even before we need them if the conditions for raising capital are favorable. Any sale of
additional equity or debt securities will likely result in dilution to our stockholders. The incurrence of indebtedness would result
in increased fixed obligations and could also result in covenants that would restrict our operations. Additional equity or debt
financing, grants or corporate collaboration and licensing arrangements may not be available on acceptable terms, if at all. If
adequate funds are not available, we may be required to delay, reduce the scope of or eliminate our research and development programs,
reduce our planned commercialization efforts or obtain funds through arrangements with collaborators or others that may require
us to relinquish rights to certain product candidates that we might otherwise seek to develop or commercialize independently.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Effects of Inflation and Currency Fluctuations </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">Inflation generally affects us by increasing
our cost of labor and clinical trial costs. We do not believe that inflation has had a material effect on our results of operations
during the three months ended March&nbsp;31, 2019 and March&nbsp;31, 2018.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">Currency fluctuations could affect us through
increased or decreased acquisition costs for certain goods and services. We do not believe currency fluctuations have had a material
effect on our results of operations during the three months ended March&nbsp;31, 2019 and March&nbsp;31, 2018.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in"></P>

<!-- Field: Page; Sequence: 19; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt; font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->15<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Off-Balance Sheet Arrangements </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">We have no off-balance sheet arrangements
as of each of March&nbsp;31, 2019 and March&nbsp;31, 2018.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in"><A NAME="a_010"></A>Item&nbsp;3. Quantitative and Qualitative
Disclosures About Market Risk</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in"><B>Currency Exchange Risk</B>&#9;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">The currency of the primary economic environment
in which our operations are conducted is the U.S. dollar. We consider the currency of the primary economic environment to be the
currency in which we generate revenues and expend cash. Most of our revenues are denominated in U.S. dollars, approximately 50%
of our expenses and capital expenditures are incurred in U.S. dollars, and a significant source of our financing has been provided
in U.S. dollars. Since the dollar is the functional currency, monetary items maintained in currencies other than the dollar are
remeasured using the rate of exchange in effect at the balance sheet dates and non-monetary items are remeasured at historical
exchange rates. Revenue and expense items are remeasured at the average rate of exchange in effect during the period in which they
occur. Foreign currency translation gains or losses are recognized in the statement of operations.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">A portion of our costs, including salaries, expenses and office
expenses, are incurred in NIS. Inflation in Israel may have the effect of increasing the U.S. dollar cost of our operations in
Israel. If the U.S. dollar declines in value in relation to the NIS, it will become more expensive for us to fund our operations
in Israel. A devaluation of 1% of the NIS will affect our income before tax by less than 1%. The exchange rate of the U.S. dollar
to the NIS, based on exchange rates published by the Bank of Israel, was as follows:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" ALIGN="CENTER" STYLE="border-collapse: collapse; width: 90%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Three Months Ended <BR>March&nbsp;31,</TD><TD STYLE="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Year Ended <BR> December&nbsp;31,</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2019</TD><TD STYLE="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2018</TD><TD STYLE="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2018</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 58%; font-size: 10pt; padding-left: 5.4pt">Average rate for period&#9;</TD><TD STYLE="width: 2%; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="width: 12%; font-size: 10pt; text-align: center">3.644</TD><TD STYLE="width: 2%; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="width: 12%; font-size: 10pt; text-align: center">3.462</TD><TD STYLE="width: 2%; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="width: 12%; font-size: 10pt; text-align: center">3.595</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; text-align: left; padding-left: 5.4pt">Rate at period end&#9;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: center">3.632</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: center">3.514</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: center">3.748</TD></TR>
</TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">To date, we have not engaged in hedging transactions. In the
future, we may enter into currency hedging transactions to decrease the risk of financial exposure from fluctuations in the exchange
rate of the U.S. dollar against the NIS. These measures, however, may not adequately protect us from material adverse effects due
to the impact of inflation in Israel.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in"><B>Interest Rate Risk</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">Our exposure to market risk is confined to
our cash and cash equivalents. We consider all short term, highly liquid investments, which include short-term deposits with original
maturities of three months or less from the date of purchase, that are not restricted as to withdrawal or use and are readily convertible
to known amounts of cash, to be cash equivalents. The primary objective of our investment activities is to preserve principal while
maximizing the interest income we receive from our investments, without increasing risk. We invest any cash balances primarily
in bank deposits and investment grade interest-bearing instruments. We are exposed to market risks resulting from changes in interest
rates. We do not use derivative financial instruments to limit exposure to interest rate risk. Our interest gains may decline in
the future as a result of changes in the financial markets.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in"><A NAME="a_011"></A>Item&nbsp;4. Controls and Procedures</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Evaluation of Disclosure Controls and Procedures</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">We conducted an evaluation of the effectiveness
of the design and operation of our disclosure controls and procedures as of the end of the period covered by this Quarterly Report
on Form 10-Q. The controls evaluation was conducted under the supervision and with the participation of management, including our
Chief Executive Officer and Chief Financial Officer. Disclosure controls and procedures are controls and procedures designed to
reasonably assure that information required to be disclosed in our reports filed under the Exchange Act, such as this Quarterly
Report on Form 10-Q, is recorded, processed, summarized and reported within the time periods specified in the Commission&rsquo;s
rules and forms. Disclosure controls and procedures are also designed to reasonably assure that such information is accumulated
and communicated to our management, including the Chief Executive Officer and Chief Financial Officer, as appropriate to allow
timely decisions regarding required disclosure.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"></P>

<!-- Field: Page; Sequence: 20; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt; font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->16<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">The evaluation of our disclosure controls
and procedures included a review of the controls&rsquo; objectives and design, our implementation of the controls and their effect
on the information generated for use in this Quarterly Report on Form 10-Q. This type of evaluation will be performed on a quarterly
basis so that the conclusions of management, including the Chief Executive Officer and Chief Financial Officer, concerning the
effectiveness of the disclosure controls and procedures can be reported in our periodic reports on Forms 10-Q and Forms 10-K.
The overall goals of these various evaluation activities are to monitor our disclosure controls and procedures, and to modify
them as necessary. Our intent is to maintain the disclosure controls and procedures as dynamic systems that change as conditions
warrant.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Based on the controls evaluation, our Chief Executive Officer
and Chief Financial Officer have concluded that, as of the end of the period covered by this Quarterly Report on Form 10-Q, our
disclosure controls and procedures were not effective as of March&nbsp;31, 2019 due to the material weakness in internal control
over financial reporting described below.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Our Chief Executive Officer and Chief Financial Officer have
concluded that notwithstanding the existence of the material weakness, the consolidated financial statements included in this Quarterly
Report on Form 10-Q present fairly, in all material respects, our financial position, results of operations and cash flows for
the periods presented in conformity with U.S. generally accepted accounting principles. Additional corrective actions continue
to address the internal control material weakness as described below under the section &ldquo;Remediation Plan.&rdquo;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">Material Weakness in Internal Control over Financial
Reporting</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">Management has concluded that
our internal control over financial reporting was not effective as of the end of our last fiscal quarter to provide
reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for
external reporting purposes in accordance with U.S. generally accepted accounting principles. We determined that a material
weakness in our internal control over financial reporting existed as of March&nbsp;31, 2019 in that we did not maintain
effective internal controls related to accounting for complex revenue contracts. Specifically, we did not properly assess
the performance obligations we had with regard to certain out-licensing arrangements which became material to our company
during 2018. We reviewed the results of management&rsquo;s assessment with the Audit Committee of our Board of Directors.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"></P>

<!-- Field: Page; Sequence: 21; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt; font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->17<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Remediation Plan</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">In response to the identified material weakness, our management,
with the oversight of the Audit Committee of the Board of Directors, has updated our revenue recognition processes and controls
with respect to out-licensing arrangements, and retained a globally recognized business and accounting advisory firm to assist
us in improving our internal processes in connection with revenue recognition. While certain remedial actions have been completed
in the first quarter of 2019, we intend to continue to update our revenue recognition processes and controls and to implement additional
control procedures as the need to do so is identified by our management. The remediation efforts are intended both to address the
identified material weakness and to enhance our overall financial control environment.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The material weakness will not be considered remediated until
our management designs and implements effective controls that operate for a sufficient period of time and management has concluded,
through testing, that these controls are effective. We will monitor the effectiveness of our remediation plan and will refine its
remediation plan as appropriated.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">Inherent Limitations on Effectiveness of Controls</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">Our management, including our Chief
Executive Officer and Chief Financial Officer, does not expect that our disclosure controls and procedures or our internal control
over financial reporting will prevent or detect all error and all fraud. A control system, no matter how well designed and operated,
can provide only reasonable, not absolute, assurance that the control system&rsquo;s objectives will be met. The design of a control
system must reflect the fact that there are resource constraints, and the benefits of controls must be considered relative to their
costs. Further, because of the inherent limitations in all control systems, no evaluation of controls can provide absolute assurance
that misstatements due to error or fraud will not occur or that all control issues and instances of fraud, if any, within a company
have been detected. These inherent limitations include the realities that judgments in decision-making can be faulty and that breakdowns
can occur because of simple error or mistake. Controls can also be circumvented by the individual acts of some persons, by collusion
of two or more people or by management override of the controls. The design of any system of controls is based in part on certain
assumptions about the likelihood of future events, and there can be no assurance that any design will succeed in achieving its
stated goals under all potential future conditions. Projections of any evaluation of controls effectiveness to future periods are
subject to risks. Over time, controls may become inadequate because of changes in conditions or deterioration in the degree of
compliance with policies or procedures.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">Changes in Internal Control over Financial Reporting</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Except with respect to the new lease accounting standard, there were no changes in our internal control over financial reporting (as defined in
Rules 13a-15f and 15d-15f under the Exchange Act) that occurred during the quarter ended March&nbsp;31, 2019 that have
materially affected, or that are reasonably likely to materially affect, our internal control over financial reporting.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 22; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt; font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->18<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 25.9pt"><B><A NAME="a_012"></A>PART II &ndash;
OTHER INFORMATION</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 25.9pt">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in"><A NAME="a_013"></A>Item&nbsp;1. Legal Proceedings</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">We are not involved in any material legal
proceedings.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.75in"><A NAME="a_014"></A>Item&nbsp;1A. Risk Factors</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.75in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">There have been no material changes to the
risk factors previously disclosed in our Annual Report on Form 10-K for the year ended December&nbsp;31, 2018.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.75in"><A NAME="a_015"></A>Item&nbsp;2. Unregistered
Sales of Equity Securities and Use of Proceeds</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.75in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.75in">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-weight: normal">There
were no unregistered sales of equity securities during the three months ended March</FONT>&nbsp;<FONT STYLE="font-family: Times New Roman, Times, Serif; font-weight: normal">31,
2019. </FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.75in"><A NAME="a_016"></A>Item&nbsp;3. Defaults
Upon Senior Securities</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.75in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in"><FONT STYLE="font-weight: normal">None.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.75in"><A NAME="a_017"></A>Item&nbsp;4. Mine Safety
Disclosure</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.75in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in"><FONT STYLE="font-weight: normal">Not applicable.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.75in"><A NAME="a_018"></A>Item&nbsp;5. Other Information</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.75in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in"><FONT STYLE="font-weight: normal">None.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in"></P>

<!-- Field: Page; Sequence: 23; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt; font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->19<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.75in"><A NAME="a_019"></A>Item&nbsp;6. Exhibits</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.75in">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.75in"></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: center; font-size: 10pt"><B>&nbsp;</B></TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: center; font-size: 10pt"><B>&nbsp;</B></TD>
    <TD COLSPAN="4" STYLE="padding-right: 5.4pt; padding-left: 5.4pt">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; border-bottom: Black 0.5pt solid"><B>Incorporated
        by Reference</B></P></TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: center; font-size: 10pt"><B>&nbsp;</B></TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="width: 10%; padding-right: 5.4pt; padding-left: 5.4pt">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; border-bottom: Black 0.5pt solid"><B>Exhibit</B><BR>
        <B>Number</B></P></TD>
    <TD STYLE="width: 36%; padding-right: 5.4pt; padding-left: 5.4pt">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; border-bottom: Black 0.5pt solid"><B>Exhibit
        Description</B></P></TD>
    <TD STYLE="width: 7%; padding-right: 5.4pt; padding-left: 5.4pt">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; border-bottom: Black 0.5pt solid"><B>Form</B></P></TD>
    <TD STYLE="width: 12%; padding-right: 5.4pt; padding-left: 5.4pt">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; border-bottom: Black 0.5pt solid"><B>File</B><BR>
        <B>Number</B></P></TD>
    <TD STYLE="width: 9%; padding-right: 5.4pt; padding-left: 5.4pt">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; border-bottom: Black 0.5pt solid"><B>Exhibit</B></P></TD>
    <TD STYLE="width: 14%; padding-right: 5.4pt; padding-left: 5.4pt">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; border-bottom: Black 0.5pt solid"><B>Date</B></P></TD>
    <TD STYLE="width: 12%; padding-right: 5.4pt; padding-left: 5.4pt">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; border-bottom: Black 0.5pt solid"><B>Filed
        or </B><BR>
        <B>Furnished</B><BR>
        <B>Herewith</B></P></TD></TR>

<TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt"><A HREF="http://www.sec.gov/Archives/edgar/data/1006281/000114420416092335/v435826_ex3-1.htm" STYLE="-sec-extract: exhibit">3.1</A></TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt"><A HREF="http://www.sec.gov/Archives/edgar/data/1006281/000114420416092335/v435826_ex3-1.htm" STYLE="-sec-extract: exhibit">Certificate of Incorporation of the Company</A></TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><A HREF="http://www.sec.gov/Archives/edgar/data/1006281/000114420416092335/v435826_ex3-1.htm" STYLE="-sec-extract: exhibit">8-K</A></TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><A HREF="http://www.sec.gov/Archives/edgar/data/1006281/000114420416092335/v435826_ex3-1.htm" STYLE="-sec-extract: exhibit">333-48677</A></TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><A HREF="http://www.sec.gov/Archives/edgar/data/1006281/000114420416092335/v435826_ex3-1.htm" STYLE="-sec-extract: exhibit">3.1</A></TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><A HREF="http://www.sec.gov/Archives/edgar/data/1006281/000114420416092335/v435826_ex3-1.htm" STYLE="-sec-extract: exhibit">April&nbsp;1, 2016</A></TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: center">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt">&nbsp;</TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt">&nbsp;</TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: center">&nbsp;</TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: center">&nbsp;</TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: center">&nbsp;</TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: center">&nbsp;</TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: center">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt"><A HREF="http://www.sec.gov/Archives/edgar/data/1006281/000114420416111273/v443094_def14a.htm">3.2</A></TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt"><A HREF="http://www.sec.gov/Archives/edgar/data/1006281/000114420416111273/v443094_def14a.htm">Amendment to Certificate of Incorporation of the Company</A></TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><A HREF="http://www.sec.gov/Archives/edgar/data/1006281/000114420416111273/v443094_def14a.htm">Def 14A</A></TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><A HREF="http://www.sec.gov/Archives/edgar/data/1006281/000114420416111273/v443094_def14a.htm">001-33357</A></TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><A HREF="http://www.sec.gov/Archives/edgar/data/1006281/000114420416111273/v443094_def14a.htm">Appen. A</A></TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><A HREF="http://www.sec.gov/Archives/edgar/data/1006281/000114420416111273/v443094_def14a.htm">July&nbsp;1, 2016</A></TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: center">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt">&nbsp;</TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt">&nbsp;</TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: center">&nbsp;</TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: center">&nbsp;</TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: center">&nbsp;</TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: center">&nbsp;</TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: center">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt"><A HREF="http://www.sec.gov/Archives/edgar/data/1006281/000114420418054229/tv504383-def14a.htm">3.3</A></TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt"><A HREF="http://www.sec.gov/Archives/edgar/data/1006281/000114420418054229/tv504383-def14a.htm">Second Amendment to Certificate of Incorporation of the Company</A></TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><A HREF="http://www.sec.gov/Archives/edgar/data/1006281/000114420418054229/tv504383-def14a.htm">Def 14A</A></TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><A HREF="http://www.sec.gov/Archives/edgar/data/1006281/000114420418054229/tv504383-def14a.htm">001-33357</A></TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><A HREF="http://www.sec.gov/Archives/edgar/data/1006281/000114420418054229/tv504383-def14a.htm">Appen. A</A></TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><A HREF="http://www.sec.gov/Archives/edgar/data/1006281/000114420418054229/tv504383-def14a.htm">October&nbsp;17, 2018</A></TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: center">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt">&nbsp;</TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt">&nbsp;</TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: center">&nbsp;</TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: center">&nbsp;</TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: center">&nbsp;</TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: center">&nbsp;</TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: center">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt"><A HREF="http://www.sec.gov/Archives/edgar/data/1006281/000114420416092335/v435826_ex3-2.htm">3.4</A></TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt"><A HREF="http://www.sec.gov/Archives/edgar/data/1006281/000114420416092335/v435826_ex3-2.htm">Bylaws of the Company</A></TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><A HREF="http://www.sec.gov/Archives/edgar/data/1006281/000114420416092335/v435826_ex3-2.htm">8-K</A></TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><A HREF="http://www.sec.gov/Archives/edgar/data/1006281/000114420416092335/v435826_ex3-2.htm">001-33357</A></TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><A HREF="http://www.sec.gov/Archives/edgar/data/1006281/000114420416092335/v435826_ex3-2.htm">3.2</A></TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><A HREF="http://www.sec.gov/Archives/edgar/data/1006281/000114420416092335/v435826_ex3-2.htm">April&nbsp;1, 2016</A></TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: center">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt">&nbsp;</TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt">&nbsp;</TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: center">&nbsp;</TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: center">&nbsp;</TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: center">&nbsp;</TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: center">&nbsp;</TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: center">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt"><A HREF="http://www.sec.gov/Archives/edgar/data/1006281/000114420412040015/v318898_ex4-1.htm">4.1</A></TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt"><A HREF="http://www.sec.gov/Archives/edgar/data/1006281/000114420412040015/v318898_ex4-1.htm">Form of Restricted Stock Agreement/Notice</A></TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><A HREF="http://www.sec.gov/Archives/edgar/data/1006281/000114420412040015/v318898_ex4-1.htm">8-K</A></TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><A HREF="http://www.sec.gov/Archives/edgar/data/1006281/000114420412040015/v318898_ex4-1.htm">001-33357</A></TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><A HREF="http://www.sec.gov/Archives/edgar/data/1006281/000114420412040015/v318898_ex4-1.htm">4.1</A></TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><A HREF="http://www.sec.gov/Archives/edgar/data/1006281/000114420412040015/v318898_ex4-1.htm">July&nbsp;18, 2012</A></TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: center">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt">&nbsp;</TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt">&nbsp;</TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: center">&nbsp;</TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: center">&nbsp;</TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: center">&nbsp;</TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: center">&nbsp;</TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: center">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt"><A HREF="http://www.sec.gov/Archives/edgar/data/1006281/000114420416138423/v454581_ex4-1.htm">4.2</A></TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt"><A HREF="http://www.sec.gov/Archives/edgar/data/1006281/000114420416138423/v454581_ex4-1.htm">Indenture, dated as of December 7, 2016, between Protalix BioTherapeutics, Inc. the guarantors party thereto, The Bank of New York Mellon Trust Company, N.A., as trustee and Wilmington Savings Fund Society, FSB, as collateral agent</A></TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><A HREF="http://www.sec.gov/Archives/edgar/data/1006281/000114420416138423/v454581_ex4-1.htm">8-K</A></TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><A HREF="http://www.sec.gov/Archives/edgar/data/1006281/000114420416138423/v454581_ex4-1.htm">001-33357</A></TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><A HREF="http://www.sec.gov/Archives/edgar/data/1006281/000114420416138423/v454581_ex4-1.htm">4.1</A></TD>
    <TD STYLE="padding-left: 1.75pt; text-align: center"><A HREF="http://www.sec.gov/Archives/edgar/data/1006281/000114420416138423/v454581_ex4-1.htm">December&nbsp;7, 2016</A></TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: center">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt">&nbsp;</TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt">&nbsp;</TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: center">&nbsp;</TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: center">&nbsp;</TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: center">&nbsp;</TD>
    <TD STYLE="padding-left: 1.75pt; text-align: center">&nbsp;</TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: center">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt"><A HREF="http://www.sec.gov/Archives/edgar/data/1006281/000114420416138423/v454581_ex4-2.htm">4.3</A></TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt"><A HREF="http://www.sec.gov/Archives/edgar/data/1006281/000114420416138423/v454581_ex4-2.htm">Form of 7.50% Convertible Note due 2021 (Issued in 2016 Financing)</A></TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><A HREF="http://www.sec.gov/Archives/edgar/data/1006281/000114420416138423/v454581_ex4-2.htm">8-K</A></TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><A HREF="http://www.sec.gov/Archives/edgar/data/1006281/000114420416138423/v454581_ex4-2.htm">001-33357</A></TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><A HREF="http://www.sec.gov/Archives/edgar/data/1006281/000114420416138423/v454581_ex4-2.htm">4.2</A></TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><A HREF="http://www.sec.gov/Archives/edgar/data/1006281/000114420416138423/v454581_ex4-2.htm">December&nbsp;7, 2016</A></TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: center">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt">&nbsp;</TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt">&nbsp;</TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: center">&nbsp;</TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: center">&nbsp;</TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: center">&nbsp;</TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt">&nbsp;</TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: center">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt"><A HREF="http://www.sec.gov/Archives/edgar/data/1006281/000114420416138423/v454581_ex4-3.htm">4.4</A></TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt"><A HREF="http://www.sec.gov/Archives/edgar/data/1006281/000114420416138423/v454581_ex4-3.htm">Form of 7.50% Convertible Note due 2021 (Issued in 2016 Exchange)</A></TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><A HREF="http://www.sec.gov/Archives/edgar/data/1006281/000114420416138423/v454581_ex4-3.htm">8-K</A></TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><A HREF="http://www.sec.gov/Archives/edgar/data/1006281/000114420416138423/v454581_ex4-3.htm">001-33357</A></TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><A HREF="http://www.sec.gov/Archives/edgar/data/1006281/000114420416138423/v454581_ex4-3.htm">4.3</A></TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><A HREF="http://www.sec.gov/Archives/edgar/data/1006281/000114420416138423/v454581_ex4-3.htm">December&nbsp;7, 2016</A></TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: center">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt">&nbsp;</TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt">&nbsp;</TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: center">&nbsp;</TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: center">&nbsp;</TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: center">&nbsp;</TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt">&nbsp;</TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: center">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt"><A HREF="http://www.sec.gov/Archives/edgar/data/1006281/000114420417038121/v471411_ex4-2.htm" STYLE="-sec-extract: exhibit">4.5</A></TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt"><A HREF="http://www.sec.gov/Archives/edgar/data/1006281/000114420417038121/v471411_ex4-2.htm" STYLE="-sec-extract: exhibit">First Supplemental Indenture, dated as of July 24, 2017, by and among Protalix BioTherapeutics, Inc., the guarantors party thereto, The Bank of New York Mellon Trust Company, N.A., as trustee, and Wilmington Savings Fund Society, FSB, as collateral agent</A></TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><A HREF="http://www.sec.gov/Archives/edgar/data/1006281/000114420417038121/v471411_ex4-2.htm" STYLE="-sec-extract: exhibit">8-K</A></TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><A HREF="http://www.sec.gov/Archives/edgar/data/1006281/000114420417038121/v471411_ex4-2.htm" STYLE="-sec-extract: exhibit">001-33357</A></TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><A HREF="http://www.sec.gov/Archives/edgar/data/1006281/000114420417038121/v471411_ex4-2.htm" STYLE="-sec-extract: exhibit">4.2</A></TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><A HREF="http://www.sec.gov/Archives/edgar/data/1006281/000114420417038121/v471411_ex4-2.htm" STYLE="-sec-extract: exhibit">July&nbsp;25, 2017</A></TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: center">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt">&nbsp;</TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt">&nbsp;</TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: center">&nbsp;</TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: center">&nbsp;</TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: center">&nbsp;</TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: center">&nbsp;</TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: center">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt"><A HREF="http://www.sec.gov/Archives/edgar/data/1006281/000114420417061920/tv480506_ex4-1.htm">4.6</A></TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt"><A HREF="http://www.sec.gov/Archives/edgar/data/1006281/000114420417061920/tv480506_ex4-1.htm">Second Supplemental Indenture, dated as of November 27, 2017, by and among Protalix BioTherapeutics, Inc., the guarantors party hereto and The Bank of New York Mellon Trust Company, N.A., as trustee, registrar, paying agent and conversion agent</A></TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><A HREF="http://www.sec.gov/Archives/edgar/data/1006281/000114420417061920/tv480506_ex4-1.htm">8-K </A></TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><A HREF="http://www.sec.gov/Archives/edgar/data/1006281/000114420417061920/tv480506_ex4-1.htm">001-33357</A></TD>
    <TD STYLE="padding-right: -5.65pt; padding-left: 1.75pt; text-align: center"><A HREF="http://www.sec.gov/Archives/edgar/data/1006281/000114420417061920/tv480506_ex4-1.htm">4.1</A></TD>
    <TD STYLE="padding-left: 1.75pt; text-align: center"><A HREF="http://www.sec.gov/Archives/edgar/data/1006281/000114420417061920/tv480506_ex4-1.htm">December&nbsp;1, 2017</A></TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: center">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt">&nbsp;</TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt">&nbsp;</TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt">&nbsp;</TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: center">&nbsp;</TD>
    <TD STYLE="padding-right: -5.65pt; padding-left: 1.75pt; text-align: center">&nbsp;</TD>
    <TD STYLE="padding-left: 1.75pt; text-align: center">&nbsp;</TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: center">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt"><A HREF="tv519981_ex31-1.htm">31.1</A></TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt"><A HREF="tv519981_ex31-1.htm">Certification of Chief Executive Officer pursuant to Rule 13a-14(a) as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002</A></TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: center">&nbsp;</TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: center">&nbsp;</TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: center">&nbsp;</TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: center">&nbsp;</TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><A HREF="tv519981_ex31-1.htm">X</A></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt">&nbsp;</TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt">&nbsp;</TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: center">&nbsp;</TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: center">&nbsp;</TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: center">&nbsp;</TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: center">&nbsp;</TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: center">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt"><A HREF="tv519981_ex31-2.htm">31.2</A></TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt"><A HREF="tv519981_ex31-2.htm">Certification of Chief Financial Officer pursuant to Rule 13a-14(a) as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002</A></TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: center">&nbsp;</TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: center">&nbsp;</TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: center">&nbsp;</TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: center">&nbsp;</TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><A HREF="tv519981_ex31-2.htm">X</A></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt">&nbsp;</TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt">&nbsp;</TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: center">&nbsp;</TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: center">&nbsp;</TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: center">&nbsp;</TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: center">&nbsp;</TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: center">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt"><A HREF="tv519981_ex32-1.htm">32.1</A></TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt"><A HREF="tv519981_ex32-1.htm">18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, Certification of Chief Executive Officer</A></TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: center">&nbsp;</TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: center">&nbsp;</TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: center">&nbsp;</TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: center">&nbsp;</TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><A HREF="tv519981_ex32-1.htm">X</A></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt">&nbsp;</TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt">&nbsp;</TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: center">&nbsp;</TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: center">&nbsp;</TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: center">&nbsp;</TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: center">&nbsp;</TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: center">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt"><A HREF="tv519981_ex32-2.htm">32.2</A></TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt"><A HREF="tv519981_ex32-2.htm">18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, Certification of Chief Financial Officer</A></TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: center">&nbsp;</TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: center">&nbsp;</TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: center">&nbsp;</TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: center">&nbsp;</TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><A HREF="tv519981_ex32-2.htm">X</A></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt">&nbsp;</TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt">&nbsp;</TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: center">&nbsp;</TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: center">&nbsp;</TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: center">&nbsp;</TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: center">&nbsp;</TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: center">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt">101.INS</TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt">XBRL INSTANCE FILE</TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: center">&nbsp;</TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: center">&nbsp;</TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: center">&nbsp;</TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: center">&nbsp;</TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: center">X</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt">&nbsp;</TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt">&nbsp;</TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: center">&nbsp;</TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: center">&nbsp;</TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: center">&nbsp;</TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: center">&nbsp;</TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: center">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt">101.SCH</TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt">XBRL SCHEMA FILE</TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: center">&nbsp;</TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: center">&nbsp;</TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: center">&nbsp;</TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: center">&nbsp;</TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: center">X</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt">&nbsp;</TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt">&nbsp;</TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: center">&nbsp;</TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: center">&nbsp;</TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: center">&nbsp;</TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: center">&nbsp;</TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: center">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt">101.CAL</TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt">XBRL CALCULATION FILE</TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: center">&nbsp;</TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: center">&nbsp;</TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: center">&nbsp;</TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: center">&nbsp;</TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: center">X</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt">&nbsp;</TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt">&nbsp;</TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: center">&nbsp;</TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: center">&nbsp;</TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: center">&nbsp;</TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: center">&nbsp;</TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: center">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt">101.DEF</TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt">XBRL DEFINITION FILE</TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: center">&nbsp;</TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: center">&nbsp;</TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: center">&nbsp;</TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: center">&nbsp;</TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: center">X</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt">&nbsp;</TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt">&nbsp;</TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: center">&nbsp;</TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: center">&nbsp;</TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: center">&nbsp;</TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: center">&nbsp;</TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: center">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt">101.LAB</TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt">XBRL LABEL FILE</TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: center">&nbsp;</TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: center">&nbsp;</TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: center">&nbsp;</TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: center">&nbsp;</TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: center">X</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt">&nbsp;</TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt">&nbsp;</TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: center">&nbsp;</TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: center">&nbsp;</TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: center">&nbsp;</TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: center">&nbsp;</TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: center">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt">101.PRE</TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt">XBRL PRESENTATION FILE</TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: center">&nbsp;</TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: center">&nbsp;</TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: center">&nbsp;</TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: center">&nbsp;</TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: center">X</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">&nbsp;</P>

<!-- Field: Page; Sequence: 24; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt; font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->20<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><A NAME="a_020"></A>SIGNATURES</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 25.9pt">Pursuant to the requirements of the Securities
Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto
duly authorized.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 25.9pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 57%">&nbsp;</TD>
    <TD STYLE="width: 5%">&nbsp;</TD>
    <TD STYLE="width: 38%">PROTALIX BIOTHERAPEUTICS, INC.</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">(Registrant)</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>Date: May 6, 2019</TD>
    <TD>By:</TD>
    <TD STYLE="border-bottom: Black 1pt solid">/s/ Moshe Manor</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Moshe Manor</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">President and Chief Executive Officer</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">(Principal Executive Officer)</P></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>Date: May 6, 2019</TD>
    <TD>By:</TD>
    <TD STYLE="border-bottom: Black 1pt solid">/s/ Yossi Maimon</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Yossi Maimon</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Vice President and Chief Financial Officer, Treasurer and Secretary</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">(Principal Financial and Accounting Officer)</P></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<!-- Field: Page; Sequence: 25; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt; font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->21<!-- Field: /Sequence --></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.1
<SEQUENCE>2
<FILENAME>tv519981_ex31-1.htm
<DESCRIPTION>EXHIBIT 31.1
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0"></P>

<P STYLE="margin: 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><B>EXHIBIT 31.1 </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>CERTIFICATION </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24.5pt">I, Moshe Manor, certify that:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24.5pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 24.5pt">1.</TD><TD>I have reviewed this quarterly report on Form 10-Q of Protalix BioTherapeutics, Inc.;</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 24.45pt">2.</TD><TD>Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact
necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with
respect to the period covered by this report;</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 24.45pt">3.</TD><TD>Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in
all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods
presented in this report;</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 24.45pt">4.</TD><TD>The registrant&rsquo;s other certifying officer and I are responsible for establishing and maintaining disclosure controls
and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined
in Exchange Act Rules 13a-15(f) and 15d-15(f)<FONT STYLE="font-weight: normal">) </FONT>for the registrant and have:</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(a)</TD><TD>Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our
supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known
to us by others within those entities, particularly during the period in which this report is being prepared;</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(b)</TD><TD>Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed
under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of
financial statements for external purposes in accordance with generally accepted accounting principles;</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(c)</TD><TD>Evaluated the effectiveness of the registrant&rsquo;s disclosure controls and procedures and presented in this report our conclusions
about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on
such evaluation; and</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(d)</TD><TD>Disclosed in this report any change in the registrant&rsquo;s internal control over financial reporting that occurred during
the registrant&rsquo;s most recent fiscal quarter (the registrant&rsquo;s fourth fiscal quarter in the case of an annual report)
that has materially affected, or is reasonably likely to materially affect, the registrant&rsquo;s internal control over financial
reporting; and</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 24.45pt">5.</TD><TD>The registrant&rsquo;s other certifying officer and I have disclosed, based on our most recent evaluation of internal control
over financial reporting, to the registrant&rsquo;s auditors and the audit committee of the registrant&rsquo;s board of directors
(or persons performing the equivalent functions):</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 24.45pt"></TD><TD STYLE="width: 24.5pt">a)</TD><TD>All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting
which are reasonably likely to adversely affect the registrant&rsquo;s ability to record, process, summarize and report financial
information; and</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 24.45pt"></TD><TD STYLE="width: 24.5pt">b)</TD><TD>Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&rsquo;s
internal control over financial reporting.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif"></P>



<P STYLE="margin: 0"></P>

<P STYLE="margin: 0"></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 50%; padding-left: 12pt; text-indent: -12pt">Date: May 6, 2019</TD>
    <TD STYLE="width: 50%; padding-left: 12pt; text-indent: -12pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-left: 12pt; text-indent: -12pt">&nbsp;</TD>
    <TD STYLE="padding-left: 12pt; text-indent: -12pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-left: 12pt; text-indent: -12pt; border-bottom: Black 1pt solid">/s/ Moshe Manor</TD>
    <TD STYLE="padding-left: 12pt; text-indent: -12pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-left: 12pt; text-indent: -12pt">Moshe Manor</TD>
    <TD STYLE="padding-left: 12pt; text-indent: -12pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-left: 12pt; text-indent: -12pt">President and Chief Executive Officer</TD>
    <TD STYLE="padding-left: 12pt; text-indent: -12pt">&nbsp;</TD></TR>
</TABLE>


<P STYLE="margin: 0">&nbsp;&nbsp;</P>

<!-- Field: Page; Sequence: 1; Options: NewSection Last; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="margin: 0"></P>

<P STYLE="margin: 0">&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.2
<SEQUENCE>3
<FILENAME>tv519981_ex31-2.htm
<DESCRIPTION>EXHIBIT 31.2
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><B>EXHIBIT 31.2 </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>CERTIFICATION </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24.5pt">I, Yossi Maimon, certify that:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24.5pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 24.5pt">1.</TD><TD>I have reviewed this quarterly report on Form 10-Q of Protalix BioTherapeutics, Inc.;</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 24.45pt">2.</TD><TD>Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact
necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with
respect to the period covered by this report;</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 24.45pt">3.</TD><TD>Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in
all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods
presented in this report;</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 24.45pt">4.</TD><TD>The registrant&rsquo;s other certifying officer and I are responsible for establishing and maintaining disclosure controls
and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined
in Exchange Act Rules 13a-15(f) and 15d-15(f)<FONT STYLE="font-weight: normal">) </FONT>for the registrant and have:</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(a)</TD><TD>Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our
supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known
to us by others within those entities, particularly during the period in which this report is being prepared;</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(b)</TD><TD>Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed
under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of
financial statements for external purposes in accordance with generally accepted accounting principles;</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(c)</TD><TD>Evaluated the effectiveness of the registrant&rsquo;s disclosure controls and procedures and presented in this report our conclusions
about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on
such evaluation; and</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(d)</TD><TD>Disclosed in this report any change in the registrant&rsquo;s internal control over financial reporting that occurred during
the registrant&rsquo;s most recent fiscal quarter (the registrant&rsquo;s fourth fiscal quarter in the case of an annual report)
that has materially affected, or is reasonably likely to materially affect, the registrant&rsquo;s internal control over financial
reporting; and</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 24.45pt">5.</TD><TD>The registrant&rsquo;s other certifying officer and I have disclosed, based on our most recent evaluation of internal control
over financial reporting, to the registrant&rsquo;s auditors and the audit committee of the registrant&rsquo;s board of directors
(or persons performing the equivalent functions):</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 24.45pt"></TD><TD STYLE="width: 24.5pt">a)</TD><TD>All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting
which are reasonably likely to adversely affect the registrant&rsquo;s ability to record, process, summarize and report financial
information; and</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 24.45pt"></TD><TD STYLE="width: 24.5pt">b)</TD><TD>Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&rsquo;s
internal control over financial reporting.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 44%; padding-left: 12pt; text-indent: -12pt">Date: May 6, 2019</TD>
    <TD STYLE="width: 56%; padding-left: 12pt; text-indent: -12pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-left: 12pt; text-indent: -12pt">&nbsp;</TD>
    <TD STYLE="padding-left: 12pt; text-indent: -12pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="border-bottom: Black 1pt solid; padding-left: 12pt; text-indent: -12pt">/s/ Yossi Maimon</TD>
    <TD STYLE="padding-left: 12pt; text-indent: -12pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-left: 12pt; text-indent: -12pt">Yossi Maimon</TD>
    <TD STYLE="padding-left: 12pt; text-indent: -12pt">&nbsp;</TD></TR>
<TR>
    <TD>Chief Financial Officer, Treasurer</TD>
    <TD>&nbsp;</TD></TR>
</TABLE>


<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0"></P>

<!-- Field: Page; Sequence: 1; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="margin: 0"></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.1
<SEQUENCE>4
<FILENAME>tv519981_ex32-1.htm
<DESCRIPTION>EXHIBIT 32.1
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><B>EXHIBIT 32.1 </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>PROTALIX BIOTHERAPEUTICS, INC.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><U>CERTIFICATION </U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">In connection with the quarterly report of Protalix BioTherapeutics,
Inc. (the &ldquo;Company&rdquo;) on Form 10-Q for the period ended March&nbsp;31, 2019 as filed with the Securities and Exchange
Commission (the &ldquo;Report&rdquo;), I, Moshe Manor, President and Chief Executive Officer of the Company, hereby certify as
of the date hereof, solely for purposes of Title 18, Chapter 63, Section&nbsp;1350 of the United States Code, that to the best
of my knowledge:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 24.45pt">(1) the Report fully complies with the requirements
of Section&nbsp;13(a) or 15(d), as applicable, of the Securities Exchange Act of 1934; and</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 24.45pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 24.45pt">(2) the information contained in the Report fairly
presents, in all material respects, the financial condition and results of operations of the Company at the dates and for the periods
indicated.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 24.45pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 12.2pt; text-indent: -12.25pt">This Certification has not
been, and shall not be deemed, &ldquo;filed&rdquo; with the Securities and Exchange Commission.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 12.2pt; text-indent: -12.25pt">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 48%; padding-left: 12pt; text-indent: -12pt">Date: May 6, 2019</TD>
    <TD STYLE="width: 52%; padding-left: 12pt; text-indent: -12pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-left: 12pt; text-indent: -12pt">&nbsp;</TD>
    <TD STYLE="padding-left: 12pt; text-indent: -12pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="border-bottom: Black 1pt solid; padding-left: 12pt; text-indent: -12pt">/s/ Moshe Manor</TD>
    <TD STYLE="padding-left: 12pt; text-indent: -12pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-left: 12pt; text-indent: -12pt">Moshe Manor</TD>
    <TD STYLE="padding-left: 12pt; text-indent: -12pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-left: 12pt; text-indent: -12pt">President and Chief Executive Officer</TD>
    <TD STYLE="padding-left: 12pt; text-indent: -12pt">&nbsp;</TD></TR>
</TABLE>


<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0"></P>

<!-- Field: Page; Sequence: 1; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="margin: 0"></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.2
<SEQUENCE>5
<FILENAME>tv519981_ex32-2.htm
<DESCRIPTION>EXHIBIT 32.2
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><B>EXHIBIT 32.2 </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>PROTALIX BIOTHERAPEUTICS, INC.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><U>CERTIFICATION </U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">In connection with the quarterly report of Protalix BioTherapeutics,
Inc. (the &ldquo;Company&rdquo;) on Form 10-Q for the period ended March&nbsp;31, 2019 as filed with the Securities and Exchange
Commission (the &ldquo;Report&rdquo;), I, Yossi Maimon, Vice President and Chief Financial Officer of the Company, hereby certify
as of the date hereof, solely for the purposes of Title 18, Chapter 63, Section&nbsp;1350 of the United States Code, that to the
best of my knowledge:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 24.45pt">(1) the Report fully complies with the requirements
of Section&nbsp;13(a) or 15(d), as applicable, of the Securities Exchange Act of 1934; and</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 24.45pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 24.45pt">(2) the information contained in the Report fairly
presents, in all material respects, the financial condition and results of operations of the Company at the dates and for the periods
indicated.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 24.45pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 12.2pt; text-indent: -12.25pt">This Certification has not
been, and shall not be deemed, &ldquo;filed&rdquo; with the Securities and Exchange Commission.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 12.2pt; text-indent: -12.25pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 49%; padding-left: 12pt; text-indent: -12pt">Date: May 6, 2019</TD>
    <TD STYLE="width: 51%; padding-left: 12pt; text-indent: -12pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-left: 12pt; text-indent: -12pt">&nbsp;</TD>
    <TD STYLE="padding-left: 12pt; text-indent: -12pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-left: 12pt; text-indent: -12pt; border-bottom: Black 1pt solid">/s/ Yossi Maimon</TD>
    <TD STYLE="padding-left: 12pt; text-indent: -12pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-left: 12pt; text-indent: -12pt">Yossi Maimon</TD>
    <TD STYLE="padding-left: 12pt; text-indent: -12pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-left: 12pt; text-indent: -12pt">Vice President and Chief Financial
        Officer</TD>
    <TD STYLE="padding-left: 12pt; text-indent: -12pt">&nbsp;</TD></TR>
</TABLE>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0"></P>

<!-- Field: Page; Sequence: 1; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0">&nbsp;</P>



<P STYLE="margin: 0"></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.INS
<SEQUENCE>6
<FILENAME>plx-20190331.xml
<DESCRIPTION>XBRL INSTANCE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="utf-8"?>
<!--Generated by DataTracks Rainbow Version 3.0 - www.datatracks.com - on 06-May-2019 [07:38:26] {PM}-->
<xbrli:xbrl xmlns:plx="http://www.protalix.com/20190331" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:deprecated="http://www.xbrl.org/2009/arcrole/deprecated" xmlns:country="http://xbrl.sec.gov/country/2017-01-31" xmlns:currency="http://xbrl.sec.gov/currency/2017-01-31" xmlns:dei="http://xbrl.sec.gov/dei/2018-01-31" xmlns:exch="http://xbrl.sec.gov/exch/2018-01-31" xmlns:invest="http://xbrl.sec.gov/invest/2013-01-31" xmlns:naics="http://xbrl.sec.gov/naics/2017-01-31" xmlns:sic="http://xbrl.sec.gov/sic/2011-01-31" xmlns:stpr="http://xbrl.sec.gov/stpr/2018-01-31" xmlns:us-gaap="http://fasb.org/us-gaap/2018-01-31" xmlns:xl="http://www.xbrl.org/2003/XLink" xmlns:utr="http://www.xbrl.org/2009/utr" xmlns:srt="http://fasb.org/srt/2018-01-31">
<link:schemaRef xlink:type="simple" xlink:href="plx-20190331.xsd" />
<xbrli:context id="P01_01_2019To03_31_2019">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>2019-01-01</xbrli:startDate>
<xbrli:endDate>2019-03-31</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="PAsOn03_31_2019">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>2019-03-31</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="PAsOn12_31_2018">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>2018-12-31</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="P01_01_2018To03_31_2018">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>2018-01-01</xbrli:startDate>
<xbrli:endDate>2018-03-31</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="PAsOn05_01_2019">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>2019-05-01</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="P01_01_2018To12_31_2018">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>2018-01-01</xbrli:startDate>
<xbrli:endDate>2018-12-31</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="PAsOn03_31_2018">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>2018-03-31</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="PAsOn01_01_2019">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>2019-01-01</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="PAsOn12_31_2017">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>2017-12-31</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="P01_01_2019To03_31_2019_LicenseAndServiceMembersrtProductOrServiceAxis">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseAndServiceMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>2019-01-01</xbrli:startDate>
<xbrli:endDate>2019-03-31</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="P01_01_2019To03_31_2019_ProductMembersrtProductOrServiceAxis">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>2019-01-01</xbrli:startDate>
<xbrli:endDate>2019-03-31</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="P01_01_2019To03_31_2019_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>2019-01-01</xbrli:startDate>
<xbrli:endDate>2019-03-31</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="P01_01_2019To03_31_2019_RetainedEarningsMemberusgaapStatementEquityComponentsAxis">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>2019-01-01</xbrli:startDate>
<xbrli:endDate>2019-03-31</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="P01_01_2019To03_31_2019_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis_SevenPointFivePercentageConvertibleNotesMemberusgaapDebtInstrumentAxis">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">plx:SevenPointFivePercentageConvertibleNotesMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>2019-01-01</xbrli:startDate>
<xbrli:endDate>2019-03-31</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="P01_01_2019To03_31_2019_Notes2021MemberusgaapDebtInstrumentAxis">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">plx:Notes2021Member</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>2019-01-01</xbrli:startDate>
<xbrli:endDate>2019-03-31</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="P01_01_2019To03_31_2019_ResearchAndDevelopmentExpenseMemberusgaapIncomeStatementLocationAxis">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>2019-01-01</xbrli:startDate>
<xbrli:endDate>2019-03-31</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="P01_01_2019To03_31_2019_SellingGeneralAndAdministrativeExpensesMemberusgaapIncomeStatementLocationAxis">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>2019-01-01</xbrli:startDate>
<xbrli:endDate>2019-03-31</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="P01_01_2019To03_31_2019_PfizerMembersrtStatementGeographicalAxis">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">plx:PfizerMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>2019-01-01</xbrli:startDate>
<xbrli:endDate>2019-03-31</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="P01_01_2019To03_31_2019_BRsrtStatementGeographicalAxis">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:BR</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>2019-01-01</xbrli:startDate>
<xbrli:endDate>2019-03-31</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="P01_01_2019To03_31_2019_MinimumMembersrtRangeAxis">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>2019-01-01</xbrli:startDate>
<xbrli:endDate>2019-03-31</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="P01_01_2019To03_31_2019_MaximumMembersrtRangeAxis">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>2019-01-01</xbrli:startDate>
<xbrli:endDate>2019-03-31</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="PAsOn03_31_2019_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis_SevenPointFivePercentageConvertibleNotesMemberusgaapDebtInstrumentAxis">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">plx:SevenPointFivePercentageConvertibleNotesMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>2019-03-31</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="PAsOn03_31_2019_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis_SevenPointFivePercentageConvertibleNoteMemberusgaapDebtInstrumentAxis">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">plx:SevenPointFivePercentageConvertibleNoteMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>2019-03-31</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="PAsOn03_31_2019_VehicleLeaseAndMaintenanceAgreementsMemberplxCommitmentsAndContingenciesAxis">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="plx:CommitmentsAndContingenciesAxis">plx:VehicleLeaseAndMaintenanceAgreementsMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>2019-03-31</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="PAsOn03_31_2019_LeaseAgreementsMemberplxCommitmentsAndContingenciesAxis">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="plx:CommitmentsAndContingenciesAxis">us-gaap:LeaseAgreementsMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>2019-03-31</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="PAsOn03_31_2019_SevenPointFivePercentageConvertibleNotes2021MemberusgaapDebtInstrumentAxis">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">plx:SevenPointFivePercentageConvertibleNotes2021Member</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>2019-03-31</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="P01_01_2018To03_31_2018_ProductMembersrtProductOrServiceAxis">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>2018-01-01</xbrli:startDate>
<xbrli:endDate>2018-03-31</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="P01_01_2018To03_31_2018_LicenseAndServiceMembersrtProductOrServiceAxis">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseAndServiceMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>2018-01-01</xbrli:startDate>
<xbrli:endDate>2018-03-31</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="P01_01_2018To03_31_2018_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>2018-01-01</xbrli:startDate>
<xbrli:endDate>2018-03-31</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="P01_01_2018To03_31_2018_CommonStockMemberusgaapStatementEquityComponentsAxis">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>2018-01-01</xbrli:startDate>
<xbrli:endDate>2018-03-31</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="P01_01_2018To03_31_2018_RetainedEarningsMemberusgaapStatementEquityComponentsAxis">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>2018-01-01</xbrli:startDate>
<xbrli:endDate>2018-03-31</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="P01_01_2018To03_31_2018_ResearchAndDevelopmentExpenseMemberusgaapIncomeStatementLocationAxis">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>2018-01-01</xbrli:startDate>
<xbrli:endDate>2018-03-31</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="P01_01_2018To03_31_2018_SellingGeneralAndAdministrativeExpensesMemberusgaapIncomeStatementLocationAxis">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>2018-01-01</xbrli:startDate>
<xbrli:endDate>2018-03-31</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="P01_01_2018To03_31_2018_PfizerMembersrtStatementGeographicalAxis">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">plx:PfizerMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>2018-01-01</xbrli:startDate>
<xbrli:endDate>2018-03-31</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="P01_01_2018To03_31_2018_BRsrtStatementGeographicalAxis">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:BR</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>2018-01-01</xbrli:startDate>
<xbrli:endDate>2018-03-31</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="PAsOn10_19_2017_ChiesiExUSAgreementMemberusgaapTypeOfArrangementAxis">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">plx:ChiesiExUSAgreementMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>2017-10-19</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="PAsOn07_23_2018_ChiesiUSAgreementMemberusgaapTypeOfArrangementAxis">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">plx:ChiesiUSAgreementMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>2018-07-23</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="P10_01_2017To10_19_2017_ChiesiExUSAgreementMemberusgaapTypeOfArrangementAxis_MinimumMembersrtRangeAxis">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">plx:ChiesiExUSAgreementMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>2017-10-01</xbrli:startDate>
<xbrli:endDate>2017-10-19</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="P10_01_2017To10_19_2017_ChiesiExUSAgreementMemberusgaapTypeOfArrangementAxis_MaximumMembersrtRangeAxis">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">plx:ChiesiExUSAgreementMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>2017-10-01</xbrli:startDate>
<xbrli:endDate>2017-10-19</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="P07_01_2018To07_23_2018_ChiesiUSAgreementMemberusgaapTypeOfArrangementAxis_MinimumMembersrtRangeAxis">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">plx:ChiesiUSAgreementMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>2018-07-01</xbrli:startDate>
<xbrli:endDate>2018-07-23</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="P07_01_2018To07_23_2018_ChiesiUSAgreementMemberusgaapTypeOfArrangementAxis_MaximumMembersrtRangeAxis">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">plx:ChiesiUSAgreementMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>2018-07-01</xbrli:startDate>
<xbrli:endDate>2018-07-23</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="PAsOn10_31_2015_AmendedPfizerAgreementMemberusgaapTypeOfArrangementAxis_BRsrtStatementGeographicalAxis_ProtalixBioTherapeuticsIncorporationMemberdeiLegalEntityAxis">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">plx:AmendedPfizerAgreementMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="dei:LegalEntityAxis">plx:ProtalixBioTherapeuticsIncorporationMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:BR</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>2015-10-31</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="PAsOn12_31_2018_CommonStockMemberusgaapStatementEquityComponentsAxis">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>2018-12-31</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="PAsOn12_31_2018_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>2018-12-31</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="PAsOn12_31_2018_RetainedEarningsMemberusgaapStatementEquityComponentsAxis">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>2018-12-31</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="PAsOn03_31_2019_CommonStockMemberusgaapStatementEquityComponentsAxis">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>2019-03-31</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="PAsOn03_31_2019_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>2019-03-31</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="PAsOn03_31_2019_RetainedEarningsMemberusgaapStatementEquityComponentsAxis">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>2019-03-31</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="PAsOn12_31_2017_CommonStockMemberusgaapStatementEquityComponentsAxis">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>2017-12-31</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="PAsOn12_31_2017_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>2017-12-31</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="PAsOn12_31_2017_RetainedEarningsMemberusgaapStatementEquityComponentsAxis">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>2017-12-31</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="PAsOn03_31_2018_CommonStockMemberusgaapStatementEquityComponentsAxis">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>2018-03-31</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="PAsOn03_31_2018_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>2018-03-31</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="PAsOn03_31_2018_RetainedEarningsMemberusgaapStatementEquityComponentsAxis">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>2018-03-31</xbrli:instant>
</xbrli:period>
</xbrli:context>
<us-gaap:CashAndCashEquivalentsAtCarryingValue id="Factid_5205381" contextRef="PAsOn03_31_2019" unitRef="Unit_USD" decimals="-3">30363000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
<us-gaap:CashAndCashEquivalentsAtCarryingValue id="Factid_5205382" contextRef="PAsOn12_31_2018" unitRef="Unit_USD" decimals="-3">37808000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
<us-gaap:AccountsReceivableNetCurrent id="Factid_5205383" contextRef="PAsOn03_31_2019" unitRef="Unit_USD" decimals="-3">8565000</us-gaap:AccountsReceivableNetCurrent>
<us-gaap:AccountsReceivableNetCurrent id="Factid_5205384" contextRef="PAsOn12_31_2018" unitRef="Unit_USD" decimals="-3">4729000</us-gaap:AccountsReceivableNetCurrent>
<us-gaap:OtherAssetsCurrent id="Factid_5205385" contextRef="PAsOn03_31_2019" unitRef="Unit_USD" decimals="-3">1706000</us-gaap:OtherAssetsCurrent>
<us-gaap:OtherAssetsCurrent id="Factid_5205386" contextRef="PAsOn12_31_2018" unitRef="Unit_USD" decimals="-3">1877000</us-gaap:OtherAssetsCurrent>
<us-gaap:InventoryNet id="Factid_5205387" contextRef="PAsOn03_31_2019" unitRef="Unit_USD" decimals="-3">6707000</us-gaap:InventoryNet>
<us-gaap:InventoryNet id="Factid_5205388" contextRef="PAsOn12_31_2018" unitRef="Unit_USD" decimals="-3">8569000</us-gaap:InventoryNet>
<us-gaap:AssetsCurrent id="Factid_5205389" contextRef="PAsOn03_31_2019" unitRef="Unit_USD" decimals="-3">47341000</us-gaap:AssetsCurrent>
<us-gaap:AssetsCurrent id="Factid_5205390" contextRef="PAsOn12_31_2018" unitRef="Unit_USD" decimals="-3">52983000</us-gaap:AssetsCurrent>
<us-gaap:DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent id="Factid_5205391" contextRef="PAsOn03_31_2019" unitRef="Unit_USD" decimals="-3">1801000</us-gaap:DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent>
<us-gaap:DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent id="Factid_5205392" contextRef="PAsOn12_31_2018" unitRef="Unit_USD" decimals="-3">1758000</us-gaap:DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent>
<us-gaap:PropertyPlantAndEquipmentNet id="Factid_5205393" contextRef="PAsOn03_31_2019" unitRef="Unit_USD" decimals="-3">6058000</us-gaap:PropertyPlantAndEquipmentNet>
<us-gaap:PropertyPlantAndEquipmentNet id="Factid_5205394" contextRef="PAsOn12_31_2018" unitRef="Unit_USD" decimals="-3">6390000</us-gaap:PropertyPlantAndEquipmentNet>
<us-gaap:Assets id="Factid_5205395" contextRef="PAsOn03_31_2019" unitRef="Unit_USD" decimals="-3">61044000</us-gaap:Assets>
<us-gaap:Assets id="Factid_5205396" contextRef="PAsOn12_31_2018" unitRef="Unit_USD" decimals="-3">61131000</us-gaap:Assets>
<us-gaap:AccountsPayableTradeCurrent id="Factid_5205397" contextRef="PAsOn03_31_2019" unitRef="Unit_USD" decimals="-3">5870000</us-gaap:AccountsPayableTradeCurrent>
<us-gaap:AccountsPayableTradeCurrent id="Factid_5205398" contextRef="PAsOn12_31_2018" unitRef="Unit_USD" decimals="-3">5211000</us-gaap:AccountsPayableTradeCurrent>
<us-gaap:AccountsPayableOtherCurrent id="Factid_5205399" contextRef="PAsOn03_31_2019" unitRef="Unit_USD" decimals="-3">10480000</us-gaap:AccountsPayableOtherCurrent>
<us-gaap:AccountsPayableOtherCurrent id="Factid_5205400" contextRef="PAsOn12_31_2018" unitRef="Unit_USD" decimals="-3">10274000</us-gaap:AccountsPayableOtherCurrent>
<us-gaap:LiabilitiesCurrent id="Factid_5205401" contextRef="PAsOn12_31_2018" unitRef="Unit_USD" decimals="-3">25353000</us-gaap:LiabilitiesCurrent>
<us-gaap:LiabilitiesCurrent id="Factid_5205402" contextRef="PAsOn03_31_2019" unitRef="Unit_USD" decimals="-3">27036000</us-gaap:LiabilitiesCurrent>
<us-gaap:ConvertibleDebtNoncurrent id="Factid_5205403" contextRef="PAsOn03_31_2019" unitRef="Unit_USD" decimals="-3">48670000</us-gaap:ConvertibleDebtNoncurrent>
<us-gaap:ConvertibleDebtNoncurrent id="Factid_5205404" contextRef="PAsOn12_31_2018" unitRef="Unit_USD" decimals="-3">47966000</us-gaap:ConvertibleDebtNoncurrent>
<us-gaap:PensionAndOtherPostretirementAndPostemploymentBenefitPlansLiabilitiesNoncurrent id="Factid_5205405" contextRef="PAsOn03_31_2019" unitRef="Unit_USD" decimals="-3">2426000</us-gaap:PensionAndOtherPostretirementAndPostemploymentBenefitPlansLiabilitiesNoncurrent>
<us-gaap:PensionAndOtherPostretirementAndPostemploymentBenefitPlansLiabilitiesNoncurrent id="Factid_5205406" contextRef="PAsOn12_31_2018" unitRef="Unit_USD" decimals="-3">2374000</us-gaap:PensionAndOtherPostretirementAndPostemploymentBenefitPlansLiabilitiesNoncurrent>
<us-gaap:OtherLiabilitiesNoncurrent id="Factid_5205407" contextRef="PAsOn03_31_2019" unitRef="Unit_USD" decimals="-3">5290000</us-gaap:OtherLiabilitiesNoncurrent>
<us-gaap:OtherLiabilitiesNoncurrent id="Factid_5205408" contextRef="PAsOn12_31_2018" unitRef="Unit_USD" decimals="-3">5292000</us-gaap:OtherLiabilitiesNoncurrent>
<us-gaap:LiabilitiesNoncurrent id="Factid_5205409" contextRef="PAsOn03_31_2019" unitRef="Unit_USD" decimals="-3">93863000</us-gaap:LiabilitiesNoncurrent>
<us-gaap:LiabilitiesNoncurrent id="Factid_5205410" contextRef="PAsOn12_31_2018" unitRef="Unit_USD" decimals="-3">88659000</us-gaap:LiabilitiesNoncurrent>
<us-gaap:Liabilities id="Factid_5205411" contextRef="PAsOn03_31_2019" unitRef="Unit_USD" decimals="-3">120899000</us-gaap:Liabilities>
<us-gaap:Liabilities id="Factid_5205412" contextRef="PAsOn12_31_2018" unitRef="Unit_USD" decimals="-3">114012000</us-gaap:Liabilities>
<us-gaap:ContractWithCustomerLiabilityNoncurrent id="Factid_5205415" contextRef="PAsOn03_31_2019" unitRef="Unit_USD" decimals="-3">32979000</us-gaap:ContractWithCustomerLiabilityNoncurrent>
<us-gaap:ContractWithCustomerLiabilityNoncurrent id="Factid_5205416" contextRef="PAsOn12_31_2018" unitRef="Unit_USD" decimals="-3">33027000</us-gaap:ContractWithCustomerLiabilityNoncurrent>
<us-gaap:ContractWithCustomerLiabilityCurrent id="Factid_5205417" contextRef="PAsOn12_31_2018" unitRef="Unit_USD" decimals="-3">9868000</us-gaap:ContractWithCustomerLiabilityCurrent>
<us-gaap:Revenues id="Factid_5205430" contextRef="P01_01_2019To03_31_2019_ProductMembersrtProductOrServiceAxis" unitRef="Unit_USD" decimals="-3">3530000</us-gaap:Revenues>
<us-gaap:Revenues id="Factid_5205431" contextRef="P01_01_2018To03_31_2018_ProductMembersrtProductOrServiceAxis" unitRef="Unit_USD" decimals="-3">4553000</us-gaap:Revenues>
<us-gaap:CostOfRevenue id="Factid_5205432" contextRef="P01_01_2019To03_31_2019" unitRef="Unit_USD" decimals="-3">2045000</us-gaap:CostOfRevenue>
<us-gaap:CostOfRevenue id="Factid_5205433" contextRef="P01_01_2018To03_31_2018" unitRef="Unit_USD" decimals="-3">2924000</us-gaap:CostOfRevenue>
<us-gaap:ResearchAndDevelopmentExpense id="Factid_5205434" contextRef="P01_01_2019To03_31_2019" unitRef="Unit_USD" decimals="-3">11701000</us-gaap:ResearchAndDevelopmentExpense>
<us-gaap:ResearchAndDevelopmentExpense id="Factid_5205435" contextRef="P01_01_2018To03_31_2018" unitRef="Unit_USD" decimals="-3">7286000</us-gaap:ResearchAndDevelopmentExpense>
<plx:GrantsAndReimbursementsReceivedOrReceivable id="Factid_5205436" contextRef="P01_01_2019To03_31_2019" unitRef="Unit_USD" decimals="-3">3000</plx:GrantsAndReimbursementsReceivedOrReceivable>
<plx:GrantsAndReimbursementsReceivedOrReceivable id="Factid_5205437" contextRef="P01_01_2018To03_31_2018" unitRef="Unit_USD" decimals="-3">843000</plx:GrantsAndReimbursementsReceivedOrReceivable>
<plx:ResearchDevelopmentAndEngineeringExpenseNet id="Factid_5205438" contextRef="P01_01_2019To03_31_2019" unitRef="Unit_USD" decimals="-3">11698000</plx:ResearchDevelopmentAndEngineeringExpenseNet>
<plx:ResearchDevelopmentAndEngineeringExpenseNet id="Factid_5205439" contextRef="P01_01_2018To03_31_2018" unitRef="Unit_USD" decimals="-3">6443000</plx:ResearchDevelopmentAndEngineeringExpenseNet>
<us-gaap:SellingGeneralAndAdministrativeExpense id="Factid_5205440" contextRef="P01_01_2019To03_31_2019" unitRef="Unit_USD" decimals="-3">2230000</us-gaap:SellingGeneralAndAdministrativeExpense>
<us-gaap:SellingGeneralAndAdministrativeExpense id="Factid_5205441" contextRef="P01_01_2018To03_31_2018" unitRef="Unit_USD" decimals="-3">2498000</us-gaap:SellingGeneralAndAdministrativeExpense>
<us-gaap:Revenues id="Factid_5205442" contextRef="P01_01_2018To03_31_2018_LicenseAndServiceMembersrtProductOrServiceAxis" unitRef="Unit_USD" decimals="-3">2161000</us-gaap:Revenues>
<us-gaap:OperatingIncomeLoss id="Factid_5205443" contextRef="P01_01_2019To03_31_2019" unitRef="Unit_USD" decimals="-3">-5534000</us-gaap:OperatingIncomeLoss>
<us-gaap:OperatingIncomeLoss id="Factid_5205444" contextRef="P01_01_2018To03_31_2018" unitRef="Unit_USD" decimals="-3">-5151000</us-gaap:OperatingIncomeLoss>
<us-gaap:OtherNonoperatingExpense id="Factid_5205445" contextRef="P01_01_2019To03_31_2019" unitRef="Unit_USD" decimals="-3">1920000</us-gaap:OtherNonoperatingExpense>
<us-gaap:OtherNonoperatingExpense id="Factid_5205446" contextRef="P01_01_2018To03_31_2018" unitRef="Unit_USD" decimals="-3">2220000</us-gaap:OtherNonoperatingExpense>
<us-gaap:OtherNonoperatingIncome id="Factid_5205447" contextRef="P01_01_2019To03_31_2019" unitRef="Unit_USD" decimals="-3">190000</us-gaap:OtherNonoperatingIncome>
<us-gaap:OtherNonoperatingIncome id="Factid_5205448" contextRef="P01_01_2018To03_31_2018" unitRef="Unit_USD" decimals="-3">132000</us-gaap:OtherNonoperatingIncome>
<us-gaap:NonoperatingIncomeExpense id="Factid_5205449" contextRef="P01_01_2019To03_31_2019" unitRef="Unit_USD" decimals="-3">-1730000</us-gaap:NonoperatingIncomeExpense>
<us-gaap:NonoperatingIncomeExpense id="Factid_5205450" contextRef="P01_01_2018To03_31_2018" unitRef="Unit_USD" decimals="-3">-2088000</us-gaap:NonoperatingIncomeExpense>
<us-gaap:NetIncomeLoss id="Factid_5205451" contextRef="P01_01_2019To03_31_2019" unitRef="Unit_USD" decimals="-3">-7264000</us-gaap:NetIncomeLoss>
<us-gaap:NetIncomeLoss id="Factid_5205452" contextRef="P01_01_2018To03_31_2018" unitRef="Unit_USD" decimals="-3">-7239000</us-gaap:NetIncomeLoss>
<us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue id="Factid_5205519" contextRef="P01_01_2018To03_31_2018_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3">46000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
<us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue id="Factid_5205520" contextRef="P01_01_2018To03_31_2018" unitRef="Unit_USD" decimals="-3">46000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
<plx:ShareBasedCompensationRestrictedStockAwardsNetOfForfeituresShares id="Factid_5205521" contextRef="P01_01_2018To03_31_2018" unitRef="Unit_shares" decimals="0">-29898</plx:ShareBasedCompensationRestrictedStockAwardsNetOfForfeituresShares>
<plx:ShareBasedCompensationRestrictedStockAwardsNetOfForfeitures id="Factid_5205522" contextRef="P01_01_2018To03_31_2018_CommonStockMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" xsi:nil="true" />
<plx:ShareBasedCompensationRestrictedStockAwardsNetOfForfeitures id="Factid_5205523" contextRef="P01_01_2018To03_31_2018_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3">16000</plx:ShareBasedCompensationRestrictedStockAwardsNetOfForfeitures>
<plx:ShareBasedCompensationRestrictedStockAwardsNetOfForfeitures id="Factid_5205524" contextRef="P01_01_2018To03_31_2018" unitRef="Unit_USD" decimals="-3">16000</plx:ShareBasedCompensationRestrictedStockAwardsNetOfForfeitures>
<us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue id="Factid_5205530" contextRef="P01_01_2019To03_31_2019_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3">290000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
<us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue id="Factid_5205531" contextRef="P01_01_2019To03_31_2019" unitRef="Unit_USD" decimals="-3">290000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
<us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities id="Factid_5205539" contextRef="P01_01_2018To03_31_2018_CommonStockMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3">2000</us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities>
<us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities id="Factid_5205540" contextRef="P01_01_2018To03_31_2018_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3">1190000</us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities>
<us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities id="Factid_5205541" contextRef="P01_01_2018To03_31_2018" unitRef="Unit_USD" decimals="-3">1192000</us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities>
<us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities id="Factid_5205544" contextRef="P01_01_2018To03_31_2018" unitRef="Unit_shares" decimals="0">1811260</us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities>
<us-gaap:NetIncomeLoss id="Factid_5205636" contextRef="P01_01_2019To03_31_2019" unitRef="Unit_USD" decimals="-3">-7264000</us-gaap:NetIncomeLoss>
<us-gaap:NetIncomeLoss id="Factid_5205637" contextRef="P01_01_2018To03_31_2018" unitRef="Unit_USD" decimals="-3">-7239000</us-gaap:NetIncomeLoss>
<us-gaap:ShareBasedCompensation id="Factid_5205638" contextRef="P01_01_2019To03_31_2019" unitRef="Unit_USD" decimals="-3">290000</us-gaap:ShareBasedCompensation>
<us-gaap:ShareBasedCompensation id="Factid_5205639" contextRef="P01_01_2018To03_31_2018" unitRef="Unit_USD" decimals="-3">62000</us-gaap:ShareBasedCompensation>
<us-gaap:Depreciation id="Factid_5205640" contextRef="P01_01_2019To03_31_2019" unitRef="Unit_USD" decimals="-3">405000</us-gaap:Depreciation>
<us-gaap:Depreciation id="Factid_5205641" contextRef="P01_01_2018To03_31_2018" unitRef="Unit_USD" decimals="-3">430000</us-gaap:Depreciation>
<us-gaap:ForeignCurrencyTransactionGainLossUnrealized id="Factid_5205642" contextRef="P01_01_2019To03_31_2019" unitRef="Unit_USD" decimals="-3">-20000</us-gaap:ForeignCurrencyTransactionGainLossUnrealized>
<us-gaap:ForeignCurrencyTransactionGainLossUnrealized id="Factid_5205643" contextRef="P01_01_2018To03_31_2018" unitRef="Unit_USD" decimals="-3">-28000</us-gaap:ForeignCurrencyTransactionGainLossUnrealized>
<us-gaap:PensionAndOtherPostretirementBenefitExpense id="Factid_5205644" contextRef="P01_01_2019To03_31_2019" unitRef="Unit_USD" decimals="-3">-24000</us-gaap:PensionAndOtherPostretirementBenefitExpense>
<us-gaap:PensionAndOtherPostretirementBenefitExpense id="Factid_5205645" contextRef="P01_01_2018To03_31_2018" unitRef="Unit_USD" decimals="-3">-124000</us-gaap:PensionAndOtherPostretirementBenefitExpense>
<plx:GainLossOnAmountsFundedInRespectOfEmployeeRightsUponRetirement id="Factid_5205647" contextRef="P01_01_2018To03_31_2018" unitRef="Unit_USD" decimals="-3">44000</plx:GainLossOnAmountsFundedInRespectOfEmployeeRightsUponRetirement>
<us-gaap:GainsLossesOnExtinguishmentOfDebt id="Factid_5205649" contextRef="P01_01_2018To03_31_2018" unitRef="Unit_USD" decimals="-3">-218000</us-gaap:GainsLossesOnExtinguishmentOfDebt>
<us-gaap:AmortizationOfFinancingCosts id="Factid_5205650" contextRef="P01_01_2019To03_31_2019" unitRef="Unit_USD" decimals="-3">704000</us-gaap:AmortizationOfFinancingCosts>
<us-gaap:AmortizationOfFinancingCosts id="Factid_5205651" contextRef="P01_01_2018To03_31_2018" unitRef="Unit_USD" decimals="-3">619000</us-gaap:AmortizationOfFinancingCosts>
<plx:IssuanceOfSharesForInterestPaymentRegardingConversionOfConvertibleNotes id="Factid_5205652" contextRef="P01_01_2018To03_31_2018" unitRef="Unit_USD" decimals="-3">205000</plx:IssuanceOfSharesForInterestPaymentRegardingConversionOfConvertibleNotes>
<us-gaap:IncreaseDecreaseInAccountsReceivable id="Factid_5205653" contextRef="P01_01_2019To03_31_2019" unitRef="Unit_USD" decimals="-3">3608000</us-gaap:IncreaseDecreaseInAccountsReceivable>
<us-gaap:IncreaseDecreaseInAccountsReceivable id="Factid_5205654" contextRef="P01_01_2018To03_31_2018" unitRef="Unit_USD" decimals="-3">3512000</us-gaap:IncreaseDecreaseInAccountsReceivable>
<us-gaap:IncreaseDecreaseInInventories id="Factid_5205655" contextRef="P01_01_2019To03_31_2019" unitRef="Unit_USD" decimals="-3">-1862000</us-gaap:IncreaseDecreaseInInventories>
<us-gaap:IncreaseDecreaseInInventories id="Factid_5205656" contextRef="P01_01_2018To03_31_2018" unitRef="Unit_USD" decimals="-3">-814000</us-gaap:IncreaseDecreaseInInventories>
<us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities id="Factid_5205657" contextRef="P01_01_2019To03_31_2019" unitRef="Unit_USD" decimals="-3">864000</us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities>
<us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities id="Factid_5205658" contextRef="P01_01_2018To03_31_2018" unitRef="Unit_USD" decimals="-3">-1009000</us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities>
<us-gaap:IncreaseDecreaseInOtherNoncurrentLiabilities id="Factid_5205659" contextRef="P01_01_2018To03_31_2018" unitRef="Unit_USD" decimals="-3">121000</us-gaap:IncreaseDecreaseInOtherNoncurrentLiabilities>
<us-gaap:NetCashProvidedByUsedInOperatingActivities id="Factid_5205660" contextRef="P01_01_2019To03_31_2019" unitRef="Unit_USD" decimals="-3">-7276000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
<us-gaap:NetCashProvidedByUsedInOperatingActivities id="Factid_5205661" contextRef="P01_01_2018To03_31_2018" unitRef="Unit_USD" decimals="-3">-9413000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
<us-gaap:PaymentsToAcquirePropertyPlantAndEquipment id="Factid_5205662" contextRef="P01_01_2019To03_31_2019" unitRef="Unit_USD" decimals="-3">170000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
<us-gaap:PaymentsToAcquirePropertyPlantAndEquipment id="Factid_5205663" contextRef="P01_01_2018To03_31_2018" unitRef="Unit_USD" decimals="-3">249000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
<us-gaap:IncreaseDecreaseInRestrictedCash id="Factid_5205664" contextRef="P01_01_2019To03_31_2019" unitRef="Unit_USD" decimals="-3">214000</us-gaap:IncreaseDecreaseInRestrictedCash>
<us-gaap:IncreaseDecreaseInRestrictedCash id="Factid_5205665" contextRef="P01_01_2018To03_31_2018" unitRef="Unit_USD" decimals="-3">188000</us-gaap:IncreaseDecreaseInRestrictedCash>
<us-gaap:PaymentsForProceedsFromOtherInvestingActivities id="Factid_5205666" contextRef="P01_01_2019To03_31_2019" unitRef="Unit_USD" decimals="-3">-13000</us-gaap:PaymentsForProceedsFromOtherInvestingActivities>
<us-gaap:PaymentsForProceedsFromOtherInvestingActivities id="Factid_5205667" contextRef="P01_01_2018To03_31_2018" unitRef="Unit_USD" decimals="-3">-109000</us-gaap:PaymentsForProceedsFromOtherInvestingActivities>
<us-gaap:EffectOfExchangeRateOnCashAndCashEquivalents id="Factid_5205668" contextRef="P01_01_2019To03_31_2019" unitRef="Unit_USD" decimals="-3">202000</us-gaap:EffectOfExchangeRateOnCashAndCashEquivalents>
<us-gaap:EffectOfExchangeRateOnCashAndCashEquivalents id="Factid_5205669" contextRef="P01_01_2018To03_31_2018" unitRef="Unit_USD" decimals="-3">-103000</us-gaap:EffectOfExchangeRateOnCashAndCashEquivalents>
<us-gaap:CashAndCashEquivalentsPeriodIncreaseDecrease id="Factid_5205670" contextRef="P01_01_2019To03_31_2019" unitRef="Unit_USD" decimals="-3">-7445000</us-gaap:CashAndCashEquivalentsPeriodIncreaseDecrease>
<us-gaap:CashAndCashEquivalentsPeriodIncreaseDecrease id="Factid_5205671" contextRef="P01_01_2018To03_31_2018" unitRef="Unit_USD" decimals="-3">-9844000</us-gaap:CashAndCashEquivalentsPeriodIncreaseDecrease>
<us-gaap:CashAndCashEquivalentsAtCarryingValue id="Factid_5205672" contextRef="PAsOn12_31_2018" unitRef="Unit_USD" decimals="-3">37808000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
<us-gaap:CashAndCashEquivalentsAtCarryingValue id="Factid_5205673" contextRef="PAsOn12_31_2017" unitRef="Unit_USD" decimals="-3">51163000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
<us-gaap:CashAndCashEquivalentsAtCarryingValue id="Factid_5205674" contextRef="PAsOn03_31_2019" unitRef="Unit_USD" decimals="-3">30363000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
<us-gaap:CashAndCashEquivalentsAtCarryingValue id="Factid_5205675" contextRef="PAsOn03_31_2018" unitRef="Unit_USD" decimals="-3">41319000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
<us-gaap:IncreaseDecreaseInContractWithCustomerLiability id="Factid_5205676" contextRef="P01_01_2019To03_31_2019" unitRef="Unit_USD" decimals="-3">-487000</us-gaap:IncreaseDecreaseInContractWithCustomerLiability>
<us-gaap:IncreaseDecreaseInContractWithCustomerLiability id="Factid_5205677" contextRef="P01_01_2018To03_31_2018" unitRef="Unit_USD" decimals="-3">18000</us-gaap:IncreaseDecreaseInContractWithCustomerLiability>
<us-gaap:NetCashProvidedByUsedInInvestingActivities id="Factid_5205678" contextRef="P01_01_2019To03_31_2019" unitRef="Unit_USD" decimals="-3">-371000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
<us-gaap:NetCashProvidedByUsedInInvestingActivities id="Factid_5205679" contextRef="P01_01_2018To03_31_2018" unitRef="Unit_USD" decimals="-3">-328000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
<plx:IncreaseInLiabilitiesForPropertyPlantAndEquipment id="Factid_5205681" contextRef="P01_01_2019To03_31_2019" unitRef="Unit_USD" decimals="-3">128000</plx:IncreaseInLiabilitiesForPropertyPlantAndEquipment>
<plx:IncreaseInLiabilitiesForPropertyPlantAndEquipment id="Factid_5205682" contextRef="P01_01_2018To03_31_2018" unitRef="Unit_USD" decimals="-3">342000</plx:IncreaseInLiabilitiesForPropertyPlantAndEquipment>
<us-gaap:DebtConversionConvertedInstrumentAmount1 id="Factid_5205683" contextRef="P01_01_2018To03_31_2018" unitRef="Unit_USD" decimals="-3">987000</us-gaap:DebtConversionConvertedInstrumentAmount1>
<us-gaap:InterestPaidNet id="Factid_5205685" contextRef="P01_01_2018To03_31_2018" unitRef="Unit_USD" decimals="-3">145000</us-gaap:InterestPaidNet>
<plx:AdditionalAmountsPayableToCoverDevelopmentCosts id="Factid_5205702" contextRef="PAsOn07_23_2018_ChiesiUSAgreementMemberusgaapTypeOfArrangementAxis" unitRef="Unit_USD" decimals="-5">20000000</plx:AdditionalAmountsPayableToCoverDevelopmentCosts>
<plx:UpfrontNonrefundableNoncreditablePaymentReceivable id="Factid_5205703" contextRef="PAsOn07_23_2018_ChiesiUSAgreementMemberusgaapTypeOfArrangementAxis" unitRef="Unit_USD" decimals="-5">25000000</plx:UpfrontNonrefundableNoncreditablePaymentReceivable>
<plx:PaymentOnNetSalesPercentage id="Factid_5205704" contextRef="P10_01_2017To10_19_2017_ChiesiExUSAgreementMemberusgaapTypeOfArrangementAxis_MinimumMembersrtRangeAxis" unitRef="Unit_pure" decimals="2">0.15</plx:PaymentOnNetSalesPercentage>
<plx:PaymentOnNetSalesPercentage id="Factid_5205705" contextRef="P10_01_2017To10_19_2017_ChiesiExUSAgreementMemberusgaapTypeOfArrangementAxis_MaximumMembersrtRangeAxis" unitRef="Unit_pure" decimals="2">0.35</plx:PaymentOnNetSalesPercentage>
<plx:PaymentOnNetSalesPercentage id="Factid_5205706" contextRef="P07_01_2018To07_23_2018_ChiesiUSAgreementMemberusgaapTypeOfArrangementAxis_MinimumMembersrtRangeAxis" unitRef="Unit_pure" decimals="2">0.15</plx:PaymentOnNetSalesPercentage>
<plx:PaymentOnNetSalesPercentage id="Factid_5205707" contextRef="P07_01_2018To07_23_2018_ChiesiUSAgreementMemberusgaapTypeOfArrangementAxis_MaximumMembersrtRangeAxis" unitRef="Unit_pure" decimals="2">0.40</plx:PaymentOnNetSalesPercentage>
<plx:CollaborativeArrangementRevenuesExpensesSharingPercentage id="Factid_5205708" contextRef="PAsOn10_31_2015_AmendedPfizerAgreementMemberusgaapTypeOfArrangementAxis_BRsrtStatementGeographicalAxis_ProtalixBioTherapeuticsIncorporationMemberdeiLegalEntityAxis" unitRef="Unit_pure" decimals="2">1.00</plx:CollaborativeArrangementRevenuesExpensesSharingPercentage>
<us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount id="Factid_5205767" contextRef="P01_01_2018To03_31_2018" unitRef="Unit_shares" decimals="0">73800491</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
<us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount id="Factid_5205768" contextRef="P01_01_2019To03_31_2019" unitRef="Unit_shares" decimals="0">78202020</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
<us-gaap:CommonStockParOrStatedValuePerShare id="Factid_5205769" contextRef="PAsOn03_31_2019" unitRef="Unit_USD_per_Share" decimals="3">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
<us-gaap:InventoryRawMaterialsNetOfReserves id="Factid_5205779" contextRef="PAsOn03_31_2019" unitRef="Unit_USD" decimals="-3">3047000</us-gaap:InventoryRawMaterialsNetOfReserves>
<us-gaap:InventoryRawMaterialsNetOfReserves id="Factid_5205780" contextRef="PAsOn12_31_2018" unitRef="Unit_USD" decimals="-3">3792000</us-gaap:InventoryRawMaterialsNetOfReserves>
<us-gaap:InventoryWorkInProcessNetOfReserves id="Factid_5205781" contextRef="PAsOn03_31_2019" unitRef="Unit_USD" decimals="-3">45000</us-gaap:InventoryWorkInProcessNetOfReserves>
<us-gaap:InventoryFinishedGoodsNetOfReserves id="Factid_5205782" contextRef="PAsOn03_31_2019" unitRef="Unit_USD" decimals="-3">3615000</us-gaap:InventoryFinishedGoodsNetOfReserves>
<us-gaap:InventoryFinishedGoodsNetOfReserves id="Factid_5205783" contextRef="PAsOn12_31_2018" unitRef="Unit_USD" decimals="-3">4777000</us-gaap:InventoryFinishedGoodsNetOfReserves>
<us-gaap:InventoryNet id="Factid_5205784" contextRef="PAsOn03_31_2019" unitRef="Unit_USD" decimals="-3">6707000</us-gaap:InventoryNet>
<us-gaap:InventoryNet id="Factid_5205785" contextRef="PAsOn12_31_2018" unitRef="Unit_USD" decimals="-3">8569000</us-gaap:InventoryNet>
<us-gaap:DebtInstrumentFaceAmount id="Factid_5205792" contextRef="PAsOn03_31_2019_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis_SevenPointFivePercentageConvertibleNoteMemberusgaapDebtInstrumentAxis" unitRef="Unit_USD" decimals="-5">57900000</us-gaap:DebtInstrumentFaceAmount>
<us-gaap:ContractWithCustomerLiabilityCurrent id="Factid_5205953" contextRef="PAsOn03_31_2019" unitRef="Unit_USD" decimals="-3">9429000</us-gaap:ContractWithCustomerLiabilityCurrent>
<us-gaap:StockholdersEquity id="Factid_5206058" contextRef="PAsOn03_31_2019" unitRef="Unit_USD" decimals="-3">-59855000</us-gaap:StockholdersEquity>
<us-gaap:StockholdersEquity id="Factid_5206059" contextRef="PAsOn12_31_2018" unitRef="Unit_USD" decimals="-3">-52881000</us-gaap:StockholdersEquity>
<us-gaap:Revenues id="Factid_5206111" contextRef="P01_01_2019To03_31_2019_LicenseAndServiceMembersrtProductOrServiceAxis" unitRef="Unit_USD" decimals="-3">6909000</us-gaap:Revenues>
<us-gaap:EarningsPerShareBasicAndDiluted id="Factid_5206112" contextRef="P01_01_2019To03_31_2019" unitRef="Unit_USD_per_Share" decimals="2">-0.05</us-gaap:EarningsPerShareBasicAndDiluted>
<us-gaap:EarningsPerShareBasicAndDiluted id="Factid_5206113" contextRef="P01_01_2018To03_31_2018" unitRef="Unit_USD_per_Share" decimals="2">-0.05</us-gaap:EarningsPerShareBasicAndDiluted>
<us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted id="Factid_5206114" contextRef="P01_01_2019To03_31_2019" unitRef="Unit_shares" decimals="-3">148382299000</us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted>
<us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted id="Factid_5206115" contextRef="P01_01_2018To03_31_2018" unitRef="Unit_shares" decimals="-3">145305982000</us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted>
<us-gaap:AllocatedShareBasedCompensationExpense id="Factid_5207731" contextRef="P01_01_2019To03_31_2019_ResearchAndDevelopmentExpenseMemberusgaapIncomeStatementLocationAxis" unitRef="Unit_USD" decimals="-3">178000</us-gaap:AllocatedShareBasedCompensationExpense>
<us-gaap:AllocatedShareBasedCompensationExpense id="Factid_5207732" contextRef="P01_01_2018To03_31_2018_ResearchAndDevelopmentExpenseMemberusgaapIncomeStatementLocationAxis" unitRef="Unit_USD" decimals="-3">42000</us-gaap:AllocatedShareBasedCompensationExpense>
<us-gaap:AllocatedShareBasedCompensationExpense id="Factid_5207733" contextRef="P01_01_2019To03_31_2019_SellingGeneralAndAdministrativeExpensesMemberusgaapIncomeStatementLocationAxis" unitRef="Unit_USD" decimals="-3">112000</us-gaap:AllocatedShareBasedCompensationExpense>
<us-gaap:AllocatedShareBasedCompensationExpense id="Factid_5207734" contextRef="P01_01_2018To03_31_2018_SellingGeneralAndAdministrativeExpensesMemberusgaapIncomeStatementLocationAxis" unitRef="Unit_USD" decimals="-3">20000</us-gaap:AllocatedShareBasedCompensationExpense>
<us-gaap:SharesOutstanding id="Factid_5208976" contextRef="PAsOn12_31_2017" unitRef="Unit_shares" decimals="0">143728797</us-gaap:SharesOutstanding>
<us-gaap:StockholdersEquity id="Factid_5208977" contextRef="PAsOn12_31_2017_CommonStockMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3">144000</us-gaap:StockholdersEquity>
<us-gaap:StockholdersEquity id="Factid_5208978" contextRef="PAsOn12_31_2017_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3">266495000</us-gaap:StockholdersEquity>
<us-gaap:StockholdersEquity id="Factid_5208979" contextRef="PAsOn12_31_2017_RetainedEarningsMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3">-296096000</us-gaap:StockholdersEquity>
<us-gaap:StockholdersEquity id="Factid_5208980" contextRef="PAsOn12_31_2017" unitRef="Unit_USD" decimals="-3">-29457000</us-gaap:StockholdersEquity>
<us-gaap:SharesOutstanding id="Factid_5208981" contextRef="PAsOn03_31_2018" unitRef="Unit_shares" decimals="0">145569955</us-gaap:SharesOutstanding>
<us-gaap:StockholdersEquity id="Factid_5208982" contextRef="PAsOn03_31_2018_CommonStockMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3">146000</us-gaap:StockholdersEquity>
<us-gaap:StockholdersEquity id="Factid_5208983" contextRef="PAsOn03_31_2018_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3">267747000</us-gaap:StockholdersEquity>
<us-gaap:StockholdersEquity id="Factid_5208984" contextRef="PAsOn03_31_2018_RetainedEarningsMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3">-303335000</us-gaap:StockholdersEquity>
<us-gaap:StockholdersEquity id="Factid_5208985" contextRef="PAsOn03_31_2018" unitRef="Unit_USD" decimals="-3">-35442000</us-gaap:StockholdersEquity>
<us-gaap:SharesOutstanding id="Factid_5208986" contextRef="PAsOn12_31_2018" unitRef="Unit_shares" decimals="0">148382299</us-gaap:SharesOutstanding>
<us-gaap:StockholdersEquity id="Factid_5208987" contextRef="PAsOn12_31_2018_CommonStockMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3">148000</us-gaap:StockholdersEquity>
<us-gaap:StockholdersEquity id="Factid_5208988" contextRef="PAsOn12_31_2018_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3">269524000</us-gaap:StockholdersEquity>
<us-gaap:StockholdersEquity id="Factid_5208989" contextRef="PAsOn12_31_2018_RetainedEarningsMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3">-322553000</us-gaap:StockholdersEquity>
<us-gaap:StockholdersEquity id="Factid_5208990" contextRef="PAsOn12_31_2018" unitRef="Unit_USD" decimals="-3">-52881000</us-gaap:StockholdersEquity>
<us-gaap:SharesOutstanding id="Factid_5208991" contextRef="PAsOn03_31_2019" unitRef="Unit_shares" decimals="0">148382299</us-gaap:SharesOutstanding>
<us-gaap:StockholdersEquity id="Factid_5208992" contextRef="PAsOn03_31_2019_CommonStockMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3">148000</us-gaap:StockholdersEquity>
<us-gaap:StockholdersEquity id="Factid_5208993" contextRef="PAsOn03_31_2019_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3">269814000</us-gaap:StockholdersEquity>
<us-gaap:StockholdersEquity id="Factid_5208994" contextRef="PAsOn03_31_2019_RetainedEarningsMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3">-329817000</us-gaap:StockholdersEquity>
<us-gaap:StockholdersEquity id="Factid_5208995" contextRef="PAsOn03_31_2019" unitRef="Unit_USD" decimals="-3">-59855000</us-gaap:StockholdersEquity>
<us-gaap:NetIncomeLoss id="Factid_5209097" contextRef="P01_01_2018To03_31_2018_RetainedEarningsMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3">-7239000</us-gaap:NetIncomeLoss>
<us-gaap:NetIncomeLoss id="Factid_5209098" contextRef="P01_01_2018To03_31_2018" unitRef="Unit_USD" decimals="-3">-7239000</us-gaap:NetIncomeLoss>
<us-gaap:NetIncomeLoss id="Factid_5209099" contextRef="P01_01_2019To03_31_2019_RetainedEarningsMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3">-7264000</us-gaap:NetIncomeLoss>
<us-gaap:NetIncomeLoss id="Factid_5209100" contextRef="P01_01_2019To03_31_2019" unitRef="Unit_USD" decimals="-3">-7264000</us-gaap:NetIncomeLoss>
<us-gaap:CommonStockParOrStatedValuePerShare id="Factid_5209120" contextRef="PAsOn03_31_2018" unitRef="Unit_USD_per_Share" decimals="3">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
<us-gaap:CommonStockSharesAuthorized id="Factid_5209121" contextRef="PAsOn03_31_2019" unitRef="Unit_shares" decimals="0">250000000</us-gaap:CommonStockSharesAuthorized>
<us-gaap:CommonStockSharesAuthorized id="Factid_5209122" contextRef="PAsOn03_31_2018" unitRef="Unit_shares" decimals="0">250000000</us-gaap:CommonStockSharesAuthorized>
<us-gaap:IncreaseDecreaseInOtherNoncurrentLiabilities id="Factid_5209131" contextRef="P01_01_2019To03_31_2019" unitRef="Unit_USD" decimals="-3">-2000</us-gaap:IncreaseDecreaseInOtherNoncurrentLiabilities>
<us-gaap:SubsequentEventsTextBlock id="Factid_5209196" contextRef="P01_01_2019To03_31_2019">&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; margin-bottom: 0px; margin-top: 0px; margin-right: 0px;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;NOTE 6&amp;#160;&amp;#8211; SUBSEQUENT EVENTS&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; margin-bottom: 0px; margin-top: 0px; margin-right: 0px; background: none;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; margin-bottom: 0px; margin-top: 0px; margin-right: 0px;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;The Company has evaluated subsequent events through the date on which the consolidated financial statements were available to be issued and no subsequent events were identified.&lt;/div&gt;&lt;/div&gt; &lt;table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"&gt;&lt;tr&gt;&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:SubsequentEventsTextBlock>
<us-gaap:Revenues id="Factid_5209294" contextRef="P01_01_2019To03_31_2019_PfizerMembersrtStatementGeographicalAxis" unitRef="Unit_USD" decimals="-3">1356000</us-gaap:Revenues>
<us-gaap:Revenues id="Factid_5209295" contextRef="P01_01_2018To03_31_2018_PfizerMembersrtStatementGeographicalAxis" unitRef="Unit_USD" decimals="-3">1980000</us-gaap:Revenues>
<us-gaap:Revenues id="Factid_5209296" contextRef="P01_01_2019To03_31_2019_BRsrtStatementGeographicalAxis" unitRef="Unit_USD" decimals="-3">2174000</us-gaap:Revenues>
<us-gaap:Revenues id="Factid_5209297" contextRef="P01_01_2018To03_31_2018_BRsrtStatementGeographicalAxis" unitRef="Unit_USD" decimals="-3">2573000</us-gaap:Revenues>
<us-gaap:Revenues id="Factid_5209298" contextRef="P01_01_2019To03_31_2019_ProductMembersrtProductOrServiceAxis" unitRef="Unit_USD" decimals="-3">3530000</us-gaap:Revenues>
<us-gaap:Revenues id="Factid_5209299" contextRef="P01_01_2018To03_31_2018_ProductMembersrtProductOrServiceAxis" unitRef="Unit_USD" decimals="-3">4553000</us-gaap:Revenues>
<us-gaap:Revenues id="Factid_5209300" contextRef="P01_01_2019To03_31_2019_LicenseAndServiceMembersrtProductOrServiceAxis" unitRef="Unit_USD" decimals="-3">6909000</us-gaap:Revenues>
<us-gaap:Revenues id="Factid_5209301" contextRef="P01_01_2018To03_31_2018_LicenseAndServiceMembersrtProductOrServiceAxis" unitRef="Unit_USD" decimals="-3">2161000</us-gaap:Revenues>
<us-gaap:FairValueDisclosuresTextBlock id="Factid_5211852" contextRef="P01_01_2019To03_31_2019">&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; margin-bottom: 0px; margin-top: 0px; margin-right: 0px;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;NOTE 3 &amp;#8211; FAIR VALUE MEASUREMENT&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; margin-bottom: 0px; margin-top: 0px; margin-right: 0px; background: none;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; margin: 0px 0px 0px 0.49in;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;The Company measures fair value and discloses fair value measurements for financial assets and liabilities. Fair value is based on the price that would be received from the sale of an asset, or paid to transfer a liability, in an orderly transaction between market participants at the measurement date.&lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; margin: 0px 0px 0px 0.49in; background: none;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; margin: 0px 0px 0px 0.49in;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;The accounting standard establishes a fair value hierarchy that prioritizes observable and unobservable inputs used to measure fair value into three broad levels, which are described below:&lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; margin: 0px 0px 0px 0.49in; background: none;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; margin: 0px 0px 0px 0.49in;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;Level 1: Quoted prices (unadjusted) in active markets that are accessible at the measurement date for assets or liabilities. The fair value hierarchy gives the highest priority to Level 1 inputs.&lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; margin: 0px 0px 0px 0.49in; background: none;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; margin: 0px 0px 0px 0.49in;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;Level 2: Observable prices that are based on inputs not quoted on active markets, but corroborated by market data.&lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; margin: 0px 0px 0px 0.49in; background: none;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; margin: 0px 0px 0px 0.49in;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;Level 3: Unobservable inputs are used when little or no market data is available. The fair value hierarchy gives the lowest priority to Level 3 inputs.&lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; margin: 0px 0px 0px 0.49in; background: none;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; margin: 0px 0px 0px 0.49in;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;In determining fair value, the Company utilizes valuation techniques that maximize the use of observable inputs and minimize the use of unobservable inputs to the extent possible and considers counterparty credit risk in its assessment of fair value.&lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; margin: 0px 0px 0px 0.49in; background: none;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; margin: 0px 0px 0px 0.49in;"&gt;&lt;div style="color:#000000;font-family:&amp;quot;times new roman&amp;quot;,times,serif;font-size:10pt;letter-spacing:0px;top:0px;;display:inline;"&gt;The fair value of the financial instruments included in the working capital of the Company is usually identical or close to their carrying value. The fair value of the convertible notes derivative is based on Level &lt;/div&gt;&lt;div style="color:#000000;font-family:&amp;quot;times new roman&amp;quot;,times,serif;font-size:10pt;letter-spacing:0px;top:0px;;display:inline;"&gt;3&lt;/div&gt;&lt;div style="color:#000000;font-family:&amp;quot;times new roman&amp;quot;,times,serif;font-size:10pt;letter-spacing:0px;top:0px;;display:inline;"&gt; measurement.&lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; margin: 0px 0px 0px 0.49in; background: none;"&gt;&lt;div style="color: rgb(0, 0, 0); font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px; background: none; text-decoration: none;;display:inline;"&gt;&lt;div style="background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; margin: 0px 0px 0px 0.49in;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;The fair value of the $57.9&amp;#160;&lt;/div&gt;million &lt;div style="color:#000000;font-family:&amp;quot;times new roman&amp;quot;,times,serif;font-size:10pt;letter-spacing:0px;top:0px;;display:inline;"&gt;principal amount of the Company&amp;#8217;s outstanding 7.50% convertible promissory notes due 2021 (the &amp;#8220;2021 Notes&amp;#8221;) as of March&amp;#160;31, 2019 is appro&lt;/div&gt;ximately $64.5&amp;#160;million based on a Level 3 measurement.&lt;/div&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; margin: 0px 0px 0px 0.49in; background: none;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;div style="color: rgb(0, 0, 0); font: 10pt &amp;quot;times new roman&amp;quot;, times, serif; letter-spacing: normal; orphans: 2; text-align: start; text-indent: 0px; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; margin: 0px 0px 0px 35.45pt;"&gt;The Company prepared a valuation of the fair value of the Company&amp;#8217;s outstanding 2021 Notes (a Level 3 valuation) as of March&amp;#160;31, 2019. The value of these notes was estimated by implementing the binomial model. The liability component was valued based on the Income Approach. The following parameters were used:&lt;/div&gt;&lt;div style="color: rgb(0, 0, 0); font: 10pt &amp;quot;times new roman&amp;quot;, times, serif; letter-spacing: normal; orphans: 2; text-align: start; text-indent: 0px; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; margin: 0px 0px 0px 35.45pt; background: none;"&gt;&amp;#160;&lt;/div&gt;&lt;table style="font: 10pt &amp;quot;times new roman&amp;quot;, times, serif; letter-spacing: normal; orphans: 2; text-indent: 0px; text-transform: none; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; border-collapse: collapse; width: 55%; margin-left: 0.5in; border-spacing: 0px;"&gt;&lt;tr style="vertical-align:bottom; background-color:white"&gt;&lt;td style="font-size: 10pt; padding-bottom: 1pt; padding-left: 5.4pt; padding-top: 0px;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font: 10pt &amp;quot;times new roman&amp;quot;, times, serif; padding-bottom: 1pt; padding-left: 0px; padding-top: 0px;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font: 10pt &amp;quot;times new roman&amp;quot;, times, serif; text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font: 10pt &amp;quot;times new roman&amp;quot;, times, serif; text-align: right; padding-left: 0px; padding-top: 0px;"&gt;&lt;div style="border-bottom: 0.5pt solid black; font-style: normal; font-variant: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: &amp;quot;times new roman&amp;quot;, times, serif; margin: 0px; text-align: center;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2021 Notes&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font: 10pt &amp;quot;times new roman&amp;quot;, times, serif; text-align: left; padding-left: 0px; padding-top: 0px;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align:bottom; background-color:#cceeff"&gt;&lt;td style="font-size: 10pt; width: 775.672px; text-indent: -10pt; padding-left: 10pt; padding-top: 0px; padding-bottom: 0px;"&gt;Stock price (USD)&lt;/td&gt;&lt;td style="font-size: 10pt; width: 21px; padding-left: 0px; padding-top: 0px; padding-bottom: 0px;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-size: 10pt; width: 10px; text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-size: 10pt; width: 207px; text-align: center; padding-left: 0px; padding-top: 0px; padding-bottom: 0px;"&gt;0.44&lt;/td&gt;&lt;td style="font-size: 10pt; width: 10px; text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align:bottom; background-color:white"&gt;&lt;td style="font-size: 10pt; text-align: left; text-indent: -10pt; padding-left: 10pt; padding-top: 0px; padding-bottom: 0px;"&gt;Expected term&lt;/td&gt;&lt;td style="font-size: 10pt; padding-left: 0px; padding-top: 0px; padding-bottom: 0px;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: center; padding-left: 0px; padding-top: 0px; padding-bottom: 0px;"&gt;2.63&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align:bottom; background-color:#cceeff"&gt;&lt;td style="font-size: 10pt; text-align: left; text-indent: -10pt; padding-left: 10pt; padding-top: 0px; padding-bottom: 0px;"&gt;Risk free rate&lt;/td&gt;&lt;td style="font-size: 10pt; padding-left: 0px; padding-top: 0px; padding-bottom: 0px;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: center; padding-left: 0px; line-height: 10pt; padding-top: 0px; padding-bottom: 0px;"&gt;2.21%&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align:bottom; background-color:white"&gt;&lt;td style="font-size: 10pt; text-indent: -10pt; padding-left: 10pt; padding-top: 0px; padding-bottom: 0px;"&gt;Volatility&lt;/td&gt;&lt;td style="font-size: 10pt; padding-left: 0px; padding-top: 0px; padding-bottom: 0px;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: center; padding-left: 0px; padding-top: 0px; padding-bottom: 0px;"&gt;81.56%&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align:bottom; background-color:#cceeff"&gt;&lt;td style="font-size: 10pt; text-indent: -10pt; padding-left: 10pt; padding-top: 0px; padding-bottom: 0px;"&gt;Yield&lt;/td&gt;&lt;td style="font-size: 10pt; padding-left: 0px; padding-top: 0px; padding-bottom: 0px;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: center; padding-left: 0px; padding-top: 0px; padding-bottom: 0px;"&gt;12.6%&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="clear: both; max-height: 0px;"&gt;&lt;/div&gt;&lt;div style="clear: both; max-height: 0px; background: none;"&gt;&lt;/div&gt;&lt;div style="color: rgb(0, 0, 0); font: 10pt &amp;quot;times new roman&amp;quot;, times, serif; letter-spacing: normal; orphans: 2; text-align: start; text-indent: 0px; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; margin: 0px 0px 0px 70.75pt; background: none;"&gt;&amp;#160;&lt;/div&gt; &lt;table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"&gt;&lt;tr&gt;&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="clear: both; max-height: 0px;"&gt;&lt;/div&gt;&lt;div style="clear: both; max-height: 0px;"&gt;&lt;/div&gt;&lt;div style="clear: both; max-height: 0px;"&gt;&lt;/div&gt;&lt;div style="clear: both; max-height: 0px;"&gt;&lt;/div&gt;&lt;div style="clear: both; max-height: 0px;"&gt;&lt;/div&gt;&lt;div style="clear: both; max-height: 0px;"&gt;&lt;/div&gt;&lt;div style="clear: both; max-height: 0px;"&gt;&lt;/div&gt;&lt;table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"&gt;&lt;tr&gt;&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:FairValueDisclosuresTextBlock>
<us-gaap:InventoryWriteDown id="Factid_5211853" contextRef="P01_01_2018To12_31_2018" unitRef="Unit_USD" decimals="-5">1100000</us-gaap:InventoryWriteDown>
<us-gaap:InventoryWriteDown id="Factid_5211854" contextRef="P01_01_2019To03_31_2019" unitRef="Unit_USD" decimals="0">65000</us-gaap:InventoryWriteDown>
<us-gaap:ScheduleOfInventoryCurrentTableTextBlock id="Factid_5211866" contextRef="P01_01_2019To03_31_2019">&lt;table cellpadding="0" cellspacing="0" style="font: 10pt &amp;quot;times new roman&amp;quot;, times, serif; letter-spacing: normal; orphans: 2; text-indent: 0px; text-transform: none; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; margin-top: 0pt; margin-bottom: 0pt; border-collapse: collapse; border-spacing: 0px; table-layout: fixed;;width:100%;"&gt;&lt;tr style="vertical-align: top;"&gt;&lt;td style="width: 0.5in; padding: 0px;"&gt;&lt;/td&gt;&lt;td style="width: 0.25in; padding-left: 0px; padding-top: 0px; padding-bottom: 0px;"&gt;a.&lt;/td&gt;&lt;td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;"&gt;Inventories at March&amp;#160;31, 2019 and December&amp;#160;31, 2018 consisted of the following:&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="clear: both; max-height: 0px;"&gt;&lt;/div&gt;&lt;div style="clear: both; max-height: 0px;"&gt;&lt;/div&gt;&lt;div style="clear: both; max-height: 0px;"&gt;&lt;/div&gt;&lt;div style="clear: both; max-height: 0px;"&gt;&lt;/div&gt;&lt;div style="clear: both; max-height: 0px;"&gt;&lt;/div&gt;&lt;div style="clear: both; max-height: 0px;"&gt;&lt;/div&gt;&lt;table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"&gt;&lt;tr&gt;&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt &amp;quot;times new roman&amp;quot;, times, serif; letter-spacing: normal; orphans: 2; text-indent: 0px; text-transform: none; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; border-collapse: collapse; width: 94%; border-spacing: 0px; margin: 0in 0in 0in auto;;text-align:left;"&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td style="font-size: 10pt; text-align: center; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; font-family: &amp;quot;times new roman&amp;quot;, times, serif; vertical-align: middle;;width:;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font: 10pt &amp;quot;times new roman&amp;quot;, times, serif; padding-bottom: 1pt; padding-left: 0px; padding-top: 0px; vertical-align: middle;;width:;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2" style="font: 10pt &amp;quot;times new roman&amp;quot;, times, serif; text-align: center; border-bottom: 1pt solid black; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; vertical-align: middle;;width:;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;March&amp;#160;31,&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font: 10pt &amp;quot;times new roman&amp;quot;, times, serif; padding-left: 0px; padding-top: 0px; vertical-align: middle;;width:;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font: 10pt &amp;quot;times new roman&amp;quot;, times, serif; padding-bottom: 1pt; padding-left: 0px; padding-top: 0px; vertical-align: middle;;width:;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2" style="font: 10pt &amp;quot;times new roman&amp;quot;, times, serif; text-align: center; border-bottom: 1pt solid black; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; vertical-align: middle;;width:;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;December&amp;#160;31,&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font: 10pt &amp;quot;times new roman&amp;quot;, times, serif; padding-left: 0px; padding-top: 0px; vertical-align: middle;;width:;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td style="font-size: 10pt; padding-bottom: 1pt; padding-left: 0px; padding-top: 0px; vertical-align: middle;;width:;"&gt;(&lt;div style="font-style:italic;display:inline;;font-style:italic;display:inline;"&gt;U.S. dollars in thousands)&lt;/div&gt;&lt;/td&gt;&lt;td style="font: 10pt &amp;quot;times new roman&amp;quot;, times, serif; padding-bottom: 1pt; padding-left: 0px; padding-top: 0px; vertical-align: middle;;width:;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2" style="font: 10pt &amp;quot;times new roman&amp;quot;, times, serif; text-align: center; border-bottom: 1pt solid black; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; vertical-align: middle;;width:;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2019&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font: 10pt &amp;quot;times new roman&amp;quot;, times, serif; padding-left: 0px; padding-top: 0px; vertical-align: middle;;width:;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font: 10pt &amp;quot;times new roman&amp;quot;, times, serif; padding-bottom: 1pt; padding-left: 0px; padding-top: 0px; vertical-align: middle;;width:;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2" style="font: 10pt &amp;quot;times new roman&amp;quot;, times, serif; text-align: center; border-bottom: 1pt solid black; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; vertical-align: middle;;width:;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2018&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font: 10pt &amp;quot;times new roman&amp;quot;, times, serif; padding-left: 0px; padding-top: 0px; vertical-align: middle;;width:;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&lt;td style="width: 70%; font-size: 10pt; text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; vertical-align: middle;"&gt;Raw materials&lt;/td&gt;&lt;td style="width: 0%; font-size: 10pt; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; font-family: &amp;quot;times new roman&amp;quot;, times, serif; vertical-align: middle;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 1%; font-size: 10pt; text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; vertical-align: middle;"&gt;$&lt;/td&gt;&lt;td style="width: 12%; font-size: 10pt; text-align: right; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; vertical-align: middle;"&gt;3,047&lt;/td&gt;&lt;td style="width: 1%; font-size: 10pt; text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; font-family: &amp;quot;times new roman&amp;quot;, times, serif; vertical-align: middle;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 2%; font-size: 10pt; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; font-family: &amp;quot;times new roman&amp;quot;, times, serif; vertical-align: middle;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 1%; font-size: 10pt; text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; vertical-align: middle;"&gt;$&lt;/td&gt;&lt;td style="width: 12%; font-size: 10pt; text-align: right; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; vertical-align: middle;"&gt;3,792&lt;/td&gt;&lt;td style="width: 1%; font-size: 10pt; text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; font-family: &amp;quot;times new roman&amp;quot;, times, serif; vertical-align: middle;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: white;"&gt;&lt;td style="font-size: 10pt; text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; vertical-align: middle; width: 70%;"&gt;Work in progress&lt;/td&gt;&lt;td style="font-size: 10pt; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; font-family: &amp;quot;times new roman&amp;quot;, times, serif; vertical-align: middle; width: 0%;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; font-family: &amp;quot;times new roman&amp;quot;, times, serif; vertical-align: middle; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; vertical-align: middle; width: 12%;"&gt;45&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; font-family: &amp;quot;times new roman&amp;quot;, times, serif; vertical-align: middle; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-size: 10pt; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; font-family: &amp;quot;times new roman&amp;quot;, times, serif; vertical-align: middle; width: 2%;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; font-family: &amp;quot;times new roman&amp;quot;, times, serif; vertical-align: middle; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; font-family: &amp;quot;times new roman&amp;quot;, times, serif; vertical-align: middle; width: 12%;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; font-family: &amp;quot;times new roman&amp;quot;, times, serif; vertical-align: middle; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&lt;td style="font-size: 10pt; text-align: left; padding-bottom: 1pt; padding-left: 0px; padding-top: 0px; vertical-align: middle; width: 70%;"&gt;Finished goods&lt;/td&gt;&lt;td style="font: 10pt &amp;quot;times new roman&amp;quot;, times, serif; padding-bottom: 1pt; padding-left: 0px; padding-top: 0px; vertical-align: middle; width: 0%;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: 1pt solid black; font: 10pt &amp;quot;times new roman&amp;quot;, times, serif; text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; vertical-align: middle; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: 1pt solid black; font: 10pt &amp;quot;times new roman&amp;quot;, times, serif; text-align: right; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; vertical-align: middle; width: 12%;"&gt;3,615&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font: 10pt &amp;quot;times new roman&amp;quot;, times, serif; text-align: left; padding-left: 0px; padding-top: 0px; vertical-align: middle; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font: 10pt &amp;quot;times new roman&amp;quot;, times, serif; padding-bottom: 1pt; padding-left: 0px; padding-top: 0px; vertical-align: middle; width: 2%;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: 1pt solid black; font: 10pt &amp;quot;times new roman&amp;quot;, times, serif; text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; vertical-align: middle; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: 1pt solid black; font: 10pt &amp;quot;times new roman&amp;quot;, times, serif; text-align: right; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; vertical-align: middle; width: 12%;"&gt;4,777&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font: 10pt &amp;quot;times new roman&amp;quot;, times, serif; text-align: left; padding-left: 0px; padding-top: 0px; vertical-align: middle; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: white;"&gt;&lt;td style="font-size: 10pt; text-align: left; padding-bottom: 2.5pt; padding-left: 0px; padding-top: 0px; vertical-align: middle; width: 70%;"&gt;Total inventory&lt;/td&gt;&lt;td style="font: 10pt &amp;quot;times new roman&amp;quot;, times, serif; padding-bottom: 2.5pt; padding-left: 0px; padding-top: 0px; vertical-align: middle; width: 0%;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: 2.5pt double black; font: 10pt &amp;quot;times new roman&amp;quot;, times, serif; text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; vertical-align: middle; width: 1%;"&gt;$&lt;/td&gt;&lt;td style="border-bottom: 2.5pt double black; font: 10pt &amp;quot;times new roman&amp;quot;, times, serif; text-align: right; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; vertical-align: middle; width: 12%;"&gt;6,707&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font: 10pt &amp;quot;times new roman&amp;quot;, times, serif; text-align: left; padding-left: 0px; padding-top: 0px; vertical-align: middle; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font: 10pt &amp;quot;times new roman&amp;quot;, times, serif; padding-bottom: 2.5pt; padding-left: 0px; padding-top: 0px; vertical-align: middle; width: 2%;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: 2.5pt double black; font: 10pt &amp;quot;times new roman&amp;quot;, times, serif; text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; vertical-align: middle; width: 1%;"&gt;$&lt;/td&gt;&lt;td style="border-bottom: 2.5pt double black; font: 10pt &amp;quot;times new roman&amp;quot;, times, serif; text-align: right; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; vertical-align: middle; width: 12%;"&gt;8,569&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font: 10pt &amp;quot;times new roman&amp;quot;, times, serif; text-align: left; padding-left: 0px; padding-top: 0px; vertical-align: middle; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="clear: both; max-height: 0px;"&gt;&lt;/div&gt;&lt;div style="clear: both; max-height: 0px;"&gt;&lt;/div&gt;&lt;div style="clear: both; max-height: 0px;"&gt;&lt;/div&gt;&lt;div style="clear: both; max-height: 0px;"&gt;&lt;/div&gt;&lt;div style="clear: both; max-height: 0px;"&gt;&lt;/div&gt;&lt;div style="clear: both; max-height: 0px;"&gt;&lt;/div&gt;&lt;table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"&gt;&lt;tr&gt;&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfInventoryCurrentTableTextBlock>
<us-gaap:InventoryDisclosureTextBlock id="Factid_5211999" contextRef="P01_01_2019To03_31_2019">&lt;div style="color: rgb(0, 0, 0); font: 10pt &amp;quot;times new roman&amp;quot;, times, serif; letter-spacing: normal; orphans: 2; text-align: start; text-indent: 0in; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; margin: 0px;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;NOTE 2 - INVENTORIES&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="color: rgb(0, 0, 0); font: 10pt &amp;quot;times new roman&amp;quot;, times, serif; letter-spacing: normal; orphans: 2; text-align: start; text-indent: 0in; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; margin: 0px; background: none;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt &amp;quot;times new roman&amp;quot;, times, serif; letter-spacing: normal; orphans: 2; text-indent: 0px; text-transform: none; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; margin-top: 0pt; margin-bottom: 0pt; border-collapse: collapse; border-spacing: 0px; table-layout: fixed;;width:100%;"&gt;&lt;tr style="vertical-align: top;"&gt;&lt;td style="width: 0.5in; padding: 0px;"&gt;&lt;/td&gt;&lt;td style="width: 0.25in; padding-left: 0px; padding-top: 0px; padding-bottom: 0px;"&gt;a.&lt;/td&gt;&lt;td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;"&gt;Inventories at March&amp;#160;31, 2019 and December&amp;#160;31, 2018 consisted of the following:&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="clear: both; max-height: 0px;"&gt;&lt;/div&gt;&lt;div style="clear: both; max-height: 0px;"&gt;&lt;/div&gt;&lt;div style="clear: both; max-height: 0px;"&gt;&lt;/div&gt;&lt;div style="clear: both; max-height: 0px;"&gt;&lt;/div&gt;&lt;div style="clear: both; max-height: 0px;"&gt;&lt;/div&gt;&lt;div style="clear: both; max-height: 0px;"&gt;&lt;/div&gt;&lt;div style="color: rgb(0, 0, 0); font: 10pt &amp;quot;times new roman&amp;quot;, times, serif; letter-spacing: normal; orphans: 2; text-align: start; text-indent: 0px; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; margin-top: 0px; margin-bottom: 0px; margin-right: 0px; background: none;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt &amp;quot;times new roman&amp;quot;, times, serif; letter-spacing: normal; orphans: 2; text-indent: 0px; text-transform: none; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; border-collapse: collapse; width: 94%; border-spacing: 0px; margin: 0in 0in 0in auto;;text-align:left;"&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td style="font-size: 10pt; text-align: center; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; font-family: &amp;quot;times new roman&amp;quot;, times, serif; vertical-align: middle;;width:;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font: 10pt &amp;quot;times new roman&amp;quot;, times, serif; padding-bottom: 1pt; padding-left: 0px; padding-top: 0px; vertical-align: middle;;width:;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2" style="font: 10pt &amp;quot;times new roman&amp;quot;, times, serif; text-align: center; border-bottom: 1pt solid black; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; vertical-align: middle;;width:;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;March&amp;#160;31,&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font: 10pt &amp;quot;times new roman&amp;quot;, times, serif; padding-left: 0px; padding-top: 0px; vertical-align: middle;;width:;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font: 10pt &amp;quot;times new roman&amp;quot;, times, serif; padding-bottom: 1pt; padding-left: 0px; padding-top: 0px; vertical-align: middle;;width:;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2" style="font: 10pt &amp;quot;times new roman&amp;quot;, times, serif; text-align: center; border-bottom: 1pt solid black; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; vertical-align: middle;;width:;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;December&amp;#160;31,&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font: 10pt &amp;quot;times new roman&amp;quot;, times, serif; padding-left: 0px; padding-top: 0px; vertical-align: middle;;width:;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td style="font-size: 10pt; padding-bottom: 1pt; padding-left: 0px; padding-top: 0px; vertical-align: middle;;width:;"&gt;(&lt;div style="font-style:italic;display:inline;;font-style:italic;display:inline;"&gt;U.S. dollars in thousands)&lt;/div&gt;&lt;/td&gt;&lt;td style="font: 10pt &amp;quot;times new roman&amp;quot;, times, serif; padding-bottom: 1pt; padding-left: 0px; padding-top: 0px; vertical-align: middle;;width:;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2" style="font: 10pt &amp;quot;times new roman&amp;quot;, times, serif; text-align: center; border-bottom: 1pt solid black; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; vertical-align: middle;;width:;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2019&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font: 10pt &amp;quot;times new roman&amp;quot;, times, serif; padding-left: 0px; padding-top: 0px; vertical-align: middle;;width:;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font: 10pt &amp;quot;times new roman&amp;quot;, times, serif; padding-bottom: 1pt; padding-left: 0px; padding-top: 0px; vertical-align: middle;;width:;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2" style="font: 10pt &amp;quot;times new roman&amp;quot;, times, serif; text-align: center; border-bottom: 1pt solid black; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; vertical-align: middle;;width:;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2018&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font: 10pt &amp;quot;times new roman&amp;quot;, times, serif; padding-left: 0px; padding-top: 0px; vertical-align: middle;;width:;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&lt;td style="width: 70%; font-size: 10pt; text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; vertical-align: middle;"&gt;Raw materials&lt;/td&gt;&lt;td style="width: 0%; font-size: 10pt; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; font-family: &amp;quot;times new roman&amp;quot;, times, serif; vertical-align: middle;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 1%; font-size: 10pt; text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; vertical-align: middle;"&gt;$&lt;/td&gt;&lt;td style="width: 12%; font-size: 10pt; text-align: right; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; vertical-align: middle;"&gt;3,047&lt;/td&gt;&lt;td style="width: 1%; font-size: 10pt; text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; font-family: &amp;quot;times new roman&amp;quot;, times, serif; vertical-align: middle;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 2%; font-size: 10pt; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; font-family: &amp;quot;times new roman&amp;quot;, times, serif; vertical-align: middle;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 1%; font-size: 10pt; text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; vertical-align: middle;"&gt;$&lt;/td&gt;&lt;td style="width: 12%; font-size: 10pt; text-align: right; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; vertical-align: middle;"&gt;3,792&lt;/td&gt;&lt;td style="width: 1%; font-size: 10pt; text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; font-family: &amp;quot;times new roman&amp;quot;, times, serif; vertical-align: middle;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: white;"&gt;&lt;td style="font-size: 10pt; text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; vertical-align: middle; width: 70%;"&gt;Work in progress&lt;/td&gt;&lt;td style="font-size: 10pt; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; font-family: &amp;quot;times new roman&amp;quot;, times, serif; vertical-align: middle; width: 0%;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; font-family: &amp;quot;times new roman&amp;quot;, times, serif; vertical-align: middle; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; vertical-align: middle; width: 12%;"&gt;45&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; font-family: &amp;quot;times new roman&amp;quot;, times, serif; vertical-align: middle; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-size: 10pt; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; font-family: &amp;quot;times new roman&amp;quot;, times, serif; vertical-align: middle; width: 2%;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; font-family: &amp;quot;times new roman&amp;quot;, times, serif; vertical-align: middle; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; font-family: &amp;quot;times new roman&amp;quot;, times, serif; vertical-align: middle; width: 12%;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; font-family: &amp;quot;times new roman&amp;quot;, times, serif; vertical-align: middle; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&lt;td style="font-size: 10pt; text-align: left; padding-bottom: 1pt; padding-left: 0px; padding-top: 0px; vertical-align: middle; width: 70%;"&gt;Finished goods&lt;/td&gt;&lt;td style="font: 10pt &amp;quot;times new roman&amp;quot;, times, serif; padding-bottom: 1pt; padding-left: 0px; padding-top: 0px; vertical-align: middle; width: 0%;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: 1pt solid black; font: 10pt &amp;quot;times new roman&amp;quot;, times, serif; text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; vertical-align: middle; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: 1pt solid black; font: 10pt &amp;quot;times new roman&amp;quot;, times, serif; text-align: right; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; vertical-align: middle; width: 12%;"&gt;3,615&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font: 10pt &amp;quot;times new roman&amp;quot;, times, serif; text-align: left; padding-left: 0px; padding-top: 0px; vertical-align: middle; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font: 10pt &amp;quot;times new roman&amp;quot;, times, serif; padding-bottom: 1pt; padding-left: 0px; padding-top: 0px; vertical-align: middle; width: 2%;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: 1pt solid black; font: 10pt &amp;quot;times new roman&amp;quot;, times, serif; text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; vertical-align: middle; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: 1pt solid black; font: 10pt &amp;quot;times new roman&amp;quot;, times, serif; text-align: right; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; vertical-align: middle; width: 12%;"&gt;4,777&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font: 10pt &amp;quot;times new roman&amp;quot;, times, serif; text-align: left; padding-left: 0px; padding-top: 0px; vertical-align: middle; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: white;"&gt;&lt;td style="font-size: 10pt; text-align: left; padding-bottom: 2.5pt; padding-left: 0px; padding-top: 0px; vertical-align: middle; width: 70%;"&gt;Total inventory&lt;/td&gt;&lt;td style="font: 10pt &amp;quot;times new roman&amp;quot;, times, serif; padding-bottom: 2.5pt; padding-left: 0px; padding-top: 0px; vertical-align: middle; width: 0%;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: 2.5pt double black; font: 10pt &amp;quot;times new roman&amp;quot;, times, serif; text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; vertical-align: middle; width: 1%;"&gt;$&lt;/td&gt;&lt;td style="border-bottom: 2.5pt double black; font: 10pt &amp;quot;times new roman&amp;quot;, times, serif; text-align: right; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; vertical-align: middle; width: 12%;"&gt;6,707&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font: 10pt &amp;quot;times new roman&amp;quot;, times, serif; text-align: left; padding-left: 0px; padding-top: 0px; vertical-align: middle; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font: 10pt &amp;quot;times new roman&amp;quot;, times, serif; padding-bottom: 2.5pt; padding-left: 0px; padding-top: 0px; vertical-align: middle; width: 2%;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: 2.5pt double black; font: 10pt &amp;quot;times new roman&amp;quot;, times, serif; text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; vertical-align: middle; width: 1%;"&gt;$&lt;/td&gt;&lt;td style="border-bottom: 2.5pt double black; font: 10pt &amp;quot;times new roman&amp;quot;, times, serif; text-align: right; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; vertical-align: middle; width: 12%;"&gt;8,569&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font: 10pt &amp;quot;times new roman&amp;quot;, times, serif; text-align: left; padding-left: 0px; padding-top: 0px; vertical-align: middle; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="clear: both; max-height: 0px;"&gt;&lt;/div&gt;&lt;div style="clear: both; max-height: 0px;"&gt;&lt;/div&gt;&lt;div style="clear: both; max-height: 0px;"&gt;&lt;/div&gt;&lt;div style="clear: both; max-height: 0px;"&gt;&lt;/div&gt;&lt;div style="clear: both; max-height: 0px;"&gt;&lt;/div&gt;&lt;div style="clear: both; max-height: 0px;"&gt;&lt;/div&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt &amp;quot;times new roman&amp;quot;, times, serif; letter-spacing: normal; orphans: 2; text-indent: 0px; text-transform: none; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; margin-top: 0pt; margin-bottom: 0pt; border-collapse: collapse; border-spacing: 0px; table-layout: fixed;;width:100%;"&gt;&lt;tr style="vertical-align: top;"&gt;&lt;td style="width: 0.5in; padding: 0px;"&gt;&lt;/td&gt;&lt;td style="width: 0.25in; padding-left: 0px; padding-top: 0px; padding-bottom: 0px;"&gt;b.&lt;/td&gt;&lt;td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;"&gt;During the year ended December&amp;#160;31, 2018 and the three months ended March&amp;#160;31, 2019, the Company recorded approximately $&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;1.1&lt;/div&gt;&amp;#160;million and $&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;65,000&lt;/div&gt;, respectively, for write-down of inventory under cost of goods sold.&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="clear: both; max-height: 0px;"&gt;&lt;/div&gt;&lt;div style="clear: both; max-height: 0px;"&gt;&lt;/div&gt;&lt;div style="clear: both; max-height: 0px;"&gt;&lt;/div&gt;&lt;div style="clear: both; max-height: 0px;"&gt;&lt;/div&gt;&lt;div style="clear: both; max-height: 0px;"&gt;&lt;/div&gt;&lt;div style="clear: both; max-height: 0px;"&gt;&lt;/div&gt; &lt;table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"&gt;&lt;tr&gt;&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:InventoryDisclosureTextBlock>
<us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock id="Factid_5212000" contextRef="P01_01_2019To03_31_2019">&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; margin-bottom: 0px; margin-top: 0px; margin-right: 0px;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;NOTE 1 - SIGNIFICANT ACCOUNTING POLICIES &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; margin-bottom: 0px; margin-top: 0px; margin-right: 0px; background: none;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border: none; border-collapse: collapse; margin-bottom: 0.001pt; width: 100%; table-layout: fixed;"&gt;&lt;tr&gt;&lt;td style="border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: top;width: 36pt;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; margin-right: 0px; margin-bottom: 0px; margin-top: 0px; line-height: normal;"&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: top;width: 18pt;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; margin-right: 0px; margin-bottom: 0px; margin-top: 0px; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;a.&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: top;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; margin-right: 0px; margin-bottom: 0px; margin-top: 0px; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;General&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="clear: both; max-height: 0px;"&gt;&lt;/div&gt;&lt;div style="clear: both; max-height: 0px;"&gt;&lt;/div&gt;&lt;div style="clear: both; max-height: 0px;"&gt;&lt;/div&gt;&lt;div style="clear: both; max-height: 0px;"&gt;&lt;/div&gt;&lt;div style="clear: both; max-height: 0px;"&gt;&lt;/div&gt;&lt;div style="clear: both; max-height: 0px;"&gt;&lt;/div&gt;&lt;div style="clear: both; max-height: 0px;"&gt;&lt;/div&gt;&lt;div style="clear: both; max-height: 0px;"&gt;&lt;/div&gt;&lt;div style="clear: both; max-height: 0px;"&gt;&lt;/div&gt;&lt;div style="clear: both; max-height: 0px;"&gt;&lt;/div&gt;&lt;div style="clear: both; max-height: 0px;"&gt;&lt;/div&gt;&lt;div style="clear: both; max-height: 0px;"&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; margin-bottom: 0px; margin-top: 0px; margin-right: 0px; background: none;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; margin: 0px 0px 0px 0.5in;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;Protalix BioTherapeutics, Inc. (collectively with its subsidiaries, the &amp;#8220;Company&amp;#8221;)&amp;#160;and its wholly-owned subsidiaries, Protalix Ltd. and Protalix B.V. (the &amp;#8220;Subsidiaries&amp;#8221;), are biopharmaceutical companies focused on the development and commercialization of recombinant therapeutic proteins based on the Company&amp;#8217;s proprietary ProCellEx&lt;div style="vertical-align: super;font-size: smaller;display:inline;"&gt;&amp;#174;&lt;/div&gt; protein expression system (&amp;#8220;ProCellEx&amp;#8221;). To date, the Company has successfully developed taliglucerase alfa (marketed under the name alfataliglicerase in Brazil and certain other Latin American countries and Elelyso&lt;div style="vertical-align: super;font-size: smaller;display:inline;"&gt;&amp;#174;&lt;/div&gt; in the rest of the territories) for the treatment of Gaucher disease that has been approved for marketing in the United States, Brazil, Israel and other markets. The Company has a number of product candidates in varying stages of the clinical development process. The Company&amp;#8217;s strategy is to develop proprietary recombinant proteins that are therapeutically superior to existing recombinant proteins currently marketed for the same indications.&lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; margin: 0px 0px 0px 0.5in; background: none;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; margin: 0px 0px 0px 0.5in;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;The Company&amp;#8217;s product pipeline currently includes, among other candidates:&lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; margin: 0px 0px 0px 0.5in; background: none;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; margin: 0px 0px 0px 0.5in;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;(1) pegunigalsidase alfa, or PRX-102, a therapeutic protein candidate for the treatment of Fabry disease, a rare, genetic lysosomal disorder;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; margin: 0px 0px 0px 0.5in; background: none;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; margin: 0px 0px 0px 0.5in;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;(2) alidornase alfa, or PRX-110, a proprietary plant cell recombinant human Deoxyribonuclease 1, or DNase, under development for the treatment of Cystic Fibrosis, to be administered by inhalation; and&lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; margin: 0px 0px 0px 0.5in; background: none;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; margin: 0px 0px 0px 0.5in;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;(3) OPRX-106, the Company&amp;#8217;s oral antiTNF product candidate which is being developed as an orally-delivered anti-inflammatory treatment using plant cells as a natural capsule for the expressed protein.&lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; margin: 0px 0px 0px 0.5in; background: none;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; margin: 0px 0px 0px 0.5in;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;Obtaining marketing approval with respect to any product candidate in any country is dependent on the Company&amp;#8217;s ability to implement the necessary regulatory steps required to obtain such approvals. The Company cannot reasonably predict the outcome of these activities.&lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; margin: 0px 0px 0px 0.5in; background: none;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; margin: 0px 0px 0px 0.5in;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;On October&amp;#160;19, 2017, Protalix Ltd. and Chiesi Farmaceutici S.p.A. (&amp;#8220;Chiesi&amp;#8221;) entered into an Exclusive License and Supply Agreement (the &amp;#8220;Chiesi Ex-US Agreement&amp;#8221;) pursuant to which Chiesi was granted an exclusive license for all markets outside of the United States to commercialize pegunigalsidase alfa. On July&amp;#160;23, 2018, Protalix Ltd. entered into an Exclusive License and Supply Agreement with Chiesi (the &amp;#8220;Chiesi US Agreement&amp;#8221;)&amp;#160;with respect to the commercialization of pegunigalsidase alfa in the United States.&lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; margin: 0px 0px 0px 0.5in; background: none;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; margin: 0px 0px 0px 0.5in;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;Under each of the Chiesi Ex-US Agreement and the Chiesi US Agreement&amp;#160;(collectively,&amp;#160;the &lt;/div&gt;&amp;#8220;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;Chiesi Agreements&lt;/div&gt;&amp;#8221;)&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;, Chiesi made an upfront payment to Protalix Ltd. of $25.0&amp;#160;million in connection with the execution of the agreement. In addition, under the Chiesi Ex-US Agreement, Protalix Ltd. is entitled to additional payments of up to $25.0&amp;#160;million in pegunigalsidase alfa development costs, capped at $10.0&amp;#160;million per year, and to receive additional payments of up to $320.0&amp;#160;million, in the aggregate, in regulatory and commercial milestone payments. Under the Chiesi US Agreement, Protalix Ltd. is entitled to payments of up to a maximum of $20.0&amp;#160;million to cover development costs for pegunigalsidase alfa, subject to a maximum of $7.5&amp;#160;million per year, and to receive an additional up to a maximum of $760.0&amp;#160;million, in the aggregate, in regulatory and commercial milestone payments.&lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; margin: 0px 0px 0px 0.5in; background: none;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; margin: 0px 0px 0px 0.5in;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;Under the terms of both of the Chiesi Agreements, Protalix Ltd. will manufacture all of the pegunigalsidase alfa needed under the agreements, subject to certain exceptions, and Chiesi will purchase pegunigalsidase alfa from Protalix, subject to certain terms and conditions. Under the Chiesi Ex-US Agreement, Chiesi is required to make tiered payments of 15% to 35% of its net sales, depending on the amount of annual sales outside of the United States, as consideration for product supply. Under the Chiesi US Agreement, Chiesi is required to make tiered payments of 15% to 40% of its net sales, depending on the amount of annual sales in the United States, as consideration for product supply.&lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; margin: 0px 0px 0px 0.5in; background: none;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; margin: 0px 0px 0px 0.5in;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;Since its approval by the FDA, taliglucerase alfa has been marketed by Pfizer in accordance with the exclusive license and supply agreement entered&amp;#160;into&amp;#160;between Protalix Ltd. and Pfizer, which is referred to herein as the Pfizer Agreement. In October 2015, the Company sold to Pfizer its share in the collaboration created under the Pfizer Agreement for the commercialization of Elelyso. As part of the sale, the Company agreed to transfer its rights to Elelyso in Israel to Pfizer while gaining full rights to it in Brazil. Under the Amended Pfizer Agreement, Pfizer is entitled to all of the revenues, and is responsible for 100% of expenses globally for Elelyso, excluding Brazil where the Company is responsible for all expenses and retains all revenues.&lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; margin: 0px 0px 0px 0.5in; background: none;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; margin: 0px 0px 0px 0.5in;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;On June&amp;#160;18, 2013, the Company entered into a Supply and Technology Transfer Agreement (the &amp;#8220;Brazil Agreement&amp;#8221;) with Fiocruz, an arm of the Brazilian MoH, for taliglucerase alfa. Fiocruz&amp;#8217;s purchases of alfataliglicerase to date have been significantly below certain agreed upon purchase milestones and, accordingly, the Company has the right to terminate the Brazil Agreement. Notwithstanding the termination right, the Company is, at this time, continuing to supply alfataliglicerase to Fiocruz under the Brazil Agreement, and patients continue to be treated with alfataliglicerase in Brazil.&lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; margin: 0px 0px 0px 0.5in; background: none;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;div style="color: rgb(0, 0, 0); font: 10pt &amp;quot;times new roman&amp;quot;, times, serif; letter-spacing: normal; orphans: 2; text-align: start; text-indent: 0in; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; margin: 0px 0px 0px 0.5in;"&gt;Based on its current cash resources and commitments, the Company believes it will be able to maintain its current planned development activities and the corresponding level of expenditures for at least 12 months from the date of approval of the financial statements as of March&amp;#160;31, 2019, although no assurance can be given that it will not need additional funds prior to such time. If there are unexpected increases in general and administrative expenses or research and development expenses, the Company may need to seek additional financing.&lt;/div&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; margin: 0px 0px 0px 0.5in; background: none;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border: none; border-collapse: collapse; margin-bottom: 0.001pt; width: 100%; table-layout: fixed;"&gt;&lt;tr&gt;&lt;td style="border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: top;width: 36pt;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; margin-right: 0px; margin-bottom: 0px; margin-top: 0px; line-height: normal;"&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: top;width: 18pt;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; margin-right: 0px; margin-bottom: 0px; margin-top: 0px; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;b.&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0;padding-left: 0;padding-right: 81.4pt;padding-top: 0;vertical-align: top;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; margin-right: 0px; margin-bottom: 0px; margin-top: 0px; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Basis of presentation&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="clear: both; max-height: 0px;"&gt;&lt;/div&gt;&lt;div style="clear: both; max-height: 0px;"&gt;&lt;/div&gt;&lt;div style="clear: both; max-height: 0px;"&gt;&lt;/div&gt;&lt;div style="clear: both; max-height: 0px;"&gt;&lt;/div&gt;&lt;div style="clear: both; max-height: 0px;"&gt;&lt;/div&gt;&lt;div style="clear: both; max-height: 0px;"&gt;&lt;/div&gt;&lt;div style="clear: both; max-height: 0px;"&gt;&lt;/div&gt;&lt;div style="clear: both; max-height: 0px;"&gt;&lt;/div&gt;&lt;div style="clear: both; max-height: 0px;"&gt;&lt;/div&gt;&lt;div style="clear: both; max-height: 0px;"&gt;&lt;/div&gt;&lt;div style="clear: both; max-height: 0px;"&gt;&lt;/div&gt;&lt;div style="clear: both; max-height: 0px;"&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; margin-bottom: 0px; margin-top: 0px; margin-right: 0px; background: none;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; margin: 0px 0px 0px 0.5in;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;The accompanying unaudited condensed consolidated financial statements of the Company have been prepared in accordance with accounting principles generally accepted in the United States (&amp;#8220;GAAP&amp;#8221;) for interim financial information. Accordingly, they do not include all of the information and notes required by GAAP for annual financial statements. In the opinion of management, all adjustments (of a normal recurring nature) considered necessary for a fair statement of the results for the interim periods presented have been included. Operating results for the interim period are not necessarily indicative of the results that may be expected for the full year.&lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; margin: 0px 0px 0px 0.5in; background: none;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; margin: 0px 0px 0px 0.5in;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;These unaudited condensed consolidated financial statements should be read in conjunction with the audited consolidated financial statements in the Annual Report on Form 10-K for the year ended December&amp;#160;31, 2018, filed by the Company with the Commission. The comparative balance sheet at December&amp;#160;31, 2018 has been derived from the audited financial statements at that date.&lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; margin: 0px 0px 0px 0.5in; background: none;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border: none; border-collapse: collapse; margin-bottom: 0.001pt; width: 100%; table-layout: fixed;"&gt;&lt;tr&gt;&lt;td style="border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: top;width: 36pt;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; margin-right: 0px; margin-bottom: 0px; margin-top: 0px; line-height: normal;"&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: top;width: 18pt;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; margin-right: 0px; margin-bottom: 0px; margin-top: 0px; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;c.&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0;padding-left: 0;padding-right: 81.4pt;padding-top: 0;vertical-align: top;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; margin-right: 0px; margin-bottom: 0px; margin-top: 0px; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Net loss per share&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="clear: both; max-height: 0px;"&gt;&lt;/div&gt;&lt;div style="clear: both; max-height: 0px;"&gt;&lt;/div&gt;&lt;div style="clear: both; max-height: 0px;"&gt;&lt;/div&gt;&lt;div style="clear: both; max-height: 0px;"&gt;&lt;/div&gt;&lt;div style="clear: both; max-height: 0px;"&gt;&lt;/div&gt;&lt;div style="clear: both; max-height: 0px;"&gt;&lt;/div&gt;&lt;div style="clear: both; max-height: 0px;"&gt;&lt;/div&gt;&lt;div style="clear: both; max-height: 0px;"&gt;&lt;/div&gt;&lt;div style="clear: both; max-height: 0px;"&gt;&lt;/div&gt;&lt;div style="clear: both; max-height: 0px;"&gt;&lt;/div&gt;&lt;div style="clear: both; max-height: 0px;"&gt;&lt;/div&gt;&lt;div style="clear: both; max-height: 0px;"&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; margin-bottom: 0px; margin-top: 0px; margin-right: 0px; background: none;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; margin: 0px 0px 0px 0.5in;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;Basic and diluted loss per share (&amp;#8220;LPS&amp;#8221;) are computed by dividing net loss by the weighted average number of shares of the Company&amp;#8217;s common stock, par value $0.001 per share (the &amp;#8220;Common Stock&amp;#8221;), outstanding for each period.&lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; margin: 0px 0px 0px 0.5in; background: none;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; margin: 0px 0px 0px 0.5in;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;Diluted LPS is calculated in continuing operations. The calculation of diluted LPS does not include 73,800,491 and 78,202,020 shares of Common Stock underlying outstanding options and restricted shares of Common Stock and shares issuable upon conversion of outstanding convertible notes for the three months ended March&amp;#160;31, 2018 and 2019, respectively, because the effect would be anti-dilutive.&lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; margin-bottom: 0px; margin-top: 0px; margin-right: 0px; background: none;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;div style="background: none; letter-spacing: 0px; font-size: 10pt; text-decoration: none; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;div style="background: none; letter-spacing: 0px; font-size: 10pt; text-decoration: none; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt &amp;quot;times new roman&amp;quot;, times, serif; letter-spacing: normal; orphans: 2; text-indent: 0px; text-transform: none; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; margin-top: 0pt; margin-bottom: 0pt; border-collapse: collapse; border-spacing: 0px; table-layout: fixed;;width:100%;"&gt;&lt;tr style="vertical-align: top;"&gt;&lt;td style="width: 0.5in; padding: 0px;"&gt;&lt;/td&gt;&lt;td style="width: 0.25in; padding-left: 0px; padding-top: 0px; padding-bottom: 0px;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;d.&lt;/div&gt;&lt;/td&gt;&lt;td style="padding: 0px 81.35pt 0px 0px;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Recently adopted standards&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="clear: both; max-height: 0px;"&gt;&lt;/div&gt;&lt;div style="clear: both; max-height: 0px;"&gt;&lt;/div&gt;&lt;div style="clear: both; max-height: 0px; background: none;"&gt;&lt;/div&gt;&lt;div style="color: rgb(0, 0, 0); font: 10pt &amp;quot;times new roman&amp;quot;, times, serif; letter-spacing: normal; orphans: 2; text-align: start; text-indent: 0px; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; margin-top: 0px; margin-bottom: 0px; margin-right: 0px; background: none;"&gt;&amp;#160;&amp;#160;&lt;/div&gt;&lt;div style="color: rgb(0, 0, 0); font: 10pt &amp;quot;times new roman&amp;quot;, times, serif; letter-spacing: normal; orphans: 2; text-align: start; text-indent: 0in; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; margin: 0px 0px 0px 0.5in; background: none;"&gt;&lt;/div&gt;&lt;div style="color: rgb(0, 0, 0); font: 10pt &amp;quot;times new roman&amp;quot;, times, serif; letter-spacing: normal; orphans: 2; text-align: start; text-indent: 0px; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; margin: 0px 0px 0px 0.5in;"&gt;In February 2016, the Financial Accounting Standards Board (&amp;#8220;FASB&amp;#8221;) issued ASU No. 2016-02, Leases (Topic 842), which supersedes the existing guidance for lease accounting, Leases (Topic 840). The new standard requires a lessee to record assets and liabilities on its balance sheet for all leases with terms longer than 12 months. Leases will be classified as either finance or operating, with classification affecting the pattern of expense recognition in the lessee&amp;#8217;s income statement. The Company adopted this standard as of January 1, 2019 on a modified retrospective basis and will not restate comparative periods. The Company will elect the package of practical expedients permitted under the transition guidance within the new standard which, among other things, allows the Company to carryforward the historical lease classification. The Company made an accounting policy election to keep leases with an initial term of 12 months or less off of its balance sheet. The Company recognized those lease payments in its statements of operations on a straight-line basis over the lease period.&lt;/div&gt;&lt;div style="color: rgb(0, 0, 0); font: 10pt &amp;quot;times new roman&amp;quot;, times, serif; letter-spacing: normal; orphans: 2; text-align: start; text-indent: 0px; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; margin: 0px 0px 0px 0.5in; background: none;"&gt;&amp;#160;&lt;/div&gt;&lt;div style="color: rgb(0, 0, 0); font: 10pt &amp;quot;times new roman&amp;quot;, times, serif; letter-spacing: normal; orphans: 2; text-align: start; text-indent: 0px; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; margin: 0px 0px 0px 0.5in;"&gt;As of the adoption date, the Company recognized an operating lease asset and liability of $5.9&amp;#160;million and $5.7 million, respectively, as of January&amp;#160;1, 2019 on its balance sheet.&lt;/div&gt;&lt;div style="color: rgb(0, 0, 0); font: 10pt &amp;quot;times new roman&amp;quot;, times, serif; letter-spacing: normal; orphans: 2; text-align: start; text-indent: 0px; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; margin: 0px 0px 0px 0.5in; background: none;"&gt;&amp;#160;&lt;/div&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt &amp;quot;times new roman&amp;quot;, times, serif; letter-spacing: normal; orphans: 2; text-indent: 0px; text-transform: none; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; margin-top: 0pt; margin-bottom: 0pt; border-collapse: collapse; border-spacing: 0px; table-layout: fixed;;width:100%;"&gt;&lt;tr style="vertical-align: top;"&gt;&lt;td style="width: 0.5in; padding: 0px;"&gt;&lt;/td&gt;&lt;td style="width: 0.25in; padding-left: 0px; padding-top: 0px; padding-bottom: 0px;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;e.&lt;/div&gt;&lt;/td&gt;&lt;td style="padding: 0px 81.35pt 0px 0px;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Newly issued accounting pronouncements&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="clear: both; max-height: 0px;"&gt;&lt;/div&gt;&lt;div style="clear: both; max-height: 0px;"&gt;&lt;/div&gt;&lt;div style="clear: both; max-height: 0px; background: none;"&gt;&lt;/div&gt;&lt;div style="color: rgb(0, 0, 0); font: 10pt &amp;quot;times new roman&amp;quot;, times, serif; letter-spacing: normal; orphans: 2; text-align: start; text-indent: 0px; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; margin-top: 0px; margin-bottom: 0px; margin-right: 0px; background: none;"&gt;&amp;#160;&lt;/div&gt;&lt;div style="color: rgb(0, 0, 0); font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 13.3333px; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; orphans: 2; text-align: start; text-indent: 0px; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; margin: 0px 0px 0px 0.5in;"&gt;In June 2018, the FASB issued ASU 2018-07, &amp;#8220;Compensation &amp;#8211; Stock Compensation (Topic 718): Improvements to Nonemployee Share-based Payment Accounting&amp;#8221; that expands the scope of ASC Topic 718 to include share-based payment transactions for acquiring goods and services from nonemployees. An entity should apply the requirements of ASC Topic 718 to nonemployee awards except for certain exemptions specified in ASU 2018-07. The guidance is effective for fiscal years beginning after December 15, 2018, including interim reporting periods within that fiscal year. Early adoption is permitted, but no earlier than an entity&amp;#8217;s adoption date of Topic 606. The Company does not expect the adoption of ASU 2018-07 to have a material impact on its financial statements.&lt;div style="background-color: initial; font-size: 10pt; text-indent: 0in; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;div style="color: rgb(0, 0, 0); font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 13.3333px; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; orphans: 2; text-align: start; text-indent: 0px; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; margin: 0px 0px 0px 0.5in; background: none;"&gt;&lt;div style="background: none; font-size: 10pt; text-indent: 0in; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt; &lt;table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"&gt;&lt;tr&gt;&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock>
<plx:NatureOfOperationsPolicyTextBlock id="Factid_5212048" contextRef="P01_01_2019To03_31_2019">&lt;div&gt;&lt;table style="border: none; border-collapse: collapse; margin-bottom: 0.001pt; width: 100%; table-layout: fixed;"&gt;&lt;tr&gt;&lt;td style="border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: top;width: 36pt;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; margin-right: 0px; margin-bottom: 0px; margin-top: 0px; line-height: normal;"&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: top;width: 18pt;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; margin-right: 0px; margin-bottom: 0px; margin-top: 0px; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;a.&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: top;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; margin-right: 0px; margin-bottom: 0px; margin-top: 0px; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;General&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="clear: both; max-height: 0px;"&gt;&lt;/div&gt;&lt;div style="clear: both; max-height: 0px;"&gt;&lt;/div&gt;&lt;div style="clear: both; max-height: 0px;"&gt;&lt;/div&gt;&lt;div style="clear: both; max-height: 0px;"&gt;&lt;/div&gt;&lt;div style="clear: both; max-height: 0px;"&gt;&lt;/div&gt;&lt;div style="clear: both; max-height: 0px;"&gt;&lt;/div&gt;&lt;div style="clear: both; max-height: 0px;"&gt;&lt;/div&gt;&lt;div style="clear: both; max-height: 0px;"&gt;&lt;/div&gt;&lt;div style="clear: both; max-height: 0px;"&gt;&lt;/div&gt;&lt;div style="clear: both; max-height: 0px;"&gt;&lt;/div&gt;&lt;div style="clear: both; max-height: 0px;"&gt;&lt;/div&gt;&lt;div style="clear: both; max-height: 0px;"&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; margin-bottom: 0px; margin-top: 0px; margin-right: 0px; background: none;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; margin: 0px 0px 0px 0.5in;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;Protalix BioTherapeutics, Inc. (collectively with its subsidiaries, the &amp;#8220;Company&amp;#8221;)&amp;#160;and its wholly-owned subsidiaries, Protalix Ltd. and Protalix B.V. (the &amp;#8220;Subsidiaries&amp;#8221;), are biopharmaceutical companies focused on the development and commercialization of recombinant therapeutic proteins based on the Company&amp;#8217;s proprietary ProCellEx&lt;div style="vertical-align: super;font-size: smaller;display:inline;"&gt;&amp;#174;&lt;/div&gt; protein expression system (&amp;#8220;ProCellEx&amp;#8221;). To date, the Company has successfully developed taliglucerase alfa (marketed under the name alfataliglicerase in Brazil and certain other Latin American countries and Elelyso&lt;div style="vertical-align: super;font-size: smaller;display:inline;"&gt;&amp;#174;&lt;/div&gt; in the rest of the territories) for the treatment of Gaucher disease that has been approved for marketing in the United States, Brazil, Israel and other markets. The Company has a number of product candidates in varying stages of the clinical development process. The Company&amp;#8217;s strategy is to develop proprietary recombinant proteins that are therapeutically superior to existing recombinant proteins currently marketed for the same indications.&lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; margin: 0px 0px 0px 0.5in; background: none;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; margin: 0px 0px 0px 0.5in;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;The Company&amp;#8217;s product pipeline currently includes, among other candidates:&lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; margin: 0px 0px 0px 0.5in; background: none;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; margin: 0px 0px 0px 0.5in;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;(1) pegunigalsidase alfa, or PRX-102, a therapeutic protein candidate for the treatment of Fabry disease, a rare, genetic lysosomal disorder;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; margin: 0px 0px 0px 0.5in; background: none;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; margin: 0px 0px 0px 0.5in;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;(2) alidornase alfa, or PRX-110, a proprietary plant cell recombinant human Deoxyribonuclease 1, or DNase, under development for the treatment of Cystic Fibrosis, to be administered by inhalation; and&lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; margin: 0px 0px 0px 0.5in; background: none;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; margin: 0px 0px 0px 0.5in;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;(3) OPRX-106, the Company&amp;#8217;s oral antiTNF product candidate which is being developed as an orally-delivered anti-inflammatory treatment using plant cells as a natural capsule for the expressed protein.&lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; margin: 0px 0px 0px 0.5in; background: none;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; margin: 0px 0px 0px 0.5in;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;Obtaining marketing approval with respect to any product candidate in any country is dependent on the Company&amp;#8217;s ability to implement the necessary regulatory steps required to obtain such approvals. The Company cannot reasonably predict the outcome of these activities.&lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; margin: 0px 0px 0px 0.5in; background: none;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; margin: 0px 0px 0px 0.5in;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;On October&amp;#160;19, 2017, Protalix Ltd. and Chiesi Farmaceutici S.p.A. (&amp;#8220;Chiesi&amp;#8221;) entered into an Exclusive License and Supply Agreement (the &amp;#8220;Chiesi Ex-US Agreement&amp;#8221;) pursuant to which Chiesi was granted an exclusive license for all markets outside of the United States to commercialize pegunigalsidase alfa. On July&amp;#160;23, 2018, Protalix Ltd. entered into an Exclusive License and Supply Agreement with Chiesi (the &amp;#8220;Chiesi US Agreement&amp;#8221;)&amp;#160;with respect to the commercialization of pegunigalsidase alfa in the United States.&lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; margin: 0px 0px 0px 0.5in; background: none;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; margin: 0px 0px 0px 0.5in;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;Under each of the Chiesi Ex-US Agreement and the Chiesi US Agreement&amp;#160;(collectively,&amp;#160;the &lt;/div&gt;&amp;#8220;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;Chiesi Agreements&lt;/div&gt;&amp;#8221;)&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;, Chiesi made an upfront payment to Protalix Ltd. of $25.0&amp;#160;million in connection with the execution of the agreement. In addition, under the Chiesi Ex-US Agreement, Protalix Ltd. is entitled to additional payments of up to $25.0&amp;#160;million in pegunigalsidase alfa development costs, capped at $10.0&amp;#160;million per year, and to receive additional payments of up to $320.0&amp;#160;million, in the aggregate, in regulatory and commercial milestone payments. Under the Chiesi US Agreement, Protalix Ltd. is entitled to payments of up to a maximum of $20.0&amp;#160;million to cover development costs for pegunigalsidase alfa, subject to a maximum of $7.5&amp;#160;million per year, and to receive an additional up to a maximum of $760.0&amp;#160;million, in the aggregate, in regulatory and commercial milestone payments.&lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; margin: 0px 0px 0px 0.5in; background: none;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; margin: 0px 0px 0px 0.5in;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;Under the terms of both of the Chiesi Agreements, Protalix Ltd. will manufacture all of the pegunigalsidase alfa needed under the agreements, subject to certain exceptions, and Chiesi will purchase pegunigalsidase alfa from Protalix, subject to certain terms and conditions. Under the Chiesi Ex-US Agreement, Chiesi is required to make tiered payments of 15% to 35% of its net sales, depending on the amount of annual sales outside of the United States, as consideration for product supply. Under the Chiesi US Agreement, Chiesi is required to make tiered payments of 15% to 40% of its net sales, depending on the amount of annual sales in the United States, as consideration for product supply.&lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; margin: 0px 0px 0px 0.5in; background: none;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; margin: 0px 0px 0px 0.5in;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;Since its approval by the FDA, taliglucerase alfa has been marketed by Pfizer in accordance with the exclusive license and supply agreement entered&amp;#160;into&amp;#160;between Protalix Ltd. and Pfizer, which is referred to herein as the Pfizer Agreement. In October 2015, the Company sold to Pfizer its share in the collaboration created under the Pfizer Agreement for the commercialization of Elelyso. As part of the sale, the Company agreed to transfer its rights to Elelyso in Israel to Pfizer while gaining full rights to it in Brazil. Under the Amended Pfizer Agreement, Pfizer is entitled to all of the revenues, and is responsible for 100% of expenses globally for Elelyso, excluding Brazil where the Company is responsible for all expenses and retains all revenues.&lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; margin: 0px 0px 0px 0.5in; background: none;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; margin: 0px 0px 0px 0.5in;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;On June&amp;#160;18, 2013, the Company entered into a Supply and Technology Transfer Agreement (the &amp;#8220;Brazil Agreement&amp;#8221;) with Fiocruz, an arm of the Brazilian MoH, for taliglucerase alfa. Fiocruz&amp;#8217;s purchases of alfataliglicerase to date have been significantly below certain agreed upon purchase milestones and, accordingly, the Company has the right to terminate the Brazil Agreement. Notwithstanding the termination right, the Company is, at this time, continuing to supply alfataliglicerase to Fiocruz under the Brazil Agreement, and patients continue to be treated with alfataliglicerase in Brazil.&lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; margin: 0px 0px 0px 0.5in; background: none;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;div style="color: rgb(0, 0, 0); font: 10pt &amp;quot;times new roman&amp;quot;, times, serif; letter-spacing: normal; orphans: 2; text-align: start; text-indent: 0in; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; margin: 0px 0px 0px 0.5in;"&gt;Based on its current cash resources and commitments, the Company believes it will be able to maintain its current planned development activities and the corresponding level of expenditures for at least 12 months from the date of approval of the financial statements as of March&amp;#160;31, 2019, although no assurance can be given that it will not need additional funds prior to such time. If there are unexpected increases in general and administrative expenses or research and development expenses, the Company may need to seek additional financing.&lt;/div&gt;&lt;table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"&gt;&lt;tr&gt;&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</plx:NatureOfOperationsPolicyTextBlock>
<us-gaap:BasisOfAccountingPolicyPolicyTextBlock id="Factid_5212049" contextRef="P01_01_2019To03_31_2019">&lt;div&gt;&lt;table style="border: none; border-collapse: collapse; margin-bottom: 0.001pt; width: 100%; table-layout: fixed;"&gt;&lt;tr&gt;&lt;td style="border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: top;width: 36pt;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; margin-right: 0px; margin-bottom: 0px; margin-top: 0px; line-height: normal;"&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: top;width: 18pt;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; margin-right: 0px; margin-bottom: 0px; margin-top: 0px; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;b.&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0;padding-left: 0;padding-right: 81.4pt;padding-top: 0;vertical-align: top;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; margin-right: 0px; margin-bottom: 0px; margin-top: 0px; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Basis of presentation&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="clear: both; max-height: 0px;"&gt;&lt;/div&gt;&lt;div style="clear: both; max-height: 0px;"&gt;&lt;/div&gt;&lt;div style="clear: both; max-height: 0px;"&gt;&lt;/div&gt;&lt;div style="clear: both; max-height: 0px;"&gt;&lt;/div&gt;&lt;div style="clear: both; max-height: 0px;"&gt;&lt;/div&gt;&lt;div style="clear: both; max-height: 0px;"&gt;&lt;/div&gt;&lt;div style="clear: both; max-height: 0px;"&gt;&lt;/div&gt;&lt;div style="clear: both; max-height: 0px;"&gt;&lt;/div&gt;&lt;div style="clear: both; max-height: 0px;"&gt;&lt;/div&gt;&lt;div style="clear: both; max-height: 0px;"&gt;&lt;/div&gt;&lt;div style="clear: both; max-height: 0px;"&gt;&lt;/div&gt;&lt;div style="clear: both; max-height: 0px;"&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; margin-bottom: 0px; margin-top: 0px; margin-right: 0px; background: none;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; margin: 0px 0px 0px 0.5in;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;The accompanying unaudited condensed consolidated financial statements of the Company have been prepared in accordance with accounting principles generally accepted in the United States (&amp;#8220;GAAP&amp;#8221;) for interim financial information. Accordingly, they do not include all of the information and notes required by GAAP for annual financial statements. In the opinion of management, all adjustments (of a normal recurring nature) considered necessary for a fair statement of the results for the interim periods presented have been included. Operating results for the interim period are not necessarily indicative of the results that may be expected for the full year.&lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; margin: 0px 0px 0px 0.5in; background: none;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; margin: 0px 0px 0px 0.5in;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;These unaudited condensed consolidated financial statements should be read in conjunction with the audited consolidated financial statements in the Annual Report on Form 10-K for the year ended December&amp;#160;31, 2018, filed by the Company with the Commission. The comparative balance sheet at December&amp;#160;31, 2018 has been derived from the audited financial statements at that date.&lt;/div&gt;&lt;/div&gt;&lt;table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"&gt;&lt;tr&gt;&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:BasisOfAccountingPolicyPolicyTextBlock>
<us-gaap:EarningsPerSharePolicyTextBlock id="Factid_5212051" contextRef="P01_01_2019To03_31_2019">&lt;div&gt;&lt;table style="border: none; border-collapse: collapse; margin-bottom: 0.001pt; width: 100%; table-layout: fixed;"&gt;&lt;tr&gt;&lt;td style="border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: top;width: 36pt;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; margin-right: 0px; margin-bottom: 0px; margin-top: 0px; line-height: normal;"&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: top;width: 18pt;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; margin-right: 0px; margin-bottom: 0px; margin-top: 0px; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;c.&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0;padding-left: 0;padding-right: 81.4pt;padding-top: 0;vertical-align: top;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; margin-right: 0px; margin-bottom: 0px; margin-top: 0px; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Net loss per share&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="clear: both; max-height: 0px;"&gt;&lt;/div&gt;&lt;div style="clear: both; max-height: 0px;"&gt;&lt;/div&gt;&lt;div style="clear: both; max-height: 0px;"&gt;&lt;/div&gt;&lt;div style="clear: both; max-height: 0px;"&gt;&lt;/div&gt;&lt;div style="clear: both; max-height: 0px;"&gt;&lt;/div&gt;&lt;div style="clear: both; max-height: 0px;"&gt;&lt;/div&gt;&lt;div style="clear: both; max-height: 0px;"&gt;&lt;/div&gt;&lt;div style="clear: both; max-height: 0px;"&gt;&lt;/div&gt;&lt;div style="clear: both; max-height: 0px;"&gt;&lt;/div&gt;&lt;div style="clear: both; max-height: 0px;"&gt;&lt;/div&gt;&lt;div style="clear: both; max-height: 0px;"&gt;&lt;/div&gt;&lt;div style="clear: both; max-height: 0px;"&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; margin-bottom: 0px; margin-top: 0px; margin-right: 0px; background: none;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; margin: 0px 0px 0px 0.5in;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;Basic and diluted loss per share (&amp;#8220;LPS&amp;#8221;) are computed by dividing net loss by the weighted average number of shares of the Company&amp;#8217;s common stock, par value $0.001 per share (the &amp;#8220;Common Stock&amp;#8221;), outstanding for each period.&lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; margin: 0px 0px 0px 0.5in; background: none;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; margin: 0px 0px 0px 0.5in;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;Diluted LPS is calculated in continuing operations. The calculation of diluted LPS does not include 73,800,491 and 78,202,020 shares of Common Stock underlying outstanding options and restricted shares of Common Stock and shares issuable upon conversion of outstanding convertible notes for the three months ended March&amp;#160;31, 2018 and 2019, respectively, because the effect would be anti-dilutive.&lt;/div&gt;&lt;/div&gt;&lt;table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"&gt;&lt;tr&gt;&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:EarningsPerSharePolicyTextBlock>
<plx:UpfrontNonrefundableNoncreditablePaymentReceivable id="Factid_5212092" contextRef="PAsOn10_19_2017_ChiesiExUSAgreementMemberusgaapTypeOfArrangementAxis" unitRef="Unit_USD" decimals="-5">25000000</plx:UpfrontNonrefundableNoncreditablePaymentReceivable>
<plx:MaximumEntitlementOfDevelopmentCostsToCoverPerYear id="Factid_5212096" contextRef="PAsOn10_19_2017_ChiesiExUSAgreementMemberusgaapTypeOfArrangementAxis" unitRef="Unit_USD" decimals="-5">10000000</plx:MaximumEntitlementOfDevelopmentCostsToCoverPerYear>
<plx:AdditionalAmountpayableForAchievementOfRegulatoryAndCommercialMilestones id="Factid_5212097" contextRef="PAsOn10_19_2017_ChiesiExUSAgreementMemberusgaapTypeOfArrangementAxis" unitRef="Unit_USD" decimals="-5">320000000</plx:AdditionalAmountpayableForAchievementOfRegulatoryAndCommercialMilestones>
<plx:MaximumEntitlementOfDevelopmentCostsToCoverPerYear id="Factid_5212105" contextRef="PAsOn07_23_2018_ChiesiUSAgreementMemberusgaapTypeOfArrangementAxis" unitRef="Unit_USD" decimals="-5">7500000</plx:MaximumEntitlementOfDevelopmentCostsToCoverPerYear>
<plx:AdditionalAmountpayableForAchievementOfRegulatoryAndCommercialMilestones id="Factid_5212106" contextRef="PAsOn07_23_2018_ChiesiUSAgreementMemberusgaapTypeOfArrangementAxis" unitRef="Unit_USD" decimals="-5">760000000</plx:AdditionalAmountpayableForAchievementOfRegulatoryAndCommercialMilestones>
<plx:SupplementaryIncomeStatementInformationTableTextBlock id="Factid_5212885" contextRef="P01_01_2019To03_31_2019">&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; margin: 0px 0px 0px 0.5in;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;The following table summarizes the Company&amp;#8217;s disaggregation of revenues:&lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; margin: 0px 0px 0px 0.5in; background: none;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;table style="border: none; border-collapse: collapse; margin: 0in 6.75pt 0in 0.5in; width: 55%;;text-align:left;"&gt;&lt;tr&gt;&lt;td style="border-bottom: none; border-top: none; padding: 0px 0px 1pt; vertical-align: bottom;;width:;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; margin-right: 0px; margin-bottom: 0px; margin-top: 0px; line-height: normal; background: none; text-align: center;"&gt;&lt;div style="background: none;;font-weight:bold;display:inline;width:100%;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="border-top: none; padding: 0in 0in 1pt; vertical-align: bottom;;width:;"&gt;&lt;div style="font-size: 10pt; font-family: &amp;quot;times new roman&amp;quot;, times, serif; line-height: normal; margin-bottom: 0px; margin-top: 0px;"&gt;&lt;div style="background: none;;font-weight:bold;display:inline;width:100%;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="6" style="border-bottom: 1pt solid rgb(0, 0, 0); border-top-style: none; padding: 0in; vertical-align: bottom; white-space: nowrap;;width:;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; text-align: center; margin-right: 0px; margin-bottom: 0px; margin-top: 0px; line-height: normal; white-space: nowrap;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Three months ended March&amp;#160;31,&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="border-top-style: none; padding: 0in 0in 0.5pt; vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="font-size: 10pt; font-family: &amp;quot;times new roman&amp;quot;, times, serif; line-height: normal; margin-bottom: 0px; margin-top: 0px;"&gt;&lt;div style="background: none;;font-weight:bold;display:inline;width:100%;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="border-bottom: none; border-top: none; padding: 0px 0px 1pt; vertical-align: bottom;;width:;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; margin-right: 0px; margin-bottom: 0px; margin-top: 0px; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;;font-style:italic;display:inline;"&gt;(U.S.&amp;#160;dollars&amp;#160;in&amp;#160;thousands)&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding: 0in 0in 1pt; vertical-align: bottom;;width:;"&gt;&lt;div style="font-size: 10pt; font-family: &amp;quot;times new roman&amp;quot;, times, serif; line-height: normal; margin-bottom: 0px; margin-top: 0px;"&gt;&lt;div style="background: none;;font-weight:bold;display:inline;width:100%;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="border-bottom: 1pt solid rgb(0, 0, 0); border-top-style: none; padding: 0in; vertical-align: bottom; white-space: nowrap;;width:;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; text-align: center; margin-right: 0px; margin-bottom: 0px; margin-top: 0px; line-height: normal; white-space: nowrap;"&gt;&lt;div style="font-weight:bold;display:inline;width:100%;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;"&gt;2019&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="border-top-style: none; padding: 0in 0in 0.5pt; vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="font-size: 10pt; font-family: &amp;quot;times new roman&amp;quot;, times, serif; line-height: normal; margin-bottom: 0px; margin-top: 0px;"&gt;&lt;div style="background: none;;font-weight:bold;display:inline;width:100%;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="border-top-style: none; padding: 0in 0in 1pt; vertical-align: bottom; white-space: nowrap;;width:;"&gt;&lt;div style="font-size: 10pt; font-family: &amp;quot;times new roman&amp;quot;, times, serif; line-height: normal; margin-bottom: 0px; margin-top: 0px;"&gt;&lt;div style="background: none;;font-weight:bold;display:inline;width:100%;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="border-bottom: 1pt solid rgb(0, 0, 0); border-top-style: none; padding: 0in; vertical-align: bottom; white-space: nowrap;;width:;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; text-align: center; margin-right: 0px; margin-bottom: 0px; margin-top: 0px; line-height: normal; white-space: nowrap;"&gt;&lt;div style="font-weight:bold;display:inline;width:100%;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;"&gt;2018&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding: 0in 0in 0.5pt; vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="font-size: 10pt; font-family: &amp;quot;times new roman&amp;quot;, times, serif; line-height: normal; margin-bottom: 0px; margin-top: 0px;"&gt;&lt;div style="background: none;;font-weight:bold;display:inline;width:100%;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background: rgb(204, 238, 255); border-bottom: none; border-top: none; padding: 0px 0px 0px 27pt; vertical-align: bottom; width: 57%; font-size: 10pt;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; margin-right: 0px; margin-bottom: 0px; margin-top: 0px; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;Pfizer&lt;/div&gt;&lt;div style="font-size: 10pt; font-family: &amp;quot;times new roman&amp;quot;, times, serif; color: rgb(0, 0, 0); background: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px; font-size: 10pt;;display:inline;"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background: rgb(204, 238, 255); border-top: none; padding: 0in; vertical-align: bottom; width: 1%;"&gt;&lt;div style="font-size: 10pt; font-family: &amp;quot;times new roman&amp;quot;, times, serif; line-height: normal; background: none; margin-bottom: 0px; margin-top: 0px;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255); width: 1%; border-bottom: none; border-top: 0px none; text-align: left; vertical-align: bottom; padding: 0in;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; text-align: left; margin: 0px 0px 0px 0in; line-height: normal; white-space: nowrap; text-indent: 0in;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;"&gt;$&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background: rgb(204, 238, 255); border-bottom: none; border-top: 0px none; padding: 0in; vertical-align: bottom; width: 18%; white-space: nowrap; text-align: right;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; text-align: right; margin-right: 0in; margin-bottom: 0px; margin-top: 0px; line-height: normal; white-space: nowrap;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;"&gt;1,356&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background: rgb(204, 238, 255); padding: 0in; vertical-align: bottom; width: 1%; white-space: nowrap; text-align: left;"&gt;&lt;div style="font-size: 10pt; font-family: &amp;quot;times new roman&amp;quot;, times, serif; margin-left: 0in; text-indent: 0in; text-align: left; white-space: nowrap; line-height: normal; background: none; margin-bottom: 0px; margin-top: 0px;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255); width: 2%; vertical-align: bottom; padding: 0in;"&gt;&lt;div style="font-size: 10pt; font-family: &amp;quot;times new roman&amp;quot;, times, serif; line-height: normal; background: none; margin-bottom: 0px; margin-top: 0px;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background: rgb(204, 238, 255); border-top: 0px none; border-bottom: none; padding: 0in; vertical-align: bottom; width: 1%; white-space: nowrap; text-align: left;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; text-align: left; margin: 0px 0px 0px 0in; line-height: normal; white-space: nowrap; text-indent: 0in;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;"&gt;$&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background: rgb(204, 238, 255); border-bottom: none; border-top: 0px none; padding: 0in; vertical-align: bottom; width: 18%; white-space: nowrap; text-align: right;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; text-align: right; margin-right: 0in; margin-bottom: 0px; margin-top: 0px; line-height: normal; white-space: nowrap;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;"&gt;1,980&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background: rgb(204, 238, 255); padding: 0in; vertical-align: bottom; width: 1%; white-space: nowrap; text-align: left;"&gt;&lt;div style="font-size: 10pt; font-family: &amp;quot;times new roman&amp;quot;, times, serif; margin-left: 0in; text-indent: 0in; text-align: left; white-space: nowrap; line-height: normal; background: none; margin-bottom: 0px; margin-top: 0px;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background: rgb(255, 255, 255); border-top: none; border-bottom: none; padding: 0px 0px 1pt 27pt; vertical-align: bottom; width: 57%; font-size: 10pt;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; margin-right: 0px; margin-bottom: 0px; margin-top: 0px; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;Brazil&lt;/div&gt;&lt;div style="font-size: 10pt; font-family: &amp;quot;times new roman&amp;quot;, times, serif; color: rgb(0, 0, 0); background: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px; font-size: 10pt;;display:inline;"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background: rgb(255, 255, 255); padding: 0in 0in 1pt; vertical-align: bottom; width: 1%;"&gt;&lt;div style="font-size: 10pt; font-family: &amp;quot;times new roman&amp;quot;, times, serif; line-height: normal; background: none; margin-bottom: 0px; margin-top: 0px;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color: rgb(255, 255, 255); width: 1%; border-bottom: 1pt solid rgb(0, 0, 0); text-align: left; vertical-align: bottom; padding: 0in;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; text-align: left; margin: 0px 0px 0px 0in; line-height: normal; white-space: nowrap; text-indent: 0in;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;"&gt;$&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background: rgb(255, 255, 255); border-bottom: 1pt solid rgb(0, 0, 0); border-top-style: none; padding: 0in; vertical-align: bottom; width: 18%; white-space: nowrap; text-align: right;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; text-align: right; margin-right: 0in; margin-bottom: 0px; margin-top: 0px; line-height: normal; white-space: nowrap;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;"&gt;2,174&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background: rgb(255, 255, 255); padding: 0in 0in 0.5pt; vertical-align: bottom; width: 1%; white-space: nowrap; text-align: left;"&gt;&lt;div style="font-size: 10pt; font-family: &amp;quot;times new roman&amp;quot;, times, serif; margin-left: 0in; text-indent: 0in; text-align: left; white-space: nowrap; line-height: normal; background: none; margin-bottom: 0px; margin-top: 0px;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color: rgb(255, 255, 255); width: 2%; vertical-align: bottom; padding: 0in 0in 1pt;"&gt;&lt;div style="font-size: 10pt; font-family: &amp;quot;times new roman&amp;quot;, times, serif; line-height: normal; background: none; margin-bottom: 0px; margin-top: 0px;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background: rgb(255, 255, 255); border-bottom: 1pt solid rgb(0, 0, 0); padding: 0in; vertical-align: bottom; width: 1%; white-space: nowrap; text-align: left;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; text-align: left; margin: 0px 0px 0px 0in; line-height: normal; white-space: nowrap; text-indent: 0in;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;"&gt;$&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background: rgb(255, 255, 255); border-bottom: 1pt solid rgb(0, 0, 0); border-top-style: none; padding: 0in; vertical-align: bottom; width: 18%; white-space: nowrap; text-align: right;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; text-align: right; margin-right: 0in; margin-bottom: 0px; margin-top: 0px; line-height: normal; white-space: nowrap;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;"&gt;2,573&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background: rgb(255, 255, 255); padding: 0in 0in 0.5pt; vertical-align: bottom; width: 1%; white-space: nowrap; text-align: left;"&gt;&lt;div style="font-size: 10pt; font-family: &amp;quot;times new roman&amp;quot;, times, serif; margin-left: 0in; text-indent: 0in; text-align: left; white-space: nowrap; line-height: normal; background: none; margin-bottom: 0px; margin-top: 0px;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background: rgb(204, 238, 255); border-top: none; border-bottom: none; padding: 0px 0px 2.5pt 27pt; vertical-align: bottom; width: 57%;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; margin-right: 0px; margin-bottom: 0px; margin-top: 0px; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;Total revenues from selling goods&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background: rgb(204, 238, 255); padding: 0in 0in 2.5pt; vertical-align: bottom; width: 1%;"&gt;&lt;div style="font-size: 10pt; font-family: &amp;quot;times new roman&amp;quot;, times, serif; line-height: normal; background: none; margin-bottom: 0px; margin-top: 0px;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255); width: 1%; border-bottom: 2.5pt double rgb(0, 0, 0); text-align: left; vertical-align: bottom; padding: 0in;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; text-align: left; margin: 0px 0px 0px 0in; line-height: normal; white-space: nowrap; text-indent: 0in;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;"&gt;&lt;div style="white-space: nowrap;;font-weight:bold;display:inline;"&gt;$&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background: rgb(204, 238, 255); border-bottom: 2.5pt double rgb(0, 0, 0); border-top-style: none; padding: 0in; vertical-align: bottom; width: 18%; white-space: nowrap; text-align: right;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; text-align: right; margin-right: 0in; margin-bottom: 0px; margin-top: 0px; line-height: normal; white-space: nowrap;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;"&gt;&lt;div style="white-space: nowrap;;font-weight:bold;display:inline;"&gt;3,530&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background: rgb(204, 238, 255); padding: 0in 0in 1.5pt; vertical-align: bottom; width: 1%; white-space: nowrap; text-align: left;"&gt;&lt;div style="font-size: 10pt; font-family: &amp;quot;times new roman&amp;quot;, times, serif; margin-left: 0in; text-indent: 0in; text-align: left; white-space: nowrap; line-height: normal; background: none; margin-bottom: 0px; margin-top: 0px;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding: 0in 0in 2.5pt; background-color: rgb(204, 238, 255); width: 2%; vertical-align: bottom;"&gt;&lt;div style="font-size: 10pt; font-family: &amp;quot;times new roman&amp;quot;, times, serif; line-height: normal; background: none; margin-bottom: 0px; margin-top: 0px;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background: rgb(204, 238, 255); border-bottom: 2.5pt double rgb(0, 0, 0); padding: 0in; vertical-align: bottom; width: 1%; white-space: nowrap; text-align: left;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; text-align: left; margin: 0px 0px 0px 0in; line-height: normal; white-space: nowrap; text-indent: 0in;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;"&gt;&lt;div style="white-space: nowrap;;font-weight:bold;display:inline;"&gt;$&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background: rgb(204, 238, 255); border-bottom: 2.5pt double rgb(0, 0, 0); border-top-style: none; padding: 0in; vertical-align: bottom; width: 18%; white-space: nowrap; text-align: right;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; text-align: right; margin-right: 0in; margin-bottom: 0px; margin-top: 0px; line-height: normal; white-space: nowrap;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;"&gt;&lt;div style="white-space: nowrap;;font-weight:bold;display:inline;"&gt;4,553&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background: rgb(204, 238, 255); padding: 0in 0in 1.5pt; vertical-align: bottom; width: 1%; white-space: nowrap; text-align: left;"&gt;&lt;div style="font-size: 10pt; font-family: &amp;quot;times new roman&amp;quot;, times, serif; margin-left: 0in; text-indent: 0in; text-align: left; white-space: nowrap; line-height: normal; background: none; margin-bottom: 0px; margin-top: 0px;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background: rgb(255, 255, 255); border-top: none; border-bottom: none; padding: 0px 0px 2.5pt 27pt; vertical-align: bottom; width: 57%;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; margin-right: 0px; margin-bottom: 0px; margin-top: 0px; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;Revenues from license and R&amp;amp;D services&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background: rgb(255, 255, 255); padding: 0in 0in 2.5pt; vertical-align: bottom; width: 1%;"&gt;&lt;div style="font-size: 10pt; font-family: &amp;quot;times new roman&amp;quot;, times, serif; line-height: normal; background: none; margin-bottom: 0px; margin-top: 0px;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color: rgb(255, 255, 255); width: 1%; border-bottom: 2.5pt double rgb(0, 0, 0); text-align: left; vertical-align: bottom; padding: 0in;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; text-align: left; margin: 0px 0px 0px 0in; line-height: normal; white-space: nowrap; text-indent: 0in;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;"&gt;&lt;div style="white-space: nowrap;;font-weight:bold;display:inline;"&gt;$&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background: rgb(255, 255, 255); border-bottom: 2.5pt double rgb(0, 0, 0); border-top-style: none; padding: 0in; vertical-align: bottom; width: 18%; white-space: nowrap; text-align: right;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; text-align: right; margin-right: 0in; margin-bottom: 0px; margin-top: 0px; line-height: normal; white-space: nowrap;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;"&gt;&lt;div style="white-space: nowrap;;font-weight:bold;display:inline;"&gt;6,909&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background: rgb(255, 255, 255); padding: 0in 0in 1.5pt; vertical-align: bottom; width: 1%; white-space: nowrap; text-align: left;"&gt;&lt;div style="font-size: 10pt; font-family: &amp;quot;times new roman&amp;quot;, times, serif; margin-left: 0in; text-indent: 0in; text-align: left; white-space: nowrap; line-height: normal; background: none; margin-bottom: 0px; margin-top: 0px;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding: 0in 0in 2.5pt; background-color: rgb(255, 255, 255); width: 2%; vertical-align: bottom;"&gt;&lt;div style="font-size: 10pt; font-family: &amp;quot;times new roman&amp;quot;, times, serif; line-height: normal; background: none; margin-bottom: 0px; margin-top: 0px;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background: rgb(255, 255, 255); border-bottom: 2.5pt double rgb(0, 0, 0); padding: 0in; vertical-align: bottom; width: 1%; white-space: nowrap; text-align: left;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; text-align: left; margin: 0px 0px 0px 0in; line-height: normal; white-space: nowrap; text-indent: 0in;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;"&gt;&lt;div style="white-space: nowrap;;font-weight:bold;display:inline;"&gt;$&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background: rgb(255, 255, 255); border-bottom: 2.5pt double rgb(0, 0, 0); border-top-style: none; padding: 0in; vertical-align: bottom; width: 18%; white-space: nowrap; text-align: right;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; text-align: right; margin-right: 0in; margin-bottom: 0px; margin-top: 0px; line-height: normal; white-space: nowrap;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;"&gt;&lt;div style="white-space: nowrap;;font-weight:bold;display:inline;"&gt;2,161&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background: rgb(255, 255, 255); padding: 0in 0in 1.5pt; vertical-align: bottom; width: 1%; white-space: nowrap; text-align: left;"&gt;&lt;div style="font-size: 10pt; font-family: &amp;quot;times new roman&amp;quot;, times, serif; margin-left: 0in; text-indent: 0in; text-align: left; white-space: nowrap; line-height: normal; background: none; margin-bottom: 0px; margin-top: 0px;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="clear: both; max-height: 0px;"&gt;&lt;/div&gt;&lt;div style="clear: both; max-height: 0px;"&gt;&lt;/div&gt;&lt;div style="clear: both; max-height: 0px;"&gt;&lt;/div&gt;&lt;div style="clear: both; max-height: 0px;"&gt;&lt;/div&gt;&lt;div style="clear: both; max-height: 0px;"&gt;&lt;/div&gt;&lt;table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"&gt;&lt;tr&gt;&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</plx:SupplementaryIncomeStatementInformationTableTextBlock>
<us-gaap:ConvertibleDebtFairValueDisclosures id="Factid_5257426" contextRef="PAsOn03_31_2019_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis_SevenPointFivePercentageConvertibleNoteMemberusgaapDebtInstrumentAxis" unitRef="Unit_USD" decimals="-5">64500000</us-gaap:ConvertibleDebtFairValueDisclosures>
<us-gaap:OperatingLeaseRightOfUseAsset id="Factid_5257570" contextRef="PAsOn03_31_2019" unitRef="Unit_USD" decimals="-3">5844000</us-gaap:OperatingLeaseRightOfUseAsset>
<us-gaap:OperatingLeaseRightOfUseAsset id="Factid_5257571" contextRef="PAsOn12_31_2018" unitRef="Unit_USD" decimals="-3">0</us-gaap:OperatingLeaseRightOfUseAsset>
<us-gaap:OperatingLeaseLiabilityCurrent id="Factid_5257572" contextRef="PAsOn03_31_2019" unitRef="Unit_USD" decimals="-3">1257000</us-gaap:OperatingLeaseLiabilityCurrent>
<us-gaap:OperatingLeaseLiabilityNoncurrent id="Factid_5257573" contextRef="PAsOn03_31_2019" unitRef="Unit_USD" decimals="-3">4498000</us-gaap:OperatingLeaseLiabilityNoncurrent>
<us-gaap:LesseeOperatingLeasesTextBlock id="Factid_5259122" contextRef="P01_01_2019To03_31_2019">&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; margin-bottom: 0px; margin-top: 0px; margin-right: 0px;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;NOTE 4 &amp;#8211; &lt;/div&gt;&lt;/div&gt;&lt;div style="color: rgb(0, 0, 0); font-family: 'times new roman', times, serif; font-size: 13.3333px; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; letter-spacing: normal; orphans: 2; text-align: start; text-indent: 0px; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;;font-weight:bold;display:inline;"&gt;OPERATING LEASES&lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; margin-bottom: 0px; margin-top: 0px; margin-right: 0px; background: none;"&gt;&amp;#160;&lt;/div&gt;&lt;div style="color: rgb(0, 0, 0); font: 10pt &amp;quot;times new roman&amp;quot;, times, serif; letter-spacing: normal; orphans: 2; text-align: start; text-indent: 0px; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; margin: 0px 0px 0px 0.5in;"&gt;The Company is a party to a number of lease agreements for its facilities, the latest of which has been extended until 2021. The Company has the option to extend certain of such agreements on two additional occasions for additional five-year periods each, for a total of 10 additional years. During the extended lease period, the aggregate monthly rental payments will increase by&amp;#160;7.5%&amp;#160;- 10% for each option. The Company expects to exercise these options in future periods. As of March&amp;#160;31, 2019, the Company provided bank guarantees of approximately&amp;#160;$412,000, in the aggregate, to secure the fulfillment of its obligations under the lease agreements. As of December 31, 2018, the future minimum lease payments required under the operating leases for such premises are approximately $758,000, $758,000 and $621,000, for fiscal years 2019 through 2021, respectively.&lt;/div&gt;&lt;div style="color: rgb(0, 0, 0); font: 10pt &amp;quot;times new roman&amp;quot;, times, serif; letter-spacing: normal; orphans: 2; text-align: start; text-indent: 0px; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; margin: 0px 0px 0px 0.5in; background: none;"&gt;&amp;#160;&lt;/div&gt;&lt;div style="color: rgb(0, 0, 0); font: 10pt &amp;quot;times new roman&amp;quot;, times, serif; letter-spacing: normal; orphans: 2; text-align: start; text-indent: 0px; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; margin: 0px 0px 0px 0.5in;"&gt;The Company entered into several three-year leases for vehicles which are regularly amended as new vehicles are leased. As of December 31, 2018, the future minimum lease payments for the years ending December&amp;#160;31, 2019, 2020 and 2021 are approximately $474,000, $333,000 and $82,000, respectively.&lt;/div&gt;&lt;div style="color: rgb(0, 0, 0); font: 10pt &amp;quot;times new roman&amp;quot;, times, serif; letter-spacing: normal; orphans: 2; text-align: start; text-indent: 0px; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; margin: 0px 0px 0px 0.5in; background: none;"&gt;&lt;/div&gt;&lt;div style="color: rgb(0, 0, 0); font: 10pt &amp;quot;times new roman&amp;quot;, times, serif; letter-spacing: normal; orphans: 2; text-align: start; text-indent: 0px; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; margin: 0px; background: none;"&gt;&lt;/div&gt;&lt;div style="color: rgb(0, 0, 0); font: 10pt &amp;quot;times new roman&amp;quot;, times, serif; letter-spacing: normal; orphans: 2; text-align: start; text-indent: 0px; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; margin: 0px; background: none;"&gt;&amp;#160;&lt;/div&gt;&lt;div style="color: rgb(0, 0, 0); font: 10pt &amp;quot;times new roman&amp;quot;, times, serif; letter-spacing: normal; orphans: 2; text-align: start; text-indent: 0in; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; margin: 0px 0px 0px 0.5in;"&gt;The following table sets forth data regarding the Company&amp;#8217;s operating leases for the three months ended March 31, 2019:&lt;/div&gt;&lt;div style="color: rgb(0, 0, 0); font: 10pt &amp;quot;times new roman&amp;quot;, times, serif; letter-spacing: normal; orphans: 2; text-align: start; text-indent: 0px; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; margin: 0px 0px 0px 0.5in; background: none;"&gt;&amp;#160;&amp;#160;&lt;/div&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt &amp;quot;times new roman&amp;quot;, times, serif; letter-spacing: normal; orphans: 2; text-indent: 0px; text-transform: none; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; border-collapse: collapse; width: 55%; margin-left: 0.5in; border-spacing: 0px;"&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td style="font-size: 10pt; padding-bottom: 1pt; padding-left: 0px; padding-top: 0px;"&gt;(&lt;div style="font-style:italic;display:inline;;font-style:italic;display:inline;"&gt;U.S. dollars in thousands)&lt;/div&gt;&lt;/td&gt;&lt;td style="font: 10pt &amp;quot;times new roman&amp;quot;, times, serif; padding-bottom: 1pt; padding-left: 0px; padding-top: 0px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2" style="font: 10pt &amp;quot;times new roman&amp;quot;, times, serif; text-align: center; border-bottom: 1pt solid black; padding-left: 0px; padding-top: 0px; padding-bottom: 0px;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;March 31, 2019&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font: 10pt &amp;quot;times new roman&amp;quot;, times, serif; padding-left: 0px; padding-top: 0px;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&lt;td style="width: 788px; font-size: 10pt; text-align: left; padding-bottom: 2.5pt; padding-left: 0in; padding-top: 0px;"&gt;&lt;div style="line-height: normal;"&gt;Operating lease costs&lt;/div&gt;&lt;/td&gt;&lt;td style="width: 20px; font: 10pt &amp;quot;times new roman&amp;quot;, times, serif; padding-bottom: 2.5pt; padding-left: 0px; padding-top: 0px;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 10px; border-bottom: 2.5pt double black; font: 10pt &amp;quot;times new roman&amp;quot;, times, serif; text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px;"&gt;$&lt;/td&gt;&lt;td style="width: 207px; border-bottom: 2.5pt double black; font: 10pt &amp;quot;times new roman&amp;quot;, times, serif; text-align: right; padding-left: 0px; padding-top: 0px; padding-bottom: 0px;"&gt;292&lt;/td&gt;&lt;td style="width: 12px; padding-bottom: 1.5pt; font: 10pt &amp;quot;times new roman&amp;quot;, times, serif; text-align: left; padding-left: 0px; padding-top: 0px;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: white;"&gt;&lt;td style="font-size: 10pt; text-align: left; padding-bottom: 2.5pt; padding-left: 0in; padding-top: 0px;"&gt;Cash paid for amounts included in the&amp;#160;measurement of lease liabilities&lt;/td&gt;&lt;td style="font: 10pt &amp;quot;times new roman&amp;quot;, times, serif; padding-bottom: 2.5pt; padding-left: 0px; padding-top: 0px;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: 2.5pt double black; font: 10pt &amp;quot;times new roman&amp;quot;, times, serif; text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: 2.5pt double black; font: 10pt &amp;quot;times new roman&amp;quot;, times, serif; text-align: right; padding-left: 0px; padding-top: 0px; padding-bottom: 1.5pt;"&gt;328&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font: 10pt &amp;quot;times new roman&amp;quot;, times, serif; text-align: left; padding-left: 0px; padding-top: 0px;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&lt;td style="font-size: 10pt; text-align: left; padding-left: 0in; padding-bottom: 2.5pt; padding-top: 0px;"&gt;Right of use assets obtained in exchange&amp;#160;for new operating lease liabilities&lt;/td&gt;&lt;td style="font-size: 10pt; padding-bottom: 2.5pt; padding-left: 0px; padding-top: 0px;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left; border-bottom: 2.5pt double black; padding-left: 0px; padding-top: 0px; padding-bottom: 0px;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right; border-bottom: 2.5pt double black; padding-left: 0px; padding-top: 0px; padding-bottom: 1.5pt;"&gt;52&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left; padding-bottom: 1.5pt; padding-left: 0px; padding-top: 0px;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: white;"&gt;&lt;td style="font-size: 10pt; text-align: left; padding-bottom: 2.5pt; padding-left: 0in; padding-top: 0px;"&gt;Weighted average remaining lease term&amp;#160;(in years)&lt;/td&gt;&lt;td style="font: 10pt &amp;quot;times new roman&amp;quot;, times, serif; padding-bottom: 2.5pt; padding-left: 0px; padding-top: 0px;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: 2.5pt double black; font: 10pt &amp;quot;times new roman&amp;quot;, times, serif; text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: 2.5pt double black; font: 10pt &amp;quot;times new roman&amp;quot;, times, serif; text-align: right; padding-left: 0px; padding-top: 0px; padding-bottom: 1.5pt;"&gt;10.84&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font: 10pt &amp;quot;times new roman&amp;quot;, times, serif; text-align: left; padding-left: 0px; padding-top: 0px;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&lt;td style="font-size: 10pt; padding-bottom: 2.5pt; padding-left: 0in; padding-top: 0px;"&gt;Weighted average discount rate&lt;/td&gt;&lt;td style="font: 10pt &amp;quot;times new roman&amp;quot;, times, serif; padding-bottom: 2.5pt; padding-left: 0px; padding-top: 0px;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: 2.5pt double black; font: 10pt &amp;quot;times new roman&amp;quot;, times, serif; text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: 2.5pt double black; font: 10pt &amp;quot;times new roman&amp;quot;, times, serif; text-align: right; padding-left: 0px; padding-top: 0px; padding-bottom: 1.5pt;"&gt;12.58&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font: 10pt &amp;quot;times new roman&amp;quot;, times, serif; text-align: left; padding-left: 0px; padding-top: 0px;"&gt;%&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="clear: both; max-height: 0px;"&gt;&lt;/div&gt;&lt;div style="clear: both; max-height: 0px;"&gt;&lt;/div&gt;&lt;div style="clear: both; max-height: 0px;"&gt;&lt;/div&gt;&lt;div style="color: rgb(0, 0, 0); font: 10pt &amp;quot;times new roman&amp;quot;, times, serif; letter-spacing: normal; orphans: 2; text-align: start; text-indent: 0px; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; margin: 0px 0px 0px 56.9pt; background: none;"&gt;&lt;/div&gt;&lt;div style="color: rgb(0, 0, 0); font: 10pt &amp;quot;times new roman&amp;quot;, times, serif; letter-spacing: normal; orphans: 2; text-align: start; text-indent: 0px; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; margin: 0px 0px 0px 0.5in; background: none;"&gt;&lt;/div&gt;&lt;div style="color: rgb(0, 0, 0); font: 10pt &amp;quot;times new roman&amp;quot;, times, serif; letter-spacing: normal; orphans: 2; text-align: start; text-indent: 0px; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; margin: 0px 0px 0px 0.5in; background: none;"&gt;&lt;/div&gt;&lt;div style="color: rgb(0, 0, 0); font: 10pt &amp;quot;times new roman&amp;quot;, times, serif; letter-spacing: normal; orphans: 2; text-align: start; text-indent: 0px; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; margin: 0px 0px 0px 0.5in; background: none;"&gt;&lt;/div&gt;&lt;div style="color: rgb(0, 0, 0); font: 10pt &amp;quot;times new roman&amp;quot;, times, serif; letter-spacing: normal; orphans: 2; text-align: start; text-indent: 0px; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; margin: 0px 0px 0px 0.5in; background: none;"&gt;&amp;#160;&lt;/div&gt;&lt;div style="color: rgb(0, 0, 0); font: 10pt &amp;quot;times new roman&amp;quot;, times, serif; letter-spacing: normal; orphans: 2; text-align: start; text-indent: 0px; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; margin: 0px 0px 0px 0.5in;"&gt;The following table sets forth a maturity analysis of the Company&amp;#8217;s operating lease liabilities as of March&amp;#160;31, 2019:&lt;/div&gt;&lt;div style="color: rgb(0, 0, 0); font: 10pt &amp;quot;times new roman&amp;quot;, times, serif; letter-spacing: normal; orphans: 2; text-align: start; text-indent: 0px; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; margin: 0px 0px 0px 0.5in; background: none;"&gt;&amp;#160;&lt;/div&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt &amp;quot;times new roman&amp;quot;, times, serif; letter-spacing: normal; orphans: 2; text-indent: 0px; text-transform: none; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; border-collapse: collapse; width: 55%; margin-left: 0.5in; border-spacing: 0px;"&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td style="font-size: 10pt; padding-bottom: 1pt; padding-left: 0px; padding-top: 0px;"&gt;(&lt;div style="font-style:italic;display:inline;;font-style:italic;display:inline;"&gt;U.S. dollars in thousands)&lt;/div&gt;&lt;/td&gt;&lt;td style="font: 10pt &amp;quot;times new roman&amp;quot;, times, serif; padding-bottom: 1pt; padding-left: 0px; padding-top: 0px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2" style="font: 10pt &amp;quot;times new roman&amp;quot;, times, serif; text-align: center; border-bottom: 1pt solid black; padding-left: 0px; padding-top: 0px; padding-bottom: 0px;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;March 31, 2019&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font: 10pt &amp;quot;times new roman&amp;quot;, times, serif; padding-left: 0px; padding-top: 0px;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&lt;td style="width: 789px; font-size: 10pt; text-align: left; padding-left: 0in; padding-top: 0px; padding-bottom: 0px;"&gt;2019&amp;#160;(excluding&amp;#160;the&amp;#160;three&amp;#160;months&amp;#160;ended&amp;#160;March&amp;#160;31,&amp;#160;2019)&lt;/td&gt;&lt;td style="width: 21px; font-size: 10pt; padding-left: 0px; padding-top: 0px; padding-bottom: 0px;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 10px; font-size: 10pt; text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px;"&gt;$&lt;/td&gt;&lt;td style="width: 207px; font-size: 10pt; text-align: right; padding-left: 0px; padding-top: 0px; padding-bottom: 0px;"&gt;947&lt;/td&gt;&lt;td style="width: 10px; font-size: 10pt; text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: white;"&gt;&lt;td style="font-size: 10pt; text-align: left; padding-left: 0in; padding-top: 0px; padding-bottom: 0px;"&gt;2020&lt;/td&gt;&lt;td style="font-size: 10pt; padding-left: 0px; padding-top: 0px; padding-bottom: 0px;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px;"&gt;$&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right; padding-left: 0px; padding-top: 0px; padding-bottom: 0px;"&gt;1,135&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&lt;td style="font-size: 10pt; text-align: left; padding-left: 0in; padding-top: 0px; padding-bottom: 0px;"&gt;2021&lt;/td&gt;&lt;td style="font-size: 10pt; padding-left: 0px; padding-top: 0px; padding-bottom: 0px;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px;"&gt;$&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right; padding-left: 0px; padding-top: 0px; padding-bottom: 0px;"&gt;888&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: white;"&gt;&lt;td style="font-size: 10pt; text-align: left; padding-left: 0in; padding-top: 0px; padding-bottom: 0px;"&gt;2022&lt;/td&gt;&lt;td style="font-size: 10pt; padding-left: 0px; padding-top: 0px; padding-bottom: 0px;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px;"&gt;$&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right; padding-left: 0px; padding-top: 0px; padding-bottom: 0px;"&gt;774&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&lt;td style="font-size: 10pt; text-align: left; padding-left: 0in; padding-top: 0px; padding-bottom: 0px;"&gt;2023&lt;/td&gt;&lt;td style="font-size: 10pt; padding-left: 0px; padding-top: 0px; padding-bottom: 0px;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px;"&gt;$&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right; padding-left: 0px; padding-top: 0px; padding-bottom: 0px;"&gt;770&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: white;"&gt;&lt;td style="font-size: 10pt; padding-bottom: 2.5pt; padding-left: 0in; padding-top: 0px;"&gt;After&amp;#160;2024&amp;#160;&lt;/td&gt;&lt;td style="font: 10pt &amp;quot;times new roman&amp;quot;, times, serif; padding-bottom: 2.5pt; padding-left: 0px; padding-top: 0px;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: 2.5pt double black; font: 10pt &amp;quot;times new roman&amp;quot;, times, serif; text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px;"&gt;$&lt;/td&gt;&lt;td style="border-bottom: 2.5pt double black; font: 10pt &amp;quot;times new roman&amp;quot;, times, serif; text-align: right; padding-left: 0px; padding-top: 0px; padding-bottom: 0px;"&gt;6,380&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font: 10pt &amp;quot;times new roman&amp;quot;, times, serif; text-align: left; padding-left: 0px; padding-top: 0px;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&lt;td style="font-size: 10pt; text-align: left; padding-bottom: 2.5pt; padding-left: 0in; padding-top: 0px;"&gt;Total undiscounted cash flows&lt;/td&gt;&lt;td style="font: 10pt &amp;quot;times new roman&amp;quot;, times, serif; padding-bottom: 2.5pt; padding-left: 0px; padding-top: 0px;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: 2.5pt double black; font: 10pt &amp;quot;times new roman&amp;quot;, times, serif; text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px;"&gt;$&lt;/td&gt;&lt;td style="border-bottom: 2.5pt double black; font: 10pt &amp;quot;times new roman&amp;quot;, times, serif; text-align: right; padding-left: 0px; padding-top: 0px; padding-bottom: 0px;"&gt;10,894&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font: 10pt &amp;quot;times new roman&amp;quot;, times, serif; text-align: left; padding-left: 0px; padding-top: 0px;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: white;"&gt;&lt;td style="font-size: 10pt; padding-bottom: 2.5pt; padding-left: 0in; padding-top: 0px;"&gt;Less:&amp;#160;imputed&amp;#160;interest&lt;/td&gt;&lt;td style="font: 10pt &amp;quot;times new roman&amp;quot;, times, serif; padding-bottom: 2.5pt; padding-left: 0px; padding-top: 0px;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: 2.5pt double black; font: 10pt &amp;quot;times new roman&amp;quot;, times, serif; text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px;"&gt;$&lt;/td&gt;&lt;td style="border-bottom: 2.5pt double black; font: 10pt &amp;quot;times new roman&amp;quot;, times, serif; text-align: right; padding-left: 0px; padding-top: 0px; padding-bottom: 0px;"&gt;5,139&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font: 10pt &amp;quot;times new roman&amp;quot;, times, serif; text-align: left; padding-left: 0px; padding-top: 0px;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&lt;td style="font-size: 10pt; text-align: left; padding-bottom: 2.5pt; padding-left: 0in; padding-top: 0px;"&gt;Present&amp;#160;value&amp;#160;of lease liabilities&lt;/td&gt;&lt;td style="font: 10pt &amp;quot;times new roman&amp;quot;, times, serif; padding-bottom: 2.5pt; padding-left: 0px; padding-top: 0px;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: 2.5pt double black; font: 10pt &amp;quot;times new roman&amp;quot;, times, serif; text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px;"&gt;$&lt;/td&gt;&lt;td style="border-bottom: 2.5pt double black; font: 10pt &amp;quot;times new roman&amp;quot;, times, serif; text-align: right; padding-left: 0px; padding-top: 0px; padding-bottom: 0px;"&gt;5,755&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font: 10pt &amp;quot;times new roman&amp;quot;, times, serif; text-align: left; padding-left: 0px; padding-top: 0px;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="clear: both; max-height: 0px;"&gt;&lt;/div&gt;&lt;div style="clear: both; max-height: 0px;"&gt;&lt;/div&gt;&lt;div style="clear: both; max-height: 0px;"&gt;&lt;/div&gt;&lt;table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"&gt;&lt;tr&gt;&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:LesseeOperatingLeasesTextBlock>
<us-gaap:LeaseCostTableTextBlock id="Factid_5259239" contextRef="P01_01_2019To03_31_2019">&lt;div style="color: rgb(0, 0, 0); font: 10pt &amp;quot;times new roman&amp;quot;, times, serif; letter-spacing: normal; orphans: 2; text-align: start; text-indent: 0in; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; margin: 0px 0px 0px 0.5in;"&gt;The following table sets forth data regarding the Company&amp;#8217;s operating leases for the three months ended March 31, 2019:&lt;/div&gt;&lt;div style="color: rgb(0, 0, 0); font: 10pt &amp;quot;times new roman&amp;quot;, times, serif; letter-spacing: normal; orphans: 2; text-align: start; text-indent: 0px; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; margin: 0px 0px 0px 0.5in; background: none;"&gt;&amp;#160;&amp;#160;&lt;/div&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt &amp;quot;times new roman&amp;quot;, times, serif; letter-spacing: normal; orphans: 2; text-indent: 0px; text-transform: none; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; border-collapse: collapse; width: 55%; margin-left: 0.5in; border-spacing: 0px;"&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td style="font-size: 10pt; padding-bottom: 1pt; padding-left: 0px; padding-top: 0px;"&gt;(&lt;div style="font-style:italic;display:inline;;font-style:italic;display:inline;"&gt;U.S. dollars in thousands)&lt;/div&gt;&lt;/td&gt;&lt;td style="font: 10pt &amp;quot;times new roman&amp;quot;, times, serif; padding-bottom: 1pt; padding-left: 0px; padding-top: 0px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2" style="font: 10pt &amp;quot;times new roman&amp;quot;, times, serif; text-align: center; border-bottom: 1pt solid black; padding-left: 0px; padding-top: 0px; padding-bottom: 0px;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;March 31, 2019&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font: 10pt &amp;quot;times new roman&amp;quot;, times, serif; padding-left: 0px; padding-top: 0px;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&lt;td style="width: 788px; font-size: 10pt; text-align: left; padding-bottom: 2.5pt; padding-left: 0in; padding-top: 0px;"&gt;&lt;div style="line-height: normal;"&gt;Operating lease costs&lt;/div&gt;&lt;/td&gt;&lt;td style="width: 20px; font: 10pt &amp;quot;times new roman&amp;quot;, times, serif; padding-bottom: 2.5pt; padding-left: 0px; padding-top: 0px;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 10px; border-bottom: 2.5pt double black; font: 10pt &amp;quot;times new roman&amp;quot;, times, serif; text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px;"&gt;$&lt;/td&gt;&lt;td style="width: 207px; border-bottom: 2.5pt double black; font: 10pt &amp;quot;times new roman&amp;quot;, times, serif; text-align: right; padding-left: 0px; padding-top: 0px; padding-bottom: 0px;"&gt;292&lt;/td&gt;&lt;td style="width: 12px; padding-bottom: 1.5pt; font: 10pt &amp;quot;times new roman&amp;quot;, times, serif; text-align: left; padding-left: 0px; padding-top: 0px;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: white;"&gt;&lt;td style="font-size: 10pt; text-align: left; padding-bottom: 2.5pt; padding-left: 0in; padding-top: 0px;"&gt;Cash paid for amounts included in the&amp;#160;measurement of lease liabilities&lt;/td&gt;&lt;td style="font: 10pt &amp;quot;times new roman&amp;quot;, times, serif; padding-bottom: 2.5pt; padding-left: 0px; padding-top: 0px;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: 2.5pt double black; font: 10pt &amp;quot;times new roman&amp;quot;, times, serif; text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: 2.5pt double black; font: 10pt &amp;quot;times new roman&amp;quot;, times, serif; text-align: right; padding-left: 0px; padding-top: 0px; padding-bottom: 1.5pt;"&gt;328&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font: 10pt &amp;quot;times new roman&amp;quot;, times, serif; text-align: left; padding-left: 0px; padding-top: 0px;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&lt;td style="font-size: 10pt; text-align: left; padding-left: 0in; padding-bottom: 2.5pt; padding-top: 0px;"&gt;Right of use assets obtained in exchange&amp;#160;for new operating lease liabilities&lt;/td&gt;&lt;td style="font-size: 10pt; padding-bottom: 2.5pt; padding-left: 0px; padding-top: 0px;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left; border-bottom: 2.5pt double black; padding-left: 0px; padding-top: 0px; padding-bottom: 0px;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right; border-bottom: 2.5pt double black; padding-left: 0px; padding-top: 0px; padding-bottom: 1.5pt;"&gt;52&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left; padding-bottom: 1.5pt; padding-left: 0px; padding-top: 0px;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: white;"&gt;&lt;td style="font-size: 10pt; text-align: left; padding-bottom: 2.5pt; padding-left: 0in; padding-top: 0px;"&gt;Weighted average remaining lease term&amp;#160;(in years)&lt;/td&gt;&lt;td style="font: 10pt &amp;quot;times new roman&amp;quot;, times, serif; padding-bottom: 2.5pt; padding-left: 0px; padding-top: 0px;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: 2.5pt double black; font: 10pt &amp;quot;times new roman&amp;quot;, times, serif; text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: 2.5pt double black; font: 10pt &amp;quot;times new roman&amp;quot;, times, serif; text-align: right; padding-left: 0px; padding-top: 0px; padding-bottom: 1.5pt;"&gt;10.84&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font: 10pt &amp;quot;times new roman&amp;quot;, times, serif; text-align: left; padding-left: 0px; padding-top: 0px;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&lt;td style="font-size: 10pt; padding-bottom: 2.5pt; padding-left: 0in; padding-top: 0px;"&gt;Weighted average discount rate&lt;/td&gt;&lt;td style="font: 10pt &amp;quot;times new roman&amp;quot;, times, serif; padding-bottom: 2.5pt; padding-left: 0px; padding-top: 0px;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: 2.5pt double black; font: 10pt &amp;quot;times new roman&amp;quot;, times, serif; text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: 2.5pt double black; font: 10pt &amp;quot;times new roman&amp;quot;, times, serif; text-align: right; padding-left: 0px; padding-top: 0px; padding-bottom: 1.5pt;"&gt;12.58&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font: 10pt &amp;quot;times new roman&amp;quot;, times, serif; text-align: left; padding-left: 0px; padding-top: 0px;"&gt;%&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="clear: both; max-height: 0px;"&gt;&lt;/div&gt;&lt;div style="clear: both; max-height: 0px;"&gt;&lt;/div&gt;&lt;div style="clear: both; max-height: 0px;"&gt;&lt;/div&gt;&lt;table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"&gt;&lt;tr&gt;&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:LeaseCostTableTextBlock>
<us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock id="Factid_5259243" contextRef="P01_01_2019To03_31_2019">&lt;div style="color: rgb(0, 0, 0); font: 10pt &amp;quot;times new roman&amp;quot;, times, serif; letter-spacing: normal; orphans: 2; text-align: start; text-indent: 0px; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; margin: 0px 0px 0px 0.5in;"&gt;The following table sets forth a maturity analysis of the Company&amp;#8217;s operating lease liabilities as of March&amp;#160;31, 2019:&lt;/div&gt;&lt;div style="color: rgb(0, 0, 0); font: 10pt &amp;quot;times new roman&amp;quot;, times, serif; letter-spacing: normal; orphans: 2; text-align: start; text-indent: 0px; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; margin: 0px 0px 0px 0.5in; background: none;"&gt;&amp;#160;&lt;/div&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt &amp;quot;times new roman&amp;quot;, times, serif; letter-spacing: normal; orphans: 2; text-indent: 0px; text-transform: none; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; border-collapse: collapse; width: 55%; margin-left: 0.5in; border-spacing: 0px;"&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td style="font-size: 10pt; padding-bottom: 1pt; padding-left: 0px; padding-top: 0px;"&gt;(&lt;div style="font-style:italic;display:inline;;font-style:italic;display:inline;"&gt;U.S. dollars in thousands)&lt;/div&gt;&lt;/td&gt;&lt;td style="font: 10pt &amp;quot;times new roman&amp;quot;, times, serif; padding-bottom: 1pt; padding-left: 0px; padding-top: 0px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2" style="font: 10pt &amp;quot;times new roman&amp;quot;, times, serif; text-align: center; border-bottom: 1pt solid black; padding-left: 0px; padding-top: 0px; padding-bottom: 0px;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;March 31, 2019&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font: 10pt &amp;quot;times new roman&amp;quot;, times, serif; padding-left: 0px; padding-top: 0px;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&lt;td style="width: 789px; font-size: 10pt; text-align: left; padding-left: 0in; padding-top: 0px; padding-bottom: 0px;"&gt;2019&amp;#160;(excluding&amp;#160;the&amp;#160;three&amp;#160;months&amp;#160;ended&amp;#160;March&amp;#160;31,&amp;#160;2019)&lt;/td&gt;&lt;td style="width: 21px; font-size: 10pt; padding-left: 0px; padding-top: 0px; padding-bottom: 0px;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 10px; font-size: 10pt; text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px;"&gt;$&lt;/td&gt;&lt;td style="width: 207px; font-size: 10pt; text-align: right; padding-left: 0px; padding-top: 0px; padding-bottom: 0px;"&gt;947&lt;/td&gt;&lt;td style="width: 10px; font-size: 10pt; text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: white;"&gt;&lt;td style="font-size: 10pt; text-align: left; padding-left: 0in; padding-top: 0px; padding-bottom: 0px;"&gt;2020&lt;/td&gt;&lt;td style="font-size: 10pt; padding-left: 0px; padding-top: 0px; padding-bottom: 0px;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px;"&gt;$&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right; padding-left: 0px; padding-top: 0px; padding-bottom: 0px;"&gt;1,135&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&lt;td style="font-size: 10pt; text-align: left; padding-left: 0in; padding-top: 0px; padding-bottom: 0px;"&gt;2021&lt;/td&gt;&lt;td style="font-size: 10pt; padding-left: 0px; padding-top: 0px; padding-bottom: 0px;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px;"&gt;$&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right; padding-left: 0px; padding-top: 0px; padding-bottom: 0px;"&gt;888&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: white;"&gt;&lt;td style="font-size: 10pt; text-align: left; padding-left: 0in; padding-top: 0px; padding-bottom: 0px;"&gt;2022&lt;/td&gt;&lt;td style="font-size: 10pt; padding-left: 0px; padding-top: 0px; padding-bottom: 0px;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px;"&gt;$&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right; padding-left: 0px; padding-top: 0px; padding-bottom: 0px;"&gt;774&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&lt;td style="font-size: 10pt; text-align: left; padding-left: 0in; padding-top: 0px; padding-bottom: 0px;"&gt;2023&lt;/td&gt;&lt;td style="font-size: 10pt; padding-left: 0px; padding-top: 0px; padding-bottom: 0px;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px;"&gt;$&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right; padding-left: 0px; padding-top: 0px; padding-bottom: 0px;"&gt;770&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: white;"&gt;&lt;td style="font-size: 10pt; padding-bottom: 2.5pt; padding-left: 0in; padding-top: 0px;"&gt;After&amp;#160;2024&amp;#160;&lt;/td&gt;&lt;td style="font: 10pt &amp;quot;times new roman&amp;quot;, times, serif; padding-bottom: 2.5pt; padding-left: 0px; padding-top: 0px;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: 2.5pt double black; font: 10pt &amp;quot;times new roman&amp;quot;, times, serif; text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px;"&gt;$&lt;/td&gt;&lt;td style="border-bottom: 2.5pt double black; font: 10pt &amp;quot;times new roman&amp;quot;, times, serif; text-align: right; padding-left: 0px; padding-top: 0px; padding-bottom: 0px;"&gt;6,380&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font: 10pt &amp;quot;times new roman&amp;quot;, times, serif; text-align: left; padding-left: 0px; padding-top: 0px;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&lt;td style="font-size: 10pt; text-align: left; padding-bottom: 2.5pt; padding-left: 0in; padding-top: 0px;"&gt;Total undiscounted cash flows&lt;/td&gt;&lt;td style="font: 10pt &amp;quot;times new roman&amp;quot;, times, serif; padding-bottom: 2.5pt; padding-left: 0px; padding-top: 0px;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: 2.5pt double black; font: 10pt &amp;quot;times new roman&amp;quot;, times, serif; text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px;"&gt;$&lt;/td&gt;&lt;td style="border-bottom: 2.5pt double black; font: 10pt &amp;quot;times new roman&amp;quot;, times, serif; text-align: right; padding-left: 0px; padding-top: 0px; padding-bottom: 0px;"&gt;10,894&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font: 10pt &amp;quot;times new roman&amp;quot;, times, serif; text-align: left; padding-left: 0px; padding-top: 0px;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: white;"&gt;&lt;td style="font-size: 10pt; padding-bottom: 2.5pt; padding-left: 0in; padding-top: 0px;"&gt;Less:&amp;#160;imputed&amp;#160;interest&lt;/td&gt;&lt;td style="font: 10pt &amp;quot;times new roman&amp;quot;, times, serif; padding-bottom: 2.5pt; padding-left: 0px; padding-top: 0px;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: 2.5pt double black; font: 10pt &amp;quot;times new roman&amp;quot;, times, serif; text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px;"&gt;$&lt;/td&gt;&lt;td style="border-bottom: 2.5pt double black; font: 10pt &amp;quot;times new roman&amp;quot;, times, serif; text-align: right; padding-left: 0px; padding-top: 0px; padding-bottom: 0px;"&gt;5,139&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font: 10pt &amp;quot;times new roman&amp;quot;, times, serif; text-align: left; padding-left: 0px; padding-top: 0px;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&lt;td style="font-size: 10pt; text-align: left; padding-bottom: 2.5pt; padding-left: 0in; padding-top: 0px;"&gt;Present&amp;#160;value&amp;#160;of lease liabilities&lt;/td&gt;&lt;td style="font: 10pt &amp;quot;times new roman&amp;quot;, times, serif; padding-bottom: 2.5pt; padding-left: 0px; padding-top: 0px;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: 2.5pt double black; font: 10pt &amp;quot;times new roman&amp;quot;, times, serif; text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px;"&gt;$&lt;/td&gt;&lt;td style="border-bottom: 2.5pt double black; font: 10pt &amp;quot;times new roman&amp;quot;, times, serif; text-align: right; padding-left: 0px; padding-top: 0px; padding-bottom: 0px;"&gt;5,755&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font: 10pt &amp;quot;times new roman&amp;quot;, times, serif; text-align: left; padding-left: 0px; padding-top: 0px;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="clear: both; max-height: 0px;"&gt;&lt;/div&gt;&lt;div style="clear: both; max-height: 0px;"&gt;&lt;/div&gt;&lt;div style="clear: both; max-height: 0px;"&gt;&lt;/div&gt;&lt;table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"&gt;&lt;tr&gt;&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock>
<us-gaap:OperatingLeaseCost id="Factid_5259351" contextRef="P01_01_2019To03_31_2019" unitRef="Unit_USD" decimals="-3">292000</us-gaap:OperatingLeaseCost>
<us-gaap:OperatingLeasePayments id="Factid_5259352" contextRef="P01_01_2019To03_31_2019" unitRef="Unit_USD" decimals="-3">328000</us-gaap:OperatingLeasePayments>
<us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability id="Factid_5259353" contextRef="P01_01_2019To03_31_2019" unitRef="Unit_USD" decimals="-3">52000</us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability>
<us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent id="Factid_5259355" contextRef="PAsOn03_31_2019" unitRef="Unit_pure" decimals="4">0.1258</us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent>
<us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear id="Factid_5259506" contextRef="PAsOn03_31_2019" unitRef="Unit_USD" decimals="-3">947000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear>
<us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo id="Factid_5259507" contextRef="PAsOn03_31_2019" unitRef="Unit_USD" decimals="-3">1135000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo>
<us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree id="Factid_5259508" contextRef="PAsOn03_31_2019" unitRef="Unit_USD" decimals="-3">888000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree>
<us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour id="Factid_5259509" contextRef="PAsOn03_31_2019" unitRef="Unit_USD" decimals="-3">774000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour>
<us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFive id="Factid_5259510" contextRef="PAsOn03_31_2019" unitRef="Unit_USD" decimals="-3">770000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFive>
<us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive id="Factid_5259511" contextRef="PAsOn03_31_2019" unitRef="Unit_USD" decimals="-3">6380000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive>
<us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue id="Factid_5259512" contextRef="PAsOn03_31_2019" unitRef="Unit_USD" decimals="-3">10894000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue>
<us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount id="Factid_5259513" contextRef="PAsOn03_31_2019" unitRef="Unit_USD" decimals="-3">5139000</us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount>
<us-gaap:OperatingLeaseLiability id="Factid_5259514" contextRef="PAsOn03_31_2019" unitRef="Unit_USD" decimals="-3">5755000</us-gaap:OperatingLeaseLiability>
<us-gaap:OperatingLeasesFutureMinimumPaymentsDueCurrent id="Factid_5259532" contextRef="PAsOn03_31_2019_VehicleLeaseAndMaintenanceAgreementsMemberplxCommitmentsAndContingenciesAxis" unitRef="Unit_USD" decimals="0">474000</us-gaap:OperatingLeasesFutureMinimumPaymentsDueCurrent>
<us-gaap:OperatingLeasesFutureMinimumPaymentsDueInTwoYears id="Factid_5259533" contextRef="PAsOn03_31_2019_VehicleLeaseAndMaintenanceAgreementsMemberplxCommitmentsAndContingenciesAxis" unitRef="Unit_USD" decimals="0">333000</us-gaap:OperatingLeasesFutureMinimumPaymentsDueInTwoYears>
<us-gaap:OperatingLeasesFutureMinimumPaymentsDueInThreeYears id="Factid_5259534" contextRef="PAsOn03_31_2019_VehicleLeaseAndMaintenanceAgreementsMemberplxCommitmentsAndContingenciesAxis" unitRef="Unit_USD" decimals="0">82000</us-gaap:OperatingLeasesFutureMinimumPaymentsDueInThreeYears>
<us-gaap:SecurityDeposit id="Factid_5259689" contextRef="PAsOn03_31_2019_LeaseAgreementsMemberplxCommitmentsAndContingenciesAxis" unitRef="Unit_USD" decimals="0">412000</us-gaap:SecurityDeposit>
<us-gaap:OperatingLeasesFutureMinimumPaymentsDueCurrent id="Factid_5259746" contextRef="PAsOn03_31_2019_LeaseAgreementsMemberplxCommitmentsAndContingenciesAxis" unitRef="Unit_USD" decimals="0">758000</us-gaap:OperatingLeasesFutureMinimumPaymentsDueCurrent>
<us-gaap:OperatingLeasesFutureMinimumPaymentsDueInTwoYears id="Factid_5259747" contextRef="PAsOn03_31_2019_LeaseAgreementsMemberplxCommitmentsAndContingenciesAxis" unitRef="Unit_USD" decimals="0">758000</us-gaap:OperatingLeasesFutureMinimumPaymentsDueInTwoYears>
<us-gaap:OperatingLeasesFutureMinimumPaymentsDueInThreeYears id="Factid_5259748" contextRef="PAsOn03_31_2019_LeaseAgreementsMemberplxCommitmentsAndContingenciesAxis" unitRef="Unit_USD" decimals="0">621000</us-gaap:OperatingLeasesFutureMinimumPaymentsDueInThreeYears>
<us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1 id="Factid_5263741" contextRef="PAsOn03_31_2019">P10Y10M2D</us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1>
<us-gaap:LiabilitiesAndStockholdersEquity id="Factid_5264283" contextRef="PAsOn03_31_2019" unitRef="Unit_USD" decimals="-3">61044000</us-gaap:LiabilitiesAndStockholdersEquity>
<us-gaap:LiabilitiesAndStockholdersEquity id="Factid_5264284" contextRef="PAsOn12_31_2018" unitRef="Unit_USD" decimals="-3">61131000</us-gaap:LiabilitiesAndStockholdersEquity>
<us-gaap:DebtInstrumentInterestRateStatedPercentage id="Factid_5284659" contextRef="PAsOn03_31_2019_SevenPointFivePercentageConvertibleNotes2021MemberusgaapDebtInstrumentAxis" unitRef="Unit_pure" decimals="4">0.0750</us-gaap:DebtInstrumentInterestRateStatedPercentage>
<us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock id="Factid_5300452" contextRef="P01_01_2019To03_31_2019_Notes2021MemberusgaapDebtInstrumentAxis">&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; margin-bottom: 0px; margin-top: 0px; margin-right: 0px; background: none;"&gt;&amp;#160;&lt;/div&gt;&lt;div&gt;&lt;div style="clear: both; max-height: 0px;"&gt;&lt;/div&gt;&lt;div style="clear: both; max-height: 0px;"&gt;&lt;/div&gt;&lt;div style="clear: both; max-height: 0px;"&gt;&lt;/div&gt;&lt;div style="clear: both; max-height: 0px;"&gt;&lt;/div&gt;&lt;div style="clear: both; max-height: 0px;"&gt;&lt;/div&gt;&lt;div style="clear: both; max-height: 0px;"&gt;&lt;/div&gt;&lt;div style="clear: both; max-height: 0px;"&gt;&lt;/div&gt;&lt;/div&gt; &lt;table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"&gt;&lt;tr&gt;&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock>
<dei:DocumentType id="Factid_5324958" contextRef="P01_01_2019To03_31_2019">10-Q</dei:DocumentType>
<dei:AmendmentFlag id="Factid_5324959" contextRef="P01_01_2019To03_31_2019">false</dei:AmendmentFlag>
<dei:DocumentPeriodEndDate id="Factid_5324960" contextRef="P01_01_2019To03_31_2019">2019-03-31</dei:DocumentPeriodEndDate>
<dei:DocumentFiscalYearFocus id="Factid_5324961" contextRef="P01_01_2019To03_31_2019">2019</dei:DocumentFiscalYearFocus>
<dei:DocumentFiscalPeriodFocus id="Factid_5324962" contextRef="P01_01_2019To03_31_2019">Q1</dei:DocumentFiscalPeriodFocus>
<dei:EntityRegistrantName id="Factid_5324963" contextRef="P01_01_2019To03_31_2019">Protalix BioTherapeutics, Inc.</dei:EntityRegistrantName>
<dei:EntityCentralIndexKey id="Factid_5324964" contextRef="P01_01_2019To03_31_2019">0001006281</dei:EntityCentralIndexKey>
<dei:CurrentFiscalYearEndDate id="Factid_5324965" contextRef="P01_01_2019To03_31_2019">--12-31</dei:CurrentFiscalYearEndDate>
<dei:EntityFilerCategory id="Factid_5324966" contextRef="P01_01_2019To03_31_2019">Accelerated Filer</dei:EntityFilerCategory>
<dei:TradingSymbol id="Factid_5324967" contextRef="P01_01_2019To03_31_2019">PLX</dei:TradingSymbol>
<dei:EntityCommonStockSharesOutstanding id="Factid_5324968" contextRef="PAsOn05_01_2019" unitRef="Unit_shares" decimals="0">148382299</dei:EntityCommonStockSharesOutstanding>
<dei:EntityEmergingGrowthCompany id="Factid_5324969" contextRef="P01_01_2019To03_31_2019">false</dei:EntityEmergingGrowthCompany>
<dei:EntitySmallBusiness id="Factid_5324970" contextRef="P01_01_2019To03_31_2019">true</dei:EntitySmallBusiness>
<plx:ChangeInOperatingLeaseRightOfUseAssets id="Factid_5326056" contextRef="P01_01_2019To03_31_2019" unitRef="Unit_USD" decimals="-3">36000</plx:ChangeInOperatingLeaseRightOfUseAssets>
<us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock id="Factid_5326071" contextRef="P01_01_2019To03_31_2019">&lt;table cellpadding="0" cellspacing="0" style="font: 10pt &amp;quot;times new roman&amp;quot;, times, serif; letter-spacing: normal; orphans: 2; text-indent: 0px; text-transform: none; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; margin-top: 0pt; margin-bottom: 0pt; border-collapse: collapse; border-spacing: 0px; table-layout: fixed;;width:100%;"&gt;&lt;tr style="vertical-align: top;"&gt;&lt;td style="width: 0.5in; padding: 0px;"&gt;&lt;/td&gt;&lt;td style="width: 0.25in; padding-left: 0px; padding-top: 0px; padding-bottom: 0px;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;e.&lt;/div&gt;&lt;/td&gt;&lt;td style="padding: 0px 81.35pt 0px 0px;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Newly issued accounting pronouncements&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="clear: both; max-height: 0px;"&gt;&lt;/div&gt;&lt;div style="clear: both; max-height: 0px;"&gt;&lt;/div&gt;&lt;div style="clear: both; max-height: 0px; background: none;"&gt;&lt;/div&gt;&lt;div style="color: rgb(0, 0, 0); font: 10pt &amp;quot;times new roman&amp;quot;, times, serif; letter-spacing: normal; orphans: 2; text-align: start; text-indent: 0px; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; margin-top: 0px; margin-bottom: 0px; margin-right: 0px; background: none;"&gt;&amp;#160;&lt;/div&gt;&lt;div style="color: rgb(0, 0, 0); font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 13.3333px; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; orphans: 2; text-align: start; text-indent: 0px; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; margin: 0px 0px 0px 0.5in;"&gt;In June 2018, the FASB issued ASU 2018-07, &amp;#8220;Compensation &amp;#8211; Stock Compensation (Topic 718): Improvements to Nonemployee Share-based Payment Accounting&amp;#8221; that expands the scope of ASC Topic 718 to include share-based payment transactions for acquiring goods and services from nonemployees. An entity should apply the requirements of ASC Topic 718 to nonemployee awards except for certain exemptions specified in ASU 2018-07. The guidance is effective for fiscal years beginning after December 15, 2018, including interim reporting periods within that fiscal year. Early adoption is permitted, but no earlier than an entity&amp;#8217;s adoption date of Topic 606. The Company does not expect the adoption of ASU 2018-07 to have a material impact on its financial statements.&lt;div style="background-color: initial; font-size: 10pt; text-indent: 0in; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"&gt;&lt;tr&gt;&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock>
<plx:RecentlyAdoptedStandardsPolicyTextBlockPolicyTextBlock id="Factid_5326072" contextRef="P01_01_2019To03_31_2019">&lt;table cellpadding="0" cellspacing="0" style="font: 10pt &amp;quot;times new roman&amp;quot;, times, serif; letter-spacing: normal; orphans: 2; text-indent: 0px; text-transform: none; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; margin-top: 0pt; margin-bottom: 0pt; border-collapse: collapse; border-spacing: 0px; table-layout: fixed;;width:100%;"&gt;&lt;tr style="vertical-align: top;"&gt;&lt;td style="width: 0.5in; padding: 0px;"&gt;&lt;/td&gt;&lt;td style="width: 0.25in; padding-left: 0px; padding-top: 0px; padding-bottom: 0px;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;d.&lt;/div&gt;&lt;/td&gt;&lt;td style="padding: 0px 81.35pt 0px 0px;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Recently adopted standards&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="clear: both; max-height: 0px;"&gt;&lt;/div&gt;&lt;div style="clear: both; max-height: 0px;"&gt;&lt;/div&gt;&lt;div style="clear: both; max-height: 0px; background: none;"&gt;&lt;/div&gt;&lt;div style="color: rgb(0, 0, 0); font: 10pt &amp;quot;times new roman&amp;quot;, times, serif; letter-spacing: normal; orphans: 2; text-align: start; text-indent: 0px; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; margin-top: 0px; margin-bottom: 0px; margin-right: 0px; background: none;"&gt;&amp;#160;&amp;#160;&lt;/div&gt;&lt;div style="color: rgb(0, 0, 0); font: 10pt &amp;quot;times new roman&amp;quot;, times, serif; letter-spacing: normal; orphans: 2; text-align: start; text-indent: 0in; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; margin: 0px 0px 0px 0.5in; background: none;"&gt;&lt;/div&gt;&lt;div style="color: rgb(0, 0, 0); font: 10pt &amp;quot;times new roman&amp;quot;, times, serif; letter-spacing: normal; orphans: 2; text-align: start; text-indent: 0px; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; margin: 0px 0px 0px 0.5in;"&gt;In February 2016, the Financial Accounting Standards Board (&amp;#8220;FASB&amp;#8221;) issued ASU No. 2016-02, Leases (Topic 842), which supersedes the existing guidance for lease accounting, Leases (Topic 840). The new standard requires a lessee to record assets and liabilities on its balance sheet for all leases with terms longer than 12 months. Leases will be classified as either finance or operating, with classification affecting the pattern of expense recognition in the lessee&amp;#8217;s income statement. The Company adopted this standard as of January 1, 2019 on a modified retrospective basis and will not restate comparative periods. The Company will elect the package of practical expedients permitted under the transition guidance within the new standard which, among other things, allows the Company to carryforward the historical lease classification. The Company made an accounting policy election to keep leases with an initial term of 12 months or less off of its balance sheet. The Company recognized those lease payments in its statements of operations on a straight-line basis over the lease period.&lt;/div&gt;&lt;div style="color: rgb(0, 0, 0); font: 10pt &amp;quot;times new roman&amp;quot;, times, serif; letter-spacing: normal; orphans: 2; text-align: start; text-indent: 0px; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; margin: 0px 0px 0px 0.5in; background: none;"&gt;&amp;#160;&lt;/div&gt;&lt;div style="color: rgb(0, 0, 0); font: 10pt &amp;quot;times new roman&amp;quot;, times, serif; letter-spacing: normal; orphans: 2; text-align: start; text-indent: 0px; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; margin: 0px 0px 0px 0.5in;"&gt;As of the adoption date, the Company recognized an operating lease asset and liability of $5.9&amp;#160;million and $5.7 million, respectively, as of January&amp;#160;1, 2019 on its balance sheet.&lt;/div&gt;&lt;table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"&gt;&lt;tr&gt;&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</plx:RecentlyAdoptedStandardsPolicyTextBlockPolicyTextBlock>
<us-gaap:OperatingLeaseRightOfUseAsset id="Factid_5326075" contextRef="PAsOn01_01_2019" unitRef="Unit_USD" decimals="-5">5900000</us-gaap:OperatingLeaseRightOfUseAsset>
<us-gaap:OperatingLeaseLiability id="Factid_5326076" contextRef="PAsOn01_01_2019" unitRef="Unit_USD" decimals="-5">5700000</us-gaap:OperatingLeaseLiability>
<us-gaap:SharePrice id="Factid_5326077" contextRef="PAsOn03_31_2019_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis_SevenPointFivePercentageConvertibleNotesMemberusgaapDebtInstrumentAxis" unitRef="Unit_USD_per_Share" decimals="2">0.44</us-gaap:SharePrice>
<plx:FairValueAssumptionsTerm id="Factid_5326078" contextRef="P01_01_2019To03_31_2019_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis_SevenPointFivePercentageConvertibleNotesMemberusgaapDebtInstrumentAxis">P2Y7M17D</plx:FairValueAssumptionsTerm>
<plx:FairValueAssumptionsRiskFreeInterestRates id="Factid_5326079" contextRef="P01_01_2019To03_31_2019_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis_SevenPointFivePercentageConvertibleNotesMemberusgaapDebtInstrumentAxis" unitRef="Unit_pure" decimals="4">0.0221</plx:FairValueAssumptionsRiskFreeInterestRates>
<plx:FairValueAssumptionsExpectedVolatilityRates id="Factid_5326080" contextRef="P01_01_2019To03_31_2019_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis_SevenPointFivePercentageConvertibleNotesMemberusgaapDebtInstrumentAxis" unitRef="Unit_pure" decimals="4">0.8156</plx:FairValueAssumptionsExpectedVolatilityRates>
<plx:FairValueAssumptionsExpectedDividendRates id="Factid_5326081" contextRef="P01_01_2019To03_31_2019_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis_SevenPointFivePercentageConvertibleNotesMemberusgaapDebtInstrumentAxis" unitRef="Unit_pure" decimals="3">0.126</plx:FairValueAssumptionsExpectedDividendRates>
<plx:PercentageOfChangeInOperatingLeaseMonthlyRentalPayments id="Factid_5326082" contextRef="P01_01_2019To03_31_2019_MinimumMembersrtRangeAxis" unitRef="Unit_pure" decimals="3">0.075</plx:PercentageOfChangeInOperatingLeaseMonthlyRentalPayments>
<plx:PercentageOfChangeInOperatingLeaseMonthlyRentalPayments id="Factid_5326083" contextRef="P01_01_2019To03_31_2019_MaximumMembersrtRangeAxis" unitRef="Unit_pure" decimals="2">0.10</plx:PercentageOfChangeInOperatingLeaseMonthlyRentalPayments>
<us-gaap:ContractWithCustomerAssetAndLiabilityTableTextBlock id="Factid_5326096" contextRef="P01_01_2019To03_31_2019">&lt;div style="color: rgb(0, 0, 0); font: 10pt &amp;quot;times new roman&amp;quot;, times, serif; letter-spacing: normal; orphans: 2; text-align: start; text-indent: 0in; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; margin: 0px 0px 0px 0.5in;"&gt;The following table sets forth data regarding the Company&amp;#8217;s contract liability:&lt;/div&gt;&lt;div style="color: rgb(0, 0, 0); font: 10pt &amp;quot;times new roman&amp;quot;, times, serif; letter-spacing: normal; orphans: 2; text-align: start; text-indent: 0in; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; margin: 0px; background: none;"&gt;&amp;#160;&lt;/div&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt &amp;quot;times new roman&amp;quot;, times, serif; letter-spacing: normal; orphans: 2; text-indent: 0px; text-transform: none; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; border-collapse: collapse; width: 55%; margin-left: 0.5in; border-spacing: 0px;"&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td style="font-size: 10pt; padding: 0px; text-indent: 0px;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font: 10pt &amp;quot;times new roman&amp;quot;, times, serif; padding-bottom: 1pt; padding-left: 0px; padding-top: 0px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="6" style="font: 10pt &amp;quot;times new roman&amp;quot;, times, serif; text-align: center; border-bottom: 1pt solid black; white-space: nowrap; padding-left: 0px; padding-top: 0px; padding-bottom: 0px;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Three months ended March&amp;#160;31,&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font: 10pt &amp;quot;times new roman&amp;quot;, times, serif; padding-left: 0px; padding-top: 0px;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td style="font: 10pt &amp;quot;times new roman&amp;quot;, times, serif; padding: 0px; border-bottom: 1pt solid black; text-indent: 0px;"&gt;&lt;div style="font-style:italic;display:inline;;font-style:italic;display:inline;"&gt;(U.S. dollars in thousands)&lt;/div&gt;&lt;/td&gt;&lt;td style="font: 10pt &amp;quot;times new roman&amp;quot;, times, serif; padding-bottom: 1pt; padding-left: 0px; padding-top: 0px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2" style="font: 10pt &amp;quot;times new roman&amp;quot;, times, serif; text-align: center; border-bottom: 1pt solid black; white-space: nowrap; padding-left: 0px; padding-top: 0px; padding-bottom: 0px;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2019&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font: 10pt &amp;quot;times new roman&amp;quot;, times, serif; white-space: nowrap; padding-left: 0px; padding-top: 0px;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font: 10pt &amp;quot;times new roman&amp;quot;, times, serif; padding-bottom: 1pt; white-space: nowrap; padding-left: 0px; padding-top: 0px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2" style="font: 10pt &amp;quot;times new roman&amp;quot;, times, serif; text-align: center; border-bottom: 1pt solid black; white-space: nowrap; padding-left: 0px; padding-top: 0px; padding-bottom: 0px;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2018&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font: 10pt &amp;quot;times new roman&amp;quot;, times, serif; padding-left: 0px; padding-top: 0px;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&lt;td style="width: 581px; font: 10pt 'times new roman', times, serif; padding: 0px; text-align: left; text-indent: 0px;"&gt;Contract liabilities at the beginning of the period&lt;/td&gt;&lt;td style="width: 21px; font: 10pt &amp;quot;times new roman&amp;quot;, times, serif; padding-left: 0px; padding-top: 0px; padding-bottom: 0px;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 11px; font: 10pt &amp;quot;times new roman&amp;quot;, times, serif; text-align: left; white-space: nowrap; padding-left: 0px; padding-top: 0px; padding-bottom: 0px;"&gt;$&lt;/td&gt;&lt;td style="width: 187px; font: 10pt &amp;quot;times new roman&amp;quot;, times, serif; text-align: right; white-space: nowrap; padding-left: 0px; padding-top: 0px; padding-bottom: 0px;"&gt;42,895&lt;/td&gt;&lt;td style="width: 11px; font: 10pt &amp;quot;times new roman&amp;quot;, times, serif; text-align: left; white-space: nowrap; padding-left: 0px; padding-top: 0px; padding-bottom: 0px;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 20px; font: 10pt &amp;quot;times new roman&amp;quot;, times, serif; white-space: nowrap; padding-left: 0px; padding-top: 0px; padding-bottom: 0px;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 10px; font: 10pt &amp;quot;times new roman&amp;quot;, times, serif; text-align: left; white-space: nowrap; padding-left: 0px; padding-top: 0px; padding-bottom: 0px;"&gt;$&lt;/td&gt;&lt;td style="width: 186px; font: 10pt &amp;quot;times new roman&amp;quot;, times, serif; text-align: right; white-space: nowrap; padding-left: 0px; padding-top: 0px; padding-bottom: 0px;"&gt;25,015&lt;/td&gt;&lt;td style="width: 10px; font: 10pt &amp;quot;times new roman&amp;quot;, times, serif; text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: white;"&gt;&lt;td style="font: 10pt 'times new roman', times, serif; padding: 0px; text-align: left; text-indent: 0px;"&gt;Additions during the period&lt;/td&gt;&lt;td style="font: 10pt &amp;quot;times new roman&amp;quot;, times, serif; padding-left: 0px; padding-top: 0px; padding-bottom: 0px;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font: 10pt &amp;quot;times new roman&amp;quot;, times, serif; text-align: left; white-space: nowrap; padding-left: 0px; padding-top: 0px; padding-bottom: 0px;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font: 10pt &amp;quot;times new roman&amp;quot;, times, serif; text-align: right; white-space: nowrap; padding-left: 0px; padding-top: 0px; padding-bottom: 0px;"&gt;6,422&lt;/td&gt;&lt;td style="font: 10pt &amp;quot;times new roman&amp;quot;, times, serif; text-align: left; white-space: nowrap; padding-left: 0px; padding-top: 0px; padding-bottom: 0px;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font: 10pt &amp;quot;times new roman&amp;quot;, times, serif; white-space: nowrap; padding-left: 0px; padding-top: 0px; padding-bottom: 0px;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font: 10pt &amp;quot;times new roman&amp;quot;, times, serif; text-align: left; white-space: nowrap; padding-left: 0px; padding-top: 0px; padding-bottom: 0px;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font: 10pt &amp;quot;times new roman&amp;quot;, times, serif; text-align: right; white-space: nowrap; padding-left: 0px; padding-top: 0px; padding-bottom: 0px;"&gt;2,179&lt;/td&gt;&lt;td style="font: 10pt &amp;quot;times new roman&amp;quot;, times, serif; text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&lt;td style="font: 10pt 'times new roman', times, serif; padding: 0px; text-align: left; text-indent: 0px;"&gt;Revenue recognized during the period&lt;/td&gt;&lt;td style="font: 10pt &amp;quot;times new roman&amp;quot;, times, serif; padding-bottom: 1pt; padding-left: 0px; padding-top: 0px;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: 1pt solid black; font: 10pt &amp;quot;times new roman&amp;quot;, times, serif; text-align: left; white-space: nowrap; padding-left: 0px; padding-top: 0px; padding-bottom: 0px;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: 1pt solid black; font: 10pt &amp;quot;times new roman&amp;quot;, times, serif; text-align: right; white-space: nowrap; padding-left: 0px; padding-top: 0px; padding-bottom: 0px;"&gt;(6,909&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font: 10pt &amp;quot;times new roman&amp;quot;, times, serif; text-align: left; white-space: nowrap; padding-left: 0px; padding-top: 0px;"&gt;)&lt;/td&gt;&lt;td style="font: 10pt &amp;quot;times new roman&amp;quot;, times, serif; padding-bottom: 1pt; white-space: nowrap; padding-left: 0px; padding-top: 0px;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: 1pt solid black; font: 10pt &amp;quot;times new roman&amp;quot;, times, serif; text-align: left; white-space: nowrap; padding-left: 0px; padding-top: 0px; padding-bottom: 0px;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: 1pt solid black; font: 10pt &amp;quot;times new roman&amp;quot;, times, serif; text-align: right; white-space: nowrap; padding-left: 0px; padding-top: 0px; padding-bottom: 0px;"&gt;(2,161&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font: 10pt &amp;quot;times new roman&amp;quot;, times, serif; text-align: left; padding-left: 0px; padding-top: 0px;"&gt;)&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: white;"&gt;&lt;td style="font: 10pt 'times new roman', times, serif; padding: 0px; text-align: left; text-indent: 0px;"&gt;Contract liabilities at the end of the period&lt;/td&gt;&lt;td style="font: 10pt &amp;quot;times new roman&amp;quot;, times, serif; padding-bottom: 2.5pt; padding-left: 0px; padding-top: 0px;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: 2.5pt double black; font: 10pt &amp;quot;times new roman&amp;quot;, times, serif; text-align: left; white-space: nowrap; padding-left: 0px; padding-top: 0px; padding-bottom: 0px;"&gt;$&lt;/td&gt;&lt;td style="border-bottom: 2.5pt double black; font: 10pt &amp;quot;times new roman&amp;quot;, times, serif; text-align: right; white-space: nowrap; padding-left: 0px; padding-top: 0px; padding-bottom: 0px;"&gt;42,408&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; font: 10pt &amp;quot;times new roman&amp;quot;, times, serif; text-align: left; white-space: nowrap; padding-left: 0px; padding-top: 0px;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font: 10pt &amp;quot;times new roman&amp;quot;, times, serif; padding-bottom: 2.5pt; white-space: nowrap; padding-left: 0px; padding-top: 0px;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: 2.5pt double black; font: 10pt &amp;quot;times new roman&amp;quot;, times, serif; text-align: left; white-space: nowrap; padding-left: 0px; padding-top: 0px; padding-bottom: 0px;"&gt;$&lt;/td&gt;&lt;td style="border-bottom: 2.5pt double black; font: 10pt &amp;quot;times new roman&amp;quot;, times, serif; text-align: right; white-space: nowrap; padding-left: 0px; padding-top: 0px; padding-bottom: 0px;"&gt;25,033&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; font: 10pt &amp;quot;times new roman&amp;quot;, times, serif; text-align: left; padding-left: 0px; padding-top: 0px;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"&gt;&lt;tr&gt;&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ContractWithCustomerAssetAndLiabilityTableTextBlock>
<plx:RevenueRemainingPerformanceObligationAmountTableTextBlock id="Factid_5326097" contextRef="P01_01_2019To03_31_2019">&lt;div style="color: rgb(0, 0, 0); font: 10pt &amp;quot;times new roman&amp;quot;, times, serif; letter-spacing: normal; orphans: 2; text-align: start; text-indent: 0in; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; margin: 0px 0px 0px 0.5in;"&gt;The following table represents the Company's unsatisfied performance obligation:&lt;/div&gt;&lt;div style="color: rgb(0, 0, 0); font: 10pt &amp;quot;times new roman&amp;quot;, times, serif; letter-spacing: normal; orphans: 2; text-align: start; text-indent: 0in; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; margin: 0px; background: none;"&gt;&amp;#160;&lt;/div&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt &amp;quot;times new roman&amp;quot;, times, serif; letter-spacing: normal; orphans: 2; text-indent: 0px; text-transform: none; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; border-collapse: collapse; width: 55%; margin-left: 0.5in; border-spacing: 0px;"&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td style="font-size: 10pt; padding: 0px; text-indent: 0px;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font: 10pt &amp;quot;times new roman&amp;quot;, times, serif; padding-bottom: 1pt; padding-left: 0px; padding-top: 0px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="6" style="font: 10pt &amp;quot;times new roman&amp;quot;, times, serif; text-align: center; border-bottom: 1pt solid black; padding-left: 0px; padding-top: 0px; padding-bottom: 0px;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;March&amp;#160;31,&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font: 10pt &amp;quot;times new roman&amp;quot;, times, serif; padding-left: 0px; padding-top: 0px;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td style="font: 10pt &amp;quot;times new roman&amp;quot;, times, serif; padding: 0px; border-bottom: 1pt solid black; text-indent: 0px;"&gt;&lt;div style="font-style:italic;display:inline;;font-style:italic;display:inline;"&gt;(U.S. dollars in thousands)&lt;/div&gt;&lt;/td&gt;&lt;td style="font: 10pt &amp;quot;times new roman&amp;quot;, times, serif; padding-bottom: 1pt; padding-left: 0px; padding-top: 0px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2" style="font: 10pt &amp;quot;times new roman&amp;quot;, times, serif; text-align: center; border-bottom: 1pt solid black; padding-left: 0px; padding-top: 0px; padding-bottom: 0px;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2019&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font: 10pt &amp;quot;times new roman&amp;quot;, times, serif; padding-left: 0px; padding-top: 0px;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font: 10pt &amp;quot;times new roman&amp;quot;, times, serif; padding-bottom: 1pt; padding-left: 0px; padding-top: 0px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2" style="font: 10pt &amp;quot;times new roman&amp;quot;, times, serif; text-align: center; border-bottom: 1pt solid black; padding-left: 0px; padding-top: 0px; padding-bottom: 0px;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2018&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font: 10pt &amp;quot;times new roman&amp;quot;, times, serif; padding-left: 0px; padding-top: 0px;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&lt;td style="width: 581px; font: 10pt 'times new roman', times, serif; padding: 0px; text-align: left; text-indent: 0px;"&gt;Unsatisfied performance obligation&lt;/td&gt;&lt;td style="width: 21px; font: 10pt &amp;quot;times new roman&amp;quot;, times, serif; padding-left: 0px; padding-top: 0px; padding-bottom: 0px;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 11px; font: 10pt &amp;quot;times new roman&amp;quot;, times, serif; text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px;"&gt;$&lt;/td&gt;&lt;td style="width: 187px; font: 10pt &amp;quot;times new roman&amp;quot;, times, serif; text-align: right; padding-left: 0px; padding-top: 0px; padding-bottom: 0px;"&gt;64,581&lt;/td&gt;&lt;td style="width: 11px; font: 10pt &amp;quot;times new roman&amp;quot;, times, serif; text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 20px; font: 10pt &amp;quot;times new roman&amp;quot;, times, serif; padding-left: 0px; padding-top: 0px; padding-bottom: 0px;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 10px; font: 10pt &amp;quot;times new roman&amp;quot;, times, serif; text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px;"&gt;$&lt;/td&gt;&lt;td style="width: 186px; font: 10pt &amp;quot;times new roman&amp;quot;, times, serif; text-align: right; padding-left: 0px; padding-top: 0px; padding-bottom: 0px;"&gt;91,033&lt;/td&gt;&lt;td style="width: 10px; font: 10pt &amp;quot;times new roman&amp;quot;, times, serif; text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"&gt;&lt;tr&gt;&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</plx:RevenueRemainingPerformanceObligationAmountTableTextBlock>
<us-gaap:ContractWithCustomerLiability id="Factid_5326118" contextRef="PAsOn12_31_2018" unitRef="Unit_USD" decimals="-3">42895000</us-gaap:ContractWithCustomerLiability>
<us-gaap:ContractWithCustomerLiability id="Factid_5326119" contextRef="PAsOn12_31_2017" unitRef="Unit_USD" decimals="-3">25015000</us-gaap:ContractWithCustomerLiability>
<us-gaap:ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToRevenueChangeInMeasureOfProgress id="Factid_5326120" contextRef="P01_01_2019To03_31_2019" unitRef="Unit_USD" decimals="-3">6422000</us-gaap:ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToRevenueChangeInMeasureOfProgress>
<us-gaap:ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToRevenueChangeInMeasureOfProgress id="Factid_5326121" contextRef="P01_01_2018To03_31_2018" unitRef="Unit_USD" decimals="-3">2179000</us-gaap:ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToRevenueChangeInMeasureOfProgress>
<us-gaap:ContractWithCustomerLiabilityRevenueRecognized id="Factid_5326122" contextRef="P01_01_2019To03_31_2019" unitRef="Unit_USD" decimals="-3">-6909000</us-gaap:ContractWithCustomerLiabilityRevenueRecognized>
<us-gaap:ContractWithCustomerLiabilityRevenueRecognized id="Factid_5326123" contextRef="P01_01_2018To03_31_2018" unitRef="Unit_USD" decimals="-3">-2161000</us-gaap:ContractWithCustomerLiabilityRevenueRecognized>
<us-gaap:ContractWithCustomerLiability id="Factid_5326124" contextRef="PAsOn03_31_2019" unitRef="Unit_USD" decimals="-3">42408000</us-gaap:ContractWithCustomerLiability>
<us-gaap:ContractWithCustomerLiability id="Factid_5326125" contextRef="PAsOn03_31_2018" unitRef="Unit_USD" decimals="-3">25033000</us-gaap:ContractWithCustomerLiability>
<us-gaap:RevenueRemainingPerformanceObligation id="Factid_5328387" contextRef="PAsOn03_31_2019" unitRef="Unit_USD" decimals="-3">64581000</us-gaap:RevenueRemainingPerformanceObligation>
<us-gaap:RevenueRemainingPerformanceObligation id="Factid_5328388" contextRef="PAsOn03_31_2018" unitRef="Unit_USD" decimals="-3">91033000</us-gaap:RevenueRemainingPerformanceObligation>
<plx:RevenueDisclosureTextBlock id="Factid_5331411" contextRef="P01_01_2019To03_31_2019">&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; margin-bottom: 0px; margin-top: 0px; margin-right: 0px;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;NOTE 5 &amp;#8211; REVENUES&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; margin-bottom: 0px; margin-top: 0px; margin-right: 0px; background: none;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; margin: 0px 0px 0px 0.5in;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;The following table summarizes the Company&amp;#8217;s disaggregation of revenues:&lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; margin: 0px 0px 0px 0.5in; background: none;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;table style="border: none; border-collapse: collapse; margin: 0in 6.75pt 0in 0.5in; width: 55%;;text-align:left;"&gt;&lt;tr&gt;&lt;td style="border-bottom: none; border-top: none; padding: 0px 0px 1pt; vertical-align: bottom;;width:;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; margin-right: 0px; margin-bottom: 0px; margin-top: 0px; line-height: normal; background: none; text-align: center;"&gt;&lt;div style="background: none;;font-weight:bold;display:inline;width:100%;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="border-top: none; padding: 0in 0in 1pt; vertical-align: bottom;;width:;"&gt;&lt;div style="font-size: 10pt; font-family: &amp;quot;times new roman&amp;quot;, times, serif; line-height: normal; margin-bottom: 0px; margin-top: 0px;"&gt;&lt;div style="background: none;;font-weight:bold;display:inline;width:100%;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="6" style="border-bottom: 1pt solid rgb(0, 0, 0); border-top-style: none; padding: 0in; vertical-align: bottom; white-space: nowrap;;width:;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; text-align: center; margin-right: 0px; margin-bottom: 0px; margin-top: 0px; line-height: normal; white-space: nowrap;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Three months ended March&amp;#160;31,&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="border-top-style: none; padding: 0in 0in 0.5pt; vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="font-size: 10pt; font-family: &amp;quot;times new roman&amp;quot;, times, serif; line-height: normal; margin-bottom: 0px; margin-top: 0px;"&gt;&lt;div style="background: none;;font-weight:bold;display:inline;width:100%;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="border-bottom: none; border-top: none; padding: 0px 0px 1pt; vertical-align: bottom;;width:;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; margin-right: 0px; margin-bottom: 0px; margin-top: 0px; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;;font-style:italic;display:inline;"&gt;(U.S.&amp;#160;dollars&amp;#160;in&amp;#160;thousands)&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding: 0in 0in 1pt; vertical-align: bottom;;width:;"&gt;&lt;div style="font-size: 10pt; font-family: &amp;quot;times new roman&amp;quot;, times, serif; line-height: normal; margin-bottom: 0px; margin-top: 0px;"&gt;&lt;div style="background: none;;font-weight:bold;display:inline;width:100%;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="border-bottom: 1pt solid rgb(0, 0, 0); border-top-style: none; padding: 0in; vertical-align: bottom; white-space: nowrap;;width:;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; text-align: center; margin-right: 0px; margin-bottom: 0px; margin-top: 0px; line-height: normal; white-space: nowrap;"&gt;&lt;div style="font-weight:bold;display:inline;width:100%;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;"&gt;2019&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="border-top-style: none; padding: 0in 0in 0.5pt; vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="font-size: 10pt; font-family: &amp;quot;times new roman&amp;quot;, times, serif; line-height: normal; margin-bottom: 0px; margin-top: 0px;"&gt;&lt;div style="background: none;;font-weight:bold;display:inline;width:100%;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="border-top-style: none; padding: 0in 0in 1pt; vertical-align: bottom; white-space: nowrap;;width:;"&gt;&lt;div style="font-size: 10pt; font-family: &amp;quot;times new roman&amp;quot;, times, serif; line-height: normal; margin-bottom: 0px; margin-top: 0px;"&gt;&lt;div style="background: none;;font-weight:bold;display:inline;width:100%;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="border-bottom: 1pt solid rgb(0, 0, 0); border-top-style: none; padding: 0in; vertical-align: bottom; white-space: nowrap;;width:;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; text-align: center; margin-right: 0px; margin-bottom: 0px; margin-top: 0px; line-height: normal; white-space: nowrap;"&gt;&lt;div style="font-weight:bold;display:inline;width:100%;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;"&gt;2018&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding: 0in 0in 0.5pt; vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="font-size: 10pt; font-family: &amp;quot;times new roman&amp;quot;, times, serif; line-height: normal; margin-bottom: 0px; margin-top: 0px;"&gt;&lt;div style="background: none;;font-weight:bold;display:inline;width:100%;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background: rgb(204, 238, 255); border-bottom: none; border-top: none; padding: 0px 0px 0px 27pt; vertical-align: bottom; width: 57%; font-size: 10pt;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; margin-right: 0px; margin-bottom: 0px; margin-top: 0px; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;Pfizer&lt;/div&gt;&lt;div style="font-size: 10pt; font-family: &amp;quot;times new roman&amp;quot;, times, serif; color: rgb(0, 0, 0); background: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px; font-size: 10pt;;display:inline;"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background: rgb(204, 238, 255); border-top: none; padding: 0in; vertical-align: bottom; width: 1%;"&gt;&lt;div style="font-size: 10pt; font-family: &amp;quot;times new roman&amp;quot;, times, serif; line-height: normal; background: none; margin-bottom: 0px; margin-top: 0px;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255); width: 1%; border-bottom: none; border-top: 0px none; text-align: left; vertical-align: bottom; padding: 0in;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; text-align: left; margin: 0px 0px 0px 0in; line-height: normal; white-space: nowrap; text-indent: 0in;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;"&gt;$&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background: rgb(204, 238, 255); border-bottom: none; border-top: 0px none; padding: 0in; vertical-align: bottom; width: 18%; white-space: nowrap; text-align: right;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; text-align: right; margin-right: 0in; margin-bottom: 0px; margin-top: 0px; line-height: normal; white-space: nowrap;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;"&gt;1,356&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background: rgb(204, 238, 255); padding: 0in; vertical-align: bottom; width: 1%; white-space: nowrap; text-align: left;"&gt;&lt;div style="font-size: 10pt; font-family: &amp;quot;times new roman&amp;quot;, times, serif; margin-left: 0in; text-indent: 0in; text-align: left; white-space: nowrap; line-height: normal; background: none; margin-bottom: 0px; margin-top: 0px;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255); width: 2%; vertical-align: bottom; padding: 0in;"&gt;&lt;div style="font-size: 10pt; font-family: &amp;quot;times new roman&amp;quot;, times, serif; line-height: normal; background: none; margin-bottom: 0px; margin-top: 0px;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background: rgb(204, 238, 255); border-top: 0px none; border-bottom: none; padding: 0in; vertical-align: bottom; width: 1%; white-space: nowrap; text-align: left;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; text-align: left; margin: 0px 0px 0px 0in; line-height: normal; white-space: nowrap; text-indent: 0in;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;"&gt;$&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background: rgb(204, 238, 255); border-bottom: none; border-top: 0px none; padding: 0in; vertical-align: bottom; width: 18%; white-space: nowrap; text-align: right;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; text-align: right; margin-right: 0in; margin-bottom: 0px; margin-top: 0px; line-height: normal; white-space: nowrap;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;"&gt;1,980&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background: rgb(204, 238, 255); padding: 0in; vertical-align: bottom; width: 1%; white-space: nowrap; text-align: left;"&gt;&lt;div style="font-size: 10pt; font-family: &amp;quot;times new roman&amp;quot;, times, serif; margin-left: 0in; text-indent: 0in; text-align: left; white-space: nowrap; line-height: normal; background: none; margin-bottom: 0px; margin-top: 0px;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background: rgb(255, 255, 255); border-top: none; border-bottom: none; padding: 0px 0px 1pt 27pt; vertical-align: bottom; width: 57%; font-size: 10pt;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; margin-right: 0px; margin-bottom: 0px; margin-top: 0px; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;Brazil&lt;/div&gt;&lt;div style="font-size: 10pt; font-family: &amp;quot;times new roman&amp;quot;, times, serif; color: rgb(0, 0, 0); background: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px; font-size: 10pt;;display:inline;"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background: rgb(255, 255, 255); padding: 0in 0in 1pt; vertical-align: bottom; width: 1%;"&gt;&lt;div style="font-size: 10pt; font-family: &amp;quot;times new roman&amp;quot;, times, serif; line-height: normal; background: none; margin-bottom: 0px; margin-top: 0px;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color: rgb(255, 255, 255); width: 1%; border-bottom: 1pt solid rgb(0, 0, 0); text-align: left; vertical-align: bottom; padding: 0in;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; text-align: left; margin: 0px 0px 0px 0in; line-height: normal; white-space: nowrap; text-indent: 0in;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;"&gt;$&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background: rgb(255, 255, 255); border-bottom: 1pt solid rgb(0, 0, 0); border-top-style: none; padding: 0in; vertical-align: bottom; width: 18%; white-space: nowrap; text-align: right;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; text-align: right; margin-right: 0in; margin-bottom: 0px; margin-top: 0px; line-height: normal; white-space: nowrap;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;"&gt;2,174&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background: rgb(255, 255, 255); padding: 0in 0in 0.5pt; vertical-align: bottom; width: 1%; white-space: nowrap; text-align: left;"&gt;&lt;div style="font-size: 10pt; font-family: &amp;quot;times new roman&amp;quot;, times, serif; margin-left: 0in; text-indent: 0in; text-align: left; white-space: nowrap; line-height: normal; background: none; margin-bottom: 0px; margin-top: 0px;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color: rgb(255, 255, 255); width: 2%; vertical-align: bottom; padding: 0in 0in 1pt;"&gt;&lt;div style="font-size: 10pt; font-family: &amp;quot;times new roman&amp;quot;, times, serif; line-height: normal; background: none; margin-bottom: 0px; margin-top: 0px;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background: rgb(255, 255, 255); border-bottom: 1pt solid rgb(0, 0, 0); padding: 0in; vertical-align: bottom; width: 1%; white-space: nowrap; text-align: left;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; text-align: left; margin: 0px 0px 0px 0in; line-height: normal; white-space: nowrap; text-indent: 0in;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;"&gt;$&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background: rgb(255, 255, 255); border-bottom: 1pt solid rgb(0, 0, 0); border-top-style: none; padding: 0in; vertical-align: bottom; width: 18%; white-space: nowrap; text-align: right;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; text-align: right; margin-right: 0in; margin-bottom: 0px; margin-top: 0px; line-height: normal; white-space: nowrap;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;"&gt;2,573&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background: rgb(255, 255, 255); padding: 0in 0in 0.5pt; vertical-align: bottom; width: 1%; white-space: nowrap; text-align: left;"&gt;&lt;div style="font-size: 10pt; font-family: &amp;quot;times new roman&amp;quot;, times, serif; margin-left: 0in; text-indent: 0in; text-align: left; white-space: nowrap; line-height: normal; background: none; margin-bottom: 0px; margin-top: 0px;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background: rgb(204, 238, 255); border-top: none; border-bottom: none; padding: 0px 0px 2.5pt 27pt; vertical-align: bottom; width: 57%;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; margin-right: 0px; margin-bottom: 0px; margin-top: 0px; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;Total revenues from selling goods&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background: rgb(204, 238, 255); padding: 0in 0in 2.5pt; vertical-align: bottom; width: 1%;"&gt;&lt;div style="font-size: 10pt; font-family: &amp;quot;times new roman&amp;quot;, times, serif; line-height: normal; background: none; margin-bottom: 0px; margin-top: 0px;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255); width: 1%; border-bottom: 2.5pt double rgb(0, 0, 0); text-align: left; vertical-align: bottom; padding: 0in;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; text-align: left; margin: 0px 0px 0px 0in; line-height: normal; white-space: nowrap; text-indent: 0in;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;"&gt;&lt;div style="white-space: nowrap;;font-weight:bold;display:inline;"&gt;$&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background: rgb(204, 238, 255); border-bottom: 2.5pt double rgb(0, 0, 0); border-top-style: none; padding: 0in; vertical-align: bottom; width: 18%; white-space: nowrap; text-align: right;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; text-align: right; margin-right: 0in; margin-bottom: 0px; margin-top: 0px; line-height: normal; white-space: nowrap;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;"&gt;&lt;div style="white-space: nowrap;;font-weight:bold;display:inline;"&gt;3,530&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background: rgb(204, 238, 255); padding: 0in 0in 1.5pt; vertical-align: bottom; width: 1%; white-space: nowrap; text-align: left;"&gt;&lt;div style="font-size: 10pt; font-family: &amp;quot;times new roman&amp;quot;, times, serif; margin-left: 0in; text-indent: 0in; text-align: left; white-space: nowrap; line-height: normal; background: none; margin-bottom: 0px; margin-top: 0px;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding: 0in 0in 2.5pt; background-color: rgb(204, 238, 255); width: 2%; vertical-align: bottom;"&gt;&lt;div style="font-size: 10pt; font-family: &amp;quot;times new roman&amp;quot;, times, serif; line-height: normal; background: none; margin-bottom: 0px; margin-top: 0px;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background: rgb(204, 238, 255); border-bottom: 2.5pt double rgb(0, 0, 0); padding: 0in; vertical-align: bottom; width: 1%; white-space: nowrap; text-align: left;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; text-align: left; margin: 0px 0px 0px 0in; line-height: normal; white-space: nowrap; text-indent: 0in;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;"&gt;&lt;div style="white-space: nowrap;;font-weight:bold;display:inline;"&gt;$&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background: rgb(204, 238, 255); border-bottom: 2.5pt double rgb(0, 0, 0); border-top-style: none; padding: 0in; vertical-align: bottom; width: 18%; white-space: nowrap; text-align: right;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; text-align: right; margin-right: 0in; margin-bottom: 0px; margin-top: 0px; line-height: normal; white-space: nowrap;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;"&gt;&lt;div style="white-space: nowrap;;font-weight:bold;display:inline;"&gt;4,553&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background: rgb(204, 238, 255); padding: 0in 0in 1.5pt; vertical-align: bottom; width: 1%; white-space: nowrap; text-align: left;"&gt;&lt;div style="font-size: 10pt; font-family: &amp;quot;times new roman&amp;quot;, times, serif; margin-left: 0in; text-indent: 0in; text-align: left; white-space: nowrap; line-height: normal; background: none; margin-bottom: 0px; margin-top: 0px;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background: rgb(255, 255, 255); border-top: none; border-bottom: none; padding: 0px 0px 2.5pt 27pt; vertical-align: bottom; width: 57%;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; margin-right: 0px; margin-bottom: 0px; margin-top: 0px; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;Revenues from license and R&amp;amp;D services&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background: rgb(255, 255, 255); padding: 0in 0in 2.5pt; vertical-align: bottom; width: 1%;"&gt;&lt;div style="font-size: 10pt; font-family: &amp;quot;times new roman&amp;quot;, times, serif; line-height: normal; background: none; margin-bottom: 0px; margin-top: 0px;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color: rgb(255, 255, 255); width: 1%; border-bottom: 2.5pt double rgb(0, 0, 0); text-align: left; vertical-align: bottom; padding: 0in;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; text-align: left; margin: 0px 0px 0px 0in; line-height: normal; white-space: nowrap; text-indent: 0in;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;"&gt;&lt;div style="white-space: nowrap;;font-weight:bold;display:inline;"&gt;$&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background: rgb(255, 255, 255); border-bottom: 2.5pt double rgb(0, 0, 0); border-top-style: none; padding: 0in; vertical-align: bottom; width: 18%; white-space: nowrap; text-align: right;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; text-align: right; margin-right: 0in; margin-bottom: 0px; margin-top: 0px; line-height: normal; white-space: nowrap;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;"&gt;&lt;div style="white-space: nowrap;;font-weight:bold;display:inline;"&gt;6,909&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background: rgb(255, 255, 255); padding: 0in 0in 1.5pt; vertical-align: bottom; width: 1%; white-space: nowrap; text-align: left;"&gt;&lt;div style="font-size: 10pt; font-family: &amp;quot;times new roman&amp;quot;, times, serif; margin-left: 0in; text-indent: 0in; text-align: left; white-space: nowrap; line-height: normal; background: none; margin-bottom: 0px; margin-top: 0px;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding: 0in 0in 2.5pt; background-color: rgb(255, 255, 255); width: 2%; vertical-align: bottom;"&gt;&lt;div style="font-size: 10pt; font-family: &amp;quot;times new roman&amp;quot;, times, serif; line-height: normal; background: none; margin-bottom: 0px; margin-top: 0px;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background: rgb(255, 255, 255); border-bottom: 2.5pt double rgb(0, 0, 0); padding: 0in; vertical-align: bottom; width: 1%; white-space: nowrap; text-align: left;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; text-align: left; margin: 0px 0px 0px 0in; line-height: normal; white-space: nowrap; text-indent: 0in;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;"&gt;&lt;div style="white-space: nowrap;;font-weight:bold;display:inline;"&gt;$&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background: rgb(255, 255, 255); border-bottom: 2.5pt double rgb(0, 0, 0); border-top-style: none; padding: 0in; vertical-align: bottom; width: 18%; white-space: nowrap; text-align: right;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; text-align: right; margin-right: 0in; margin-bottom: 0px; margin-top: 0px; line-height: normal; white-space: nowrap;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;"&gt;&lt;div style="white-space: nowrap;;font-weight:bold;display:inline;"&gt;2,161&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background: rgb(255, 255, 255); padding: 0in 0in 1.5pt; vertical-align: bottom; width: 1%; white-space: nowrap; text-align: left;"&gt;&lt;div style="font-size: 10pt; font-family: &amp;quot;times new roman&amp;quot;, times, serif; margin-left: 0in; text-indent: 0in; text-align: left; white-space: nowrap; line-height: normal; background: none; margin-bottom: 0px; margin-top: 0px;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="clear: both; max-height: 0px;"&gt;&lt;/div&gt;&lt;div style="clear: both; max-height: 0px;"&gt;&lt;/div&gt;&lt;div style="clear: both; max-height: 0px;"&gt;&lt;/div&gt;&lt;div style="clear: both; max-height: 0px;"&gt;&lt;/div&gt;&lt;div style="clear: both; max-height: 0px;"&gt;&lt;/div&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; margin: 0px 0px 0px 0.5in; background: none;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;div style="color: rgb(0, 0, 0); font: 10pt &amp;quot;times new roman&amp;quot;, times, serif; letter-spacing: normal; orphans: 2; text-align: start; text-indent: 0in; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; margin: 0px 0px 0px 0.5in;"&gt;The following table sets forth data regarding the Company&amp;#8217;s contract liability:&lt;/div&gt;&lt;div style="color: rgb(0, 0, 0); font: 10pt &amp;quot;times new roman&amp;quot;, times, serif; letter-spacing: normal; orphans: 2; text-align: start; text-indent: 0in; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; margin: 0px; background: none;"&gt;&amp;#160;&lt;/div&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt &amp;quot;times new roman&amp;quot;, times, serif; letter-spacing: normal; orphans: 2; text-indent: 0px; text-transform: none; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; border-collapse: collapse; width: 55%; margin-left: 0.5in; border-spacing: 0px;"&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td style="font-size: 10pt; padding: 0px; text-indent: 0px;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font: 10pt &amp;quot;times new roman&amp;quot;, times, serif; padding-bottom: 1pt; padding-left: 0px; padding-top: 0px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="6" style="font: 10pt &amp;quot;times new roman&amp;quot;, times, serif; text-align: center; border-bottom: 1pt solid black; white-space: nowrap; padding-left: 0px; padding-top: 0px; padding-bottom: 0px;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Three months ended March&amp;#160;31,&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font: 10pt &amp;quot;times new roman&amp;quot;, times, serif; padding-left: 0px; padding-top: 0px;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td style="font: 10pt &amp;quot;times new roman&amp;quot;, times, serif; padding: 0px; border-bottom: 1pt solid black; text-indent: 0px;"&gt;&lt;div style="font-style:italic;display:inline;;font-style:italic;display:inline;"&gt;(U.S. dollars in thousands)&lt;/div&gt;&lt;/td&gt;&lt;td style="font: 10pt &amp;quot;times new roman&amp;quot;, times, serif; padding-bottom: 1pt; padding-left: 0px; padding-top: 0px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2" style="font: 10pt &amp;quot;times new roman&amp;quot;, times, serif; text-align: center; border-bottom: 1pt solid black; white-space: nowrap; padding-left: 0px; padding-top: 0px; padding-bottom: 0px;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2019&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font: 10pt &amp;quot;times new roman&amp;quot;, times, serif; white-space: nowrap; padding-left: 0px; padding-top: 0px;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font: 10pt &amp;quot;times new roman&amp;quot;, times, serif; padding-bottom: 1pt; white-space: nowrap; padding-left: 0px; padding-top: 0px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2" style="font: 10pt &amp;quot;times new roman&amp;quot;, times, serif; text-align: center; border-bottom: 1pt solid black; white-space: nowrap; padding-left: 0px; padding-top: 0px; padding-bottom: 0px;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2018&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font: 10pt &amp;quot;times new roman&amp;quot;, times, serif; padding-left: 0px; padding-top: 0px;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&lt;td style="width: 581px; font: 10pt 'times new roman', times, serif; padding: 0px; text-align: left; text-indent: 0px;"&gt;Contract liabilities at the beginning of the period&lt;/td&gt;&lt;td style="width: 21px; font: 10pt &amp;quot;times new roman&amp;quot;, times, serif; padding-left: 0px; padding-top: 0px; padding-bottom: 0px;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 11px; font: 10pt &amp;quot;times new roman&amp;quot;, times, serif; text-align: left; white-space: nowrap; padding-left: 0px; padding-top: 0px; padding-bottom: 0px;"&gt;$&lt;/td&gt;&lt;td style="width: 187px; font: 10pt &amp;quot;times new roman&amp;quot;, times, serif; text-align: right; white-space: nowrap; padding-left: 0px; padding-top: 0px; padding-bottom: 0px;"&gt;42,895&lt;/td&gt;&lt;td style="width: 11px; font: 10pt &amp;quot;times new roman&amp;quot;, times, serif; text-align: left; white-space: nowrap; padding-left: 0px; padding-top: 0px; padding-bottom: 0px;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 20px; font: 10pt &amp;quot;times new roman&amp;quot;, times, serif; white-space: nowrap; padding-left: 0px; padding-top: 0px; padding-bottom: 0px;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 10px; font: 10pt &amp;quot;times new roman&amp;quot;, times, serif; text-align: left; white-space: nowrap; padding-left: 0px; padding-top: 0px; padding-bottom: 0px;"&gt;$&lt;/td&gt;&lt;td style="width: 186px; font: 10pt &amp;quot;times new roman&amp;quot;, times, serif; text-align: right; white-space: nowrap; padding-left: 0px; padding-top: 0px; padding-bottom: 0px;"&gt;25,015&lt;/td&gt;&lt;td style="width: 10px; font: 10pt &amp;quot;times new roman&amp;quot;, times, serif; text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: white;"&gt;&lt;td style="font: 10pt 'times new roman', times, serif; padding: 0px; text-align: left; text-indent: 0px;"&gt;Additions during the period&lt;/td&gt;&lt;td style="font: 10pt &amp;quot;times new roman&amp;quot;, times, serif; padding-left: 0px; padding-top: 0px; padding-bottom: 0px;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font: 10pt &amp;quot;times new roman&amp;quot;, times, serif; text-align: left; white-space: nowrap; padding-left: 0px; padding-top: 0px; padding-bottom: 0px;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font: 10pt &amp;quot;times new roman&amp;quot;, times, serif; text-align: right; white-space: nowrap; padding-left: 0px; padding-top: 0px; padding-bottom: 0px;"&gt;6,422&lt;/td&gt;&lt;td style="font: 10pt &amp;quot;times new roman&amp;quot;, times, serif; text-align: left; white-space: nowrap; padding-left: 0px; padding-top: 0px; padding-bottom: 0px;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font: 10pt &amp;quot;times new roman&amp;quot;, times, serif; white-space: nowrap; padding-left: 0px; padding-top: 0px; padding-bottom: 0px;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font: 10pt &amp;quot;times new roman&amp;quot;, times, serif; text-align: left; white-space: nowrap; padding-left: 0px; padding-top: 0px; padding-bottom: 0px;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font: 10pt &amp;quot;times new roman&amp;quot;, times, serif; text-align: right; white-space: nowrap; padding-left: 0px; padding-top: 0px; padding-bottom: 0px;"&gt;2,179&lt;/td&gt;&lt;td style="font: 10pt &amp;quot;times new roman&amp;quot;, times, serif; text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&lt;td style="font: 10pt 'times new roman', times, serif; padding: 0px; text-align: left; text-indent: 0px;"&gt;Revenue recognized during the period&lt;/td&gt;&lt;td style="font: 10pt &amp;quot;times new roman&amp;quot;, times, serif; padding-bottom: 1pt; padding-left: 0px; padding-top: 0px;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: 1pt solid black; font: 10pt &amp;quot;times new roman&amp;quot;, times, serif; text-align: left; white-space: nowrap; padding-left: 0px; padding-top: 0px; padding-bottom: 0px;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: 1pt solid black; font: 10pt &amp;quot;times new roman&amp;quot;, times, serif; text-align: right; white-space: nowrap; padding-left: 0px; padding-top: 0px; padding-bottom: 0px;"&gt;(6,909&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font: 10pt &amp;quot;times new roman&amp;quot;, times, serif; text-align: left; white-space: nowrap; padding-left: 0px; padding-top: 0px;"&gt;)&lt;/td&gt;&lt;td style="font: 10pt &amp;quot;times new roman&amp;quot;, times, serif; padding-bottom: 1pt; white-space: nowrap; padding-left: 0px; padding-top: 0px;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: 1pt solid black; font: 10pt &amp;quot;times new roman&amp;quot;, times, serif; text-align: left; white-space: nowrap; padding-left: 0px; padding-top: 0px; padding-bottom: 0px;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: 1pt solid black; font: 10pt &amp;quot;times new roman&amp;quot;, times, serif; text-align: right; white-space: nowrap; padding-left: 0px; padding-top: 0px; padding-bottom: 0px;"&gt;(2,161&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font: 10pt &amp;quot;times new roman&amp;quot;, times, serif; text-align: left; padding-left: 0px; padding-top: 0px;"&gt;)&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: white;"&gt;&lt;td style="font: 10pt 'times new roman', times, serif; padding: 0px; text-align: left; text-indent: 0px;"&gt;Contract liabilities at the end of the period&lt;/td&gt;&lt;td style="font: 10pt &amp;quot;times new roman&amp;quot;, times, serif; padding-bottom: 2.5pt; padding-left: 0px; padding-top: 0px;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: 2.5pt double black; font: 10pt &amp;quot;times new roman&amp;quot;, times, serif; text-align: left; white-space: nowrap; padding-left: 0px; padding-top: 0px; padding-bottom: 0px;"&gt;$&lt;/td&gt;&lt;td style="border-bottom: 2.5pt double black; font: 10pt &amp;quot;times new roman&amp;quot;, times, serif; text-align: right; white-space: nowrap; padding-left: 0px; padding-top: 0px; padding-bottom: 0px;"&gt;42,408&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; font: 10pt &amp;quot;times new roman&amp;quot;, times, serif; text-align: left; white-space: nowrap; padding-left: 0px; padding-top: 0px;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font: 10pt &amp;quot;times new roman&amp;quot;, times, serif; padding-bottom: 2.5pt; white-space: nowrap; padding-left: 0px; padding-top: 0px;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: 2.5pt double black; font: 10pt &amp;quot;times new roman&amp;quot;, times, serif; text-align: left; white-space: nowrap; padding-left: 0px; padding-top: 0px; padding-bottom: 0px;"&gt;$&lt;/td&gt;&lt;td style="border-bottom: 2.5pt double black; font: 10pt &amp;quot;times new roman&amp;quot;, times, serif; text-align: right; white-space: nowrap; padding-left: 0px; padding-top: 0px; padding-bottom: 0px;"&gt;25,033&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; font: 10pt &amp;quot;times new roman&amp;quot;, times, serif; text-align: left; padding-left: 0px; padding-top: 0px;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="clear: both; max-height: 0px; background: none;"&gt;&lt;/div&gt;&lt;div style="color: rgb(0, 0, 0); font: 10pt &amp;quot;times new roman&amp;quot;, times, serif; letter-spacing: normal; orphans: 2; text-align: start; text-indent: 0in; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; margin: 0px; background: none;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&amp;#160;&lt;/div&gt;&amp;#160;&lt;/div&gt;&lt;div style="color: rgb(0, 0, 0); font: 10pt &amp;quot;times new roman&amp;quot;, times, serif; letter-spacing: normal; orphans: 2; text-align: start; text-indent: 0in; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; margin: 0px 0px 0px 0.5in;"&gt;The following table represents the Company's unsatisfied performance obligation:&lt;/div&gt;&lt;div style="color: rgb(0, 0, 0); font: 10pt &amp;quot;times new roman&amp;quot;, times, serif; letter-spacing: normal; orphans: 2; text-align: start; text-indent: 0in; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; margin: 0px; background: none;"&gt;&amp;#160;&lt;/div&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt &amp;quot;times new roman&amp;quot;, times, serif; letter-spacing: normal; orphans: 2; text-indent: 0px; text-transform: none; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; border-collapse: collapse; width: 55%; margin-left: 0.5in; border-spacing: 0px;"&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td style="font-size: 10pt; padding: 0px; text-indent: 0px;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font: 10pt &amp;quot;times new roman&amp;quot;, times, serif; padding-bottom: 1pt; padding-left: 0px; padding-top: 0px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="6" style="font: 10pt &amp;quot;times new roman&amp;quot;, times, serif; text-align: center; border-bottom: 1pt solid black; padding-left: 0px; padding-top: 0px; padding-bottom: 0px;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;March&amp;#160;31,&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font: 10pt &amp;quot;times new roman&amp;quot;, times, serif; padding-left: 0px; padding-top: 0px;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td style="font: 10pt &amp;quot;times new roman&amp;quot;, times, serif; padding: 0px; border-bottom: 1pt solid black; text-indent: 0px;"&gt;&lt;div style="font-style:italic;display:inline;;font-style:italic;display:inline;"&gt;(U.S. dollars in thousands)&lt;/div&gt;&lt;/td&gt;&lt;td style="font: 10pt &amp;quot;times new roman&amp;quot;, times, serif; padding-bottom: 1pt; padding-left: 0px; padding-top: 0px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2" style="font: 10pt &amp;quot;times new roman&amp;quot;, times, serif; text-align: center; border-bottom: 1pt solid black; padding-left: 0px; padding-top: 0px; padding-bottom: 0px;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2019&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font: 10pt &amp;quot;times new roman&amp;quot;, times, serif; padding-left: 0px; padding-top: 0px;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font: 10pt &amp;quot;times new roman&amp;quot;, times, serif; padding-bottom: 1pt; padding-left: 0px; padding-top: 0px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2" style="font: 10pt &amp;quot;times new roman&amp;quot;, times, serif; text-align: center; border-bottom: 1pt solid black; padding-left: 0px; padding-top: 0px; padding-bottom: 0px;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2018&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font: 10pt &amp;quot;times new roman&amp;quot;, times, serif; padding-left: 0px; padding-top: 0px;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&lt;td style="width: 581px; font: 10pt 'times new roman', times, serif; padding: 0px; text-align: left; text-indent: 0px;"&gt;Unsatisfied performance obligation&lt;/td&gt;&lt;td style="width: 21px; font: 10pt &amp;quot;times new roman&amp;quot;, times, serif; padding-left: 0px; padding-top: 0px; padding-bottom: 0px;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 11px; font: 10pt &amp;quot;times new roman&amp;quot;, times, serif; text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px;"&gt;$&lt;/td&gt;&lt;td style="width: 187px; font: 10pt &amp;quot;times new roman&amp;quot;, times, serif; text-align: right; padding-left: 0px; padding-top: 0px; padding-bottom: 0px;"&gt;64,581&lt;/td&gt;&lt;td style="width: 11px; font: 10pt &amp;quot;times new roman&amp;quot;, times, serif; text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 20px; font: 10pt &amp;quot;times new roman&amp;quot;, times, serif; padding-left: 0px; padding-top: 0px; padding-bottom: 0px;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 10px; font: 10pt &amp;quot;times new roman&amp;quot;, times, serif; text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px;"&gt;$&lt;/td&gt;&lt;td style="width: 186px; font: 10pt &amp;quot;times new roman&amp;quot;, times, serif; text-align: right; padding-left: 0px; padding-top: 0px; padding-bottom: 0px;"&gt;91,033&lt;/td&gt;&lt;td style="width: 10px; font: 10pt &amp;quot;times new roman&amp;quot;, times, serif; text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"&gt;&lt;tr&gt;&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</plx:RevenueDisclosureTextBlock>
<xbrli:unit id="Unit_USD">
<xbrli:measure>iso4217:USD</xbrli:measure>
</xbrli:unit>
<xbrli:unit id="Unit_shares">
<xbrli:measure>xbrli:shares</xbrli:measure>
</xbrli:unit>
<xbrli:unit id="Unit_pure">
<xbrli:measure>xbrli:pure</xbrli:measure>
</xbrli:unit>
<xbrli:unit id="Unit_USD_per_Share">
<xbrli:divide>
<xbrli:unitNumerator>
<xbrli:measure>iso4217:USD</xbrli:measure>
</xbrli:unitNumerator>
<xbrli:unitDenominator>
<xbrli:measure>xbrli:shares</xbrli:measure>
</xbrli:unitDenominator>
</xbrli:divide>
</xbrli:unit>
<link:footnoteLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:type="extended">
<link:loc xlink:href="#Factid_5205434" xlink:type="locator" xlink:label="loc_1" />
<link:footnote xlink:role="http://www.xbrl.org/2003/role/footnote" xml:lang="en-US" xlink:type="resource" xlink:label="FN_19791">(1) Includes share-based compensation</link:footnote>
<link:footnoteArc xlink:type="arc" xlink:to="FN_19791" order="1" xlink:from="loc_1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" />
<link:loc xlink:href="#Factid_5205435" xlink:type="locator" xlink:label="loc_2" />
<link:footnoteArc xlink:type="arc" xlink:to="FN_19791" order="1" xlink:from="loc_2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" />
<link:loc xlink:href="#Factid_5205440" xlink:type="locator" xlink:label="loc_3" />
<link:footnote xlink:role="http://www.xbrl.org/2003/role/footnote" xml:lang="en-US" xlink:type="resource" xlink:label="FN_19792">(2) Includes share-based compensation</link:footnote>
<link:footnoteArc xlink:type="arc" xlink:to="FN_19792" order="1" xlink:from="loc_3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" />
<link:loc xlink:href="#Factid_5205441" xlink:type="locator" xlink:label="loc_4" />
<link:footnoteArc xlink:type="arc" xlink:to="FN_19792" order="1" xlink:from="loc_4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" />
<link:loc xlink:href="#Factid_5205521" xlink:type="locator" xlink:label="loc_5" />
<link:footnote xlink:role="http://www.xbrl.org/2003/role/footnote" xml:lang="en-US" xlink:type="resource" xlink:label="FN_19832">Common Stock, $0.001 par value; Authorized &#8211; as of March 31, 2019 and 2018 - 250,000,000.</link:footnote>
<link:footnoteArc xlink:type="arc" xlink:to="FN_19832" order="1" xlink:from="loc_5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" />
<link:loc xlink:href="#Factid_5205544" xlink:type="locator" xlink:label="loc_6" />
<link:footnoteArc xlink:type="arc" xlink:to="FN_19832" order="1" xlink:from="loc_6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" />
<link:loc xlink:href="#Factid_5208976" xlink:type="locator" xlink:label="loc_7" />
<link:footnoteArc xlink:type="arc" xlink:to="FN_19832" order="1" xlink:from="loc_7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" />
<link:loc xlink:href="#Factid_5208981" xlink:type="locator" xlink:label="loc_8" />
<link:footnoteArc xlink:type="arc" xlink:to="FN_19832" order="1" xlink:from="loc_8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" />
<link:loc xlink:href="#Factid_5208986" xlink:type="locator" xlink:label="loc_9" />
<link:footnoteArc xlink:type="arc" xlink:to="FN_19832" order="1" xlink:from="loc_9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" />
<link:loc xlink:href="#Factid_5208991" xlink:type="locator" xlink:label="loc_10" />
<link:footnoteArc xlink:type="arc" xlink:to="FN_19832" order="1" xlink:from="loc_10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" />
<link:loc xlink:href="#Factid_5205522" xlink:type="locator" xlink:label="loc_11" />
<link:footnote xlink:role="http://www.xbrl.org/2003/role/footnote" xml:lang="en-US" xlink:type="resource" xlink:label="FN_19830">* Represents an amount less than $1.</link:footnote>
<link:footnoteArc xlink:type="arc" xlink:to="FN_19830" order="1" xlink:from="loc_11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" />
</link:footnoteLink>
</xbrli:xbrl>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>7
<FILENAME>plx-20190331.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA
<TEXT>
<XBRL>
<?xml version="1.0" encoding="utf-8"?>
<!--Generated by DataTracks Rainbow Version 3.0 - www.datatracks.com - on 06-May-2019 [07:38:26] {PM}-->
<schema targetNamespace="http://www.protalix.com/20190331" elementFormDefault="qualified" xmlns:plx="http://www.protalix.com/20190331" xmlns="http://www.w3.org/2001/XMLSchema" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xl="http://www.xbrl.org/2003/XLink" xmlns:us-gaap="http://fasb.org/us-gaap/2018-01-31" xmlns:country="http://xbrl.sec.gov/country/2017-01-31" xmlns:currency="http://xbrl.sec.gov/currency/2017-01-31" xmlns:dei="http://xbrl.sec.gov/dei/2018-01-31" xmlns:exch="http://xbrl.sec.gov/exch/2018-01-31" xmlns:invest="http://xbrl.sec.gov/invest/2013-01-31" xmlns:naics="http://xbrl.sec.gov/naics/2017-01-31" xmlns:sic="http://xbrl.sec.gov/sic/2011-01-31" xmlns:us-types="http://fasb.org/us-types/2018-01-31" xmlns:stpr="http://xbrl.sec.gov/stpr/2018-01-31" xmlns:deprecated="http://www.xbrl.org/2009/arcrole/fact-explanatoryFact" xmlns:nonnum="http://www.xbrl.org/dtr/type/non-numeric" xmlns:num="http://www.xbrl.org/dtr/type/numeric" xmlns:srt="http://fasb.org/srt/2018-01-31">
<annotation>
<appinfo>
<link:roleType roleURI="http://www.protalix.com/role/DocumentAndEntityInformation" id="DocumentAndEntityInformation">
<link:definition>1001 - Document - Document and Entity Information</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.protalix.com/role/CondensedConsolidatedBalanceSheets" id="CondensedConsolidatedBalanceSheets">
<link:definition>1002 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.protalix.com/role/CondensedConsolidatedStatementsOfOperations" id="CondensedConsolidatedStatementsOfOperations">
<link:definition>1003 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.protalix.com/role/CondensedConsolidatedStatementsOfOperationsParenthetical" id="CondensedConsolidatedStatementsOfOperationsParenthetical">
<link:definition>1004 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (Parenthetical)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.protalix.com/role/CondensedConsolidatedStatementsOfChangesInCapitalDeficiency" id="CondensedConsolidatedStatementsOfChangesInCapitalDeficiency">
<link:definition>1005 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN CAPITAL DEFICIENCY</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.protalix.com/role/CondensedConsolidatedStatementsOfChangesInCapitalDeficiencyParenthetical" id="CondensedConsolidatedStatementsOfChangesInCapitalDeficiencyParenthetical">
<link:definition>1006 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN CAPITAL DEFICIENCY [Parenthetical]</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.protalix.com/role/CondensedConsolidatedStatementsOfCashFlows" id="CondensedConsolidatedStatementsOfCashFlows">
<link:definition>1007 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.protalix.com/role/SignificantAccountingPolicies" id="SignificantAccountingPolicies">
<link:definition>1008 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.protalix.com/role/Inventories" id="Inventories">
<link:definition>1009 - Disclosure - INVENTORIES</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.protalix.com/role/FairValueMeasurement" id="FairValueMeasurement">
<link:definition>1010 - Disclosure - FAIR VALUE MEASUREMENT</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.protalix.com/role/OperatingLeases" id="OperatingLeases">
<link:definition>1011 - Disclosure - OPERATING LEASES</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.protalix.com/role/Revenues" id="Revenues">
<link:definition>1012 - Disclosure - REVENUES</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.protalix.com/role/SubsequentEvents" id="SubsequentEvents">
<link:definition>1013 - Disclosure - SUBSEQUENT EVENTS</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.protalix.com/role/SignificantAccountingPoliciesPolicies" id="SignificantAccountingPoliciesPolicies">
<link:definition>1014 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES (Policies)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.protalix.com/role/InventoriesTables" id="InventoriesTables">
<link:definition>1015 - Disclosure - INVENTORIES (Tables)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.protalix.com/role/FairValueMeasurementTables" id="FairValueMeasurementTables">
<link:definition>1016 - Disclosure - FAIR VALUE MEASUREMENT (Tables)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.protalix.com/role/OperatingLeasesTables" id="OperatingLeasesTables">
<link:definition>1017 - Disclosure - OPERATING LEASES (Tables)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.protalix.com/role/RevenuesTables" id="RevenuesTables">
<link:definition>1018 - Disclosure - REVENUES (Tables)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.protalix.com/role/SignificantAccountingPoliciesNarrativeDetails" id="SignificantAccountingPoliciesNarrativeDetails">
<link:definition>1019 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES (Narrative) (Details)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.protalix.com/role/InventoriesDetails" id="InventoriesDetails">
<link:definition>1020 - Disclosure - INVENTORIES (Details)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.protalix.com/role/InventoriesDetailsTextual" id="InventoriesDetailsTextual">
<link:definition>1021 - Disclosure - INVENTORIES (Details Textual)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.protalix.com/role/FairValueMeasurementTheLiabilityComponentWasValuedBasedOnTheIncomeApproachDetails" id="FairValueMeasurementTheLiabilityComponentWasValuedBasedOnTheIncomeApproachDetails">
<link:definition>1022 - Disclosure - FAIR VALUE MEASUREMENT (The liability component was valued based on the Income Approach) (Details)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.protalix.com/role/FairValueMeasurementNarrativeDetails" id="FairValueMeasurementNarrativeDetails">
<link:definition>1023 - Disclosure - FAIR VALUE MEASUREMENT (Narrative) (Details)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.protalix.com/role/OperatingLeasesLeaseCostDetails" id="OperatingLeasesLeaseCostDetails">
<link:definition>1024 - Disclosure - OPERATING LEASES (Lease, Cost) (Details)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.protalix.com/role/OperatingLeasesLesseeOperatingLeaseLiabilityMaturityDetails" id="OperatingLeasesLesseeOperatingLeaseLiabilityMaturityDetails">
<link:definition>1025 - Disclosure - OPERATING LEASES (Lessee, Operating Lease, Liability, Maturity) (Details)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.protalix.com/role/OperatingLeasesNarrativeDetails" id="OperatingLeasesNarrativeDetails">
<link:definition>1026 - Disclosure - OPERATING LEASES (Narrative) (Details)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.protalix.com/role/RevenuesStatementsOfOperationsDetails" id="RevenuesStatementsOfOperationsDetails">
<link:definition>1027 - Disclosure - REVENUES (Statements of operations) (Details)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.protalix.com/role/RevenuesContractWithCustomerAssetAndLiabilityDetail" id="RevenuesContractWithCustomerAssetAndLiabilityDetail">
<link:definition>1028 - Disclosure - REVENUES (Contract With Customer Asset And Liability) (Detail)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.protalix.com/role/RevenuesUnsatisfiedPerformanceObligationsDetail" id="RevenuesUnsatisfiedPerformanceObligationsDetail">
<link:definition>1029 - Disclosure - REVENUES (Unsatisfied Performance Obligations) (Detail)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:linkbaseRef xlink:type="simple" xlink:href="plx-20190331_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" />
<link:linkbaseRef xlink:type="simple" xlink:href="plx-20190331_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" />
<link:linkbaseRef xlink:type="simple" xlink:href="plx-20190331_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" />
<link:linkbaseRef xlink:type="simple" xlink:href="plx-20190331_cal.xml" xlink:role="http://www.xbrl.org/2003/role/calculationLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" />
</appinfo>
</annotation>
<import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd" />
<import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" />
<import namespace="http://xbrl.org/2005/xbrldt" schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd" />
<import namespace="http://fasb.org/us-gaap/2018-01-31" schemaLocation="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd" />
<import namespace="http://xbrl.sec.gov/invest/2013-01-31" schemaLocation="http://xbrl.sec.gov/invest/2013/invest-2013-01-31.xsd" />
<import namespace="http://xbrl.sec.gov/country/2017-01-31" schemaLocation="http://xbrl.sec.gov/country/2017/country-2017-01-31.xsd" />
<import namespace="http://xbrl.sec.gov/currency/2017-01-31" schemaLocation="http://xbrl.sec.gov/currency/2017/currency-2017-01-31.xsd" />
<import namespace="http://xbrl.sec.gov/exch/2018-01-31" schemaLocation="https://xbrl.sec.gov/exch/2018/exch-2018-01-31.xsd" />
<import namespace="http://xbrl.sec.gov/naics/2017-01-31" schemaLocation="http://xbrl.sec.gov/naics/2017/naics-2017-01-31.xsd" />
<import namespace="http://xbrl.sec.gov/sic/2011-01-31" schemaLocation="http://xbrl.sec.gov/sic/2011/sic-2011-01-31.xsd" />
<import namespace="http://xbrl.sec.gov/stpr/2018-01-31" schemaLocation="https://xbrl.sec.gov/stpr/2018/stpr-2018-01-31.xsd" />
<import namespace="http://www.xbrl.org/2009/role/negated" schemaLocation="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd" />
<import namespace="http://www.xbrl.org/2009/role/net" schemaLocation="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd" />
<import namespace="http://www.xbrl.org/2009/arcrole/fact-explanatoryFact" schemaLocation="http://www.xbrl.org/lrr/arcrole/factExplanatory-2009-12-16.xsd" />
<import namespace="http://xbrl.sec.gov/dei/2018-01-31" schemaLocation="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd" />
<import namespace="http://www.xbrl.org/dtr/type/numeric" schemaLocation="http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd" />
<import namespace="http://www.xbrl.org/dtr/type/non-numeric" schemaLocation="http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd" />
<import namespace="http://fasb.org/us-types/2018-01-31" schemaLocation="http://xbrl.fasb.org/us-gaap/2018/elts/us-types-2018-01-31.xsd" />
<import namespace="http://fasb.org/srt/2018-01-31" schemaLocation="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd" />
<element name="DocumentAndEntityInformationAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="plx_DocumentAndEntityInformationAbstract" substitutionGroup="xbrli:item" />
<element name="GrantsAndReimbursementsReceivedOrReceivable" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="plx_GrantsAndReimbursementsReceivedOrReceivable" substitutionGroup="xbrli:item" xbrli:balance="credit" />
<element name="ResearchDevelopmentAndEngineeringExpenseNet" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="plx_ResearchDevelopmentAndEngineeringExpenseNet" substitutionGroup="xbrli:item" xbrli:balance="debit" />
<element name="ShareBasedCompensationRestrictedStockAwardsNetOfForfeitures" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="plx_ShareBasedCompensationRestrictedStockAwardsNetOfForfeitures" substitutionGroup="xbrli:item" xbrli:balance="credit" />
<element name="ShareBasedCompensationRestrictedStockAwardsNetOfForfeituresShares" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="plx_ShareBasedCompensationRestrictedStockAwardsNetOfForfeituresShares" substitutionGroup="xbrli:item" />
<element name="GainLossOnAmountsFundedInRespectOfEmployeeRightsUponRetirement" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="plx_GainLossOnAmountsFundedInRespectOfEmployeeRightsUponRetirement" substitutionGroup="xbrli:item" xbrli:balance="credit" />
<element name="IssuanceOfSharesForInterestPaymentRegardingConversionOfConvertibleNotes" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="plx_IssuanceOfSharesForInterestPaymentRegardingConversionOfConvertibleNotes" substitutionGroup="xbrli:item" xbrli:balance="debit" />
<element name="ChangeInOperatingLeaseRightOfUseAssets" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="plx_ChangeInOperatingLeaseRightOfUseAssets" substitutionGroup="xbrli:item" xbrli:balance="credit" />
<element name="IncreaseInLiabilitiesForPropertyPlantAndEquipment" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="plx_IncreaseInLiabilitiesForPropertyPlantAndEquipment" substitutionGroup="xbrli:item" xbrli:balance="credit" />
<element name="RevenueDisclosureTextBlock" type="nonnum:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="plx_RevenueDisclosureTextBlock" substitutionGroup="xbrli:item" />
<element name="NatureOfOperationsPolicyTextBlock" type="nonnum:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="plx_NatureOfOperationsPolicyTextBlock" substitutionGroup="xbrli:item" />
<element name="RecentlyAdoptedStandardsPolicyTextBlockPolicyTextBlock" type="nonnum:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="plx_RecentlyAdoptedStandardsPolicyTextBlockPolicyTextBlock" substitutionGroup="xbrli:item" />
<element name="Notes2021Member" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="plx_Notes2021Member" substitutionGroup="xbrli:item" />
<element name="SupplementaryIncomeStatementInformationTableTextBlock" type="nonnum:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="plx_SupplementaryIncomeStatementInformationTableTextBlock" substitutionGroup="xbrli:item" />
<element name="RevenueRemainingPerformanceObligationAmountTableTextBlock" type="nonnum:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="plx_RevenueRemainingPerformanceObligationAmountTableTextBlock" substitutionGroup="xbrli:item" />
<element name="SignificantAccountingPoliciesTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="plx_SignificantAccountingPoliciesTable" substitutionGroup="xbrldt:hypercubeItem" />
<element name="AmendedPfizerAgreementMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="plx_AmendedPfizerAgreementMember" substitutionGroup="xbrli:item" />
<element name="ChiesiUSAgreementMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="plx_ChiesiUSAgreementMember" substitutionGroup="xbrli:item" />
<element name="ChiesiExUSAgreementMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="plx_ChiesiExUSAgreementMember" substitutionGroup="xbrli:item" />
<element name="ProtalixBioTherapeuticsIncorporationMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="plx_ProtalixBioTherapeuticsIncorporationMember" substitutionGroup="xbrli:item" />
<element name="SignificantAccountingPoliciesLineItems" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="plx_SignificantAccountingPoliciesLineItems" substitutionGroup="xbrli:item" />
<element name="CollaborativeArrangementRevenuesExpensesSharingPercentage" type="num:percentItemType" abstract="false" xbrli:periodType="instant" nillable="true" id="plx_CollaborativeArrangementRevenuesExpensesSharingPercentage" substitutionGroup="xbrli:item" />
<element name="UpfrontNonrefundableNoncreditablePaymentReceivable" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" nillable="true" id="plx_UpfrontNonrefundableNoncreditablePaymentReceivable" substitutionGroup="xbrli:item" xbrli:balance="debit" />
<element name="AdditionalAmountsPayableToCoverDevelopmentCosts" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" nillable="true" id="plx_AdditionalAmountsPayableToCoverDevelopmentCosts" substitutionGroup="xbrli:item" xbrli:balance="debit" />
<element name="MaximumEntitlementOfDevelopmentCostsToCoverPerYear" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" nillable="true" id="plx_MaximumEntitlementOfDevelopmentCostsToCoverPerYear" substitutionGroup="xbrli:item" xbrli:balance="debit" />
<element name="AdditionalAmountpayableForAchievementOfRegulatoryAndCommercialMilestones" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" nillable="true" id="plx_AdditionalAmountpayableForAchievementOfRegulatoryAndCommercialMilestones" substitutionGroup="xbrli:item" xbrli:balance="debit" />
<element name="PaymentOnNetSalesPercentage" type="num:percentItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="plx_PaymentOnNetSalesPercentage" substitutionGroup="xbrli:item" />
<element name="SevenPointFivePercentageConvertibleNotesMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="plx_SevenPointFivePercentageConvertibleNotesMember" substitutionGroup="xbrli:item" />
<element name="FairValueAssumptionsTerm" type="xbrli:durationItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="plx_FairValueAssumptionsTerm" substitutionGroup="xbrli:item" />
<element name="FairValueAssumptionsRiskFreeInterestRates" type="num:percentItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="plx_FairValueAssumptionsRiskFreeInterestRates" substitutionGroup="xbrli:item" />
<element name="FairValueAssumptionsExpectedVolatilityRates" type="num:percentItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="plx_FairValueAssumptionsExpectedVolatilityRates" substitutionGroup="xbrli:item" />
<element name="FairValueAssumptionsExpectedDividendRates" type="num:percentItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="plx_FairValueAssumptionsExpectedDividendRates" substitutionGroup="xbrli:item" />
<element name="SevenPointFivePercentageConvertibleNoteMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="plx_SevenPointFivePercentageConvertibleNoteMember" substitutionGroup="xbrli:item" />
<element name="SevenPointFivePercentageConvertibleNotes2021Member" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="plx_SevenPointFivePercentageConvertibleNotes2021Member" substitutionGroup="xbrli:item" />
<element name="DisclosureOfLeasesOperatingTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="plx_DisclosureOfLeasesOperatingTable" substitutionGroup="xbrldt:hypercubeItem" />
<element name="DisclosureOfLeasesOperatingLineItems" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="plx_DisclosureOfLeasesOperatingLineItems" substitutionGroup="xbrli:item" />
<element name="PercentageOfChangeInOperatingLeaseMonthlyRentalPayments" type="num:percentItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="plx_PercentageOfChangeInOperatingLeaseMonthlyRentalPayments" substitutionGroup="xbrli:item" />
<element name="CommitmentsAndContingenciesAxis" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="plx_CommitmentsAndContingenciesAxis" substitutionGroup="xbrldt:dimensionItem" />
<element name="CommitmentsAndContingenciesDomain" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="plx_CommitmentsAndContingenciesDomain" substitutionGroup="xbrli:item" />
<element name="VehicleLeaseAndMaintenanceAgreementsMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="plx_VehicleLeaseAndMaintenanceAgreementsMember" substitutionGroup="xbrli:item" />
<element name="PfizerMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="plx_PfizerMember" substitutionGroup="xbrli:item" />
</schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.CAL
<SEQUENCE>8
<FILENAME>plx-20190331_cal.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION CALCULATION LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="utf-8"?>
<!--Generated by DataTracks Rainbow Version 3.0 - www.datatracks.com - on 06-May-2019 [07:38:26] {PM}-->
<linkbase xmlns="http://www.xbrl.org/2003/linkbase" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
<roleRef xlink:type="simple" xlink:href="plx-20190331.xsd#CondensedConsolidatedBalanceSheets" roleURI="http://www.protalix.com/role/CondensedConsolidatedBalanceSheets" />
<roleRef xlink:type="simple" xlink:href="plx-20190331.xsd#CondensedConsolidatedStatementsOfOperations" roleURI="http://www.protalix.com/role/CondensedConsolidatedStatementsOfOperations" />
<roleRef xlink:type="simple" xlink:href="plx-20190331.xsd#CondensedConsolidatedStatementsOfCashFlows" roleURI="http://www.protalix.com/role/CondensedConsolidatedStatementsOfCashFlows" />
<roleRef xlink:type="simple" xlink:href="plx-20190331.xsd#InventoriesDetails" roleURI="http://www.protalix.com/role/InventoriesDetails" />
<roleRef xlink:type="simple" xlink:href="plx-20190331.xsd#OperatingLeasesLesseeOperatingLeaseLiabilityMaturityDetails" roleURI="http://www.protalix.com/role/OperatingLeasesLesseeOperatingLeaseLiabilityMaturityDetails" />
<calculationLink xlink:type="extended" xlink:role="http://www.protalix.com/role/CondensedConsolidatedBalanceSheets">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_Assets" xlink:label="loc_us-gaap_Assets" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AssetsCurrent" xlink:label="loc_us-gaap_AssetsCurrent" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets" xlink:to="loc_us-gaap_AssetsCurrent" use="optional" order="110" weight="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue" use="optional" order="70" weight="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AccountsReceivableNetCurrent" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent" xlink:to="loc_us-gaap_AccountsReceivableNetCurrent" use="optional" order="80" weight="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OtherAssetsCurrent" xlink:label="loc_us-gaap_OtherAssetsCurrent" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent" xlink:to="loc_us-gaap_OtherAssetsCurrent" use="optional" order="90" weight="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_InventoryNet" xlink:label="loc_us-gaap_InventoryNet" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent" xlink:to="loc_us-gaap_InventoryNet" use="optional" order="100" weight="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent" xlink:label="loc_us-gaap_DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets" xlink:to="loc_us-gaap_DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent" use="optional" order="120" weight="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet" use="optional" order="140" weight="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset" use="optional" order="3372830" weight="1" />
</calculationLink>
<calculationLink xlink:type="extended" xlink:role="http://www.protalix.com/role/CondensedConsolidatedBalanceSheets">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_Liabilities" xlink:label="loc_us-gaap_Liabilities" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="loc_us-gaap_Liabilities" use="optional" order="290" weight="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LiabilitiesCurrent" xlink:label="loc_us-gaap_LiabilitiesCurrent" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities" xlink:to="loc_us-gaap_LiabilitiesCurrent" use="optional" order="220" weight="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AccountsPayableTradeCurrent" xlink:label="loc_us-gaap_AccountsPayableTradeCurrent" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent" xlink:to="loc_us-gaap_AccountsPayableTradeCurrent" use="optional" order="180" weight="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AccountsPayableOtherCurrent" xlink:label="loc_us-gaap_AccountsPayableOtherCurrent" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent" xlink:to="loc_us-gaap_AccountsPayableOtherCurrent" use="optional" order="190" weight="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ContractWithCustomerLiabilityCurrent" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityCurrent" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityCurrent" use="optional" order="210" weight="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrent" use="optional" order="4136980" weight="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LiabilitiesNoncurrent" xlink:label="loc_us-gaap_LiabilitiesNoncurrent" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities" xlink:to="loc_us-gaap_LiabilitiesNoncurrent" use="optional" order="280" weight="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ConvertibleDebtNoncurrent" xlink:label="loc_us-gaap_ConvertibleDebtNoncurrent" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesNoncurrent" xlink:to="loc_us-gaap_ConvertibleDebtNoncurrent" use="optional" order="240" weight="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PensionAndOtherPostretirementAndPostemploymentBenefitPlansLiabilitiesNoncurrent" xlink:label="loc_us-gaap_PensionAndOtherPostretirementAndPostemploymentBenefitPlansLiabilitiesNoncurrent" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesNoncurrent" xlink:to="loc_us-gaap_PensionAndOtherPostretirementAndPostemploymentBenefitPlansLiabilitiesNoncurrent" use="optional" order="260" weight="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OtherLiabilitiesNoncurrent" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesNoncurrent" xlink:to="loc_us-gaap_OtherLiabilitiesNoncurrent" use="optional" order="3372860" weight="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ContractWithCustomerLiabilityNoncurrent" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesNoncurrent" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent" use="optional" order="250" weight="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesNoncurrent" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent" use="optional" order="270" weight="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaap_StockholdersEquity" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="loc_us-gaap_StockholdersEquity" use="optional" order="310" weight="1" />
</calculationLink>
<calculationLink xlink:type="extended" xlink:role="http://www.protalix.com/role/CondensedConsolidatedStatementsOfCashFlows">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" xlink:label="loc_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities" use="optional" order="340" weight="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" use="optional" order="310" weight="-1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncreaseDecreaseInRestrictedCash" xlink:label="loc_us-gaap_IncreaseDecreaseInRestrictedCash" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="loc_us-gaap_IncreaseDecreaseInRestrictedCash" use="optional" order="320" weight="-1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PaymentsForProceedsFromOtherInvestingActivities" xlink:label="loc_us-gaap_PaymentsForProceedsFromOtherInvestingActivities" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="loc_us-gaap_PaymentsForProceedsFromOtherInvestingActivities" use="optional" order="330" weight="-1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents" xlink:label="loc_us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" xlink:to="loc_us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents" use="optional" order="440" weight="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" use="optional" order="290" weight="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsReceivable" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsReceivable" use="optional" order="220" weight="-1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncreaseDecreaseInInventories" xlink:label="loc_us-gaap_IncreaseDecreaseInInventories" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaap_IncreaseDecreaseInInventories" use="optional" order="240" weight="-1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" use="optional" order="250" weight="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities" use="optional" order="260" weight="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:label="loc_us-gaap_IncreaseDecreaseInContractWithCustomerLiability" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaap_IncreaseDecreaseInContractWithCustomerLiability" use="optional" order="180" weight="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:label="loc_us-gaap_ShareBasedCompensation" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaap_ShareBasedCompensation" use="optional" order="100" weight="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_Depreciation" xlink:label="loc_us-gaap_Depreciation" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaap_Depreciation" use="optional" order="110" weight="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ForeignCurrencyTransactionGainLossUnrealized" xlink:label="loc_us-gaap_ForeignCurrencyTransactionGainLossUnrealized" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaap_ForeignCurrencyTransactionGainLossUnrealized" use="optional" order="120" weight="-1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PensionAndOtherPostretirementBenefitExpense" xlink:label="loc_us-gaap_PensionAndOtherPostretirementBenefitExpense" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaap_PensionAndOtherPostretirementBenefitExpense" use="optional" order="130" weight="1" />
<loc xlink:type="locator" xlink:href="plx-20190331.xsd#plx_GainLossOnAmountsFundedInRespectOfEmployeeRightsUponRetirement" xlink:label="loc_plx_GainLossOnAmountsFundedInRespectOfEmployeeRightsUponRetirement" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="loc_plx_GainLossOnAmountsFundedInRespectOfEmployeeRightsUponRetirement" use="optional" order="140" weight="-1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:label="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt" use="optional" order="150" weight="-1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AmortizationOfFinancingCosts" xlink:label="loc_us-gaap_AmortizationOfFinancingCosts" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaap_AmortizationOfFinancingCosts" use="optional" order="160" weight="1" />
<loc xlink:type="locator" xlink:href="plx-20190331.xsd#plx_IssuanceOfSharesForInterestPaymentRegardingConversionOfConvertibleNotes" xlink:label="loc_plx_IssuanceOfSharesForInterestPaymentRegardingConversionOfConvertibleNotes" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="loc_plx_IssuanceOfSharesForInterestPaymentRegardingConversionOfConvertibleNotes" use="optional" order="170" weight="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaap_NetIncomeLoss" use="optional" order="60" weight="1" />
<loc xlink:type="locator" xlink:href="plx-20190331.xsd#plx_ChangeInOperatingLeaseRightOfUseAssets" xlink:label="loc_PLX_ChangeInOperatingLeaseRightOfUseAssets" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="loc_PLX_ChangeInOperatingLeaseRightOfUseAssets" use="optional" order="230" weight="-1" />
</calculationLink>
<calculationLink xlink:type="extended" xlink:role="http://www.protalix.com/role/InventoriesDetails">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_InventoryNet" xlink:label="loc_us-gaap_InventoryNet" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_InventoryRawMaterialsNetOfReserves" xlink:label="loc_us-gaap_InventoryRawMaterialsNetOfReserves" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_InventoryNet" xlink:to="loc_us-gaap_InventoryRawMaterialsNetOfReserves" use="optional" order="50" weight="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_InventoryWorkInProcessNetOfReserves" xlink:label="loc_us-gaap_InventoryWorkInProcessNetOfReserves" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_InventoryNet" xlink:to="loc_us-gaap_InventoryWorkInProcessNetOfReserves" use="optional" order="60" weight="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_InventoryFinishedGoodsNetOfReserves" xlink:label="loc_us-gaap_InventoryFinishedGoodsNetOfReserves" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_InventoryNet" xlink:to="loc_us-gaap_InventoryFinishedGoodsNetOfReserves" use="optional" order="70" weight="1" />
</calculationLink>
<calculationLink xlink:type="extended" xlink:role="http://www.protalix.com/role/CondensedConsolidatedStatementsOfOperations">
<loc xlink:type="locator" xlink:href="plx-20190331.xsd#plx_ResearchDevelopmentAndEngineeringExpenseNet" xlink:label="loc_plx_ResearchDevelopmentAndEngineeringExpenseNet" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_plx_ResearchDevelopmentAndEngineeringExpenseNet" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense" use="optional" order="80" weight="1" />
<loc xlink:type="locator" xlink:href="plx-20190331.xsd#plx_GrantsAndReimbursementsReceivedOrReceivable" xlink:label="loc_plx_GrantsAndReimbursementsReceivedOrReceivable" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_plx_ResearchDevelopmentAndEngineeringExpenseNet" xlink:to="loc_plx_GrantsAndReimbursementsReceivedOrReceivable" use="optional" order="90" weight="-1" />
</calculationLink>
<calculationLink xlink:type="extended" xlink:role="http://www.protalix.com/role/CondensedConsolidatedStatementsOfOperations">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NonoperatingIncomeExpense" xlink:label="loc_us-gaap_NonoperatingIncomeExpense" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss" xlink:to="loc_us-gaap_NonoperatingIncomeExpense" use="optional" order="150" weight="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OtherNonoperatingExpense" xlink:label="loc_us-gaap_OtherNonoperatingExpense" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NonoperatingIncomeExpense" xlink:to="loc_us-gaap_OtherNonoperatingExpense" use="optional" order="130" weight="-1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OtherNonoperatingIncome" xlink:label="loc_us-gaap_OtherNonoperatingIncome" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NonoperatingIncomeExpense" xlink:to="loc_us-gaap_OtherNonoperatingIncome" use="optional" order="140" weight="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:label="loc_us-gaap_OperatingIncomeLoss" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss" xlink:to="loc_us-gaap_OperatingIncomeLoss" use="optional" order="120" weight="1" />
</calculationLink>
<calculationLink xlink:type="extended" xlink:role="http://www.protalix.com/role/OperatingLeasesLesseeOperatingLeaseLiabilityMaturityDetails">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" use="optional" order="4138410" weight="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" use="optional" order="4138420" weight="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" use="optional" order="4138440" weight="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" use="optional" order="4138450" weight="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" use="optional" order="4138460" weight="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" use="optional" order="4138470" weight="1" />
</calculationLink>
</linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>9
<FILENAME>plx-20190331_def.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION DEFINITION LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="utf-8"?>
<!--Generated by DataTracks Rainbow Version 3.0 - www.datatracks.com - on 06-May-2019 [07:38:26] {PM}-->
<linkbase xmlns="http://www.xbrl.org/2003/linkbase" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:xbrldt="http://xbrl.org/2005/xbrldt">
<roleRef xlink:type="simple" xlink:href="plx-20190331.xsd#CondensedConsolidatedBalanceSheets" roleURI="http://www.protalix.com/role/CondensedConsolidatedBalanceSheets" />
<roleRef xlink:type="simple" xlink:href="plx-20190331.xsd#CondensedConsolidatedStatementsOfOperations" roleURI="http://www.protalix.com/role/CondensedConsolidatedStatementsOfOperations" />
<roleRef xlink:type="simple" xlink:href="plx-20190331.xsd#CondensedConsolidatedStatementsOfOperationsParenthetical" roleURI="http://www.protalix.com/role/CondensedConsolidatedStatementsOfOperationsParenthetical" />
<roleRef xlink:type="simple" xlink:href="plx-20190331.xsd#CondensedConsolidatedStatementsOfChangesInCapitalDeficiency" roleURI="http://www.protalix.com/role/CondensedConsolidatedStatementsOfChangesInCapitalDeficiency" />
<roleRef xlink:type="simple" xlink:href="plx-20190331.xsd#CondensedConsolidatedStatementsOfChangesInCapitalDeficiencyParenthetical" roleURI="http://www.protalix.com/role/CondensedConsolidatedStatementsOfChangesInCapitalDeficiencyParenthetical" />
<roleRef xlink:type="simple" xlink:href="plx-20190331.xsd#CondensedConsolidatedStatementsOfCashFlows" roleURI="http://www.protalix.com/role/CondensedConsolidatedStatementsOfCashFlows" />
<roleRef xlink:type="simple" xlink:href="plx-20190331.xsd#FairValueMeasurementTables" roleURI="http://www.protalix.com/role/FairValueMeasurementTables" />
<roleRef xlink:type="simple" xlink:href="plx-20190331.xsd#SignificantAccountingPoliciesNarrativeDetails" roleURI="http://www.protalix.com/role/SignificantAccountingPoliciesNarrativeDetails" />
<roleRef xlink:type="simple" xlink:href="plx-20190331.xsd#InventoriesDetails" roleURI="http://www.protalix.com/role/InventoriesDetails" />
<roleRef xlink:type="simple" xlink:href="plx-20190331.xsd#InventoriesDetailsTextual" roleURI="http://www.protalix.com/role/InventoriesDetailsTextual" />
<roleRef xlink:type="simple" xlink:href="plx-20190331.xsd#FairValueMeasurementTheLiabilityComponentWasValuedBasedOnTheIncomeApproachDetails" roleURI="http://www.protalix.com/role/FairValueMeasurementTheLiabilityComponentWasValuedBasedOnTheIncomeApproachDetails" />
<roleRef xlink:type="simple" xlink:href="plx-20190331.xsd#FairValueMeasurementNarrativeDetails" roleURI="http://www.protalix.com/role/FairValueMeasurementNarrativeDetails" />
<roleRef xlink:type="simple" xlink:href="plx-20190331.xsd#OperatingLeasesLeaseCostDetails" roleURI="http://www.protalix.com/role/OperatingLeasesLeaseCostDetails" />
<roleRef xlink:type="simple" xlink:href="plx-20190331.xsd#OperatingLeasesLesseeOperatingLeaseLiabilityMaturityDetails" roleURI="http://www.protalix.com/role/OperatingLeasesLesseeOperatingLeaseLiabilityMaturityDetails" />
<roleRef xlink:type="simple" xlink:href="plx-20190331.xsd#OperatingLeasesNarrativeDetails" roleURI="http://www.protalix.com/role/OperatingLeasesNarrativeDetails" />
<roleRef xlink:type="simple" xlink:href="plx-20190331.xsd#RevenuesStatementsOfOperationsDetails" roleURI="http://www.protalix.com/role/RevenuesStatementsOfOperationsDetails" />
<roleRef xlink:type="simple" xlink:href="plx-20190331.xsd#RevenuesContractWithCustomerAssetAndLiabilityDetail" roleURI="http://www.protalix.com/role/RevenuesContractWithCustomerAssetAndLiabilityDetail" />
<roleRef xlink:type="simple" xlink:href="plx-20190331.xsd#RevenuesUnsatisfiedPerformanceObligationsDetail" roleURI="http://www.protalix.com/role/RevenuesUnsatisfiedPerformanceObligationsDetail" />
<arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/all" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all" />
<arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default" />
<arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain" />
<arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member" />
<arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension" />
<arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/notAll" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#notAll" />
<definitionLink xlink:type="extended" xlink:role="http://www.protalix.com/role/CondensedConsolidatedBalanceSheets">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_35" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_33" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_35" xlink:to="loc_us-gaap_StatementTable_33" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_34" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_33" xlink:to="loc_us-gaap_StatementClassOfStockAxis_34" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_43" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis_34" xlink:to="loc_us-gaap_ClassOfStockDomain_43" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_43_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementClassOfStockAxis_34" xlink:to="loc_us-gaap_ClassOfStockDomain_43_default" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AssetsAbstract" xlink:label="loc_us-gaap_AssetsAbstract_36" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_35" xlink:to="loc_us-gaap_AssetsAbstract_36" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="loc_us-gaap_AssetsCurrentAbstract_37" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsAbstract_36" xlink:to="loc_us-gaap_AssetsCurrentAbstract_37" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_44" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsCurrentAbstract_37" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_44" use="optional" order="7" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AccountsReceivableNetCurrent" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent_45" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsCurrentAbstract_37" xlink:to="loc_us-gaap_AccountsReceivableNetCurrent_45" use="optional" order="8" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OtherAssetsCurrent" xlink:label="loc_us-gaap_OtherAssetsCurrent_46" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsCurrentAbstract_37" xlink:to="loc_us-gaap_OtherAssetsCurrent_46" use="optional" order="9" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_InventoryNet" xlink:label="loc_us-gaap_InventoryNet_47" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsCurrentAbstract_37" xlink:to="loc_us-gaap_InventoryNet_47" use="optional" order="10" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AssetsCurrent" xlink:label="loc_us-gaap_AssetsCurrent_48" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsCurrentAbstract_37" xlink:to="loc_us-gaap_AssetsCurrent_48" use="optional" order="11" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent" xlink:label="loc_us-gaap_DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent_49" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsAbstract_36" xlink:to="loc_us-gaap_DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent_49" use="optional" order="12" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_50" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsAbstract_36" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_50" use="optional" order="13" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_Assets" xlink:label="loc_us-gaap_Assets_51" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsAbstract_36" xlink:to="loc_us-gaap_Assets_51" use="optional" order="14" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_413685" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsAbstract_36" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset_413685" use="optional" order="15" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_38" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_35" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_38" use="optional" order="16" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract_39" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_38" xlink:to="loc_us-gaap_LiabilitiesCurrentAbstract_39" use="optional" order="17" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAbstract" xlink:label="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAbstract_40" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_39" xlink:to="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAbstract_40" use="optional" order="18" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AccountsPayableTradeCurrent" xlink:label="loc_us-gaap_AccountsPayableTradeCurrent_52" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAbstract_40" xlink:to="loc_us-gaap_AccountsPayableTradeCurrent_52" use="optional" order="19" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AccountsPayableOtherCurrent" xlink:label="loc_us-gaap_AccountsPayableOtherCurrent_53" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAbstract_40" xlink:to="loc_us-gaap_AccountsPayableOtherCurrent_53" use="optional" order="20" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_413698" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAbstract_40" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrent_413698" use="optional" order="21" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LiabilitiesCurrent" xlink:label="loc_us-gaap_LiabilitiesCurrent_56" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_39" xlink:to="loc_us-gaap_LiabilitiesCurrent_56" use="optional" order="22" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ContractWithCustomerLiabilityCurrent" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityCurrent_337285" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_39" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityCurrent_337285" use="optional" order="23" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LiabilitiesNoncurrentAbstract" xlink:label="loc_us-gaap_LiabilitiesNoncurrentAbstract_41" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_38" xlink:to="loc_us-gaap_LiabilitiesNoncurrentAbstract_41" use="optional" order="24" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ConvertibleDebtNoncurrent" xlink:label="loc_us-gaap_ConvertibleDebtNoncurrent_57" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesNoncurrentAbstract_41" xlink:to="loc_us-gaap_ConvertibleDebtNoncurrent_57" use="optional" order="25" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PensionAndOtherPostretirementAndPostemploymentBenefitPlansLiabilitiesNoncurrent" xlink:label="loc_us-gaap_PensionAndOtherPostretirementAndPostemploymentBenefitPlansLiabilitiesNoncurrent_59" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesNoncurrentAbstract_41" xlink:to="loc_us-gaap_PensionAndOtherPostretirementAndPostemploymentBenefitPlansLiabilitiesNoncurrent_59" use="optional" order="26" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OtherLiabilitiesNoncurrent" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent_60" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesNoncurrentAbstract_41" xlink:to="loc_us-gaap_OtherLiabilitiesNoncurrent_60" use="optional" order="27" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ContractWithCustomerLiabilityNoncurrent" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent_337286" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesNoncurrentAbstract_41" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent_337286" use="optional" order="28" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_413697" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesNoncurrentAbstract_41" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_413697" use="optional" order="29" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LiabilitiesNoncurrent" xlink:label="loc_us-gaap_LiabilitiesNoncurrent_61" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_38" xlink:to="loc_us-gaap_LiabilitiesNoncurrent_61" use="optional" order="30" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_Liabilities" xlink:label="loc_us-gaap_Liabilities_62" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_38" xlink:to="loc_us-gaap_Liabilities_62" use="optional" order="31" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaap_StockholdersEquity_411566" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_38" xlink:to="loc_us-gaap_StockholdersEquity_411566" use="optional" order="32" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_68" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_38" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquity_68" use="optional" order="33" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://www.protalix.com/role/CondensedConsolidatedStatementsOfOperations">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_274" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_272" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_274" xlink:to="loc_us-gaap_StatementTable_272" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_273" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_272" xlink:to="loc_us-gaap_StatementClassOfStockAxis_273" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_276" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis_273" xlink:to="loc_us-gaap_ClassOfStockDomain_276" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_276_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementClassOfStockAxis_273" xlink:to="loc_us-gaap_ClassOfStockDomain_276_default" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_ProductOrServiceAxis" xlink:label="loc_srt_ProductOrServiceAxis_337383" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_272" xlink:to="loc_srt_ProductOrServiceAxis_337383" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_ProductsAndServicesDomain" xlink:label="loc_srt_ProductsAndServicesDomain_337384" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_337383" xlink:to="loc_srt_ProductsAndServicesDomain_337384" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_ProductsAndServicesDomain" xlink:label="loc_srt_ProductsAndServicesDomain_337384_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_337383" xlink:to="loc_srt_ProductsAndServicesDomain_337384_default" use="optional" order="7" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ProductMember" xlink:label="loc_us-gaap_ProductMember_337385" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_337384" xlink:to="loc_us-gaap_ProductMember_337385" use="optional" order="8" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LicenseAndServiceMember" xlink:label="loc_us-gaap_LicenseAndServiceMember_337386" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_337384" xlink:to="loc_us-gaap_LicenseAndServiceMember_337386" use="optional" order="9" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_Revenues" xlink:label="loc_us-gaap_Revenues_277" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_274" xlink:to="loc_us-gaap_Revenues_277" use="optional" order="10" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CostOfRevenue" xlink:label="loc_us-gaap_CostOfRevenue_278" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_274" xlink:to="loc_us-gaap_CostOfRevenue_278" use="optional" order="11" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_280" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_274" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_280" use="optional" order="12" />
<loc xlink:type="locator" xlink:href="plx-20190331.xsd#plx_GrantsAndReimbursementsReceivedOrReceivable" xlink:label="loc_plx_GrantsAndReimbursementsReceivedOrReceivable_281" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_274" xlink:to="loc_plx_GrantsAndReimbursementsReceivedOrReceivable_281" use="optional" order="13" />
<loc xlink:type="locator" xlink:href="plx-20190331.xsd#plx_ResearchDevelopmentAndEngineeringExpenseNet" xlink:label="loc_plx_ResearchDevelopmentAndEngineeringExpenseNet_282" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_274" xlink:to="loc_plx_ResearchDevelopmentAndEngineeringExpenseNet_282" use="optional" order="14" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpense" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpense_283" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_274" xlink:to="loc_us-gaap_SellingGeneralAndAdministrativeExpense_283" use="optional" order="15" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:label="loc_us-gaap_OperatingIncomeLoss_284" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_274" xlink:to="loc_us-gaap_OperatingIncomeLoss_284" use="optional" order="16" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OtherNonoperatingExpense" xlink:label="loc_us-gaap_OtherNonoperatingExpense_285" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_274" xlink:to="loc_us-gaap_OtherNonoperatingExpense_285" use="optional" order="17" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OtherNonoperatingIncome" xlink:label="loc_us-gaap_OtherNonoperatingIncome_286" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_274" xlink:to="loc_us-gaap_OtherNonoperatingIncome_286" use="optional" order="18" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NonoperatingIncomeExpense" xlink:label="loc_us-gaap_NonoperatingIncomeExpense_289" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_274" xlink:to="loc_us-gaap_NonoperatingIncomeExpense_289" use="optional" order="19" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss_292" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_274" xlink:to="loc_us-gaap_NetIncomeLoss_292" use="optional" order="20" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EarningsPerShareBasicAndDiluted" xlink:label="loc_us-gaap_EarningsPerShareBasicAndDiluted_411589" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_274" xlink:to="loc_us-gaap_EarningsPerShareBasicAndDiluted_411589" use="optional" order="21" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:label="loc_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_296" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_274" xlink:to="loc_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_296" use="optional" order="22" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://www.protalix.com/role/CondensedConsolidatedStatementsOfOperationsParenthetical">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_411782" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_411764" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_411782" xlink:to="loc_us-gaap_StatementTable_411764" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_411769" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_411764" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_411769" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_411770" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_411769" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_411770" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_411770_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_411769" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_411770_default" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember_411772" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_411770" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseMember_411772" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpensesMember" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember_411775" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_411770" xlink:to="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember_411775" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_411784" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_411782" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_411784" use="optional" order="7" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://www.protalix.com/role/CondensedConsolidatedStatementsOfChangesInCapitalDeficiency">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_680" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_677" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_680" xlink:to="loc_us-gaap_StatementTable_677" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_678" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_677" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_678" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain_679" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_678" xlink:to="loc_us-gaap_EquityComponentDomain_679" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain_679_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_678" xlink:to="loc_us-gaap_EquityComponentDomain_679_default" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaap_CommonStockMember_681" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_679" xlink:to="loc_us-gaap_CommonStockMember_681" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember_682" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_679" xlink:to="loc_us-gaap_AdditionalPaidInCapitalMember_682" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RetainedEarningsMember" xlink:label="loc_us-gaap_RetainedEarningsMember_683" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_679" xlink:to="loc_us-gaap_RetainedEarningsMember_683" use="optional" order="7" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaap_StockholdersEquity_684" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_680" xlink:to="loc_us-gaap_StockholdersEquity_684" use="optional" order="8" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SharesOutstanding" xlink:label="loc_us-gaap_SharesOutstanding_685" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_680" xlink:to="loc_us-gaap_SharesOutstanding_685" use="optional" order="9" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_689" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_680" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_689" use="optional" order="10" />
<loc xlink:type="locator" xlink:href="plx-20190331.xsd#plx_ShareBasedCompensationRestrictedStockAwardsNetOfForfeitures" xlink:label="loc_plx_ShareBasedCompensationRestrictedStockAwardsNetOfForfeitures_690" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_680" xlink:to="loc_plx_ShareBasedCompensationRestrictedStockAwardsNetOfForfeitures_690" use="optional" order="11" />
<loc xlink:type="locator" xlink:href="plx-20190331.xsd#plx_ShareBasedCompensationRestrictedStockAwardsNetOfForfeituresShares" xlink:label="loc_plx_ShareBasedCompensationRestrictedStockAwardsNetOfForfeituresShares_691" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_680" xlink:to="loc_plx_ShareBasedCompensationRestrictedStockAwardsNetOfForfeituresShares_691" use="optional" order="12" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_693" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_680" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_693" use="optional" order="13" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss_337393" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_680" xlink:to="loc_us-gaap_NetIncomeLoss_337393" use="optional" order="14" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_337394" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_680" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_337394" use="optional" order="15" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://www.protalix.com/role/CondensedConsolidatedStatementsOfChangesInCapitalDeficiencyParenthetical">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_742" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_739" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_742" xlink:to="loc_us-gaap_StatementTable_739" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaap_AwardTypeAxis_740" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_739" xlink:to="loc_us-gaap_AwardTypeAxis_740" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_741" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_740" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_741" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_741_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_740" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_741_default" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare_411858" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_742" xlink:to="loc_us-gaap_CommonStockParOrStatedValuePerShare_411858" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="loc_us-gaap_CommonStockSharesAuthorized_411859" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_742" xlink:to="loc_us-gaap_CommonStockSharesAuthorized_411859" use="optional" order="6" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://www.protalix.com/role/CondensedConsolidatedStatementsOfCashFlows">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_749" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_747" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_749" xlink:to="loc_us-gaap_StatementTable_747" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_748" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_747" xlink:to="loc_us-gaap_StatementClassOfStockAxis_748" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_757" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis_748" xlink:to="loc_us-gaap_ClassOfStockDomain_757" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_757_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementClassOfStockAxis_748" xlink:to="loc_us-gaap_ClassOfStockDomain_757_default" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_750" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_749" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_750" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss_758" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_750" xlink:to="loc_us-gaap_NetIncomeLoss_758" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_751" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_750" xlink:to="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_751" use="optional" order="7" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:label="loc_us-gaap_ShareBasedCompensation_761" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_751" xlink:to="loc_us-gaap_ShareBasedCompensation_761" use="optional" order="8" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_Depreciation" xlink:label="loc_us-gaap_Depreciation_762" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_751" xlink:to="loc_us-gaap_Depreciation_762" use="optional" order="9" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ForeignCurrencyTransactionGainLossUnrealized" xlink:label="loc_us-gaap_ForeignCurrencyTransactionGainLossUnrealized_763" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_751" xlink:to="loc_us-gaap_ForeignCurrencyTransactionGainLossUnrealized_763" use="optional" order="10" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PensionAndOtherPostretirementBenefitExpense" xlink:label="loc_us-gaap_PensionAndOtherPostretirementBenefitExpense_764" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_751" xlink:to="loc_us-gaap_PensionAndOtherPostretirementBenefitExpense_764" use="optional" order="11" />
<loc xlink:type="locator" xlink:href="plx-20190331.xsd#plx_GainLossOnAmountsFundedInRespectOfEmployeeRightsUponRetirement" xlink:label="loc_plx_GainLossOnAmountsFundedInRespectOfEmployeeRightsUponRetirement_765" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_751" xlink:to="loc_plx_GainLossOnAmountsFundedInRespectOfEmployeeRightsUponRetirement_765" use="optional" order="12" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:label="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_767" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_751" xlink:to="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_767" use="optional" order="13" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AmortizationOfFinancingCosts" xlink:label="loc_us-gaap_AmortizationOfFinancingCosts_770" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_751" xlink:to="loc_us-gaap_AmortizationOfFinancingCosts_770" use="optional" order="14" />
<loc xlink:type="locator" xlink:href="plx-20190331.xsd#plx_IssuanceOfSharesForInterestPaymentRegardingConversionOfConvertibleNotes" xlink:label="loc_plx_IssuanceOfSharesForInterestPaymentRegardingConversionOfConvertibleNotes_771" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_751" xlink:to="loc_plx_IssuanceOfSharesForInterestPaymentRegardingConversionOfConvertibleNotes_771" use="optional" order="15" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_752" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_751" xlink:to="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_752" use="optional" order="16" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_773" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_752" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_773" use="optional" order="17" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncreaseDecreaseInInventories" xlink:label="loc_us-gaap_IncreaseDecreaseInInventories_774" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_752" xlink:to="loc_us-gaap_IncreaseDecreaseInInventories_774" use="optional" order="18" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_775" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_752" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_775" use="optional" order="19" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities_776" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_752" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities_776" use="optional" order="20" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:label="loc_us-gaap_IncreaseDecreaseInContractWithCustomerLiability_337371" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_752" xlink:to="loc_us-gaap_IncreaseDecreaseInContractWithCustomerLiability_337371" use="optional" order="21" />
<loc xlink:type="locator" xlink:href="plx-20190331.xsd#plx_ChangeInOperatingLeaseRightOfUseAssets" xlink:label="loc_plx_ChangeInOperatingLeaseRightOfUseAssets_413883" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_752" xlink:to="loc_plx_ChangeInOperatingLeaseRightOfUseAssets_413883" use="optional" order="22" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_779" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_750" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_779" use="optional" order="23" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_753" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_749" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_753" use="optional" order="24" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_780" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_753" xlink:to="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_780" use="optional" order="25" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncreaseDecreaseInRestrictedCash" xlink:label="loc_us-gaap_IncreaseDecreaseInRestrictedCash_782" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_753" xlink:to="loc_us-gaap_IncreaseDecreaseInRestrictedCash_782" use="optional" order="26" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PaymentsForProceedsFromOtherInvestingActivities" xlink:label="loc_us-gaap_PaymentsForProceedsFromOtherInvestingActivities_783" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_753" xlink:to="loc_us-gaap_PaymentsForProceedsFromOtherInvestingActivities_783" use="optional" order="27" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_341648" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_753" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_341648" use="optional" order="28" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents" xlink:label="loc_us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents_792" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_749" xlink:to="loc_us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents_792" use="optional" order="29" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" xlink:label="loc_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease_793" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_749" xlink:to="loc_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease_793" use="optional" order="30" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_794" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_749" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_794" use="optional" order="31" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:label="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_755" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_749" xlink:to="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_755" use="optional" order="32" />
<loc xlink:type="locator" xlink:href="plx-20190331.xsd#plx_IncreaseInLiabilitiesForPropertyPlantAndEquipment" xlink:label="loc_plx_IncreaseInLiabilitiesForPropertyPlantAndEquipment_796" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_755" xlink:to="loc_plx_IncreaseInLiabilitiesForPropertyPlantAndEquipment_796" use="optional" order="33" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DebtConversionConvertedInstrumentAmount1" xlink:label="loc_us-gaap_DebtConversionConvertedInstrumentAmount1_799" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_755" xlink:to="loc_us-gaap_DebtConversionConvertedInstrumentAmount1_799" use="optional" order="34" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SupplementalCashFlowInformationAbstract" xlink:label="loc_us-gaap_SupplementalCashFlowInformationAbstract_756" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_749" xlink:to="loc_us-gaap_SupplementalCashFlowInformationAbstract_756" use="optional" order="35" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_InterestPaidNet" xlink:label="loc_us-gaap_InterestPaidNet_800" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SupplementalCashFlowInformationAbstract_756" xlink:to="loc_us-gaap_InterestPaidNet_800" use="optional" order="36" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://www.protalix.com/role/FairValueMeasurementTables">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_341437" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_341434" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_341437" xlink:to="loc_us-gaap_StatementTable_341434" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DebtInstrumentAxis" xlink:label="loc_us-gaap_DebtInstrumentAxis_341439" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_341434" xlink:to="loc_us-gaap_DebtInstrumentAxis_341439" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_341440" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DebtInstrumentAxis_341439" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_341440" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_341440_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DebtInstrumentAxis_341439" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_341440_default" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="plx-20190331.xsd#plx_Notes2021Member" xlink:label="loc_plx_Notes2021Member_341443" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_341440" xlink:to="loc_plx_Notes2021Member_341443" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock_341438" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_341437" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock_341438" use="optional" order="6" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://www.protalix.com/role/SignificantAccountingPoliciesNarrativeDetails">
<loc xlink:type="locator" xlink:href="plx-20190331.xsd#plx_SignificantAccountingPoliciesLineItems" xlink:label="loc_plx_SignificantAccountingPoliciesLineItems_192" />
<loc xlink:type="locator" xlink:href="plx-20190331.xsd#plx_SignificantAccountingPoliciesTable" xlink:label="loc_plx_SignificantAccountingPoliciesTable_178" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_plx_SignificantAccountingPoliciesLineItems_192" xlink:to="loc_plx_SignificantAccountingPoliciesTable_178" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaap_TypeOfArrangementAxis_180" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_plx_SignificantAccountingPoliciesTable_178" xlink:to="loc_us-gaap_TypeOfArrangementAxis_180" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_181" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_TypeOfArrangementAxis_180" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_181" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_181_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_TypeOfArrangementAxis_180" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_181_default" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="plx-20190331.xsd#plx_AmendedPfizerAgreementMember" xlink:label="loc_plx_AmendedPfizerAgreementMember_195" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_181" xlink:to="loc_plx_AmendedPfizerAgreementMember_195" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="plx-20190331.xsd#plx_ChiesiUSAgreementMember" xlink:label="loc_plx_ChiesiUSAgreementMember_196" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_181" xlink:to="loc_plx_ChiesiUSAgreementMember_196" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="plx-20190331.xsd#plx_ChiesiExUSAgreementMember" xlink:label="loc_plx_ChiesiExUSAgreementMember_337391" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_181" xlink:to="loc_plx_ChiesiExUSAgreementMember_337391" use="optional" order="7" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_182" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_plx_SignificantAccountingPoliciesTable_178" xlink:to="loc_dei_LegalEntityAxis_182" use="optional" order="8" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_183" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_dei_LegalEntityAxis_182" xlink:to="loc_dei_EntityDomain_183" use="optional" order="9" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_183_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_dei_LegalEntityAxis_182" xlink:to="loc_dei_EntityDomain_183_default" use="optional" order="10" />
<loc xlink:type="locator" xlink:href="plx-20190331.xsd#plx_ProtalixBioTherapeuticsIncorporationMember" xlink:label="loc_plx_ProtalixBioTherapeuticsIncorporationMember_197" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityDomain_183" xlink:to="loc_plx_ProtalixBioTherapeuticsIncorporationMember_197" use="optional" order="11" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_StatementGeographicalAxis" xlink:label="loc_srt_StatementGeographicalAxis_185" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_plx_SignificantAccountingPoliciesTable_178" xlink:to="loc_srt_StatementGeographicalAxis_185" use="optional" order="12" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_SegmentGeographicalDomain" xlink:label="loc_srt_SegmentGeographicalDomain_186" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_StatementGeographicalAxis_185" xlink:to="loc_srt_SegmentGeographicalDomain_186" use="optional" order="13" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_SegmentGeographicalDomain" xlink:label="loc_srt_SegmentGeographicalDomain_186_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_StatementGeographicalAxis_185" xlink:to="loc_srt_SegmentGeographicalDomain_186_default" use="optional" order="14" />
<loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/country/2017/country-2017-01-31.xsd#country_BR" xlink:label="loc_country_BR_199" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_186" xlink:to="loc_country_BR_199" use="optional" order="15" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_RangeAxis" xlink:label="loc_srt_RangeAxis_190" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_plx_SignificantAccountingPoliciesTable_178" xlink:to="loc_srt_RangeAxis_190" use="optional" order="16" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_RangeMember" xlink:label="loc_srt_RangeMember_191" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_190" xlink:to="loc_srt_RangeMember_191" use="optional" order="17" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_RangeMember" xlink:label="loc_srt_RangeMember_191_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_190" xlink:to="loc_srt_RangeMember_191_default" use="optional" order="18" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_MinimumMember" xlink:label="loc_srt_MinimumMember_203" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_191" xlink:to="loc_srt_MinimumMember_203" use="optional" order="19" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_MaximumMember" xlink:label="loc_srt_MaximumMember_204" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_191" xlink:to="loc_srt_MaximumMember_204" use="optional" order="20" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DebtInstrumentAxis" xlink:label="loc_us-gaap_DebtInstrumentAxis_337415" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_plx_SignificantAccountingPoliciesTable_178" xlink:to="loc_us-gaap_DebtInstrumentAxis_337415" use="optional" order="21" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_337416" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DebtInstrumentAxis_337415" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_337416" use="optional" order="22" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_337416_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DebtInstrumentAxis_337415" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_337416_default" use="optional" order="23" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_RestatementAxis" xlink:label="loc_srt_RestatementAxis_344221" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_plx_SignificantAccountingPoliciesTable_178" xlink:to="loc_srt_RestatementAxis_344221" use="optional" order="24" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_RestatementDomain" xlink:label="loc_srt_RestatementDomain_344222" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RestatementAxis_344221" xlink:to="loc_srt_RestatementDomain_344222" use="optional" order="25" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_RestatementDomain" xlink:label="loc_srt_RestatementDomain_344222_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RestatementAxis_344221" xlink:to="loc_srt_RestatementDomain_344222_default" use="optional" order="26" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:label="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_344230" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_plx_SignificantAccountingPoliciesTable_178" xlink:to="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_344230" use="optional" order="27" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_TypeOfAdoptionMember" xlink:label="loc_us-gaap_TypeOfAdoptionMember_344231" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_344230" xlink:to="loc_us-gaap_TypeOfAdoptionMember_344231" use="optional" order="28" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_TypeOfAdoptionMember" xlink:label="loc_us-gaap_TypeOfAdoptionMember_344231_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_344230" xlink:to="loc_us-gaap_TypeOfAdoptionMember_344231_default" use="optional" order="29" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare_206" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_plx_SignificantAccountingPoliciesLineItems_192" xlink:to="loc_us-gaap_CommonStockParOrStatedValuePerShare_206" use="optional" order="30" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_207" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_plx_SignificantAccountingPoliciesLineItems_192" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_207" use="optional" order="31" />
<loc xlink:type="locator" xlink:href="plx-20190331.xsd#plx_CollaborativeArrangementRevenuesExpensesSharingPercentage" xlink:label="loc_plx_CollaborativeArrangementRevenuesExpensesSharingPercentage_208" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_plx_SignificantAccountingPoliciesLineItems_192" xlink:to="loc_plx_CollaborativeArrangementRevenuesExpensesSharingPercentage_208" use="optional" order="32" />
<loc xlink:type="locator" xlink:href="plx-20190331.xsd#plx_UpfrontNonrefundableNoncreditablePaymentReceivable" xlink:label="loc_plx_UpfrontNonrefundableNoncreditablePaymentReceivable_212" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_plx_SignificantAccountingPoliciesLineItems_192" xlink:to="loc_plx_UpfrontNonrefundableNoncreditablePaymentReceivable_212" use="optional" order="33" />
<loc xlink:type="locator" xlink:href="plx-20190331.xsd#plx_AdditionalAmountsPayableToCoverDevelopmentCosts" xlink:label="loc_plx_AdditionalAmountsPayableToCoverDevelopmentCosts_213" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_plx_SignificantAccountingPoliciesLineItems_192" xlink:to="loc_plx_AdditionalAmountsPayableToCoverDevelopmentCosts_213" use="optional" order="34" />
<loc xlink:type="locator" xlink:href="plx-20190331.xsd#plx_MaximumEntitlementOfDevelopmentCostsToCoverPerYear" xlink:label="loc_plx_MaximumEntitlementOfDevelopmentCostsToCoverPerYear_214" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_plx_SignificantAccountingPoliciesLineItems_192" xlink:to="loc_plx_MaximumEntitlementOfDevelopmentCostsToCoverPerYear_214" use="optional" order="35" />
<loc xlink:type="locator" xlink:href="plx-20190331.xsd#plx_AdditionalAmountpayableForAchievementOfRegulatoryAndCommercialMilestones" xlink:label="loc_plx_AdditionalAmountpayableForAchievementOfRegulatoryAndCommercialMilestones_215" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_plx_SignificantAccountingPoliciesLineItems_192" xlink:to="loc_plx_AdditionalAmountpayableForAchievementOfRegulatoryAndCommercialMilestones_215" use="optional" order="36" />
<loc xlink:type="locator" xlink:href="plx-20190331.xsd#plx_PaymentOnNetSalesPercentage" xlink:label="loc_plx_PaymentOnNetSalesPercentage_216" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_plx_SignificantAccountingPoliciesLineItems_192" xlink:to="loc_plx_PaymentOnNetSalesPercentage_216" use="optional" order="37" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_417529" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_plx_SignificantAccountingPoliciesLineItems_192" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset_417529" use="optional" order="38" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OperatingLeaseLiability" xlink:label="loc_us-gaap_OperatingLeaseLiability_417530" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_plx_SignificantAccountingPoliciesLineItems_192" xlink:to="loc_us-gaap_OperatingLeaseLiability_417530" use="optional" order="39" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://www.protalix.com/role/InventoriesDetails">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_264" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_262" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_264" xlink:to="loc_us-gaap_StatementTable_262" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_263" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_262" xlink:to="loc_us-gaap_StatementClassOfStockAxis_263" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_265" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis_263" xlink:to="loc_us-gaap_ClassOfStockDomain_265" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_265_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementClassOfStockAxis_263" xlink:to="loc_us-gaap_ClassOfStockDomain_265_default" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_InventoryRawMaterialsNetOfReserves" xlink:label="loc_us-gaap_InventoryRawMaterialsNetOfReserves_266" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_264" xlink:to="loc_us-gaap_InventoryRawMaterialsNetOfReserves_266" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_InventoryWorkInProcessNetOfReserves" xlink:label="loc_us-gaap_InventoryWorkInProcessNetOfReserves_267" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_264" xlink:to="loc_us-gaap_InventoryWorkInProcessNetOfReserves_267" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_InventoryFinishedGoodsNetOfReserves" xlink:label="loc_us-gaap_InventoryFinishedGoodsNetOfReserves_268" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_264" xlink:to="loc_us-gaap_InventoryFinishedGoodsNetOfReserves_268" use="optional" order="7" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_InventoryNet" xlink:label="loc_us-gaap_InventoryNet_269" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_264" xlink:to="loc_us-gaap_InventoryNet_269" use="optional" order="8" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://www.protalix.com/role/InventoriesDetailsTextual">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_353305" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_353302" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_353305" xlink:to="loc_us-gaap_StatementTable_353302" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_353303" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_353302" xlink:to="loc_us-gaap_StatementClassOfStockAxis_353303" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_353304" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis_353303" xlink:to="loc_us-gaap_ClassOfStockDomain_353304" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_353304_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementClassOfStockAxis_353303" xlink:to="loc_us-gaap_ClassOfStockDomain_353304_default" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_InventoryWriteDown" xlink:label="loc_us-gaap_InventoryWriteDown_353306" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_353305" xlink:to="loc_us-gaap_InventoryWriteDown_353306" use="optional" order="5" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://www.protalix.com/role/FairValueMeasurementTheLiabilityComponentWasValuedBasedOnTheIncomeApproachDetails">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_573" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_567" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_573" xlink:to="loc_us-gaap_StatementTable_567" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_568" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_567" xlink:to="loc_us-gaap_StatementClassOfStockAxis_568" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_574" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis_568" xlink:to="loc_us-gaap_ClassOfStockDomain_574" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_574_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementClassOfStockAxis_568" xlink:to="loc_us-gaap_ClassOfStockDomain_574_default" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DebtInstrumentAxis" xlink:label="loc_us-gaap_DebtInstrumentAxis_569" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_567" xlink:to="loc_us-gaap_DebtInstrumentAxis_569" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_570" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DebtInstrumentAxis_569" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_570" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_570_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DebtInstrumentAxis_569" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_570_default" use="optional" order="7" />
<loc xlink:type="locator" xlink:href="plx-20190331.xsd#plx_SevenPointFivePercentageConvertibleNotesMember" xlink:label="loc_plx_SevenPointFivePercentageConvertibleNotesMember_576" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_570" xlink:to="loc_plx_SevenPointFivePercentageConvertibleNotesMember_576" use="optional" order="8" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_571" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_567" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_571" use="optional" order="9" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_572" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_571" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_572" use="optional" order="10" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_572_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_571" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_572_default" use="optional" order="11" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueInputsLevel3Member" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_577" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_572" xlink:to="loc_us-gaap_FairValueInputsLevel3Member_577" use="optional" order="12" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_MeasurementInputTypeAxis" xlink:label="loc_us-gaap_MeasurementInputTypeAxis_337297" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_567" xlink:to="loc_us-gaap_MeasurementInputTypeAxis_337297" use="optional" order="13" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_MeasurementInputTypeDomain" xlink:label="loc_us-gaap_MeasurementInputTypeDomain_337298" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_MeasurementInputTypeAxis_337297" xlink:to="loc_us-gaap_MeasurementInputTypeDomain_337298" use="optional" order="14" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_MeasurementInputTypeDomain" xlink:label="loc_us-gaap_MeasurementInputTypeDomain_337298_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_MeasurementInputTypeAxis_337297" xlink:to="loc_us-gaap_MeasurementInputTypeDomain_337298_default" use="optional" order="15" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SharePrice" xlink:label="loc_us-gaap_SharePrice_578" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_573" xlink:to="loc_us-gaap_SharePrice_578" use="optional" order="16" />
<loc xlink:type="locator" xlink:href="plx-20190331.xsd#plx_FairValueAssumptionsTerm" xlink:label="loc_plx_FairValueAssumptionsTerm_339502" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_573" xlink:to="loc_plx_FairValueAssumptionsTerm_339502" use="optional" order="17" />
<loc xlink:type="locator" xlink:href="plx-20190331.xsd#plx_FairValueAssumptionsRiskFreeInterestRates" xlink:label="loc_plx_FairValueAssumptionsRiskFreeInterestRates_339504" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_573" xlink:to="loc_plx_FairValueAssumptionsRiskFreeInterestRates_339504" use="optional" order="18" />
<loc xlink:type="locator" xlink:href="plx-20190331.xsd#plx_FairValueAssumptionsExpectedVolatilityRates" xlink:label="loc_plx_FairValueAssumptionsExpectedVolatilityRates_339505" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_573" xlink:to="loc_plx_FairValueAssumptionsExpectedVolatilityRates_339505" use="optional" order="19" />
<loc xlink:type="locator" xlink:href="plx-20190331.xsd#plx_FairValueAssumptionsExpectedDividendRates" xlink:label="loc_plx_FairValueAssumptionsExpectedDividendRates_339511" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_573" xlink:to="loc_plx_FairValueAssumptionsExpectedDividendRates_339511" use="optional" order="20" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://www.protalix.com/role/FairValueMeasurementNarrativeDetails">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_591" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_585" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_591" xlink:to="loc_us-gaap_StatementTable_585" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_586" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_585" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_586" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_587" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_586" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_587" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_587_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_586" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_587_default" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueInputsLevel3Member" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_592" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_587" xlink:to="loc_us-gaap_FairValueInputsLevel3Member_592" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DebtInstrumentAxis" xlink:label="loc_us-gaap_DebtInstrumentAxis_588" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_585" xlink:to="loc_us-gaap_DebtInstrumentAxis_588" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_589" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DebtInstrumentAxis_588" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_589" use="optional" order="7" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_589_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DebtInstrumentAxis_588" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_589_default" use="optional" order="8" />
<loc xlink:type="locator" xlink:href="plx-20190331.xsd#plx_SevenPointFivePercentageConvertibleNoteMember" xlink:label="loc_plx_SevenPointFivePercentageConvertibleNoteMember_594" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_589" xlink:to="loc_plx_SevenPointFivePercentageConvertibleNoteMember_594" use="optional" order="9" />
<loc xlink:type="locator" xlink:href="plx-20190331.xsd#plx_SevenPointFivePercentageConvertibleNotes2021Member" xlink:label="loc_plx_SevenPointFivePercentageConvertibleNotes2021Member_415034" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_589" xlink:to="loc_plx_SevenPointFivePercentageConvertibleNotes2021Member_415034" use="optional" order="10" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DebtInstrumentRedemptionPeriodAxis" xlink:label="loc_us-gaap_DebtInstrumentRedemptionPeriodAxis_590" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_585" xlink:to="loc_us-gaap_DebtInstrumentRedemptionPeriodAxis_590" use="optional" order="11" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DebtInstrumentRedemptionPeriodDomain" xlink:label="loc_us-gaap_DebtInstrumentRedemptionPeriodDomain_597" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DebtInstrumentRedemptionPeriodAxis_590" xlink:to="loc_us-gaap_DebtInstrumentRedemptionPeriodDomain_597" use="optional" order="12" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DebtInstrumentRedemptionPeriodDomain" xlink:label="loc_us-gaap_DebtInstrumentRedemptionPeriodDomain_597_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DebtInstrumentRedemptionPeriodAxis_590" xlink:to="loc_us-gaap_DebtInstrumentRedemptionPeriodDomain_597_default" use="optional" order="13" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ConvertibleDebtFairValueDisclosures" xlink:label="loc_us-gaap_ConvertibleDebtFairValueDisclosures_598" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_591" xlink:to="loc_us-gaap_ConvertibleDebtFairValueDisclosures_598" use="optional" order="14" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DebtInstrumentFaceAmount" xlink:label="loc_us-gaap_DebtInstrumentFaceAmount_599" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_591" xlink:to="loc_us-gaap_DebtInstrumentFaceAmount_599" use="optional" order="15" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_413952" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_591" xlink:to="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_413952" use="optional" order="16" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://www.protalix.com/role/OperatingLeasesLeaseCostDetails">
<loc xlink:type="locator" xlink:href="plx-20190331.xsd#plx_DisclosureOfLeasesOperatingLineItems" xlink:label="loc_plx_DisclosureOfLeasesOperatingLineItems_413819" />
<loc xlink:type="locator" xlink:href="plx-20190331.xsd#plx_DisclosureOfLeasesOperatingTable" xlink:label="loc_plx_DisclosureOfLeasesOperatingTable_413818" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_plx_DisclosureOfLeasesOperatingLineItems_413819" xlink:to="loc_plx_DisclosureOfLeasesOperatingTable_413818" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_413980" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_plx_DisclosureOfLeasesOperatingTable_413818" xlink:to="loc_us-gaap_StatementClassOfStockAxis_413980" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_413981" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis_413980" xlink:to="loc_us-gaap_ClassOfStockDomain_413981" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_413981_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementClassOfStockAxis_413980" xlink:to="loc_us-gaap_ClassOfStockDomain_413981_default" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OperatingLeaseCost" xlink:label="loc_us-gaap_OperatingLeaseCost_413820" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_plx_DisclosureOfLeasesOperatingLineItems_413819" xlink:to="loc_us-gaap_OperatingLeaseCost_413820" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OperatingLeasePayments" xlink:label="loc_us-gaap_OperatingLeasePayments_413821" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_plx_DisclosureOfLeasesOperatingLineItems_413819" xlink:to="loc_us-gaap_OperatingLeasePayments_413821" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:label="loc_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_413822" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_plx_DisclosureOfLeasesOperatingLineItems_413819" xlink:to="loc_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_413822" use="optional" order="7" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_413823" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_plx_DisclosureOfLeasesOperatingLineItems_413819" xlink:to="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_413823" use="optional" order="8" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_413824" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_plx_DisclosureOfLeasesOperatingLineItems_413819" xlink:to="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_413824" use="optional" order="9" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://www.protalix.com/role/OperatingLeasesLesseeOperatingLeaseLiabilityMaturityDetails">
<loc xlink:type="locator" xlink:href="plx-20190331.xsd#plx_DisclosureOfLeasesOperatingLineItems" xlink:label="loc_plx_DisclosureOfLeasesOperatingLineItems_413833" />
<loc xlink:type="locator" xlink:href="plx-20190331.xsd#plx_DisclosureOfLeasesOperatingTable" xlink:label="loc_plx_DisclosureOfLeasesOperatingTable_413832" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_plx_DisclosureOfLeasesOperatingLineItems_413833" xlink:to="loc_plx_DisclosureOfLeasesOperatingTable_413832" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_413982" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_plx_DisclosureOfLeasesOperatingTable_413832" xlink:to="loc_us-gaap_StatementClassOfStockAxis_413982" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_413983" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis_413982" xlink:to="loc_us-gaap_ClassOfStockDomain_413983" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_413983_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementClassOfStockAxis_413982" xlink:to="loc_us-gaap_ClassOfStockDomain_413983_default" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_413841" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_plx_DisclosureOfLeasesOperatingLineItems_413833" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_413841" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_413842" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_plx_DisclosureOfLeasesOperatingLineItems_413833" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_413842" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_413844" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_plx_DisclosureOfLeasesOperatingLineItems_413833" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_413844" use="optional" order="7" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_413845" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_plx_DisclosureOfLeasesOperatingLineItems_413833" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_413845" use="optional" order="8" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_413846" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_plx_DisclosureOfLeasesOperatingLineItems_413833" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_413846" use="optional" order="9" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_413847" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_plx_DisclosureOfLeasesOperatingLineItems_413833" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_413847" use="optional" order="10" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_413848" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_plx_DisclosureOfLeasesOperatingLineItems_413833" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_413848" use="optional" order="11" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_413850" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_plx_DisclosureOfLeasesOperatingLineItems_413833" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_413850" use="optional" order="12" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OperatingLeaseLiability" xlink:label="loc_us-gaap_OperatingLeaseLiability_413851" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_plx_DisclosureOfLeasesOperatingLineItems_413833" xlink:to="loc_us-gaap_OperatingLeaseLiability_413851" use="optional" order="13" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://www.protalix.com/role/OperatingLeasesNarrativeDetails">
<loc xlink:type="locator" xlink:href="plx-20190331.xsd#plx_DisclosureOfLeasesOperatingLineItems" xlink:label="loc_plx_DisclosureOfLeasesOperatingLineItems_413856" />
<loc xlink:type="locator" xlink:href="plx-20190331.xsd#plx_DisclosureOfLeasesOperatingTable" xlink:label="loc_plx_DisclosureOfLeasesOperatingTable_413855" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_plx_DisclosureOfLeasesOperatingLineItems_413856" xlink:to="loc_plx_DisclosureOfLeasesOperatingTable_413855" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="plx-20190331.xsd#plx_CommitmentsAndContingenciesAxis" xlink:label="loc_plx_CommitmentsAndContingenciesAxis_413858" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_plx_DisclosureOfLeasesOperatingTable_413855" xlink:to="loc_plx_CommitmentsAndContingenciesAxis_413858" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="plx-20190331.xsd#plx_CommitmentsAndContingenciesDomain" xlink:label="loc_plx_CommitmentsAndContingenciesDomain_413859" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_plx_CommitmentsAndContingenciesAxis_413858" xlink:to="loc_plx_CommitmentsAndContingenciesDomain_413859" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="plx-20190331.xsd#plx_CommitmentsAndContingenciesDomain" xlink:label="loc_plx_CommitmentsAndContingenciesDomain_413859_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_plx_CommitmentsAndContingenciesAxis_413858" xlink:to="loc_plx_CommitmentsAndContingenciesDomain_413859_default" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="plx-20190331.xsd#plx_VehicleLeaseAndMaintenanceAgreementsMember" xlink:label="loc_plx_VehicleLeaseAndMaintenanceAgreementsMember_413860" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_plx_CommitmentsAndContingenciesDomain_413859" xlink:to="loc_plx_VehicleLeaseAndMaintenanceAgreementsMember_413860" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LeaseAgreementsMember" xlink:label="loc_us-gaap_LeaseAgreementsMember_413861" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_plx_CommitmentsAndContingenciesDomain_413859" xlink:to="loc_us-gaap_LeaseAgreementsMember_413861" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_RangeAxis" xlink:label="loc_srt_RangeAxis_417532" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_plx_DisclosureOfLeasesOperatingTable_413855" xlink:to="loc_srt_RangeAxis_417532" use="optional" order="7" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_RangeMember" xlink:label="loc_srt_RangeMember_417533" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_417532" xlink:to="loc_srt_RangeMember_417533" use="optional" order="8" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_RangeMember" xlink:label="loc_srt_RangeMember_417533_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_417532" xlink:to="loc_srt_RangeMember_417533_default" use="optional" order="9" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_MinimumMember" xlink:label="loc_srt_MinimumMember_417534" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_417533" xlink:to="loc_srt_MinimumMember_417534" use="optional" order="10" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_MaximumMember" xlink:label="loc_srt_MaximumMember_417535" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_417533" xlink:to="loc_srt_MaximumMember_417535" use="optional" order="11" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent" xlink:label="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent_413863" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_plx_DisclosureOfLeasesOperatingLineItems_413856" xlink:to="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent_413863" use="optional" order="12" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears" xlink:label="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears_413864" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_plx_DisclosureOfLeasesOperatingLineItems_413856" xlink:to="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears_413864" use="optional" order="13" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears" xlink:label="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears_413865" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_plx_DisclosureOfLeasesOperatingLineItems_413856" xlink:to="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears_413865" use="optional" order="14" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SecurityDeposit" xlink:label="loc_us-gaap_SecurityDeposit_413876" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_plx_DisclosureOfLeasesOperatingLineItems_413856" xlink:to="loc_us-gaap_SecurityDeposit_413876" use="optional" order="15" />
<loc xlink:type="locator" xlink:href="plx-20190331.xsd#plx_PercentageOfChangeInOperatingLeaseMonthlyRentalPayments" xlink:label="loc_plx_PercentageOfChangeInOperatingLeaseMonthlyRentalPayments_417531" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_plx_DisclosureOfLeasesOperatingLineItems_413856" xlink:to="loc_plx_PercentageOfChangeInOperatingLeaseMonthlyRentalPayments_417531" use="optional" order="16" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://www.protalix.com/role/RevenuesStatementsOfOperationsDetails">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_411900" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_411887" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_411900" xlink:to="loc_us-gaap_StatementTable_411887" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_ProductOrServiceAxis" xlink:label="loc_srt_ProductOrServiceAxis_411888" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_411887" xlink:to="loc_srt_ProductOrServiceAxis_411888" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_ProductsAndServicesDomain" xlink:label="loc_srt_ProductsAndServicesDomain_411889" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_411888" xlink:to="loc_srt_ProductsAndServicesDomain_411889" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_ProductsAndServicesDomain" xlink:label="loc_srt_ProductsAndServicesDomain_411889_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_411888" xlink:to="loc_srt_ProductsAndServicesDomain_411889_default" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ProductMember" xlink:label="loc_us-gaap_ProductMember_411890" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_411889" xlink:to="loc_us-gaap_ProductMember_411890" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LicenseAndServiceMember" xlink:label="loc_us-gaap_LicenseAndServiceMember_411891" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_411889" xlink:to="loc_us-gaap_LicenseAndServiceMember_411891" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_StatementGeographicalAxis" xlink:label="loc_srt_StatementGeographicalAxis_411894" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_411887" xlink:to="loc_srt_StatementGeographicalAxis_411894" use="optional" order="7" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_SegmentGeographicalDomain" xlink:label="loc_srt_SegmentGeographicalDomain_411896" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_StatementGeographicalAxis_411894" xlink:to="loc_srt_SegmentGeographicalDomain_411896" use="optional" order="8" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_SegmentGeographicalDomain" xlink:label="loc_srt_SegmentGeographicalDomain_411896_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_StatementGeographicalAxis_411894" xlink:to="loc_srt_SegmentGeographicalDomain_411896_default" use="optional" order="9" />
<loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/country/2017/country-2017-01-31.xsd#country_BR" xlink:label="loc_country_BR_411899" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_411896" xlink:to="loc_country_BR_411899" use="optional" order="10" />
<loc xlink:type="locator" xlink:href="plx-20190331.xsd#plx_PfizerMember" xlink:label="loc_plx_PfizerMember_411902" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_411896" xlink:to="loc_plx_PfizerMember_411902" use="optional" order="11" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_Revenues" xlink:label="loc_us-gaap_Revenues_411901" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_411900" xlink:to="loc_us-gaap_Revenues_411901" use="optional" order="12" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://www.protalix.com/role/RevenuesContractWithCustomerAssetAndLiabilityDetail">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_417544" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_417541" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_417544" xlink:to="loc_us-gaap_StatementTable_417541" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_417542" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_417541" xlink:to="loc_us-gaap_StatementClassOfStockAxis_417542" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_417543" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis_417542" xlink:to="loc_us-gaap_ClassOfStockDomain_417543" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_417543_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementClassOfStockAxis_417542" xlink:to="loc_us-gaap_ClassOfStockDomain_417543_default" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ContractWithCustomerLiability" xlink:label="loc_us-gaap_ContractWithCustomerLiability_417545" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_417544" xlink:to="loc_us-gaap_ContractWithCustomerLiability_417545" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToRevenueChangeInMeasureOfProgress" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToRevenueChangeInMeasureOfProgress_417546" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_417544" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToRevenueChangeInMeasureOfProgress_417546" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ContractWithCustomerLiabilityRevenueRecognized" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityRevenueRecognized_417547" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_417544" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityRevenueRecognized_417547" use="optional" order="7" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://www.protalix.com/role/RevenuesUnsatisfiedPerformanceObligationsDetail">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_417555" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_417552" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_417555" xlink:to="loc_us-gaap_StatementTable_417552" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_417553" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_417552" xlink:to="loc_us-gaap_StatementClassOfStockAxis_417553" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_417554" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis_417553" xlink:to="loc_us-gaap_ClassOfStockDomain_417554" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_417554_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementClassOfStockAxis_417553" xlink:to="loc_us-gaap_ClassOfStockDomain_417554_default" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RevenueRemainingPerformanceObligation" xlink:label="loc_us-gaap_RevenueRemainingPerformanceObligation_417556" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_417555" xlink:to="loc_us-gaap_RevenueRemainingPerformanceObligation_417556" use="optional" order="5" />
</definitionLink>
</linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>10
<FILENAME>plx-20190331_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="utf-8"?>
<!--Generated by DataTracks Rainbow Version 3.0 - www.datatracks.com - on 06-May-2019 [07:38:26] {PM}-->
<linkbase xmlns="http://www.xbrl.org/2003/linkbase" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
<roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" roleURI="http://www.xbrl.org/2009/role/negatedLabel" />
<roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel" roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" />
<roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel" roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" />
<roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel" roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" />
<roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel" roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" />
<roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel" roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" />
<roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel" roleURI="http://www.xbrl.org/2009/role/netLabel" />
<labelLink xlink:type="extended" xlink:role="http://www.xbrl.org/2003/role/link">
<loc xlink:type="locator" xlink:href="plx-20190331.xsd#plx_DocumentAndEntityInformationAbstract" xlink:label="loc_plx_DocumentAndEntityInformationAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_plx_DocumentAndEntityInformationAbstract" xml:lang="en-US">Document and Entity Information [Abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_plx_DocumentAndEntityInformationAbstract" xlink:to="lab_plx_DocumentAndEntityInformationAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_plx_DocumentAndEntityInformationAbstract" xml:lang="en-US">Document and Entity Information [Abstract]</label>
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_DocumentType" xlink:label="loc_dei_DocumentType" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_DocumentType" xml:lang="en-US">Document Type</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentType" xlink:to="lab_dei_DocumentType" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_AmendmentFlag" xlink:label="loc_dei_AmendmentFlag" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_AmendmentFlag" xml:lang="en-US">Amendment Flag</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AmendmentFlag" xlink:to="lab_dei_AmendmentFlag" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_DocumentPeriodEndDate" xlink:label="loc_dei_DocumentPeriodEndDate" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_DocumentPeriodEndDate" xml:lang="en-US">Document Period End Date</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentPeriodEndDate" xlink:to="lab_dei_DocumentPeriodEndDate" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_DocumentFiscalYearFocus" xlink:label="loc_dei_DocumentFiscalYearFocus" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_DocumentFiscalYearFocus" xml:lang="en-US">Document Fiscal Year Focus</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentFiscalYearFocus" xlink:to="lab_dei_DocumentFiscalYearFocus" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="loc_dei_DocumentFiscalPeriodFocus" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_DocumentFiscalPeriodFocus" xml:lang="en-US">Document Fiscal Period Focus</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentFiscalPeriodFocus" xlink:to="lab_dei_DocumentFiscalPeriodFocus" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntityRegistrantName" xlink:label="loc_dei_EntityRegistrantName" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_EntityRegistrantName" xml:lang="en-US">Entity Registrant Name</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityRegistrantName" xlink:to="lab_dei_EntityRegistrantName" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntityCentralIndexKey" xlink:label="loc_dei_EntityCentralIndexKey" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_EntityCentralIndexKey" xml:lang="en-US">Entity Central Index Key</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCentralIndexKey" xlink:to="lab_dei_EntityCentralIndexKey" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_CurrentFiscalYearEndDate" xlink:label="loc_dei_CurrentFiscalYearEndDate" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_CurrentFiscalYearEndDate" xml:lang="en-US">Current Fiscal Year End Date</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CurrentFiscalYearEndDate" xlink:to="lab_dei_CurrentFiscalYearEndDate" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntityFilerCategory" xlink:label="loc_dei_EntityFilerCategory" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_EntityFilerCategory" xml:lang="en-US">Entity Filer Category</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFilerCategory" xlink:to="lab_dei_EntityFilerCategory" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_TradingSymbol" xlink:label="loc_dei_TradingSymbol" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_TradingSymbol" xml:lang="en-US">Trading Symbol</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_TradingSymbol" xlink:to="lab_dei_TradingSymbol" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="loc_dei_EntityCommonStockSharesOutstanding" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_EntityCommonStockSharesOutstanding" xml:lang="en-US">Entity Common Stock, Shares Outstanding</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCommonStockSharesOutstanding" xlink:to="lab_dei_EntityCommonStockSharesOutstanding" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntityEmergingGrowthCompany" xlink:label="loc_dei_EntityEmergingGrowthCompany" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_EntityEmergingGrowthCompany" xml:lang="en-US">Entity Emerging Growth Company</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityEmergingGrowthCompany" xlink:to="lab_dei_EntityEmergingGrowthCompany" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntitySmallBusiness" xlink:label="loc_dei_EntitySmallBusiness" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_EntitySmallBusiness" xml:lang="en-US">Entity Small Business</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntitySmallBusiness" xlink:to="lab_dei_EntitySmallBusiness" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_StatementOfFinancialPositionAbstract" xml:lang="en-US">Statement of Financial Position [Abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract" xlink:to="lab_us-gaap_StatementOfFinancialPositionAbstract" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_StatementTable" xml:lang="en-US">Statement [Table]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementTable" xlink:to="lab_us-gaap_StatementTable" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_StatementClassOfStockAxis" xml:lang="en-US">Class of Stock [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementClassOfStockAxis" xlink:to="lab_us-gaap_StatementClassOfStockAxis" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ClassOfStockDomain" xml:lang="en-US">Class of Stock [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfStockDomain" xlink:to="lab_us-gaap_ClassOfStockDomain" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_StatementLineItems" xml:lang="en-US">Statement [Line Items]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementLineItems" xlink:to="lab_us-gaap_StatementLineItems" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AssetsAbstract" xlink:label="loc_us-gaap_AssetsAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AssetsAbstract" xml:lang="en-US">Assets [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_AssetsAbstract" xml:lang="en-US">ASSETS</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsAbstract" xlink:to="lab_us-gaap_AssetsAbstract" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="loc_us-gaap_AssetsCurrentAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AssetsCurrentAbstract" xml:lang="en-US">Assets, Current [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_AssetsCurrentAbstract" xml:lang="en-US">CURRENT ASSETS:</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsCurrentAbstract" xlink:to="lab_us-gaap_AssetsCurrentAbstract" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xml:lang="en-US">Cash and Cash Equivalents, at Carrying Value</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xml:lang="en-US">Cash and cash equivalents</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xml:lang="en-US">BALANCE OF CASH AND CASH EQUIVALENTS AT BEGINNING OF PERIOD</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xml:lang="en-US">BALANCE OF CASH AND CASH EQUIVALENTS AT END OF PERIOD</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:to="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AccountsReceivableNetCurrent" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AccountsReceivableNetCurrent" xml:lang="en-US">Accounts Receivable, Net, Current</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_AccountsReceivableNetCurrent" xml:lang="en-US">Accounts receivable &#8211; Trade</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsReceivableNetCurrent" xlink:to="lab_us-gaap_AccountsReceivableNetCurrent" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OtherAssetsCurrent" xlink:label="loc_us-gaap_OtherAssetsCurrent" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_OtherAssetsCurrent" xml:lang="en-US">Other Assets, Current</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_OtherAssetsCurrent" xml:lang="en-US">Other assets</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherAssetsCurrent" xlink:to="lab_us-gaap_OtherAssetsCurrent" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_InventoryNet" xlink:label="loc_us-gaap_InventoryNet" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_InventoryNet" xml:lang="en-US">Inventory, Net</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_InventoryNet" xml:lang="en-US">Inventories</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_InventoryNet" xml:lang="en-US">Total inventory</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryNet" xlink:to="lab_us-gaap_InventoryNet" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AssetsCurrent" xlink:label="loc_us-gaap_AssetsCurrent" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AssetsCurrent" xml:lang="en-US">Assets, Current</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_AssetsCurrent" xml:lang="en-US">Total current assets</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsCurrent" xlink:to="lab_us-gaap_AssetsCurrent" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent" xlink:label="loc_us-gaap_DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent" xml:lang="en-US">Assets for Plan Benefits, Defined Benefit Plan</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent" xml:lang="en-US">FUNDS IN RESPECT OF EMPLOYEE RIGHTS UPON RETIREMENT</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent" xlink:to="lab_us-gaap_DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet" xml:lang="en-US">Property, Plant and Equipment, Net</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet" xml:lang="en-US">PROPERTY AND EQUIPMENT, NET</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNet" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentNet" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_Assets" xlink:label="loc_us-gaap_Assets" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_Assets" xml:lang="en-US">Assets</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_Assets" xml:lang="en-US">Total assets</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Assets" xlink:to="lab_us-gaap_Assets" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_OperatingLeaseRightOfUseAsset" xml:lang="en-US">Operating Lease, Right-of-Use Asset</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_OperatingLeaseRightOfUseAsset" xml:lang="en-US">OPERATING LEASE RIGHT OF USE ASSETS</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseRightOfUseAsset" xlink:to="lab_us-gaap_OperatingLeaseRightOfUseAsset" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xml:lang="en-US">Liabilities and Equity [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xml:lang="en-US">LIABILITIES NET OF CAPITAL DEFICIENCY</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_LiabilitiesCurrentAbstract" xml:lang="en-US">Liabilities, Current [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_LiabilitiesCurrentAbstract" xml:lang="en-US">CURRENT LIABILITIES:</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract" xlink:to="lab_us-gaap_LiabilitiesCurrentAbstract" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAbstract" xlink:label="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAbstract" xml:lang="en-US">Accounts Payable and Accrued Liabilities, Current [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAbstract" xml:lang="en-US">Accounts payable and accruals:</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAbstract" xlink:to="lab_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAbstract" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AccountsPayableTradeCurrent" xlink:label="loc_us-gaap_AccountsPayableTradeCurrent" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AccountsPayableTradeCurrent" xml:lang="en-US">Accounts Payable, Trade, Current</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_AccountsPayableTradeCurrent" xml:lang="en-US">Trade</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsPayableTradeCurrent" xlink:to="lab_us-gaap_AccountsPayableTradeCurrent" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AccountsPayableOtherCurrent" xlink:label="loc_us-gaap_AccountsPayableOtherCurrent" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AccountsPayableOtherCurrent" xml:lang="en-US">Accounts Payable, Other, Current</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_AccountsPayableOtherCurrent" xml:lang="en-US">Other</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsPayableOtherCurrent" xlink:to="lab_us-gaap_AccountsPayableOtherCurrent" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_OperatingLeaseLiabilityCurrent" xml:lang="en-US">Operating Lease, Liability, Current</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_OperatingLeaseLiabilityCurrent" xml:lang="en-US">Operating lease liabilities</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiabilityCurrent" xlink:to="lab_us-gaap_OperatingLeaseLiabilityCurrent" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LiabilitiesCurrent" xlink:label="loc_us-gaap_LiabilitiesCurrent" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_LiabilitiesCurrent" xml:lang="en-US">Liabilities, Current</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_LiabilitiesCurrent" xml:lang="en-US">Total current liabilities</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesCurrent" xlink:to="lab_us-gaap_LiabilitiesCurrent" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ContractWithCustomerLiabilityCurrent" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityCurrent" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ContractWithCustomerLiabilityCurrent" xml:lang="en-US">Contract with Customer, Liability, Current</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ContractWithCustomerLiabilityCurrent" xml:lang="en-US">Contracts liability</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContractWithCustomerLiabilityCurrent" xlink:to="lab_us-gaap_ContractWithCustomerLiabilityCurrent" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LiabilitiesNoncurrentAbstract" xlink:label="loc_us-gaap_LiabilitiesNoncurrentAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_LiabilitiesNoncurrentAbstract" xml:lang="en-US">Liabilities, Noncurrent [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_LiabilitiesNoncurrentAbstract" xml:lang="en-US">LONG TERM LIABILITIES:</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesNoncurrentAbstract" xlink:to="lab_us-gaap_LiabilitiesNoncurrentAbstract" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ConvertibleDebtNoncurrent" xlink:label="loc_us-gaap_ConvertibleDebtNoncurrent" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ConvertibleDebtNoncurrent" xml:lang="en-US">Convertible Debt, Noncurrent</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ConvertibleDebtNoncurrent" xml:lang="en-US">Convertible notes</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConvertibleDebtNoncurrent" xlink:to="lab_us-gaap_ConvertibleDebtNoncurrent" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PensionAndOtherPostretirementAndPostemploymentBenefitPlansLiabilitiesNoncurrent" xlink:label="loc_us-gaap_PensionAndOtherPostretirementAndPostemploymentBenefitPlansLiabilitiesNoncurrent" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_PensionAndOtherPostretirementAndPostemploymentBenefitPlansLiabilitiesNoncurrent" xml:lang="en-US">Liability, Pension and Other Postretirement and Postemployment Benefits, Noncurrent</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_PensionAndOtherPostretirementAndPostemploymentBenefitPlansLiabilitiesNoncurrent" xml:lang="en-US">Liability for employee rights upon retirement</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PensionAndOtherPostretirementAndPostemploymentBenefitPlansLiabilitiesNoncurrent" xlink:to="lab_us-gaap_PensionAndOtherPostretirementAndPostemploymentBenefitPlansLiabilitiesNoncurrent" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OtherLiabilitiesNoncurrent" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_OtherLiabilitiesNoncurrent" xml:lang="en-US">Other Liabilities, Noncurrent</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_OtherLiabilitiesNoncurrent" xml:lang="en-US">Other long term liabilities</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherLiabilitiesNoncurrent" xlink:to="lab_us-gaap_OtherLiabilitiesNoncurrent" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ContractWithCustomerLiabilityNoncurrent" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ContractWithCustomerLiabilityNoncurrent" xml:lang="en-US">Contract with Customer, Liability, Noncurrent</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ContractWithCustomerLiabilityNoncurrent" xml:lang="en-US">Contracts liability</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent" xlink:to="lab_us-gaap_ContractWithCustomerLiabilityNoncurrent" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_OperatingLeaseLiabilityNoncurrent" xml:lang="en-US">Operating Lease, Liability, Noncurrent</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_OperatingLeaseLiabilityNoncurrent" xml:lang="en-US">Operating lease liabilities</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:to="lab_us-gaap_OperatingLeaseLiabilityNoncurrent" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LiabilitiesNoncurrent" xlink:label="loc_us-gaap_LiabilitiesNoncurrent" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_LiabilitiesNoncurrent" xml:lang="en-US">Liabilities, Noncurrent</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_LiabilitiesNoncurrent" xml:lang="en-US">Total long term liabilities</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesNoncurrent" xlink:to="lab_us-gaap_LiabilitiesNoncurrent" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_Liabilities" xlink:label="loc_us-gaap_Liabilities" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_Liabilities" xml:lang="en-US">Liabilities</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_Liabilities" xml:lang="en-US">Total liabilities</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Liabilities" xlink:to="lab_us-gaap_Liabilities" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquity" xml:lang="en-US">Liabilities and Equity</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquity" xml:lang="en-US">Total liabilities net of capital deficiency</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="lab_us-gaap_LiabilitiesAndStockholdersEquity" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaap_StockholdersEquity" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_StockholdersEquity" xml:lang="en-US">Stockholders' Equity Attributable to Parent</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_StockholdersEquity" xml:lang="en-US">CAPITAL DEFICIENCY</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="lab_us-gaap_StockholdersEquity" xml:lang="en-US">Balance</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="lab_us-gaap_StockholdersEquity" xml:lang="en-US">Balance</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquity" xlink:to="lab_us-gaap_StockholdersEquity" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeStatementAbstract" xlink:label="loc_us-gaap_IncomeStatementAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IncomeStatementAbstract" xml:lang="en-US">Income Statement [Abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementAbstract" xlink:to="lab_us-gaap_IncomeStatementAbstract" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_Revenues" xlink:label="loc_us-gaap_Revenues" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_Revenues" xml:lang="en-US">Revenues</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_Revenues" xml:lang="en-US">REVENUES</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Revenues" xlink:to="lab_us-gaap_Revenues" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CostOfRevenue" xlink:label="loc_us-gaap_CostOfRevenue" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CostOfRevenue" xml:lang="en-US">Cost of Revenue</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_us-gaap_CostOfRevenue" xml:lang="en-US">COST OF GOODS SOLD</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CostOfRevenue" xlink:to="lab_us-gaap_CostOfRevenue" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpense" xml:lang="en-US">Research and Development Expense</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpense" xml:lang="en-US">RESEARCH AND DEVELOPMENT EXPENSES (1)</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpense" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpense" />
<loc xlink:type="locator" xlink:href="plx-20190331.xsd#plx_GrantsAndReimbursementsReceivedOrReceivable" xlink:label="loc_plx_GrantsAndReimbursementsReceivedOrReceivable" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_plx_GrantsAndReimbursementsReceivedOrReceivable" xml:lang="en-US">Grants And Reimbursements Received Or Receivable</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_plx_GrantsAndReimbursementsReceivedOrReceivable" xml:lang="en-US">Less - grants</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_plx_GrantsAndReimbursementsReceivedOrReceivable" xlink:to="lab_plx_GrantsAndReimbursementsReceivedOrReceivable" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_plx_GrantsAndReimbursementsReceivedOrReceivable" xml:lang="en-US">Grants and reimbursements received or receivable from governmental institutions and collaboration partners for research and development expenses incurred.</label>
<loc xlink:type="locator" xlink:href="plx-20190331.xsd#plx_ResearchDevelopmentAndEngineeringExpenseNet" xlink:label="loc_plx_ResearchDevelopmentAndEngineeringExpenseNet" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_plx_ResearchDevelopmentAndEngineeringExpenseNet" xml:lang="en-US">Research Development And Engineering Expense Net</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:label="lab_plx_ResearchDevelopmentAndEngineeringExpenseNet" xml:lang="en-US">RESEARCH AND DEVELOPMENT EXPENSES, NET</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_plx_ResearchDevelopmentAndEngineeringExpenseNet" xlink:to="lab_plx_ResearchDevelopmentAndEngineeringExpenseNet" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_plx_ResearchDevelopmentAndEngineeringExpenseNet" xml:lang="en-US">Research and development expenses, net.</label>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpense" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpense" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SellingGeneralAndAdministrativeExpense" xml:lang="en-US">Selling, General and Administrative Expense</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_us-gaap_SellingGeneralAndAdministrativeExpense" xml:lang="en-US">SELLING, GENERAL AND ADMINISTRATIVE EXPENSES (2)</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SellingGeneralAndAdministrativeExpense" xlink:to="lab_us-gaap_SellingGeneralAndAdministrativeExpense" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:label="loc_us-gaap_OperatingIncomeLoss" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_OperatingIncomeLoss" xml:lang="en-US">Operating Income (Loss)</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_OperatingIncomeLoss" xml:lang="en-US">OPERATING LOSS</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingIncomeLoss" xlink:to="lab_us-gaap_OperatingIncomeLoss" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OtherNonoperatingExpense" xlink:label="loc_us-gaap_OtherNonoperatingExpense" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_OtherNonoperatingExpense" xml:lang="en-US">Other Nonoperating Expense</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_us-gaap_OtherNonoperatingExpense" xml:lang="en-US">FINANCIAL EXPENSES</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherNonoperatingExpense" xlink:to="lab_us-gaap_OtherNonoperatingExpense" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OtherNonoperatingIncome" xlink:label="loc_us-gaap_OtherNonoperatingIncome" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_OtherNonoperatingIncome" xml:lang="en-US">Other Nonoperating Income</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_OtherNonoperatingIncome" xml:lang="en-US">FINANCIAL INCOME</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherNonoperatingIncome" xlink:to="lab_us-gaap_OtherNonoperatingIncome" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NonoperatingIncomeExpense" xlink:label="loc_us-gaap_NonoperatingIncomeExpense" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_NonoperatingIncomeExpense" xml:lang="en-US">Nonoperating Income (Expense)</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_NonoperatingIncomeExpense" xml:lang="en-US">FINANCIAL EXPENSES, NET</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NonoperatingIncomeExpense" xlink:to="lab_us-gaap_NonoperatingIncomeExpense" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_NetIncomeLoss" xml:lang="en-US">Net Income (Loss) Attributable to Parent</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_NetIncomeLoss" xml:lang="en-US">LOSS FOR THE PERIOD</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_NetIncomeLoss" xml:lang="en-US">Net loss for the period</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_NetIncomeLoss" xml:lang="en-US">Net loss</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLoss" xlink:to="lab_us-gaap_NetIncomeLoss" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:label="loc_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Basic and Diluted</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xml:lang="en-US">WEIGHTED AVERAGE NUMBER OF SHARES OF COMMON STOCK USED IN COMPUTING LOSS PER SHARE-BASIC AND DILUTED</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:to="lab_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EarningsPerShareBasicAndDiluted" xlink:label="loc_us-gaap_EarningsPerShareBasicAndDiluted" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_EarningsPerShareBasicAndDiluted" xml:lang="en-US">Earnings Per Share, Basic and Diluted</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/definitionGuidance" xlink:label="lab_us-gaap_EarningsPerShareBasicAndDiluted" xml:lang="en-US">NET LOSS PER SHARE OF COMMON STOCK &#8211; BASIC AND DILUTED</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareBasicAndDiluted" xlink:to="lab_us-gaap_EarningsPerShareBasicAndDiluted" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_ProductOrServiceAxis" xlink:label="loc_srt_ProductOrServiceAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_srt_ProductOrServiceAxis" xml:lang="en-US">Product and Service [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ProductOrServiceAxis" xlink:to="lab_srt_ProductOrServiceAxis" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_ProductsAndServicesDomain" xlink:label="loc_srt_ProductsAndServicesDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_srt_ProductsAndServicesDomain" xml:lang="en-US">Product and Service [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ProductsAndServicesDomain" xlink:to="lab_srt_ProductsAndServicesDomain" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ProductMember" xlink:label="loc_us-gaap_ProductMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ProductMember" xml:lang="en-US">Product [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ProductMember" xml:lang="en-US">Goods [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_ProductMember" xml:lang="en-US">Goods [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProductMember" xlink:to="lab_us-gaap_ProductMember" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LicenseAndServiceMember" xlink:label="loc_us-gaap_LicenseAndServiceMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_LicenseAndServiceMember" xml:lang="en-US">License and Service [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_LicenseAndServiceMember" xml:lang="en-US">License and R&amp;D Services [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LicenseAndServiceMember" xlink:to="lab_us-gaap_LicenseAndServiceMember" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="loc_us-gaap_IncomeStatementLocationAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IncomeStatementLocationAxis" xml:lang="en-US">Income Statement Location [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementLocationAxis" xlink:to="lab_us-gaap_IncomeStatementLocationAxis" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="loc_us-gaap_IncomeStatementLocationDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IncomeStatementLocationDomain" xml:lang="en-US">Income Statement Location [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementLocationDomain" xlink:to="lab_us-gaap_IncomeStatementLocationDomain" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpenseMember" xml:lang="en-US">Research and Development Expense [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpenseMember" xml:lang="en-US">Research and Development Expenses [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpenseMember" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpensesMember" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SellingGeneralAndAdministrativeExpensesMember" xml:lang="en-US">Selling, General and Administrative Expenses [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember" xlink:to="lab_us-gaap_SellingGeneralAndAdministrativeExpensesMember" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AllocatedShareBasedCompensationExpense" xml:lang="en-US">Allocated Share-based Compensation Expense</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_AllocatedShareBasedCompensationExpense" xml:lang="en-US">Share-based compensation</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AllocatedShareBasedCompensationExpense" xlink:to="lab_us-gaap_AllocatedShareBasedCompensationExpense" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementOfStockholdersEquityAbstract" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_StatementOfStockholdersEquityAbstract" xml:lang="en-US">Statement of Stockholders' Equity [Abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="lab_us-gaap_StatementOfStockholdersEquityAbstract" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaap_StatementEquityComponentsAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_StatementEquityComponentsAxis" xml:lang="en-US">Equity Components [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementEquityComponentsAxis" xlink:to="lab_us-gaap_StatementEquityComponentsAxis" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_EquityComponentDomain" xml:lang="en-US">Equity Component [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityComponentDomain" xlink:to="lab_us-gaap_EquityComponentDomain" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaap_CommonStockMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CommonStockMember" xml:lang="en-US">Common Stock [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockMember" xlink:to="lab_us-gaap_CommonStockMember" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AdditionalPaidInCapitalMember" xml:lang="en-US">Additional Paid-in Capital [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdditionalPaidInCapitalMember" xlink:to="lab_us-gaap_AdditionalPaidInCapitalMember" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RetainedEarningsMember" xlink:label="loc_us-gaap_RetainedEarningsMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_RetainedEarningsMember" xml:lang="en-US">Retained Earnings [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_RetainedEarningsMember" xml:lang="en-US">Accumulated Deficit [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetainedEarningsMember" xlink:to="lab_us-gaap_RetainedEarningsMember" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SharesOutstanding" xlink:label="loc_us-gaap_SharesOutstanding" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SharesOutstanding" xml:lang="en-US">Shares, Outstanding</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="lab_us-gaap_SharesOutstanding" xml:lang="en-US">Balance (in shares)</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="lab_us-gaap_SharesOutstanding" xml:lang="en-US">Balance (in shares)</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharesOutstanding" xlink:to="lab_us-gaap_SharesOutstanding" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xml:lang="en-US">Adjustments to Additional Paid in Capital, Share-based Compensation, Requisite Service Period Recognition</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xml:lang="en-US">Share-based compensation related to stock options</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:to="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" />
<loc xlink:type="locator" xlink:href="plx-20190331.xsd#plx_ShareBasedCompensationRestrictedStockAwardsNetOfForfeitures" xlink:label="loc_plx_ShareBasedCompensationRestrictedStockAwardsNetOfForfeitures" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_plx_ShareBasedCompensationRestrictedStockAwardsNetOfForfeitures" xml:lang="en-US">Share Based Compensation Restricted Stock Awards Net Of Forfeitures</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_plx_ShareBasedCompensationRestrictedStockAwardsNetOfForfeitures" xml:lang="en-US">Share-based compensation related to restricted stock award</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_plx_ShareBasedCompensationRestrictedStockAwardsNetOfForfeitures" xlink:to="lab_plx_ShareBasedCompensationRestrictedStockAwardsNetOfForfeitures" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_plx_ShareBasedCompensationRestrictedStockAwardsNetOfForfeitures" xml:lang="en-US">Amount of recognized equity-based compensation during the period for restricted stock awards.</label>
<loc xlink:type="locator" xlink:href="plx-20190331.xsd#plx_ShareBasedCompensationRestrictedStockAwardsNetOfForfeituresShares" xlink:label="loc_plx_ShareBasedCompensationRestrictedStockAwardsNetOfForfeituresShares" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_plx_ShareBasedCompensationRestrictedStockAwardsNetOfForfeituresShares" xml:lang="en-US">Share Based Compensation Restricted Stock Awards Net Of Forfeitures Shares</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_plx_ShareBasedCompensationRestrictedStockAwardsNetOfForfeituresShares" xml:lang="en-US">Share-based compensation related to restricted stock award (in shares)</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_plx_ShareBasedCompensationRestrictedStockAwardsNetOfForfeituresShares" xlink:to="lab_plx_ShareBasedCompensationRestrictedStockAwardsNetOfForfeituresShares" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_plx_ShareBasedCompensationRestrictedStockAwardsNetOfForfeituresShares" xml:lang="en-US">Share Based Compensation Restricted Stock Awards Net Of Forfeitures Shares</label>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xml:lang="en-US">Stock Issued During Period, Value, Conversion of Convertible Securities</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xml:lang="en-US">Convertible notes conversions</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xml:lang="en-US">Stock Issued During Period, Shares, Conversion of Convertible Securities</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xml:lang="en-US">Convertible notes conversions (in shares)</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaap_AwardTypeAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AwardTypeAxis" xml:lang="en-US">Award Type [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AwardTypeAxis" xlink:to="lab_us-gaap_AwardTypeAxis" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xml:lang="en-US">Equity Award [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CommonStockParOrStatedValuePerShare" xml:lang="en-US">Common Stock, Par or Stated Value Per Share</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockParOrStatedValuePerShare" xlink:to="lab_us-gaap_CommonStockParOrStatedValuePerShare" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="loc_us-gaap_CommonStockSharesAuthorized" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CommonStockSharesAuthorized" xml:lang="en-US">Common Stock, Shares Authorized</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesAuthorized" xlink:to="lab_us-gaap_CommonStockSharesAuthorized" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="loc_us-gaap_StatementOfCashFlowsAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_StatementOfCashFlowsAbstract" xml:lang="en-US">Statement of Cash Flows [Abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract" xlink:to="lab_us-gaap_StatementOfCashFlowsAbstract" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xml:lang="en-US">CASH FLOWS FROM OPERATING ACTIVITIES:</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xml:lang="en-US">Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xml:lang="en-US">Adjustments required to reconcile net loss to net cash used in operating activities:</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:label="loc_us-gaap_ShareBasedCompensation" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensation" xml:lang="en-US">Share-based Compensation</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ShareBasedCompensation" xml:lang="en-US">Share based compensation</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensation" xlink:to="lab_us-gaap_ShareBasedCompensation" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_Depreciation" xlink:label="loc_us-gaap_Depreciation" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_Depreciation" xml:lang="en-US">Depreciation</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_Depreciation" xml:lang="en-US">Depreciation</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Depreciation" xlink:to="lab_us-gaap_Depreciation" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ForeignCurrencyTransactionGainLossUnrealized" xlink:label="loc_us-gaap_ForeignCurrencyTransactionGainLossUnrealized" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ForeignCurrencyTransactionGainLossUnrealized" xml:lang="en-US">Foreign Currency Transaction Gain (Loss), Unrealized</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_us-gaap_ForeignCurrencyTransactionGainLossUnrealized" xml:lang="en-US">Financial expenses, net (mainly exchange differences)</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ForeignCurrencyTransactionGainLossUnrealized" xlink:to="lab_us-gaap_ForeignCurrencyTransactionGainLossUnrealized" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PensionAndOtherPostretirementBenefitExpense" xlink:label="loc_us-gaap_PensionAndOtherPostretirementBenefitExpense" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_PensionAndOtherPostretirementBenefitExpense" xml:lang="en-US">Pension and Other Postretirement Benefits Cost (Reversal of Cost)</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_PensionAndOtherPostretirementBenefitExpense" xml:lang="en-US">Changes in accrued liability for employee rights upon retirement</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PensionAndOtherPostretirementBenefitExpense" xlink:to="lab_us-gaap_PensionAndOtherPostretirementBenefitExpense" />
<loc xlink:type="locator" xlink:href="plx-20190331.xsd#plx_GainLossOnAmountsFundedInRespectOfEmployeeRightsUponRetirement" xlink:label="loc_plx_GainLossOnAmountsFundedInRespectOfEmployeeRightsUponRetirement" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_plx_GainLossOnAmountsFundedInRespectOfEmployeeRightsUponRetirement" xml:lang="en-US">Gain Loss On Amounts Funded In Respect Of Employee Rights Upon Retirement</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_plx_GainLossOnAmountsFundedInRespectOfEmployeeRightsUponRetirement" xml:lang="en-US">Gain on amounts funded in respect of employee rights upon retirement</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_plx_GainLossOnAmountsFundedInRespectOfEmployeeRightsUponRetirement" xlink:to="lab_plx_GainLossOnAmountsFundedInRespectOfEmployeeRightsUponRetirement" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_plx_GainLossOnAmountsFundedInRespectOfEmployeeRightsUponRetirement" xml:lang="en-US">Gain (loss) on amounts funded in respect of employee rights upon retirement.</label>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:label="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_GainsLossesOnExtinguishmentOfDebt" xml:lang="en-US">Gain (Loss) on Extinguishment of Debt</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_us-gaap_GainsLossesOnExtinguishmentOfDebt" xml:lang="en-US">Net loss in connection with conversions of convertible notes</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:to="lab_us-gaap_GainsLossesOnExtinguishmentOfDebt" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AmortizationOfFinancingCosts" xlink:label="loc_us-gaap_AmortizationOfFinancingCosts" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AmortizationOfFinancingCosts" xml:lang="en-US">Amortization of Debt Issuance Costs</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_AmortizationOfFinancingCosts" xml:lang="en-US">Amortization of debt issuance costs and debt discount</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AmortizationOfFinancingCosts" xlink:to="lab_us-gaap_AmortizationOfFinancingCosts" />
<loc xlink:type="locator" xlink:href="plx-20190331.xsd#plx_IssuanceOfSharesForInterestPaymentRegardingConversionOfConvertibleNotes" xlink:label="loc_plx_IssuanceOfSharesForInterestPaymentRegardingConversionOfConvertibleNotes" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_plx_IssuanceOfSharesForInterestPaymentRegardingConversionOfConvertibleNotes" xml:lang="en-US">Issuance Of Shares For Interest Payment Regarding Conversion Of Convertible Notes</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_plx_IssuanceOfSharesForInterestPaymentRegardingConversionOfConvertibleNotes" xml:lang="en-US">Issuance of shares for interest payment in connection with conversions of convertible notes</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_plx_IssuanceOfSharesForInterestPaymentRegardingConversionOfConvertibleNotes" xlink:to="lab_plx_IssuanceOfSharesForInterestPaymentRegardingConversionOfConvertibleNotes" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_plx_IssuanceOfSharesForInterestPaymentRegardingConversionOfConvertibleNotes" xml:lang="en-US">Issuance of shares for interest payment regarding conversion of convertible notes,</label>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xml:lang="en-US">Increase (Decrease) in Operating Capital [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xml:lang="en-US">Changes in operating assets and liabilities:</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsReceivable" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsReceivable" xml:lang="en-US">Increase (Decrease) in Accounts Receivable</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsReceivable" xml:lang="en-US">Increase in accounts receivable and other assets</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:to="lab_us-gaap_IncreaseDecreaseInAccountsReceivable" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncreaseDecreaseInInventories" xlink:label="loc_us-gaap_IncreaseDecreaseInInventories" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IncreaseDecreaseInInventories" xml:lang="en-US">Increase (Decrease) in Inventories</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_us-gaap_IncreaseDecreaseInInventories" xml:lang="en-US">Decrease in inventories</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInInventories" xlink:to="lab_us-gaap_IncreaseDecreaseInInventories" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xml:lang="en-US">Increase (Decrease) in Accounts Payable and Accrued Liabilities</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xml:lang="en-US">Increase (decrease) in accounts payable and accruals</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:to="lab_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities" xml:lang="en-US">Increase (Decrease) in Other Noncurrent Liabilities</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities" xml:lang="en-US">Increase (decrease) in other long term liabilities</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities" xlink:to="lab_us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:label="loc_us-gaap_IncreaseDecreaseInContractWithCustomerLiability" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xml:lang="en-US">Increase (Decrease) in Contract with Customer, Liability</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xml:lang="en-US">Increase (decrease) in contracts liability (including non-current portion)</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:to="lab_us-gaap_IncreaseDecreaseInContractWithCustomerLiability" />
<loc xlink:type="locator" xlink:href="plx-20190331.xsd#plx_ChangeInOperatingLeaseRightOfUseAssets" xlink:label="loc_plx_ChangeInOperatingLeaseRightOfUseAssets" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_plx_ChangeInOperatingLeaseRightOfUseAssets" xml:lang="en-US">Change in Operating Lease Right Of use Assets</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_plx_ChangeInOperatingLeaseRightOfUseAssets" xml:lang="en-US">Changes in right of use assets</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_plx_ChangeInOperatingLeaseRightOfUseAssets" xlink:to="lab_plx_ChangeInOperatingLeaseRightOfUseAssets" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_plx_ChangeInOperatingLeaseRightOfUseAssets" xml:lang="en-US">Amount of Net Change in Operating Lease Right Of use Assets.</label>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xml:lang="en-US">Net cash used in operating activities</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xml:lang="en-US">CASH FLOWS FROM INVESTING ACTIVITIES:</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xml:lang="en-US">Payments to Acquire Property, Plant, and Equipment</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xml:lang="en-US">Purchase of property and equipment</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:to="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncreaseDecreaseInRestrictedCash" xlink:label="loc_us-gaap_IncreaseDecreaseInRestrictedCash" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IncreaseDecreaseInRestrictedCash" xml:lang="en-US">Increase (Decrease) in Restricted Cash</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_us-gaap_IncreaseDecreaseInRestrictedCash" xml:lang="en-US">Increase in restricted deposit</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInRestrictedCash" xlink:to="lab_us-gaap_IncreaseDecreaseInRestrictedCash" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PaymentsForProceedsFromOtherInvestingActivities" xlink:label="loc_us-gaap_PaymentsForProceedsFromOtherInvestingActivities" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_PaymentsForProceedsFromOtherInvestingActivities" xml:lang="en-US">Payments for (Proceeds from) Other Investing Activities</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_us-gaap_PaymentsForProceedsFromOtherInvestingActivities" xml:lang="en-US">Amounts funded in respect of employee rights upon retirement, net</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsForProceedsFromOtherInvestingActivities" xlink:to="lab_us-gaap_PaymentsForProceedsFromOtherInvestingActivities" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xml:lang="en-US">Net cash used in investing activities</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents" xlink:label="loc_us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents" xml:lang="en-US">Effect of Exchange Rate on Cash and Cash Equivalents</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents" xml:lang="en-US">EFFECT OF EXCHANGE RATE CHANGES ON CASH AND CASH EQUIVALENTS</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents" xlink:to="lab_us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" xlink:label="loc_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" xml:lang="en-US">Cash and Cash Equivalents, Period Increase (Decrease)</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" xml:lang="en-US">NET DECREASE IN CASH AND CASH EQUIVALENTS</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" xlink:to="lab_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:label="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xml:lang="en-US">Cash Flow, Noncash Investing and Financing Activities Disclosure [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xml:lang="en-US">SUPPLEMENTARY INFORMATION ON INVESTING AND FINANCING ACTIVITIES NOT INVOLVING CASH FLOWS:</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:to="lab_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" />
<loc xlink:type="locator" xlink:href="plx-20190331.xsd#plx_IncreaseInLiabilitiesForPropertyPlantAndEquipment" xlink:label="loc_plx_IncreaseInLiabilitiesForPropertyPlantAndEquipment" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_plx_IncreaseInLiabilitiesForPropertyPlantAndEquipment" xml:lang="en-US">Increase In Liabilities For Property Plant And Equipment</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_plx_IncreaseInLiabilitiesForPropertyPlantAndEquipment" xml:lang="en-US">Purchase of property and equipment</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_plx_IncreaseInLiabilitiesForPropertyPlantAndEquipment" xlink:to="lab_plx_IncreaseInLiabilitiesForPropertyPlantAndEquipment" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_plx_IncreaseInLiabilitiesForPropertyPlantAndEquipment" xml:lang="en-US">Increase in liabilities for property, plant and equipment.</label>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DebtConversionConvertedInstrumentAmount1" xlink:label="loc_us-gaap_DebtConversionConvertedInstrumentAmount1" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DebtConversionConvertedInstrumentAmount1" xml:lang="en-US">Debt Conversion, Converted Instrument, Amount</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_DebtConversionConvertedInstrumentAmount1" xml:lang="en-US">Convertible notes conversions</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtConversionConvertedInstrumentAmount1" xlink:to="lab_us-gaap_DebtConversionConvertedInstrumentAmount1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SupplementalCashFlowInformationAbstract" xlink:label="loc_us-gaap_SupplementalCashFlowInformationAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SupplementalCashFlowInformationAbstract" xml:lang="en-US">Supplemental Cash Flow Information [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_SupplementalCashFlowInformationAbstract" xml:lang="en-US">SUPPLEMENTARY DISCLOSURE ON CASH FLOWS</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SupplementalCashFlowInformationAbstract" xlink:to="lab_us-gaap_SupplementalCashFlowInformationAbstract" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_InterestPaidNet" xlink:label="loc_us-gaap_InterestPaidNet" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_InterestPaidNet" xml:lang="en-US">Interest Paid, Excluding Capitalized Interest, Operating Activities</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_InterestPaidNet" xml:lang="en-US">Interest paid</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestPaidNet" xlink:to="lab_us-gaap_InterestPaidNet" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaap_AccountingPoliciesAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AccountingPoliciesAbstract" xml:lang="en-US">Accounting Policies [Abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountingPoliciesAbstract" xlink:to="lab_us-gaap_AccountingPoliciesAbstract" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock" xlink:label="loc_us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock" xml:lang="en-US">Basis of Presentation and Significant Accounting Policies [Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock" xml:lang="en-US">SIGNIFICANT ACCOUNTING POLICIES</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock" xlink:to="lab_us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_InventoryDisclosureAbstract" xlink:label="loc_us-gaap_InventoryDisclosureAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_InventoryDisclosureAbstract" xml:lang="en-US">Inventory Disclosure [Abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryDisclosureAbstract" xlink:to="lab_us-gaap_InventoryDisclosureAbstract" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_InventoryDisclosureTextBlock" xlink:label="loc_us-gaap_InventoryDisclosureTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_InventoryDisclosureTextBlock" xml:lang="en-US">Inventory Disclosure [Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_InventoryDisclosureTextBlock" xml:lang="en-US">INVENTORIES</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryDisclosureTextBlock" xlink:to="lab_us-gaap_InventoryDisclosureTextBlock" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_FairValueDisclosuresAbstract" xml:lang="en-US">Fair Value Disclosures [Abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract" xlink:to="lab_us-gaap_FairValueDisclosuresAbstract" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueDisclosuresTextBlock" xlink:label="loc_us-gaap_FairValueDisclosuresTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_FairValueDisclosuresTextBlock" xml:lang="en-US">Fair Value Disclosures [Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_FairValueDisclosuresTextBlock" xml:lang="en-US">FAIR VALUE MEASUREMENT</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueDisclosuresTextBlock" xlink:to="lab_us-gaap_FairValueDisclosuresTextBlock" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LeasesOperatingAbstract" xlink:label="loc_us-gaap_LeasesOperatingAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_LeasesOperatingAbstract" xml:lang="en-US">Leases, Operating [Abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LeasesOperatingAbstract" xlink:to="lab_us-gaap_LeasesOperatingAbstract" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LesseeOperatingLeasesTextBlock" xlink:label="loc_us-gaap_LesseeOperatingLeasesTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_LesseeOperatingLeasesTextBlock" xml:lang="en-US">Lessee, Operating Leases [Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_LesseeOperatingLeasesTextBlock" xml:lang="en-US">OPERATING LEASES</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeasesTextBlock" xlink:to="lab_us-gaap_LesseeOperatingLeasesTextBlock" />
<loc xlink:type="locator" xlink:href="plx-20190331.xsd#plx_RevenueDisclosureTextBlock" xlink:label="loc_plx_RevenueDisclosureTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_plx_RevenueDisclosureTextBlock" xml:lang="en-US">Revenue Disclosure [Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_plx_RevenueDisclosureTextBlock" xml:lang="en-US">REVENUES</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_plx_RevenueDisclosureTextBlock" xlink:to="lab_plx_RevenueDisclosureTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_plx_RevenueDisclosureTextBlock" xml:lang="en-US">The entire disclosure pertaining to revenue.</label>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SubsequentEventsAbstract" xlink:label="loc_us-gaap_SubsequentEventsAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SubsequentEventsAbstract" xml:lang="en-US">Subsequent Events [Abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventsAbstract" xlink:to="lab_us-gaap_SubsequentEventsAbstract" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SubsequentEventsTextBlock" xlink:label="loc_us-gaap_SubsequentEventsTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SubsequentEventsTextBlock" xml:lang="en-US">Subsequent Events [Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_SubsequentEventsTextBlock" xml:lang="en-US">SUBSEQUENT EVENTS</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventsTextBlock" xlink:to="lab_us-gaap_SubsequentEventsTextBlock" />
<loc xlink:type="locator" xlink:href="plx-20190331.xsd#plx_NatureOfOperationsPolicyTextBlock" xlink:label="loc_plx_NatureOfOperationsPolicyTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_plx_NatureOfOperationsPolicyTextBlock" xml:lang="en-US">Nature Of Operations [Policy Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_plx_NatureOfOperationsPolicyTextBlock" xml:lang="en-US">General</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_plx_NatureOfOperationsPolicyTextBlock" xlink:to="lab_plx_NatureOfOperationsPolicyTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_plx_NatureOfOperationsPolicyTextBlock" xml:lang="en-US">Nature Of Operations Policy</label>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:label="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xml:lang="en-US">Basis of Accounting, Policy [Policy Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xml:lang="en-US">Basis of presentation</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:to="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EarningsPerSharePolicyTextBlock" xlink:label="loc_us-gaap_EarningsPerSharePolicyTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_EarningsPerSharePolicyTextBlock" xml:lang="en-US">Earnings Per Share, Policy [Policy Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_EarningsPerSharePolicyTextBlock" xml:lang="en-US">Net loss per share</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerSharePolicyTextBlock" xlink:to="lab_us-gaap_EarningsPerSharePolicyTextBlock" />
<loc xlink:type="locator" xlink:href="plx-20190331.xsd#plx_RecentlyAdoptedStandardsPolicyTextBlockPolicyTextBlock" xlink:label="loc_plx_RecentlyAdoptedStandardsPolicyTextBlockPolicyTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_plx_RecentlyAdoptedStandardsPolicyTextBlockPolicyTextBlock" xml:lang="en-US">Recently Adopted standards [Policy Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_plx_RecentlyAdoptedStandardsPolicyTextBlockPolicyTextBlock" xml:lang="en-US">Recently adopted standards</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_plx_RecentlyAdoptedStandardsPolicyTextBlockPolicyTextBlock" xlink:to="lab_plx_RecentlyAdoptedStandardsPolicyTextBlockPolicyTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_plx_RecentlyAdoptedStandardsPolicyTextBlockPolicyTextBlock" xml:lang="en-US">Disclosure of accounting policy pertaining to recently adopted standards that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.</label>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:label="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xml:lang="en-US">New Accounting Pronouncements, Policy [Policy Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xml:lang="en-US">Newly issued accounting pronouncements</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:to="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfInventoryCurrentTableTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xml:lang="en-US">Schedule of Inventory, Current [Table Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xml:lang="en-US">Schedule of Inventory</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfInventoryCurrentTableTextBlock" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock" xml:lang="en-US">Fair Value Measurement Inputs and Valuation Techniques [Table Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock" xml:lang="en-US">Fair Value Measurements, Recurring and Nonrecurring</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock" xlink:to="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DebtInstrumentAxis" xlink:label="loc_us-gaap_DebtInstrumentAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DebtInstrumentAxis" xml:lang="en-US">Debt Instrument [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentAxis" xlink:to="lab_us-gaap_DebtInstrumentAxis" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="loc_us-gaap_DebtInstrumentNameDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DebtInstrumentNameDomain" xml:lang="en-US">Debt Instrument, Name [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentNameDomain" xlink:to="lab_us-gaap_DebtInstrumentNameDomain" />
<loc xlink:type="locator" xlink:href="plx-20190331.xsd#plx_Notes2021Member" xlink:label="loc_plx_Notes2021Member" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_plx_Notes2021Member" xml:lang="en-US">Notes 2021 [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_plx_Notes2021Member" xlink:to="lab_plx_Notes2021Member" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LeaseCostTableTextBlock" xlink:label="loc_us-gaap_LeaseCostTableTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_LeaseCostTableTextBlock" xml:lang="en-US">Lease, Cost [Table Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_LeaseCostTableTextBlock" xml:lang="en-US">Lease, Cost</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LeaseCostTableTextBlock" xlink:to="lab_us-gaap_LeaseCostTableTextBlock" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xml:lang="en-US">Lessee, Operating Lease, Liability, Maturity [Table Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xml:lang="en-US">Lessee, Operating Lease, Liability, Maturity</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" />
<loc xlink:type="locator" xlink:href="plx-20190331.xsd#plx_SupplementaryIncomeStatementInformationTableTextBlock" xlink:label="loc_plx_SupplementaryIncomeStatementInformationTableTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_plx_SupplementaryIncomeStatementInformationTableTextBlock" xml:lang="en-US">Supplementary Income Statement Information [Table Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_plx_SupplementaryIncomeStatementInformationTableTextBlock" xml:lang="en-US">Statements of operations</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_plx_SupplementaryIncomeStatementInformationTableTextBlock" xlink:to="lab_plx_SupplementaryIncomeStatementInformationTableTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_plx_SupplementaryIncomeStatementInformationTableTextBlock" xml:lang="en-US">The tabular disclosure for supplemental income statements.</label>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock" xlink:label="loc_us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock" xml:lang="en-US">Contract with Customer, Asset and Liability [Table Text Block]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock" xlink:to="lab_us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock" />
<loc xlink:type="locator" xlink:href="plx-20190331.xsd#plx_RevenueRemainingPerformanceObligationAmountTableTextBlock" xlink:label="loc_plx_RevenueRemainingPerformanceObligationAmountTableTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_plx_RevenueRemainingPerformanceObligationAmountTableTextBlock" xml:lang="en-US">Revenue Remaining Performance Obligation Amount [Table Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_plx_RevenueRemainingPerformanceObligationAmountTableTextBlock" xml:lang="en-US">Revenue, Remaining Performance Obligation, Amount [Table Text Block]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_plx_RevenueRemainingPerformanceObligationAmountTableTextBlock" xlink:to="lab_plx_RevenueRemainingPerformanceObligationAmountTableTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_plx_RevenueRemainingPerformanceObligationAmountTableTextBlock" xml:lang="en-US">Tabular disclosure of revenue remaining performance obligation amount.</label>
<loc xlink:type="locator" xlink:href="plx-20190331.xsd#plx_SignificantAccountingPoliciesTable" xlink:label="loc_plx_SignificantAccountingPoliciesTable" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_plx_SignificantAccountingPoliciesTable" xml:lang="en-US">Significant Accounting Policies [Table]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_plx_SignificantAccountingPoliciesTable" xlink:to="lab_plx_SignificantAccountingPoliciesTable" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_plx_SignificantAccountingPoliciesTable" xml:lang="en-US">Significant Accounting Policies [Table].</label>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaap_TypeOfArrangementAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_TypeOfArrangementAxis" xml:lang="en-US">Type of Arrangement and Non-arrangement Transactions [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TypeOfArrangementAxis" xlink:to="lab_us-gaap_TypeOfArrangementAxis" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember" xml:lang="en-US">Arrangements and Non-arrangement Transactions [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember" />
<loc xlink:type="locator" xlink:href="plx-20190331.xsd#plx_AmendedPfizerAgreementMember" xlink:label="loc_plx_AmendedPfizerAgreementMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_plx_AmendedPfizerAgreementMember" xml:lang="en-US">Amended Pfizer Agreement [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_plx_AmendedPfizerAgreementMember" xlink:to="lab_plx_AmendedPfizerAgreementMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_plx_AmendedPfizerAgreementMember" xml:lang="en-US">Amended Pfizer Agreement [Member]</label>
<loc xlink:type="locator" xlink:href="plx-20190331.xsd#plx_ChiesiUSAgreementMember" xlink:label="loc_plx_ChiesiUSAgreementMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_plx_ChiesiUSAgreementMember" xml:lang="en-US">Chiesi US Agreement [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_plx_ChiesiUSAgreementMember" xlink:to="lab_plx_ChiesiUSAgreementMember" />
<loc xlink:type="locator" xlink:href="plx-20190331.xsd#plx_ChiesiExUSAgreementMember" xlink:label="loc_plx_ChiesiExUSAgreementMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_plx_ChiesiExUSAgreementMember" xml:lang="en-US">Chiesi Ex US Agreement [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_plx_ChiesiExUSAgreementMember" xlink:to="lab_plx_ChiesiExUSAgreementMember" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_LegalEntityAxis" xml:lang="en-US">Legal Entity [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_LegalEntityAxis" xlink:to="lab_dei_LegalEntityAxis" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_EntityDomain" xml:lang="en-US">Entity [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityDomain" xlink:to="lab_dei_EntityDomain" />
<loc xlink:type="locator" xlink:href="plx-20190331.xsd#plx_ProtalixBioTherapeuticsIncorporationMember" xlink:label="loc_plx_ProtalixBioTherapeuticsIncorporationMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_plx_ProtalixBioTherapeuticsIncorporationMember" xml:lang="en-US">Protalix Bio Therapeutics Incorporation [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_plx_ProtalixBioTherapeuticsIncorporationMember" xlink:to="lab_plx_ProtalixBioTherapeuticsIncorporationMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_plx_ProtalixBioTherapeuticsIncorporationMember" xml:lang="en-US">Protalix Bio Therapeutics Incorporation [Member].</label>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_StatementGeographicalAxis" xlink:label="loc_srt_StatementGeographicalAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_srt_StatementGeographicalAxis" xml:lang="en-US">Geographical [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_StatementGeographicalAxis" xlink:to="lab_srt_StatementGeographicalAxis" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_SegmentGeographicalDomain" xlink:label="loc_srt_SegmentGeographicalDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_srt_SegmentGeographicalDomain" xml:lang="en-US">Geographical [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_SegmentGeographicalDomain" xlink:to="lab_srt_SegmentGeographicalDomain" />
<loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/country/2017/country-2017-01-31.xsd#country_BR" xlink:label="loc_country_BR" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_country_BR" xml:lang="en-US">BRAZIL</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_country_BR" xml:lang="en-US">Brazil [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_country_BR" xml:lang="en-US">Brazil [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_country_BR" xlink:to="lab_country_BR" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_RangeAxis" xlink:label="loc_srt_RangeAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_srt_RangeAxis" xml:lang="en-US">Range [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RangeAxis" xlink:to="lab_srt_RangeAxis" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_RangeMember" xlink:label="loc_srt_RangeMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_srt_RangeMember" xml:lang="en-US">Range [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RangeMember" xlink:to="lab_srt_RangeMember" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_MinimumMember" xlink:label="loc_srt_MinimumMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_srt_MinimumMember" xml:lang="en-US">Minimum [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_MinimumMember" xlink:to="lab_srt_MinimumMember" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_MaximumMember" xlink:label="loc_srt_MaximumMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_srt_MaximumMember" xml:lang="en-US">Maximum [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_MaximumMember" xlink:to="lab_srt_MaximumMember" />
<loc xlink:type="locator" xlink:href="plx-20190331.xsd#plx_SignificantAccountingPoliciesLineItems" xlink:label="loc_plx_SignificantAccountingPoliciesLineItems" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_plx_SignificantAccountingPoliciesLineItems" xml:lang="en-US">Significant Accounting Policies [Line Items]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_plx_SignificantAccountingPoliciesLineItems" xlink:to="lab_plx_SignificantAccountingPoliciesLineItems" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:to="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" />
<loc xlink:type="locator" xlink:href="plx-20190331.xsd#plx_CollaborativeArrangementRevenuesExpensesSharingPercentage" xlink:label="loc_plx_CollaborativeArrangementRevenuesExpensesSharingPercentage" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_plx_CollaborativeArrangementRevenuesExpensesSharingPercentage" xml:lang="en-US">Collaborative Arrangement Revenues and Expenses Sharing Percentage</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_plx_CollaborativeArrangementRevenuesExpensesSharingPercentage" xlink:to="lab_plx_CollaborativeArrangementRevenuesExpensesSharingPercentage" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_plx_CollaborativeArrangementRevenuesExpensesSharingPercentage" xml:lang="en-US">Collaborative arrangement revenues and expense sharing percentage.</label>
<loc xlink:type="locator" xlink:href="plx-20190331.xsd#plx_UpfrontNonrefundableNoncreditablePaymentReceivable" xlink:label="loc_plx_UpfrontNonrefundableNoncreditablePaymentReceivable" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_plx_UpfrontNonrefundableNoncreditablePaymentReceivable" xml:lang="en-US">Upfront Nonrefundable Noncreditable Payment Receivable</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_plx_UpfrontNonrefundableNoncreditablePaymentReceivable" xlink:to="lab_plx_UpfrontNonrefundableNoncreditablePaymentReceivable" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_plx_UpfrontNonrefundableNoncreditablePaymentReceivable" xml:lang="en-US">The amount of upfront,non refundable and non creditable payment receivable under the agreement for licencing rights.</label>
<loc xlink:type="locator" xlink:href="plx-20190331.xsd#plx_AdditionalAmountsPayableToCoverDevelopmentCosts" xlink:label="loc_plx_AdditionalAmountsPayableToCoverDevelopmentCosts" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_plx_AdditionalAmountsPayableToCoverDevelopmentCosts" xml:lang="en-US">Additional Amounts Payable To Cover Development Costs</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_plx_AdditionalAmountsPayableToCoverDevelopmentCosts" xlink:to="lab_plx_AdditionalAmountsPayableToCoverDevelopmentCosts" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_plx_AdditionalAmountsPayableToCoverDevelopmentCosts" xml:lang="en-US">The definition should be: "The maximum amount payable to the entity to cover development costs under agreement.</label>
<loc xlink:type="locator" xlink:href="plx-20190331.xsd#plx_MaximumEntitlementOfDevelopmentCostsToCoverPerYear" xlink:label="loc_plx_MaximumEntitlementOfDevelopmentCostsToCoverPerYear" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_plx_MaximumEntitlementOfDevelopmentCostsToCoverPerYear" xml:lang="en-US">Maximum Entitlement Of Development Costs To Cover Per Year</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_plx_MaximumEntitlementOfDevelopmentCostsToCoverPerYear" xlink:to="lab_plx_MaximumEntitlementOfDevelopmentCostsToCoverPerYear" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_plx_MaximumEntitlementOfDevelopmentCostsToCoverPerYear" xml:lang="en-US">The maximum amount payable to entity to cover development costs in any year under agreement.</label>
<loc xlink:type="locator" xlink:href="plx-20190331.xsd#plx_AdditionalAmountpayableForAchievementOfRegulatoryAndCommercialMilestones" xlink:label="loc_plx_AdditionalAmountpayableForAchievementOfRegulatoryAndCommercialMilestones" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_plx_AdditionalAmountpayableForAchievementOfRegulatoryAndCommercialMilestones" xml:lang="en-US">Additional AmountPayable For Achievement Of Regulatory And Commercial Milestones</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_plx_AdditionalAmountpayableForAchievementOfRegulatoryAndCommercialMilestones" xlink:to="lab_plx_AdditionalAmountpayableForAchievementOfRegulatoryAndCommercialMilestones" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_plx_AdditionalAmountpayableForAchievementOfRegulatoryAndCommercialMilestones" xml:lang="en-US">The total amount payable to entity for the achievement of regulatory and commercial milestones.</label>
<loc xlink:type="locator" xlink:href="plx-20190331.xsd#plx_PaymentOnNetSalesPercentage" xlink:label="loc_plx_PaymentOnNetSalesPercentage" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_plx_PaymentOnNetSalesPercentage" xml:lang="en-US">Payment On Net Sales Percentage</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_plx_PaymentOnNetSalesPercentage" xlink:to="lab_plx_PaymentOnNetSalesPercentage" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_plx_PaymentOnNetSalesPercentage" xml:lang="en-US">Represents the payment as a percentage of future net sales.</label>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OperatingLeaseLiability" xlink:label="loc_us-gaap_OperatingLeaseLiability" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_OperatingLeaseLiability" xml:lang="en-US">Operating Lease, Liability</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_OperatingLeaseLiability" xml:lang="en-US">Present value of lease liabilities</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiability" xlink:to="lab_us-gaap_OperatingLeaseLiability" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_RestatementAxis" xlink:label="loc_srt_RestatementAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_srt_RestatementAxis" xml:lang="en-US">Restatement [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RestatementAxis" xlink:to="lab_srt_RestatementAxis" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_RestatementDomain" xlink:label="loc_srt_RestatementDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_srt_RestatementDomain" xml:lang="en-US">Restatement [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RestatementDomain" xlink:to="lab_srt_RestatementDomain" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:label="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xml:lang="en-US">Adjustments for New Accounting Pronouncements [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:to="lab_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_TypeOfAdoptionMember" xlink:label="loc_us-gaap_TypeOfAdoptionMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_TypeOfAdoptionMember" xml:lang="en-US">Type of Adoption [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TypeOfAdoptionMember" xlink:to="lab_us-gaap_TypeOfAdoptionMember" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_InventoryRawMaterialsNetOfReserves" xlink:label="loc_us-gaap_InventoryRawMaterialsNetOfReserves" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_InventoryRawMaterialsNetOfReserves" xml:lang="en-US">Inventory, Raw Materials, Net of Reserves</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_InventoryRawMaterialsNetOfReserves" xml:lang="en-US">Raw materials</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryRawMaterialsNetOfReserves" xlink:to="lab_us-gaap_InventoryRawMaterialsNetOfReserves" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_InventoryWorkInProcessNetOfReserves" xlink:label="loc_us-gaap_InventoryWorkInProcessNetOfReserves" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_InventoryWorkInProcessNetOfReserves" xml:lang="en-US">Inventory, Work in Process, Net of Reserves</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_InventoryWorkInProcessNetOfReserves" xml:lang="en-US">Work in progress</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryWorkInProcessNetOfReserves" xlink:to="lab_us-gaap_InventoryWorkInProcessNetOfReserves" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_InventoryFinishedGoodsNetOfReserves" xlink:label="loc_us-gaap_InventoryFinishedGoodsNetOfReserves" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_InventoryFinishedGoodsNetOfReserves" xml:lang="en-US">Inventory, Finished Goods, Net of Reserves</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_InventoryFinishedGoodsNetOfReserves" xml:lang="en-US">Finished goods</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryFinishedGoodsNetOfReserves" xlink:to="lab_us-gaap_InventoryFinishedGoodsNetOfReserves" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_InventoryWriteDown" xlink:label="loc_us-gaap_InventoryWriteDown" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_InventoryWriteDown" xml:lang="en-US">Inventory Write-down</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryWriteDown" xlink:to="lab_us-gaap_InventoryWriteDown" />
<loc xlink:type="locator" xlink:href="plx-20190331.xsd#plx_SevenPointFivePercentageConvertibleNotesMember" xlink:label="loc_plx_SevenPointFivePercentageConvertibleNotesMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_plx_SevenPointFivePercentageConvertibleNotesMember" xml:lang="en-US">Seven Point Five Percentage Convertible Notes [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_plx_SevenPointFivePercentageConvertibleNotesMember" xml:lang="en-US">2021 Notes [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_plx_SevenPointFivePercentageConvertibleNotesMember" xlink:to="lab_plx_SevenPointFivePercentageConvertibleNotesMember" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" xml:lang="en-US">Fair Value Hierarchy and NAV [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xml:lang="en-US">Fair Value Hierarchy and NAV [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueInputsLevel3Member" xlink:label="loc_us-gaap_FairValueInputsLevel3Member" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_FairValueInputsLevel3Member" xml:lang="en-US">Fair Value, Inputs, Level 3 [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel3Member" xlink:to="lab_us-gaap_FairValueInputsLevel3Member" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SharePrice" xlink:label="loc_us-gaap_SharePrice" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SharePrice" xml:lang="en-US">Share Price</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_SharePrice" xml:lang="en-US">Stock price (USD)</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharePrice" xlink:to="lab_us-gaap_SharePrice" />
<loc xlink:type="locator" xlink:href="plx-20190331.xsd#plx_FairValueAssumptionsTerm" xlink:label="loc_plx_FairValueAssumptionsTerm" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_plx_FairValueAssumptionsTerm" xml:lang="en-US">Fair Value Assumptions Term</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_plx_FairValueAssumptionsTerm" xml:lang="en-US">Expected term</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_plx_FairValueAssumptionsTerm" xlink:to="lab_plx_FairValueAssumptionsTerm" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_plx_FairValueAssumptionsTerm" xml:lang="en-US">Period the instrument, asset or liability is expected to be outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</label>
<loc xlink:type="locator" xlink:href="plx-20190331.xsd#plx_FairValueAssumptionsRiskFreeInterestRates" xlink:label="loc_plx_FairValueAssumptionsRiskFreeInterestRates" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_plx_FairValueAssumptionsRiskFreeInterestRates" xml:lang="en-US">Fair Value Assumptions Risk Free Interest Rates</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_plx_FairValueAssumptionsRiskFreeInterestRates" xml:lang="en-US">Risk free rate</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_plx_FairValueAssumptionsRiskFreeInterestRates" xlink:to="lab_plx_FairValueAssumptionsRiskFreeInterestRates" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_plx_FairValueAssumptionsRiskFreeInterestRates" xml:lang="en-US">Risk-free interest rate assumption used in valuing an instrument.</label>
<loc xlink:type="locator" xlink:href="plx-20190331.xsd#plx_FairValueAssumptionsExpectedVolatilityRates" xlink:label="loc_plx_FairValueAssumptionsExpectedVolatilityRates" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_plx_FairValueAssumptionsExpectedVolatilityRates" xml:lang="en-US">Fair Value Assumptions Expected Volatility Rates</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_plx_FairValueAssumptionsExpectedVolatilityRates" xml:lang="en-US">Volatility</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_plx_FairValueAssumptionsExpectedVolatilityRates" xlink:to="lab_plx_FairValueAssumptionsExpectedVolatilityRates" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_plx_FairValueAssumptionsExpectedVolatilityRates" xml:lang="en-US">Measure of dispersion, in percentage terms (for instance, the standard deviation or variance), for a given stock price.</label>
<loc xlink:type="locator" xlink:href="plx-20190331.xsd#plx_FairValueAssumptionsExpectedDividendRates" xlink:label="loc_plx_FairValueAssumptionsExpectedDividendRates" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_plx_FairValueAssumptionsExpectedDividendRates" xml:lang="en-US">Fair Value Assumptions Expected Dividend Rates</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_plx_FairValueAssumptionsExpectedDividendRates" xml:lang="en-US">Yield</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_plx_FairValueAssumptionsExpectedDividendRates" xlink:to="lab_plx_FairValueAssumptionsExpectedDividendRates" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_plx_FairValueAssumptionsExpectedDividendRates" xml:lang="en-US">Expected dividends to be paid to holders of the underlying shares or financial instruments (expressed as a percentage of the share or instrument's price).</label>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_MeasurementInputTypeAxis" xlink:label="loc_us-gaap_MeasurementInputTypeAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_MeasurementInputTypeAxis" xml:lang="en-US">Measurement Input Type [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MeasurementInputTypeAxis" xlink:to="lab_us-gaap_MeasurementInputTypeAxis" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_MeasurementInputTypeDomain" xlink:label="loc_us-gaap_MeasurementInputTypeDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_MeasurementInputTypeDomain" xml:lang="en-US">Measurement Input Type [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MeasurementInputTypeDomain" xlink:to="lab_us-gaap_MeasurementInputTypeDomain" />
<loc xlink:type="locator" xlink:href="plx-20190331.xsd#plx_SevenPointFivePercentageConvertibleNoteMember" xlink:label="loc_plx_SevenPointFivePercentageConvertibleNoteMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_plx_SevenPointFivePercentageConvertibleNoteMember" xml:lang="en-US">Seven Point Five Percentage Convertible Note [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_plx_SevenPointFivePercentageConvertibleNoteMember" xml:lang="en-US">Seven Point Five Percentage Convertible Notes [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_plx_SevenPointFivePercentageConvertibleNoteMember" xlink:to="lab_plx_SevenPointFivePercentageConvertibleNoteMember" />
<loc xlink:type="locator" xlink:href="plx-20190331.xsd#plx_SevenPointFivePercentageConvertibleNotes2021Member" xlink:label="loc_plx_SevenPointFivePercentageConvertibleNotes2021Member" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_plx_SevenPointFivePercentageConvertibleNotes2021Member" xml:lang="en-US">Seven Point Five Percentage Convertible Notes 2021 [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_plx_SevenPointFivePercentageConvertibleNotes2021Member" xlink:to="lab_plx_SevenPointFivePercentageConvertibleNotes2021Member" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DebtInstrumentRedemptionPeriodAxis" xlink:label="loc_us-gaap_DebtInstrumentRedemptionPeriodAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DebtInstrumentRedemptionPeriodAxis" xml:lang="en-US">Debt Instrument, Redemption, Period [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentRedemptionPeriodAxis" xlink:to="lab_us-gaap_DebtInstrumentRedemptionPeriodAxis" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DebtInstrumentRedemptionPeriodDomain" xlink:label="loc_us-gaap_DebtInstrumentRedemptionPeriodDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DebtInstrumentRedemptionPeriodDomain" xml:lang="en-US">Debt Instrument, Redemption, Period [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentRedemptionPeriodDomain" xlink:to="lab_us-gaap_DebtInstrumentRedemptionPeriodDomain" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ConvertibleDebtFairValueDisclosures" xlink:label="loc_us-gaap_ConvertibleDebtFairValueDisclosures" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ConvertibleDebtFairValueDisclosures" xml:lang="en-US">Convertible Debt, Fair Value Disclosures</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConvertibleDebtFairValueDisclosures" xlink:to="lab_us-gaap_ConvertibleDebtFairValueDisclosures" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DebtInstrumentFaceAmount" xlink:label="loc_us-gaap_DebtInstrumentFaceAmount" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DebtInstrumentFaceAmount" xml:lang="en-US">Debt Instrument, Face Amount</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentFaceAmount" xlink:to="lab_us-gaap_DebtInstrumentFaceAmount" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage" xml:lang="en-US">Debt Instrument, Interest Rate, Stated Percentage</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:to="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage" />
<loc xlink:type="locator" xlink:href="plx-20190331.xsd#plx_DisclosureOfLeasesOperatingTable" xlink:label="loc_plx_DisclosureOfLeasesOperatingTable" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_plx_DisclosureOfLeasesOperatingTable" xml:lang="en-US">Disclosure of Leases Operating [Table]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_plx_DisclosureOfLeasesOperatingTable" xlink:to="lab_plx_DisclosureOfLeasesOperatingTable" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_plx_DisclosureOfLeasesOperatingTable" xml:lang="en-US">Disclosure of Leases, Operating</label>
<loc xlink:type="locator" xlink:href="plx-20190331.xsd#plx_DisclosureOfLeasesOperatingLineItems" xlink:label="loc_plx_DisclosureOfLeasesOperatingLineItems" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_plx_DisclosureOfLeasesOperatingLineItems" xml:lang="en-US">Disclosure of Leases Operating [Line Items]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_plx_DisclosureOfLeasesOperatingLineItems" xlink:to="lab_plx_DisclosureOfLeasesOperatingLineItems" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_plx_DisclosureOfLeasesOperatingLineItems" xml:lang="en-US">Disclosure of Leases Operating</label>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OperatingLeaseCost" xlink:label="loc_us-gaap_OperatingLeaseCost" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_OperatingLeaseCost" xml:lang="en-US">Operating Lease, Cost</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_OperatingLeaseCost" xml:lang="en-US">Operating lease costs</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseCost" xlink:to="lab_us-gaap_OperatingLeaseCost" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OperatingLeasePayments" xlink:label="loc_us-gaap_OperatingLeasePayments" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_OperatingLeasePayments" xml:lang="en-US">Operating Lease, Payments</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_OperatingLeasePayments" xml:lang="en-US">Cash paid for amounts included in the&#160;measurement of lease liabilities</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeasePayments" xlink:to="lab_us-gaap_OperatingLeasePayments" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:label="loc_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xml:lang="en-US">Right-of-Use Asset Obtained in Exchange for Operating Lease Liability</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xml:lang="en-US">Right of use assets obtained in exchange&#160;for new operating lease liabilities</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:to="lab_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xml:lang="en-US">Operating Lease, Weighted Average Remaining Lease Term</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xml:lang="en-US">Weighted average remaining lease term&#160;(in years)</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:to="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xml:lang="en-US">Operating Lease, Weighted Average Discount Rate, Percent</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xml:lang="en-US">Weighted average discount rate</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:to="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" xml:lang="en-US">Lessee, Operating Lease, Liability, Payments, Remainder of Fiscal Year</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" xml:lang="en-US">2019 (excluding the three months ended March 31, 2019)</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xml:lang="en-US">Lessee, Operating Lease, Liability, Payments, Due Year Two</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xml:lang="en-US">2020</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xml:lang="en-US">Lessee, Operating Lease, Liability, Payments, Due Year Three</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xml:lang="en-US">2021</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xml:lang="en-US">Lessee, Operating Lease, Liability, Payments, Due Year Four</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xml:lang="en-US">2022</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xml:lang="en-US">Lessee, Operating Lease, Liability, Payments, Due Year Five</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xml:lang="en-US">2023</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xml:lang="en-US">Lessee, Operating Lease, Liability, Payments, Due after Year Five</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xml:lang="en-US">After 2024</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xml:lang="en-US">Lessee, Operating Lease, Liability, Payments, Due</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xml:lang="en-US">Total undiscounted cash flows</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xml:lang="en-US">Lessee, Operating Lease, Liability, Undiscounted Excess Amount</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xml:lang="en-US">Less: imputed interest</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent" xlink:label="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent" xml:lang="en-US">Operating Leases, Future Minimum Payments Due, Next Twelve Months</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent" xlink:to="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears" xlink:label="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears" xml:lang="en-US">Operating Leases, Future Minimum Payments, Due in Two Years</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears" xlink:to="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears" xlink:label="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears" xml:lang="en-US">Operating Leases, Future Minimum Payments, Due in Three Years</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears" xlink:to="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SecurityDeposit" xlink:label="loc_us-gaap_SecurityDeposit" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SecurityDeposit" xml:lang="en-US">Security Deposit</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SecurityDeposit" xlink:to="lab_us-gaap_SecurityDeposit" />
<loc xlink:type="locator" xlink:href="plx-20190331.xsd#plx_PercentageOfChangeInOperatingLeaseMonthlyRentalPayments" xlink:label="loc_plx_PercentageOfChangeInOperatingLeaseMonthlyRentalPayments" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_plx_PercentageOfChangeInOperatingLeaseMonthlyRentalPayments" xml:lang="en-US">Percentage of Change in Operating Lease Monthly Rental Payments</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_plx_PercentageOfChangeInOperatingLeaseMonthlyRentalPayments" xlink:to="lab_plx_PercentageOfChangeInOperatingLeaseMonthlyRentalPayments" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_plx_PercentageOfChangeInOperatingLeaseMonthlyRentalPayments" xml:lang="en-US">Percentage of Change in Operating Lease Monthly Rental Payments.</label>
<loc xlink:type="locator" xlink:href="plx-20190331.xsd#plx_CommitmentsAndContingenciesAxis" xlink:label="loc_plx_CommitmentsAndContingenciesAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_plx_CommitmentsAndContingenciesAxis" xml:lang="en-US">Commitments And Contingencies [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_plx_CommitmentsAndContingenciesAxis" xlink:to="lab_plx_CommitmentsAndContingenciesAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_plx_CommitmentsAndContingenciesAxis" xml:lang="en-US">Commitments And Contingencies Axis</label>
<loc xlink:type="locator" xlink:href="plx-20190331.xsd#plx_CommitmentsAndContingenciesDomain" xlink:label="loc_plx_CommitmentsAndContingenciesDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_plx_CommitmentsAndContingenciesDomain" xml:lang="en-US">Commitments And Contingencies [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_plx_CommitmentsAndContingenciesDomain" xlink:to="lab_plx_CommitmentsAndContingenciesDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_plx_CommitmentsAndContingenciesDomain" xml:lang="en-US">Commitments And Contingencies [Domain]</label>
<loc xlink:type="locator" xlink:href="plx-20190331.xsd#plx_VehicleLeaseAndMaintenanceAgreementsMember" xlink:label="loc_plx_VehicleLeaseAndMaintenanceAgreementsMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_plx_VehicleLeaseAndMaintenanceAgreementsMember" xml:lang="en-US">Vehicle Lease And Maintenance Agreements [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_plx_VehicleLeaseAndMaintenanceAgreementsMember" xml:lang="en-US">Vehicle Lease [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_plx_VehicleLeaseAndMaintenanceAgreementsMember" xlink:to="lab_plx_VehicleLeaseAndMaintenanceAgreementsMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_plx_VehicleLeaseAndMaintenanceAgreementsMember" xml:lang="en-US">Vehicle Lease and Maintenance Agreements Member</label>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LeaseAgreementsMember" xlink:label="loc_us-gaap_LeaseAgreementsMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_LeaseAgreementsMember" xml:lang="en-US">Lease Agreements [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LeaseAgreementsMember" xlink:to="lab_us-gaap_LeaseAgreementsMember" />
<loc xlink:type="locator" xlink:href="plx-20190331.xsd#plx_PfizerMember" xlink:label="loc_plx_PfizerMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_plx_PfizerMember" xml:lang="en-US">Pfizer [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_plx_PfizerMember" xlink:to="lab_plx_PfizerMember" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ContractWithCustomerAssetAndLiabilityAbstract" xlink:label="loc_us-gaap_ContractWithCustomerAssetAndLiabilityAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ContractWithCustomerAssetAndLiabilityAbstract" xml:lang="en-US">Contract with Customer, Asset and Liability [Abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContractWithCustomerAssetAndLiabilityAbstract" xlink:to="lab_us-gaap_ContractWithCustomerAssetAndLiabilityAbstract" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ContractWithCustomerLiability" xlink:label="loc_us-gaap_ContractWithCustomerLiability" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ContractWithCustomerLiability" xml:lang="en-US">Contract with Customer, Liability</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="lab_us-gaap_ContractWithCustomerLiability" xml:lang="en-US">Contract liabilities at the beginning of the period</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="lab_us-gaap_ContractWithCustomerLiability" xml:lang="en-US">Contract liabilities at the end of the period</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContractWithCustomerLiability" xlink:to="lab_us-gaap_ContractWithCustomerLiability" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToRevenueChangeInMeasureOfProgress" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToRevenueChangeInMeasureOfProgress" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToRevenueChangeInMeasureOfProgress" xml:lang="en-US">Contract with Customer, Liability, Cumulative Catch-up Adjustment to Revenue, Change in Measure of Progress</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToRevenueChangeInMeasureOfProgress" xml:lang="en-US">Additions during the period</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToRevenueChangeInMeasureOfProgress" xlink:to="lab_us-gaap_ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToRevenueChangeInMeasureOfProgress" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ContractWithCustomerLiabilityRevenueRecognized" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityRevenueRecognized" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ContractWithCustomerLiabilityRevenueRecognized" xml:lang="en-US">Contract with Customer, Liability, Revenue Recognized</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_ContractWithCustomerLiabilityRevenueRecognized" xml:lang="en-US">Revenue recognized during the period</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContractWithCustomerLiabilityRevenueRecognized" xlink:to="lab_us-gaap_ContractWithCustomerLiabilityRevenueRecognized" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RevenuePerformanceObligationAbstract" xlink:label="loc_us-gaap_RevenuePerformanceObligationAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_RevenuePerformanceObligationAbstract" xml:lang="en-US">Revenue, Performance Obligation [Abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenuePerformanceObligationAbstract" xlink:to="lab_us-gaap_RevenuePerformanceObligationAbstract" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RevenueRemainingPerformanceObligation" xlink:label="loc_us-gaap_RevenueRemainingPerformanceObligation" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_RevenueRemainingPerformanceObligation" xml:lang="en-US">Revenue, Remaining Performance Obligation, Amount</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_RevenueRemainingPerformanceObligation" xml:lang="en-US">Unsatisfied performance obligation</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueRemainingPerformanceObligation" xlink:to="lab_us-gaap_RevenueRemainingPerformanceObligation" />
</labelLink>
</linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>11
<FILENAME>plx-20190331_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="utf-8"?>
<!--Generated by DataTracks Rainbow Version 3.0 - www.datatracks.com - on 06-May-2019 [07:38:26] {PM}-->
<linkbase xmlns="http://www.xbrl.org/2003/linkbase" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
<roleRef xlink:type="simple" xlink:href="plx-20190331.xsd#DocumentAndEntityInformation" roleURI="http://www.protalix.com/role/DocumentAndEntityInformation" />
<roleRef xlink:type="simple" xlink:href="plx-20190331.xsd#CondensedConsolidatedBalanceSheets" roleURI="http://www.protalix.com/role/CondensedConsolidatedBalanceSheets" />
<roleRef xlink:type="simple" xlink:href="plx-20190331.xsd#CondensedConsolidatedStatementsOfOperations" roleURI="http://www.protalix.com/role/CondensedConsolidatedStatementsOfOperations" />
<roleRef xlink:type="simple" xlink:href="plx-20190331.xsd#CondensedConsolidatedStatementsOfOperationsParenthetical" roleURI="http://www.protalix.com/role/CondensedConsolidatedStatementsOfOperationsParenthetical" />
<roleRef xlink:type="simple" xlink:href="plx-20190331.xsd#CondensedConsolidatedStatementsOfChangesInCapitalDeficiency" roleURI="http://www.protalix.com/role/CondensedConsolidatedStatementsOfChangesInCapitalDeficiency" />
<roleRef xlink:type="simple" xlink:href="plx-20190331.xsd#CondensedConsolidatedStatementsOfChangesInCapitalDeficiencyParenthetical" roleURI="http://www.protalix.com/role/CondensedConsolidatedStatementsOfChangesInCapitalDeficiencyParenthetical" />
<roleRef xlink:type="simple" xlink:href="plx-20190331.xsd#CondensedConsolidatedStatementsOfCashFlows" roleURI="http://www.protalix.com/role/CondensedConsolidatedStatementsOfCashFlows" />
<roleRef xlink:type="simple" xlink:href="plx-20190331.xsd#SignificantAccountingPolicies" roleURI="http://www.protalix.com/role/SignificantAccountingPolicies" />
<roleRef xlink:type="simple" xlink:href="plx-20190331.xsd#Inventories" roleURI="http://www.protalix.com/role/Inventories" />
<roleRef xlink:type="simple" xlink:href="plx-20190331.xsd#FairValueMeasurement" roleURI="http://www.protalix.com/role/FairValueMeasurement" />
<roleRef xlink:type="simple" xlink:href="plx-20190331.xsd#OperatingLeases" roleURI="http://www.protalix.com/role/OperatingLeases" />
<roleRef xlink:type="simple" xlink:href="plx-20190331.xsd#Revenues" roleURI="http://www.protalix.com/role/Revenues" />
<roleRef xlink:type="simple" xlink:href="plx-20190331.xsd#SubsequentEvents" roleURI="http://www.protalix.com/role/SubsequentEvents" />
<roleRef xlink:type="simple" xlink:href="plx-20190331.xsd#SignificantAccountingPoliciesPolicies" roleURI="http://www.protalix.com/role/SignificantAccountingPoliciesPolicies" />
<roleRef xlink:type="simple" xlink:href="plx-20190331.xsd#InventoriesTables" roleURI="http://www.protalix.com/role/InventoriesTables" />
<roleRef xlink:type="simple" xlink:href="plx-20190331.xsd#FairValueMeasurementTables" roleURI="http://www.protalix.com/role/FairValueMeasurementTables" />
<roleRef xlink:type="simple" xlink:href="plx-20190331.xsd#OperatingLeasesTables" roleURI="http://www.protalix.com/role/OperatingLeasesTables" />
<roleRef xlink:type="simple" xlink:href="plx-20190331.xsd#RevenuesTables" roleURI="http://www.protalix.com/role/RevenuesTables" />
<roleRef xlink:type="simple" xlink:href="plx-20190331.xsd#SignificantAccountingPoliciesNarrativeDetails" roleURI="http://www.protalix.com/role/SignificantAccountingPoliciesNarrativeDetails" />
<roleRef xlink:type="simple" xlink:href="plx-20190331.xsd#InventoriesDetails" roleURI="http://www.protalix.com/role/InventoriesDetails" />
<roleRef xlink:type="simple" xlink:href="plx-20190331.xsd#InventoriesDetailsTextual" roleURI="http://www.protalix.com/role/InventoriesDetailsTextual" />
<roleRef xlink:type="simple" xlink:href="plx-20190331.xsd#FairValueMeasurementTheLiabilityComponentWasValuedBasedOnTheIncomeApproachDetails" roleURI="http://www.protalix.com/role/FairValueMeasurementTheLiabilityComponentWasValuedBasedOnTheIncomeApproachDetails" />
<roleRef xlink:type="simple" xlink:href="plx-20190331.xsd#FairValueMeasurementNarrativeDetails" roleURI="http://www.protalix.com/role/FairValueMeasurementNarrativeDetails" />
<roleRef xlink:type="simple" xlink:href="plx-20190331.xsd#OperatingLeasesLeaseCostDetails" roleURI="http://www.protalix.com/role/OperatingLeasesLeaseCostDetails" />
<roleRef xlink:type="simple" xlink:href="plx-20190331.xsd#OperatingLeasesLesseeOperatingLeaseLiabilityMaturityDetails" roleURI="http://www.protalix.com/role/OperatingLeasesLesseeOperatingLeaseLiabilityMaturityDetails" />
<roleRef xlink:type="simple" xlink:href="plx-20190331.xsd#OperatingLeasesNarrativeDetails" roleURI="http://www.protalix.com/role/OperatingLeasesNarrativeDetails" />
<roleRef xlink:type="simple" xlink:href="plx-20190331.xsd#RevenuesStatementsOfOperationsDetails" roleURI="http://www.protalix.com/role/RevenuesStatementsOfOperationsDetails" />
<roleRef xlink:type="simple" xlink:href="plx-20190331.xsd#RevenuesContractWithCustomerAssetAndLiabilityDetail" roleURI="http://www.protalix.com/role/RevenuesContractWithCustomerAssetAndLiabilityDetail" />
<roleRef xlink:type="simple" xlink:href="plx-20190331.xsd#RevenuesUnsatisfiedPerformanceObligationsDetail" roleURI="http://www.protalix.com/role/RevenuesUnsatisfiedPerformanceObligationsDetail" />
<presentationLink xlink:type="extended" xlink:role="http://www.protalix.com/role/DocumentAndEntityInformation">
<loc xlink:type="locator" xlink:href="plx-20190331.xsd#plx_DocumentAndEntityInformationAbstract" xlink:label="loc_plx_DocumentAndEntityInformationAbstract_187665" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_DocumentType" xlink:label="loc_dei_DocumentType_187411" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_plx_DocumentAndEntityInformationAbstract_187665" xlink:to="loc_dei_DocumentType_187411" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_AmendmentFlag" xlink:label="loc_dei_AmendmentFlag_187412" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_plx_DocumentAndEntityInformationAbstract_187665" xlink:to="loc_dei_AmendmentFlag_187412" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_DocumentPeriodEndDate" xlink:label="loc_dei_DocumentPeriodEndDate_187421" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_plx_DocumentAndEntityInformationAbstract_187665" xlink:to="loc_dei_DocumentPeriodEndDate_187421" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_DocumentFiscalYearFocus" xlink:label="loc_dei_DocumentFiscalYearFocus_187422" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_plx_DocumentAndEntityInformationAbstract_187665" xlink:to="loc_dei_DocumentFiscalYearFocus_187422" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="loc_dei_DocumentFiscalPeriodFocus_187423" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_plx_DocumentAndEntityInformationAbstract_187665" xlink:to="loc_dei_DocumentFiscalPeriodFocus_187423" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntityRegistrantName" xlink:label="loc_dei_EntityRegistrantName_187436" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_plx_DocumentAndEntityInformationAbstract_187665" xlink:to="loc_dei_EntityRegistrantName_187436" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntityCentralIndexKey" xlink:label="loc_dei_EntityCentralIndexKey_187437" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_plx_DocumentAndEntityInformationAbstract_187665" xlink:to="loc_dei_EntityCentralIndexKey_187437" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_CurrentFiscalYearEndDate" xlink:label="loc_dei_CurrentFiscalYearEndDate_187453" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_plx_DocumentAndEntityInformationAbstract_187665" xlink:to="loc_dei_CurrentFiscalYearEndDate_187453" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntityFilerCategory" xlink:label="loc_dei_EntityFilerCategory_187458" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_plx_DocumentAndEntityInformationAbstract_187665" xlink:to="loc_dei_EntityFilerCategory_187458" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_TradingSymbol" xlink:label="loc_dei_TradingSymbol_187540" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_plx_DocumentAndEntityInformationAbstract_187665" xlink:to="loc_dei_TradingSymbol_187540" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="loc_dei_EntityCommonStockSharesOutstanding_187547" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_plx_DocumentAndEntityInformationAbstract_187665" xlink:to="loc_dei_EntityCommonStockSharesOutstanding_187547" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntityEmergingGrowthCompany" xlink:label="loc_dei_EntityEmergingGrowthCompany_187659" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_plx_DocumentAndEntityInformationAbstract_187665" xlink:to="loc_dei_EntityEmergingGrowthCompany_187659" use="optional" order="12" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntitySmallBusiness" xlink:label="loc_dei_EntitySmallBusiness_187661" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_plx_DocumentAndEntityInformationAbstract_187665" xlink:to="loc_dei_EntitySmallBusiness_187661" use="optional" order="13" preferredLabel="http://www.xbrl.org/2003/role/label" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.protalix.com/role/CondensedConsolidatedBalanceSheets">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract_32" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_33" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_32" xlink:to="loc_us-gaap_StatementTable_33" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_34" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_33" xlink:to="loc_us-gaap_StatementClassOfStockAxis_34" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_43" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementClassOfStockAxis_34" xlink:to="loc_us-gaap_ClassOfStockDomain_43" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_35" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_33" xlink:to="loc_us-gaap_StatementLineItems_35" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AssetsAbstract" xlink:label="loc_us-gaap_AssetsAbstract_36" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_35" xlink:to="loc_us-gaap_AssetsAbstract_36" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="loc_us-gaap_AssetsCurrentAbstract_37" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_36" xlink:to="loc_us-gaap_AssetsCurrentAbstract_37" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_44" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_37" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_44" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AccountsReceivableNetCurrent" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent_45" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_37" xlink:to="loc_us-gaap_AccountsReceivableNetCurrent_45" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OtherAssetsCurrent" xlink:label="loc_us-gaap_OtherAssetsCurrent_46" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_37" xlink:to="loc_us-gaap_OtherAssetsCurrent_46" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_InventoryNet" xlink:label="loc_us-gaap_InventoryNet_47" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_37" xlink:to="loc_us-gaap_InventoryNet_47" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AssetsCurrent" xlink:label="loc_us-gaap_AssetsCurrent_48" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_37" xlink:to="loc_us-gaap_AssetsCurrent_48" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent" xlink:label="loc_us-gaap_DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent_49" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_36" xlink:to="loc_us-gaap_DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent_49" use="optional" order="12" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_50" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_36" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_50" use="optional" order="13" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_413685" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_36" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset_413685" use="optional" order="14" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_Assets" xlink:label="loc_us-gaap_Assets_51" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_36" xlink:to="loc_us-gaap_Assets_51" use="optional" order="15" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_38" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_35" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_38" use="optional" order="16" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract_39" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_38" xlink:to="loc_us-gaap_LiabilitiesCurrentAbstract_39" use="optional" order="17" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAbstract" xlink:label="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAbstract_40" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_39" xlink:to="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAbstract_40" use="optional" order="18" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AccountsPayableTradeCurrent" xlink:label="loc_us-gaap_AccountsPayableTradeCurrent_52" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAbstract_40" xlink:to="loc_us-gaap_AccountsPayableTradeCurrent_52" use="optional" order="19" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AccountsPayableOtherCurrent" xlink:label="loc_us-gaap_AccountsPayableOtherCurrent_53" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAbstract_40" xlink:to="loc_us-gaap_AccountsPayableOtherCurrent_53" use="optional" order="20" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_413698" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAbstract_40" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrent_413698" use="optional" order="21" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ContractWithCustomerLiabilityCurrent" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityCurrent_337285" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_39" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityCurrent_337285" use="optional" order="22" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LiabilitiesCurrent" xlink:label="loc_us-gaap_LiabilitiesCurrent_56" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_39" xlink:to="loc_us-gaap_LiabilitiesCurrent_56" use="optional" order="23" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LiabilitiesNoncurrentAbstract" xlink:label="loc_us-gaap_LiabilitiesNoncurrentAbstract_41" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_38" xlink:to="loc_us-gaap_LiabilitiesNoncurrentAbstract_41" use="optional" order="24" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ConvertibleDebtNoncurrent" xlink:label="loc_us-gaap_ConvertibleDebtNoncurrent_57" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesNoncurrentAbstract_41" xlink:to="loc_us-gaap_ConvertibleDebtNoncurrent_57" use="optional" order="25" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ContractWithCustomerLiabilityNoncurrent" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent_337286" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesNoncurrentAbstract_41" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent_337286" use="optional" order="26" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PensionAndOtherPostretirementAndPostemploymentBenefitPlansLiabilitiesNoncurrent" xlink:label="loc_us-gaap_PensionAndOtherPostretirementAndPostemploymentBenefitPlansLiabilitiesNoncurrent_59" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesNoncurrentAbstract_41" xlink:to="loc_us-gaap_PensionAndOtherPostretirementAndPostemploymentBenefitPlansLiabilitiesNoncurrent_59" use="optional" order="27" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_413697" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesNoncurrentAbstract_41" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_413697" use="optional" order="28" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OtherLiabilitiesNoncurrent" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent_60" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesNoncurrentAbstract_41" xlink:to="loc_us-gaap_OtherLiabilitiesNoncurrent_60" use="optional" order="29" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LiabilitiesNoncurrent" xlink:label="loc_us-gaap_LiabilitiesNoncurrent_61" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_38" xlink:to="loc_us-gaap_LiabilitiesNoncurrent_61" use="optional" order="30" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_Liabilities" xlink:label="loc_us-gaap_Liabilities_62" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_38" xlink:to="loc_us-gaap_Liabilities_62" use="optional" order="31" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaap_StockholdersEquity_411566" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_38" xlink:to="loc_us-gaap_StockholdersEquity_411566" use="optional" order="32" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_68" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_38" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquity_68" use="optional" order="33" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.protalix.com/role/CondensedConsolidatedStatementsOfOperations">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeStatementAbstract" xlink:label="loc_us-gaap_IncomeStatementAbstract_271" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_272" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_271" xlink:to="loc_us-gaap_StatementTable_272" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_273" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_272" xlink:to="loc_us-gaap_StatementClassOfStockAxis_273" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_276" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementClassOfStockAxis_273" xlink:to="loc_us-gaap_ClassOfStockDomain_276" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_ProductOrServiceAxis" xlink:label="loc_srt_ProductOrServiceAxis_337383" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_272" xlink:to="loc_srt_ProductOrServiceAxis_337383" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_ProductsAndServicesDomain" xlink:label="loc_srt_ProductsAndServicesDomain_337384" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_337383" xlink:to="loc_srt_ProductsAndServicesDomain_337384" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ProductMember" xlink:label="loc_us-gaap_ProductMember_337385" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_337384" xlink:to="loc_us-gaap_ProductMember_337385" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LicenseAndServiceMember" xlink:label="loc_us-gaap_LicenseAndServiceMember_337386" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_337384" xlink:to="loc_us-gaap_LicenseAndServiceMember_337386" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_274" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_272" xlink:to="loc_us-gaap_StatementLineItems_274" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_Revenues" xlink:label="loc_us-gaap_Revenues_277" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_274" xlink:to="loc_us-gaap_Revenues_277" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CostOfRevenue" xlink:label="loc_us-gaap_CostOfRevenue_278" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_274" xlink:to="loc_us-gaap_CostOfRevenue_278" use="optional" order="10" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_280" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_274" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_280" use="optional" order="11" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
<loc xlink:type="locator" xlink:href="plx-20190331.xsd#plx_GrantsAndReimbursementsReceivedOrReceivable" xlink:label="loc_plx_GrantsAndReimbursementsReceivedOrReceivable_281" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_274" xlink:to="loc_plx_GrantsAndReimbursementsReceivedOrReceivable_281" use="optional" order="12" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="plx-20190331.xsd#plx_ResearchDevelopmentAndEngineeringExpenseNet" xlink:label="loc_plx_ResearchDevelopmentAndEngineeringExpenseNet_282" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_274" xlink:to="loc_plx_ResearchDevelopmentAndEngineeringExpenseNet_282" use="optional" order="13" preferredLabel="http://www.xbrl.org/2009/role/negatedTotalLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpense" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpense_283" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_274" xlink:to="loc_us-gaap_SellingGeneralAndAdministrativeExpense_283" use="optional" order="14" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:label="loc_us-gaap_OperatingIncomeLoss_284" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_274" xlink:to="loc_us-gaap_OperatingIncomeLoss_284" use="optional" order="15" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OtherNonoperatingExpense" xlink:label="loc_us-gaap_OtherNonoperatingExpense_285" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_274" xlink:to="loc_us-gaap_OtherNonoperatingExpense_285" use="optional" order="16" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OtherNonoperatingIncome" xlink:label="loc_us-gaap_OtherNonoperatingIncome_286" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_274" xlink:to="loc_us-gaap_OtherNonoperatingIncome_286" use="optional" order="17" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NonoperatingIncomeExpense" xlink:label="loc_us-gaap_NonoperatingIncomeExpense_289" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_274" xlink:to="loc_us-gaap_NonoperatingIncomeExpense_289" use="optional" order="18" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss_292" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_274" xlink:to="loc_us-gaap_NetIncomeLoss_292" use="optional" order="19" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EarningsPerShareBasicAndDiluted" xlink:label="loc_us-gaap_EarningsPerShareBasicAndDiluted_411589" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_274" xlink:to="loc_us-gaap_EarningsPerShareBasicAndDiluted_411589" use="optional" order="20" preferredLabel="http://www.xbrl.org/2003/role/definitionGuidance" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:label="loc_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_296" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_274" xlink:to="loc_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_296" use="optional" order="21" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.protalix.com/role/CondensedConsolidatedStatementsOfOperationsParenthetical">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeStatementAbstract" xlink:label="loc_us-gaap_IncomeStatementAbstract_411762" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_411764" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_411762" xlink:to="loc_us-gaap_StatementTable_411764" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_411769" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_411764" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_411769" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_411770" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_411769" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_411770" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember_411772" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_411770" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseMember_411772" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpensesMember" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember_411775" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_411770" xlink:to="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember_411775" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_411782" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_411764" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_411782" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_411784" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_411782" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_411784" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.protalix.com/role/CondensedConsolidatedStatementsOfChangesInCapitalDeficiency">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementOfStockholdersEquityAbstract" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract_676" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_677" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract_676" xlink:to="loc_us-gaap_StatementTable_677" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_678" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_677" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_678" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain_679" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_678" xlink:to="loc_us-gaap_EquityComponentDomain_679" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaap_CommonStockMember_681" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_679" xlink:to="loc_us-gaap_CommonStockMember_681" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember_682" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_679" xlink:to="loc_us-gaap_AdditionalPaidInCapitalMember_682" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RetainedEarningsMember" xlink:label="loc_us-gaap_RetainedEarningsMember_683" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_679" xlink:to="loc_us-gaap_RetainedEarningsMember_683" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_680" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_677" xlink:to="loc_us-gaap_StatementLineItems_680" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaap_StockholdersEquity_684" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_680" xlink:to="loc_us-gaap_StockholdersEquity_684" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SharesOutstanding" xlink:label="loc_us-gaap_SharesOutstanding_685" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_680" xlink:to="loc_us-gaap_SharesOutstanding_685" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_689" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_680" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_689" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="plx-20190331.xsd#plx_ShareBasedCompensationRestrictedStockAwardsNetOfForfeitures" xlink:label="loc_plx_ShareBasedCompensationRestrictedStockAwardsNetOfForfeitures_690" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_680" xlink:to="loc_plx_ShareBasedCompensationRestrictedStockAwardsNetOfForfeitures_690" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="plx-20190331.xsd#plx_ShareBasedCompensationRestrictedStockAwardsNetOfForfeituresShares" xlink:label="loc_plx_ShareBasedCompensationRestrictedStockAwardsNetOfForfeituresShares_691" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_680" xlink:to="loc_plx_ShareBasedCompensationRestrictedStockAwardsNetOfForfeituresShares_691" use="optional" order="12" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_693" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_680" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_693" use="optional" order="13" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_337394" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_680" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_337394" use="optional" order="14" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss_337393" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_680" xlink:to="loc_us-gaap_NetIncomeLoss_337393" use="optional" order="15" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaap_StockholdersEquity_699" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_680" xlink:to="loc_us-gaap_StockholdersEquity_699" use="optional" order="16" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SharesOutstanding" xlink:label="loc_us-gaap_SharesOutstanding_700" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_680" xlink:to="loc_us-gaap_SharesOutstanding_700" use="optional" order="17" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.protalix.com/role/CondensedConsolidatedStatementsOfChangesInCapitalDeficiencyParenthetical">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementOfStockholdersEquityAbstract" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract_738" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_739" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract_738" xlink:to="loc_us-gaap_StatementTable_739" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaap_AwardTypeAxis_740" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_739" xlink:to="loc_us-gaap_AwardTypeAxis_740" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_741" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_740" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_741" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_742" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_739" xlink:to="loc_us-gaap_StatementLineItems_742" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare_411858" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_742" xlink:to="loc_us-gaap_CommonStockParOrStatedValuePerShare_411858" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="loc_us-gaap_CommonStockSharesAuthorized_411859" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_742" xlink:to="loc_us-gaap_CommonStockSharesAuthorized_411859" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/label" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.protalix.com/role/CondensedConsolidatedStatementsOfCashFlows">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="loc_us-gaap_StatementOfCashFlowsAbstract_746" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_747" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_746" xlink:to="loc_us-gaap_StatementTable_747" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_748" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_747" xlink:to="loc_us-gaap_StatementClassOfStockAxis_748" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_757" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementClassOfStockAxis_748" xlink:to="loc_us-gaap_ClassOfStockDomain_757" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_749" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_747" xlink:to="loc_us-gaap_StatementLineItems_749" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_750" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_749" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_750" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss_758" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_750" xlink:to="loc_us-gaap_NetIncomeLoss_758" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_751" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_750" xlink:to="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_751" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:label="loc_us-gaap_ShareBasedCompensation_761" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_751" xlink:to="loc_us-gaap_ShareBasedCompensation_761" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_Depreciation" xlink:label="loc_us-gaap_Depreciation_762" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_751" xlink:to="loc_us-gaap_Depreciation_762" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ForeignCurrencyTransactionGainLossUnrealized" xlink:label="loc_us-gaap_ForeignCurrencyTransactionGainLossUnrealized_763" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_751" xlink:to="loc_us-gaap_ForeignCurrencyTransactionGainLossUnrealized_763" use="optional" order="10" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PensionAndOtherPostretirementBenefitExpense" xlink:label="loc_us-gaap_PensionAndOtherPostretirementBenefitExpense_764" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_751" xlink:to="loc_us-gaap_PensionAndOtherPostretirementBenefitExpense_764" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="plx-20190331.xsd#plx_GainLossOnAmountsFundedInRespectOfEmployeeRightsUponRetirement" xlink:label="loc_plx_GainLossOnAmountsFundedInRespectOfEmployeeRightsUponRetirement_765" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_751" xlink:to="loc_plx_GainLossOnAmountsFundedInRespectOfEmployeeRightsUponRetirement_765" use="optional" order="12" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:label="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_767" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_751" xlink:to="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_767" use="optional" order="13" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AmortizationOfFinancingCosts" xlink:label="loc_us-gaap_AmortizationOfFinancingCosts_770" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_751" xlink:to="loc_us-gaap_AmortizationOfFinancingCosts_770" use="optional" order="14" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="plx-20190331.xsd#plx_IssuanceOfSharesForInterestPaymentRegardingConversionOfConvertibleNotes" xlink:label="loc_plx_IssuanceOfSharesForInterestPaymentRegardingConversionOfConvertibleNotes_771" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_751" xlink:to="loc_plx_IssuanceOfSharesForInterestPaymentRegardingConversionOfConvertibleNotes_771" use="optional" order="15" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_752" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_751" xlink:to="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_752" use="optional" order="16" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:label="loc_us-gaap_IncreaseDecreaseInContractWithCustomerLiability_337371" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_752" xlink:to="loc_us-gaap_IncreaseDecreaseInContractWithCustomerLiability_337371" use="optional" order="17" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_773" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_752" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_773" use="optional" order="18" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
<loc xlink:type="locator" xlink:href="plx-20190331.xsd#plx_ChangeInOperatingLeaseRightOfUseAssets" xlink:label="loc_plx_ChangeInOperatingLeaseRightOfUseAssets_413883" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_752" xlink:to="loc_plx_ChangeInOperatingLeaseRightOfUseAssets_413883" use="optional" order="19" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncreaseDecreaseInInventories" xlink:label="loc_us-gaap_IncreaseDecreaseInInventories_774" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_752" xlink:to="loc_us-gaap_IncreaseDecreaseInInventories_774" use="optional" order="20" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_775" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_752" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_775" use="optional" order="21" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities_776" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_752" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities_776" use="optional" order="22" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_779" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_750" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_779" use="optional" order="23" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_753" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_749" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_753" use="optional" order="24" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_780" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_753" xlink:to="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_780" use="optional" order="25" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncreaseDecreaseInRestrictedCash" xlink:label="loc_us-gaap_IncreaseDecreaseInRestrictedCash_782" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_753" xlink:to="loc_us-gaap_IncreaseDecreaseInRestrictedCash_782" use="optional" order="26" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PaymentsForProceedsFromOtherInvestingActivities" xlink:label="loc_us-gaap_PaymentsForProceedsFromOtherInvestingActivities_783" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_753" xlink:to="loc_us-gaap_PaymentsForProceedsFromOtherInvestingActivities_783" use="optional" order="27" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_341648" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_753" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_341648" use="optional" order="28" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents" xlink:label="loc_us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents_792" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_749" xlink:to="loc_us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents_792" use="optional" order="29" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" xlink:label="loc_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease_793" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_749" xlink:to="loc_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease_793" use="optional" order="30" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_794" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_749" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_794" use="optional" order="31" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_795" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_749" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_795" use="optional" order="32" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:label="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_755" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_749" xlink:to="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_755" use="optional" order="33" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="plx-20190331.xsd#plx_IncreaseInLiabilitiesForPropertyPlantAndEquipment" xlink:label="loc_plx_IncreaseInLiabilitiesForPropertyPlantAndEquipment_796" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_755" xlink:to="loc_plx_IncreaseInLiabilitiesForPropertyPlantAndEquipment_796" use="optional" order="34" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DebtConversionConvertedInstrumentAmount1" xlink:label="loc_us-gaap_DebtConversionConvertedInstrumentAmount1_799" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_755" xlink:to="loc_us-gaap_DebtConversionConvertedInstrumentAmount1_799" use="optional" order="35" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SupplementalCashFlowInformationAbstract" xlink:label="loc_us-gaap_SupplementalCashFlowInformationAbstract_756" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_749" xlink:to="loc_us-gaap_SupplementalCashFlowInformationAbstract_756" use="optional" order="36" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_InterestPaidNet" xlink:label="loc_us-gaap_InterestPaidNet_800" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SupplementalCashFlowInformationAbstract_756" xlink:to="loc_us-gaap_InterestPaidNet_800" use="optional" order="37" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.protalix.com/role/SignificantAccountingPolicies">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_802" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock" xlink:label="loc_us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock_803" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_802" xlink:to="loc_us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock_803" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.protalix.com/role/Inventories">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_InventoryDisclosureAbstract" xlink:label="loc_us-gaap_InventoryDisclosureAbstract_8" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_InventoryDisclosureTextBlock" xlink:label="loc_us-gaap_InventoryDisclosureTextBlock_9" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryDisclosureAbstract_8" xlink:to="loc_us-gaap_InventoryDisclosureTextBlock_9" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.protalix.com/role/FairValueMeasurement">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_23" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueDisclosuresTextBlock" xlink:label="loc_us-gaap_FairValueDisclosuresTextBlock_24" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_23" xlink:to="loc_us-gaap_FairValueDisclosuresTextBlock_24" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.protalix.com/role/OperatingLeases">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LeasesOperatingAbstract" xlink:label="loc_us-gaap_LeasesOperatingAbstract_413802" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LesseeOperatingLeasesTextBlock" xlink:label="loc_us-gaap_LesseeOperatingLeasesTextBlock_413803" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesOperatingAbstract_413802" xlink:to="loc_us-gaap_LesseeOperatingLeasesTextBlock_413803" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.protalix.com/role/Revenues">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeStatementAbstract" xlink:label="loc_us-gaap_IncomeStatementAbstract_411871" />
<loc xlink:type="locator" xlink:href="plx-20190331.xsd#plx_RevenueDisclosureTextBlock" xlink:label="loc_plx_RevenueDisclosureTextBlock_411872" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_411871" xlink:to="loc_plx_RevenueDisclosureTextBlock_411872" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.protalix.com/role/SubsequentEvents">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SubsequentEventsAbstract" xlink:label="loc_us-gaap_SubsequentEventsAbstract_349978" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SubsequentEventsTextBlock" xlink:label="loc_us-gaap_SubsequentEventsTextBlock_349979" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventsAbstract_349978" xlink:to="loc_us-gaap_SubsequentEventsTextBlock_349979" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.protalix.com/role/SignificantAccountingPoliciesPolicies">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_76" />
<loc xlink:type="locator" xlink:href="plx-20190331.xsd#plx_NatureOfOperationsPolicyTextBlock" xlink:label="loc_plx_NatureOfOperationsPolicyTextBlock_77" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_76" xlink:to="loc_plx_NatureOfOperationsPolicyTextBlock_77" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:label="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_78" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_76" xlink:to="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_78" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EarningsPerSharePolicyTextBlock" xlink:label="loc_us-gaap_EarningsPerSharePolicyTextBlock_90" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_76" xlink:to="loc_us-gaap_EarningsPerSharePolicyTextBlock_90" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="plx-20190331.xsd#plx_RecentlyAdoptedStandardsPolicyTextBlockPolicyTextBlock" xlink:label="loc_plx_RecentlyAdoptedStandardsPolicyTextBlockPolicyTextBlock_92" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_76" xlink:to="loc_plx_RecentlyAdoptedStandardsPolicyTextBlockPolicyTextBlock_92" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:label="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_93" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_76" xlink:to="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_93" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.protalix.com/role/InventoriesTables">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_InventoryDisclosureAbstract" xlink:label="loc_us-gaap_InventoryDisclosureAbstract_101" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfInventoryCurrentTableTextBlock_102" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryDisclosureAbstract_101" xlink:to="loc_us-gaap_ScheduleOfInventoryCurrentTableTextBlock_102" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.protalix.com/role/FairValueMeasurementTables">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_129" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_341434" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_129" xlink:to="loc_us-gaap_StatementTable_341434" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DebtInstrumentAxis" xlink:label="loc_us-gaap_DebtInstrumentAxis_341439" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_341434" xlink:to="loc_us-gaap_DebtInstrumentAxis_341439" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_341440" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentAxis_341439" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_341440" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="plx-20190331.xsd#plx_Notes2021Member" xlink:label="loc_plx_Notes2021Member_341443" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_341440" xlink:to="loc_plx_Notes2021Member_341443" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_341437" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_341434" xlink:to="loc_us-gaap_StatementLineItems_341437" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock_341438" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_341437" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock_341438" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.protalix.com/role/OperatingLeasesTables">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LeasesOperatingAbstract" xlink:label="loc_us-gaap_LeasesOperatingAbstract_413805" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LeaseCostTableTextBlock" xlink:label="loc_us-gaap_LeaseCostTableTextBlock_413807" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesOperatingAbstract_413805" xlink:to="loc_us-gaap_LeaseCostTableTextBlock_413807" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_413808" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesOperatingAbstract_413805" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_413808" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.protalix.com/role/RevenuesTables">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeStatementAbstract" xlink:label="loc_us-gaap_IncomeStatementAbstract_411881" />
<loc xlink:type="locator" xlink:href="plx-20190331.xsd#plx_SupplementaryIncomeStatementInformationTableTextBlock" xlink:label="loc_plx_SupplementaryIncomeStatementInformationTableTextBlock_411884" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_411881" xlink:to="loc_plx_SupplementaryIncomeStatementInformationTableTextBlock_411884" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock" xlink:label="loc_us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock_417536" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_411881" xlink:to="loc_us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock_417536" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="plx-20190331.xsd#plx_RevenueRemainingPerformanceObligationAmountTableTextBlock" xlink:label="loc_plx_RevenueRemainingPerformanceObligationAmountTableTextBlock_417537" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_411881" xlink:to="loc_plx_RevenueRemainingPerformanceObligationAmountTableTextBlock_417537" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.protalix.com/role/SignificantAccountingPoliciesNarrativeDetails">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_177" />
<loc xlink:type="locator" xlink:href="plx-20190331.xsd#plx_SignificantAccountingPoliciesTable" xlink:label="loc_plx_SignificantAccountingPoliciesTable_178" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_177" xlink:to="loc_plx_SignificantAccountingPoliciesTable_178" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaap_TypeOfArrangementAxis_180" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_plx_SignificantAccountingPoliciesTable_178" xlink:to="loc_us-gaap_TypeOfArrangementAxis_180" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_181" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfArrangementAxis_180" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_181" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="plx-20190331.xsd#plx_AmendedPfizerAgreementMember" xlink:label="loc_plx_AmendedPfizerAgreementMember_195" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_181" xlink:to="loc_plx_AmendedPfizerAgreementMember_195" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="plx-20190331.xsd#plx_ChiesiUSAgreementMember" xlink:label="loc_plx_ChiesiUSAgreementMember_196" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_181" xlink:to="loc_plx_ChiesiUSAgreementMember_196" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="plx-20190331.xsd#plx_ChiesiExUSAgreementMember" xlink:label="loc_plx_ChiesiExUSAgreementMember_337391" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_181" xlink:to="loc_plx_ChiesiExUSAgreementMember_337391" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_182" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_plx_SignificantAccountingPoliciesTable_178" xlink:to="loc_dei_LegalEntityAxis_182" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_183" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_LegalEntityAxis_182" xlink:to="loc_dei_EntityDomain_183" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="plx-20190331.xsd#plx_ProtalixBioTherapeuticsIncorporationMember" xlink:label="loc_plx_ProtalixBioTherapeuticsIncorporationMember_197" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityDomain_183" xlink:to="loc_plx_ProtalixBioTherapeuticsIncorporationMember_197" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_StatementGeographicalAxis" xlink:label="loc_srt_StatementGeographicalAxis_185" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_plx_SignificantAccountingPoliciesTable_178" xlink:to="loc_srt_StatementGeographicalAxis_185" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_SegmentGeographicalDomain" xlink:label="loc_srt_SegmentGeographicalDomain_186" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_StatementGeographicalAxis_185" xlink:to="loc_srt_SegmentGeographicalDomain_186" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/country/2017/country-2017-01-31.xsd#country_BR" xlink:label="loc_country_BR_199" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_186" xlink:to="loc_country_BR_199" use="optional" order="12" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_RangeAxis" xlink:label="loc_srt_RangeAxis_190" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_plx_SignificantAccountingPoliciesTable_178" xlink:to="loc_srt_RangeAxis_190" use="optional" order="13" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_RangeMember" xlink:label="loc_srt_RangeMember_191" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_190" xlink:to="loc_srt_RangeMember_191" use="optional" order="14" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_MinimumMember" xlink:label="loc_srt_MinimumMember_203" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_191" xlink:to="loc_srt_MinimumMember_203" use="optional" order="15" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_MaximumMember" xlink:label="loc_srt_MaximumMember_204" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_191" xlink:to="loc_srt_MaximumMember_204" use="optional" order="16" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DebtInstrumentAxis" xlink:label="loc_us-gaap_DebtInstrumentAxis_337415" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_plx_SignificantAccountingPoliciesTable_178" xlink:to="loc_us-gaap_DebtInstrumentAxis_337415" use="optional" order="17" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_337416" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentAxis_337415" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_337416" use="optional" order="18" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_RestatementAxis" xlink:label="loc_srt_RestatementAxis_344221" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_plx_SignificantAccountingPoliciesTable_178" xlink:to="loc_srt_RestatementAxis_344221" use="optional" order="19" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_RestatementDomain" xlink:label="loc_srt_RestatementDomain_344222" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RestatementAxis_344221" xlink:to="loc_srt_RestatementDomain_344222" use="optional" order="20" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:label="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_344230" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_plx_SignificantAccountingPoliciesTable_178" xlink:to="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_344230" use="optional" order="21" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_TypeOfAdoptionMember" xlink:label="loc_us-gaap_TypeOfAdoptionMember_344231" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_344230" xlink:to="loc_us-gaap_TypeOfAdoptionMember_344231" use="optional" order="22" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="plx-20190331.xsd#plx_SignificantAccountingPoliciesLineItems" xlink:label="loc_plx_SignificantAccountingPoliciesLineItems_192" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_plx_SignificantAccountingPoliciesTable_178" xlink:to="loc_plx_SignificantAccountingPoliciesLineItems_192" use="optional" order="23" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare_206" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_plx_SignificantAccountingPoliciesLineItems_192" xlink:to="loc_us-gaap_CommonStockParOrStatedValuePerShare_206" use="optional" order="24" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_207" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_plx_SignificantAccountingPoliciesLineItems_192" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_207" use="optional" order="25" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="plx-20190331.xsd#plx_CollaborativeArrangementRevenuesExpensesSharingPercentage" xlink:label="loc_plx_CollaborativeArrangementRevenuesExpensesSharingPercentage_208" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_plx_SignificantAccountingPoliciesLineItems_192" xlink:to="loc_plx_CollaborativeArrangementRevenuesExpensesSharingPercentage_208" use="optional" order="26" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="plx-20190331.xsd#plx_UpfrontNonrefundableNoncreditablePaymentReceivable" xlink:label="loc_plx_UpfrontNonrefundableNoncreditablePaymentReceivable_212" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_plx_SignificantAccountingPoliciesLineItems_192" xlink:to="loc_plx_UpfrontNonrefundableNoncreditablePaymentReceivable_212" use="optional" order="27" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="plx-20190331.xsd#plx_AdditionalAmountsPayableToCoverDevelopmentCosts" xlink:label="loc_plx_AdditionalAmountsPayableToCoverDevelopmentCosts_213" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_plx_SignificantAccountingPoliciesLineItems_192" xlink:to="loc_plx_AdditionalAmountsPayableToCoverDevelopmentCosts_213" use="optional" order="28" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="plx-20190331.xsd#plx_MaximumEntitlementOfDevelopmentCostsToCoverPerYear" xlink:label="loc_plx_MaximumEntitlementOfDevelopmentCostsToCoverPerYear_214" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_plx_SignificantAccountingPoliciesLineItems_192" xlink:to="loc_plx_MaximumEntitlementOfDevelopmentCostsToCoverPerYear_214" use="optional" order="29" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="plx-20190331.xsd#plx_AdditionalAmountpayableForAchievementOfRegulatoryAndCommercialMilestones" xlink:label="loc_plx_AdditionalAmountpayableForAchievementOfRegulatoryAndCommercialMilestones_215" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_plx_SignificantAccountingPoliciesLineItems_192" xlink:to="loc_plx_AdditionalAmountpayableForAchievementOfRegulatoryAndCommercialMilestones_215" use="optional" order="30" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="plx-20190331.xsd#plx_PaymentOnNetSalesPercentage" xlink:label="loc_plx_PaymentOnNetSalesPercentage_216" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_plx_SignificantAccountingPoliciesLineItems_192" xlink:to="loc_plx_PaymentOnNetSalesPercentage_216" use="optional" order="31" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_417529" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_plx_SignificantAccountingPoliciesLineItems_192" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset_417529" use="optional" order="32" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OperatingLeaseLiability" xlink:label="loc_us-gaap_OperatingLeaseLiability_417530" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_plx_SignificantAccountingPoliciesLineItems_192" xlink:to="loc_us-gaap_OperatingLeaseLiability_417530" use="optional" order="33" preferredLabel="http://www.xbrl.org/2003/role/label" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.protalix.com/role/InventoriesDetails">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_InventoryDisclosureAbstract" xlink:label="loc_us-gaap_InventoryDisclosureAbstract_261" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_262" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryDisclosureAbstract_261" xlink:to="loc_us-gaap_StatementTable_262" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_263" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_262" xlink:to="loc_us-gaap_StatementClassOfStockAxis_263" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_265" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementClassOfStockAxis_263" xlink:to="loc_us-gaap_ClassOfStockDomain_265" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_264" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_262" xlink:to="loc_us-gaap_StatementLineItems_264" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_InventoryRawMaterialsNetOfReserves" xlink:label="loc_us-gaap_InventoryRawMaterialsNetOfReserves_266" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_264" xlink:to="loc_us-gaap_InventoryRawMaterialsNetOfReserves_266" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_InventoryWorkInProcessNetOfReserves" xlink:label="loc_us-gaap_InventoryWorkInProcessNetOfReserves_267" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_264" xlink:to="loc_us-gaap_InventoryWorkInProcessNetOfReserves_267" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_InventoryFinishedGoodsNetOfReserves" xlink:label="loc_us-gaap_InventoryFinishedGoodsNetOfReserves_268" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_264" xlink:to="loc_us-gaap_InventoryFinishedGoodsNetOfReserves_268" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_InventoryNet" xlink:label="loc_us-gaap_InventoryNet_269" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_264" xlink:to="loc_us-gaap_InventoryNet_269" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.protalix.com/role/InventoriesDetailsTextual">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_InventoryDisclosureAbstract" xlink:label="loc_us-gaap_InventoryDisclosureAbstract_353300" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_353302" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryDisclosureAbstract_353300" xlink:to="loc_us-gaap_StatementTable_353302" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_353303" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_353302" xlink:to="loc_us-gaap_StatementClassOfStockAxis_353303" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_353304" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementClassOfStockAxis_353303" xlink:to="loc_us-gaap_ClassOfStockDomain_353304" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_353305" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_353302" xlink:to="loc_us-gaap_StatementLineItems_353305" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_InventoryWriteDown" xlink:label="loc_us-gaap_InventoryWriteDown_353306" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_353305" xlink:to="loc_us-gaap_InventoryWriteDown_353306" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/label" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.protalix.com/role/FairValueMeasurementTheLiabilityComponentWasValuedBasedOnTheIncomeApproachDetails">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_566" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_567" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_566" xlink:to="loc_us-gaap_StatementTable_567" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_568" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_567" xlink:to="loc_us-gaap_StatementClassOfStockAxis_568" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_574" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementClassOfStockAxis_568" xlink:to="loc_us-gaap_ClassOfStockDomain_574" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DebtInstrumentAxis" xlink:label="loc_us-gaap_DebtInstrumentAxis_569" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_567" xlink:to="loc_us-gaap_DebtInstrumentAxis_569" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_570" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentAxis_569" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_570" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="plx-20190331.xsd#plx_SevenPointFivePercentageConvertibleNotesMember" xlink:label="loc_plx_SevenPointFivePercentageConvertibleNotesMember_576" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_570" xlink:to="loc_plx_SevenPointFivePercentageConvertibleNotesMember_576" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_571" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_567" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_571" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_572" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_571" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_572" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueInputsLevel3Member" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_577" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_572" xlink:to="loc_us-gaap_FairValueInputsLevel3Member_577" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_MeasurementInputTypeAxis" xlink:label="loc_us-gaap_MeasurementInputTypeAxis_337297" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_567" xlink:to="loc_us-gaap_MeasurementInputTypeAxis_337297" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_MeasurementInputTypeDomain" xlink:label="loc_us-gaap_MeasurementInputTypeDomain_337298" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MeasurementInputTypeAxis_337297" xlink:to="loc_us-gaap_MeasurementInputTypeDomain_337298" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_573" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_567" xlink:to="loc_us-gaap_StatementLineItems_573" use="optional" order="12" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SharePrice" xlink:label="loc_us-gaap_SharePrice_578" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_573" xlink:to="loc_us-gaap_SharePrice_578" use="optional" order="13" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="plx-20190331.xsd#plx_FairValueAssumptionsTerm" xlink:label="loc_plx_FairValueAssumptionsTerm_339502" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_573" xlink:to="loc_plx_FairValueAssumptionsTerm_339502" use="optional" order="14" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="plx-20190331.xsd#plx_FairValueAssumptionsRiskFreeInterestRates" xlink:label="loc_plx_FairValueAssumptionsRiskFreeInterestRates_339504" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_573" xlink:to="loc_plx_FairValueAssumptionsRiskFreeInterestRates_339504" use="optional" order="15" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="plx-20190331.xsd#plx_FairValueAssumptionsExpectedVolatilityRates" xlink:label="loc_plx_FairValueAssumptionsExpectedVolatilityRates_339505" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_573" xlink:to="loc_plx_FairValueAssumptionsExpectedVolatilityRates_339505" use="optional" order="16" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="plx-20190331.xsd#plx_FairValueAssumptionsExpectedDividendRates" xlink:label="loc_plx_FairValueAssumptionsExpectedDividendRates_339511" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_573" xlink:to="loc_plx_FairValueAssumptionsExpectedDividendRates_339511" use="optional" order="17" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.protalix.com/role/FairValueMeasurementNarrativeDetails">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_584" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_585" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_584" xlink:to="loc_us-gaap_StatementTable_585" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_586" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_585" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_586" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_587" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_586" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_587" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueInputsLevel3Member" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_592" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_587" xlink:to="loc_us-gaap_FairValueInputsLevel3Member_592" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DebtInstrumentAxis" xlink:label="loc_us-gaap_DebtInstrumentAxis_588" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_585" xlink:to="loc_us-gaap_DebtInstrumentAxis_588" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_589" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentAxis_588" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_589" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="plx-20190331.xsd#plx_SevenPointFivePercentageConvertibleNoteMember" xlink:label="loc_plx_SevenPointFivePercentageConvertibleNoteMember_594" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_589" xlink:to="loc_plx_SevenPointFivePercentageConvertibleNoteMember_594" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="plx-20190331.xsd#plx_SevenPointFivePercentageConvertibleNotes2021Member" xlink:label="loc_plx_SevenPointFivePercentageConvertibleNotes2021Member_415034" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_589" xlink:to="loc_plx_SevenPointFivePercentageConvertibleNotes2021Member_415034" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DebtInstrumentRedemptionPeriodAxis" xlink:label="loc_us-gaap_DebtInstrumentRedemptionPeriodAxis_590" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_585" xlink:to="loc_us-gaap_DebtInstrumentRedemptionPeriodAxis_590" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DebtInstrumentRedemptionPeriodDomain" xlink:label="loc_us-gaap_DebtInstrumentRedemptionPeriodDomain_597" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentRedemptionPeriodAxis_590" xlink:to="loc_us-gaap_DebtInstrumentRedemptionPeriodDomain_597" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_591" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_585" xlink:to="loc_us-gaap_StatementLineItems_591" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ConvertibleDebtFairValueDisclosures" xlink:label="loc_us-gaap_ConvertibleDebtFairValueDisclosures_598" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_591" xlink:to="loc_us-gaap_ConvertibleDebtFairValueDisclosures_598" use="optional" order="12" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DebtInstrumentFaceAmount" xlink:label="loc_us-gaap_DebtInstrumentFaceAmount_599" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_591" xlink:to="loc_us-gaap_DebtInstrumentFaceAmount_599" use="optional" order="13" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_413952" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_591" xlink:to="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_413952" use="optional" order="14" preferredLabel="http://www.xbrl.org/2003/role/label" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.protalix.com/role/OperatingLeasesLeaseCostDetails">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LeasesOperatingAbstract" xlink:label="loc_us-gaap_LeasesOperatingAbstract_413817" />
<loc xlink:type="locator" xlink:href="plx-20190331.xsd#plx_DisclosureOfLeasesOperatingTable" xlink:label="loc_plx_DisclosureOfLeasesOperatingTable_413818" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesOperatingAbstract_413817" xlink:to="loc_plx_DisclosureOfLeasesOperatingTable_413818" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_413980" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_plx_DisclosureOfLeasesOperatingTable_413818" xlink:to="loc_us-gaap_StatementClassOfStockAxis_413980" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_413981" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementClassOfStockAxis_413980" xlink:to="loc_us-gaap_ClassOfStockDomain_413981" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="plx-20190331.xsd#plx_DisclosureOfLeasesOperatingLineItems" xlink:label="loc_plx_DisclosureOfLeasesOperatingLineItems_413819" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_plx_DisclosureOfLeasesOperatingTable_413818" xlink:to="loc_plx_DisclosureOfLeasesOperatingLineItems_413819" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OperatingLeaseCost" xlink:label="loc_us-gaap_OperatingLeaseCost_413820" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_plx_DisclosureOfLeasesOperatingLineItems_413819" xlink:to="loc_us-gaap_OperatingLeaseCost_413820" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OperatingLeasePayments" xlink:label="loc_us-gaap_OperatingLeasePayments_413821" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_plx_DisclosureOfLeasesOperatingLineItems_413819" xlink:to="loc_us-gaap_OperatingLeasePayments_413821" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:label="loc_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_413822" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_plx_DisclosureOfLeasesOperatingLineItems_413819" xlink:to="loc_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_413822" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_413823" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_plx_DisclosureOfLeasesOperatingLineItems_413819" xlink:to="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_413823" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_413824" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_plx_DisclosureOfLeasesOperatingLineItems_413819" xlink:to="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_413824" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.protalix.com/role/OperatingLeasesLesseeOperatingLeaseLiabilityMaturityDetails">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LeasesOperatingAbstract" xlink:label="loc_us-gaap_LeasesOperatingAbstract_413830" />
<loc xlink:type="locator" xlink:href="plx-20190331.xsd#plx_DisclosureOfLeasesOperatingTable" xlink:label="loc_plx_DisclosureOfLeasesOperatingTable_413832" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesOperatingAbstract_413830" xlink:to="loc_plx_DisclosureOfLeasesOperatingTable_413832" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_413982" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_plx_DisclosureOfLeasesOperatingTable_413832" xlink:to="loc_us-gaap_StatementClassOfStockAxis_413982" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_413983" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementClassOfStockAxis_413982" xlink:to="loc_us-gaap_ClassOfStockDomain_413983" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="plx-20190331.xsd#plx_DisclosureOfLeasesOperatingLineItems" xlink:label="loc_plx_DisclosureOfLeasesOperatingLineItems_413833" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_plx_DisclosureOfLeasesOperatingTable_413832" xlink:to="loc_plx_DisclosureOfLeasesOperatingLineItems_413833" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_413841" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_plx_DisclosureOfLeasesOperatingLineItems_413833" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_413841" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_413842" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_plx_DisclosureOfLeasesOperatingLineItems_413833" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_413842" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_413844" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_plx_DisclosureOfLeasesOperatingLineItems_413833" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_413844" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_413845" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_plx_DisclosureOfLeasesOperatingLineItems_413833" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_413845" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_413846" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_plx_DisclosureOfLeasesOperatingLineItems_413833" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_413846" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_413847" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_plx_DisclosureOfLeasesOperatingLineItems_413833" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_413847" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_413848" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_plx_DisclosureOfLeasesOperatingLineItems_413833" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_413848" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_413850" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_plx_DisclosureOfLeasesOperatingLineItems_413833" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_413850" use="optional" order="12" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OperatingLeaseLiability" xlink:label="loc_us-gaap_OperatingLeaseLiability_413851" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_plx_DisclosureOfLeasesOperatingLineItems_413833" xlink:to="loc_us-gaap_OperatingLeaseLiability_413851" use="optional" order="13" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.protalix.com/role/OperatingLeasesNarrativeDetails">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LeasesOperatingAbstract" xlink:label="loc_us-gaap_LeasesOperatingAbstract_413854" />
<loc xlink:type="locator" xlink:href="plx-20190331.xsd#plx_DisclosureOfLeasesOperatingTable" xlink:label="loc_plx_DisclosureOfLeasesOperatingTable_413855" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesOperatingAbstract_413854" xlink:to="loc_plx_DisclosureOfLeasesOperatingTable_413855" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="plx-20190331.xsd#plx_CommitmentsAndContingenciesAxis" xlink:label="loc_plx_CommitmentsAndContingenciesAxis_413858" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_plx_DisclosureOfLeasesOperatingTable_413855" xlink:to="loc_plx_CommitmentsAndContingenciesAxis_413858" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="plx-20190331.xsd#plx_CommitmentsAndContingenciesDomain" xlink:label="loc_plx_CommitmentsAndContingenciesDomain_413859" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_plx_CommitmentsAndContingenciesAxis_413858" xlink:to="loc_plx_CommitmentsAndContingenciesDomain_413859" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="plx-20190331.xsd#plx_VehicleLeaseAndMaintenanceAgreementsMember" xlink:label="loc_plx_VehicleLeaseAndMaintenanceAgreementsMember_413860" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_plx_CommitmentsAndContingenciesDomain_413859" xlink:to="loc_plx_VehicleLeaseAndMaintenanceAgreementsMember_413860" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LeaseAgreementsMember" xlink:label="loc_us-gaap_LeaseAgreementsMember_413861" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_plx_CommitmentsAndContingenciesDomain_413859" xlink:to="loc_us-gaap_LeaseAgreementsMember_413861" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_RangeAxis" xlink:label="loc_srt_RangeAxis_417532" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_plx_DisclosureOfLeasesOperatingTable_413855" xlink:to="loc_srt_RangeAxis_417532" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_RangeMember" xlink:label="loc_srt_RangeMember_417533" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_417532" xlink:to="loc_srt_RangeMember_417533" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_MinimumMember" xlink:label="loc_srt_MinimumMember_417534" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_417533" xlink:to="loc_srt_MinimumMember_417534" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_MaximumMember" xlink:label="loc_srt_MaximumMember_417535" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_417533" xlink:to="loc_srt_MaximumMember_417535" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="plx-20190331.xsd#plx_DisclosureOfLeasesOperatingLineItems" xlink:label="loc_plx_DisclosureOfLeasesOperatingLineItems_413856" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_plx_DisclosureOfLeasesOperatingTable_413855" xlink:to="loc_plx_DisclosureOfLeasesOperatingLineItems_413856" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent" xlink:label="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent_413863" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_plx_DisclosureOfLeasesOperatingLineItems_413856" xlink:to="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent_413863" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears" xlink:label="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears_413864" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_plx_DisclosureOfLeasesOperatingLineItems_413856" xlink:to="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears_413864" use="optional" order="12" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears" xlink:label="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears_413865" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_plx_DisclosureOfLeasesOperatingLineItems_413856" xlink:to="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears_413865" use="optional" order="13" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SecurityDeposit" xlink:label="loc_us-gaap_SecurityDeposit_413876" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_plx_DisclosureOfLeasesOperatingLineItems_413856" xlink:to="loc_us-gaap_SecurityDeposit_413876" use="optional" order="14" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="plx-20190331.xsd#plx_PercentageOfChangeInOperatingLeaseMonthlyRentalPayments" xlink:label="loc_plx_PercentageOfChangeInOperatingLeaseMonthlyRentalPayments_417531" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_plx_DisclosureOfLeasesOperatingLineItems_413856" xlink:to="loc_plx_PercentageOfChangeInOperatingLeaseMonthlyRentalPayments_417531" use="optional" order="15" preferredLabel="http://www.xbrl.org/2003/role/label" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.protalix.com/role/RevenuesStatementsOfOperationsDetails">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeStatementAbstract" xlink:label="loc_us-gaap_IncomeStatementAbstract_411886" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_411887" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_411886" xlink:to="loc_us-gaap_StatementTable_411887" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_ProductOrServiceAxis" xlink:label="loc_srt_ProductOrServiceAxis_411888" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_411887" xlink:to="loc_srt_ProductOrServiceAxis_411888" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_ProductsAndServicesDomain" xlink:label="loc_srt_ProductsAndServicesDomain_411889" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_411888" xlink:to="loc_srt_ProductsAndServicesDomain_411889" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ProductMember" xlink:label="loc_us-gaap_ProductMember_411890" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_411889" xlink:to="loc_us-gaap_ProductMember_411890" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LicenseAndServiceMember" xlink:label="loc_us-gaap_LicenseAndServiceMember_411891" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_411889" xlink:to="loc_us-gaap_LicenseAndServiceMember_411891" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_StatementGeographicalAxis" xlink:label="loc_srt_StatementGeographicalAxis_411894" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_411887" xlink:to="loc_srt_StatementGeographicalAxis_411894" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_SegmentGeographicalDomain" xlink:label="loc_srt_SegmentGeographicalDomain_411896" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_StatementGeographicalAxis_411894" xlink:to="loc_srt_SegmentGeographicalDomain_411896" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="plx-20190331.xsd#plx_PfizerMember" xlink:label="loc_plx_PfizerMember_411902" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_411896" xlink:to="loc_plx_PfizerMember_411902" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/country/2017/country-2017-01-31.xsd#country_BR" xlink:label="loc_country_BR_411899" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_411896" xlink:to="loc_country_BR_411899" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_411900" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_411887" xlink:to="loc_us-gaap_StatementLineItems_411900" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_Revenues" xlink:label="loc_us-gaap_Revenues_411901" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_411900" xlink:to="loc_us-gaap_Revenues_411901" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/label" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.protalix.com/role/RevenuesContractWithCustomerAssetAndLiabilityDetail">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ContractWithCustomerAssetAndLiabilityAbstract" xlink:label="loc_us-gaap_ContractWithCustomerAssetAndLiabilityAbstract_417539" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_417541" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ContractWithCustomerAssetAndLiabilityAbstract_417539" xlink:to="loc_us-gaap_StatementTable_417541" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_417542" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_417541" xlink:to="loc_us-gaap_StatementClassOfStockAxis_417542" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_417543" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementClassOfStockAxis_417542" xlink:to="loc_us-gaap_ClassOfStockDomain_417543" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_417544" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_417541" xlink:to="loc_us-gaap_StatementLineItems_417544" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ContractWithCustomerLiability" xlink:label="loc_us-gaap_ContractWithCustomerLiability_417545" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_417544" xlink:to="loc_us-gaap_ContractWithCustomerLiability_417545" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToRevenueChangeInMeasureOfProgress" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToRevenueChangeInMeasureOfProgress_417546" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_417544" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToRevenueChangeInMeasureOfProgress_417546" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ContractWithCustomerLiabilityRevenueRecognized" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityRevenueRecognized_417547" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_417544" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityRevenueRecognized_417547" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ContractWithCustomerLiability" xlink:label="loc_us-gaap_ContractWithCustomerLiability_417548" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_417544" xlink:to="loc_us-gaap_ContractWithCustomerLiability_417548" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.protalix.com/role/RevenuesUnsatisfiedPerformanceObligationsDetail">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RevenuePerformanceObligationAbstract" xlink:label="loc_us-gaap_RevenuePerformanceObligationAbstract_417550" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_417552" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenuePerformanceObligationAbstract_417550" xlink:to="loc_us-gaap_StatementTable_417552" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_417553" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_417552" xlink:to="loc_us-gaap_StatementClassOfStockAxis_417553" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_417554" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementClassOfStockAxis_417553" xlink:to="loc_us-gaap_ClassOfStockDomain_417554" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_417555" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_417552" xlink:to="loc_us-gaap_StatementLineItems_417555" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RevenueRemainingPerformanceObligation" xlink:label="loc_us-gaap_RevenueRemainingPerformanceObligation_417556" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_417555" xlink:to="loc_us-gaap_RevenueRemainingPerformanceObligation_417556" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
</presentationLink>
</linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>12
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.1</span><table class="report" border="0" cellspacing="2" id="idp6813200432">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Document and Entity Information - shares<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2019</div></th>
<th class="th"><div>May 01, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_plx_DocumentAndEntityInformationAbstract', window );"><strong>Document and Entity Information [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">10-Q<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Mar. 31,  2019<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentFiscalYearFocus', window );">Document Fiscal Year Focus</a></td>
<td class="text">2019<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentFiscalPeriodFocus', window );">Document Fiscal Period Focus</a></td>
<td class="text">Q1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">Protalix BioTherapeutics, Inc.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001006281<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CurrentFiscalYearEndDate', window );">Current Fiscal Year End Date</a></td>
<td class="text">--12-31<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFilerCategory', window );">Entity Filer Category</a></td>
<td class="text">Accelerated Filer<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">PLX<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCommonStockSharesOutstanding', window );">Entity Common Stock, Shares Outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">148,382,299<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntitySmallBusiness', window );">Entity Small Business</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>If the value is true, then the document is an amendment to previously-filed/accepted document.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CurrentFiscalYearEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>End date of current fiscal year in the format --MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CurrentFiscalYearEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gMonthDayItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalPeriodFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This is focus fiscal period of the document report. For a first quarter 2006 quarterly report, which may also provide financial information from prior periods, the first fiscal quarter should be given as the fiscal period focus. Values: FY, Q1, Q2, Q3, Q4, H1, H2, M9, T1, T2, T3, M8, CY.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalPeriodFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fiscalPeriodItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalYearFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This is focus fiscal year of the document report in CCYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalYearFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented.  If there is no historical data in the report, use the filing date. The format of the date is CCYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFilerCategory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate whether the registrant is one of the following: (1) Large Accelerated Filer, (2) Accelerated Filer, (3) Non-accelerated Filer, (4) Smaller Reporting Company (Non-accelerated), (5) Smaller Reporting Accelerated Filer or (6) Smaller Reporting Company and Large Accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFilerCategory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:filerCategoryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntitySmallBusiness">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicates that the company is a smaller reporting company with both a public float and revenues of less than $75 million.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntitySmallBusiness</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_plx_DocumentAndEntityInformationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Document and Entity Information [Abstract]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">plx_DocumentAndEntityInformationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>plx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>13
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.1</span><table class="report" border="0" cellspacing="2" id="idp6813015408">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>CONDENSED CONSOLIDATED BALANCE SHEETS - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Mar. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrentAbstract', window );"><strong>CURRENT ASSETS:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 30,363<span></span>
</td>
<td class="nump">$ 37,808<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsReceivableNetCurrent', window );">Accounts receivable &#8211; Trade</a></td>
<td class="nump">8,565<span></span>
</td>
<td class="nump">4,729<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherAssetsCurrent', window );">Other assets</a></td>
<td class="nump">1,706<span></span>
</td>
<td class="nump">1,877<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryNet', window );">Inventories</a></td>
<td class="nump">6,707<span></span>
</td>
<td class="nump">8,569<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">Total current assets</a></td>
<td class="nump">47,341<span></span>
</td>
<td class="nump">52,983<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent', window );">FUNDS IN RESPECT OF EMPLOYEE RIGHTS UPON RETIREMENT</a></td>
<td class="nump">1,801<span></span>
</td>
<td class="nump">1,758<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">PROPERTY AND EQUIPMENT, NET</a></td>
<td class="nump">6,058<span></span>
</td>
<td class="nump">6,390<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">OPERATING LEASE RIGHT OF USE ASSETS</a></td>
<td class="nump">5,844<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Assets', window );">Total assets</a></td>
<td class="nump">61,044<span></span>
</td>
<td class="nump">61,131<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAbstract', window );"><strong>Accounts payable and accruals:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsPayableTradeCurrent', window );">Trade</a></td>
<td class="nump">5,870<span></span>
</td>
<td class="nump">5,211<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsPayableOtherCurrent', window );">Other</a></td>
<td class="nump">10,480<span></span>
</td>
<td class="nump">10,274<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrent', window );">Operating lease liabilities</a></td>
<td class="nump">1,257<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityCurrent', window );">Contracts liability</a></td>
<td class="nump">9,429<span></span>
</td>
<td class="nump">9,868<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Total current liabilities</a></td>
<td class="nump">27,036<span></span>
</td>
<td class="nump">25,353<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesNoncurrentAbstract', window );"><strong>LONG TERM LIABILITIES:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConvertibleDebtNoncurrent', window );">Convertible notes</a></td>
<td class="nump">48,670<span></span>
</td>
<td class="nump">47,966<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityNoncurrent', window );">Contracts liability</a></td>
<td class="nump">32,979<span></span>
</td>
<td class="nump">33,027<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PensionAndOtherPostretirementAndPostemploymentBenefitPlansLiabilitiesNoncurrent', window );">Liability for employee rights upon retirement</a></td>
<td class="nump">2,426<span></span>
</td>
<td class="nump">2,374<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrent', window );">Operating lease liabilities</a></td>
<td class="nump">4,498<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesNoncurrent', window );">Other long term liabilities</a></td>
<td class="nump">5,290<span></span>
</td>
<td class="nump">5,292<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesNoncurrent', window );">Total long term liabilities</a></td>
<td class="nump">93,863<span></span>
</td>
<td class="nump">88,659<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Liabilities', window );">Total liabilities</a></td>
<td class="nump">120,899<span></span>
</td>
<td class="nump">114,012<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">CAPITAL DEFICIENCY</a></td>
<td class="num">(59,855)<span></span>
</td>
<td class="num">(52,881)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquity', window );">Total liabilities net of capital deficiency</a></td>
<td class="nump">$ 61,044<span></span>
</td>
<td class="nump">$ 61,131<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableOtherCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of obligations incurred classified as other, payable within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=82887183&amp;loc=d3e6935-107765<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableOtherCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableTradeCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=82887183&amp;loc=d3e6935-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableTradeCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsReceivableNetCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount due from customers or clients, within one year of the balance sheet date (or the normal operating cycle, whichever is longer), for goods or services (including trade receivables) that have been delivered or sold in the normal course of business, reduced to the estimated net realizable fair value by an allowance established by the entity of the amount it deems uncertain of collection.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109196051&amp;loc=SL49130549-203045<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsReceivableNetCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(11))<br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=115929826&amp;loc=d3e8736-108599<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(12))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879938&amp;loc=d3e572229-122910<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=82887183&amp;loc=d3e6801-107765<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.9)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=82887183&amp;loc=d3e6676-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3044-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=82887183&amp;loc=d3e6676-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=82913815&amp;loc=SL49130532-203044<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=82913815&amp;loc=SL49130531-203044<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109196051&amp;loc=SL49130549-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109196051&amp;loc=SL49130549-203045<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=82913815&amp;loc=SL49130532-203044<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=82913815&amp;loc=SL49130531-203044<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConvertibleDebtNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying amount of long-term convertible debt as of the balance sheet date, net of the amount due in the next twelve months or greater than the normal operating cycle, if longer. The debt is convertible into another form of financial instrument, typically the entity's common stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConvertibleDebtNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of asset, recognized in statement of financial position, for overfunded defined benefit pension and other postretirement plans.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109237824&amp;loc=d3e1731-114919<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109237824&amp;loc=d3e1703-114919<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=108410482&amp;loc=d3e1928-114920<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(17))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(10))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879938&amp;loc=d3e572229-122910<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(10))<br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=82887183&amp;loc=d3e6676-107765<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -SubTopic 10<br> -Section 35<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=68049868&amp;loc=d3e3927-108312<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.6(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Liabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19-26)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Liabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAndStockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879938&amp;loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(32))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAndStockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.21)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation due after one year or beyond the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 201.5-02(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 201.5-02(26))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 201.5-02(24))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesNoncurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesNoncurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=77888419&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=77888419&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=77888419&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.8)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.24)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PensionAndOtherPostretirementAndPostemploymentBenefitPlansLiabilitiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liability, recognized in statement of financial position, for pension, other postretirement and postemployment benefits, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(24))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=108410482&amp;loc=d3e1928-114920<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109237824&amp;loc=d3e1703-114919<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 712<br> -SubTopic 10<br> -Section 25<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=6410138&amp;loc=d3e79691-111665<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109237824&amp;loc=d3e1731-114919<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PensionAndOtherPostretirementAndPostemploymentBenefitPlansLiabilitiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(14))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879938&amp;loc=d3e572229-122910<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI http://asc.fasb.org/extlink&amp;oid=27010918&amp;loc=d3e74512-122707<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>14
<FILENAME>R3.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.1</span><table class="report" border="0" cellspacing="2" id="idp6813597664">
<tr>
<th class="tl" colspan="2" rowspan="2"><div style="width: 200px;"><strong>CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS - USD ($)<br> shares in Thousands, $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2019</div></th>
<th class="th"><div>Mar. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CostOfRevenue', window );">COST OF GOODS SOLD</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">$ (2,045)<span></span>
</td>
<td class="num">$ (2,924)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">RESEARCH AND DEVELOPMENT EXPENSES (1)</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="num">(11,701)<span></span>
</td>
<td class="num">(7,286)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_plx_GrantsAndReimbursementsReceivedOrReceivable', window );">Less - grants</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">3<span></span>
</td>
<td class="nump">843<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_plx_ResearchDevelopmentAndEngineeringExpenseNet', window );">RESEARCH AND DEVELOPMENT EXPENSES, NET</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(11,698)<span></span>
</td>
<td class="num">(6,443)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SellingGeneralAndAdministrativeExpense', window );">SELLING, GENERAL AND ADMINISTRATIVE EXPENSES (2)</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[2]</sup></td>
<td class="num">(2,230)<span></span>
</td>
<td class="num">(2,498)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">OPERATING LOSS</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(5,534)<span></span>
</td>
<td class="num">(5,151)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherNonoperatingExpense', window );">FINANCIAL EXPENSES</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(1,920)<span></span>
</td>
<td class="num">(2,220)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherNonoperatingIncome', window );">FINANCIAL INCOME</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">190<span></span>
</td>
<td class="nump">132<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpense', window );">FINANCIAL EXPENSES, NET</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(1,730)<span></span>
</td>
<td class="num">(2,088)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">LOSS FOR THE PERIOD</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">$ (7,264)<span></span>
</td>
<td class="num">$ (7,239)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasicAndDiluted', window );">NET LOSS PER SHARE OF COMMON STOCK &#8211; BASIC AND DILUTED</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">$ (0.05)<span></span>
</td>
<td class="num">$ (0.05)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted', window );">WEIGHTED AVERAGE NUMBER OF SHARES OF COMMON STOCK USED IN COMPUTING LOSS PER SHARE-BASIC AND DILUTED</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">148,382,299<span></span>
</td>
<td class="nump">145,305,982<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_ProductMember', window );">Goods [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">REVENUES</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 3,530<span></span>
</td>
<td class="nump">$ 4,553<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_LicenseAndServiceMember', window );">License and R&amp;D Services [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">REVENUES</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 6,909<span></span>
</td>
<td class="nump">$ 2,161<span></span>
</td>
</tr>
<tr><td colspan="4"></td></tr>
<tr><td colspan="4"><table class="outerFootnotes" width="100%">
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top">(1) Includes share-based compensation</td>
</tr>
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[2]</td>
<td style="vertical-align: top;" valign="top">(2) Includes share-based compensation</td>
</tr>
</table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_plx_GrantsAndReimbursementsReceivedOrReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Grants and reimbursements received or receivable from governmental institutions and collaboration partners for research and development expenses incurred.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">plx_GrantsAndReimbursementsReceivedOrReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>plx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_plx_ResearchDevelopmentAndEngineeringExpenseNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Research and development expenses, net.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">plx_ResearchDevelopmentAndEngineeringExpenseNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>plx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostOfRevenue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate cost of goods produced and sold and services rendered during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.2)<br> -URI http://asc.fasb.org/extlink&amp;oid=115205541&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostOfRevenue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasicAndDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income or loss for the period per each share in instances when basic and diluted earnings per share are the same amount and reported as a single line item on the face of the financial statements.  Basic earnings per share is the amount of net income or loss for the period per each share of common stock or unit outstanding during the reporting period.  Diluted earnings per share includes the amount of net income or loss for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109260490&amp;loc=d3e1337-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasicAndDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=114867106&amp;loc=SL7669619-108580<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=114873765&amp;loc=SL114874048-224260<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=114867106&amp;loc=SL7669625-108580<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=114873790&amp;loc=SL114874131-224263<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=115205541&amp;loc=SL114868664-224227<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3602-108585<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=115205541&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of deducting operating expenses from operating revenues.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNonoperatingExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expense related to nonoperating activities, classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.9)<br> -URI http://asc.fasb.org/extlink&amp;oid=115205541&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNonoperatingExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNonoperatingIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of income related to nonoperating activities, classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=115205541&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNonoperatingIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 985<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6501960&amp;loc=d3e128462-111756<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Revenues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=115929826&amp;loc=d3e8736-108599<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=115205541&amp;loc=SL114868664-224227<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=115929826&amp;loc=d3e8933-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=115929826&amp;loc=d3e8736-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Revenues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SellingGeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate total costs related to selling a firm's product and services, as well as all other general and administrative expenses. Direct selling expenses (for example, credit, warranty, and advertising) are expenses that can be directly linked to the sale of specific products. Indirect selling expenses are expenses that cannot be directly linked to the sale of specific products, for example telephone expenses, Internet, and postal charges. General and administrative expenses include salaries of non-sales personnel, rent, utilities, communication, etc.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -SubTopic 10<br> -Section 30<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=68048583&amp;loc=d3e3636-108311<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=115205541&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SellingGeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Average number of shares or units issued and outstanding that are used in calculating basic and diluted earnings per share (EPS).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=us-gaap_ProductMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=us-gaap_ProductMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=us-gaap_LicenseAndServiceMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=us-gaap_LicenseAndServiceMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>15
<FILENAME>R4.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.1</span><table class="report" border="0" cellspacing="2" id="idp6809397952">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (Parenthetical) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2019</div></th>
<th class="th"><div>Mar. 31, 2018</div></th>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember', window );">Research and Development Expenses [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Share-based compensation</a></td>
<td class="nump">$ 178<span></span>
</td>
<td class="nump">$ 42<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_SellingGeneralAndAdministrativeExpensesMember', window );">Selling, General and Administrative Expenses [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Share-based compensation</a></td>
<td class="nump">$ 112<span></span>
</td>
<td class="nump">$ 20<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the expense recognized during the period arising from equity-based compensation arrangements (for example, shares of stock, unit, stock options or other equity instruments) with employees, directors and certain consultants qualifying for treatment as employees.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109197908&amp;loc=d3e5047-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -URI http://asc.fasb.org/extlink&amp;oid=115993241&amp;loc=d3e301413-122809<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=109197908&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_SellingGeneralAndAdministrativeExpensesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_SellingGeneralAndAdministrativeExpensesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>16
<FILENAME>R5.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.1</span><table class="report" border="0" cellspacing="2" id="idp6813002800">
<tr>
<th class="tl" colspan="2" rowspan="2"><div style="width: 200px;"><strong>CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN CAPITAL DEFICIENCY - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2019</div></th>
<th class="th"><div>Mar. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">$ (52,881)<span></span>
</td>
<td class="num">$ (29,457)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance (in shares)</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">148,382,299<span></span>
</td>
<td class="nump">143,728,797<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Share-based compensation related to stock options</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 290<span></span>
</td>
<td class="nump">$ 46<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_plx_ShareBasedCompensationRestrictedStockAwardsNetOfForfeitures', window );">Share-based compensation related to restricted stock award</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 16<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_plx_ShareBasedCompensationRestrictedStockAwardsNetOfForfeituresShares', window );">Share-based compensation related to restricted stock award (in shares)</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">29,898<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities', window );">Convertible notes conversions</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,192<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities', window );">Convertible notes conversions (in shares)</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,811,260<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss for the period</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(7,264)<span></span>
</td>
<td class="num">$ (7,239)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">$ (59,855)<span></span>
</td>
<td class="num">$ (35,442)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance (in shares)</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">148,382,299<span></span>
</td>
<td class="nump">145,569,955<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember', window );">Common Stock [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 148<span></span>
</td>
<td class="nump">$ 144<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_plx_ShareBasedCompensationRestrictedStockAwardsNetOfForfeitures', window );">Share-based compensation related to restricted stock award</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[2]</sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities', window );">Convertible notes conversions</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">148<span></span>
</td>
<td class="nump">146<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AdditionalPaidInCapitalMember', window );">Additional Paid-in Capital [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">269,524<span></span>
</td>
<td class="nump">266,495<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Share-based compensation related to stock options</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">290<span></span>
</td>
<td class="nump">46<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_plx_ShareBasedCompensationRestrictedStockAwardsNetOfForfeitures', window );">Share-based compensation related to restricted stock award</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">16<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities', window );">Convertible notes conversions</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,190<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">269,814<span></span>
</td>
<td class="nump">267,747<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_RetainedEarningsMember', window );">Accumulated Deficit [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(322,553)<span></span>
</td>
<td class="num">(296,096)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss for the period</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(7,264)<span></span>
</td>
<td class="num">(7,239)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">$ (329,817)<span></span>
</td>
<td class="num">$ (303,335)<span></span>
</td>
</tr>
<tr><td colspan="4"></td></tr>
<tr><td colspan="4"><table class="outerFootnotes" width="100%">
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top">Common Stock, $0.001 par value; Authorized &#8211; as of March 31, 2019 and 2018 - 250,000,000.</td>
</tr>
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[2]</td>
<td style="vertical-align: top;" valign="top">* Represents an amount less than $1.</td>
</tr>
</table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_plx_ShareBasedCompensationRestrictedStockAwardsNetOfForfeitures">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of recognized equity-based compensation during the period for restricted stock awards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">plx_ShareBasedCompensationRestrictedStockAwardsNetOfForfeitures</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>plx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_plx_ShareBasedCompensationRestrictedStockAwardsNetOfForfeituresShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Share Based Compensation Restricted Stock Awards Net Of Forfeitures Shares</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">plx_ShareBasedCompensationRestrictedStockAwardsNetOfForfeituresShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>plx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase to additional paid-in capital (APIC) from recognition of equity-based compensation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=109196918&amp;loc=d3e11149-113907<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109197908&amp;loc=d3e5047-113901<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=109196918&amp;loc=d3e11178-113907<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 35<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=79507207&amp;loc=d3e4534-113899<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=114867106&amp;loc=SL7669619-108580<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=114873765&amp;loc=SL114874048-224260<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=114867106&amp;loc=SL7669625-108580<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=114873790&amp;loc=SL114874131-224263<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=115205541&amp;loc=SL114868664-224227<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3602-108585<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued which are neither cancelled nor held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued during the period as a result of the conversion of convertible securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29-30)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21475-112644<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The gross value of stock issued during the period upon the conversion of convertible securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29-31)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI http://asc.fasb.org/extlink&amp;oid=27010918&amp;loc=d3e74512-122707<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AdditionalPaidInCapitalMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_AdditionalPaidInCapitalMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_RetainedEarningsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_RetainedEarningsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>17
<FILENAME>R6.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.1</span><table class="report" border="0" cellspacing="2" id="idp6629631824">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN CAPITAL DEFICIENCY [Parenthetical] - $ / shares<br></strong></div></th>
<th class="th"><div>Mar. 31, 2019</div></th>
<th class="th"><div>Mar. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common Stock, Par or Stated Value Per Share</a></td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common Stock, Shares Authorized</a></td>
<td class="nump">250,000,000<span></span>
</td>
<td class="nump">250,000,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>18
<FILENAME>R7.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.1</span><table class="report" border="0" cellspacing="2" id="idp6813113472">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2019</div></th>
<th class="th"><div>Mar. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>CASH FLOWS FROM OPERATING ACTIVITIES:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (7,264)<span></span>
</td>
<td class="num">$ (7,239)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Adjustments required to reconcile net loss to net cash used in operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Share based compensation</a></td>
<td class="nump">290<span></span>
</td>
<td class="nump">62<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Depreciation', window );">Depreciation</a></td>
<td class="nump">405<span></span>
</td>
<td class="nump">430<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ForeignCurrencyTransactionGainLossUnrealized', window );">Financial expenses, net (mainly exchange differences)</a></td>
<td class="nump">20<span></span>
</td>
<td class="nump">28<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PensionAndOtherPostretirementBenefitExpense', window );">Changes in accrued liability for employee rights upon retirement</a></td>
<td class="num">(24)<span></span>
</td>
<td class="num">(124)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_plx_GainLossOnAmountsFundedInRespectOfEmployeeRightsUponRetirement', window );">Gain on amounts funded in respect of employee rights upon retirement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(44)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainsLossesOnExtinguishmentOfDebt', window );">Net loss in connection with conversions of convertible notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">218<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AmortizationOfFinancingCosts', window );">Amortization of debt issuance costs and debt discount</a></td>
<td class="nump">704<span></span>
</td>
<td class="nump">619<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_plx_IssuanceOfSharesForInterestPaymentRegardingConversionOfConvertibleNotes', window );">Issuance of shares for interest payment in connection with conversions of convertible notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">205<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract', window );"><strong>Changes in operating assets and liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInContractWithCustomerLiability', window );">Increase (decrease) in contracts liability (including non-current portion)</a></td>
<td class="num">(487)<span></span>
</td>
<td class="nump">18<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsReceivable', window );">Increase in accounts receivable and other assets</a></td>
<td class="num">(3,608)<span></span>
</td>
<td class="num">(3,512)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_plx_ChangeInOperatingLeaseRightOfUseAssets', window );">Changes in right of use assets</a></td>
<td class="num">(36)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInInventories', window );">Decrease in inventories</a></td>
<td class="nump">1,862<span></span>
</td>
<td class="nump">814<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities', window );">Increase (decrease) in accounts payable and accruals</a></td>
<td class="nump">864<span></span>
</td>
<td class="num">(1,009)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities', window );">Increase (decrease) in other long term liabilities</a></td>
<td class="num">(2)<span></span>
</td>
<td class="nump">121<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Net cash used in operating activities</a></td>
<td class="num">(7,276)<span></span>
</td>
<td class="num">(9,413)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract', window );"><strong>CASH FLOWS FROM INVESTING ACTIVITIES:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment', window );">Purchase of property and equipment</a></td>
<td class="num">(170)<span></span>
</td>
<td class="num">(249)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInRestrictedCash', window );">Increase in restricted deposit</a></td>
<td class="num">(214)<span></span>
</td>
<td class="num">(188)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsForProceedsFromOtherInvestingActivities', window );">Amounts funded in respect of employee rights upon retirement, net</a></td>
<td class="nump">13<span></span>
</td>
<td class="nump">109<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivities', window );">Net cash used in investing activities</a></td>
<td class="num">(371)<span></span>
</td>
<td class="num">(328)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents', window );">EFFECT OF EXCHANGE RATE CHANGES ON CASH AND CASH EQUIVALENTS</a></td>
<td class="nump">202<span></span>
</td>
<td class="num">(103)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease', window );">NET DECREASE IN CASH AND CASH EQUIVALENTS</a></td>
<td class="num">(7,445)<span></span>
</td>
<td class="num">(9,844)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">BALANCE OF CASH AND CASH EQUIVALENTS AT BEGINNING OF PERIOD</a></td>
<td class="nump">37,808<span></span>
</td>
<td class="nump">51,163<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">BALANCE OF CASH AND CASH EQUIVALENTS AT END OF PERIOD</a></td>
<td class="nump">30,363<span></span>
</td>
<td class="nump">41,319<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract', window );"><strong>SUPPLEMENTARY INFORMATION ON INVESTING AND FINANCING ACTIVITIES NOT INVOLVING CASH FLOWS:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_plx_IncreaseInLiabilitiesForPropertyPlantAndEquipment', window );">Purchase of property and equipment</a></td>
<td class="nump">$ 128<span></span>
</td>
<td class="nump">342<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtConversionConvertedInstrumentAmount1', window );">Convertible notes conversions</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">987<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SupplementalCashFlowInformationAbstract', window );"><strong>SUPPLEMENTARY DISCLOSURE ON CASH FLOWS</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestPaidNet', window );">Interest paid</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 145<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_plx_ChangeInOperatingLeaseRightOfUseAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of Net Change in Operating Lease Right Of use Assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">plx_ChangeInOperatingLeaseRightOfUseAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>plx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_plx_GainLossOnAmountsFundedInRespectOfEmployeeRightsUponRetirement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Gain (loss) on amounts funded in respect of employee rights upon retirement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">plx_GainLossOnAmountsFundedInRespectOfEmployeeRightsUponRetirement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>plx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_plx_IncreaseInLiabilitiesForPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Increase in liabilities for property, plant and equipment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">plx_IncreaseInLiabilitiesForPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>plx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_plx_IssuanceOfSharesForInterestPaymentRegardingConversionOfConvertibleNotes">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Issuance of shares for interest payment regarding conversion of convertible notes,</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">plx_IssuanceOfSharesForInterestPaymentRegardingConversionOfConvertibleNotes</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>plx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfFinancingCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization expense attributable to debt issuance costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3602-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=115205541&amp;loc=SL114868664-224227<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=114775744&amp;loc=d3e28555-108399<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AmortizationOfFinancingCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3044-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=82887183&amp;loc=d3e6676-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in cash and cash equivalents. Cash and cash equivalents are the amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Includes effect from exchange rate changes.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtConversionConvertedInstrumentAmount1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The value of the financial instrument(s) that the original debt is being converted into in a noncash (or part noncash) transaction. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=98513485&amp;loc=d3e4304-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=98513485&amp;loc=d3e4332-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtConversionConvertedInstrumentAmount1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Depreciation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Depreciation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) from the effect of exchange rate changes on cash and cash equivalent balances held in foreign currencies.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 230<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=98513438&amp;loc=d3e33268-110906<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ForeignCurrencyTransactionGainLossUnrealized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before tax of foreign currency transaction unrealized gain (loss) recognized in the income statement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=109240200&amp;loc=d3e30690-110894<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109240200&amp;loc=d3e30700-110894<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3602-108585<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6450222&amp;loc=d3e30840-110895<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ForeignCurrencyTransactionGainLossUnrealized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainsLossesOnExtinguishmentOfDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Difference between the fair value of payments made and the carrying amount of debt which is extinguished prior to maturity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 50<br> -Section 40<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=114001942&amp;loc=d3e12355-112629<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 50<br> -Section 40<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=114001942&amp;loc=d3e12317-112629<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainsLossesOnExtinguishmentOfDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the amounts payable to vendors for goods and services received and the amount of obligations and expenses incurred but not paid.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInContractWithCustomerLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in obligation to transfer good or service to customer for which consideration has been received or is receivable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInContractWithCustomerLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInInventories">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInInventories</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingCapitalAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in noncurrent operating liabilities classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInRestrictedCash">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The net cash inflow or outflow for the increase (decrease) associated with funds that are not available for withdrawal or use (such as funds held in escrow) and are associated with underlying transactions that are classified as investing activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3179-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInRestrictedCash</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestPaidNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=98513485&amp;loc=d3e4297-108586<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 17<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3367-108585<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3536-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestPaidNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3536-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3521-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=114867106&amp;loc=SL7669619-108580<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=114873765&amp;loc=SL114874048-224260<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=114867106&amp;loc=SL7669625-108580<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=114873790&amp;loc=SL114874131-224263<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=115205541&amp;loc=SL114868664-224227<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3602-108585<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsForProceedsFromOtherInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash (inflow) outflow from investing activities classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e24072-122690<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3213-108585<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3179-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsForProceedsFromOtherInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquirePropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PensionAndOtherPostretirementBenefitExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cost (reversal of cost) for pension and other postretirement benefits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PensionAndOtherPostretirementBenefitExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount of noncash, equity-based employee remuneration. This may include the value of stock or unit options, amortization of restricted stock or units, and adjustment for officers' compensation. As noncash, this element is an add back when calculating net cash generated by operating activities using the indirect method.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SupplementalCashFlowInformationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SupplementalCashFlowInformationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>19
<FILENAME>R8.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.1</span><table class="report" border="0" cellspacing="2" id="idp6635278496">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SIGNIFICANT ACCOUNTING POLICIES<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2019</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock', window );">SIGNIFICANT ACCOUNTING POLICIES</a></td>
<td class="text"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; margin-bottom: 0px; margin-top: 0px; margin-right: 0px;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">NOTE 1 - SIGNIFICANT ACCOUNTING POLICIES </div></div></div><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; margin-bottom: 0px; margin-top: 0px; margin-right: 0px; background: none;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div><div><table style="border: none; border-collapse: collapse; margin-bottom: 0.001pt; width: 100%; table-layout: fixed;"><tr><td style="border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: top;width: 36pt;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; margin-right: 0px; margin-bottom: 0px; margin-top: 0px; line-height: normal;">&#160;</div></td><td style="border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: top;width: 18pt;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; margin-right: 0px; margin-bottom: 0px; margin-top: 0px; line-height: normal;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">a.</div></div></div></td><td style="border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: top;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; margin-right: 0px; margin-bottom: 0px; margin-top: 0px; line-height: normal;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">General</div></div></div></td></tr></table><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px;"></div></div><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; margin-bottom: 0px; margin-top: 0px; margin-right: 0px; background: none;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; margin: 0px 0px 0px 0.5in;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">Protalix BioTherapeutics, Inc. (collectively with its subsidiaries, the &#8220;Company&#8221;)&#160;and its wholly-owned subsidiaries, Protalix Ltd. and Protalix B.V. (the &#8220;Subsidiaries&#8221;), are biopharmaceutical companies focused on the development and commercialization of recombinant therapeutic proteins based on the Company&#8217;s proprietary ProCellEx<div style="vertical-align: super;font-size: smaller;display:inline;">&#174;</div> protein expression system (&#8220;ProCellEx&#8221;). To date, the Company has successfully developed taliglucerase alfa (marketed under the name alfataliglicerase in Brazil and certain other Latin American countries and Elelyso<div style="vertical-align: super;font-size: smaller;display:inline;">&#174;</div> in the rest of the territories) for the treatment of Gaucher disease that has been approved for marketing in the United States, Brazil, Israel and other markets. The Company has a number of product candidates in varying stages of the clinical development process. The Company&#8217;s strategy is to develop proprietary recombinant proteins that are therapeutically superior to existing recombinant proteins currently marketed for the same indications.</div></div><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; margin: 0px 0px 0px 0.5in; background: none;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; margin: 0px 0px 0px 0.5in;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">The Company&#8217;s product pipeline currently includes, among other candidates:</div></div><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; margin: 0px 0px 0px 0.5in; background: none;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; margin: 0px 0px 0px 0.5in;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">(1) pegunigalsidase alfa, or PRX-102, a therapeutic protein candidate for the treatment of Fabry disease, a rare, genetic lysosomal disorder;</div></div><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; margin: 0px 0px 0px 0.5in; background: none;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; margin: 0px 0px 0px 0.5in;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">(2) alidornase alfa, or PRX-110, a proprietary plant cell recombinant human Deoxyribonuclease 1, or DNase, under development for the treatment of Cystic Fibrosis, to be administered by inhalation; and</div></div><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; margin: 0px 0px 0px 0.5in; background: none;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; margin: 0px 0px 0px 0.5in;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">(3) OPRX-106, the Company&#8217;s oral antiTNF product candidate which is being developed as an orally-delivered anti-inflammatory treatment using plant cells as a natural capsule for the expressed protein.</div></div><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; margin: 0px 0px 0px 0.5in; background: none;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; margin: 0px 0px 0px 0.5in;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">Obtaining marketing approval with respect to any product candidate in any country is dependent on the Company&#8217;s ability to implement the necessary regulatory steps required to obtain such approvals. The Company cannot reasonably predict the outcome of these activities.</div></div><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; margin: 0px 0px 0px 0.5in; background: none;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; margin: 0px 0px 0px 0.5in;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">On October&#160;19, 2017, Protalix Ltd. and Chiesi Farmaceutici S.p.A. (&#8220;Chiesi&#8221;) entered into an Exclusive License and Supply Agreement (the &#8220;Chiesi Ex-US Agreement&#8221;) pursuant to which Chiesi was granted an exclusive license for all markets outside of the United States to commercialize pegunigalsidase alfa. On July&#160;23, 2018, Protalix Ltd. entered into an Exclusive License and Supply Agreement with Chiesi (the &#8220;Chiesi US Agreement&#8221;)&#160;with respect to the commercialization of pegunigalsidase alfa in the United States.</div></div><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; margin: 0px 0px 0px 0.5in; background: none;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; margin: 0px 0px 0px 0.5in;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">Under each of the Chiesi Ex-US Agreement and the Chiesi US Agreement&#160;(collectively,&#160;the </div>&#8220;<div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">Chiesi Agreements</div>&#8221;)<div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">, Chiesi made an upfront payment to Protalix Ltd. of $25.0&#160;million in connection with the execution of the agreement. In addition, under the Chiesi Ex-US Agreement, Protalix Ltd. is entitled to additional payments of up to $25.0&#160;million in pegunigalsidase alfa development costs, capped at $10.0&#160;million per year, and to receive additional payments of up to $320.0&#160;million, in the aggregate, in regulatory and commercial milestone payments. Under the Chiesi US Agreement, Protalix Ltd. is entitled to payments of up to a maximum of $20.0&#160;million to cover development costs for pegunigalsidase alfa, subject to a maximum of $7.5&#160;million per year, and to receive an additional up to a maximum of $760.0&#160;million, in the aggregate, in regulatory and commercial milestone payments.</div></div><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; margin: 0px 0px 0px 0.5in; background: none;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; margin: 0px 0px 0px 0.5in;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">Under the terms of both of the Chiesi Agreements, Protalix Ltd. will manufacture all of the pegunigalsidase alfa needed under the agreements, subject to certain exceptions, and Chiesi will purchase pegunigalsidase alfa from Protalix, subject to certain terms and conditions. Under the Chiesi Ex-US Agreement, Chiesi is required to make tiered payments of 15% to 35% of its net sales, depending on the amount of annual sales outside of the United States, as consideration for product supply. Under the Chiesi US Agreement, Chiesi is required to make tiered payments of 15% to 40% of its net sales, depending on the amount of annual sales in the United States, as consideration for product supply.</div></div><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; margin: 0px 0px 0px 0.5in; background: none;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; margin: 0px 0px 0px 0.5in;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">Since its approval by the FDA, taliglucerase alfa has been marketed by Pfizer in accordance with the exclusive license and supply agreement entered&#160;into&#160;between Protalix Ltd. and Pfizer, which is referred to herein as the Pfizer Agreement. In October 2015, the Company sold to Pfizer its share in the collaboration created under the Pfizer Agreement for the commercialization of Elelyso. As part of the sale, the Company agreed to transfer its rights to Elelyso in Israel to Pfizer while gaining full rights to it in Brazil. Under the Amended Pfizer Agreement, Pfizer is entitled to all of the revenues, and is responsible for 100% of expenses globally for Elelyso, excluding Brazil where the Company is responsible for all expenses and retains all revenues.</div></div><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; margin: 0px 0px 0px 0.5in; background: none;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; margin: 0px 0px 0px 0.5in;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">On June&#160;18, 2013, the Company entered into a Supply and Technology Transfer Agreement (the &#8220;Brazil Agreement&#8221;) with Fiocruz, an arm of the Brazilian MoH, for taliglucerase alfa. Fiocruz&#8217;s purchases of alfataliglicerase to date have been significantly below certain agreed upon purchase milestones and, accordingly, the Company has the right to terminate the Brazil Agreement. Notwithstanding the termination right, the Company is, at this time, continuing to supply alfataliglicerase to Fiocruz under the Brazil Agreement, and patients continue to be treated with alfataliglicerase in Brazil.</div></div><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; margin: 0px 0px 0px 0.5in; background: none;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div><div style="color: rgb(0, 0, 0); font: 10pt &quot;times new roman&quot;, times, serif; letter-spacing: normal; orphans: 2; text-align: start; text-indent: 0in; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; margin: 0px 0px 0px 0.5in;">Based on its current cash resources and commitments, the Company believes it will be able to maintain its current planned development activities and the corresponding level of expenditures for at least 12 months from the date of approval of the financial statements as of March&#160;31, 2019, although no assurance can be given that it will not need additional funds prior to such time. If there are unexpected increases in general and administrative expenses or research and development expenses, the Company may need to seek additional financing.</div><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; margin: 0px 0px 0px 0.5in; background: none;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div><div><table style="border: none; border-collapse: collapse; margin-bottom: 0.001pt; width: 100%; table-layout: fixed;"><tr><td style="border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: top;width: 36pt;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; margin-right: 0px; margin-bottom: 0px; margin-top: 0px; line-height: normal;">&#160;</div></td><td style="border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: top;width: 18pt;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; margin-right: 0px; margin-bottom: 0px; margin-top: 0px; line-height: normal;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">b.</div></div></div></td><td style="border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0;padding-left: 0;padding-right: 81.4pt;padding-top: 0;vertical-align: top;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; margin-right: 0px; margin-bottom: 0px; margin-top: 0px; line-height: normal;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Basis of presentation</div></div></div></td></tr></table><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px;"></div></div><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; margin-bottom: 0px; margin-top: 0px; margin-right: 0px; background: none;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; margin: 0px 0px 0px 0.5in;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">The accompanying unaudited condensed consolidated financial statements of the Company have been prepared in accordance with accounting principles generally accepted in the United States (&#8220;GAAP&#8221;) for interim financial information. Accordingly, they do not include all of the information and notes required by GAAP for annual financial statements. In the opinion of management, all adjustments (of a normal recurring nature) considered necessary for a fair statement of the results for the interim periods presented have been included. Operating results for the interim period are not necessarily indicative of the results that may be expected for the full year.</div></div><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; margin: 0px 0px 0px 0.5in; background: none;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; margin: 0px 0px 0px 0.5in;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">These unaudited condensed consolidated financial statements should be read in conjunction with the audited consolidated financial statements in the Annual Report on Form 10-K for the year ended December&#160;31, 2018, filed by the Company with the Commission. The comparative balance sheet at December&#160;31, 2018 has been derived from the audited financial statements at that date.</div></div><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; margin: 0px 0px 0px 0.5in; background: none;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div><div><table style="border: none; border-collapse: collapse; margin-bottom: 0.001pt; width: 100%; table-layout: fixed;"><tr><td style="border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: top;width: 36pt;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; margin-right: 0px; margin-bottom: 0px; margin-top: 0px; line-height: normal;">&#160;</div></td><td style="border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: top;width: 18pt;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; margin-right: 0px; margin-bottom: 0px; margin-top: 0px; line-height: normal;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">c.</div></div></div></td><td style="border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0;padding-left: 0;padding-right: 81.4pt;padding-top: 0;vertical-align: top;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; margin-right: 0px; margin-bottom: 0px; margin-top: 0px; line-height: normal;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Net loss per share</div></div></div></td></tr></table><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px;"></div></div><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; margin-bottom: 0px; margin-top: 0px; margin-right: 0px; background: none;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; margin: 0px 0px 0px 0.5in;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">Basic and diluted loss per share (&#8220;LPS&#8221;) are computed by dividing net loss by the weighted average number of shares of the Company&#8217;s common stock, par value $0.001 per share (the &#8220;Common Stock&#8221;), outstanding for each period.</div></div><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; margin: 0px 0px 0px 0.5in; background: none;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; margin: 0px 0px 0px 0.5in;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">Diluted LPS is calculated in continuing operations. The calculation of diluted LPS does not include 73,800,491 and 78,202,020 shares of Common Stock underlying outstanding options and restricted shares of Common Stock and shares issuable upon conversion of outstanding convertible notes for the three months ended March&#160;31, 2018 and 2019, respectively, because the effect would be anti-dilutive.</div></div><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; margin-bottom: 0px; margin-top: 0px; margin-right: 0px; background: none;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div><div style="background: none; letter-spacing: 0px; font-size: 10pt; text-decoration: none; top: 0px;;display:inline;">&#160;</div><div style="background: none; letter-spacing: 0px; font-size: 10pt; text-decoration: none; top: 0px;;display:inline;">&#160;</div></div><table cellpadding="0" cellspacing="0" style="font: 10pt &quot;times new roman&quot;, times, serif; letter-spacing: normal; orphans: 2; text-indent: 0px; text-transform: none; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; margin-top: 0pt; margin-bottom: 0pt; border-collapse: collapse; border-spacing: 0px; table-layout: fixed;;width:100%;"><tr style="vertical-align: top;"><td style="width: 0.5in; padding: 0px;"></td><td style="width: 0.25in; padding-left: 0px; padding-top: 0px; padding-bottom: 0px;"><div style="font-weight:bold;display:inline;">d.</div></td><td style="padding: 0px 81.35pt 0px 0px;"><div style="font-weight:bold;display:inline;">Recently adopted standards</div></td></tr></table><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px; background: none;"></div><div style="color: rgb(0, 0, 0); font: 10pt &quot;times new roman&quot;, times, serif; letter-spacing: normal; orphans: 2; text-align: start; text-indent: 0px; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; margin-top: 0px; margin-bottom: 0px; margin-right: 0px; background: none;">&#160;&#160;</div><div style="color: rgb(0, 0, 0); font: 10pt &quot;times new roman&quot;, times, serif; letter-spacing: normal; orphans: 2; text-align: start; text-indent: 0in; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; margin: 0px 0px 0px 0.5in; background: none;"></div><div style="color: rgb(0, 0, 0); font: 10pt &quot;times new roman&quot;, times, serif; letter-spacing: normal; orphans: 2; text-align: start; text-indent: 0px; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; margin: 0px 0px 0px 0.5in;">In February 2016, the Financial Accounting Standards Board (&#8220;FASB&#8221;) issued ASU No. 2016-02, Leases (Topic 842), which supersedes the existing guidance for lease accounting, Leases (Topic 840). The new standard requires a lessee to record assets and liabilities on its balance sheet for all leases with terms longer than 12 months. Leases will be classified as either finance or operating, with classification affecting the pattern of expense recognition in the lessee&#8217;s income statement. The Company adopted this standard as of January 1, 2019 on a modified retrospective basis and will not restate comparative periods. The Company will elect the package of practical expedients permitted under the transition guidance within the new standard which, among other things, allows the Company to carryforward the historical lease classification. The Company made an accounting policy election to keep leases with an initial term of 12 months or less off of its balance sheet. The Company recognized those lease payments in its statements of operations on a straight-line basis over the lease period.</div><div style="color: rgb(0, 0, 0); font: 10pt &quot;times new roman&quot;, times, serif; letter-spacing: normal; orphans: 2; text-align: start; text-indent: 0px; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; margin: 0px 0px 0px 0.5in; background: none;">&#160;</div><div style="color: rgb(0, 0, 0); font: 10pt &quot;times new roman&quot;, times, serif; letter-spacing: normal; orphans: 2; text-align: start; text-indent: 0px; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; margin: 0px 0px 0px 0.5in;">As of the adoption date, the Company recognized an operating lease asset and liability of $5.9&#160;million and $5.7 million, respectively, as of January&#160;1, 2019 on its balance sheet.</div><div style="color: rgb(0, 0, 0); font: 10pt &quot;times new roman&quot;, times, serif; letter-spacing: normal; orphans: 2; text-align: start; text-indent: 0px; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; margin: 0px 0px 0px 0.5in; background: none;">&#160;</div><table cellpadding="0" cellspacing="0" style="font: 10pt &quot;times new roman&quot;, times, serif; letter-spacing: normal; orphans: 2; text-indent: 0px; text-transform: none; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; margin-top: 0pt; margin-bottom: 0pt; border-collapse: collapse; border-spacing: 0px; table-layout: fixed;;width:100%;"><tr style="vertical-align: top;"><td style="width: 0.5in; padding: 0px;"></td><td style="width: 0.25in; padding-left: 0px; padding-top: 0px; padding-bottom: 0px;"><div style="font-weight:bold;display:inline;">e.</div></td><td style="padding: 0px 81.35pt 0px 0px;"><div style="font-weight:bold;display:inline;">Newly issued accounting pronouncements</div></td></tr></table><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px; background: none;"></div><div style="color: rgb(0, 0, 0); font: 10pt &quot;times new roman&quot;, times, serif; letter-spacing: normal; orphans: 2; text-align: start; text-indent: 0px; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; margin-top: 0px; margin-bottom: 0px; margin-right: 0px; background: none;">&#160;</div><div style="color: rgb(0, 0, 0); font-family: &quot;times new roman&quot;, times, serif; font-size: 13.3333px; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; orphans: 2; text-align: start; text-indent: 0px; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; margin: 0px 0px 0px 0.5in;">In June 2018, the FASB issued ASU 2018-07, &#8220;Compensation &#8211; Stock Compensation (Topic 718): Improvements to Nonemployee Share-based Payment Accounting&#8221; that expands the scope of ASC Topic 718 to include share-based payment transactions for acquiring goods and services from nonemployees. An entity should apply the requirements of ASC Topic 718 to nonemployee awards except for certain exemptions specified in ASU 2018-07. The guidance is effective for fiscal years beginning after December 15, 2018, including interim reporting periods within that fiscal year. Early adoption is permitted, but no earlier than an entity&#8217;s adoption date of Topic 606. The Company does not expect the adoption of ASU 2018-07 to have a material impact on its financial statements.<div style="background-color: initial; font-size: 10pt; text-indent: 0in; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div><div style="color: rgb(0, 0, 0); font-family: &quot;times new roman&quot;, times, serif; font-size: 13.3333px; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; orphans: 2; text-align: start; text-indent: 0px; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; margin: 0px 0px 0px 0.5in; background: none;"><div style="background: none; font-size: 10pt; text-indent: 0in; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the basis of presentation and significant accounting policies concepts. Basis of presentation describes the underlying basis used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).  Accounting policies describe all significant accounting policies of the reporting entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -URI http://asc.fasb.org/topic&amp;trid=2122369<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>20
<FILENAME>R9.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.1</span><table class="report" border="0" cellspacing="2" id="idp6611064064">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>INVENTORIES<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2019</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryDisclosureAbstract', window );"><strong>Inventory Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryDisclosureTextBlock', window );">INVENTORIES</a></td>
<td class="text"><div style="color: rgb(0, 0, 0); font: 10pt &quot;times new roman&quot;, times, serif; letter-spacing: normal; orphans: 2; text-align: start; text-indent: 0in; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; margin: 0px;"><div style="font-family: &quot;times new roman&quot;, times, serif; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">NOTE 2 - INVENTORIES</div></div></div><div style="color: rgb(0, 0, 0); font: 10pt &quot;times new roman&quot;, times, serif; letter-spacing: normal; orphans: 2; text-align: start; text-indent: 0in; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; margin: 0px; background: none;"><div style="font-family: &quot;times new roman&quot;, times, serif; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div><table cellpadding="0" cellspacing="0" style="font: 10pt &quot;times new roman&quot;, times, serif; letter-spacing: normal; orphans: 2; text-indent: 0px; text-transform: none; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; margin-top: 0pt; margin-bottom: 0pt; border-collapse: collapse; border-spacing: 0px; table-layout: fixed;;width:100%;"><tr style="vertical-align: top;"><td style="width: 0.5in; padding: 0px;"></td><td style="width: 0.25in; padding-left: 0px; padding-top: 0px; padding-bottom: 0px;">a.</td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;">Inventories at March&#160;31, 2019 and December&#160;31, 2018 consisted of the following:</td></tr></table><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px;"></div><div style="color: rgb(0, 0, 0); font: 10pt &quot;times new roman&quot;, times, serif; letter-spacing: normal; orphans: 2; text-align: start; text-indent: 0px; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; margin-top: 0px; margin-bottom: 0px; margin-right: 0px; background: none;"><div style="font-family: &quot;times new roman&quot;, times, serif; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div><table cellpadding="0" cellspacing="0" style="font: 10pt &quot;times new roman&quot;, times, serif; letter-spacing: normal; orphans: 2; text-indent: 0px; text-transform: none; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; border-collapse: collapse; width: 94%; border-spacing: 0px; margin: 0in 0in 0in auto;;text-align:left;"><tr style="vertical-align: bottom;"><td style="font-size: 10pt; text-align: center; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; font-family: &quot;times new roman&quot;, times, serif; vertical-align: middle;;width:;">&#160;</td><td style="font: 10pt &quot;times new roman&quot;, times, serif; padding-bottom: 1pt; padding-left: 0px; padding-top: 0px; vertical-align: middle;;width:;">&#160;</td><td colspan="2" style="font: 10pt &quot;times new roman&quot;, times, serif; text-align: center; border-bottom: 1pt solid black; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; vertical-align: middle;;width:;"><div style="font-weight:bold;display:inline;">March&#160;31,</div></td><td style="padding-bottom: 1pt; font: 10pt &quot;times new roman&quot;, times, serif; padding-left: 0px; padding-top: 0px; vertical-align: middle;;width:;">&#160;</td><td style="font: 10pt &quot;times new roman&quot;, times, serif; padding-bottom: 1pt; padding-left: 0px; padding-top: 0px; vertical-align: middle;;width:;">&#160;</td><td colspan="2" style="font: 10pt &quot;times new roman&quot;, times, serif; text-align: center; border-bottom: 1pt solid black; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; vertical-align: middle;;width:;"><div style="font-weight:bold;display:inline;">December&#160;31,</div></td><td style="padding-bottom: 1pt; font: 10pt &quot;times new roman&quot;, times, serif; padding-left: 0px; padding-top: 0px; vertical-align: middle;;width:;">&#160;</td></tr><tr style="vertical-align: bottom;"><td style="font-size: 10pt; padding-bottom: 1pt; padding-left: 0px; padding-top: 0px; vertical-align: middle;;width:;">(<div style="font-style:italic;display:inline;;font-style:italic;display:inline;">U.S. dollars in thousands)</div></td><td style="font: 10pt &quot;times new roman&quot;, times, serif; padding-bottom: 1pt; padding-left: 0px; padding-top: 0px; vertical-align: middle;;width:;">&#160;</td><td colspan="2" style="font: 10pt &quot;times new roman&quot;, times, serif; text-align: center; border-bottom: 1pt solid black; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; vertical-align: middle;;width:;"><div style="font-weight:bold;display:inline;">2019</div></td><td style="padding-bottom: 1pt; font: 10pt &quot;times new roman&quot;, times, serif; padding-left: 0px; padding-top: 0px; vertical-align: middle;;width:;">&#160;</td><td style="font: 10pt &quot;times new roman&quot;, times, serif; padding-bottom: 1pt; padding-left: 0px; padding-top: 0px; vertical-align: middle;;width:;">&#160;</td><td colspan="2" style="font: 10pt &quot;times new roman&quot;, times, serif; text-align: center; border-bottom: 1pt solid black; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; vertical-align: middle;;width:;"><div style="font-weight:bold;display:inline;">2018</div></td><td style="padding-bottom: 1pt; font: 10pt &quot;times new roman&quot;, times, serif; padding-left: 0px; padding-top: 0px; vertical-align: middle;;width:;">&#160;</td></tr><tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="width: 70%; font-size: 10pt; text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; vertical-align: middle;">Raw materials</td><td style="width: 0%; font-size: 10pt; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; font-family: &quot;times new roman&quot;, times, serif; vertical-align: middle;">&#160;</td><td style="width: 1%; font-size: 10pt; text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; vertical-align: middle;">$</td><td style="width: 12%; font-size: 10pt; text-align: right; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; vertical-align: middle;">3,047</td><td style="width: 1%; font-size: 10pt; text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; font-family: &quot;times new roman&quot;, times, serif; vertical-align: middle;">&#160;</td><td style="width: 2%; font-size: 10pt; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; font-family: &quot;times new roman&quot;, times, serif; vertical-align: middle;">&#160;</td><td style="width: 1%; font-size: 10pt; text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; vertical-align: middle;">$</td><td style="width: 12%; font-size: 10pt; text-align: right; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; vertical-align: middle;">3,792</td><td style="width: 1%; font-size: 10pt; text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; font-family: &quot;times new roman&quot;, times, serif; vertical-align: middle;">&#160;</td></tr><tr style="vertical-align: bottom; background-color: white;"><td style="font-size: 10pt; text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; vertical-align: middle; width: 70%;">Work in progress</td><td style="font-size: 10pt; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; font-family: &quot;times new roman&quot;, times, serif; vertical-align: middle; width: 0%;">&#160;</td><td style="font-size: 10pt; text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; font-family: &quot;times new roman&quot;, times, serif; vertical-align: middle; width: 1%;">&#160;</td><td style="font-size: 10pt; text-align: right; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; vertical-align: middle; width: 12%;">45</td><td style="font-size: 10pt; text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; font-family: &quot;times new roman&quot;, times, serif; vertical-align: middle; width: 1%;">&#160;</td><td style="font-size: 10pt; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; font-family: &quot;times new roman&quot;, times, serif; vertical-align: middle; width: 2%;">&#160;</td><td style="font-size: 10pt; text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; font-family: &quot;times new roman&quot;, times, serif; vertical-align: middle; width: 1%;">&#160;</td><td style="font-size: 10pt; text-align: right; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; font-family: &quot;times new roman&quot;, times, serif; vertical-align: middle; width: 12%;">&#160;</td><td style="font-size: 10pt; text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; font-family: &quot;times new roman&quot;, times, serif; vertical-align: middle; width: 1%;">&#160;</td></tr><tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-size: 10pt; text-align: left; padding-bottom: 1pt; padding-left: 0px; padding-top: 0px; vertical-align: middle; width: 70%;">Finished goods</td><td style="font: 10pt &quot;times new roman&quot;, times, serif; padding-bottom: 1pt; padding-left: 0px; padding-top: 0px; vertical-align: middle; width: 0%;">&#160;</td><td style="border-bottom: 1pt solid black; font: 10pt &quot;times new roman&quot;, times, serif; text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; vertical-align: middle; width: 1%;">&#160;</td><td style="border-bottom: 1pt solid black; font: 10pt &quot;times new roman&quot;, times, serif; text-align: right; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; vertical-align: middle; width: 12%;">3,615</td><td style="padding-bottom: 1pt; font: 10pt &quot;times new roman&quot;, times, serif; text-align: left; padding-left: 0px; padding-top: 0px; vertical-align: middle; width: 1%;">&#160;</td><td style="font: 10pt &quot;times new roman&quot;, times, serif; padding-bottom: 1pt; padding-left: 0px; padding-top: 0px; vertical-align: middle; width: 2%;">&#160;</td><td style="border-bottom: 1pt solid black; font: 10pt &quot;times new roman&quot;, times, serif; text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; vertical-align: middle; width: 1%;">&#160;</td><td style="border-bottom: 1pt solid black; font: 10pt &quot;times new roman&quot;, times, serif; text-align: right; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; vertical-align: middle; width: 12%;">4,777</td><td style="padding-bottom: 1pt; font: 10pt &quot;times new roman&quot;, times, serif; text-align: left; padding-left: 0px; padding-top: 0px; vertical-align: middle; width: 1%;">&#160;</td></tr><tr style="vertical-align: bottom; background-color: white;"><td style="font-size: 10pt; text-align: left; padding-bottom: 2.5pt; padding-left: 0px; padding-top: 0px; vertical-align: middle; width: 70%;">Total inventory</td><td style="font: 10pt &quot;times new roman&quot;, times, serif; padding-bottom: 2.5pt; padding-left: 0px; padding-top: 0px; vertical-align: middle; width: 0%;">&#160;</td><td style="border-bottom: 2.5pt double black; font: 10pt &quot;times new roman&quot;, times, serif; text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; vertical-align: middle; width: 1%;">$</td><td style="border-bottom: 2.5pt double black; font: 10pt &quot;times new roman&quot;, times, serif; text-align: right; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; vertical-align: middle; width: 12%;">6,707</td><td style="padding-bottom: 1.5pt; font: 10pt &quot;times new roman&quot;, times, serif; text-align: left; padding-left: 0px; padding-top: 0px; vertical-align: middle; width: 1%;">&#160;</td><td style="font: 10pt &quot;times new roman&quot;, times, serif; padding-bottom: 2.5pt; padding-left: 0px; padding-top: 0px; vertical-align: middle; width: 2%;">&#160;</td><td style="border-bottom: 2.5pt double black; font: 10pt &quot;times new roman&quot;, times, serif; text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; vertical-align: middle; width: 1%;">$</td><td style="border-bottom: 2.5pt double black; font: 10pt &quot;times new roman&quot;, times, serif; text-align: right; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; vertical-align: middle; width: 12%;">8,569</td><td style="padding-bottom: 1.5pt; font: 10pt &quot;times new roman&quot;, times, serif; text-align: left; padding-left: 0px; padding-top: 0px; vertical-align: middle; width: 1%;">&#160;</td></tr></table><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px;"></div><table cellpadding="0" cellspacing="0" style="font: 10pt &quot;times new roman&quot;, times, serif; letter-spacing: normal; orphans: 2; text-indent: 0px; text-transform: none; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; margin-top: 0pt; margin-bottom: 0pt; border-collapse: collapse; border-spacing: 0px; table-layout: fixed;;width:100%;"><tr style="vertical-align: top;"><td style="width: 0.5in; padding: 0px;"></td><td style="width: 0.25in; padding-left: 0px; padding-top: 0px; padding-bottom: 0px;">b.</td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;">During the year ended December&#160;31, 2018 and the three months ended March&#160;31, 2019, the Company recorded approximately $<div style="letter-spacing: 0px; top: 0px;;display:inline;">1.1</div>&#160;million and $<div style="letter-spacing: 0px; top: 0px;;display:inline;">65,000</div>, respectively, for write-down of inventory under cost of goods sold.</td></tr></table><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px;"></div> <table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for inventory. Includes, but is not limited to, the basis of stating inventory, the method of determining inventory cost, the classes of inventory, and the nature of the cost elements included in inventory.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -URI http://asc.fasb.org/topic&amp;trid=2126998<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>21
<FILENAME>R10.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.1</span><table class="report" border="0" cellspacing="2" id="idp6622800400">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>FAIR VALUE MEASUREMENT<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2019</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresTextBlock', window );">FAIR VALUE MEASUREMENT</a></td>
<td class="text"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; margin-bottom: 0px; margin-top: 0px; margin-right: 0px;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">NOTE 3 &#8211; FAIR VALUE MEASUREMENT</div></div></div><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; margin-bottom: 0px; margin-top: 0px; margin-right: 0px; background: none;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; margin: 0px 0px 0px 0.49in;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">The Company measures fair value and discloses fair value measurements for financial assets and liabilities. Fair value is based on the price that would be received from the sale of an asset, or paid to transfer a liability, in an orderly transaction between market participants at the measurement date.</div></div><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; margin: 0px 0px 0px 0.49in; background: none;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; margin: 0px 0px 0px 0.49in;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">The accounting standard establishes a fair value hierarchy that prioritizes observable and unobservable inputs used to measure fair value into three broad levels, which are described below:</div></div><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; margin: 0px 0px 0px 0.49in; background: none;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; margin: 0px 0px 0px 0.49in;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">Level 1: Quoted prices (unadjusted) in active markets that are accessible at the measurement date for assets or liabilities. The fair value hierarchy gives the highest priority to Level 1 inputs.</div></div><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; margin: 0px 0px 0px 0.49in; background: none;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; margin: 0px 0px 0px 0.49in;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">Level 2: Observable prices that are based on inputs not quoted on active markets, but corroborated by market data.</div></div><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; margin: 0px 0px 0px 0.49in; background: none;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; margin: 0px 0px 0px 0.49in;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">Level 3: Unobservable inputs are used when little or no market data is available. The fair value hierarchy gives the lowest priority to Level 3 inputs.</div></div><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; margin: 0px 0px 0px 0.49in; background: none;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; margin: 0px 0px 0px 0.49in;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">In determining fair value, the Company utilizes valuation techniques that maximize the use of observable inputs and minimize the use of unobservable inputs to the extent possible and considers counterparty credit risk in its assessment of fair value.</div></div><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; margin: 0px 0px 0px 0.49in; background: none;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; margin: 0px 0px 0px 0.49in;"><div style="color:#000000;font-family:&quot;times new roman&quot;,times,serif;font-size:10pt;letter-spacing:0px;top:0px;;display:inline;">The fair value of the financial instruments included in the working capital of the Company is usually identical or close to their carrying value. The fair value of the convertible notes derivative is based on Level </div><div style="color:#000000;font-family:&quot;times new roman&quot;,times,serif;font-size:10pt;letter-spacing:0px;top:0px;;display:inline;">3</div><div style="color:#000000;font-family:&quot;times new roman&quot;,times,serif;font-size:10pt;letter-spacing:0px;top:0px;;display:inline;"> measurement.</div></div><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; margin: 0px 0px 0px 0.49in; background: none;"><div style="color: rgb(0, 0, 0); font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px; background: none; text-decoration: none;;display:inline;"><div style="background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; margin: 0px 0px 0px 0.49in;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">The fair value of the $57.9&#160;</div>million <div style="color:#000000;font-family:&quot;times new roman&quot;,times,serif;font-size:10pt;letter-spacing:0px;top:0px;;display:inline;">principal amount of the Company&#8217;s outstanding 7.50% convertible promissory notes due 2021 (the &#8220;2021 Notes&#8221;) as of March&#160;31, 2019 is appro</div>ximately $64.5&#160;million based on a Level 3 measurement.</div><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; margin: 0px 0px 0px 0.49in; background: none;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div><div style="color: rgb(0, 0, 0); font: 10pt &quot;times new roman&quot;, times, serif; letter-spacing: normal; orphans: 2; text-align: start; text-indent: 0px; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; margin: 0px 0px 0px 35.45pt;">The Company prepared a valuation of the fair value of the Company&#8217;s outstanding 2021 Notes (a Level 3 valuation) as of March&#160;31, 2019. The value of these notes was estimated by implementing the binomial model. The liability component was valued based on the Income Approach. The following parameters were used:</div><div style="color: rgb(0, 0, 0); font: 10pt &quot;times new roman&quot;, times, serif; letter-spacing: normal; orphans: 2; text-align: start; text-indent: 0px; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; margin: 0px 0px 0px 35.45pt; background: none;">&#160;</div><table style="font: 10pt &quot;times new roman&quot;, times, serif; letter-spacing: normal; orphans: 2; text-indent: 0px; text-transform: none; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; border-collapse: collapse; width: 55%; margin-left: 0.5in; border-spacing: 0px;"><tr style="vertical-align:bottom; background-color:white"><td style="font-size: 10pt; padding-bottom: 1pt; padding-left: 5.4pt; padding-top: 0px;">&#160;</td><td style="font: 10pt &quot;times new roman&quot;, times, serif; padding-bottom: 1pt; padding-left: 0px; padding-top: 0px;">&#160;</td><td style="font: 10pt &quot;times new roman&quot;, times, serif; text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px;">&#160;</td><td style="padding-bottom: 1pt; font: 10pt &quot;times new roman&quot;, times, serif; text-align: right; padding-left: 0px; padding-top: 0px;"><div style="border-bottom: 0.5pt solid black; font-style: normal; font-variant: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: &quot;times new roman&quot;, times, serif; margin: 0px; text-align: center;"><div style="font-weight:bold;display:inline;">2021 Notes</div></div></td><td style="padding-bottom: 1pt; font: 10pt &quot;times new roman&quot;, times, serif; text-align: left; padding-left: 0px; padding-top: 0px;">&#160;</td></tr><tr style="vertical-align:bottom; background-color:#cceeff"><td style="font-size: 10pt; width: 775.672px; text-indent: -10pt; padding-left: 10pt; padding-top: 0px; padding-bottom: 0px;">Stock price (USD)</td><td style="font-size: 10pt; width: 21px; padding-left: 0px; padding-top: 0px; padding-bottom: 0px;">&#160;</td><td style="font-size: 10pt; width: 10px; text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px;">&#160;</td><td style="font-size: 10pt; width: 207px; text-align: center; padding-left: 0px; padding-top: 0px; padding-bottom: 0px;">0.44</td><td style="font-size: 10pt; width: 10px; text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px;">&#160;</td></tr><tr style="vertical-align:bottom; background-color:white"><td style="font-size: 10pt; text-align: left; text-indent: -10pt; padding-left: 10pt; padding-top: 0px; padding-bottom: 0px;">Expected term</td><td style="font-size: 10pt; padding-left: 0px; padding-top: 0px; padding-bottom: 0px;">&#160;</td><td style="font-size: 10pt; text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px;">&#160;</td><td style="font-size: 10pt; text-align: center; padding-left: 0px; padding-top: 0px; padding-bottom: 0px;">2.63</td><td style="font-size: 10pt; text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px;">&#160;</td></tr><tr style="vertical-align:bottom; background-color:#cceeff"><td style="font-size: 10pt; text-align: left; text-indent: -10pt; padding-left: 10pt; padding-top: 0px; padding-bottom: 0px;">Risk free rate</td><td style="font-size: 10pt; padding-left: 0px; padding-top: 0px; padding-bottom: 0px;">&#160;</td><td style="font-size: 10pt; text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px;">&#160;</td><td style="font-size: 10pt; text-align: center; padding-left: 0px; line-height: 10pt; padding-top: 0px; padding-bottom: 0px;">2.21%</td><td style="font-size: 10pt; text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px;">&#160;</td></tr><tr style="vertical-align:bottom; background-color:white"><td style="font-size: 10pt; text-indent: -10pt; padding-left: 10pt; padding-top: 0px; padding-bottom: 0px;">Volatility</td><td style="font-size: 10pt; padding-left: 0px; padding-top: 0px; padding-bottom: 0px;">&#160;</td><td style="font-size: 10pt; text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px;">&#160;</td><td style="font-size: 10pt; text-align: center; padding-left: 0px; padding-top: 0px; padding-bottom: 0px;">81.56%</td><td style="font-size: 10pt; text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px;">&#160;</td></tr><tr style="vertical-align:bottom; background-color:#cceeff"><td style="font-size: 10pt; text-indent: -10pt; padding-left: 10pt; padding-top: 0px; padding-bottom: 0px;">Yield</td><td style="font-size: 10pt; padding-left: 0px; padding-top: 0px; padding-bottom: 0px;">&#160;</td><td style="font-size: 10pt; text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px;">&#160;</td><td style="font-size: 10pt; text-align: center; padding-left: 0px; padding-top: 0px; padding-bottom: 0px;">12.6%</td><td style="font-size: 10pt; text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px;">&#160;</td></tr></table><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px; background: none;"></div><div style="color: rgb(0, 0, 0); font: 10pt &quot;times new roman&quot;, times, serif; letter-spacing: normal; orphans: 2; text-align: start; text-indent: 0px; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; margin: 0px 0px 0px 70.75pt; background: none;">&#160;</div> <table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px;"></div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -URI http://asc.fasb.org/topic&amp;trid=2155941<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>22
<FILENAME>R11.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.1</span><table class="report" border="0" cellspacing="2" id="idp6606061232">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>OPERATING LEASES<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2019</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeasesOperatingAbstract', window );"><strong>Leases, Operating [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeasesTextBlock', window );">OPERATING LEASES</a></td>
<td class="text"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; margin-bottom: 0px; margin-top: 0px; margin-right: 0px;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">NOTE 4 &#8211; </div></div><div style="color: rgb(0, 0, 0); font-family: 'times new roman', times, serif; font-size: 13.3333px; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; letter-spacing: normal; orphans: 2; text-align: start; text-indent: 0px; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;;font-weight:bold;display:inline;">OPERATING LEASES</div></div><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; margin-bottom: 0px; margin-top: 0px; margin-right: 0px; background: none;">&#160;</div><div style="color: rgb(0, 0, 0); font: 10pt &quot;times new roman&quot;, times, serif; letter-spacing: normal; orphans: 2; text-align: start; text-indent: 0px; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; margin: 0px 0px 0px 0.5in;">The Company is a party to a number of lease agreements for its facilities, the latest of which has been extended until 2021. The Company has the option to extend certain of such agreements on two additional occasions for additional five-year periods each, for a total of 10 additional years. During the extended lease period, the aggregate monthly rental payments will increase by&#160;7.5%&#160;- 10% for each option. The Company expects to exercise these options in future periods. As of March&#160;31, 2019, the Company provided bank guarantees of approximately&#160;$412,000, in the aggregate, to secure the fulfillment of its obligations under the lease agreements. As of December 31, 2018, the future minimum lease payments required under the operating leases for such premises are approximately $758,000, $758,000 and $621,000, for fiscal years 2019 through 2021, respectively.</div><div style="color: rgb(0, 0, 0); font: 10pt &quot;times new roman&quot;, times, serif; letter-spacing: normal; orphans: 2; text-align: start; text-indent: 0px; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; margin: 0px 0px 0px 0.5in; background: none;">&#160;</div><div style="color: rgb(0, 0, 0); font: 10pt &quot;times new roman&quot;, times, serif; letter-spacing: normal; orphans: 2; text-align: start; text-indent: 0px; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; margin: 0px 0px 0px 0.5in;">The Company entered into several three-year leases for vehicles which are regularly amended as new vehicles are leased. As of December 31, 2018, the future minimum lease payments for the years ending December&#160;31, 2019, 2020 and 2021 are approximately $474,000, $333,000 and $82,000, respectively.</div><div style="color: rgb(0, 0, 0); font: 10pt &quot;times new roman&quot;, times, serif; letter-spacing: normal; orphans: 2; text-align: start; text-indent: 0px; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; margin: 0px 0px 0px 0.5in; background: none;"></div><div style="color: rgb(0, 0, 0); font: 10pt &quot;times new roman&quot;, times, serif; letter-spacing: normal; orphans: 2; text-align: start; text-indent: 0px; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; margin: 0px; background: none;"></div><div style="color: rgb(0, 0, 0); font: 10pt &quot;times new roman&quot;, times, serif; letter-spacing: normal; orphans: 2; text-align: start; text-indent: 0px; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; margin: 0px; background: none;">&#160;</div><div style="color: rgb(0, 0, 0); font: 10pt &quot;times new roman&quot;, times, serif; letter-spacing: normal; orphans: 2; text-align: start; text-indent: 0in; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; margin: 0px 0px 0px 0.5in;">The following table sets forth data regarding the Company&#8217;s operating leases for the three months ended March 31, 2019:</div><div style="color: rgb(0, 0, 0); font: 10pt &quot;times new roman&quot;, times, serif; letter-spacing: normal; orphans: 2; text-align: start; text-indent: 0px; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; margin: 0px 0px 0px 0.5in; background: none;">&#160;&#160;</div><table cellpadding="0" cellspacing="0" style="font: 10pt &quot;times new roman&quot;, times, serif; letter-spacing: normal; orphans: 2; text-indent: 0px; text-transform: none; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; border-collapse: collapse; width: 55%; margin-left: 0.5in; border-spacing: 0px;"><tr style="vertical-align: bottom;"><td style="font-size: 10pt; padding-bottom: 1pt; padding-left: 0px; padding-top: 0px;">(<div style="font-style:italic;display:inline;;font-style:italic;display:inline;">U.S. dollars in thousands)</div></td><td style="font: 10pt &quot;times new roman&quot;, times, serif; padding-bottom: 1pt; padding-left: 0px; padding-top: 0px;">&#160;</td><td colspan="2" style="font: 10pt &quot;times new roman&quot;, times, serif; text-align: center; border-bottom: 1pt solid black; padding-left: 0px; padding-top: 0px; padding-bottom: 0px;"><div style="font-weight:bold;display:inline;">March 31, 2019</div></td><td style="padding-bottom: 1pt; font: 10pt &quot;times new roman&quot;, times, serif; padding-left: 0px; padding-top: 0px;">&#160;</td></tr><tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="width: 788px; font-size: 10pt; text-align: left; padding-bottom: 2.5pt; padding-left: 0in; padding-top: 0px;"><div style="line-height: normal;">Operating lease costs</div></td><td style="width: 20px; font: 10pt &quot;times new roman&quot;, times, serif; padding-bottom: 2.5pt; padding-left: 0px; padding-top: 0px;">&#160;</td><td style="width: 10px; border-bottom: 2.5pt double black; font: 10pt &quot;times new roman&quot;, times, serif; text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px;">$</td><td style="width: 207px; border-bottom: 2.5pt double black; font: 10pt &quot;times new roman&quot;, times, serif; text-align: right; padding-left: 0px; padding-top: 0px; padding-bottom: 0px;">292</td><td style="width: 12px; padding-bottom: 1.5pt; font: 10pt &quot;times new roman&quot;, times, serif; text-align: left; padding-left: 0px; padding-top: 0px;">&#160;</td></tr><tr style="vertical-align: bottom; background-color: white;"><td style="font-size: 10pt; text-align: left; padding-bottom: 2.5pt; padding-left: 0in; padding-top: 0px;">Cash paid for amounts included in the&#160;measurement of lease liabilities</td><td style="font: 10pt &quot;times new roman&quot;, times, serif; padding-bottom: 2.5pt; padding-left: 0px; padding-top: 0px;">&#160;</td><td style="border-bottom: 2.5pt double black; font: 10pt &quot;times new roman&quot;, times, serif; text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px;">&#160;</td><td style="border-bottom: 2.5pt double black; font: 10pt &quot;times new roman&quot;, times, serif; text-align: right; padding-left: 0px; padding-top: 0px; padding-bottom: 1.5pt;">328</td><td style="padding-bottom: 1.5pt; font: 10pt &quot;times new roman&quot;, times, serif; text-align: left; padding-left: 0px; padding-top: 0px;">&#160;</td></tr><tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-size: 10pt; text-align: left; padding-left: 0in; padding-bottom: 2.5pt; padding-top: 0px;">Right of use assets obtained in exchange&#160;for new operating lease liabilities</td><td style="font-size: 10pt; padding-bottom: 2.5pt; padding-left: 0px; padding-top: 0px;">&#160;</td><td style="font-size: 10pt; text-align: left; border-bottom: 2.5pt double black; padding-left: 0px; padding-top: 0px; padding-bottom: 0px;">&#160;</td><td style="font-size: 10pt; text-align: right; border-bottom: 2.5pt double black; padding-left: 0px; padding-top: 0px; padding-bottom: 1.5pt;">52</td><td style="font-size: 10pt; text-align: left; padding-bottom: 1.5pt; padding-left: 0px; padding-top: 0px;">&#160;</td></tr><tr style="vertical-align: bottom; background-color: white;"><td style="font-size: 10pt; text-align: left; padding-bottom: 2.5pt; padding-left: 0in; padding-top: 0px;">Weighted average remaining lease term&#160;(in years)</td><td style="font: 10pt &quot;times new roman&quot;, times, serif; padding-bottom: 2.5pt; padding-left: 0px; padding-top: 0px;">&#160;</td><td style="border-bottom: 2.5pt double black; font: 10pt &quot;times new roman&quot;, times, serif; text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px;">&#160;</td><td style="border-bottom: 2.5pt double black; font: 10pt &quot;times new roman&quot;, times, serif; text-align: right; padding-left: 0px; padding-top: 0px; padding-bottom: 1.5pt;">10.84</td><td style="padding-bottom: 1.5pt; font: 10pt &quot;times new roman&quot;, times, serif; text-align: left; padding-left: 0px; padding-top: 0px;">&#160;</td></tr><tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-size: 10pt; padding-bottom: 2.5pt; padding-left: 0in; padding-top: 0px;">Weighted average discount rate</td><td style="font: 10pt &quot;times new roman&quot;, times, serif; padding-bottom: 2.5pt; padding-left: 0px; padding-top: 0px;">&#160;</td><td style="border-bottom: 2.5pt double black; font: 10pt &quot;times new roman&quot;, times, serif; text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px;">&#160;</td><td style="border-bottom: 2.5pt double black; font: 10pt &quot;times new roman&quot;, times, serif; text-align: right; padding-left: 0px; padding-top: 0px; padding-bottom: 1.5pt;">12.58</td><td style="padding-bottom: 1.5pt; font: 10pt &quot;times new roman&quot;, times, serif; text-align: left; padding-left: 0px; padding-top: 0px;">%</td></tr></table><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px;"></div><div style="color: rgb(0, 0, 0); font: 10pt &quot;times new roman&quot;, times, serif; letter-spacing: normal; orphans: 2; text-align: start; text-indent: 0px; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; margin: 0px 0px 0px 56.9pt; background: none;"></div><div style="color: rgb(0, 0, 0); font: 10pt &quot;times new roman&quot;, times, serif; letter-spacing: normal; orphans: 2; text-align: start; text-indent: 0px; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; margin: 0px 0px 0px 0.5in; background: none;"></div><div style="color: rgb(0, 0, 0); font: 10pt &quot;times new roman&quot;, times, serif; letter-spacing: normal; orphans: 2; text-align: start; text-indent: 0px; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; margin: 0px 0px 0px 0.5in; background: none;"></div><div style="color: rgb(0, 0, 0); font: 10pt &quot;times new roman&quot;, times, serif; letter-spacing: normal; orphans: 2; text-align: start; text-indent: 0px; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; margin: 0px 0px 0px 0.5in; background: none;"></div><div style="color: rgb(0, 0, 0); font: 10pt &quot;times new roman&quot;, times, serif; letter-spacing: normal; orphans: 2; text-align: start; text-indent: 0px; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; margin: 0px 0px 0px 0.5in; background: none;">&#160;</div><div style="color: rgb(0, 0, 0); font: 10pt &quot;times new roman&quot;, times, serif; letter-spacing: normal; orphans: 2; text-align: start; text-indent: 0px; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; margin: 0px 0px 0px 0.5in;">The following table sets forth a maturity analysis of the Company&#8217;s operating lease liabilities as of March&#160;31, 2019:</div><div style="color: rgb(0, 0, 0); font: 10pt &quot;times new roman&quot;, times, serif; letter-spacing: normal; orphans: 2; text-align: start; text-indent: 0px; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; margin: 0px 0px 0px 0.5in; background: none;">&#160;</div><table cellpadding="0" cellspacing="0" style="font: 10pt &quot;times new roman&quot;, times, serif; letter-spacing: normal; orphans: 2; text-indent: 0px; text-transform: none; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; border-collapse: collapse; width: 55%; margin-left: 0.5in; border-spacing: 0px;"><tr style="vertical-align: bottom;"><td style="font-size: 10pt; padding-bottom: 1pt; padding-left: 0px; padding-top: 0px;">(<div style="font-style:italic;display:inline;;font-style:italic;display:inline;">U.S. dollars in thousands)</div></td><td style="font: 10pt &quot;times new roman&quot;, times, serif; padding-bottom: 1pt; padding-left: 0px; padding-top: 0px;">&#160;</td><td colspan="2" style="font: 10pt &quot;times new roman&quot;, times, serif; text-align: center; border-bottom: 1pt solid black; padding-left: 0px; padding-top: 0px; padding-bottom: 0px;"><div style="font-weight:bold;display:inline;">March 31, 2019</div></td><td style="padding-bottom: 1pt; font: 10pt &quot;times new roman&quot;, times, serif; padding-left: 0px; padding-top: 0px;">&#160;</td></tr><tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="width: 789px; font-size: 10pt; text-align: left; padding-left: 0in; padding-top: 0px; padding-bottom: 0px;">2019&#160;(excluding&#160;the&#160;three&#160;months&#160;ended&#160;March&#160;31,&#160;2019)</td><td style="width: 21px; font-size: 10pt; padding-left: 0px; padding-top: 0px; padding-bottom: 0px;">&#160;</td><td style="width: 10px; font-size: 10pt; text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px;">$</td><td style="width: 207px; font-size: 10pt; text-align: right; padding-left: 0px; padding-top: 0px; padding-bottom: 0px;">947</td><td style="width: 10px; font-size: 10pt; text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px;">&#160;</td></tr><tr style="vertical-align: bottom; background-color: white;"><td style="font-size: 10pt; text-align: left; padding-left: 0in; padding-top: 0px; padding-bottom: 0px;">2020</td><td style="font-size: 10pt; padding-left: 0px; padding-top: 0px; padding-bottom: 0px;">&#160;</td><td style="font-size: 10pt; text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px;">$</td><td style="font-size: 10pt; text-align: right; padding-left: 0px; padding-top: 0px; padding-bottom: 0px;">1,135</td><td style="font-size: 10pt; text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px;">&#160;</td></tr><tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-size: 10pt; text-align: left; padding-left: 0in; padding-top: 0px; padding-bottom: 0px;">2021</td><td style="font-size: 10pt; padding-left: 0px; padding-top: 0px; padding-bottom: 0px;">&#160;</td><td style="font-size: 10pt; text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px;">$</td><td style="font-size: 10pt; text-align: right; padding-left: 0px; padding-top: 0px; padding-bottom: 0px;">888</td><td style="font-size: 10pt; text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px;">&#160;</td></tr><tr style="vertical-align: bottom; background-color: white;"><td style="font-size: 10pt; text-align: left; padding-left: 0in; padding-top: 0px; padding-bottom: 0px;">2022</td><td style="font-size: 10pt; padding-left: 0px; padding-top: 0px; padding-bottom: 0px;">&#160;</td><td style="font-size: 10pt; text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px;">$</td><td style="font-size: 10pt; text-align: right; padding-left: 0px; padding-top: 0px; padding-bottom: 0px;">774</td><td style="font-size: 10pt; text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px;">&#160;</td></tr><tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-size: 10pt; text-align: left; padding-left: 0in; padding-top: 0px; padding-bottom: 0px;">2023</td><td style="font-size: 10pt; padding-left: 0px; padding-top: 0px; padding-bottom: 0px;">&#160;</td><td style="font-size: 10pt; text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px;">$</td><td style="font-size: 10pt; text-align: right; padding-left: 0px; padding-top: 0px; padding-bottom: 0px;">770</td><td style="font-size: 10pt; text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px;">&#160;</td></tr><tr style="vertical-align: bottom; background-color: white;"><td style="font-size: 10pt; padding-bottom: 2.5pt; padding-left: 0in; padding-top: 0px;">After&#160;2024&#160;</td><td style="font: 10pt &quot;times new roman&quot;, times, serif; padding-bottom: 2.5pt; padding-left: 0px; padding-top: 0px;">&#160;</td><td style="border-bottom: 2.5pt double black; font: 10pt &quot;times new roman&quot;, times, serif; text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px;">$</td><td style="border-bottom: 2.5pt double black; font: 10pt &quot;times new roman&quot;, times, serif; text-align: right; padding-left: 0px; padding-top: 0px; padding-bottom: 0px;">6,380</td><td style="padding-bottom: 1.5pt; font: 10pt &quot;times new roman&quot;, times, serif; text-align: left; padding-left: 0px; padding-top: 0px;">&#160;</td></tr><tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-size: 10pt; text-align: left; padding-bottom: 2.5pt; padding-left: 0in; padding-top: 0px;">Total undiscounted cash flows</td><td style="font: 10pt &quot;times new roman&quot;, times, serif; padding-bottom: 2.5pt; padding-left: 0px; padding-top: 0px;">&#160;</td><td style="border-bottom: 2.5pt double black; font: 10pt &quot;times new roman&quot;, times, serif; text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px;">$</td><td style="border-bottom: 2.5pt double black; font: 10pt &quot;times new roman&quot;, times, serif; text-align: right; padding-left: 0px; padding-top: 0px; padding-bottom: 0px;">10,894</td><td style="padding-bottom: 1.5pt; font: 10pt &quot;times new roman&quot;, times, serif; text-align: left; padding-left: 0px; padding-top: 0px;">&#160;</td></tr><tr style="vertical-align: bottom; background-color: white;"><td style="font-size: 10pt; padding-bottom: 2.5pt; padding-left: 0in; padding-top: 0px;">Less:&#160;imputed&#160;interest</td><td style="font: 10pt &quot;times new roman&quot;, times, serif; padding-bottom: 2.5pt; padding-left: 0px; padding-top: 0px;">&#160;</td><td style="border-bottom: 2.5pt double black; font: 10pt &quot;times new roman&quot;, times, serif; text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px;">$</td><td style="border-bottom: 2.5pt double black; font: 10pt &quot;times new roman&quot;, times, serif; text-align: right; padding-left: 0px; padding-top: 0px; padding-bottom: 0px;">5,139</td><td style="padding-bottom: 1.5pt; font: 10pt &quot;times new roman&quot;, times, serif; text-align: left; padding-left: 0px; padding-top: 0px;">&#160;</td></tr><tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-size: 10pt; text-align: left; padding-bottom: 2.5pt; padding-left: 0in; padding-top: 0px;">Present&#160;value&#160;of lease liabilities</td><td style="font: 10pt &quot;times new roman&quot;, times, serif; padding-bottom: 2.5pt; padding-left: 0px; padding-top: 0px;">&#160;</td><td style="border-bottom: 2.5pt double black; font: 10pt &quot;times new roman&quot;, times, serif; text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px;">$</td><td style="border-bottom: 2.5pt double black; font: 10pt &quot;times new roman&quot;, times, serif; text-align: right; padding-left: 0px; padding-top: 0px; padding-bottom: 0px;">5,755</td><td style="padding-bottom: 1.5pt; font: 10pt &quot;times new roman&quot;, times, serif; text-align: left; padding-left: 0px; padding-top: 0px;">&#160;</td></tr></table><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px;"></div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesOperatingAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesOperatingAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeasesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for operating leases of lessee. Includes, but is not limited to, description of operating lease and maturity analysis of operating lease liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -URI http://asc.fasb.org/subtopic&amp;trid=77888251<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeasesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>23
<FILENAME>R12.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.1</span><table class="report" border="0" cellspacing="2" id="idp6806168704">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>REVENUES<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2019</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementAbstract', window );"><strong>Income Statement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_plx_RevenueDisclosureTextBlock', window );">REVENUES</a></td>
<td class="text"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; margin-bottom: 0px; margin-top: 0px; margin-right: 0px;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">NOTE 5 &#8211; REVENUES</div></div></div><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; margin-bottom: 0px; margin-top: 0px; margin-right: 0px; background: none;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; margin: 0px 0px 0px 0.5in;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">The following table summarizes the Company&#8217;s disaggregation of revenues:</div></div><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; margin: 0px 0px 0px 0.5in; background: none;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div><table style="border: none; border-collapse: collapse; margin: 0in 6.75pt 0in 0.5in; width: 55%;;text-align:left;"><tr><td style="border-bottom: none; border-top: none; padding: 0px 0px 1pt; vertical-align: bottom;;width:;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; margin-right: 0px; margin-bottom: 0px; margin-top: 0px; line-height: normal; background: none; text-align: center;"><div style="background: none;;font-weight:bold;display:inline;width:100%;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div></td><td style="border-top: none; padding: 0in 0in 1pt; vertical-align: bottom;;width:;"><div style="font-size: 10pt; font-family: &quot;times new roman&quot;, times, serif; line-height: normal; margin-bottom: 0px; margin-top: 0px;"><div style="background: none;;font-weight:bold;display:inline;width:100%;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div></td><td colspan="6" style="border-bottom: 1pt solid rgb(0, 0, 0); border-top-style: none; padding: 0in; vertical-align: bottom; white-space: nowrap;;width:;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; text-align: center; margin-right: 0px; margin-bottom: 0px; margin-top: 0px; line-height: normal; white-space: nowrap;"><div style="font-weight:bold;display:inline;">Three months ended March&#160;31,</div></div></td><td style="border-top-style: none; padding: 0in 0in 0.5pt; vertical-align: bottom; white-space: nowrap;"><div style="font-size: 10pt; font-family: &quot;times new roman&quot;, times, serif; line-height: normal; margin-bottom: 0px; margin-top: 0px;"><div style="background: none;;font-weight:bold;display:inline;width:100%;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div></td></tr><tr><td style="border-bottom: none; border-top: none; padding: 0px 0px 1pt; vertical-align: bottom;;width:;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; margin-right: 0px; margin-bottom: 0px; margin-top: 0px; line-height: normal;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;;font-style:italic;display:inline;">(U.S.&#160;dollars&#160;in&#160;thousands)</div></div></div></td><td style="padding: 0in 0in 1pt; vertical-align: bottom;;width:;"><div style="font-size: 10pt; font-family: &quot;times new roman&quot;, times, serif; line-height: normal; margin-bottom: 0px; margin-top: 0px;"><div style="background: none;;font-weight:bold;display:inline;width:100%;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div></td><td colspan="2" style="border-bottom: 1pt solid rgb(0, 0, 0); border-top-style: none; padding: 0in; vertical-align: bottom; white-space: nowrap;;width:;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; text-align: center; margin-right: 0px; margin-bottom: 0px; margin-top: 0px; line-height: normal; white-space: nowrap;"><div style="font-weight:bold;display:inline;width:100%;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;">2019</div></div></div></td><td style="border-top-style: none; padding: 0in 0in 0.5pt; vertical-align: bottom; white-space: nowrap;"><div style="font-size: 10pt; font-family: &quot;times new roman&quot;, times, serif; line-height: normal; margin-bottom: 0px; margin-top: 0px;"><div style="background: none;;font-weight:bold;display:inline;width:100%;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div></td><td style="border-top-style: none; padding: 0in 0in 1pt; vertical-align: bottom; white-space: nowrap;;width:;"><div style="font-size: 10pt; font-family: &quot;times new roman&quot;, times, serif; line-height: normal; margin-bottom: 0px; margin-top: 0px;"><div style="background: none;;font-weight:bold;display:inline;width:100%;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div></td><td colspan="2" style="border-bottom: 1pt solid rgb(0, 0, 0); border-top-style: none; padding: 0in; vertical-align: bottom; white-space: nowrap;;width:;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; text-align: center; margin-right: 0px; margin-bottom: 0px; margin-top: 0px; line-height: normal; white-space: nowrap;"><div style="font-weight:bold;display:inline;width:100%;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;">2018</div></div></div></td><td style="padding: 0in 0in 0.5pt; vertical-align: bottom; white-space: nowrap;"><div style="font-size: 10pt; font-family: &quot;times new roman&quot;, times, serif; line-height: normal; margin-bottom: 0px; margin-top: 0px;"><div style="background: none;;font-weight:bold;display:inline;width:100%;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div></td></tr><tr><td style="background: rgb(204, 238, 255); border-bottom: none; border-top: none; padding: 0px 0px 0px 27pt; vertical-align: bottom; width: 57%; font-size: 10pt;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; margin-right: 0px; margin-bottom: 0px; margin-top: 0px; line-height: normal;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">Pfizer</div><div style="font-size: 10pt; font-family: &quot;times new roman&quot;, times, serif; color: rgb(0, 0, 0); background: none; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;times new roman&quot;, times, serif; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px; font-size: 10pt;;display:inline;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</div></div></div></td><td style="background: rgb(204, 238, 255); border-top: none; padding: 0in; vertical-align: bottom; width: 1%;"><div style="font-size: 10pt; font-family: &quot;times new roman&quot;, times, serif; line-height: normal; background: none; margin-bottom: 0px; margin-top: 0px;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="background-color: rgb(204, 238, 255); width: 1%; border-bottom: none; border-top: 0px none; text-align: left; vertical-align: bottom; padding: 0in;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; text-align: left; margin: 0px 0px 0px 0in; line-height: normal; white-space: nowrap; text-indent: 0in;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;">$</div></div></td><td style="background: rgb(204, 238, 255); border-bottom: none; border-top: 0px none; padding: 0in; vertical-align: bottom; width: 18%; white-space: nowrap; text-align: right;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; text-align: right; margin-right: 0in; margin-bottom: 0px; margin-top: 0px; line-height: normal; white-space: nowrap;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;">1,356</div></div></td><td style="background: rgb(204, 238, 255); padding: 0in; vertical-align: bottom; width: 1%; white-space: nowrap; text-align: left;"><div style="font-size: 10pt; font-family: &quot;times new roman&quot;, times, serif; margin-left: 0in; text-indent: 0in; text-align: left; white-space: nowrap; line-height: normal; background: none; margin-bottom: 0px; margin-top: 0px;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="background-color: rgb(204, 238, 255); width: 2%; vertical-align: bottom; padding: 0in;"><div style="font-size: 10pt; font-family: &quot;times new roman&quot;, times, serif; line-height: normal; background: none; margin-bottom: 0px; margin-top: 0px;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="background: rgb(204, 238, 255); border-top: 0px none; border-bottom: none; padding: 0in; vertical-align: bottom; width: 1%; white-space: nowrap; text-align: left;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; text-align: left; margin: 0px 0px 0px 0in; line-height: normal; white-space: nowrap; text-indent: 0in;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;">$</div></div></td><td style="background: rgb(204, 238, 255); border-bottom: none; border-top: 0px none; padding: 0in; vertical-align: bottom; width: 18%; white-space: nowrap; text-align: right;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; text-align: right; margin-right: 0in; margin-bottom: 0px; margin-top: 0px; line-height: normal; white-space: nowrap;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;">1,980</div></div></td><td style="background: rgb(204, 238, 255); padding: 0in; vertical-align: bottom; width: 1%; white-space: nowrap; text-align: left;"><div style="font-size: 10pt; font-family: &quot;times new roman&quot;, times, serif; margin-left: 0in; text-indent: 0in; text-align: left; white-space: nowrap; line-height: normal; background: none; margin-bottom: 0px; margin-top: 0px;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td></tr><tr><td style="background: rgb(255, 255, 255); border-top: none; border-bottom: none; padding: 0px 0px 1pt 27pt; vertical-align: bottom; width: 57%; font-size: 10pt;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; margin-right: 0px; margin-bottom: 0px; margin-top: 0px; line-height: normal;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">Brazil</div><div style="font-size: 10pt; font-family: &quot;times new roman&quot;, times, serif; color: rgb(0, 0, 0); background: none; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;times new roman&quot;, times, serif; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px; font-size: 10pt;;display:inline;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</div></div></div></td><td style="background: rgb(255, 255, 255); padding: 0in 0in 1pt; vertical-align: bottom; width: 1%;"><div style="font-size: 10pt; font-family: &quot;times new roman&quot;, times, serif; line-height: normal; background: none; margin-bottom: 0px; margin-top: 0px;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="background-color: rgb(255, 255, 255); width: 1%; border-bottom: 1pt solid rgb(0, 0, 0); text-align: left; vertical-align: bottom; padding: 0in;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; text-align: left; margin: 0px 0px 0px 0in; line-height: normal; white-space: nowrap; text-indent: 0in;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;">$</div></div></td><td style="background: rgb(255, 255, 255); border-bottom: 1pt solid rgb(0, 0, 0); border-top-style: none; padding: 0in; vertical-align: bottom; width: 18%; white-space: nowrap; text-align: right;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; text-align: right; margin-right: 0in; margin-bottom: 0px; margin-top: 0px; line-height: normal; white-space: nowrap;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;">2,174</div></div></td><td style="background: rgb(255, 255, 255); padding: 0in 0in 0.5pt; vertical-align: bottom; width: 1%; white-space: nowrap; text-align: left;"><div style="font-size: 10pt; font-family: &quot;times new roman&quot;, times, serif; margin-left: 0in; text-indent: 0in; text-align: left; white-space: nowrap; line-height: normal; background: none; margin-bottom: 0px; margin-top: 0px;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="background-color: rgb(255, 255, 255); width: 2%; vertical-align: bottom; padding: 0in 0in 1pt;"><div style="font-size: 10pt; font-family: &quot;times new roman&quot;, times, serif; line-height: normal; background: none; margin-bottom: 0px; margin-top: 0px;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="background: rgb(255, 255, 255); border-bottom: 1pt solid rgb(0, 0, 0); padding: 0in; vertical-align: bottom; width: 1%; white-space: nowrap; text-align: left;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; text-align: left; margin: 0px 0px 0px 0in; line-height: normal; white-space: nowrap; text-indent: 0in;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;">$</div></div></td><td style="background: rgb(255, 255, 255); border-bottom: 1pt solid rgb(0, 0, 0); border-top-style: none; padding: 0in; vertical-align: bottom; width: 18%; white-space: nowrap; text-align: right;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; text-align: right; margin-right: 0in; margin-bottom: 0px; margin-top: 0px; line-height: normal; white-space: nowrap;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;">2,573</div></div></td><td style="background: rgb(255, 255, 255); padding: 0in 0in 0.5pt; vertical-align: bottom; width: 1%; white-space: nowrap; text-align: left;"><div style="font-size: 10pt; font-family: &quot;times new roman&quot;, times, serif; margin-left: 0in; text-indent: 0in; text-align: left; white-space: nowrap; line-height: normal; background: none; margin-bottom: 0px; margin-top: 0px;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td></tr><tr><td style="background: rgb(204, 238, 255); border-top: none; border-bottom: none; padding: 0px 0px 2.5pt 27pt; vertical-align: bottom; width: 57%;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; margin-right: 0px; margin-bottom: 0px; margin-top: 0px; line-height: normal;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">Total revenues from selling goods</div></div></td><td style="background: rgb(204, 238, 255); padding: 0in 0in 2.5pt; vertical-align: bottom; width: 1%;"><div style="font-size: 10pt; font-family: &quot;times new roman&quot;, times, serif; line-height: normal; background: none; margin-bottom: 0px; margin-top: 0px;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="background-color: rgb(204, 238, 255); width: 1%; border-bottom: 2.5pt double rgb(0, 0, 0); text-align: left; vertical-align: bottom; padding: 0in;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; text-align: left; margin: 0px 0px 0px 0in; line-height: normal; white-space: nowrap; text-indent: 0in;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;"><div style="white-space: nowrap;;font-weight:bold;display:inline;">$</div></div></div></td><td style="background: rgb(204, 238, 255); border-bottom: 2.5pt double rgb(0, 0, 0); border-top-style: none; padding: 0in; vertical-align: bottom; width: 18%; white-space: nowrap; text-align: right;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; text-align: right; margin-right: 0in; margin-bottom: 0px; margin-top: 0px; line-height: normal; white-space: nowrap;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;"><div style="white-space: nowrap;;font-weight:bold;display:inline;">3,530</div></div></div></td><td style="background: rgb(204, 238, 255); padding: 0in 0in 1.5pt; vertical-align: bottom; width: 1%; white-space: nowrap; text-align: left;"><div style="font-size: 10pt; font-family: &quot;times new roman&quot;, times, serif; margin-left: 0in; text-indent: 0in; text-align: left; white-space: nowrap; line-height: normal; background: none; margin-bottom: 0px; margin-top: 0px;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="padding: 0in 0in 2.5pt; background-color: rgb(204, 238, 255); width: 2%; vertical-align: bottom;"><div style="font-size: 10pt; font-family: &quot;times new roman&quot;, times, serif; line-height: normal; background: none; margin-bottom: 0px; margin-top: 0px;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="background: rgb(204, 238, 255); border-bottom: 2.5pt double rgb(0, 0, 0); padding: 0in; vertical-align: bottom; width: 1%; white-space: nowrap; text-align: left;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; text-align: left; margin: 0px 0px 0px 0in; line-height: normal; white-space: nowrap; text-indent: 0in;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;"><div style="white-space: nowrap;;font-weight:bold;display:inline;">$</div></div></div></td><td style="background: rgb(204, 238, 255); border-bottom: 2.5pt double rgb(0, 0, 0); border-top-style: none; padding: 0in; vertical-align: bottom; width: 18%; white-space: nowrap; text-align: right;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; text-align: right; margin-right: 0in; margin-bottom: 0px; margin-top: 0px; line-height: normal; white-space: nowrap;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;"><div style="white-space: nowrap;;font-weight:bold;display:inline;">4,553</div></div></div></td><td style="background: rgb(204, 238, 255); padding: 0in 0in 1.5pt; vertical-align: bottom; width: 1%; white-space: nowrap; text-align: left;"><div style="font-size: 10pt; font-family: &quot;times new roman&quot;, times, serif; margin-left: 0in; text-indent: 0in; text-align: left; white-space: nowrap; line-height: normal; background: none; margin-bottom: 0px; margin-top: 0px;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td></tr><tr><td style="background: rgb(255, 255, 255); border-top: none; border-bottom: none; padding: 0px 0px 2.5pt 27pt; vertical-align: bottom; width: 57%;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; margin-right: 0px; margin-bottom: 0px; margin-top: 0px; line-height: normal;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">Revenues from license and R&amp;D services</div></div></td><td style="background: rgb(255, 255, 255); padding: 0in 0in 2.5pt; vertical-align: bottom; width: 1%;"><div style="font-size: 10pt; font-family: &quot;times new roman&quot;, times, serif; line-height: normal; background: none; margin-bottom: 0px; margin-top: 0px;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="background-color: rgb(255, 255, 255); width: 1%; border-bottom: 2.5pt double rgb(0, 0, 0); text-align: left; vertical-align: bottom; padding: 0in;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; text-align: left; margin: 0px 0px 0px 0in; line-height: normal; white-space: nowrap; text-indent: 0in;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;"><div style="white-space: nowrap;;font-weight:bold;display:inline;">$</div></div></div></td><td style="background: rgb(255, 255, 255); border-bottom: 2.5pt double rgb(0, 0, 0); border-top-style: none; padding: 0in; vertical-align: bottom; width: 18%; white-space: nowrap; text-align: right;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; text-align: right; margin-right: 0in; margin-bottom: 0px; margin-top: 0px; line-height: normal; white-space: nowrap;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;"><div style="white-space: nowrap;;font-weight:bold;display:inline;">6,909</div></div></div></td><td style="background: rgb(255, 255, 255); padding: 0in 0in 1.5pt; vertical-align: bottom; width: 1%; white-space: nowrap; text-align: left;"><div style="font-size: 10pt; font-family: &quot;times new roman&quot;, times, serif; margin-left: 0in; text-indent: 0in; text-align: left; white-space: nowrap; line-height: normal; background: none; margin-bottom: 0px; margin-top: 0px;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="padding: 0in 0in 2.5pt; background-color: rgb(255, 255, 255); width: 2%; vertical-align: bottom;"><div style="font-size: 10pt; font-family: &quot;times new roman&quot;, times, serif; line-height: normal; background: none; margin-bottom: 0px; margin-top: 0px;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="background: rgb(255, 255, 255); border-bottom: 2.5pt double rgb(0, 0, 0); padding: 0in; vertical-align: bottom; width: 1%; white-space: nowrap; text-align: left;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; text-align: left; margin: 0px 0px 0px 0in; line-height: normal; white-space: nowrap; text-indent: 0in;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;"><div style="white-space: nowrap;;font-weight:bold;display:inline;">$</div></div></div></td><td style="background: rgb(255, 255, 255); border-bottom: 2.5pt double rgb(0, 0, 0); border-top-style: none; padding: 0in; vertical-align: bottom; width: 18%; white-space: nowrap; text-align: right;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; text-align: right; margin-right: 0in; margin-bottom: 0px; margin-top: 0px; line-height: normal; white-space: nowrap;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;"><div style="white-space: nowrap;;font-weight:bold;display:inline;">2,161</div></div></div></td><td style="background: rgb(255, 255, 255); padding: 0in 0in 1.5pt; vertical-align: bottom; width: 1%; white-space: nowrap; text-align: left;"><div style="font-size: 10pt; font-family: &quot;times new roman&quot;, times, serif; margin-left: 0in; text-indent: 0in; text-align: left; white-space: nowrap; line-height: normal; background: none; margin-bottom: 0px; margin-top: 0px;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td></tr></table><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px;"></div><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; margin: 0px 0px 0px 0.5in; background: none;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div><div style="color: rgb(0, 0, 0); font: 10pt &quot;times new roman&quot;, times, serif; letter-spacing: normal; orphans: 2; text-align: start; text-indent: 0in; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; margin: 0px 0px 0px 0.5in;">The following table sets forth data regarding the Company&#8217;s contract liability:</div><div style="color: rgb(0, 0, 0); font: 10pt &quot;times new roman&quot;, times, serif; letter-spacing: normal; orphans: 2; text-align: start; text-indent: 0in; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; margin: 0px; background: none;">&#160;</div><table cellpadding="0" cellspacing="0" style="font: 10pt &quot;times new roman&quot;, times, serif; letter-spacing: normal; orphans: 2; text-indent: 0px; text-transform: none; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; border-collapse: collapse; width: 55%; margin-left: 0.5in; border-spacing: 0px;"><tr style="vertical-align: bottom;"><td style="font-size: 10pt; padding: 0px; text-indent: 0px;">&#160;</td><td style="font: 10pt &quot;times new roman&quot;, times, serif; padding-bottom: 1pt; padding-left: 0px; padding-top: 0px;">&#160;</td><td colspan="6" style="font: 10pt &quot;times new roman&quot;, times, serif; text-align: center; border-bottom: 1pt solid black; white-space: nowrap; padding-left: 0px; padding-top: 0px; padding-bottom: 0px;"><div style="font-weight:bold;display:inline;">Three months ended March&#160;31,</div></td><td style="padding-bottom: 1pt; font: 10pt &quot;times new roman&quot;, times, serif; padding-left: 0px; padding-top: 0px;">&#160;</td></tr><tr style="vertical-align: bottom;"><td style="font: 10pt &quot;times new roman&quot;, times, serif; padding: 0px; border-bottom: 1pt solid black; text-indent: 0px;"><div style="font-style:italic;display:inline;;font-style:italic;display:inline;">(U.S. dollars in thousands)</div></td><td style="font: 10pt &quot;times new roman&quot;, times, serif; padding-bottom: 1pt; padding-left: 0px; padding-top: 0px;">&#160;</td><td colspan="2" style="font: 10pt &quot;times new roman&quot;, times, serif; text-align: center; border-bottom: 1pt solid black; white-space: nowrap; padding-left: 0px; padding-top: 0px; padding-bottom: 0px;"><div style="font-weight:bold;display:inline;">2019</div></td><td style="padding-bottom: 1pt; font: 10pt &quot;times new roman&quot;, times, serif; white-space: nowrap; padding-left: 0px; padding-top: 0px;">&#160;</td><td style="font: 10pt &quot;times new roman&quot;, times, serif; padding-bottom: 1pt; white-space: nowrap; padding-left: 0px; padding-top: 0px;">&#160;</td><td colspan="2" style="font: 10pt &quot;times new roman&quot;, times, serif; text-align: center; border-bottom: 1pt solid black; white-space: nowrap; padding-left: 0px; padding-top: 0px; padding-bottom: 0px;"><div style="font-weight:bold;display:inline;">2018</div></td><td style="padding-bottom: 1pt; font: 10pt &quot;times new roman&quot;, times, serif; padding-left: 0px; padding-top: 0px;">&#160;</td></tr><tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="width: 581px; font: 10pt 'times new roman', times, serif; padding: 0px; text-align: left; text-indent: 0px;">Contract liabilities at the beginning of the period</td><td style="width: 21px; font: 10pt &quot;times new roman&quot;, times, serif; padding-left: 0px; padding-top: 0px; padding-bottom: 0px;">&#160;</td><td style="width: 11px; font: 10pt &quot;times new roman&quot;, times, serif; text-align: left; white-space: nowrap; padding-left: 0px; padding-top: 0px; padding-bottom: 0px;">$</td><td style="width: 187px; font: 10pt &quot;times new roman&quot;, times, serif; text-align: right; white-space: nowrap; padding-left: 0px; padding-top: 0px; padding-bottom: 0px;">42,895</td><td style="width: 11px; font: 10pt &quot;times new roman&quot;, times, serif; text-align: left; white-space: nowrap; padding-left: 0px; padding-top: 0px; padding-bottom: 0px;">&#160;</td><td style="width: 20px; font: 10pt &quot;times new roman&quot;, times, serif; white-space: nowrap; padding-left: 0px; padding-top: 0px; padding-bottom: 0px;">&#160;</td><td style="width: 10px; font: 10pt &quot;times new roman&quot;, times, serif; text-align: left; white-space: nowrap; padding-left: 0px; padding-top: 0px; padding-bottom: 0px;">$</td><td style="width: 186px; font: 10pt &quot;times new roman&quot;, times, serif; text-align: right; white-space: nowrap; padding-left: 0px; padding-top: 0px; padding-bottom: 0px;">25,015</td><td style="width: 10px; font: 10pt &quot;times new roman&quot;, times, serif; text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px;">&#160;</td></tr><tr style="vertical-align: bottom; background-color: white;"><td style="font: 10pt 'times new roman', times, serif; padding: 0px; text-align: left; text-indent: 0px;">Additions during the period</td><td style="font: 10pt &quot;times new roman&quot;, times, serif; padding-left: 0px; padding-top: 0px; padding-bottom: 0px;">&#160;</td><td style="font: 10pt &quot;times new roman&quot;, times, serif; text-align: left; white-space: nowrap; padding-left: 0px; padding-top: 0px; padding-bottom: 0px;">&#160;</td><td style="font: 10pt &quot;times new roman&quot;, times, serif; text-align: right; white-space: nowrap; padding-left: 0px; padding-top: 0px; padding-bottom: 0px;">6,422</td><td style="font: 10pt &quot;times new roman&quot;, times, serif; text-align: left; white-space: nowrap; padding-left: 0px; padding-top: 0px; padding-bottom: 0px;">&#160;</td><td style="font: 10pt &quot;times new roman&quot;, times, serif; white-space: nowrap; padding-left: 0px; padding-top: 0px; padding-bottom: 0px;">&#160;</td><td style="font: 10pt &quot;times new roman&quot;, times, serif; text-align: left; white-space: nowrap; padding-left: 0px; padding-top: 0px; padding-bottom: 0px;">&#160;</td><td style="font: 10pt &quot;times new roman&quot;, times, serif; text-align: right; white-space: nowrap; padding-left: 0px; padding-top: 0px; padding-bottom: 0px;">2,179</td><td style="font: 10pt &quot;times new roman&quot;, times, serif; text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px;">&#160;</td></tr><tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font: 10pt 'times new roman', times, serif; padding: 0px; text-align: left; text-indent: 0px;">Revenue recognized during the period</td><td style="font: 10pt &quot;times new roman&quot;, times, serif; padding-bottom: 1pt; padding-left: 0px; padding-top: 0px;">&#160;</td><td style="border-bottom: 1pt solid black; font: 10pt &quot;times new roman&quot;, times, serif; text-align: left; white-space: nowrap; padding-left: 0px; padding-top: 0px; padding-bottom: 0px;">&#160;</td><td style="border-bottom: 1pt solid black; font: 10pt &quot;times new roman&quot;, times, serif; text-align: right; white-space: nowrap; padding-left: 0px; padding-top: 0px; padding-bottom: 0px;">(6,909</td><td style="padding-bottom: 1pt; font: 10pt &quot;times new roman&quot;, times, serif; text-align: left; white-space: nowrap; padding-left: 0px; padding-top: 0px;">)</td><td style="font: 10pt &quot;times new roman&quot;, times, serif; padding-bottom: 1pt; white-space: nowrap; padding-left: 0px; padding-top: 0px;">&#160;</td><td style="border-bottom: 1pt solid black; font: 10pt &quot;times new roman&quot;, times, serif; text-align: left; white-space: nowrap; padding-left: 0px; padding-top: 0px; padding-bottom: 0px;">&#160;</td><td style="border-bottom: 1pt solid black; font: 10pt &quot;times new roman&quot;, times, serif; text-align: right; white-space: nowrap; padding-left: 0px; padding-top: 0px; padding-bottom: 0px;">(2,161</td><td style="padding-bottom: 1pt; font: 10pt &quot;times new roman&quot;, times, serif; text-align: left; padding-left: 0px; padding-top: 0px;">)</td></tr><tr style="vertical-align: bottom; background-color: white;"><td style="font: 10pt 'times new roman', times, serif; padding: 0px; text-align: left; text-indent: 0px;">Contract liabilities at the end of the period</td><td style="font: 10pt &quot;times new roman&quot;, times, serif; padding-bottom: 2.5pt; padding-left: 0px; padding-top: 0px;">&#160;</td><td style="border-bottom: 2.5pt double black; font: 10pt &quot;times new roman&quot;, times, serif; text-align: left; white-space: nowrap; padding-left: 0px; padding-top: 0px; padding-bottom: 0px;">$</td><td style="border-bottom: 2.5pt double black; font: 10pt &quot;times new roman&quot;, times, serif; text-align: right; white-space: nowrap; padding-left: 0px; padding-top: 0px; padding-bottom: 0px;">42,408</td><td style="padding-bottom: 2.5pt; font: 10pt &quot;times new roman&quot;, times, serif; text-align: left; white-space: nowrap; padding-left: 0px; padding-top: 0px;">&#160;</td><td style="font: 10pt &quot;times new roman&quot;, times, serif; padding-bottom: 2.5pt; white-space: nowrap; padding-left: 0px; padding-top: 0px;">&#160;</td><td style="border-bottom: 2.5pt double black; font: 10pt &quot;times new roman&quot;, times, serif; text-align: left; white-space: nowrap; padding-left: 0px; padding-top: 0px; padding-bottom: 0px;">$</td><td style="border-bottom: 2.5pt double black; font: 10pt &quot;times new roman&quot;, times, serif; text-align: right; white-space: nowrap; padding-left: 0px; padding-top: 0px; padding-bottom: 0px;">25,033</td><td style="padding-bottom: 2.5pt; font: 10pt &quot;times new roman&quot;, times, serif; text-align: left; padding-left: 0px; padding-top: 0px;">&#160;</td></tr></table><div style="clear: both; max-height: 0px; background: none;"></div><div style="color: rgb(0, 0, 0); font: 10pt &quot;times new roman&quot;, times, serif; letter-spacing: normal; orphans: 2; text-align: start; text-indent: 0in; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; margin: 0px; background: none;"><div style="font-weight:bold;display:inline;">&#160;</div>&#160;</div><div style="color: rgb(0, 0, 0); font: 10pt &quot;times new roman&quot;, times, serif; letter-spacing: normal; orphans: 2; text-align: start; text-indent: 0in; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; margin: 0px 0px 0px 0.5in;">The following table represents the Company's unsatisfied performance obligation:</div><div style="color: rgb(0, 0, 0); font: 10pt &quot;times new roman&quot;, times, serif; letter-spacing: normal; orphans: 2; text-align: start; text-indent: 0in; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; margin: 0px; background: none;">&#160;</div><table cellpadding="0" cellspacing="0" style="font: 10pt &quot;times new roman&quot;, times, serif; letter-spacing: normal; orphans: 2; text-indent: 0px; text-transform: none; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; border-collapse: collapse; width: 55%; margin-left: 0.5in; border-spacing: 0px;"><tr style="vertical-align: bottom;"><td style="font-size: 10pt; padding: 0px; text-indent: 0px;">&#160;</td><td style="font: 10pt &quot;times new roman&quot;, times, serif; padding-bottom: 1pt; padding-left: 0px; padding-top: 0px;">&#160;</td><td colspan="6" style="font: 10pt &quot;times new roman&quot;, times, serif; text-align: center; border-bottom: 1pt solid black; padding-left: 0px; padding-top: 0px; padding-bottom: 0px;"><div style="font-weight:bold;display:inline;">March&#160;31,</div></td><td style="padding-bottom: 1pt; font: 10pt &quot;times new roman&quot;, times, serif; padding-left: 0px; padding-top: 0px;">&#160;</td></tr><tr style="vertical-align: bottom;"><td style="font: 10pt &quot;times new roman&quot;, times, serif; padding: 0px; border-bottom: 1pt solid black; text-indent: 0px;"><div style="font-style:italic;display:inline;;font-style:italic;display:inline;">(U.S. dollars in thousands)</div></td><td style="font: 10pt &quot;times new roman&quot;, times, serif; padding-bottom: 1pt; padding-left: 0px; padding-top: 0px;">&#160;</td><td colspan="2" style="font: 10pt &quot;times new roman&quot;, times, serif; text-align: center; border-bottom: 1pt solid black; padding-left: 0px; padding-top: 0px; padding-bottom: 0px;"><div style="font-weight:bold;display:inline;">2019</div></td><td style="padding-bottom: 1pt; font: 10pt &quot;times new roman&quot;, times, serif; padding-left: 0px; padding-top: 0px;">&#160;</td><td style="font: 10pt &quot;times new roman&quot;, times, serif; padding-bottom: 1pt; padding-left: 0px; padding-top: 0px;">&#160;</td><td colspan="2" style="font: 10pt &quot;times new roman&quot;, times, serif; text-align: center; border-bottom: 1pt solid black; padding-left: 0px; padding-top: 0px; padding-bottom: 0px;"><div style="font-weight:bold;display:inline;">2018</div></td><td style="padding-bottom: 1pt; font: 10pt &quot;times new roman&quot;, times, serif; padding-left: 0px; padding-top: 0px;">&#160;</td></tr><tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="width: 581px; font: 10pt 'times new roman', times, serif; padding: 0px; text-align: left; text-indent: 0px;">Unsatisfied performance obligation</td><td style="width: 21px; font: 10pt &quot;times new roman&quot;, times, serif; padding-left: 0px; padding-top: 0px; padding-bottom: 0px;">&#160;</td><td style="width: 11px; font: 10pt &quot;times new roman&quot;, times, serif; text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px;">$</td><td style="width: 187px; font: 10pt &quot;times new roman&quot;, times, serif; text-align: right; padding-left: 0px; padding-top: 0px; padding-bottom: 0px;">64,581</td><td style="width: 11px; font: 10pt &quot;times new roman&quot;, times, serif; text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px;">&#160;</td><td style="width: 20px; font: 10pt &quot;times new roman&quot;, times, serif; padding-left: 0px; padding-top: 0px; padding-bottom: 0px;">&#160;</td><td style="width: 10px; font: 10pt &quot;times new roman&quot;, times, serif; text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px;">$</td><td style="width: 186px; font: 10pt &quot;times new roman&quot;, times, serif; text-align: right; padding-left: 0px; padding-top: 0px; padding-bottom: 0px;">91,033</td><td style="width: 10px; font: 10pt &quot;times new roman&quot;, times, serif; text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px;">&#160;</td></tr></table><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_plx_RevenueDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure pertaining to revenue.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">plx_RevenueDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>plx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>24
<FILENAME>R13.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.1</span><table class="report" border="0" cellspacing="2" id="idp6635500240">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SUBSEQUENT EVENTS<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2019</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventsAbstract', window );"><strong>Subsequent Events [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventsTextBlock', window );">SUBSEQUENT EVENTS</a></td>
<td class="text"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; margin-bottom: 0px; margin-top: 0px; margin-right: 0px;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">NOTE 6&#160;&#8211; SUBSEQUENT EVENTS</div></div></div><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; margin-bottom: 0px; margin-top: 0px; margin-right: 0px; background: none;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; margin-bottom: 0px; margin-top: 0px; margin-right: 0px;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">The Company has evaluated subsequent events through the date on which the consolidated financial statements were available to be issued and no subsequent events were identified.</div></div> <table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 855<br> -URI http://asc.fasb.org/topic&amp;trid=2122774<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>25
<FILENAME>R14.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.1</span><table class="report" border="0" cellspacing="2" id="idp6805260240">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SIGNIFICANT ACCOUNTING POLICIES (Policies)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2019</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_plx_NatureOfOperationsPolicyTextBlock', window );">General</a></td>
<td class="text"><div><table style="border: none; border-collapse: collapse; margin-bottom: 0.001pt; width: 100%; table-layout: fixed;"><tr><td style="border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: top;width: 36pt;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; margin-right: 0px; margin-bottom: 0px; margin-top: 0px; line-height: normal;">&#160;</div></td><td style="border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: top;width: 18pt;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; margin-right: 0px; margin-bottom: 0px; margin-top: 0px; line-height: normal;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">a.</div></div></div></td><td style="border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: top;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; margin-right: 0px; margin-bottom: 0px; margin-top: 0px; line-height: normal;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">General</div></div></div></td></tr></table><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px;"></div></div><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; margin-bottom: 0px; margin-top: 0px; margin-right: 0px; background: none;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; margin: 0px 0px 0px 0.5in;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">Protalix BioTherapeutics, Inc. (collectively with its subsidiaries, the &#8220;Company&#8221;)&#160;and its wholly-owned subsidiaries, Protalix Ltd. and Protalix B.V. (the &#8220;Subsidiaries&#8221;), are biopharmaceutical companies focused on the development and commercialization of recombinant therapeutic proteins based on the Company&#8217;s proprietary ProCellEx<div style="vertical-align: super;font-size: smaller;display:inline;">&#174;</div> protein expression system (&#8220;ProCellEx&#8221;). To date, the Company has successfully developed taliglucerase alfa (marketed under the name alfataliglicerase in Brazil and certain other Latin American countries and Elelyso<div style="vertical-align: super;font-size: smaller;display:inline;">&#174;</div> in the rest of the territories) for the treatment of Gaucher disease that has been approved for marketing in the United States, Brazil, Israel and other markets. The Company has a number of product candidates in varying stages of the clinical development process. The Company&#8217;s strategy is to develop proprietary recombinant proteins that are therapeutically superior to existing recombinant proteins currently marketed for the same indications.</div></div><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; margin: 0px 0px 0px 0.5in; background: none;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; margin: 0px 0px 0px 0.5in;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">The Company&#8217;s product pipeline currently includes, among other candidates:</div></div><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; margin: 0px 0px 0px 0.5in; background: none;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; margin: 0px 0px 0px 0.5in;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">(1) pegunigalsidase alfa, or PRX-102, a therapeutic protein candidate for the treatment of Fabry disease, a rare, genetic lysosomal disorder;</div></div><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; margin: 0px 0px 0px 0.5in; background: none;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; margin: 0px 0px 0px 0.5in;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">(2) alidornase alfa, or PRX-110, a proprietary plant cell recombinant human Deoxyribonuclease 1, or DNase, under development for the treatment of Cystic Fibrosis, to be administered by inhalation; and</div></div><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; margin: 0px 0px 0px 0.5in; background: none;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; margin: 0px 0px 0px 0.5in;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">(3) OPRX-106, the Company&#8217;s oral antiTNF product candidate which is being developed as an orally-delivered anti-inflammatory treatment using plant cells as a natural capsule for the expressed protein.</div></div><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; margin: 0px 0px 0px 0.5in; background: none;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; margin: 0px 0px 0px 0.5in;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">Obtaining marketing approval with respect to any product candidate in any country is dependent on the Company&#8217;s ability to implement the necessary regulatory steps required to obtain such approvals. The Company cannot reasonably predict the outcome of these activities.</div></div><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; margin: 0px 0px 0px 0.5in; background: none;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; margin: 0px 0px 0px 0.5in;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">On October&#160;19, 2017, Protalix Ltd. and Chiesi Farmaceutici S.p.A. (&#8220;Chiesi&#8221;) entered into an Exclusive License and Supply Agreement (the &#8220;Chiesi Ex-US Agreement&#8221;) pursuant to which Chiesi was granted an exclusive license for all markets outside of the United States to commercialize pegunigalsidase alfa. On July&#160;23, 2018, Protalix Ltd. entered into an Exclusive License and Supply Agreement with Chiesi (the &#8220;Chiesi US Agreement&#8221;)&#160;with respect to the commercialization of pegunigalsidase alfa in the United States.</div></div><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; margin: 0px 0px 0px 0.5in; background: none;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; margin: 0px 0px 0px 0.5in;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">Under each of the Chiesi Ex-US Agreement and the Chiesi US Agreement&#160;(collectively,&#160;the </div>&#8220;<div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">Chiesi Agreements</div>&#8221;)<div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">, Chiesi made an upfront payment to Protalix Ltd. of $25.0&#160;million in connection with the execution of the agreement. In addition, under the Chiesi Ex-US Agreement, Protalix Ltd. is entitled to additional payments of up to $25.0&#160;million in pegunigalsidase alfa development costs, capped at $10.0&#160;million per year, and to receive additional payments of up to $320.0&#160;million, in the aggregate, in regulatory and commercial milestone payments. Under the Chiesi US Agreement, Protalix Ltd. is entitled to payments of up to a maximum of $20.0&#160;million to cover development costs for pegunigalsidase alfa, subject to a maximum of $7.5&#160;million per year, and to receive an additional up to a maximum of $760.0&#160;million, in the aggregate, in regulatory and commercial milestone payments.</div></div><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; margin: 0px 0px 0px 0.5in; background: none;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; margin: 0px 0px 0px 0.5in;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">Under the terms of both of the Chiesi Agreements, Protalix Ltd. will manufacture all of the pegunigalsidase alfa needed under the agreements, subject to certain exceptions, and Chiesi will purchase pegunigalsidase alfa from Protalix, subject to certain terms and conditions. Under the Chiesi Ex-US Agreement, Chiesi is required to make tiered payments of 15% to 35% of its net sales, depending on the amount of annual sales outside of the United States, as consideration for product supply. Under the Chiesi US Agreement, Chiesi is required to make tiered payments of 15% to 40% of its net sales, depending on the amount of annual sales in the United States, as consideration for product supply.</div></div><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; margin: 0px 0px 0px 0.5in; background: none;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; margin: 0px 0px 0px 0.5in;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">Since its approval by the FDA, taliglucerase alfa has been marketed by Pfizer in accordance with the exclusive license and supply agreement entered&#160;into&#160;between Protalix Ltd. and Pfizer, which is referred to herein as the Pfizer Agreement. In October 2015, the Company sold to Pfizer its share in the collaboration created under the Pfizer Agreement for the commercialization of Elelyso. As part of the sale, the Company agreed to transfer its rights to Elelyso in Israel to Pfizer while gaining full rights to it in Brazil. Under the Amended Pfizer Agreement, Pfizer is entitled to all of the revenues, and is responsible for 100% of expenses globally for Elelyso, excluding Brazil where the Company is responsible for all expenses and retains all revenues.</div></div><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; margin: 0px 0px 0px 0.5in; background: none;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; margin: 0px 0px 0px 0.5in;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">On June&#160;18, 2013, the Company entered into a Supply and Technology Transfer Agreement (the &#8220;Brazil Agreement&#8221;) with Fiocruz, an arm of the Brazilian MoH, for taliglucerase alfa. Fiocruz&#8217;s purchases of alfataliglicerase to date have been significantly below certain agreed upon purchase milestones and, accordingly, the Company has the right to terminate the Brazil Agreement. Notwithstanding the termination right, the Company is, at this time, continuing to supply alfataliglicerase to Fiocruz under the Brazil Agreement, and patients continue to be treated with alfataliglicerase in Brazil.</div></div><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; margin: 0px 0px 0px 0.5in; background: none;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div><div style="color: rgb(0, 0, 0); font: 10pt &quot;times new roman&quot;, times, serif; letter-spacing: normal; orphans: 2; text-align: start; text-indent: 0in; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; margin: 0px 0px 0px 0.5in;">Based on its current cash resources and commitments, the Company believes it will be able to maintain its current planned development activities and the corresponding level of expenditures for at least 12 months from the date of approval of the financial statements as of March&#160;31, 2019, although no assurance can be given that it will not need additional funds prior to such time. If there are unexpected increases in general and administrative expenses or research and development expenses, the Company may need to seek additional financing.</div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock', window );">Basis of presentation</a></td>
<td class="text"><div><table style="border: none; border-collapse: collapse; margin-bottom: 0.001pt; width: 100%; table-layout: fixed;"><tr><td style="border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: top;width: 36pt;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; margin-right: 0px; margin-bottom: 0px; margin-top: 0px; line-height: normal;">&#160;</div></td><td style="border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: top;width: 18pt;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; margin-right: 0px; margin-bottom: 0px; margin-top: 0px; line-height: normal;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">b.</div></div></div></td><td style="border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0;padding-left: 0;padding-right: 81.4pt;padding-top: 0;vertical-align: top;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; margin-right: 0px; margin-bottom: 0px; margin-top: 0px; line-height: normal;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Basis of presentation</div></div></div></td></tr></table><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px;"></div></div><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; margin-bottom: 0px; margin-top: 0px; margin-right: 0px; background: none;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; margin: 0px 0px 0px 0.5in;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">The accompanying unaudited condensed consolidated financial statements of the Company have been prepared in accordance with accounting principles generally accepted in the United States (&#8220;GAAP&#8221;) for interim financial information. Accordingly, they do not include all of the information and notes required by GAAP for annual financial statements. In the opinion of management, all adjustments (of a normal recurring nature) considered necessary for a fair statement of the results for the interim periods presented have been included. Operating results for the interim period are not necessarily indicative of the results that may be expected for the full year.</div></div><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; margin: 0px 0px 0px 0.5in; background: none;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; margin: 0px 0px 0px 0.5in;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">These unaudited condensed consolidated financial statements should be read in conjunction with the audited consolidated financial statements in the Annual Report on Form 10-K for the year ended December&#160;31, 2018, filed by the Company with the Commission. The comparative balance sheet at December&#160;31, 2018 has been derived from the audited financial statements at that date.</div></div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerSharePolicyTextBlock', window );">Net loss per share</a></td>
<td class="text"><div><table style="border: none; border-collapse: collapse; margin-bottom: 0.001pt; width: 100%; table-layout: fixed;"><tr><td style="border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: top;width: 36pt;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; margin-right: 0px; margin-bottom: 0px; margin-top: 0px; line-height: normal;">&#160;</div></td><td style="border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: top;width: 18pt;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; margin-right: 0px; margin-bottom: 0px; margin-top: 0px; line-height: normal;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">c.</div></div></div></td><td style="border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0;padding-left: 0;padding-right: 81.4pt;padding-top: 0;vertical-align: top;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; margin-right: 0px; margin-bottom: 0px; margin-top: 0px; line-height: normal;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Net loss per share</div></div></div></td></tr></table><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px;"></div></div><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; margin-bottom: 0px; margin-top: 0px; margin-right: 0px; background: none;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; margin: 0px 0px 0px 0.5in;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">Basic and diluted loss per share (&#8220;LPS&#8221;) are computed by dividing net loss by the weighted average number of shares of the Company&#8217;s common stock, par value $0.001 per share (the &#8220;Common Stock&#8221;), outstanding for each period.</div></div><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; margin: 0px 0px 0px 0.5in; background: none;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; margin: 0px 0px 0px 0.5in;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">Diluted LPS is calculated in continuing operations. The calculation of diluted LPS does not include 73,800,491 and 78,202,020 shares of Common Stock underlying outstanding options and restricted shares of Common Stock and shares issuable upon conversion of outstanding convertible notes for the three months ended March&#160;31, 2018 and 2019, respectively, because the effect would be anti-dilutive.</div></div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_plx_RecentlyAdoptedStandardsPolicyTextBlockPolicyTextBlock', window );">Recently adopted standards</a></td>
<td class="text"><table cellpadding="0" cellspacing="0" style="font: 10pt &quot;times new roman&quot;, times, serif; letter-spacing: normal; orphans: 2; text-indent: 0px; text-transform: none; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; margin-top: 0pt; margin-bottom: 0pt; border-collapse: collapse; border-spacing: 0px; table-layout: fixed;;width:100%;"><tr style="vertical-align: top;"><td style="width: 0.5in; padding: 0px;"></td><td style="width: 0.25in; padding-left: 0px; padding-top: 0px; padding-bottom: 0px;"><div style="font-weight:bold;display:inline;">d.</div></td><td style="padding: 0px 81.35pt 0px 0px;"><div style="font-weight:bold;display:inline;">Recently adopted standards</div></td></tr></table><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px; background: none;"></div><div style="color: rgb(0, 0, 0); font: 10pt &quot;times new roman&quot;, times, serif; letter-spacing: normal; orphans: 2; text-align: start; text-indent: 0px; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; margin-top: 0px; margin-bottom: 0px; margin-right: 0px; background: none;">&#160;&#160;</div><div style="color: rgb(0, 0, 0); font: 10pt &quot;times new roman&quot;, times, serif; letter-spacing: normal; orphans: 2; text-align: start; text-indent: 0in; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; margin: 0px 0px 0px 0.5in; background: none;"></div><div style="color: rgb(0, 0, 0); font: 10pt &quot;times new roman&quot;, times, serif; letter-spacing: normal; orphans: 2; text-align: start; text-indent: 0px; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; margin: 0px 0px 0px 0.5in;">In February 2016, the Financial Accounting Standards Board (&#8220;FASB&#8221;) issued ASU No. 2016-02, Leases (Topic 842), which supersedes the existing guidance for lease accounting, Leases (Topic 840). The new standard requires a lessee to record assets and liabilities on its balance sheet for all leases with terms longer than 12 months. Leases will be classified as either finance or operating, with classification affecting the pattern of expense recognition in the lessee&#8217;s income statement. The Company adopted this standard as of January 1, 2019 on a modified retrospective basis and will not restate comparative periods. The Company will elect the package of practical expedients permitted under the transition guidance within the new standard which, among other things, allows the Company to carryforward the historical lease classification. The Company made an accounting policy election to keep leases with an initial term of 12 months or less off of its balance sheet. The Company recognized those lease payments in its statements of operations on a straight-line basis over the lease period.</div><div style="color: rgb(0, 0, 0); font: 10pt &quot;times new roman&quot;, times, serif; letter-spacing: normal; orphans: 2; text-align: start; text-indent: 0px; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; margin: 0px 0px 0px 0.5in; background: none;">&#160;</div><div style="color: rgb(0, 0, 0); font: 10pt &quot;times new roman&quot;, times, serif; letter-spacing: normal; orphans: 2; text-align: start; text-indent: 0px; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; margin: 0px 0px 0px 0.5in;">As of the adoption date, the Company recognized an operating lease asset and liability of $5.9&#160;million and $5.7 million, respectively, as of January&#160;1, 2019 on its balance sheet.</div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock', window );">Newly issued accounting pronouncements</a></td>
<td class="text"><table cellpadding="0" cellspacing="0" style="font: 10pt &quot;times new roman&quot;, times, serif; letter-spacing: normal; orphans: 2; text-indent: 0px; text-transform: none; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; margin-top: 0pt; margin-bottom: 0pt; border-collapse: collapse; border-spacing: 0px; table-layout: fixed;;width:100%;"><tr style="vertical-align: top;"><td style="width: 0.5in; padding: 0px;"></td><td style="width: 0.25in; padding-left: 0px; padding-top: 0px; padding-bottom: 0px;"><div style="font-weight:bold;display:inline;">e.</div></td><td style="padding: 0px 81.35pt 0px 0px;"><div style="font-weight:bold;display:inline;">Newly issued accounting pronouncements</div></td></tr></table><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px; background: none;"></div><div style="color: rgb(0, 0, 0); font: 10pt &quot;times new roman&quot;, times, serif; letter-spacing: normal; orphans: 2; text-align: start; text-indent: 0px; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; margin-top: 0px; margin-bottom: 0px; margin-right: 0px; background: none;">&#160;</div><div style="color: rgb(0, 0, 0); font-family: &quot;times new roman&quot;, times, serif; font-size: 13.3333px; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; orphans: 2; text-align: start; text-indent: 0px; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; margin: 0px 0px 0px 0.5in;">In June 2018, the FASB issued ASU 2018-07, &#8220;Compensation &#8211; Stock Compensation (Topic 718): Improvements to Nonemployee Share-based Payment Accounting&#8221; that expands the scope of ASC Topic 718 to include share-based payment transactions for acquiring goods and services from nonemployees. An entity should apply the requirements of ASC Topic 718 to nonemployee awards except for certain exemptions specified in ASU 2018-07. The guidance is effective for fiscal years beginning after December 15, 2018, including interim reporting periods within that fiscal year. Early adoption is permitted, but no earlier than an entity&#8217;s adoption date of Topic 606. The Company does not expect the adoption of ASU 2018-07 to have a material impact on its financial statements.<div style="background-color: initial; font-size: 10pt; text-indent: 0in; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_plx_NatureOfOperationsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Nature Of Operations Policy</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">plx_NatureOfOperationsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>plx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_plx_RecentlyAdoptedStandardsPolicyTextBlockPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy pertaining to recently adopted standards that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">plx_RecentlyAdoptedStandardsPolicyTextBlockPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>plx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BasisOfAccountingPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerSharePolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3630-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerSharePolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>26
<FILENAME>R15.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.1</span><table class="report" border="0" cellspacing="2" id="idp6624935216">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>INVENTORIES (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2019</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryDisclosureAbstract', window );"><strong>Inventory Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfInventoryCurrentTableTextBlock', window );">Schedule of Inventory</a></td>
<td class="text"><table cellpadding="0" cellspacing="0" style="font: 10pt &quot;times new roman&quot;, times, serif; letter-spacing: normal; orphans: 2; text-indent: 0px; text-transform: none; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; margin-top: 0pt; margin-bottom: 0pt; border-collapse: collapse; border-spacing: 0px; table-layout: fixed;;width:100%;"><tr style="vertical-align: top;"><td style="width: 0.5in; padding: 0px;"></td><td style="width: 0.25in; padding-left: 0px; padding-top: 0px; padding-bottom: 0px;">a.</td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;">Inventories at March&#160;31, 2019 and December&#160;31, 2018 consisted of the following:</td></tr></table><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px;"></div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table><table cellpadding="0" cellspacing="0" style="font: 10pt &quot;times new roman&quot;, times, serif; letter-spacing: normal; orphans: 2; text-indent: 0px; text-transform: none; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; border-collapse: collapse; width: 94%; border-spacing: 0px; margin: 0in 0in 0in auto;;text-align:left;"><tr style="vertical-align: bottom;"><td style="font-size: 10pt; text-align: center; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; font-family: &quot;times new roman&quot;, times, serif; vertical-align: middle;;width:;">&#160;</td><td style="font: 10pt &quot;times new roman&quot;, times, serif; padding-bottom: 1pt; padding-left: 0px; padding-top: 0px; vertical-align: middle;;width:;">&#160;</td><td colspan="2" style="font: 10pt &quot;times new roman&quot;, times, serif; text-align: center; border-bottom: 1pt solid black; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; vertical-align: middle;;width:;"><div style="font-weight:bold;display:inline;">March&#160;31,</div></td><td style="padding-bottom: 1pt; font: 10pt &quot;times new roman&quot;, times, serif; padding-left: 0px; padding-top: 0px; vertical-align: middle;;width:;">&#160;</td><td style="font: 10pt &quot;times new roman&quot;, times, serif; padding-bottom: 1pt; padding-left: 0px; padding-top: 0px; vertical-align: middle;;width:;">&#160;</td><td colspan="2" style="font: 10pt &quot;times new roman&quot;, times, serif; text-align: center; border-bottom: 1pt solid black; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; vertical-align: middle;;width:;"><div style="font-weight:bold;display:inline;">December&#160;31,</div></td><td style="padding-bottom: 1pt; font: 10pt &quot;times new roman&quot;, times, serif; padding-left: 0px; padding-top: 0px; vertical-align: middle;;width:;">&#160;</td></tr><tr style="vertical-align: bottom;"><td style="font-size: 10pt; padding-bottom: 1pt; padding-left: 0px; padding-top: 0px; vertical-align: middle;;width:;">(<div style="font-style:italic;display:inline;;font-style:italic;display:inline;">U.S. dollars in thousands)</div></td><td style="font: 10pt &quot;times new roman&quot;, times, serif; padding-bottom: 1pt; padding-left: 0px; padding-top: 0px; vertical-align: middle;;width:;">&#160;</td><td colspan="2" style="font: 10pt &quot;times new roman&quot;, times, serif; text-align: center; border-bottom: 1pt solid black; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; vertical-align: middle;;width:;"><div style="font-weight:bold;display:inline;">2019</div></td><td style="padding-bottom: 1pt; font: 10pt &quot;times new roman&quot;, times, serif; padding-left: 0px; padding-top: 0px; vertical-align: middle;;width:;">&#160;</td><td style="font: 10pt &quot;times new roman&quot;, times, serif; padding-bottom: 1pt; padding-left: 0px; padding-top: 0px; vertical-align: middle;;width:;">&#160;</td><td colspan="2" style="font: 10pt &quot;times new roman&quot;, times, serif; text-align: center; border-bottom: 1pt solid black; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; vertical-align: middle;;width:;"><div style="font-weight:bold;display:inline;">2018</div></td><td style="padding-bottom: 1pt; font: 10pt &quot;times new roman&quot;, times, serif; padding-left: 0px; padding-top: 0px; vertical-align: middle;;width:;">&#160;</td></tr><tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="width: 70%; font-size: 10pt; text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; vertical-align: middle;">Raw materials</td><td style="width: 0%; font-size: 10pt; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; font-family: &quot;times new roman&quot;, times, serif; vertical-align: middle;">&#160;</td><td style="width: 1%; font-size: 10pt; text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; vertical-align: middle;">$</td><td style="width: 12%; font-size: 10pt; text-align: right; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; vertical-align: middle;">3,047</td><td style="width: 1%; font-size: 10pt; text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; font-family: &quot;times new roman&quot;, times, serif; vertical-align: middle;">&#160;</td><td style="width: 2%; font-size: 10pt; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; font-family: &quot;times new roman&quot;, times, serif; vertical-align: middle;">&#160;</td><td style="width: 1%; font-size: 10pt; text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; vertical-align: middle;">$</td><td style="width: 12%; font-size: 10pt; text-align: right; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; vertical-align: middle;">3,792</td><td style="width: 1%; font-size: 10pt; text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; font-family: &quot;times new roman&quot;, times, serif; vertical-align: middle;">&#160;</td></tr><tr style="vertical-align: bottom; background-color: white;"><td style="font-size: 10pt; text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; vertical-align: middle; width: 70%;">Work in progress</td><td style="font-size: 10pt; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; font-family: &quot;times new roman&quot;, times, serif; vertical-align: middle; width: 0%;">&#160;</td><td style="font-size: 10pt; text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; font-family: &quot;times new roman&quot;, times, serif; vertical-align: middle; width: 1%;">&#160;</td><td style="font-size: 10pt; text-align: right; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; vertical-align: middle; width: 12%;">45</td><td style="font-size: 10pt; text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; font-family: &quot;times new roman&quot;, times, serif; vertical-align: middle; width: 1%;">&#160;</td><td style="font-size: 10pt; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; font-family: &quot;times new roman&quot;, times, serif; vertical-align: middle; width: 2%;">&#160;</td><td style="font-size: 10pt; text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; font-family: &quot;times new roman&quot;, times, serif; vertical-align: middle; width: 1%;">&#160;</td><td style="font-size: 10pt; text-align: right; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; font-family: &quot;times new roman&quot;, times, serif; vertical-align: middle; width: 12%;">&#160;</td><td style="font-size: 10pt; text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; font-family: &quot;times new roman&quot;, times, serif; vertical-align: middle; width: 1%;">&#160;</td></tr><tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-size: 10pt; text-align: left; padding-bottom: 1pt; padding-left: 0px; padding-top: 0px; vertical-align: middle; width: 70%;">Finished goods</td><td style="font: 10pt &quot;times new roman&quot;, times, serif; padding-bottom: 1pt; padding-left: 0px; padding-top: 0px; vertical-align: middle; width: 0%;">&#160;</td><td style="border-bottom: 1pt solid black; font: 10pt &quot;times new roman&quot;, times, serif; text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; vertical-align: middle; width: 1%;">&#160;</td><td style="border-bottom: 1pt solid black; font: 10pt &quot;times new roman&quot;, times, serif; text-align: right; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; vertical-align: middle; width: 12%;">3,615</td><td style="padding-bottom: 1pt; font: 10pt &quot;times new roman&quot;, times, serif; text-align: left; padding-left: 0px; padding-top: 0px; vertical-align: middle; width: 1%;">&#160;</td><td style="font: 10pt &quot;times new roman&quot;, times, serif; padding-bottom: 1pt; padding-left: 0px; padding-top: 0px; vertical-align: middle; width: 2%;">&#160;</td><td style="border-bottom: 1pt solid black; font: 10pt &quot;times new roman&quot;, times, serif; text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; vertical-align: middle; width: 1%;">&#160;</td><td style="border-bottom: 1pt solid black; font: 10pt &quot;times new roman&quot;, times, serif; text-align: right; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; vertical-align: middle; width: 12%;">4,777</td><td style="padding-bottom: 1pt; font: 10pt &quot;times new roman&quot;, times, serif; text-align: left; padding-left: 0px; padding-top: 0px; vertical-align: middle; width: 1%;">&#160;</td></tr><tr style="vertical-align: bottom; background-color: white;"><td style="font-size: 10pt; text-align: left; padding-bottom: 2.5pt; padding-left: 0px; padding-top: 0px; vertical-align: middle; width: 70%;">Total inventory</td><td style="font: 10pt &quot;times new roman&quot;, times, serif; padding-bottom: 2.5pt; padding-left: 0px; padding-top: 0px; vertical-align: middle; width: 0%;">&#160;</td><td style="border-bottom: 2.5pt double black; font: 10pt &quot;times new roman&quot;, times, serif; text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; vertical-align: middle; width: 1%;">$</td><td style="border-bottom: 2.5pt double black; font: 10pt &quot;times new roman&quot;, times, serif; text-align: right; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; vertical-align: middle; width: 12%;">6,707</td><td style="padding-bottom: 1.5pt; font: 10pt &quot;times new roman&quot;, times, serif; text-align: left; padding-left: 0px; padding-top: 0px; vertical-align: middle; width: 1%;">&#160;</td><td style="font: 10pt &quot;times new roman&quot;, times, serif; padding-bottom: 2.5pt; padding-left: 0px; padding-top: 0px; vertical-align: middle; width: 2%;">&#160;</td><td style="border-bottom: 2.5pt double black; font: 10pt &quot;times new roman&quot;, times, serif; text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; vertical-align: middle; width: 1%;">$</td><td style="border-bottom: 2.5pt double black; font: 10pt &quot;times new roman&quot;, times, serif; text-align: right; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; vertical-align: middle; width: 12%;">8,569</td><td style="padding-bottom: 1.5pt; font: 10pt &quot;times new roman&quot;, times, serif; text-align: left; padding-left: 0px; padding-top: 0px; vertical-align: middle; width: 1%;">&#160;</td></tr></table><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px;"></div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfInventoryCurrentTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the carrying amount as of the balance sheet date of merchandise, goods, commodities, or supplies held for future sale or to be used in manufacturing, servicing or production process.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(c))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6361739&amp;loc=d3e7789-107766<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfInventoryCurrentTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>27
<FILENAME>R16.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.1</span><table class="report" border="0" cellspacing="2" id="idp6635215504">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>FAIR VALUE MEASUREMENT (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2019</div></th></tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=plx_Notes2021Member', window );">Notes 2021 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock', window );">Fair Value Measurements, Recurring and Nonrecurring</a></td>
<td class="text"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; margin-bottom: 0px; margin-top: 0px; margin-right: 0px; background: none;">&#160;</div><div><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px;"></div></div> <table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of input and valuation technique used to measure fair value and change in valuation approach and technique for each separate class of asset and liability measured on recurring and nonrecurring basis.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)<br> -URI http://asc.fasb.org/extlink&amp;oid=99377789&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=plx_Notes2021Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=plx_Notes2021Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>28
<FILENAME>R17.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.1</span><table class="report" border="0" cellspacing="2" id="idp6779753184">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>OPERATING LEASES (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2019</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeasesOperatingAbstract', window );"><strong>Leases, Operating [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeaseCostTableTextBlock', window );">Lease, Cost</a></td>
<td class="text"><div style="color: rgb(0, 0, 0); font: 10pt &quot;times new roman&quot;, times, serif; letter-spacing: normal; orphans: 2; text-align: start; text-indent: 0in; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; margin: 0px 0px 0px 0.5in;">The following table sets forth data regarding the Company&#8217;s operating leases for the three months ended March 31, 2019:</div><div style="color: rgb(0, 0, 0); font: 10pt &quot;times new roman&quot;, times, serif; letter-spacing: normal; orphans: 2; text-align: start; text-indent: 0px; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; margin: 0px 0px 0px 0.5in; background: none;">&#160;&#160;</div><table cellpadding="0" cellspacing="0" style="font: 10pt &quot;times new roman&quot;, times, serif; letter-spacing: normal; orphans: 2; text-indent: 0px; text-transform: none; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; border-collapse: collapse; width: 55%; margin-left: 0.5in; border-spacing: 0px;"><tr style="vertical-align: bottom;"><td style="font-size: 10pt; padding-bottom: 1pt; padding-left: 0px; padding-top: 0px;">(<div style="font-style:italic;display:inline;;font-style:italic;display:inline;">U.S. dollars in thousands)</div></td><td style="font: 10pt &quot;times new roman&quot;, times, serif; padding-bottom: 1pt; padding-left: 0px; padding-top: 0px;">&#160;</td><td colspan="2" style="font: 10pt &quot;times new roman&quot;, times, serif; text-align: center; border-bottom: 1pt solid black; padding-left: 0px; padding-top: 0px; padding-bottom: 0px;"><div style="font-weight:bold;display:inline;">March 31, 2019</div></td><td style="padding-bottom: 1pt; font: 10pt &quot;times new roman&quot;, times, serif; padding-left: 0px; padding-top: 0px;">&#160;</td></tr><tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="width: 788px; font-size: 10pt; text-align: left; padding-bottom: 2.5pt; padding-left: 0in; padding-top: 0px;"><div style="line-height: normal;">Operating lease costs</div></td><td style="width: 20px; font: 10pt &quot;times new roman&quot;, times, serif; padding-bottom: 2.5pt; padding-left: 0px; padding-top: 0px;">&#160;</td><td style="width: 10px; border-bottom: 2.5pt double black; font: 10pt &quot;times new roman&quot;, times, serif; text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px;">$</td><td style="width: 207px; border-bottom: 2.5pt double black; font: 10pt &quot;times new roman&quot;, times, serif; text-align: right; padding-left: 0px; padding-top: 0px; padding-bottom: 0px;">292</td><td style="width: 12px; padding-bottom: 1.5pt; font: 10pt &quot;times new roman&quot;, times, serif; text-align: left; padding-left: 0px; padding-top: 0px;">&#160;</td></tr><tr style="vertical-align: bottom; background-color: white;"><td style="font-size: 10pt; text-align: left; padding-bottom: 2.5pt; padding-left: 0in; padding-top: 0px;">Cash paid for amounts included in the&#160;measurement of lease liabilities</td><td style="font: 10pt &quot;times new roman&quot;, times, serif; padding-bottom: 2.5pt; padding-left: 0px; padding-top: 0px;">&#160;</td><td style="border-bottom: 2.5pt double black; font: 10pt &quot;times new roman&quot;, times, serif; text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px;">&#160;</td><td style="border-bottom: 2.5pt double black; font: 10pt &quot;times new roman&quot;, times, serif; text-align: right; padding-left: 0px; padding-top: 0px; padding-bottom: 1.5pt;">328</td><td style="padding-bottom: 1.5pt; font: 10pt &quot;times new roman&quot;, times, serif; text-align: left; padding-left: 0px; padding-top: 0px;">&#160;</td></tr><tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-size: 10pt; text-align: left; padding-left: 0in; padding-bottom: 2.5pt; padding-top: 0px;">Right of use assets obtained in exchange&#160;for new operating lease liabilities</td><td style="font-size: 10pt; padding-bottom: 2.5pt; padding-left: 0px; padding-top: 0px;">&#160;</td><td style="font-size: 10pt; text-align: left; border-bottom: 2.5pt double black; padding-left: 0px; padding-top: 0px; padding-bottom: 0px;">&#160;</td><td style="font-size: 10pt; text-align: right; border-bottom: 2.5pt double black; padding-left: 0px; padding-top: 0px; padding-bottom: 1.5pt;">52</td><td style="font-size: 10pt; text-align: left; padding-bottom: 1.5pt; padding-left: 0px; padding-top: 0px;">&#160;</td></tr><tr style="vertical-align: bottom; background-color: white;"><td style="font-size: 10pt; text-align: left; padding-bottom: 2.5pt; padding-left: 0in; padding-top: 0px;">Weighted average remaining lease term&#160;(in years)</td><td style="font: 10pt &quot;times new roman&quot;, times, serif; padding-bottom: 2.5pt; padding-left: 0px; padding-top: 0px;">&#160;</td><td style="border-bottom: 2.5pt double black; font: 10pt &quot;times new roman&quot;, times, serif; text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px;">&#160;</td><td style="border-bottom: 2.5pt double black; font: 10pt &quot;times new roman&quot;, times, serif; text-align: right; padding-left: 0px; padding-top: 0px; padding-bottom: 1.5pt;">10.84</td><td style="padding-bottom: 1.5pt; font: 10pt &quot;times new roman&quot;, times, serif; text-align: left; padding-left: 0px; padding-top: 0px;">&#160;</td></tr><tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-size: 10pt; padding-bottom: 2.5pt; padding-left: 0in; padding-top: 0px;">Weighted average discount rate</td><td style="font: 10pt &quot;times new roman&quot;, times, serif; padding-bottom: 2.5pt; padding-left: 0px; padding-top: 0px;">&#160;</td><td style="border-bottom: 2.5pt double black; font: 10pt &quot;times new roman&quot;, times, serif; text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px;">&#160;</td><td style="border-bottom: 2.5pt double black; font: 10pt &quot;times new roman&quot;, times, serif; text-align: right; padding-left: 0px; padding-top: 0px; padding-bottom: 1.5pt;">12.58</td><td style="padding-bottom: 1.5pt; font: 10pt &quot;times new roman&quot;, times, serif; text-align: left; padding-left: 0px; padding-top: 0px;">%</td></tr></table><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px;"></div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock', window );">Lessee, Operating Lease, Liability, Maturity</a></td>
<td class="text"><div style="color: rgb(0, 0, 0); font: 10pt &quot;times new roman&quot;, times, serif; letter-spacing: normal; orphans: 2; text-align: start; text-indent: 0px; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; margin: 0px 0px 0px 0.5in;">The following table sets forth a maturity analysis of the Company&#8217;s operating lease liabilities as of March&#160;31, 2019:</div><div style="color: rgb(0, 0, 0); font: 10pt &quot;times new roman&quot;, times, serif; letter-spacing: normal; orphans: 2; text-align: start; text-indent: 0px; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; margin: 0px 0px 0px 0.5in; background: none;">&#160;</div><table cellpadding="0" cellspacing="0" style="font: 10pt &quot;times new roman&quot;, times, serif; letter-spacing: normal; orphans: 2; text-indent: 0px; text-transform: none; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; border-collapse: collapse; width: 55%; margin-left: 0.5in; border-spacing: 0px;"><tr style="vertical-align: bottom;"><td style="font-size: 10pt; padding-bottom: 1pt; padding-left: 0px; padding-top: 0px;">(<div style="font-style:italic;display:inline;;font-style:italic;display:inline;">U.S. dollars in thousands)</div></td><td style="font: 10pt &quot;times new roman&quot;, times, serif; padding-bottom: 1pt; padding-left: 0px; padding-top: 0px;">&#160;</td><td colspan="2" style="font: 10pt &quot;times new roman&quot;, times, serif; text-align: center; border-bottom: 1pt solid black; padding-left: 0px; padding-top: 0px; padding-bottom: 0px;"><div style="font-weight:bold;display:inline;">March 31, 2019</div></td><td style="padding-bottom: 1pt; font: 10pt &quot;times new roman&quot;, times, serif; padding-left: 0px; padding-top: 0px;">&#160;</td></tr><tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="width: 789px; font-size: 10pt; text-align: left; padding-left: 0in; padding-top: 0px; padding-bottom: 0px;">2019&#160;(excluding&#160;the&#160;three&#160;months&#160;ended&#160;March&#160;31,&#160;2019)</td><td style="width: 21px; font-size: 10pt; padding-left: 0px; padding-top: 0px; padding-bottom: 0px;">&#160;</td><td style="width: 10px; font-size: 10pt; text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px;">$</td><td style="width: 207px; font-size: 10pt; text-align: right; padding-left: 0px; padding-top: 0px; padding-bottom: 0px;">947</td><td style="width: 10px; font-size: 10pt; text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px;">&#160;</td></tr><tr style="vertical-align: bottom; background-color: white;"><td style="font-size: 10pt; text-align: left; padding-left: 0in; padding-top: 0px; padding-bottom: 0px;">2020</td><td style="font-size: 10pt; padding-left: 0px; padding-top: 0px; padding-bottom: 0px;">&#160;</td><td style="font-size: 10pt; text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px;">$</td><td style="font-size: 10pt; text-align: right; padding-left: 0px; padding-top: 0px; padding-bottom: 0px;">1,135</td><td style="font-size: 10pt; text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px;">&#160;</td></tr><tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-size: 10pt; text-align: left; padding-left: 0in; padding-top: 0px; padding-bottom: 0px;">2021</td><td style="font-size: 10pt; padding-left: 0px; padding-top: 0px; padding-bottom: 0px;">&#160;</td><td style="font-size: 10pt; text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px;">$</td><td style="font-size: 10pt; text-align: right; padding-left: 0px; padding-top: 0px; padding-bottom: 0px;">888</td><td style="font-size: 10pt; text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px;">&#160;</td></tr><tr style="vertical-align: bottom; background-color: white;"><td style="font-size: 10pt; text-align: left; padding-left: 0in; padding-top: 0px; padding-bottom: 0px;">2022</td><td style="font-size: 10pt; padding-left: 0px; padding-top: 0px; padding-bottom: 0px;">&#160;</td><td style="font-size: 10pt; text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px;">$</td><td style="font-size: 10pt; text-align: right; padding-left: 0px; padding-top: 0px; padding-bottom: 0px;">774</td><td style="font-size: 10pt; text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px;">&#160;</td></tr><tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-size: 10pt; text-align: left; padding-left: 0in; padding-top: 0px; padding-bottom: 0px;">2023</td><td style="font-size: 10pt; padding-left: 0px; padding-top: 0px; padding-bottom: 0px;">&#160;</td><td style="font-size: 10pt; text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px;">$</td><td style="font-size: 10pt; text-align: right; padding-left: 0px; padding-top: 0px; padding-bottom: 0px;">770</td><td style="font-size: 10pt; text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px;">&#160;</td></tr><tr style="vertical-align: bottom; background-color: white;"><td style="font-size: 10pt; padding-bottom: 2.5pt; padding-left: 0in; padding-top: 0px;">After&#160;2024&#160;</td><td style="font: 10pt &quot;times new roman&quot;, times, serif; padding-bottom: 2.5pt; padding-left: 0px; padding-top: 0px;">&#160;</td><td style="border-bottom: 2.5pt double black; font: 10pt &quot;times new roman&quot;, times, serif; text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px;">$</td><td style="border-bottom: 2.5pt double black; font: 10pt &quot;times new roman&quot;, times, serif; text-align: right; padding-left: 0px; padding-top: 0px; padding-bottom: 0px;">6,380</td><td style="padding-bottom: 1.5pt; font: 10pt &quot;times new roman&quot;, times, serif; text-align: left; padding-left: 0px; padding-top: 0px;">&#160;</td></tr><tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-size: 10pt; text-align: left; padding-bottom: 2.5pt; padding-left: 0in; padding-top: 0px;">Total undiscounted cash flows</td><td style="font: 10pt &quot;times new roman&quot;, times, serif; padding-bottom: 2.5pt; padding-left: 0px; padding-top: 0px;">&#160;</td><td style="border-bottom: 2.5pt double black; font: 10pt &quot;times new roman&quot;, times, serif; text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px;">$</td><td style="border-bottom: 2.5pt double black; font: 10pt &quot;times new roman&quot;, times, serif; text-align: right; padding-left: 0px; padding-top: 0px; padding-bottom: 0px;">10,894</td><td style="padding-bottom: 1.5pt; font: 10pt &quot;times new roman&quot;, times, serif; text-align: left; padding-left: 0px; padding-top: 0px;">&#160;</td></tr><tr style="vertical-align: bottom; background-color: white;"><td style="font-size: 10pt; padding-bottom: 2.5pt; padding-left: 0in; padding-top: 0px;">Less:&#160;imputed&#160;interest</td><td style="font: 10pt &quot;times new roman&quot;, times, serif; padding-bottom: 2.5pt; padding-left: 0px; padding-top: 0px;">&#160;</td><td style="border-bottom: 2.5pt double black; font: 10pt &quot;times new roman&quot;, times, serif; text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px;">$</td><td style="border-bottom: 2.5pt double black; font: 10pt &quot;times new roman&quot;, times, serif; text-align: right; padding-left: 0px; padding-top: 0px; padding-bottom: 0px;">5,139</td><td style="padding-bottom: 1.5pt; font: 10pt &quot;times new roman&quot;, times, serif; text-align: left; padding-left: 0px; padding-top: 0px;">&#160;</td></tr><tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-size: 10pt; text-align: left; padding-bottom: 2.5pt; padding-left: 0in; padding-top: 0px;">Present&#160;value&#160;of lease liabilities</td><td style="font: 10pt &quot;times new roman&quot;, times, serif; padding-bottom: 2.5pt; padding-left: 0px; padding-top: 0px;">&#160;</td><td style="border-bottom: 2.5pt double black; font: 10pt &quot;times new roman&quot;, times, serif; text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px;">$</td><td style="border-bottom: 2.5pt double black; font: 10pt &quot;times new roman&quot;, times, serif; text-align: right; padding-left: 0px; padding-top: 0px; padding-bottom: 0px;">5,755</td><td style="padding-bottom: 1.5pt; font: 10pt &quot;times new roman&quot;, times, serif; text-align: left; padding-left: 0px; padding-top: 0px;">&#160;</td></tr></table><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px;"></div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseCostTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of lessee's lease cost. Includes, but is not limited to, interest expense for finance lease, amortization of right-of-use asset for finance lease, operating lease cost, short-term lease cost, variable lease cost and sublease income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=77888426&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseCostTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesOperatingAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesOperatingAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=77888426&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>29
<FILENAME>R18.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.1</span><table class="report" border="0" cellspacing="2" id="idp6805080352">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>REVENUES (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2019</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementAbstract', window );"><strong>Income Statement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_plx_SupplementaryIncomeStatementInformationTableTextBlock', window );">Statements of operations</a></td>
<td class="text"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; margin: 0px 0px 0px 0.5in;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">The following table summarizes the Company&#8217;s disaggregation of revenues:</div></div><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; margin: 0px 0px 0px 0.5in; background: none;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div><table style="border: none; border-collapse: collapse; margin: 0in 6.75pt 0in 0.5in; width: 55%;;text-align:left;"><tr><td style="border-bottom: none; border-top: none; padding: 0px 0px 1pt; vertical-align: bottom;;width:;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; margin-right: 0px; margin-bottom: 0px; margin-top: 0px; line-height: normal; background: none; text-align: center;"><div style="background: none;;font-weight:bold;display:inline;width:100%;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div></td><td style="border-top: none; padding: 0in 0in 1pt; vertical-align: bottom;;width:;"><div style="font-size: 10pt; font-family: &quot;times new roman&quot;, times, serif; line-height: normal; margin-bottom: 0px; margin-top: 0px;"><div style="background: none;;font-weight:bold;display:inline;width:100%;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div></td><td colspan="6" style="border-bottom: 1pt solid rgb(0, 0, 0); border-top-style: none; padding: 0in; vertical-align: bottom; white-space: nowrap;;width:;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; text-align: center; margin-right: 0px; margin-bottom: 0px; margin-top: 0px; line-height: normal; white-space: nowrap;"><div style="font-weight:bold;display:inline;">Three months ended March&#160;31,</div></div></td><td style="border-top-style: none; padding: 0in 0in 0.5pt; vertical-align: bottom; white-space: nowrap;"><div style="font-size: 10pt; font-family: &quot;times new roman&quot;, times, serif; line-height: normal; margin-bottom: 0px; margin-top: 0px;"><div style="background: none;;font-weight:bold;display:inline;width:100%;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div></td></tr><tr><td style="border-bottom: none; border-top: none; padding: 0px 0px 1pt; vertical-align: bottom;;width:;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; margin-right: 0px; margin-bottom: 0px; margin-top: 0px; line-height: normal;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;;font-style:italic;display:inline;">(U.S.&#160;dollars&#160;in&#160;thousands)</div></div></div></td><td style="padding: 0in 0in 1pt; vertical-align: bottom;;width:;"><div style="font-size: 10pt; font-family: &quot;times new roman&quot;, times, serif; line-height: normal; margin-bottom: 0px; margin-top: 0px;"><div style="background: none;;font-weight:bold;display:inline;width:100%;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div></td><td colspan="2" style="border-bottom: 1pt solid rgb(0, 0, 0); border-top-style: none; padding: 0in; vertical-align: bottom; white-space: nowrap;;width:;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; text-align: center; margin-right: 0px; margin-bottom: 0px; margin-top: 0px; line-height: normal; white-space: nowrap;"><div style="font-weight:bold;display:inline;width:100%;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;">2019</div></div></div></td><td style="border-top-style: none; padding: 0in 0in 0.5pt; vertical-align: bottom; white-space: nowrap;"><div style="font-size: 10pt; font-family: &quot;times new roman&quot;, times, serif; line-height: normal; margin-bottom: 0px; margin-top: 0px;"><div style="background: none;;font-weight:bold;display:inline;width:100%;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div></td><td style="border-top-style: none; padding: 0in 0in 1pt; vertical-align: bottom; white-space: nowrap;;width:;"><div style="font-size: 10pt; font-family: &quot;times new roman&quot;, times, serif; line-height: normal; margin-bottom: 0px; margin-top: 0px;"><div style="background: none;;font-weight:bold;display:inline;width:100%;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div></td><td colspan="2" style="border-bottom: 1pt solid rgb(0, 0, 0); border-top-style: none; padding: 0in; vertical-align: bottom; white-space: nowrap;;width:;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; text-align: center; margin-right: 0px; margin-bottom: 0px; margin-top: 0px; line-height: normal; white-space: nowrap;"><div style="font-weight:bold;display:inline;width:100%;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;">2018</div></div></div></td><td style="padding: 0in 0in 0.5pt; vertical-align: bottom; white-space: nowrap;"><div style="font-size: 10pt; font-family: &quot;times new roman&quot;, times, serif; line-height: normal; margin-bottom: 0px; margin-top: 0px;"><div style="background: none;;font-weight:bold;display:inline;width:100%;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div></td></tr><tr><td style="background: rgb(204, 238, 255); border-bottom: none; border-top: none; padding: 0px 0px 0px 27pt; vertical-align: bottom; width: 57%; font-size: 10pt;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; margin-right: 0px; margin-bottom: 0px; margin-top: 0px; line-height: normal;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">Pfizer</div><div style="font-size: 10pt; font-family: &quot;times new roman&quot;, times, serif; color: rgb(0, 0, 0); background: none; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;times new roman&quot;, times, serif; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px; font-size: 10pt;;display:inline;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</div></div></div></td><td style="background: rgb(204, 238, 255); border-top: none; padding: 0in; vertical-align: bottom; width: 1%;"><div style="font-size: 10pt; font-family: &quot;times new roman&quot;, times, serif; line-height: normal; background: none; margin-bottom: 0px; margin-top: 0px;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="background-color: rgb(204, 238, 255); width: 1%; border-bottom: none; border-top: 0px none; text-align: left; vertical-align: bottom; padding: 0in;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; text-align: left; margin: 0px 0px 0px 0in; line-height: normal; white-space: nowrap; text-indent: 0in;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;">$</div></div></td><td style="background: rgb(204, 238, 255); border-bottom: none; border-top: 0px none; padding: 0in; vertical-align: bottom; width: 18%; white-space: nowrap; text-align: right;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; text-align: right; margin-right: 0in; margin-bottom: 0px; margin-top: 0px; line-height: normal; white-space: nowrap;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;">1,356</div></div></td><td style="background: rgb(204, 238, 255); padding: 0in; vertical-align: bottom; width: 1%; white-space: nowrap; text-align: left;"><div style="font-size: 10pt; font-family: &quot;times new roman&quot;, times, serif; margin-left: 0in; text-indent: 0in; text-align: left; white-space: nowrap; line-height: normal; background: none; margin-bottom: 0px; margin-top: 0px;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="background-color: rgb(204, 238, 255); width: 2%; vertical-align: bottom; padding: 0in;"><div style="font-size: 10pt; font-family: &quot;times new roman&quot;, times, serif; line-height: normal; background: none; margin-bottom: 0px; margin-top: 0px;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="background: rgb(204, 238, 255); border-top: 0px none; border-bottom: none; padding: 0in; vertical-align: bottom; width: 1%; white-space: nowrap; text-align: left;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; text-align: left; margin: 0px 0px 0px 0in; line-height: normal; white-space: nowrap; text-indent: 0in;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;">$</div></div></td><td style="background: rgb(204, 238, 255); border-bottom: none; border-top: 0px none; padding: 0in; vertical-align: bottom; width: 18%; white-space: nowrap; text-align: right;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; text-align: right; margin-right: 0in; margin-bottom: 0px; margin-top: 0px; line-height: normal; white-space: nowrap;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;">1,980</div></div></td><td style="background: rgb(204, 238, 255); padding: 0in; vertical-align: bottom; width: 1%; white-space: nowrap; text-align: left;"><div style="font-size: 10pt; font-family: &quot;times new roman&quot;, times, serif; margin-left: 0in; text-indent: 0in; text-align: left; white-space: nowrap; line-height: normal; background: none; margin-bottom: 0px; margin-top: 0px;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td></tr><tr><td style="background: rgb(255, 255, 255); border-top: none; border-bottom: none; padding: 0px 0px 1pt 27pt; vertical-align: bottom; width: 57%; font-size: 10pt;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; margin-right: 0px; margin-bottom: 0px; margin-top: 0px; line-height: normal;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">Brazil</div><div style="font-size: 10pt; font-family: &quot;times new roman&quot;, times, serif; color: rgb(0, 0, 0); background: none; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;times new roman&quot;, times, serif; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px; font-size: 10pt;;display:inline;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</div></div></div></td><td style="background: rgb(255, 255, 255); padding: 0in 0in 1pt; vertical-align: bottom; width: 1%;"><div style="font-size: 10pt; font-family: &quot;times new roman&quot;, times, serif; line-height: normal; background: none; margin-bottom: 0px; margin-top: 0px;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="background-color: rgb(255, 255, 255); width: 1%; border-bottom: 1pt solid rgb(0, 0, 0); text-align: left; vertical-align: bottom; padding: 0in;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; text-align: left; margin: 0px 0px 0px 0in; line-height: normal; white-space: nowrap; text-indent: 0in;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;">$</div></div></td><td style="background: rgb(255, 255, 255); border-bottom: 1pt solid rgb(0, 0, 0); border-top-style: none; padding: 0in; vertical-align: bottom; width: 18%; white-space: nowrap; text-align: right;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; text-align: right; margin-right: 0in; margin-bottom: 0px; margin-top: 0px; line-height: normal; white-space: nowrap;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;">2,174</div></div></td><td style="background: rgb(255, 255, 255); padding: 0in 0in 0.5pt; vertical-align: bottom; width: 1%; white-space: nowrap; text-align: left;"><div style="font-size: 10pt; font-family: &quot;times new roman&quot;, times, serif; margin-left: 0in; text-indent: 0in; text-align: left; white-space: nowrap; line-height: normal; background: none; margin-bottom: 0px; margin-top: 0px;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="background-color: rgb(255, 255, 255); width: 2%; vertical-align: bottom; padding: 0in 0in 1pt;"><div style="font-size: 10pt; font-family: &quot;times new roman&quot;, times, serif; line-height: normal; background: none; margin-bottom: 0px; margin-top: 0px;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="background: rgb(255, 255, 255); border-bottom: 1pt solid rgb(0, 0, 0); padding: 0in; vertical-align: bottom; width: 1%; white-space: nowrap; text-align: left;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; text-align: left; margin: 0px 0px 0px 0in; line-height: normal; white-space: nowrap; text-indent: 0in;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;">$</div></div></td><td style="background: rgb(255, 255, 255); border-bottom: 1pt solid rgb(0, 0, 0); border-top-style: none; padding: 0in; vertical-align: bottom; width: 18%; white-space: nowrap; text-align: right;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; text-align: right; margin-right: 0in; margin-bottom: 0px; margin-top: 0px; line-height: normal; white-space: nowrap;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;">2,573</div></div></td><td style="background: rgb(255, 255, 255); padding: 0in 0in 0.5pt; vertical-align: bottom; width: 1%; white-space: nowrap; text-align: left;"><div style="font-size: 10pt; font-family: &quot;times new roman&quot;, times, serif; margin-left: 0in; text-indent: 0in; text-align: left; white-space: nowrap; line-height: normal; background: none; margin-bottom: 0px; margin-top: 0px;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td></tr><tr><td style="background: rgb(204, 238, 255); border-top: none; border-bottom: none; padding: 0px 0px 2.5pt 27pt; vertical-align: bottom; width: 57%;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; margin-right: 0px; margin-bottom: 0px; margin-top: 0px; line-height: normal;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">Total revenues from selling goods</div></div></td><td style="background: rgb(204, 238, 255); padding: 0in 0in 2.5pt; vertical-align: bottom; width: 1%;"><div style="font-size: 10pt; font-family: &quot;times new roman&quot;, times, serif; line-height: normal; background: none; margin-bottom: 0px; margin-top: 0px;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="background-color: rgb(204, 238, 255); width: 1%; border-bottom: 2.5pt double rgb(0, 0, 0); text-align: left; vertical-align: bottom; padding: 0in;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; text-align: left; margin: 0px 0px 0px 0in; line-height: normal; white-space: nowrap; text-indent: 0in;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;"><div style="white-space: nowrap;;font-weight:bold;display:inline;">$</div></div></div></td><td style="background: rgb(204, 238, 255); border-bottom: 2.5pt double rgb(0, 0, 0); border-top-style: none; padding: 0in; vertical-align: bottom; width: 18%; white-space: nowrap; text-align: right;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; text-align: right; margin-right: 0in; margin-bottom: 0px; margin-top: 0px; line-height: normal; white-space: nowrap;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;"><div style="white-space: nowrap;;font-weight:bold;display:inline;">3,530</div></div></div></td><td style="background: rgb(204, 238, 255); padding: 0in 0in 1.5pt; vertical-align: bottom; width: 1%; white-space: nowrap; text-align: left;"><div style="font-size: 10pt; font-family: &quot;times new roman&quot;, times, serif; margin-left: 0in; text-indent: 0in; text-align: left; white-space: nowrap; line-height: normal; background: none; margin-bottom: 0px; margin-top: 0px;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="padding: 0in 0in 2.5pt; background-color: rgb(204, 238, 255); width: 2%; vertical-align: bottom;"><div style="font-size: 10pt; font-family: &quot;times new roman&quot;, times, serif; line-height: normal; background: none; margin-bottom: 0px; margin-top: 0px;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="background: rgb(204, 238, 255); border-bottom: 2.5pt double rgb(0, 0, 0); padding: 0in; vertical-align: bottom; width: 1%; white-space: nowrap; text-align: left;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; text-align: left; margin: 0px 0px 0px 0in; line-height: normal; white-space: nowrap; text-indent: 0in;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;"><div style="white-space: nowrap;;font-weight:bold;display:inline;">$</div></div></div></td><td style="background: rgb(204, 238, 255); border-bottom: 2.5pt double rgb(0, 0, 0); border-top-style: none; padding: 0in; vertical-align: bottom; width: 18%; white-space: nowrap; text-align: right;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; text-align: right; margin-right: 0in; margin-bottom: 0px; margin-top: 0px; line-height: normal; white-space: nowrap;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;"><div style="white-space: nowrap;;font-weight:bold;display:inline;">4,553</div></div></div></td><td style="background: rgb(204, 238, 255); padding: 0in 0in 1.5pt; vertical-align: bottom; width: 1%; white-space: nowrap; text-align: left;"><div style="font-size: 10pt; font-family: &quot;times new roman&quot;, times, serif; margin-left: 0in; text-indent: 0in; text-align: left; white-space: nowrap; line-height: normal; background: none; margin-bottom: 0px; margin-top: 0px;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td></tr><tr><td style="background: rgb(255, 255, 255); border-top: none; border-bottom: none; padding: 0px 0px 2.5pt 27pt; vertical-align: bottom; width: 57%;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; margin-right: 0px; margin-bottom: 0px; margin-top: 0px; line-height: normal;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">Revenues from license and R&amp;D services</div></div></td><td style="background: rgb(255, 255, 255); padding: 0in 0in 2.5pt; vertical-align: bottom; width: 1%;"><div style="font-size: 10pt; font-family: &quot;times new roman&quot;, times, serif; line-height: normal; background: none; margin-bottom: 0px; margin-top: 0px;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="background-color: rgb(255, 255, 255); width: 1%; border-bottom: 2.5pt double rgb(0, 0, 0); text-align: left; vertical-align: bottom; padding: 0in;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; text-align: left; margin: 0px 0px 0px 0in; line-height: normal; white-space: nowrap; text-indent: 0in;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;"><div style="white-space: nowrap;;font-weight:bold;display:inline;">$</div></div></div></td><td style="background: rgb(255, 255, 255); border-bottom: 2.5pt double rgb(0, 0, 0); border-top-style: none; padding: 0in; vertical-align: bottom; width: 18%; white-space: nowrap; text-align: right;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; text-align: right; margin-right: 0in; margin-bottom: 0px; margin-top: 0px; line-height: normal; white-space: nowrap;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;"><div style="white-space: nowrap;;font-weight:bold;display:inline;">6,909</div></div></div></td><td style="background: rgb(255, 255, 255); padding: 0in 0in 1.5pt; vertical-align: bottom; width: 1%; white-space: nowrap; text-align: left;"><div style="font-size: 10pt; font-family: &quot;times new roman&quot;, times, serif; margin-left: 0in; text-indent: 0in; text-align: left; white-space: nowrap; line-height: normal; background: none; margin-bottom: 0px; margin-top: 0px;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="padding: 0in 0in 2.5pt; background-color: rgb(255, 255, 255); width: 2%; vertical-align: bottom;"><div style="font-size: 10pt; font-family: &quot;times new roman&quot;, times, serif; line-height: normal; background: none; margin-bottom: 0px; margin-top: 0px;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="background: rgb(255, 255, 255); border-bottom: 2.5pt double rgb(0, 0, 0); padding: 0in; vertical-align: bottom; width: 1%; white-space: nowrap; text-align: left;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; text-align: left; margin: 0px 0px 0px 0in; line-height: normal; white-space: nowrap; text-indent: 0in;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;"><div style="white-space: nowrap;;font-weight:bold;display:inline;">$</div></div></div></td><td style="background: rgb(255, 255, 255); border-bottom: 2.5pt double rgb(0, 0, 0); border-top-style: none; padding: 0in; vertical-align: bottom; width: 18%; white-space: nowrap; text-align: right;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; text-align: right; margin-right: 0in; margin-bottom: 0px; margin-top: 0px; line-height: normal; white-space: nowrap;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;"><div style="white-space: nowrap;;font-weight:bold;display:inline;">2,161</div></div></div></td><td style="background: rgb(255, 255, 255); padding: 0in 0in 1.5pt; vertical-align: bottom; width: 1%; white-space: nowrap; text-align: left;"><div style="font-size: 10pt; font-family: &quot;times new roman&quot;, times, serif; margin-left: 0in; text-indent: 0in; text-align: left; white-space: nowrap; line-height: normal; background: none; margin-bottom: 0px; margin-top: 0px;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td></tr></table><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px;"></div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock', window );">Contract with Customer, Asset and Liability [Table Text Block]</a></td>
<td class="text"><div style="color: rgb(0, 0, 0); font: 10pt &quot;times new roman&quot;, times, serif; letter-spacing: normal; orphans: 2; text-align: start; text-indent: 0in; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; margin: 0px 0px 0px 0.5in;">The following table sets forth data regarding the Company&#8217;s contract liability:</div><div style="color: rgb(0, 0, 0); font: 10pt &quot;times new roman&quot;, times, serif; letter-spacing: normal; orphans: 2; text-align: start; text-indent: 0in; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; margin: 0px; background: none;">&#160;</div><table cellpadding="0" cellspacing="0" style="font: 10pt &quot;times new roman&quot;, times, serif; letter-spacing: normal; orphans: 2; text-indent: 0px; text-transform: none; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; border-collapse: collapse; width: 55%; margin-left: 0.5in; border-spacing: 0px;"><tr style="vertical-align: bottom;"><td style="font-size: 10pt; padding: 0px; text-indent: 0px;">&#160;</td><td style="font: 10pt &quot;times new roman&quot;, times, serif; padding-bottom: 1pt; padding-left: 0px; padding-top: 0px;">&#160;</td><td colspan="6" style="font: 10pt &quot;times new roman&quot;, times, serif; text-align: center; border-bottom: 1pt solid black; white-space: nowrap; padding-left: 0px; padding-top: 0px; padding-bottom: 0px;"><div style="font-weight:bold;display:inline;">Three months ended March&#160;31,</div></td><td style="padding-bottom: 1pt; font: 10pt &quot;times new roman&quot;, times, serif; padding-left: 0px; padding-top: 0px;">&#160;</td></tr><tr style="vertical-align: bottom;"><td style="font: 10pt &quot;times new roman&quot;, times, serif; padding: 0px; border-bottom: 1pt solid black; text-indent: 0px;"><div style="font-style:italic;display:inline;;font-style:italic;display:inline;">(U.S. dollars in thousands)</div></td><td style="font: 10pt &quot;times new roman&quot;, times, serif; padding-bottom: 1pt; padding-left: 0px; padding-top: 0px;">&#160;</td><td colspan="2" style="font: 10pt &quot;times new roman&quot;, times, serif; text-align: center; border-bottom: 1pt solid black; white-space: nowrap; padding-left: 0px; padding-top: 0px; padding-bottom: 0px;"><div style="font-weight:bold;display:inline;">2019</div></td><td style="padding-bottom: 1pt; font: 10pt &quot;times new roman&quot;, times, serif; white-space: nowrap; padding-left: 0px; padding-top: 0px;">&#160;</td><td style="font: 10pt &quot;times new roman&quot;, times, serif; padding-bottom: 1pt; white-space: nowrap; padding-left: 0px; padding-top: 0px;">&#160;</td><td colspan="2" style="font: 10pt &quot;times new roman&quot;, times, serif; text-align: center; border-bottom: 1pt solid black; white-space: nowrap; padding-left: 0px; padding-top: 0px; padding-bottom: 0px;"><div style="font-weight:bold;display:inline;">2018</div></td><td style="padding-bottom: 1pt; font: 10pt &quot;times new roman&quot;, times, serif; padding-left: 0px; padding-top: 0px;">&#160;</td></tr><tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="width: 581px; font: 10pt 'times new roman', times, serif; padding: 0px; text-align: left; text-indent: 0px;">Contract liabilities at the beginning of the period</td><td style="width: 21px; font: 10pt &quot;times new roman&quot;, times, serif; padding-left: 0px; padding-top: 0px; padding-bottom: 0px;">&#160;</td><td style="width: 11px; font: 10pt &quot;times new roman&quot;, times, serif; text-align: left; white-space: nowrap; padding-left: 0px; padding-top: 0px; padding-bottom: 0px;">$</td><td style="width: 187px; font: 10pt &quot;times new roman&quot;, times, serif; text-align: right; white-space: nowrap; padding-left: 0px; padding-top: 0px; padding-bottom: 0px;">42,895</td><td style="width: 11px; font: 10pt &quot;times new roman&quot;, times, serif; text-align: left; white-space: nowrap; padding-left: 0px; padding-top: 0px; padding-bottom: 0px;">&#160;</td><td style="width: 20px; font: 10pt &quot;times new roman&quot;, times, serif; white-space: nowrap; padding-left: 0px; padding-top: 0px; padding-bottom: 0px;">&#160;</td><td style="width: 10px; font: 10pt &quot;times new roman&quot;, times, serif; text-align: left; white-space: nowrap; padding-left: 0px; padding-top: 0px; padding-bottom: 0px;">$</td><td style="width: 186px; font: 10pt &quot;times new roman&quot;, times, serif; text-align: right; white-space: nowrap; padding-left: 0px; padding-top: 0px; padding-bottom: 0px;">25,015</td><td style="width: 10px; font: 10pt &quot;times new roman&quot;, times, serif; text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px;">&#160;</td></tr><tr style="vertical-align: bottom; background-color: white;"><td style="font: 10pt 'times new roman', times, serif; padding: 0px; text-align: left; text-indent: 0px;">Additions during the period</td><td style="font: 10pt &quot;times new roman&quot;, times, serif; padding-left: 0px; padding-top: 0px; padding-bottom: 0px;">&#160;</td><td style="font: 10pt &quot;times new roman&quot;, times, serif; text-align: left; white-space: nowrap; padding-left: 0px; padding-top: 0px; padding-bottom: 0px;">&#160;</td><td style="font: 10pt &quot;times new roman&quot;, times, serif; text-align: right; white-space: nowrap; padding-left: 0px; padding-top: 0px; padding-bottom: 0px;">6,422</td><td style="font: 10pt &quot;times new roman&quot;, times, serif; text-align: left; white-space: nowrap; padding-left: 0px; padding-top: 0px; padding-bottom: 0px;">&#160;</td><td style="font: 10pt &quot;times new roman&quot;, times, serif; white-space: nowrap; padding-left: 0px; padding-top: 0px; padding-bottom: 0px;">&#160;</td><td style="font: 10pt &quot;times new roman&quot;, times, serif; text-align: left; white-space: nowrap; padding-left: 0px; padding-top: 0px; padding-bottom: 0px;">&#160;</td><td style="font: 10pt &quot;times new roman&quot;, times, serif; text-align: right; white-space: nowrap; padding-left: 0px; padding-top: 0px; padding-bottom: 0px;">2,179</td><td style="font: 10pt &quot;times new roman&quot;, times, serif; text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px;">&#160;</td></tr><tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font: 10pt 'times new roman', times, serif; padding: 0px; text-align: left; text-indent: 0px;">Revenue recognized during the period</td><td style="font: 10pt &quot;times new roman&quot;, times, serif; padding-bottom: 1pt; padding-left: 0px; padding-top: 0px;">&#160;</td><td style="border-bottom: 1pt solid black; font: 10pt &quot;times new roman&quot;, times, serif; text-align: left; white-space: nowrap; padding-left: 0px; padding-top: 0px; padding-bottom: 0px;">&#160;</td><td style="border-bottom: 1pt solid black; font: 10pt &quot;times new roman&quot;, times, serif; text-align: right; white-space: nowrap; padding-left: 0px; padding-top: 0px; padding-bottom: 0px;">(6,909</td><td style="padding-bottom: 1pt; font: 10pt &quot;times new roman&quot;, times, serif; text-align: left; white-space: nowrap; padding-left: 0px; padding-top: 0px;">)</td><td style="font: 10pt &quot;times new roman&quot;, times, serif; padding-bottom: 1pt; white-space: nowrap; padding-left: 0px; padding-top: 0px;">&#160;</td><td style="border-bottom: 1pt solid black; font: 10pt &quot;times new roman&quot;, times, serif; text-align: left; white-space: nowrap; padding-left: 0px; padding-top: 0px; padding-bottom: 0px;">&#160;</td><td style="border-bottom: 1pt solid black; font: 10pt &quot;times new roman&quot;, times, serif; text-align: right; white-space: nowrap; padding-left: 0px; padding-top: 0px; padding-bottom: 0px;">(2,161</td><td style="padding-bottom: 1pt; font: 10pt &quot;times new roman&quot;, times, serif; text-align: left; padding-left: 0px; padding-top: 0px;">)</td></tr><tr style="vertical-align: bottom; background-color: white;"><td style="font: 10pt 'times new roman', times, serif; padding: 0px; text-align: left; text-indent: 0px;">Contract liabilities at the end of the period</td><td style="font: 10pt &quot;times new roman&quot;, times, serif; padding-bottom: 2.5pt; padding-left: 0px; padding-top: 0px;">&#160;</td><td style="border-bottom: 2.5pt double black; font: 10pt &quot;times new roman&quot;, times, serif; text-align: left; white-space: nowrap; padding-left: 0px; padding-top: 0px; padding-bottom: 0px;">$</td><td style="border-bottom: 2.5pt double black; font: 10pt &quot;times new roman&quot;, times, serif; text-align: right; white-space: nowrap; padding-left: 0px; padding-top: 0px; padding-bottom: 0px;">42,408</td><td style="padding-bottom: 2.5pt; font: 10pt &quot;times new roman&quot;, times, serif; text-align: left; white-space: nowrap; padding-left: 0px; padding-top: 0px;">&#160;</td><td style="font: 10pt &quot;times new roman&quot;, times, serif; padding-bottom: 2.5pt; white-space: nowrap; padding-left: 0px; padding-top: 0px;">&#160;</td><td style="border-bottom: 2.5pt double black; font: 10pt &quot;times new roman&quot;, times, serif; text-align: left; white-space: nowrap; padding-left: 0px; padding-top: 0px; padding-bottom: 0px;">$</td><td style="border-bottom: 2.5pt double black; font: 10pt &quot;times new roman&quot;, times, serif; text-align: right; white-space: nowrap; padding-left: 0px; padding-top: 0px; padding-bottom: 0px;">25,033</td><td style="padding-bottom: 2.5pt; font: 10pt &quot;times new roman&quot;, times, serif; text-align: left; padding-left: 0px; padding-top: 0px;">&#160;</td></tr></table><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_plx_RevenueRemainingPerformanceObligationAmountTableTextBlock', window );">Revenue, Remaining Performance Obligation, Amount [Table Text Block]</a></td>
<td class="text"><div style="color: rgb(0, 0, 0); font: 10pt &quot;times new roman&quot;, times, serif; letter-spacing: normal; orphans: 2; text-align: start; text-indent: 0in; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; margin: 0px 0px 0px 0.5in;">The following table represents the Company's unsatisfied performance obligation:</div><div style="color: rgb(0, 0, 0); font: 10pt &quot;times new roman&quot;, times, serif; letter-spacing: normal; orphans: 2; text-align: start; text-indent: 0in; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; margin: 0px; background: none;">&#160;</div><table cellpadding="0" cellspacing="0" style="font: 10pt &quot;times new roman&quot;, times, serif; letter-spacing: normal; orphans: 2; text-indent: 0px; text-transform: none; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; border-collapse: collapse; width: 55%; margin-left: 0.5in; border-spacing: 0px;"><tr style="vertical-align: bottom;"><td style="font-size: 10pt; padding: 0px; text-indent: 0px;">&#160;</td><td style="font: 10pt &quot;times new roman&quot;, times, serif; padding-bottom: 1pt; padding-left: 0px; padding-top: 0px;">&#160;</td><td colspan="6" style="font: 10pt &quot;times new roman&quot;, times, serif; text-align: center; border-bottom: 1pt solid black; padding-left: 0px; padding-top: 0px; padding-bottom: 0px;"><div style="font-weight:bold;display:inline;">March&#160;31,</div></td><td style="padding-bottom: 1pt; font: 10pt &quot;times new roman&quot;, times, serif; padding-left: 0px; padding-top: 0px;">&#160;</td></tr><tr style="vertical-align: bottom;"><td style="font: 10pt &quot;times new roman&quot;, times, serif; padding: 0px; border-bottom: 1pt solid black; text-indent: 0px;"><div style="font-style:italic;display:inline;;font-style:italic;display:inline;">(U.S. dollars in thousands)</div></td><td style="font: 10pt &quot;times new roman&quot;, times, serif; padding-bottom: 1pt; padding-left: 0px; padding-top: 0px;">&#160;</td><td colspan="2" style="font: 10pt &quot;times new roman&quot;, times, serif; text-align: center; border-bottom: 1pt solid black; padding-left: 0px; padding-top: 0px; padding-bottom: 0px;"><div style="font-weight:bold;display:inline;">2019</div></td><td style="padding-bottom: 1pt; font: 10pt &quot;times new roman&quot;, times, serif; padding-left: 0px; padding-top: 0px;">&#160;</td><td style="font: 10pt &quot;times new roman&quot;, times, serif; padding-bottom: 1pt; padding-left: 0px; padding-top: 0px;">&#160;</td><td colspan="2" style="font: 10pt &quot;times new roman&quot;, times, serif; text-align: center; border-bottom: 1pt solid black; padding-left: 0px; padding-top: 0px; padding-bottom: 0px;"><div style="font-weight:bold;display:inline;">2018</div></td><td style="padding-bottom: 1pt; font: 10pt &quot;times new roman&quot;, times, serif; padding-left: 0px; padding-top: 0px;">&#160;</td></tr><tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="width: 581px; font: 10pt 'times new roman', times, serif; padding: 0px; text-align: left; text-indent: 0px;">Unsatisfied performance obligation</td><td style="width: 21px; font: 10pt &quot;times new roman&quot;, times, serif; padding-left: 0px; padding-top: 0px; padding-bottom: 0px;">&#160;</td><td style="width: 11px; font: 10pt &quot;times new roman&quot;, times, serif; text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px;">$</td><td style="width: 187px; font: 10pt &quot;times new roman&quot;, times, serif; text-align: right; padding-left: 0px; padding-top: 0px; padding-bottom: 0px;">64,581</td><td style="width: 11px; font: 10pt &quot;times new roman&quot;, times, serif; text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px;">&#160;</td><td style="width: 20px; font: 10pt &quot;times new roman&quot;, times, serif; padding-left: 0px; padding-top: 0px; padding-bottom: 0px;">&#160;</td><td style="width: 10px; font: 10pt &quot;times new roman&quot;, times, serif; text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px;">$</td><td style="width: 186px; font: 10pt &quot;times new roman&quot;, times, serif; text-align: right; padding-left: 0px; padding-top: 0px; padding-bottom: 0px;">91,033</td><td style="width: 10px; font: 10pt &quot;times new roman&quot;, times, serif; text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px;">&#160;</td></tr></table><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_plx_RevenueRemainingPerformanceObligationAmountTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of revenue remaining performance obligation amount.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">plx_RevenueRemainingPerformanceObligationAmountTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>plx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_plx_SupplementaryIncomeStatementInformationTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The tabular disclosure for supplemental income statements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">plx_SupplementaryIncomeStatementInformationTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>plx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of contract balances and changes in contract balances.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=109196051&amp;loc=SL49130551-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>30
<FILENAME>R19.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.1</span><table class="report" border="0" cellspacing="2" id="idp6816909728">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SIGNIFICANT ACCOUNTING POLICIES (Narrative) (Details) - USD ($)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="2">1 Months Ended</th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Jul. 23, 2018</div></th>
<th class="th"><div>Oct. 19, 2017</div></th>
<th class="th"><div>Mar. 31, 2019</div></th>
<th class="th"><div>Mar. 31, 2018</div></th>
<th class="th"><div>Jan. 01, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
<th class="th"><div>Oct. 31, 2015</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_plx_SignificantAccountingPoliciesLineItems', window );"><strong>Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common Stock, Par or Stated Value Per Share</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">78,202,020<span></span>
</td>
<td class="nump">73,800,491<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Operating Lease, Right-of-Use Asset</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,844<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,900<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiability', window );">Operating Lease, Liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,755<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=plx_AmendedPfizerAgreementMember', window );">Amended Pfizer Agreement [Member] | Protalix Bio Therapeutics Incorporation [Member] | Brazil [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_plx_SignificantAccountingPoliciesLineItems', window );"><strong>Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_plx_CollaborativeArrangementRevenuesExpensesSharingPercentage', window );">Collaborative Arrangement Revenues and Expenses Sharing Percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=plx_ChiesiUSAgreementMember', window );">Chiesi US Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_plx_SignificantAccountingPoliciesLineItems', window );"><strong>Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_plx_UpfrontNonrefundableNoncreditablePaymentReceivable', window );">Upfront Nonrefundable Noncreditable Payment Receivable</a></td>
<td class="nump">$ 25,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_plx_AdditionalAmountsPayableToCoverDevelopmentCosts', window );">Additional Amounts Payable To Cover Development Costs</a></td>
<td class="nump">20,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_plx_MaximumEntitlementOfDevelopmentCostsToCoverPerYear', window );">Maximum Entitlement Of Development Costs To Cover Per Year</a></td>
<td class="nump">7,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_plx_AdditionalAmountpayableForAchievementOfRegulatoryAndCommercialMilestones', window );">Additional AmountPayable For Achievement Of Regulatory And Commercial Milestones</a></td>
<td class="nump">$ 760,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=plx_ChiesiUSAgreementMember', window );">Chiesi US Agreement [Member] | Minimum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_plx_SignificantAccountingPoliciesLineItems', window );"><strong>Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_plx_PaymentOnNetSalesPercentage', window );">Payment On Net Sales Percentage</a></td>
<td class="nump">15.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=plx_ChiesiUSAgreementMember', window );">Chiesi US Agreement [Member] | Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_plx_SignificantAccountingPoliciesLineItems', window );"><strong>Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_plx_PaymentOnNetSalesPercentage', window );">Payment On Net Sales Percentage</a></td>
<td class="nump">40.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=plx_ChiesiExUSAgreementMember', window );">Chiesi Ex US Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_plx_SignificantAccountingPoliciesLineItems', window );"><strong>Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_plx_UpfrontNonrefundableNoncreditablePaymentReceivable', window );">Upfront Nonrefundable Noncreditable Payment Receivable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 25,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_plx_MaximumEntitlementOfDevelopmentCostsToCoverPerYear', window );">Maximum Entitlement Of Development Costs To Cover Per Year</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_plx_AdditionalAmountpayableForAchievementOfRegulatoryAndCommercialMilestones', window );">Additional AmountPayable For Achievement Of Regulatory And Commercial Milestones</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 320,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=plx_ChiesiExUSAgreementMember', window );">Chiesi Ex US Agreement [Member] | Minimum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_plx_SignificantAccountingPoliciesLineItems', window );"><strong>Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_plx_PaymentOnNetSalesPercentage', window );">Payment On Net Sales Percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=plx_ChiesiExUSAgreementMember', window );">Chiesi Ex US Agreement [Member] | Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_plx_SignificantAccountingPoliciesLineItems', window );"><strong>Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_plx_PaymentOnNetSalesPercentage', window );">Payment On Net Sales Percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">35.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_plx_AdditionalAmountpayableForAchievementOfRegulatoryAndCommercialMilestones">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The total amount payable to entity for the achievement of regulatory and commercial milestones.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">plx_AdditionalAmountpayableForAchievementOfRegulatoryAndCommercialMilestones</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>plx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_plx_AdditionalAmountsPayableToCoverDevelopmentCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The definition should be: "The maximum amount payable to the entity to cover development costs under agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">plx_AdditionalAmountsPayableToCoverDevelopmentCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>plx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_plx_CollaborativeArrangementRevenuesExpensesSharingPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Collaborative arrangement revenues and expense sharing percentage.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">plx_CollaborativeArrangementRevenuesExpensesSharingPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>plx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_plx_MaximumEntitlementOfDevelopmentCostsToCoverPerYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum amount payable to entity to cover development costs in any year under agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">plx_MaximumEntitlementOfDevelopmentCostsToCoverPerYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>plx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_plx_PaymentOnNetSalesPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the payment as a percentage of future net sales.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">plx_PaymentOnNetSalesPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>plx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_plx_SignificantAccountingPoliciesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">plx_SignificantAccountingPoliciesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>plx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_plx_UpfrontNonrefundableNoncreditablePaymentReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of upfront,non refundable and non creditable payment receivable under the agreement for licencing rights.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">plx_UpfrontNonrefundableNoncreditablePaymentReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>plx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=77888419&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=77888419&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=plx_AmendedPfizerAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=plx_AmendedPfizerAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=plx_ProtalixBioTherapeuticsIncorporationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=plx_ProtalixBioTherapeuticsIncorporationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=country_BR">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=country_BR</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=plx_ChiesiUSAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=plx_ChiesiUSAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=plx_ChiesiExUSAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=plx_ChiesiExUSAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>31
<FILENAME>R20.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.1</span><table class="report" border="0" cellspacing="2" id="idp6791561184">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>INVENTORIES (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Mar. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryRawMaterialsNetOfReserves', window );">Raw materials</a></td>
<td class="nump">$ 3,047<span></span>
</td>
<td class="nump">$ 3,792<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryWorkInProcessNetOfReserves', window );">Work in progress</a></td>
<td class="nump">45<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryFinishedGoodsNetOfReserves', window );">Finished goods</a></td>
<td class="nump">3,615<span></span>
</td>
<td class="nump">4,777<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryNet', window );">Total inventory</a></td>
<td class="nump">$ 6,707<span></span>
</td>
<td class="nump">$ 8,569<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryFinishedGoodsNetOfReserves">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying amount, net of valuation reserves and adjustments, as of the balance sheet date of merchandise or goods held by the company that are readily available for sale.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.BB)<br> -URI http://asc.fasb.org/extlink&amp;oid=27011343&amp;loc=d3e100047-122729<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryFinishedGoodsNetOfReserves</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=82887183&amp;loc=d3e6676-107765<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -SubTopic 10<br> -Section 35<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=68049868&amp;loc=d3e3927-108312<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.6(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryRawMaterialsNetOfReserves">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying amount, net of valuation reserves and adjustments, as of the balance sheet date of unprocessed items to be consumed in the manufacturing or production process.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.BB)<br> -URI http://asc.fasb.org/extlink&amp;oid=27011343&amp;loc=d3e100047-122729<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(a)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryRawMaterialsNetOfReserves</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryWorkInProcessNetOfReserves">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying amount, net of reserves and adjustments, as of the balance sheet date of merchandise or goods which are partially completed. This inventory is generally comprised of raw materials, labor and factory overhead costs, which require further materials, labor and overhead to be converted into finished goods, and which generally require the use of estimates to determine percentage complete and pricing.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.BB)<br> -URI http://asc.fasb.org/extlink&amp;oid=27011343&amp;loc=d3e100047-122729<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(a)(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryWorkInProcessNetOfReserves</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>32
<FILENAME>R21.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.1</span><table class="report" border="0" cellspacing="2" id="idp6625849904">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>INVENTORIES (Details Textual) - USD ($)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryWriteDown', window );">Inventory Write-down</a></td>
<td class="nump">$ 65,000<span></span>
</td>
<td class="nump">$ 1,100,000<span></span>
</td>
</tr>
</table>
<div style="display: none;"><table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryWriteDown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of loss from reductions in inventory due to subsequent measurement adjustments, including, but not limited to, physical deterioration, obsolescence, or changes in price levels.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -SubTopic 10<br> -Section 35<br> -Paragraph 1B<br> -URI http://asc.fasb.org/extlink&amp;oid=68049868&amp;loc=SL66093879-108312<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.2)<br> -URI http://asc.fasb.org/extlink&amp;oid=115205541&amp;loc=SL114868664-224227<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -SubTopic 10<br> -Section 35<br> -Paragraph 1C<br> -URI http://asc.fasb.org/extlink&amp;oid=68049868&amp;loc=SL66093883-108312<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=66092785&amp;loc=d3e4542-108314<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryWriteDown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table></div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>33
<FILENAME>R22.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.1</span><table class="report" border="0" cellspacing="2" id="idp6628740352">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>FAIR VALUE MEASUREMENT (The liability component was valued based on the Income Approach) (Details) - 2021 Notes [Member] - Fair Value, Inputs, Level 3 [Member]<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th">
<div>Mar. 31, 2019 </div>
<div>$ / shares</div>
</th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharePrice', window );">Stock price (USD)</a></td>
<td class="nump">$ 0.44<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_plx_FairValueAssumptionsTerm', window );">Expected term</a></td>
<td class="text">2 years 7 months 17 days<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_plx_FairValueAssumptionsRiskFreeInterestRates', window );">Risk free rate</a></td>
<td class="nump">2.21%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_plx_FairValueAssumptionsExpectedVolatilityRates', window );">Volatility</a></td>
<td class="nump">81.56%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_plx_FairValueAssumptionsExpectedDividendRates', window );">Yield</a></td>
<td class="nump">12.60%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_plx_FairValueAssumptionsExpectedDividendRates">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Expected dividends to be paid to holders of the underlying shares or financial instruments (expressed as a percentage of the share or instrument's price).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">plx_FairValueAssumptionsExpectedDividendRates</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>plx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_plx_FairValueAssumptionsExpectedVolatilityRates">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Measure of dispersion, in percentage terms (for instance, the standard deviation or variance), for a given stock price.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">plx_FairValueAssumptionsExpectedVolatilityRates</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>plx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_plx_FairValueAssumptionsRiskFreeInterestRates">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Risk-free interest rate assumption used in valuing an instrument.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">plx_FairValueAssumptionsRiskFreeInterestRates</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>plx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_plx_FairValueAssumptionsTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Period the instrument, asset or liability is expected to be outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">plx_FairValueAssumptionsTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>plx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Price of a single share of a number of saleable stocks of a company.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=plx_SevenPointFivePercentageConvertibleNotesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=plx_SevenPointFivePercentageConvertibleNotesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>34
<FILENAME>R23.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.1</span><table class="report" border="0" cellspacing="2" id="idp6753992944">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>FAIR VALUE MEASUREMENT (Narrative) (Details)<br> $ in Millions</strong></div></th>
<th class="th">
<div>Mar. 31, 2019 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=plx_SevenPointFivePercentageConvertibleNotes2021Member', window );">Seven Point Five Percentage Convertible Notes 2021 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Debt Instrument, Interest Rate, Stated Percentage</a></td>
<td class="nump">7.50%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member', window );">Fair Value, Inputs, Level 3 [Member] | Seven Point Five Percentage Convertible Notes [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConvertibleDebtFairValueDisclosures', window );">Convertible Debt, Fair Value Disclosures</a></td>
<td class="nump">$ 64.5<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Debt Instrument, Face Amount</a></td>
<td class="nump">$ 57.9<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConvertibleDebtFairValueDisclosures">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of borrowing which can be exchanged for a specified number of another security at the option of the issuer or the holder, for example, but not limited to, the entity's common stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConvertibleDebtFairValueDisclosures</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentFaceAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face (par) amount of debt instrument at time of issuance.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=114775744&amp;loc=d3e28551-108399<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 55<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=114775985&amp;loc=d3e28878-108400<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentFaceAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentInterestRateStatedPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Contractual interest rate for funds borrowed, under the debt agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentInterestRateStatedPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=plx_SevenPointFivePercentageConvertibleNotes2021Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=plx_SevenPointFivePercentageConvertibleNotes2021Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=plx_SevenPointFivePercentageConvertibleNoteMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=plx_SevenPointFivePercentageConvertibleNoteMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>35
<FILENAME>R24.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.1</span><table class="report" border="0" cellspacing="2" id="idp6785788512">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>OPERATING LEASES (Lease, Cost) (Details)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th">
<div>Mar. 31, 2019 </div>
<div>USD ($)</div>
</th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_plx_DisclosureOfLeasesOperatingLineItems', window );"><strong>Disclosure of Leases Operating [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseCost', window );">Operating lease costs</a></td>
<td class="nump">$ 292<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasePayments', window );">Cash paid for amounts included in the&#160;measurement of lease liabilities</a></td>
<td class="nump">328<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability', window );">Right of use assets obtained in exchange&#160;for new operating lease liabilities</a></td>
<td class="nump">$ 52<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1', window );">Weighted average remaining lease term&#160;(in years)</a></td>
<td class="text">10 years 10 months 2 days<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent', window );">Weighted average discount rate</a></td>
<td class="nump">12.58%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_plx_DisclosureOfLeasesOperatingLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of Leases Operating</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">plx_DisclosureOfLeasesOperatingLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>plx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of single lease cost, calculated by allocation of remaining cost of lease over remaining lease term. Includes, but is not limited to, single lease cost, after impairment of right-of-use asset, calculated by amortization of remaining right-of-use asset and accretion of lease liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=77888399&amp;loc=SL77918982-209971<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=77888426&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasePayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 5<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=77888419&amp;loc=SL77918643-209977<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=77888426&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasePayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average discount rate for operating lease calculated at point in time.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=77888426&amp;loc=SL77918686-209980<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=77888399&amp;loc=SL77918982-209971<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=77888399&amp;loc=SL77918982-209971<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=77888426&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in right-of-use asset obtained in exchange for operating lease liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=77888399&amp;loc=SL77918982-209971<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=77888426&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>36
<FILENAME>R25.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.1</span><table class="report" border="0" cellspacing="2" id="idp6813596640">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>OPERATING LEASES (Lessee, Operating Lease, Liability, Maturity) (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Mar. 31, 2019</div></th>
<th class="th"><div>Jan. 01, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_plx_DisclosureOfLeasesOperatingLineItems', window );"><strong>Disclosure of Leases Operating [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear', window );">2019 (excluding the three months ended March 31, 2019)</a></td>
<td class="nump">$ 947<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo', window );">2020</a></td>
<td class="nump">1,135<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree', window );">2021</a></td>
<td class="nump">888<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour', window );">2022</a></td>
<td class="nump">774<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive', window );">2023</a></td>
<td class="nump">770<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive', window );">After 2024</a></td>
<td class="nump">6,380<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue', window );">Total undiscounted cash flows</a></td>
<td class="nump">10,894<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount', window );">Less: imputed interest</a></td>
<td class="nump">5,139<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiability', window );">Present value of lease liabilities</a></td>
<td class="nump">$ 5,755<span></span>
</td>
<td class="nump">$ 5,700<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_plx_DisclosureOfLeasesOperatingLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of Leases Operating</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">plx_DisclosureOfLeasesOperatingLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>plx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments for operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=77888426&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments for operating lease, due after fifth fiscal year following latest fiscal year.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=77888426&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments for operating lease, due in fifth fiscal year following latest fiscal year.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=77888426&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments for operating lease, due in fourth fiscal year following latest fiscal year.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=77888426&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments for operating lease, due in third fiscal year following latest fiscal year.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=77888426&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments for operating lease, due in second fiscal year following latest fiscal year.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=77888426&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments for operating lease having an initial or remaining lease term in excess of one year due in remainder of fiscal year following latest fiscal year.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=77888426&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=77888426&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=77888419&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>37
<FILENAME>R26.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.1</span><table class="report" border="0" cellspacing="2" id="idp6816142096">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>OPERATING LEASES (Narrative) (Details)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th">
<div>Mar. 31, 2019 </div>
<div>USD ($)</div>
</th></tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_plx_DisclosureOfLeasesOperatingLineItems', window );"><strong>Disclosure of Leases Operating [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_plx_PercentageOfChangeInOperatingLeaseMonthlyRentalPayments', window );">Percentage of Change in Operating Lease Monthly Rental Payments</a></td>
<td class="nump">7.50%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_plx_DisclosureOfLeasesOperatingLineItems', window );"><strong>Disclosure of Leases Operating [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_plx_PercentageOfChangeInOperatingLeaseMonthlyRentalPayments', window );">Percentage of Change in Operating Lease Monthly Rental Payments</a></td>
<td class="nump">10.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_plx_CommitmentsAndContingenciesAxis=plx_VehicleLeaseAndMaintenanceAgreementsMember', window );">Vehicle Lease [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_plx_DisclosureOfLeasesOperatingLineItems', window );"><strong>Disclosure of Leases Operating [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent', window );">Operating Leases, Future Minimum Payments Due, Next Twelve Months</a></td>
<td class="nump">$ 474,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears', window );">Operating Leases, Future Minimum Payments, Due in Two Years</a></td>
<td class="nump">333,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears', window );">Operating Leases, Future Minimum Payments, Due in Three Years</a></td>
<td class="nump">82,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_plx_CommitmentsAndContingenciesAxis=us-gaap_LeaseAgreementsMember', window );">Lease Agreements [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_plx_DisclosureOfLeasesOperatingLineItems', window );"><strong>Disclosure of Leases Operating [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent', window );">Operating Leases, Future Minimum Payments Due, Next Twelve Months</a></td>
<td class="nump">758,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears', window );">Operating Leases, Future Minimum Payments, Due in Two Years</a></td>
<td class="nump">758,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears', window );">Operating Leases, Future Minimum Payments, Due in Three Years</a></td>
<td class="nump">621,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SecurityDeposit', window );">Security Deposit</a></td>
<td class="nump">$ 412,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_plx_DisclosureOfLeasesOperatingLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of Leases Operating</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">plx_DisclosureOfLeasesOperatingLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>plx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_plx_PercentageOfChangeInOperatingLeaseMonthlyRentalPayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of Change in Operating Lease Monthly Rental Payments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">plx_PercentageOfChangeInOperatingLeaseMonthlyRentalPayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>plx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of required minimum rental payments for operating leases having an initial or remaining non-cancelable lease term in excess of one year due in the next fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 20<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=77902758&amp;loc=d3e41502-112717<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 10<br> -Section 55<br> -Paragraph 40<br> -Subparagraph (Note 3)<br> -URI http://asc.fasb.org/extlink&amp;oid=82846649&amp;loc=d3e38371-112697<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of required minimum rental payments for operating leases having an initial or remaining non-cancelable lease term in excess of one year due in the third fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 10<br> -Section 55<br> -Paragraph 40<br> -Subparagraph (Note 3)<br> -URI http://asc.fasb.org/extlink&amp;oid=82846649&amp;loc=d3e38371-112697<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 20<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=77902758&amp;loc=d3e41502-112717<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of required minimum rental payments for operating leases having an initial or remaining non-cancelable lease term in excess of one year due in the second fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 10<br> -Section 55<br> -Paragraph 40<br> -Subparagraph (Note 3)<br> -URI http://asc.fasb.org/extlink&amp;oid=82846649&amp;loc=d3e38371-112697<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 20<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=77902758&amp;loc=d3e41502-112717<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SecurityDeposit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of an asset, typically cash, provided to a counterparty to provide certain assurance of performance by the entity pursuant to the terms of a written or oral agreement, such as a lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.8,17)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SecurityDeposit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_plx_CommitmentsAndContingenciesAxis=plx_VehicleLeaseAndMaintenanceAgreementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">plx_CommitmentsAndContingenciesAxis=plx_VehicleLeaseAndMaintenanceAgreementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_plx_CommitmentsAndContingenciesAxis=us-gaap_LeaseAgreementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">plx_CommitmentsAndContingenciesAxis=us-gaap_LeaseAgreementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>38
<FILENAME>R27.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.1</span><table class="report" border="0" cellspacing="2" id="idp6609495648">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>REVENUES (Statements of operations) (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2019</div></th>
<th class="th"><div>Mar. 31, 2018</div></th>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=plx_PfizerMember', window );">Pfizer [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenues</a></td>
<td class="nump">$ 1,356<span></span>
</td>
<td class="nump">$ 1,980<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=country_BR', window );">Brazil [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenues</a></td>
<td class="nump">2,174<span></span>
</td>
<td class="nump">2,573<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_ProductMember', window );">Goods [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenues</a></td>
<td class="nump">3,530<span></span>
</td>
<td class="nump">4,553<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_LicenseAndServiceMember', window );">License and R&amp;D Services [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenues</a></td>
<td class="nump">$ 6,909<span></span>
</td>
<td class="nump">$ 2,161<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Revenues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=115929826&amp;loc=d3e8736-108599<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=115205541&amp;loc=SL114868664-224227<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=115929826&amp;loc=d3e8933-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=115929826&amp;loc=d3e8736-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Revenues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=plx_PfizerMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=plx_PfizerMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=country_BR">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=country_BR</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=us-gaap_ProductMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=us-gaap_ProductMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=us-gaap_LicenseAndServiceMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=us-gaap_LicenseAndServiceMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>39
<FILENAME>R28.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.1</span><table class="report" border="0" cellspacing="2" id="idp6757927424">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>REVENUES (Contract With Customer Asset And Liability) (Detail) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2019</div></th>
<th class="th"><div>Mar. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiability', window );">Contract liabilities at the beginning of the period</a></td>
<td class="nump">$ 42,895<span></span>
</td>
<td class="nump">$ 25,015<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToRevenueChangeInMeasureOfProgress', window );">Additions during the period</a></td>
<td class="nump">6,422<span></span>
</td>
<td class="nump">2,179<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityRevenueRecognized', window );">Revenue recognized during the period</a></td>
<td class="num">(6,909)<span></span>
</td>
<td class="num">(2,161)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiability', window );">Contract liabilities at the end of the period</a></td>
<td class="nump">$ 42,408<span></span>
</td>
<td class="nump">$ 25,033<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=82913815&amp;loc=SL49130531-203044<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=82913815&amp;loc=SL49130532-203044<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109196051&amp;loc=SL49130549-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToRevenueChangeInMeasureOfProgress">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in revenue recognized for cumulative catch-up adjustment from change in measure of progress which (increases) decreases obligation to transfer good or service to customer for which consideration from customer has been received or is due.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109196051&amp;loc=SL49130551-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToRevenueChangeInMeasureOfProgress</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiabilityRevenueRecognized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue recognized that was previously included in balance of obligation to transfer good or service to customer for which consideration from customer has been received or is due.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109196051&amp;loc=SL49130549-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiabilityRevenueRecognized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>40
<FILENAME>R29.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.1</span><table class="report" border="0" cellspacing="2" id="idp6806172544">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>REVENUES (Unsatisfied Performance Obligations) (Detail) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Mar. 31, 2019</div></th>
<th class="th"><div>Mar. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueRemainingPerformanceObligation', window );">Unsatisfied performance obligation</a></td>
<td class="nump">$ 64,581<span></span>
</td>
<td class="nump">$ 91,033<span></span>
</td>
</tr>
</table>
<div style="display: none;"><table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueRemainingPerformanceObligation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of transaction price allocated to performance obligation that has not been recognized as revenue.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109196051&amp;loc=SL49130556-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueRemainingPerformanceObligation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table></div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>41
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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MMWF\81AU8\K(XK%T-8943OTJDH\ Q:X831F:3LTXXFBD(3^ G/,6+V2?$9/
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M_>%W$W:]L0?[CXVO@K*%7W<AOP!02P,$%     @ QX"F3IE<G",0!@  G"<
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M.AQG0GS/]O:1I24RS^_Y"NM./&<?5I:P7<_/Y)Z,<B.[W?98??9/1VXCUZG
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M1#KV*( A@3WVZ/AO@8./(+   3,@EDXF] 5,7X#TA:4O)O2E<P$^(H$%EJ#
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M4GP*V5W"3OY^4?OS.)W:<-XOV]GE8NRNZU8]N_]?L/L74$L#!!0    ( ,>
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MMN=6R6J81:-4^5O_6]3F]SK,?PO# ]@0P,8 /_XPP!\"_#% PWX4$ P!P7M
M8+K5EV)ZD^4J7R\;>76:_O6>\FX5T46@N[_M!DVSS3/=GE:/7M9AN/0NW3R#
M).TE;"*AH\+3DX\9&)8A92"<W2?(H"*,\ P^6H-OXH-I/+=JZ"61D=1&\HF1
MP*HTPU0)"W"6 &4)($M\GV6#2!(+MY>$4Q!*.:$6+R+C+)[I78CRA@ F(A9,
M"++X%@=4Q(&/4T0H100IK%K3"&M)E%C-S1!9%,S!<!2&0QAKQ6X0B=63E$,0
MQGRKMQFF"B9%W>'&*&X,60*+)899PM"W5!FFHN',MYZ@+ EDL=TD0=YCPNR^
M("K&)JH[%DIP:R.0)K*]C8!$-+%A,)'/9EAF;)9"%MNC!LU]:SA8,IB,D7AF
MS5#4E!\I@SRQS<.@'7)F+ZX,E_G)# ]NX11Z>&2;XJ#ATT3D@=@F_E_9/0]N
MXQ2:-+=]D4+[I4'LQXPEB<V$24.?A$D\MXYPNZ;0K_G,%TIQJZ70:SFS*XO
M*_5#N!"A*M"V,D.#>RV%3LKG9L#MCT+_@_7$@#1*"'A)4,5H--==VP#O=T*X
M(S'H2/:__@VBX3,[$(9[#4.\QK>S0 VWOQ!OLH>L1',P^_/6V<ISK;JU/!D=
MSP ;UNU!K?%4GPTH,OY(DT6J&PF?Z"XL4D;0)U0_Z<\%[U#],>5[WAR*NG5>
MI-+[9;.KW4NIA"Z8/.@/YZA/1N--*?:JN^3ZNNF/!_V-DJ?AZ..-YZ_U/U!+
M P04    " #'@*9.K9Z4!08"  "E!0  &    'AL+W=O<FMS:&5E=',O<VAE
M970T+GAM;(U4VXZ;,!#]%>0/6"= "(T :9.J:J56BK9J^^S $-#:F-I.V/Y]
M?2$L#59W7[!G?,[,G,&>;.#B638 *GAAM),Y:I3J=QC+L@%&Y /OH=,G-1>,
M*&V*,Y:] %)9$J,X7*T2S$C;H2*SOJ,H,GY1M.W@* )Y88R(/WN@?,C1&MT<
M3^VY4<:!BZPG9_@.ZD=_%-K"4Y2J9=#)EG>!@#I'C^O=(35X"_C9PB!G^\ H
M.7'^;(PO58Y6IB"@4"H3@>CE"@>@U 329?P>8Z(II2'.][?HGZQVK>5$)!PX
M_=56JLE1BH(*:G*AZHD/GV'4LT'!*/XK7(%JN*E$YR@YE?8;E!>I.!NCZ%(8
M>7%KV]EU&./?:'Y".!+"B:!S_X\0C83HE1!;\:XR*_4C4:3(!!\"X7Y63\R=
M6.\BW<S2.&WO[)E6*[7W6FR3#%]-G!&R=Y!P!EE/"*R#3QE"7X9]N*"'_R8X
M+!&;Q)\A\FJ(+#^>:]CZ^;&7'UM^-.>G?O[&R]\L\W^XZZ&#)!;2N1[.<K@V
M+#%QZ"\C\9:1+,I(5W[^ULO?OKL-J9>?OMV&=-F&]?UM6&+">QEX=KL9B+,=
M!#(H^:53YB+-O-.L>0S-Z[CS[_4,<B/C-8P;8-^(.+>=#$Y<Z;=G7TC-N0)=
MX>I!_ZE&S\S)H% KL]WJO7"3PQF*]^-0Q--D+OX"4$L#!!0    ( ,> IDX)
MQK,WVP,  (D1   8    >&PO=V]R:W-H965T<R]S:&5E=#4N>&ULC9A=CZ,V
M%(;_"N)^%WQL XZ22)-$52NUTFBK;:^9Q/G0\I$"F6S_?0UX,N!SW)F;!,Q[
M?-YCF\? \EXW/]JSUEWPLRRJ=A6>N^ZZB*)V?]9EWGZMK[HR5XYU4^:=.6U.
M47MM='X8@LHB@CA.HC*_5.%Z.;0]-^ME?>N*2Z6?FZ"]E67>_+O117U?A2Q\
M:_AV.9V[OB%:+Z_Y2?^IN^_7Y\:<18]>#I=25^VEKH)&'U?A$UOL>-P'#(J_
M+OK>3HZ#OI27NO[1G_QV6(5Q[T@7>M_U7>3F[U5O=5'T/1D?_]A.PT?./G!Z
M_-;[+T/QIIB7O-7;NOC[<NC.JS +@X,^YK>B^U;??]6V(!D&MOK?]:LNC+QW
M8G+LZZ(=?H/]K>WJTO9BK)3YS_'_4@W_=]O_6Q@= #8 /AO ;0!_!!BS_Q<@
M;(!X#Q##:(VE#&.SR[M\O6SJ>]",TWO-^U7$%L*,_KYO' 9[N&:&IS6MK^N,
M+:/7OA\KV8X2F$C>%9'I_)$!J Q;0.$P3[##"IG0&3A9 Q_BQ;0&)\5VE"2#
MI!HD7R1D;JD[0@9*R)1V(T@W KOA\S0;+)'*,3Q*Y,0)$QG/ )2CW%%*GD*6
M*H]M2=J6V+9P/$DT.J!BQPW6",]<)J2-!-N03HH$I6">%"F9(L4I$F>"L,2=
MH%V*AAU4IC+:2$8:R;"1U,F2X5J9 CJ)(I,HG"1SJL425*W"BRQC#)*8ML)B
M&C8Q-N,N?*N9IOJ20N*LQ9V5)7,95QX_'OBQC\EA-7-TJ$RZJY+2<2F$9[(8
M"<LG!A_3@] @?%C-9_A!2J5,E)K4./=.8YAA#BO?^J#1R0AVHOD0^)80F5L3
M)1(>+S0/&0%$Z<X$UB3<M8(URK-_,AJ)C&"BRPFKF>'(DX2&(B.HB(8>,X\8
M>DKDX3.CN<@P&'W,8S3T&$$]5 UF&B1* B(-I4N$\MP<0*,/"/2Y^RM@].$-
MEA#YAA=HZ@%!/9=F5C.;15\6FF1 D,Q=M4"@A_F8 31UX!-/?U;C3'7&W*DF
M=6DJ/ ]20%,,,,44]_1 LP<(]J":)-XG.8"4+H H(:@D5K[YI"D$!(7<70<P
MA:B]FY;Y]FZ@@06? );5S/=D\YC&T$*DA#'GW'>3N^":7Z6A!!\_9VT(C?+L
M6YP&#<>@<?>D#:%!.(LF;Y"E;D[#VWD;[.M;U?5S-VE]? '80/\&ZK1OV6+'
MB/8GR!9;,Y#XBAD%<T515WB\V(Z?&:)W4^-'BC_RYG2IVN"E[LS;\O!.>ZSK
M3IN"XZ]FK9UU?GB<%/K8]8>I.6[&CP/C25=?[8>/Z/'U9?T?4$L#!!0    (
M ,> IDX',9A"O@$  "4$   8    >&PO=V]R:W-H965T<R]S:&5E=#8N>&UL
MC51K;YLP%/TKEG] S*-ILPB0VDS3)FU2U&G=9P<NP:J-F>V$[M_/KS!*HZU\
MP/=>SCD^UP^*4:IGW0$8]")XKTO<&3-L"=%U!X+JE1R@MU]:J00U-E5'H@<%
MM/$DP4F6)+=$4-;CJO"UO:H*>3*<];!72)^$H.KW W YECC%E\(C.W;&%4A5
M#/0(W\'\&/;*9F12:9B 7C/9(P5MB>_3[2YW> ]X8C#J68Q<)P<IGUWRI2EQ
MX@P!A]HX!6J',^R <R=D;?R*FGB:TA'G\47]D^_=]G*@&G:2_V2-Z4J\P:B!
MEIZX>93C9XC]K#&*S7^%,W +=T[L'+7DVK]1?=)&BJABK0CZ$D;6^W&,^A?:
M=4(6"=E$2&_^2<@C(5\02'#F6_U(#:T*)4>DPF8-U)V)=)O;Q:Q=T:^=_V:[
MU;9ZKC[<%N3L="+D(4"R&21[C=B]1:S_BA [_V0BNVHB\_R;N8F[A8D V7A(
M[R')*DG2A9'_H5YYR:]ZR=]ZV2R\!,AZ-DNV3L*S\/,>9/!$9AOF+M WJHZL
MU^@@C=U[OT.ME :L:K*R@IV]LU/"H34NO+.Q"B<W)$8.\5*2Z<]0_0%02P,$
M%     @ QX"F3@+KSB 5!   ,!,  !@   !X;"]W;W)K<VAE971S+W-H965T
M-RYX;6Q]F%N/HT80A?\*XMT+5<W-(]O2V%&42(DTVBC),V.W+UHN#N#QYM^G
MP8P7JD_G90S,Z:I3[>Z/<J_N=?.M/6O=>=_+HFK7_KGKKB]!T.[/NLS;+_55
M5^8_Q[HI\\[<-J>@O38Z/PR#RB+@,$R",K]4_F8U/'MK-JOZUA672K\U7GLK
MR[SY=ZN+^K[VR?]\\/5R.G?]@V"SNN8G_8?N_KR^->8N>$8Y7$I=M9>Z\AI]
M7/NO]+)3<3]@4/QUT?=V<NWUI;S7];?^YM?#V@][1[K0^ZX/D9N/#[W31=%'
M,C[^&8/ZSYS]P.GU9_2?A^)-,>]YJW=U\??ET)W7?N9[!WW,;T7WM;[_HL>"
M8M\;J_]-?^C"R'LG)L>^+MKAK[>_M5U=CE&,E3+__OB\5,/G?8S_.0P/X'$
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MAO.XZ>KK>#X5/ _)-O\!4$L#!!0    ( ,> IDX,ROUNLP$  -(#   8
M>&PO=V]R:W-H965T<R]S:&5E=#@N>&UL?5/;;IPP$/T5RQ\0+[!MHQ4@95-5
MC=1(JU1MG[TP@!5?B&V6Y.\[-H32EN3%]HSGG#DS'N>CL8^N _#D64GM"MIY
MWQ\8<U4'BKLKTX/&F\98Q3V:MF6NM\#K"%*2I;O=1Z:XT+3,H^]DR]P,7@H-
M)TO<H!2W+T>09BQH0E\=#Z+M?'"P,N]Y"]_!_^A/%BVVL-1"@7;":&*A*>A-
M<CCN0WP,^"E@=*LS"96<C7D,QEU=T%T0!!(J'Q@X;A>X!2D#$<IXFCGIDC(
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M=',O<VAE970Q,"YX;6Q]4]MNG# 0_17+'Q#O FVV*T#*IJI:J956J9H^>V$
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M\^\:NU\C.O"I[&[\ +7^>RV&@MJ%XYT_FVG()L-A/_\?MGSBX@]02P,$%
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M_RM$!U[*YL*/4.,_V&PHJ%PX7ONS&<=L-!QVTP]B\S?._P%02P,$%     @
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M9=U+"/?5*&7!R:%W[HUV;H*7@$-C_?:=V^OXCF-@U3"/*%G^)\J_4$L#!!0
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MS71?C&?S.%"\G^X=-%]^U3]02P,$%     @ QX"F3E&(V]1O @  \P@  !D
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M=*!]+KV0C?P34VR3"=XYHM_\EIDS)H]4[TUNC'8K[#<=O-36ZX9&?N9=#=&
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MDS+31,]%WX;[A>+M\,3PQG?.YB]02P,$%     @ QX"F3DK@KZ8[ @  RP8
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MU\R,5[,1M!L^'=[X_2K^ 5!+ P04    " #'@*9.;KRCMAX"  #*!0  &0
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M!P=8LB9K-HMHO54RT78O5D-:#UD\8: 68!$<70JPQ$A5W"$@0/F6%:RZ],>
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M"2DB QVY-O3WU@F&D3G! #(@*S^^X;+_&Q[2V';J8.C%,EL":W:-^_Y!4OS
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M1VA ]BV0_6-"GAJ0 PODX)B0?0/RS )Y=DS(@0%Y;H$\=PN9I_=9>I?&45:
M*(XG\ZQ(LWLP5;AQFN0&Y(4%\L(M9)HMDJR8S+I EQ:@2[= =U$Z XMH/$_
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M+G)E;'-02P$"% ,4    " #'@*9.)^B'#H(   "Q    $
M@ 'I    9&]C4')O<',O87!P+GAM;%!+ 0(4 Q0    ( ,> IDYM-.T0[P
M "L"   1              "  9D!  !D;V-0<F]P<R]C;W)E+GAM;%!+ 0(4
M Q0    ( ,> IDZ97)PC$ 8  )PG   3              "  ;<"  !X;"]T
M:&5M92]T:&5M93$N>&UL4$L! A0#%     @ QX"F3J;7E35N @  V@@  !@
M             ( !^ @  'AL+W=O<FMS:&5E=',O<VAE970Q+GAM;%!+ 0(4
M Q0    ( ,> IDY*/#SRF@,  #L0   8              "  9P+  !X;"]W
M;W)K<VAE971S+W-H965T,BYX;6Q02P$"% ,4    " #'@*9.!4[:T%@#  "+
M#0  &               @ %L#P  >&PO=V]R:W-H965T<R]S:&5E=#,N>&UL
M4$L! A0#%     @ QX"F3JV>E 4& @  I04  !@              ( !^A(
M 'AL+W=O<FMS:&5E=',O<VAE970T+GAM;%!+ 0(4 Q0    ( ,> IDX)QK,W
MVP,  (D1   8              "  385  !X;"]W;W)K<VAE971S+W-H965T
M-2YX;6Q02P$"% ,4    " #'@*9.!S&80KX!   E!   &
M@ %'&0  >&PO=V]R:W-H965T<R]S:&5E=#8N>&UL4$L! A0#%     @ QX"F
M3@+KSB 5!   ,!,  !@              ( !.QL  'AL+W=O<FMS:&5E=',O
M<VAE970W+GAM;%!+ 0(4 Q0    ( ,> IDX,ROUNLP$  -(#   8
M      "  88?  !X;"]W;W)K<VAE971S+W-H965T."YX;6Q02P$"% ,4
M" #'@*9.92*9%K0!  #2 P  &               @ %O(0  >&PO=V]R:W-H
M965T<R]S:&5E=#DN>&UL4$L! A0#%     @ QX"F3C>,'3*U 0  T@,  !D
M             ( !62,  'AL+W=O<FMS:&5E=',O<VAE970Q,"YX;6Q02P$"
M% ,4    " #'@*9.,>=E@K,!  #2 P  &0              @ %%)0  >&PO
M=V]R:W-H965T<R]S:&5E=#$Q+GAM;%!+ 0(4 Q0    ( ,> IDX?F/ZYM0$
M - #   9              "  2\G  !X;"]W;W)K<VAE971S+W-H965T,3(N
M>&UL4$L! A0#%     @ QX"F3E@/ ?JU 0  T@,  !D              ( !
M&RD  'AL+W=O<FMS:&5E=',O<VAE970Q,RYX;6Q02P$"% ,4    " #'@*9.
MD#ZP@^P!  !F!0  &0              @ $'*P  >&PO=V]R:W-H965T<R]S
M:&5E=#$T+GAM;%!+ 0(4 Q0    ( ,> IDY)ZD.NM@$  -(#   9
M      "  2HM  !X;"]W;W)K<VAE971S+W-H965T,34N>&UL4$L! A0#%
M  @ QX"F3@5ULW^T 0  T0,  !D              ( !%R\  'AL+W=O<FMS
M:&5E=',O<VAE970Q-BYX;6Q02P$"% ,4    " #'@*9.7/1[S<8!   W!
M&0              @ $",0  >&PO=V]R:W-H965T<R]S:&5E=#$W+GAM;%!+
M 0(4 Q0    ( ,> IDXA( T4T@$  )P$   9              "  ?\R  !X
M;"]W;W)K<VAE971S+W-H965T,3@N>&UL4$L! A0#%     @ QX"F3M+-M3&3
M P  JA   !D              ( !"#4  'AL+W=O<FMS:&5E=',O<VAE970Q
M.2YX;6Q02P$"% ,4    " #'@*9.U6^)Z>@!   +!0  &0
M@ '2.   >&PO=V]R:W-H965T<R]S:&5E=#(P+GAM;%!+ 0(4 Q0    ( ,>
MIDZWE#],T0$  #,$   9              "  ?$Z  !X;"]W;W)K<VAE971S
M+W-H965T,C$N>&UL4$L! A0#%     @ QX"F3A@(ZO3I 0  * 4  !D
M         ( !^3P  'AL+W=O<FMS:&5E=',O<VAE970R,BYX;6Q02P$"% ,4
M    " #'@*9.RCUZH<0!  !G!   &0              @ $9/P  >&PO=V]R
M:W-H965T<R]S:&5E=#(S+GAM;%!+ 0(4 Q0    ( ,> IDYW9R?2^@$  &<%
M   9              "  11!  !X;"]W;W)K<VAE971S+W-H965T,C0N>&UL
M4$L! A0#%     @ QX"F3NBNA34Q @  " <  !D              ( !14,
M 'AL+W=O<FMS:&5E=',O<VAE970R-2YX;6Q02P$"% ,4    " #'@*9.48C;
MU&\"  #S"   &0              @ &M10  >&PO=V]R:W-H965T<R]S:&5E
M=#(V+GAM;%!+ 0(4 Q0    ( ,> IDY*X*^F.P(  ,L&   9
M  "  5-(  !X;"]W;W)K<VAE971S+W-H965T,C<N>&UL4$L! A0#%     @
MQX"F3FZ\H[8> @  R@4  !D              ( !Q4H  'AL+W=O<FMS:&5E
M=',O<VAE970R."YX;6Q02P$"% ,4    " #'@*9.K(80::D!  "3 P  &0
M            @ $:30  >&PO=V]R:W-H965T<R]S:&5E=#(Y+GAM;%!+ 0(4
M Q0    ( ,> IDZ,DMM-B"$  %*:   4              "  ?I.  !X;"]S
M:&%R9613=')I;F=S+GAM;%!+ 0(4 Q0    ( ,> IDX=R(,%1 (  -H*   -
M              "  ;1P  !X;"]S='EL97,N>&UL4$L! A0#%     @ QX"F
M3BET,\ F P  ]!,   \              ( !(W,  'AL+W=O<FMB;V]K+GAM
M;%!+ 0(4 Q0    ( ,> IDXBPER#9@$  (P2   :              "  79V
M  !X;"]?<F5L<R]W;W)K8F]O:RYX;6PN<F5L<U!+ 0(4 Q0    ( ,> ID[8
M%3G%A0$  $L3   3              "  11X  !;0V]N=&5N=%]4>7!E<UTN
9>&UL4$L%!@     F "8 / H  ,IY      $!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>42
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>43
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>44
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.19.1</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>54</ContextCount>
  <ElementCount>142</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>true</FootnotesReported>
  <SegmentCount>22</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>4</UnitCount>
  <MyReports>
    <Report instance="plx-20190331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>1001 - Document - Document and Entity Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.protalix.com/role/DocumentAndEntityInformation</Role>
      <ShortName>Document and Entity Information</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report instance="plx-20190331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R2.htm</HtmlFileName>
      <LongName>1002 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.protalix.com/role/CondensedConsolidatedBalanceSheets</Role>
      <ShortName>CONDENSED CONSOLIDATED BALANCE SHEETS</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>2</Position>
    </Report>
    <Report instance="plx-20190331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R3.htm</HtmlFileName>
      <LongName>1003 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.protalix.com/role/CondensedConsolidatedStatementsOfOperations</Role>
      <ShortName>CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>3</Position>
    </Report>
    <Report instance="plx-20190331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R4.htm</HtmlFileName>
      <LongName>1004 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.protalix.com/role/CondensedConsolidatedStatementsOfOperationsParenthetical</Role>
      <ShortName>CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>4</Position>
    </Report>
    <Report instance="plx-20190331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R5.htm</HtmlFileName>
      <LongName>1005 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN CAPITAL DEFICIENCY</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.protalix.com/role/CondensedConsolidatedStatementsOfChangesInCapitalDeficiency</Role>
      <ShortName>CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN CAPITAL DEFICIENCY</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>5</Position>
    </Report>
    <Report instance="plx-20190331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R6.htm</HtmlFileName>
      <LongName>1006 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN CAPITAL DEFICIENCY [Parenthetical]</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.protalix.com/role/CondensedConsolidatedStatementsOfChangesInCapitalDeficiencyParenthetical</Role>
      <ShortName>CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN CAPITAL DEFICIENCY [Parenthetical]</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>6</Position>
    </Report>
    <Report instance="plx-20190331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R7.htm</HtmlFileName>
      <LongName>1007 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.protalix.com/role/CondensedConsolidatedStatementsOfCashFlows</Role>
      <ShortName>CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>7</Position>
    </Report>
    <Report instance="plx-20190331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R8.htm</HtmlFileName>
      <LongName>1008 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.protalix.com/role/SignificantAccountingPolicies</Role>
      <ShortName>SIGNIFICANT ACCOUNTING POLICIES</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>8</Position>
    </Report>
    <Report instance="plx-20190331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R9.htm</HtmlFileName>
      <LongName>1009 - Disclosure - INVENTORIES</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.protalix.com/role/Inventories</Role>
      <ShortName>INVENTORIES</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>9</Position>
    </Report>
    <Report instance="plx-20190331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R10.htm</HtmlFileName>
      <LongName>1010 - Disclosure - FAIR VALUE MEASUREMENT</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.protalix.com/role/FairValueMeasurement</Role>
      <ShortName>FAIR VALUE MEASUREMENT</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>10</Position>
    </Report>
    <Report instance="plx-20190331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R11.htm</HtmlFileName>
      <LongName>1011 - Disclosure - OPERATING LEASES</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.protalix.com/role/OperatingLeases</Role>
      <ShortName>OPERATING LEASES</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>11</Position>
    </Report>
    <Report instance="plx-20190331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R12.htm</HtmlFileName>
      <LongName>1012 - Disclosure - REVENUES</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.protalix.com/role/Revenues</Role>
      <ShortName>REVENUES</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>12</Position>
    </Report>
    <Report instance="plx-20190331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R13.htm</HtmlFileName>
      <LongName>1013 - Disclosure - SUBSEQUENT EVENTS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.protalix.com/role/SubsequentEvents</Role>
      <ShortName>SUBSEQUENT EVENTS</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>13</Position>
    </Report>
    <Report instance="plx-20190331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R14.htm</HtmlFileName>
      <LongName>1014 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES (Policies)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.protalix.com/role/SignificantAccountingPoliciesPolicies</Role>
      <ShortName>SIGNIFICANT ACCOUNTING POLICIES (Policies)</ShortName>
      <MenuCategory>Policies</MenuCategory>
      <Position>14</Position>
    </Report>
    <Report instance="plx-20190331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R15.htm</HtmlFileName>
      <LongName>1015 - Disclosure - INVENTORIES (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.protalix.com/role/InventoriesTables</Role>
      <ShortName>INVENTORIES (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.protalix.com/role/Inventories</ParentRole>
      <Position>15</Position>
    </Report>
    <Report instance="plx-20190331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R16.htm</HtmlFileName>
      <LongName>1016 - Disclosure - FAIR VALUE MEASUREMENT (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.protalix.com/role/FairValueMeasurementTables</Role>
      <ShortName>FAIR VALUE MEASUREMENT (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.protalix.com/role/FairValueMeasurement</ParentRole>
      <Position>16</Position>
    </Report>
    <Report instance="plx-20190331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R17.htm</HtmlFileName>
      <LongName>1017 - Disclosure - OPERATING LEASES (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.protalix.com/role/OperatingLeasesTables</Role>
      <ShortName>OPERATING LEASES (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.protalix.com/role/OperatingLeases</ParentRole>
      <Position>17</Position>
    </Report>
    <Report instance="plx-20190331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R18.htm</HtmlFileName>
      <LongName>1018 - Disclosure - REVENUES (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.protalix.com/role/RevenuesTables</Role>
      <ShortName>REVENUES (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.protalix.com/role/Revenues</ParentRole>
      <Position>18</Position>
    </Report>
    <Report instance="plx-20190331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R19.htm</HtmlFileName>
      <LongName>1019 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES (Narrative) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.protalix.com/role/SignificantAccountingPoliciesNarrativeDetails</Role>
      <ShortName>SIGNIFICANT ACCOUNTING POLICIES (Narrative) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.protalix.com/role/SignificantAccountingPoliciesPolicies</ParentRole>
      <Position>19</Position>
    </Report>
    <Report instance="plx-20190331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R20.htm</HtmlFileName>
      <LongName>1020 - Disclosure - INVENTORIES (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.protalix.com/role/InventoriesDetails</Role>
      <ShortName>INVENTORIES (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.protalix.com/role/InventoriesTables</ParentRole>
      <Position>20</Position>
    </Report>
    <Report instance="plx-20190331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R21.htm</HtmlFileName>
      <LongName>1021 - Disclosure - INVENTORIES (Details Textual)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.protalix.com/role/InventoriesDetailsTextual</Role>
      <ShortName>INVENTORIES (Details Textual)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.protalix.com/role/InventoriesTables</ParentRole>
      <Position>21</Position>
    </Report>
    <Report instance="plx-20190331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R22.htm</HtmlFileName>
      <LongName>1022 - Disclosure - FAIR VALUE MEASUREMENT (The liability component was valued based on the Income Approach) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.protalix.com/role/FairValueMeasurementTheLiabilityComponentWasValuedBasedOnTheIncomeApproachDetails</Role>
      <ShortName>FAIR VALUE MEASUREMENT (The liability component was valued based on the Income Approach) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.protalix.com/role/FairValueMeasurementTables</ParentRole>
      <Position>22</Position>
    </Report>
    <Report instance="plx-20190331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R23.htm</HtmlFileName>
      <LongName>1023 - Disclosure - FAIR VALUE MEASUREMENT (Narrative) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.protalix.com/role/FairValueMeasurementNarrativeDetails</Role>
      <ShortName>FAIR VALUE MEASUREMENT (Narrative) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.protalix.com/role/FairValueMeasurementTables</ParentRole>
      <Position>23</Position>
    </Report>
    <Report instance="plx-20190331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R24.htm</HtmlFileName>
      <LongName>1024 - Disclosure - OPERATING LEASES (Lease, Cost) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.protalix.com/role/OperatingLeasesLeaseCostDetails</Role>
      <ShortName>OPERATING LEASES (Lease, Cost) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.protalix.com/role/OperatingLeasesTables</ParentRole>
      <Position>24</Position>
    </Report>
    <Report instance="plx-20190331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R25.htm</HtmlFileName>
      <LongName>1025 - Disclosure - OPERATING LEASES (Lessee, Operating Lease, Liability, Maturity) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.protalix.com/role/OperatingLeasesLesseeOperatingLeaseLiabilityMaturityDetails</Role>
      <ShortName>OPERATING LEASES (Lessee, Operating Lease, Liability, Maturity) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.protalix.com/role/OperatingLeasesTables</ParentRole>
      <Position>25</Position>
    </Report>
    <Report instance="plx-20190331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R26.htm</HtmlFileName>
      <LongName>1026 - Disclosure - OPERATING LEASES (Narrative) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.protalix.com/role/OperatingLeasesNarrativeDetails</Role>
      <ShortName>OPERATING LEASES (Narrative) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.protalix.com/role/OperatingLeasesTables</ParentRole>
      <Position>26</Position>
    </Report>
    <Report instance="plx-20190331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R27.htm</HtmlFileName>
      <LongName>1027 - Disclosure - REVENUES (Statements of operations) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.protalix.com/role/RevenuesStatementsOfOperationsDetails</Role>
      <ShortName>REVENUES (Statements of operations) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.protalix.com/role/RevenuesTables</ParentRole>
      <Position>27</Position>
    </Report>
    <Report instance="plx-20190331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R28.htm</HtmlFileName>
      <LongName>1028 - Disclosure - REVENUES (Contract With Customer Asset And Liability) (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.protalix.com/role/RevenuesContractWithCustomerAssetAndLiabilityDetail</Role>
      <ShortName>REVENUES (Contract With Customer Asset And Liability) (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.protalix.com/role/RevenuesTables</ParentRole>
      <Position>28</Position>
    </Report>
    <Report instance="plx-20190331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R29.htm</HtmlFileName>
      <LongName>1029 - Disclosure - REVENUES (Unsatisfied Performance Obligations) (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.protalix.com/role/RevenuesUnsatisfiedPerformanceObligationsDetail</Role>
      <ShortName>REVENUES (Unsatisfied Performance Obligations) (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.protalix.com/role/RevenuesTables</ParentRole>
      <Position>29</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File>plx-20190331.xml</File>
    <File>plx-20190331.xsd</File>
    <File>plx-20190331_cal.xml</File>
    <File>plx-20190331_def.xml</File>
    <File>plx-20190331_lab.xml</File>
    <File>plx-20190331_pre.xml</File>
  </InputFiles>
  <SupplementalFiles/>
  <BaseTaxonomies>
    <BaseTaxonomy>http://fasb.org/us-gaap/2018-01-31</BaseTaxonomy>
    <BaseTaxonomy>http://fasb.org/srt/2018-01-31</BaseTaxonomy>
    <BaseTaxonomy>http://xbrl.sec.gov/country/2017-01-31</BaseTaxonomy>
    <BaseTaxonomy>http://xbrl.sec.gov/dei/2018-01-31</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>true</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>46
<FILENAME>0001144204-19-023895-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001144204-19-023895-xbrl.zip
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MZ@*U5.->I?JM>:G.J:L:''7/02H]NC QXGW]IP?(7EJSN67"GTZ=USY8X17
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M%$$D&T2R81?\ON.JDL,Q\''S[Y8,4QWG[D>0CH!]_R#@#QKD$U'9#NAG%=:
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M@UV_8J89@H4I/G8WQLKE+$*5:?M314Y*TDI@$K'=S (GY"^F]"#PIGAC,KR
MY3!9"U^<I5]77OJMU-&")6!L#FYEIJ(G#]<"%[D+G4"\?OINS)T_4'"W  M\
M<N]55LG\0":JK;/W<OU"=NUM%JO*$O^*;X\KA#9Y6E2S\<+F*\+_>VMFSP5G
ML:ML1[K=2QWW+@//]O!7EC]K=U-%M=O#'YRGS8F*>MW*]K%/Y4%O%>0Q2+8
MN;(M[=.!W*D*XM0I*:PPT30;XL$E5=B];F7;WH/>*DS* +@+%"O;-#^56ZWT
M0?'JD0RVXOU*ZJ6H56;,945>@5@Q6*E('=M:W-O6,P67YN/BJX..35CT<@'
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MHIHL?S,NZ-EE75J 3^SL9.YF3S^_>]-6-W6OP*W+J^):(5^MB4* ^=?YV ;
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M7W!M$W3)&1P!"0=& &R"9M=A/P2@"54N5/FQJW*6 S=);(MAP'+@[:3J2&;
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MDP5/J0J\MC)8 EX 0!Q$=@3L;OS5(1=X_NO./_UU:U[[9[]N++M@:;)XE*P
M78U'-TGE+8 L7HZ@1/^"5^A?^0'M@^J2>V)CB4T6P6X*P0OGSBQ&;.[9)(Y9
MY^1#JRDKW4'1 JT&J731;K#6#^R\$<C]W?@&AE.-_P'ED4:LV^JMA5C.B@T[
M_<22;0[<VBA>>03?>WJQLGCUM\5+EMO=]1&+0-H8&]:8*8//8%M\!H/!YN@@
M3)LB=&-Y.7R7[CRV-C[]?F=C?!"DC=&AS]GED5O;H]/:'!T :1-T6-:^&*>T
M[5P;IUY[L!E2"< VP2R+3-K2KJ\/6H/A9AQ7&H&OL>0J&#AX](+U;<ABD[:W
M:V,#0PS+(U,$6+&-+?05NG)G:]@AU%CB[)3P )P;#YQ+\IF:=.;-8DMUZ=EV
MCOWOMI>SS[<_R)2"=\X&OS#USRHFTDS5U,C%!%0G&_XSF8V(/3=>+ZW9C+KL
M.WCV$H8%N(BI0?1]\4J=%11HG7SHI%3?>LAM0)9;$PP:RF/&A>VVE[/BGBG3
M;K<WH4R$WV;$0?-80)[EW+YG\@R6Q3"E$(S3YY%H+$*[(G/+H1FAZ0V6V_AO
M'.E=R(><Q#,%:'5ZH=]9[C[O#L5^=UF\MU<5T.\L][5K1X2=27N_L]Q+WQTE
M>HI<I60O#4X?@D86[,<G8L_D)"%Z[7YGA>_XX5YN_8_<^JQ<E8R(<R9-N%51
M AL(^.A:VO>I94!\Z5S_Z66\D%Y'&6SM0?7D5B?E#ZX 8CN \PR)K/@ #TH!
M++?EC0&^(B/WUG1<VT/FN?7W"3%!\>C"_^A^F@(['B1 'W1ZW15VX)$\$_/>
M LN'[GXT$,@!VW09&>2+Y1('2Y*YR'@.PI0$*4]0<O,PK7XW1H/R>,6I<:-2
M^P_<3&%I*:1>C):?>2\U_<Y\0,-C ]?" U\LTP[^_*@ZU,'WV6'")Z)-3?JG
M1YPE!ZW!K^F43!=^*TNM](%LMB4U5F?46)QMDI'/;&GYQQWCNP7!=]&>@O^%
M':6RUSZR6HM<NWAYS9>#SU+]=RKV(N^H8'1"SZXLC<GHTV*>5*9MI3/LIEV,
MHF8+<NOTOWY]GQXOF.,"OM#QRQM#G60G*7LOP!C4*N&S)$9,HP):E%KZM:E?
M@4[-3-=+9\^*IL/_/6VU3]MR$K/$\.FYHP3S#7SC9&<ON4?$9D_.FQHZ?V8.
M7,'<)3> /OR7G#=S;.A@[FOP'=W% YE0!X_(NU_460[!RW;LN+>QZH^^2A^I
M]30%3VQ./)=JH/)O3:W)0<J;,0G-)0!LJ\:MJ9/7_R2++#AIWZ8('/!>0!/T
ME($<GSHU?#"W'^M$:U3(?NG-G:+I3T]E)>2]HN&3J-]0@]B7\/7$LG,03X>/
M13-?:*#6T#TFNL2&C..?F".8_LE6404^+F8CR\A.G [9"AG@TW_SJ1+CI987
MHA?+9.[CXU0%]^G.<QU7-?'Y[,RY(5(WF#WMP3ELP%2T(W<&[8&B#(<)+E@"
M11+>ZQE!CV/RNVV]N%._STD6T UTX)+QDR \ B[&1\^A)G&R6J%?5A^",Y>8
M.3$LS@BQY=DEVRB]-9/Q56IG-0U$K]4MR9LE]J9[+.HH#TO<T_Y"7H#Y,=D,
M3X,Z,N&CQL/G>\N@VH+_;X'3#'CTRZKWR L1O4\VZ#T3>/1Y;K^[M$%*7@.4
MI*\G<6?O/.8,ENB0 @ M:;[@=U_QUSGMIBXY'-]J*O$W]]AC@S0S+O22:BLV
MF320FVVL'FOQID";3PZ":("6=!P/FQN&(BG-$S*Y!, CKJTJ"DB7#">:6E6M
M6%Z7YA.V3!^L7+>J\B+M9AO^;QZVU^ D">C-OGM6;0I^]"DL(]; $:?@=PW4
M9^HG7XBE3JOUXS+,6:#L^+^H&=ZM*?V'9Q()$Z8-UN3NYN+Q8Z#3+AZ_LE].
M6_V&%+2]4UKGZ, 1TV$SAM_+\KG$?$TI\?,O3]:<:E)?'KP[DVYGH!N?N5X$
M8R1] ;+-YH:U($1B+NKI")P?7?(3\E+DYX2SPRSN5'4E\CK'SE@,9D>SY@1[
M[5T\7DKA?#B!?[N#Y,0&G_N#L^5#M\@R^25PJO:G1S$Y(4TL"X:&\9%?GZF&
MM\0!1[-E]N%UFM*%*1'F9,+PEF> #9C/P2 @1#;!H7Q$\P"+C22I+ZH-TY%7
MC8 >1$@TL-LJ:SH/#W$ G3EXD&/*F]''%J8I84/#B4=UW"*%E9/(>$P JV?"
MAAJS:(QWTI9&$)*:K..VBO4DTA716#Y4DKL-GP<XQ5B<@IE?.@-<YI;-#1L+
MKAU@:7?*VI/!.L3&;TK7J@T$4'6+ 8W P"LS"D*G-Z21YP+:$CQH4()7[JDF
MD-@G8:*I8CB CL$ID(^3KM?J<6R# $6W4-M8C!D 94;Y\%U&]9!,2/.I"C1A
M_1T!#X"9PBCP%@**[1\I;C+C]PZFN=G2-5.Z,'NR(12T_,,+B7L8T]J'"WB@
MRG-=C&(-?3PUS>O&*T&4]D!PF\%87."*$OT1(U<4E-3C*Z.=L@DE$>V(:*?>
MT8Y^R&@G$$>N80G.Y@NDB'!$A%/_"&>K6$?<XKS+QLO'MR!'*%++8L ;,K(]
MU5Z@M]SSX\#0'8Z<-RGTP:2/%OQ'^B46%&+@&(O2WL6#R"]6DPU]VE(:$B_
M"@+#04=YUT"J:5/)\2!<@!"-\+".O%*'31M&-QC0\/.Y4;HM.V#K'0\3D!D"
M(Q5$9!!<P A8V(T1@8U$TX/KOC#>B_=O]P.#D6JPR9TI(3P\4PTCN#P<0R%V
M<9$C&98Y">(:6?$O$F\&T+U0>&D$OJ4!L_% 3H58#5XGMA][0*AC1PWE&WSL
MX'F-A],J#^[\^\WG*O(RBW4P!#(=PE":X,HC].Q*0Q_?1(0%49XU(U&DDXRK
M @L/49X349"WL_\/U62<XK<U1B)!2&7I'"6; /MBJ,KBSQ%N\C.R,NPQ4L-2
M(@SJ-)P*$87'_+ R"0-[@QA!6 <"\QTKJ0""N8W>/0:=B+-.68P=QIG8CX7X
M%[JC;')*A!P4AJXI]F ,V,!;(8&T%EL4?' ">D/%NP*<^ T R#J::ML+8 :,
MW=EO0"O7LAE<_F6SB95+8C=3=8+!;SQKS.(8CC*"#'-\)V2>8#35#*2:\1Q2
M(^0TB<F&@XLTQA\RK)N$P.>3O]@R6WCBG0$]#P]F<N:/8F$<TV=.S$>P=<?M
M;;3!I^@F^LMM/?OD]P=DBYMQ7(6./[31/69_Z(TL#6\4%]XODDA[-1(*)R:M
MH /2EXXP^Y4P7PL<\Z=N,];D? 8*E5D0> Q^Z4O^%PW4R;[&-A:-I)J/7H_I
M^ZQF.8Z$U.9)I>)*\-1&?3;[E'M,6BXJ[DC7"G1//G3Q5%IQ)7L*@'7/GS$8
M<X]LK 5C?RF,N>?/6+[_'@QFNOP( %IQ?"*L/;PUYY[K?"+ N>UX96_XP,=%
M^/'O%$"RM>F"/8[5OJ7+K-<KL0;Z? /TOS$$XY12L-:ZTXF=P@E)$.0\XU65
MGI_ZQ]+^+(G*%3W6C50?[I7_Z7^6^U=<&HO074:.!^I\O[$)B1>F9VMU^N5J
ME>I&GU+5^A!>%9,OESS+Z'G-]DZ(_H=E@,2BE.93=%"N!.L8*3J0N[UBBA80
MJ Q-K^@S!9=%+Z!HN3JL(Z-HFW?V*$'0!'4"<D9@W8WS:^,^8[AC+![P*2.W
MD0PC;LF3(?X1,(ZS8X.\P)2E\03[SO'<$.S*L2Y7QOSML_JZ&=;,ALFMK9$.
M3"">[,-X_A\0WEYZ$$'/B,T<F=B!@F6W+2+2P[(UPT<2W;R1;&^9VQ8ATE$A
M_IB "Q[DM/)N6=1\+HGBFV.\/O%8UU5<F+@7BA_#A8EQ5.,$7>?&A%I?4=@[
MX!6%*2WP8JOS0U09\'9;?E*976V7<X?M.H4(QWN=88%D; U^H%97,$2!F.6L
M:067C_XB;A]]\Z)]R(M(-R;! 6W+[F 67)G@RL&/84^VO1ZW.PAOAO51_EL*
MT[\MMSAQ+N$=HO-MS&4ZX&+WV?.M^*B(W-^WXEN\J\HFE33H.UJMK6[T"FY[
MK0#6+*EW(&XK[]"5!_UJ4?%[H^\ EX[2& R+.Z8?V]*4YS:EM3U*!T5 K@"!
MNHA+[UC$1>DV6O)J<=G)TNR(L79Y:=!N[>4%O,3KHG3/#JOSEMO%FIO"(Q#G
MO6*Q.TGN-3HKKN?]T=?A&&%^&Y3?DRUKR/WB6[)^#.M5_HZLW9JR!ZP2\$B\
MY'#?-JWZ)&#^+5*9A,C;D/C]8;D[C?!+KS%LK7%QWBXNS]HN^_?N;20JA>0<
MF^2 ,>W)AY6<C87D>"/ 91E38NHE<Z7B2LD#YX$.<<_D;G*IG=:@M!)0=G/[
MY)%M^?E4V+<M%3)43QG"!&N[?6@9JG2#,MF#HYZGM+:H#(XZ![$0-KPAXY[8
M6.:'!];N1JR''+5,?E_7JM+BLEV!10EJ+4J+;3+G-WPGSFO_S9$\UH_.88?4
MYQ$[2%;(#Z*B6%04BXIB45'\EBJ*]U_+)2J%1:6PJ!0^*I$]9%%P?9,!@JVV
M9RM1U5NOJMZO*X,@4<2[V^*!@]7K;EFAU&D DQXCP?=;A;LWUJX U@.P]FYJ
M:[<#>R@OS?+6F.!O)>&[5<9V52^)PJY7LIQW[=I:UP=WE,&PFVA[M12"+4#-
MNRXX!+5? E2EVY)W >JE-_,,UL7S4G6UZ=?YA?Y/>(;=K6GYBQIT!O$O!;T;
MW]O6Q,[>\M:3E9*WO)6XV;FC*.71W0J+0]&JL'G0($:K,FRLR/UAW6@5ZH.P
M!C&#?\EK'5;C?]H;MM8@0 :T*I$J;-^S[J*>*G)/W@=261SRKF5?:T$Z2J<U
MV(=>57*;,ZXE.UUP'C8#M93)2X$\: ^6MT8LI1K!E4^ 7 J2"D#/O>=T'6H/
MY32U2X,><S*NJ*,9%BJF@GW?MMR1U[DBLX;WQ1=F;:J$+7=7=)-+CC;(+GVY
M>[J6NHG+QQZN_[C^\O7Z,9-T*OA<PV5;<D'"WA<R TIZNS'X>F?76NU^@0IK
M"XY%='+;JWDSP XF<PK[J<%0ZF2"?=>"J])LKAN=3!7$X1=$"$6V$")1:1?,
MN62[/Z0N-:5>L\\NA(*//H%CQ0#GL2P%2U+D!O<%E7X),!BR_)MXMIK]8RG^
M@FRZ?\G7?A8Y1P674MVX:N%M44&!2 %S)'=J\M#*O'B^R@;F783V PK#RKVE
M9;R(_ __MN+%.(VV)7HN3Y7AQN-DJ3IS3T[Q3N$&:THF0H:++C).LUTAN^56
M,>]5'^9M+5>J(_,PW'.GPO(ZHW@) ^NY1'>LAZI0)&]/D21J"(3SM%0Q'%74
MM<NZNHCC_ *[Z MJ1I^7E-RMH^N$-R246'EO2!'>4#V]H5J$@\LY,W\U2]>C
M"@=.Z+Y:Y!%6L-0R^[F90A.,]2892QA5853W:U2SU?A;10K">-:":VJKXU9E
M/V)PYYR62!]H*9T=P7]*?REG^KM=_9^SY!1YDUWF3>[',*B]:E>Y2F50<M^J
MHAS0[@'=2+8S"[I*V*O^M)7G74Y/%.SPK=0"\A(UO7.KE%W?3>W46S0KR[EA
MR4F[V-JN-B-H+[*;]?Q\1A'O)#AL[TXSARVW7@89OK1/G.TE4E=C4M[-_6E7
M^J4, ZVG> 8_+UN6Q!&GO;.8?[(JY:@@5GL*RXZ&X>1&N]NKG.G6-6&K&2E9
MR[5+2Y?L)A-V*,KV+%K=H$X8S?T;3>7G;>V><)MJS &KG>C(GN6:OGVK)N%%
M"2]*>%%OWHL:#EK"BQ)>5.ULZ+I9[&Z7<5]Q=FJ%48UJ_$06^_ :+)>'/MKJ
M7]0066R1Q=["5*7TQ)IU)")W?30&9&48GN*$XMQU43V(R%O7U7SL->+*]SQV
M7$PDHK W%(7A+8R=W9NV585#(AX3YK1J<UHVJQWZ7L*Q.D9.V,H4BLRV\+.$
MGR7\K#WX6=U^6_A9PL^JL76MIGI[[;PWORNP=.9;)+IWVES,<E4C[ PFC0$.
MF-,PL-78Q+)T9Z<[=NR?4E:'"7^][AJENB+>Q(6B(A?ZUGST%/"Y[ZTZA57"
MV:^XI&4)4PK?7_C^E3-WN]%M+R^9J=P8RR*@$.9_>_-?Y.155:8L7,'CX87J
MC*S(W@K/4'B&PC,4S-UI=+O+T\O",Q2>87V\@0.56(M4<XU2S0^))+-!-6(Z
M1%)-77I@T."_*X3B&7ZJ(.^\:N],Y)W?C'JIK@!7Y)U%='& Z&)YP8F(+D1T
ML4_F[C6&K2W;\ZY]%D9$%\+\[SWOO'8AL7 %CX<7JC.R(N\L/$/A&0K/4#"W
MTI![LO ,A6=X)-Y +._\GMVJFD,!S2"JS1AJBB1[#8F=(%E!'X@?\>4=I<13
M'HFX%WCI N9!B'AP%#8*.U)@![K&LN=3U73 V4CJ+,=5;;=0L;DVO#.&(0*J
MI)2;;VZI;KWPH5_ 7TG1#,S1Z#N%L7! Q[6M[^34U_><IDGZ!WX.-:E+<?3T
M[S[1PM]77!">>_$V<1WXTG:GDJZZJH3W:]LZ^[W@'FX-%L56-1<4N3JB!G47
MF?NWQ;KN;%T+-4BAP/%UUHAA^*[(;R>M$_:WCP3[.Z9Y]K RX3*$U,DNPT$I
MON1:\MC%XRFWR-?P_-4$O*&2=^V TJL2,I&'F='F\6WA'(+F\4.>Y[K=6OM
MQ ^11E_Z!$'P@J]23ML2\'(N,MX.U+S;>PJ/P(X,D*\"U[4,>AG"+'54=W-;
M\)),8G*]JF&!S5<[44:QF61L#7Z@5E<P1(&8Y<5=3-=L?ZNJY%^F"EI)6G)U
MZE&*MB)$._?*R#U)[L8D.*!MV1W,@BM7W+GV)NU)N;,;.58G<  '\OPU@?+?
M4IC^;;G%R>;+\FW,93K@HC")ZK( ;43 _S0Q7+/&[(LYS&3IA:L6[ BF0=_1
M:BWAS=4Z),B$5@!KR=3D=BC]M!*30;]:5/P-@QW@TE$:@V'WS2Q->6Y36MNC
M=% $Y H0J(NX](Y%7)1NHR6O%I>=+,V.&&M+4\J(O")FVY&]O("7,*GC2+IG
M!YG,%7:QYJ;P",1YKUCL3I)[C8ZBB'6HG743E-^;+6O(_>'>UJ&>UJM<(+A[
M4^8?,9)LHED3D_Y%]+W;M.J3@$'AS(J$R-N0^/UAN3N-\$M4/[^G3%"%J\<P
M>/<V$I5"<HY-<J+ZPH-)SL9"<KP1X+*,*3'UDKG2:E6#?W!CAWH@43M]/*J@
M. ^T5_QVFDOMM :EE8#/*+59N<-L^?E4V+<M%3)43QG"!&N[?6@9JG2#<K/Z
M[24%Q*("\[ 5F!OLMA=4;1;6<HIE/7C!M$WF-G$ 5R=>(?TW1_),!R9QQI3H
MZ%DBYJJI$<D: ;5X/;U8SL-+J:B3%G72!Z]EJ[9L[9!UTONO4!/USZ+^6=0_
M'Y7('K+4N;XI#L%6V[.5J%6N5ZWRUY5!D"A-WFU)Q,&JD+>LN^HT@$F/D>#[
MK2W>&VM7 .L!6'LW%</;@3V4E^:N:TSP]=/8/(G"785XOH0C*;=:/Y_S/-HI
M&'/+<\_&])7HY]D\2RH/$UG*B( Y)C\7KE_?SXW7,[^4ZHHZFF$YGDV>@%@?
M#4O[_N%?_^77UY%MT#//I*Y$]=].OL*';U\?KTZBWV9$Q;<^4,?J*'+_#'[]
M]7WR)WCV?310T;#.5+6)DS,R_XO_O-G0<WBT<&#\<;-A =5O8,R_/2)HL?'!
M[:(Z2;[UQ9L16W4M>PO*Y8R!7U\1TYI1,W_P\L1+#?,^C4N*(.!N?C\;6Y9K
M6B[Y!'](K^PKVT*^GKKN_.S]^Y>7ER:^UK3LR7NEU6J_QY_?XX,G_O/N8@[/
M \^Q4]PGX=# @?X34YN,?SOYMQM5<ZG^K:NTNIUV)_DZ/(QP!U\:ZH@8[-MO
M\HGT/@/N&J &K\#0,P,&1K$CYNG7QR0 0%W+LS62@N#FRS=YV!_*)Q]^D=])
MMZ9F>#JH++8<IR/5(1BCS.:$>8>6^>O[!)@9N"]L+3&K:FLA&%9L-LG7,W+P
M*W9B#^G!OX)W5^#O/_%^#(0_C>CPON02=<LND9*W1!6@JNP+U4ZK+*KM.G"C
M MRH[(T;E65+U-[;$LEEEZBS.3<N1;6S)U2[2FE4NX?GQD$;N/'2FLTL4WIT
MP>EH2#^UFJV6#,Z7+3VKAD?.I0O/G5HVJ_+^=^RV))]+JH/%:BSE+;5EB/-;
M\I!=,8&Y#^D4XOY6H]5B_YI5\#'"N61QN_M:W$YIP]?;E(]7H-K;#ZJ#8;]7
M%M7^CE#M[PO506F1'>P(U<'>4"V]JL,=H3K<%ZK#TJLJMW:$J]S:EV)2E-+(
MUL E'[1;)Q_^'^DAJEE134F=69[I2@9QL(0%OOA)KLAVM):N444N>1)2C,AB
M41O^[X?_'U!+ P04    " #'@*9.+-ELVRP,  #&90  $    '!L>"TR,#$Y
M,#,S,2YX<V3M7&UOXK@6_GZE^Q]\^;0K+:6T.R^MIK/*4#J+1($+='97J]7*
M) :L"7;6=EK8J_O?[['S H$D30+#C"[],A/B\_H<^]C'L?ONI^7"18]$2,K9
M3:UY=EY#A-G<H6QV4_/5M/ZV]M/[?_[CW;_J]8^$$8$5<=!DA6ZQPF.![<\2
M#3%E$_Z$/@52T.79.:JCIZ>G,P>(E"$ZL_D"7D+K^>OZ/5[5+\Z;5^CW\S?7
MEV^O+U[_@?XSN/]OO:XU27M.%A@I+&9$]?""2 _;Y*8V5\J[;C2T7$]PA5VZ
MU%(;6M+YY643#'?)@C!UQ\7BEDRQ[ZJ;VE\^$$XI<6H(/&7RVG.71609X@3A
MT^49%S,@.6\V?KWOCHR9D527LL\)ZN5$N!']94,W3[ D$?ERASZ4WKRZNFJ8
MUI@4!-$<T91)A9E--ND=%3-L$K]J!(UK*W+D_MK=,,*7]1G&7DP^Q7)B2,,&
M#=S;^GFS'D-W;7.?*;%*&B*)?3;CCXVP4;.]V6+SA8 .F,47MJ8P.H2F\T!#
MBGED:<_3Z75+"@-ECT2J=):@33-=)ID8IK9,YS%-*7Y(:J<S0(,F;R;)(0!J
MY1&9&AK3DN*+5)[(4 (M*0P.\02Q]=C/[#%7#2QLP5T"%MBJ3I:>BQE67*SN
MX'<,"&?,7Z0+<91H:(L;0%0'*B*H'?,]SY1DD$+M0@(O-YW3V08S!N-?0=XR
MOSR/LBG7CWH,7FM_QB =Z8>'82<[<QC/;[GMZPQD,:?-%%6K#@@3"R.^ABB
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MH]1LUAYOWRZAKHBYC>"LW/O_ 5!+ P04    " #'@*9.+;B>=R4)  #>=
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MS*T?FQW5YM9NKXY<)U[$R&[QZOS.7 ?283]),49I*^?+O)C-R+TZ2C/H'%:
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M=(BNEL:NJ,3P22Y6R[KX$?$X-8LN;LCK]%>V9G]F4CMIL5/M)25ZIW5@\(?
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M]]'FYR]W>L#$WB+#ICO!7_H<EN@O_P]02P,$%     @ QX"F3I)?@%\4-P
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MZ%][@!AG&<XS@["UWM B$ 09A=08VD 1<9XL8LYEFIX@YVHU7:]<@K-YN.O
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ML$K@E\3_7B]H-28T_<?M=+Z:KM"KM]^Y]<<&T!*=M &N3,QC%ST#YG]X\[Y
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M^&G*Q?GOG,;Y[4 I;!RW0J2#;#&V7WF=9*J-PL;6+C+"*M+*,Z:*K>17T%
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MU.HNC"S9;"<=Z^-5,$$5+JC"!A5\T)&1*P/M/JR\93H>4Q.3[&5LX=HANY\
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M2JA]4+,E'Q=X--2P'2P'L,'7:0BE^&PS?@Y@RE[(I@;S7KMOK*1R <%&Z>6
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M<0O<&*S;&+D.F[#+:WCHGN@-R5V'\1ZB$Y2Q58]<:1T0"[('N!F[%4"LA1)
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MM(SAG5@0OF=102[2'ZKA62[,I>">D6!)3M59L81C!['D\))8CM]NUJAC;9K
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MR*^J<] YM.);]=:0=W38.^B^3])%,-OM.[$IJ <2$FZP 1%$:6BT#HLJP_A
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M;R0=9?YT' 6^+*>ALCP7A"OIFJL6T&H8[;M9?22C;43*551:GLL R0B@QXZ
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M,3DP,S,Q+GAM;%!+ 0(4 Q0    ( ,> IDXLV6S;+ P  ,9E   0
M      "  :]F  !P;'@M,C Q.3 S,S$N>'-D4$L! A0#%     @ QX"F3BVX
MGG<E"0  WG0  !0              ( !"7,  '!L>"TR,#$Y,#,S,5]C86PN
M>&UL4$L! A0#%     @ QX"F3JPJ.Y?'(@  F0@" !0              ( !
M8'P  '!L>"TR,#$Y,#,S,5]D968N>&UL4$L! A0#%     @ QX"F3I)?@%\4
M-P  Z[D" !0              ( !69\  '!L>"TR,#$Y,#,S,5]L86(N>&UL
M4$L! A0#%     @ QX"F3O//B=AD*   (G@" !0              ( !G]8
K '!L>"TR,#$Y,#,S,5]P<F4N>&UL4$L%!@     &  8 A $  #7_      $!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
